# 0.921570
140	140	CD	CARD		OK/0.945627
Interferons	Interferone	NP	NN		OK/0.949040
.	.	SENT	$.		OK/0.999904

# 0.756917
0.31	0,31	CD	CARD		OK/0.963956
mg	mg	NN	NN		OK/0.961165
lyophilised	lyophilisiertes	VVD	ADJA		OK/0.923141
sulesomab	Sulesomab	NN	NE		OK/0.932323
protrude	Zinnchlorid	VV	NN		OK/0.909934
from	Zinnchlorid	IN	NN		OK/0.951862
the	__unaligned__	DT	__unaligned__		OK/0.981476
upper	__unaligned__	JJ	__unaligned__		OK/0.942992
surface	__unaligned__	NN	__unaligned__		OK/0.968867
.	.	SENT	$.		OK/0.997359

# 0.706730
For	Weitere	IN	ADJA		OK/0.935394
more	Einzelheiten	JJR	NN		OK/0.982205
details	Einzelheiten	NNS	NN		OK/0.979777
on	Einzelheiten	IN	NN		OK/0.964358
liver	__unaligned__	NN	__unaligned__		OK/0.983817
problems	__unaligned__	NNS	__unaligned__		OK/0.951199
are	sind	VBP	VAFIN		OK/0.862788
included	__unaligned__	VVN	__unaligned__		OK/0.910298
in	__unaligned__	IN	__unaligned__		OK/0.985986
the	entnehmen	DT	VVINF		OK/0.999985
Package	entnehmen	NP	VVINF		OK/0.997202
Leaflet	entnehmen	NP	VVINF		OK/0.954735
.	.	SENT	$.		OK/0.999846

# 0.808328
What	Was	WP	PIS		OK/0.998512
Competact	Competact-Tabletten	JJ	NN		OK/0.940834
tablets	Competact-Tabletten	NNS	NN		OK/0.996935
contain	enthalten	VVP	VVFIN		OK/0.995065
The	Die	DT	ART		OK/0.998209
active	Wirkstoffe	JJ	NN		OK/0.997412
substances	Wirkstoffe	NNS	NN		OK/0.993195
are	Wirkstoffe	VBP	NN		OK/0.956617
15	15	CD	CARD		OK/0.999842
mg	mg	NN	NN		OK/0.997943
pioglitazone	Pioglitazon	NN	NN		OK/0.996578
(	(	(	$(		OK/0.999171
as	Hydrochlorid	IN	NN		OK/0.992890
hydrochloride	Hydrochlorid	NN	NN		OK/0.993017
)	)	)	$(		OK/0.986249
and	und	CC	KON		OK/0.993108
850	850	CD	CARD		OK/0.956044
mg	mg	NN	NN		OK/0.997057
of	__unaligned__	IN	__unaligned__		OK/0.995887
metformin	Metforminhydrochlorid	NN	NN		OK/0.998862
hydrochloride	Metforminhydrochlorid	NN	NN		OK/0.990049
.	.	SENT	$.		OK/0.995602

# 0.162747
An	Ein	DT	ART		OK/0.656958
ovarian	ovarielles	JJ	ADJA		OK/0.964660
hyperstimulation	ovarielles	NN	ADJA		OK/0.995727
syndrome	ovarielles	NN	ADJA		OK/0.993309
,	__unaligned__	,	__unaligned__		OK/0.894815
thromboembolisms	Überstimulationssyndrom	NNS	NN		OK/0.835075
occurred	trat	VVD	VVFIN		OK/0.804463
in	bei	IN	APPR		OK/0.758214
approximately	etwa	RB	ADV		OK/0.989238
4	4	CD	CARD		OK/0.998557
%	%	NN	NN		OK/0.999255
of	der	IN	ART		OK/0.987866
the	der	DT	ART		OK/0.999016
patients	Patientinnen	NNS	NN		OK/0.978467
in	in	IN	APPR		OK/0.986082
clinical	klinischen	JJ	ADJA		OK/0.986086
trials	Studien	NNS	NN		OK/0.980262
;	__unaligned__	:	__unaligned__		OK/0.984232
most	meisten	JJS	PIAT		OK/0.995239
of	dieser	IN	PDAT		OK/0.994670
these	dieser	DT	PDAT		OK/0.996491
cases	Fälle	NNS	NN		OK/0.978750
were	waren	VBD	VAFIN		OK/0.952884
mild	mittlerem	JJ	ADJA		OK/0.979627
or	oder	CC	KON		OK/0.994752
moderate	__unaligned__	JJ	__unaligned__		OK/0.788664
in	__unaligned__	IN	__unaligned__		BAD/0.770689
nature	Schweregrad	NN	NN		BAD/0.619047
.	.	SENT	$.		OK/0.996948

# 0.742052
The	Die	NP	ART		OK/0.996718
recommended	empfohlene	VVD	ADJA		OK/0.991777
starting	Anfangsdosis	VVG	NN		OK/0.998795
dose	Anfangsdosis	NN	NN		OK/0.999794
is	beträgt	VBZ	VVFIN		OK/0.999540
4	4	CD	CARD		OK/0.996433
mg	mg	NN	NN		OK/0.996767
per	täglich	IN	ADJD		OK/0.995006
day	täglich	NN	ADJD		OK/0.998550
,	,	,	$,		OK/0.995251
given	verabreicht	VVN	VVFIN		OK/0.992070
as	verabreicht	IN	VVFIN		OK/0.994439
a	verabreicht	DT	VVFIN		OK/0.986340
single	Einzeldosis	JJ	NN		OK/0.998279
dose	Einzeldosis	NN	NN		OK/0.997482
or	oder	CC	KON		OK/0.991782
in	in	IN	APPR		OK/0.987205
two	zwei	CD	CARD		OK/0.985728
2	2	CD	CARD		OK/0.934529
mg	mg-Dosen	NN	NN		OK/0.886230
doses	mg-Dosen	NNS	NN		OK/0.843241
.	.	SENT	$.		OK/0.998023

# 0.147477
Before	Vor	IN	APPR		OK/0.926403
taking	Einnahme	VVG	NN		OK/0.878829
the	__unaligned__	DT	__unaligned__		OK/0.973151
medicine	des	NN	ART		OK/0.819581
to	einzunehmende	TO	ADJA		BAD/0.792192
accurately	einzunehmende	RB	ADJA		BAD/0.954320
measure	einzunehmende	VV	ADJA		BAD/0.878650
the	__unaligned__	DT	__unaligned__		OK/0.624507
oral	einzunehmende	JJ	ADJA		OK/0.758644
dose	Dosis	NN	NN		OK/0.969864
is	wird	VBZ	VAFIN		OK/0.838659
dissolved	aufgelöst	VVN	VVPP		OK/0.677988
in	in	IN	APPR		OK/0.924198
water	Wasser	NN	NN		OK/0.952650
and	Wasser	CC	NN		OK/0.857246
taken	__unaligned__	VVN	__unaligned__		OK/0.879273
orally	__unaligned__	RB	__unaligned__		OK/0.905644
.	.	SENT	$.		OK/0.997772

# 0.881705
Children	Kinder	NP	NN		OK/0.996149
should	sollten	MD	VMFIN		OK/0.995186
not	nicht	RB	PTKNEG		OK/0.994812
take	einnehmen	VV	VVFIN		OK/0.998765
Karvea	Karvea	NP	NE		OK/0.995865
Karvea	Karvea	NP	NE		OK/0.974745
should	sollte	MD	VMFIN		OK/0.998623
not	nicht	RB	PTKNEG		OK/0.997536
be	__unaligned__	VB	__unaligned__		OK/0.972050
given	gegeben	VVN	VVPP		OK/0.986563
to	gegeben	TO	VVPP		OK/0.997791
children	Kindern	NNS	NN		OK/0.986193
under	unter	IN	APPR		OK/0.998748
18	18	CD	CARD		OK/0.997987
years	Jahren	NNS	NN		OK/0.999410
of	__unaligned__	IN	__unaligned__		OK/0.991701
age	Jahren	NN	NN		OK/0.976424
.	.	SENT	$.		OK/0.999511

# 0.934247
1	1	CD	CARD		OK/0.999031
pre-filled	Fertigspritze	JJ	NN		OK/0.998319
syringe	Fertigspritze	NN	NN		OK/0.999553
contains	enthält	VVZ	VVFIN		OK/0.998770
8	8	CD	CARD		OK/0.998153
ml	ml	NN	NN		OK/0.994980
water	Injektionszwecke	NN	NN		OK/0.998693
for	Injektionszwecke	IN	NN		OK/0.978363
injections	Injektionszwecke	NNS	NN		OK/0.954761
.	.	SENT	$.		OK/0.998510

# 0.912259
Treatment	Behandlung	NP	NN		OK/0.988453
can	kann	MD	VMFIN		OK/0.999005
be	kann	VB	VMFIN		OK/0.984585
continued	über	VVN	APPR		OK/0.971825
for	maximal	IN	ADJD		OK/0.996283
a	maximal	DT	ADJD		OK/0.992660
maximum	maximal	NN	ADJD		OK/0.979158
of	maximal	IN	ADJD		OK/0.992337
14	14	CD	CARD		OK/0.999047
consecutive	aufeinanderfolgende	JJ	ADJA		OK/0.994984
days	Tage	NNS	NN		OK/0.993794
.	.	SENT	$.		OK/0.999746

# 0.022028
8	8	CD	CARD		OK/0.997104
Distribution	Verteilung	NN	NN		OK/0.990613
of	__unaligned__	IN	__unaligned__		OK/0.964730
tacrolimus	Da	NN	ADV		OK/0.944458
systemic	systemisch	JJ	ADJD		OK/0.992922
exposure	Tacrolimussalbe	NN	NN		OK/0.977143
is	__unaligned__	VBZ	__unaligned__		OK/0.893578
low	__unaligned__	JJ	__unaligned__		OK/0.845796
,	,	,	$,		OK/0.931732
it	__unaligned__	PP	__unaligned__		OK/0.694341
is	auszugehen	VBZ	VVIZU		OK/0.707850
assumed	davon	VVN	PAV		OK/0.705754
that	dass	IN/that	KOUS		OK/0.922185
the	die	DT	ART		OK/0.873561
high	hohe	JJ	ADJA		OK/0.632798
plasma	Plasmaproteinbindung	NN	NN		OK/0.637871
protein	Plasmaproteinbindung	NN	NN		OK/0.958273
binding	Plasmaproteinbindung	VVG	NN		OK/0.965115
of	__unaligned__	IN	__unaligned__		OK/0.893651
tacrolimus	Tacrolimus	NN	NN		OK/0.901178
(	(	(	$(		OK/0.989511
>	>	SYM	$(		BAD/0.603018
98.8	98,8	CD	CARD		OK/0.929679
%	%	NN	NN		OK/0.977038
)	)	)	$(		OK/0.958025
to	__unaligned__	TO	__unaligned__		OK/0.653494
plasma	__unaligned__	NN	__unaligned__		OK/0.804833
proteins	__unaligned__	NNS	__unaligned__		OK/0.833641
is	__unaligned__	VBZ	__unaligned__		OK/0.818843
considered	__unaligned__	VVN	__unaligned__		OK/0.653728
not	keine	RB	PIAT		OK/0.912134
to	__unaligned__	TO	__unaligned__		BAD/0.654664
be	__unaligned__	VB	__unaligned__		BAD/0.638524
done	__unaligned__	VVN	__unaligned__		BAD/0.501893
.	.	SENT	$.		OK/0.996460

# 0.820062
What	Welchen	WP	PIAT		OK/0.995791
benefit	Welchen	VVP	PIAT		OK/0.850121
has	Nutzen	VHZ	NN		OK/0.996488
Raptiva	Raptiva	NP	NN		OK/0.997472
shown	__unaligned__	VVN	__unaligned__		OK/0.991622
during	in	IN	APPR		OK/0.988291
the	__unaligned__	DT	__unaligned__		OK/0.984918
studies	Studien	NNS	NN		OK/0.996919
?	?	SENT	$.		OK/0.998516

# 0.849711
Some	einigen	DT	PIAT		OK/0.992240
patients	Patienten	NNS	NN		OK/0.998871
experienced	trat	JJ	VVFIN		OK/0.982559
haematuria	Hämaturie	NN	ADJA		OK/0.883114
/	/	SYM	$(		OK/0.965722
proteinuria	Proteinurie	NN	NN		OK/0.969569
.	.	SENT	$.		OK/0.997674

# 0.557157
Temodal	Temodal	NP	NN		OK/0.990905
2.5	2,5	CD	CARD		OK/0.998891
mg	mg	NN	NN		OK/0.999608
/	/	SYM	$(		OK/0.998398
ml	ml	JJ	NN		OK/0.998769
powder	Pulver	NN	NN		OK/0.999767
for	Infusionslösung	IN	NN		OK/0.994713
solution	Infusionslösung	NN	NN		OK/0.988670
for	Infusionslösung	IN	NN		OK/0.974786
infusion	Infusionslösung	NN	NN		OK/0.986234
should	darf	MD	VMFIN		OK/0.627922
only	nur	RB	ADV		OK/0.996151
be	darf	VB	VMFIN		OK/0.993913
administered	intravenöse	VVN	ADJA		OK/0.933198
by	intravenöse	IN	ADJA		OK/0.997190
intravenous	intravenöse	JJ	ADJA		OK/0.999621
infusion	Infusion	NN	NN		OK/0.996743
.	.	SENT	$.		OK/0.999879

# 0.595295
In	Bei	IN	APPR		OK/0.962687
patients	Patienten	NNS	NN		OK/0.997193
with	mit	IN	APPR		OK/0.999286
severe	schwerer	JJ	ADJA		OK/0.999385
hepatic	Einschränkung	JJ	NN		OK/0.998727
impairment	Einschränkung	NN	NN		OK/0.996811
,	__unaligned__	,	__unaligned__		OK/0.983178
insulin	__unaligned__	NN	__unaligned__		OK/0.972707
requirements	__unaligned__	NNS	__unaligned__		OK/0.997715
may	kann	MD	VMFIN		OK/0.995687
be	kann	VB	VMFIN		OK/0.998622
diminished	Insulinbedarf	VVN	NN		OK/0.990913
due	aufgrund	RB	APPR		OK/0.998331
to	aufgrund	TO	APPR		OK/0.998042
reduced	reduzierten	VVN	ADJA		OK/0.998366
capacity	Kapazität	NN	NN		OK/0.968175
for	zur	IN	APPRART		OK/0.993600
gluconeogenesis	Glukoneogenese	NN	NN		OK/0.980449
and	und	CC	KON		OK/0.993992
reduced	vermindert	VVN	VVPP		OK/0.999481
insulin	des	NN	ART		OK/0.986698
metabolism	__unaligned__	NN	__unaligned__		OK/0.991836
may	sein	MD	VAINF		BAD/0.756351
be	Insulinabbaus	VB	NN		BAD/0.794338
.	.	SENT	$.		OK/0.995034

# 0.073137
Raloxifene	Raloxifen	NP	NN		OK/0.357269
The	wie	DT	KOKOM		OK/0.526584
effects	Wirkung	NNS	NN		OK/0.749142
on	auf	IN	APPR		OK/0.975655
the	den	DT	ART		OK/0.994355
bones	Knochen	NNS	NN		OK/0.961046
,	,	,	$,		OK/0.953527
but	doch	CC	KON		OK/0.519495
it	es	PP	PPER		OK/0.510175
does	wirkt	VVZ	VVFIN		OK/0.627801
not	nicht	RB	PTKNEG		OK/0.835935
on	auf	IN	APPR		OK/0.951651
the	auf	DT	APPR		OK/0.989858
breast	Brust	NN	NN		OK/0.841505
or	oder	CC	KON		OK/0.900595
womb	Gebärmutter	NN	NN		BAD/0.719708
.	.	SENT	$.		OK/0.991669

# 0.335725
inhibitor	Inhibitorentwicklung	NN	NN		OK/0.865772
The	Die	DT	ART		OK/0.897210
Neoantigenität	Neoantigenität	NP	NN		OK/0.514019
of	von	IN	APPR		OK/0.984756
ADVATE	ADVATE	NP	NN		OK/0.982498
was	wurde	VBD	VAFIN		OK/0.945636
evaluated	beurteilt	VVN	VVFIN		OK/0.908113
in	__unaligned__	IN	__unaligned__		OK/0.770438
previously	zuvor	RB	ADV		OK/0.841836
treated	behandelten	VVN	ADJA		OK/0.954245
patients	Patienten	NNS	NN		OK/0.976797
.	.	SENT	$.		OK/0.999842

# 0.133836
General	Allgemeinreaktionen	NP	NN		OK/0.984535
reactions	__unaligned__	NNS	__unaligned__		OK/0.975985
have	wurden	VHP	VAFIN		OK/0.797664
been	wurden	VBN	VAFIN		OK/0.834826
observed	beobachtet	VVN	VVPP		OK/0.845675
,	jedoch	,	ADV		OK/0.665665
but	jedoch	CC	ADV		BAD/0.818599
similar	vergleichbarer	JJ	ADJA		BAD/0.648607
frequency	Häufigkeit	NN	NN		BAD/0.443998
in	beiden	IN	PIAT		BAD/0.449796
both	beiden	DT	PIAT		BAD/0.502250
groups	Gruppen	NNS	NN		OK/0.926912
.	.	SENT	$.		OK/0.996986

# 0.046153
16	16	CD	CARD		OK/0.988647
cephalosporins	Cephalosporine	NNS	NE		OK/0.855523
successfully	erfolgreich	RB	ADJD		OK/0.440397
,	,	,	$,		OK/0.849422
such	wie	JJ	KOUS		OK/0.796492
as	wie	IN	KOUS		OK/0.960432
many	viele	JJ	PIAT		OK/0.891703
extended-spectrum	Breitspektrum-Beta-Laktamasen	NN	NN		OK/0.701351
beta-lactamases	Breitspektrum-Beta-Laktamasen	NNS	NN		OK/0.615718
and	und	CC	KON		OK/0.764056
cephalosporinases	Cephalosporinasen	NNS	NN		BAD/0.779579
and	__unaligned__	CC	__unaligned__		BAD/0.855754
chromosomal	__unaligned__	JJ	__unaligned__		BAD/0.745930
aberrations	chromosomale	NNS	ADJA		BAD/0.868928
in	__unaligned__	IN	__unaligned__		BAD/0.915084
AmpC	AmpC-Typus	NP	NN		BAD/0.809384
type	AmpC-Typus	NN	NN		OK/0.547132
enzymes	AmpC-Typus	NNS	NN		OK/0.673660
.	.	SENT	$.		OK/0.997299

# 0.105222
Patients	Patienten	NPS	NN		OK/0.981797
should	sollten	MD	VMFIN		OK/0.994667
be	sollten	VB	VMFIN		OK/0.993382
monitored	überwacht	VVN	VVPP		OK/0.997957
for	hinsichtlich	IN	APPR		OK/0.981882
withdrawal	Entzugserscheinungen	NN	NN		OK/0.994855
symptoms	Entzugserscheinungen	NNS	NN		OK/0.979980
and	und	CC	KON		OK/0.997598
their	ihre	PP$	PPOSAT		OK/0.983152
methadone	Methadondosis	NN	NN		OK/0.972932
dose	Methadondosis	NN	NN		OK/0.912426
should	sollte	MD	VMFIN		OK/0.920853
be	sollte	VB	VMFIN		OK/0.912816
increased	erhöht	VVN	VVPP		OK/0.821837
,	,	,	$,		OK/0.929283
if	falls	IN	KOUS		OK/0.943978
necessary	notwendig	JJ	ADJD		OK/0.931480
,	,	,	$,		OK/0.688251
will	Entzugserscheinungen	MD	NN		BAD/0.584128
be	Entzugserscheinungen	VB	NN		BAD/0.853223
accompanied	Entzugserscheinungen	VVN	NN		BAD/0.970607
by	Entzugserscheinungen	IN	NN		BAD/0.967568
withdrawal	Entzugserscheinungen	NN	NN		BAD/0.773491
symptoms	Entzugserscheinungen	NNS	NN		BAD/0.570337
.	.	SENT	$.		OK/0.995982

# 0.128516
MDS	MDS	NP	NN		OK/0.774868
and	und	CC	KON		OK/0.900065
leukaemias	Leukämien	NNS	NN		OK/0.567596
are	sind	VBP	VAFIN		OK/0.909381
natural	natürliche	JJ	ADJA		OK/0.902060
complications	Komplikationen	NNS	NN		OK/0.793371
of	der	IN	ART		OK/0.845205
the	der	DT	ART		OK/0.601635
disease	Erkrankung	NN	NN		OK/0.673559
.	.	SENT	$.		OK/0.710980
The	Ein	DT	ART		OK/0.836420
following	Behandlung	VVG	NN		OK/0.986479
treatment	Behandlung	NN	NN		OK/0.996105
with	mit	IN	APPR		OK/0.997931
filgrastim	Filgrastim	NN	NN		OK/0.989594
is	__unaligned__	VBZ	__unaligned__		OK/0.665832
doubtful	unsicher	JJ	ADJD		OK/0.630154
.	.	SENT	$.		OK/0.995774

# 0.449374
The	Die	DT	ART		OK/0.941411
inducing	induzierende	VVG	ADJA		OK/0.666968
effect	__unaligned__	NN	__unaligned__		OK/0.974658
of	__unaligned__	IN	__unaligned__		OK/0.981211
St.	Johanniskraut	NP	NN		OK/0.996394
John	Johanniskraut	NP	NN		OK/0.998540
's	Johanniskraut	POS	NN		OK/0.998102
wort	Johanniskraut	NN	NN		OK/0.990851
may	kann	MD	VMFIN		OK/0.971475
persist	anhalten	VV	VVINF		OK/0.998865
for	anhalten	IN	VVINF		OK/0.940541
at	mindestens	IN	ADV		OK/0.971486
least	mindestens	JJS	ADV		OK/0.988991
2	2	CD	CARD		OK/0.999409
weeks	Wochen	NNS	NN		OK/0.998722
of	Behandlung	IN	NN		OK/0.988858
treatment	Behandlung	NN	NN		OK/0.978886
discontinuation	Absetzen	NN	NN		OK/0.798934
(	(	(	$(		OK/0.998675
see	siehe	VV	VVIMP		OK/0.997866
section	Abschnitt	NN	NN		OK/0.988121
4.3	4.3	CD	CARD		OK/0.990412
)	)	)	$(		OK/0.999436
.	.	SENT	$.		OK/0.997513

# 0.987239
How	Wie	NP	KOKOM		OK/0.998387
is	wird	VBZ	VAFIN		OK/0.994770
Intrinsa	Intrinsa	NP	NE		OK/0.999679
used	angewendet	VVD	VVPP		OK/0.994416
?	?	SENT	$.		OK/0.999496

# 0.043914
The	Die	DT	ART		OK/0.998158
clinical	klinischen	JJ	ADJA		OK/0.985265
trials	Studien	NNS	NN		OK/0.987768
,	,	,	$,		OK/0.923724
reported	berichteten	VVN	ADJA		OK/0.925259
from	Marktzulassung	IN	NN		OK/0.386038
post-marketing	Marktzulassung	NN	NN		OK/0.487025
surveillance	Marktzulassung	NN	NN		OK/0.552641
as	__unaligned__	RB	__unaligned__		OK/0.949085
well	sowie	RB	KON		OK/0.950056
as	__unaligned__	IN	__unaligned__		OK/0.992121
laboratory	Laboruntersuchungen	NN	NN		OK/0.577258
tests	Laboruntersuchungen	NNS	NN		OK/0.569282
,	__unaligned__	,	__unaligned__		OK/0.570979
adverse	Nebenwirkungen	JJ	NN		OK/0.766525
events	Nebenwirkungen	NNS	NN		OK/0.858786
are	nachfolgend	VBP	ADJD		OK/0.956605
listed	nachfolgend	VVN	ADJD		OK/0.974931
below	nachfolgend	IN	ADJD		OK/0.913058
,	__unaligned__	,	__unaligned__		BAD/0.898462
by	Organklasse	IN	NN		BAD/0.846573
system	Organklasse	NN	NN		BAD/0.680250
organ	Organklasse	NN	NN		OK/0.728114
class	Organklasse	NN	NN		OK/0.949528
.	.	SENT	$.		OK/0.998789

# 0.176837
As	Wie	IN	KOKOM		OK/0.995488
with	__unaligned__	IN	__unaligned__		OK/0.996631
any	jeder	DT	PIAT		OK/0.998617
insulin	Insulintherapie	NN	NN		OK/0.999109
therapy	__unaligned__	NN	__unaligned__		OK/0.999607
,	__unaligned__	,	__unaligned__		OK/0.976689
lipodystrophy	Lipodystrophie	NN	NN		OK/0.978277
may	kommen	MD	VVINF		OK/0.973157
occur	kommen	VV	VVINF		OK/0.926190
at	,	IN	$,		OK/0.754718
As	Insulinresorption	IN	NN		BAD/0.668919
the	betroffenen	DT	ADJA		OK/0.834761
injection	Injektionsstelle	NN	NN		OK/0.980287
site	Injektionsstelle	NN	NN		OK/0.986864
and	__unaligned__	CC	__unaligned__		OK/0.877907
delay	einer	VV	ART		OK/0.795854
local	__unaligned__	JJ	__unaligned__		OK/0.724509
insulin	__unaligned__	NN	__unaligned__		OK/0.701657
absorption	__unaligned__	NN	__unaligned__		OK/0.777639
.	.	SENT	$.		OK/0.985518

# 0.348117
NeoSpect	NeoSpect	NP	NN		OK/0.991064
is	ist	VBZ	VAFIN		OK/0.977660
a	ist	DT	VAFIN		OK/0.940610
radioactive	radioaktives	JJ	ADJA		OK/0.544740
medicinal	Arzneimittel	JJ	NN		OK/0.797864
products	Arzneimittel	NNS	NN		OK/0.587061
for	für	IN	APPR		OK/0.923740
diagnostic	diagnostische	JJ	ADJA		OK/0.926699
use	diagnostische	NN	ADJA		OK/0.915935
.	.	SENT	$.		OK/0.998935

# 0.192844
However	jedoch	RB	ADV		OK/0.995154
,	jedoch	,	ADV		OK/0.940753
when	__unaligned__	WRB	__unaligned__		OK/0.903352
too	viel	RB	PIAT		OK/0.989471
much	viel	JJ	PIAT		OK/0.994067
cholesterol	Cholesterin	NN	NN		OK/0.985197
in	in	IN	APPR		OK/0.993057
your	Ihrem	PP$	PPOSAT		OK/0.974280
blood	Blut	NN	NN		OK/0.943220
,	,	,	$,		OK/0.704194
it	es	PP	PPER		OK/0.940978
can	kann	MD	VMFIN		OK/0.995880
stick	__unaligned__	VV	__unaligned__		OK/0.939280
to	__unaligned__	TO	__unaligned__		OK/0.963388
the	__unaligned__	DT	__unaligned__		OK/0.982666
bottom	__unaligned__	NN	__unaligned__		OK/0.931452
or	__unaligned__	CC	__unaligned__		OK/0.932000
wall	__unaligned__	NN	__unaligned__		OK/0.587499
of	der	IN	ART		OK/0.863833
the	__unaligned__	DT	__unaligned__		OK/0.873504
blood	Blutgefäße	NN	NN		OK/0.989491
vessels	Blutgefäße	NNS	NN		OK/0.979653
represented	ablagern	VVD	VVINF		OK/0.772184
,	,	,	$,		OK/0.927250
possibly	möglicherweise	RB	ADV		OK/0.802835
.	.	SENT	$.		OK/0.994005

# 0.443799
You	Sie	PP	PPER		OK/0.996201
should	sollten	MD	VMFIN		OK/0.974464
take	__unaligned__	VV	__unaligned__		OK/0.699989
great	vergewissern	JJ	VVINF		OK/0.726008
care	vergewissern	NN	VVINF		OK/0.790207
check	__unaligned__	NN	__unaligned__		OK/0.772160
with	bei	IN	APPR		OK/0.937858
your	Ihrem	PP$	PPOSAT		OK/0.993645
doctor	Arzt	NN	NN		OK/0.994354
if	wenn	IN	KOUS		OK/0.998910
you	Sie	PP	PPER		OK/0.997135
are	Sie	VBP	PPER		OK/0.959063
not	nicht	RB	PTKNEG		OK/0.871095
sure	sicher	JJ	ADJD		OK/0.837321
.	.	SENT	$.		OK/0.997666

# 0.310212
Following	Nach	VVG	APPR		OK/0.931056
withdrawal	Absetzen	NN	NN		OK/0.997854
of	Absetzen	IN	NN		OK/0.991877
treatment	Behandlung	NN	NN		OK/0.893219
,	__unaligned__	,	__unaligned__		OK/0.835288
blood	Blutdruck	NN	NN		OK/0.977512
pressure	Blutdruck	NN	NN		OK/0.971149
gradually	kehrte	RB	VVFIN		OK/0.865627
returned	kehrte	VVD	VVFIN		OK/0.919421
towards	kehrte	IN	VVFIN		OK/0.978255
gradually	schrittweise	RB	ADJD		OK/0.981359
over	Zeitraum	IN	NN		OK/0.988468
a	Zeitraum	DT	NN		OK/0.995492
period	Zeitraum	NN	NN		OK/0.990628
of	__unaligned__	IN	__unaligned__		OK/0.995949
several	einigen	JJ	PIAT		OK/0.989717
weeks	Wochen	NNS	NN		OK/0.985676
to	__unaligned__	TO	__unaligned__		BAD/0.592804
baseline	Ausgangswert	NN	NN		BAD/0.607423
.	.	SENT	$.		OK/0.987798

# 0.153776
Epoetin	Epoetin	NP	NE		OK/0.985349
alfa	alfa	NN	NE		OK/0.999246
did	keinerlei	VVD	PIAT		OK/0.986852
not	keinerlei	RB	PIAT		OK/0.998074
show	keinerlei	VV	PIAT		OK/0.990265
any	keinerlei	DT	PIAT		OK/0.966442
changes	Veränderungen	NNS	NN		OK/0.980972
in	in	IN	APPR		OK/0.995827
mutagenicity	Mutagenitätstests	NN	NN		OK/0.961898
tests	Mutagenitätstests	NNS	NN		OK/0.977783
and	und	CC	KON		OK/0.974736
/	__unaligned__	SYM	__unaligned__		OK/0.880197
or	bzw.	CC	KON		OK/0.749353
in	im	IN	APPRART		OK/0.958589
the	im	DT	APPRART		OK/0.754485
in	vivo	IN	ADJA		OK/0.665175
vivo	__unaligned__	JJ	__unaligned__		OK/0.469356
mouse	Mäusen	NN	NN		OK/0.818081
micronucleus	Mikrokerntest	NN	NN		OK/0.930843
assay	__unaligned__	NN	__unaligned__		OK/0.511197
.	.	SENT	$.		OK/0.981951

# 0.742153
Renal	renale	NP	ADJA		OK/0.982809
elimination	Ausscheidung	NN	NN		OK/0.995187
of	Ausscheidung	IN	NN		OK/0.958875
methylnaltrexone	Methylnaltrexonium	NN	NN		OK/0.946877
decreased	nahm	VVN	VVFIN		OK/0.939705
with	mit	IN	APPR		OK/0.998486
increasing	zunehmendem	VVG	ADJA		OK/0.862777
severity	Schweregrad	NN	NN		OK/0.923382
of	__unaligned__	IN	__unaligned__		OK/0.988696
renal	Nierenfunktionsstörung	JJ	NN		OK/0.998909
impairment	Nierenfunktionsstörung	NN	NN		OK/0.997730
.	.	SENT	$.		OK/0.999648

# 0.418292
263	263	CD	CARD		OK/0.965204
in	zusammen	IN	ADV		OK/0.975830
combination	zusammen	NN	ADV		OK/0.958269
with	zusammen	IN	ADV		OK/0.989029
other	anderen	JJ	PIS		OK/0.996886
methods	__unaligned__	NNS	__unaligned__		OK/0.982700
of	__unaligned__	IN	__unaligned__		OK/0.995198
contraception	empfängnisverhütenden	NN	ADJA		OK/0.972394
including	einschließlich	VVG	APPR		OK/0.994328
oral	oraler	JJ	ADJA		OK/0.923581
(	(	(	$(		OK/0.980779
pill	Pille	NN	NN		OK/0.775088
)	)	)	$(		OK/0.883488
or	oder	CC	KON		OK/0.978156
other	anderer	JJ	PIS		OK/0.990819
hormonal	hormoneller	JJ	ADJA		OK/0.943282
contraceptives	Kontrazeptiva	NNS	NN		OK/0.980707
(	(	(	$(		OK/0.994337
for	Beispiel	IN	NN		OK/0.997832
example	Beispiel	NN	NN		OK/0.984474
,	,	,	$,		OK/0.955525
implants	Implantaten	NNS	NN		OK/0.822832
,	,	,	$,		OK/0.963359
injection	Injektionen	NN	NN		OK/0.881545
)	)	)	$(		OK/0.965753
.	.	SENT	$.		OK/0.993251

# 0.616941
This	Dies	NP	PDS		OK/0.997832
should	darf	MD	VMFIN		OK/0.941390
only	nur	RB	ADV		OK/0.998945
be	darf	VB	VMFIN		OK/0.992423
carried	medizinischem	VVN	ADJA		OK/0.986384
out	medizinischem	RP	ADJA		OK/0.987698
by	medizinischem	IN	ADJA		OK/0.905742
health	Fachpersonal	NN	NN		OK/0.997883
care	Fachpersonal	NN	NN		OK/0.997707
professionals	Fachpersonal	NNS	NN		OK/0.738383
.	.	SENT	$.		OK/0.997678

# 0.738206
Using	Bei	VVG	APPR		OK/0.997018
Nonafact	Nonafact	NP	NN		OK/0.955285
with	mit	IN	APPR		OK/0.925390
other	anderen	JJ	PIS		OK/0.984965
medicinal	Arzneimitteln	JJ	NN		OK/0.986898
products	Arzneimitteln	NNS	NN		OK/0.993456
interactions	Wechselwirkungen	NNS	NN		OK/0.954010
between	zwischen	IN	APPR		OK/0.996063
Nonafact	Nonafact	NP	NN		OK/0.977513
and	und	CC	KON		OK/0.946670
other	anderen	JJ	PIS		OK/0.987525
medicines	Medikamenten	NNS	NN		OK/0.994871
are	sind	VBP	VAFIN		OK/0.970975
not	nicht	RB	PTKNEG		OK/0.985174
known	bekannt	VVN	ADJD		OK/0.957822
.	.	SENT	$.		OK/0.990384

# 0.883079
There	gibt	RB	VVFIN		OK/0.990413
is	gibt	VBZ	VVFIN		OK/0.931834
no	keine	DT	PIAT		OK/0.993958
therapeutic	therapeutische	JJ	ADJA		OK/0.989824
experience	Erfahrung	NN	NN		OK/0.979835
with	mit	IN	APPR		OK/0.999253
losartan	Losartan	NN	NE		OK/0.988915
in	bei	IN	APPR		OK/0.992441
patients	Patienten	NNS	NN		OK/0.998522
with	mit	IN	APPR		OK/0.999223
severe	schwerer	JJ	ADJA		OK/0.999771
hepatic	Leberfunktionseinschränkung	JJ	NN		OK/0.998185
impairment	Leberfunktionseinschränkung	NN	NN		OK/0.997231
.	.	SENT	$.		OK/0.999920

# 0.357676
Systemic	systemische	NP	ADJA		OK/0.944221
exposure	Verfügbarkeit	NN	NN		OK/0.712739
from	von	IN	APPR		OK/0.664051
topical	__unaligned__	JJ	__unaligned__		OK/0.741460
application	__unaligned__	NN	__unaligned__		OK/0.964797
of	von	IN	APPR		OK/0.926502
sirolimus	Sirolimus	NN	NE		OK/0.993277
in	Kombination	IN	NN		OK/0.988169
combination	Kombination	NN	NN		OK/0.984203
with	mit	IN	APPR		OK/0.985244
phenytoin	angewendetem	NN	ADJA		OK/0.948462
ciclosporin	Ciclosporin	NN	NN		OK/0.861812
(	(	(	$(		OK/0.969195
Sandimmun	Sandimmun	NP	NE		OK/0.875203
)	)	)	$(		OK/0.991277
is	beträgt	VBZ	VVFIN		OK/0.974000
about	beträgt	RB	VVFIN		OK/0.887422
14	14	CD	CARD		OK/0.996643
%	%	NN	NN		OK/0.987488
.	.	SENT	$.		OK/0.999880

# 0.302343
PRODUCT	HANDELSNAME	NP	NN		OK/0.989181
NAME	HANDELSNAME	NP	NN		OK/0.998435
belongs	gehört	VVZ	VVFIN		OK/0.991370
to	gehört	TO	VVFIN		OK/0.997762
a	gehört	DT	VVFIN		OK/0.999777
group	gehört	NN	VVFIN		OK/0.998330
of	gehört	IN	VVFIN		OK/0.998462
medicines	Arzneimitteln	NNS	NN		OK/0.997740
known	bekannt	VVN	VVPP		OK/0.987125
as	als	IN	KOKOM		OK/0.945529
statins	Statine	NNS	NN		OK/0.880690
,	__unaligned__	,	__unaligned__		OK/0.867949
which	__unaligned__	WDT	__unaligned__		OK/0.840012
are	sind	VBP	VAFIN		OK/0.742935
lipid	Blutfette	NN	NN		OK/0.706666
(	(	(	$(		OK/0.978218
fat	Blutfette	JJ	NN		OK/0.906765
)	)	)	$(		OK/0.920897
regulating	__unaligned__	NN	__unaligned__		OK/0.590065
medicines	__unaligned__	NNS	__unaligned__		OK/0.691024
.	.	SENT	$.		OK/0.985052

# 0.301289
Co-	Die	NP	ART		OK/0.763583
administration	gleichzeitige	NN	ADJA		OK/0.676546
in	von	IN	APPR		OK/0.723568
the	von	DT	APPR		OK/0.588320
presence	Nahrungsmitteln	NN	NN		OK/0.448669
of	von	IN	APPR		OK/0.837571
food	Nahrungsmitteln	NN	NN		OK/0.879388
has	keinen	VHZ	PIAT		OK/0.990576
no	keinen	DT	PIAT		OK/0.999543
influence	Einfluss	NN	NN		OK/0.999685
on	Einfluss	IN	NN		OK/0.998563
the	die	DT	ART		OK/0.999756
pharmacokinetics	Pharmakokinetik	NN	NN		OK/0.986907
of	Pharmakokinetik	IN	NN		OK/0.991003
mirtazapine	Mirtazapin	NN	NE		OK/0.948055
.	.	SENT	$.		OK/0.995843

# 0.504245
The	Die	DT	ART		OK/0.993847
hard	Hartkapseln	JJ	NN		OK/0.989810
capsules	Hartkapseln	NNS	NN		OK/0.985085
have	haben	VHP	VAFIN		OK/0.975568
an	opak	DT	ADJD		OK/0.999741
opaque	opak	JJ	ADJD		OK/0.998760
white	weißes	JJ	ADJA		OK/0.997857
body	Unterteil	NN	NN		OK/0.958183
,	,	,	$,		OK/0.994956
an	opak	DT	ADJD		OK/0.991236
opaque	opak	JJ	ADJD		OK/0.983247
guides	grünes	NNS	ADJA		OK/0.901333
,	__unaligned__	,	__unaligned__		OK/0.775861
and	und	CC	KON		OK/0.955724
are	__unaligned__	VBP	__unaligned__		OK/0.950712
imprinted	__unaligned__	VVN	__unaligned__		OK/0.935806
with	mit	IN	APPR		OK/0.895454
black	schwarzer	JJ	ADJA		OK/0.858291
ink	schwarzer	NN	ADJA		OK/0.802277
.	.	SENT	$.		OK/0.998610

# 0.020049
EQUIOXX	EQUIOXX	NP	ADJD		OK/0.986352
is	ist	VBZ	VAFIN		OK/0.990167
available	erhältlich	JJ	ADJD		OK/0.958646
as	erhältlich	IN	ADJD		OK/0.932070
a	__unaligned__	DT	__unaligned__		OK/0.771193
paste	Paste	NN	NN		OK/0.562236
with	mit	IN	APPR		OK/0.878286
a	__unaligned__	DT	__unaligned__		OK/0.970863
special	speziellen	JJ	ADJA		OK/0.979525
syringe	Applikationsspritze	NN	NN		OK/0.921152
,	,	,	$,		OK/0.879946
the	__unaligned__	DT	__unaligned__		OK/0.966686
bottom	__unaligned__	JJ	__unaligned__		OK/0.940234
wall	es	NN	PPER		OK/0.835782
of	die	IN	ART		OK/0.713591
the	die	DT	ART		OK/0.974878
plunger	aufzuziehen	NN	VVIZU		OK/0.872088
to	aufzuziehen	TO	VVIZU		OK/0.920745
draw	aufzuziehen	VV	VVIZU		OK/0.905010
foreseen	vorgesehene	VVN	ADJA		OK/0.841223
medicine	Arzneimittels	NN	NN		OK/0.815350
and	und	CC	KON		OK/0.607191
directly	direkt	RB	ADJD		OK/0.448535
into	direkt	IN	ADJD		OK/0.481893
the	das	DT	ART		OK/0.944829
mouth	Maul	NN	NN		OK/0.723156
in	__unaligned__	IN	__unaligned__		OK/0.607494
horses	Pferdes	NNS	NN		OK/0.485882
including	__unaligned__	VVG	__unaligned__		OK/0.327302
yourself	spritzen	PP	VVINF		OK/0.280492
.	.	SENT	$.		OK/0.989208

# 0.261216
Ceftriaxone	Ceftriaxon	NP	NN		OK/0.990063
is	indiziert	VBZ	VVPP		OK/0.996441
indicated	indiziert	VVN	VVPP		OK/0.982489
for	indiziert	IN	VVPP		OK/0.990202
2025	perioperativen	CD	ADJA		OK/0.832961
in	bei	IN	APPR		OK/0.876739
patients	Patienten	NNS	NN		OK/0.921834
at	Risiko	IN	NN		OK/0.533850
risk	Risiko	NN	NN		OK/0.970997
for	für	IN	APPR		OK/0.628780
severe	schwere	JJ	ADJA		OK/0.730198
post-operative	postoperative	JJ	ADJA		OK/0.936360
infections	Infektionen	NNS	NN		OK/0.990474
(	siehe	(	VVIMP		OK/0.998288
see	siehe	VV	VVIMP		OK/0.995803
section	Abschnitt	NN	NN		OK/0.994512
4.4	4.4	CD	CARD		OK/0.992118
)	)	)	$(		OK/0.991892
.	.	SENT	$.		OK/0.995742

# 0.941883
0.1	0,1	CD	CARD		OK/0.991975
mg	mg	NN	NN		OK/0.999619
meloxicam	Meloxicam	NN	NN		OK/0.993046
/	/	SYM	$(		OK/0.999119
kg	kg	NN	NN		OK/0.990721
body	Körpergewicht	NN	NN		OK/0.992231
weight	Körpergewicht	NN	NN		OK/0.998176
)	)	)	$(		OK/0.976814
.	.	SENT	$.		OK/0.992036

# 0.108047
COX-2	COX-2	NP	NN		OK/0.978761
is	ist	VBZ	VAFIN		OK/0.892118
the	die	DT	ART		OK/0.859158
isoform	Isoform	NN	NN		OK/0.613218
of	des	IN	ART		OK/0.985847
the	des	DT	ART		OK/0.989007
enzyme	Enzyms	NN	NN		OK/0.617703
that	Enzyms	WDT	NN		OK/0.594527
has	__unaligned__	VHZ	__unaligned__		OK/0.599726
been	__unaligned__	VBN	__unaligned__		OK/0.755740
postulated	__unaligned__	VVN	__unaligned__		OK/0.842653
to	__unaligned__	TO	__unaligned__		OK/0.834114
be	soll	VB	VMFIN		OK/0.831117
primarily	primär	RB	ADJD		OK/0.920421
in	die	IN	PRELS		OK/0.872497
the	die	DT	ART		OK/0.985841
synthesis	__unaligned__	NN	__unaligned__		OK/0.907557
of	__unaligned__	IN	__unaligned__		OK/0.939766
prostanoid	prostanoiden	JJ	ADJA		OK/0.606074
mediators	Mediatoren	NNS	NN		OK/0.744122
of	__unaligned__	IN	__unaligned__		OK/0.942688
pain	Schmerz	NN	NN		OK/0.974430
,	,	,	$,		OK/0.982475
inflammation	Entzündung	NN	NN		OK/0.991824
,	,	,	$,		OK/0.975620
and	und	CC	KON		OK/0.999242
fever	Fieber	NN	NN		OK/0.986526
.	.	SENT	$.		OK/0.999332

# 0.188183
Before	Bevor	IN	KOUS		OK/0.994496
you	Sie	PP	PPER		OK/0.998745
start	beginnen	VVP	VVFIN		OK/0.964843
treatment	Therapie	NN	NN		OK/0.999313
with	mit	IN	APPR		OK/0.994392
Xolair	Xolair	NP	NN		OK/0.995561
,	,	,	$,		OK/0.996020
your	Arzt	PP$	NN		OK/0.984233
doctor	Arzt	NN	NN		OK/0.976932
will	Ihr	MD	PPOSAT		OK/0.880435
check	Ihr	VV	PPOSAT		BAD/0.813803
your	Ihr	PP$	PPOSAT		BAD/0.538727
blood	Blutuntersuchung	NN	NN		BAD/0.512321
tests	__unaligned__	NNS	__unaligned__		BAD/0.655926
are	__unaligned__	VBP	__unaligned__		BAD/0.643763
due	durch	JJ	PTKVZ		BAD/0.638557
to	__unaligned__	TO	__unaligned__		OK/0.906407
determine	bestimmen	VV	VVINF		OK/0.962365
the	__unaligned__	DT	__unaligned__		OK/0.988739
amount	die	NN	ART		OK/0.946243
of	__unaligned__	IN	__unaligned__		OK/0.959272
IgE	IgE	NP	NN		OK/0.909381
in	in	IN	APPR		OK/0.984286
your	Ihrem	PP$	PPOSAT		OK/0.962672
blood	Blut	NN	NN		OK/0.966576
.	.	SENT	$.		OK/0.997855

# 0.259115
To	Zum	TO	APPRART		OK/0.995653
help	__unaligned__	VV	__unaligned__		OK/0.974292
protect	Schutz	VV	NN		OK/0.984625
the	__unaligned__	DT	__unaligned__		OK/0.977157
infusion	Infusionsflasche	NN	NN		OK/0.944407
bottle	Infusionsflasche	NN	NN		OK/0.988161
/	/	SYM	$(		OK/0.997164
bag	Infusionsbeutel	NN	NN		OK/0.944627
containing	Infusionsbeutel	VVG	NN		BAD/0.595742
the	Infusionsbeutel	DT	NN		BAD/0.621752
diluted	verdünnten	JJ	ADJA		BAD/0.692602
Infu-	Infu-	NN	TRUNC		BAD/0.748683
sionslösung	sionslösung	NN	NN		BAD/0.784276
in	in	IN	APPR		BAD/0.649909
The	Beutel	DT	NN		BAD/0.750551
Netherlands	__unaligned__	NPS	__unaligned__		BAD/0.744442
.	.	SENT	$.		OK/0.996658

# 0.494017
After	Nachdem	IN	KOUS		OK/0.983534
the	Nachdem	DT	KOUS		OK/0.991603
powder	Pulver	NN	NN		OK/0.971897
has	aufgelöst	VHZ	VVPP		OK/0.794222
dissolved	aufgelöst	VVN	VVPP		OK/0.730980
,	,	,	$,		OK/0.776139
draw	ziehen	VV	VVFIN		OK/0.786789
the	die	DT	ART		OK/0.981473
solution	Lösung	NN	NN		OK/0.997873
back	wieder	RB	ADV		OK/0.832335
into	Spritze	IN	NN		OK/0.961743
the	Spritze	DT	NN		OK/0.997817
syringe	Spritze	NN	NN		OK/0.992748
.	.	SENT	$.		OK/0.999744

# 0.794796
containing	Schnappdeckel	VVG	NN		OK/0.952234
75	75	CD	CARD		OK/0.998825
mg	mg	NN	NN		OK/0.997415
13C-urea	13C-Harnstoff	JJ	NN		OK/0.982392
powder	Pulver	NN	NN		OK/0.999485
for	Pulver	IN	NN		OK/0.999173
oral	Lösung	JJ	NN		OK/0.997654
solution	__unaligned__	NN	__unaligned__		OK/0.997644
Einnehmeng	Einnehmeng	NP	NE		OK/0.968978
breath	Atembeutel	NN	NN		OK/0.945743
bags	Atembeutel	NNS	NN		OK/0.883041
:	:	:	$.		OK/0.980027

# 0.324652
•	•	NN	NN		OK/0.995246
The	Die	DT	ART		OK/0.973063
Setup	Pens	NN	NN		BAD/0.606235
will	nun	MD	ADV		BAD/0.626722
be	__unaligned__	VB	__unaligned__		BAD/0.651427
completed	abgeschlossen	VVN	VVPP		BAD/0.463993
.	.	SENT	$.		OK/0.998637

# 0.220291
Lansoprazol-ratiopharm	Lansoprazol-ratiopharm	NP	NN		OK/0.821188
30	30	CD	CARD		OK/0.993762
mg	mg	NN	NN		OK/0.998435
is	ist	VBZ	VAFIN		OK/0.998581
available	Packungen	JJ	NN		OK/0.996213
in	Packungen	IN	NN		OK/0.994694
packs	Packungen	NNS	NN		OK/0.983829
of	Packungen	IN	NN		OK/0.987803
7	7	CD	CARD		OK/0.995027
,	,	,	$,		OK/0.999047
14	14	CD	CARD		OK/0.998788
,	,	,	$,		OK/0.997768
28	28	CD	CARD		OK/0.999432
,	__unaligned__	,	__unaligned__		OK/0.998351
56	56	CD	CARD		OK/0.999728
or	und	CC	KON		OK/0.994086
98	98	CD	CARD		OK/0.979375
capsules	Kapseln	NNS	NN		OK/0.721388
(	__unaligned__	(	__unaligned__		OK/0.425636
201	magensaftresistenten	CD	ADJA		OK/0.453301
)	__unaligned__	)	__unaligned__		OK/0.404244
.	.	SENT	$.		OK/0.939023

# 0.783557
In	Bei	IN	APPR		OK/0.991641
paediatric	pädiatrischen	JJ	ADJA		OK/0.996860
patients	Patienten	NNS	NN		OK/0.990052
,	,	,	$,		OK/0.951967
similar	ähnliche	JJ	ADJA		OK/0.946598
histamine-mediated	histamininduzierte	JJ	ADJA		OK/0.941784
symptoms	Symptome	NNS	NN		OK/0.986077
have	berichtet	VHP	VVPP		OK/0.942151
been	berichtet	VBN	VVPP		OK/0.960443
reported	berichtet	VVN	VVPP		OK/0.989727
in	bei	IN	APPR		OK/0.999651
adult	erwachsenen	JJ	ADJA		OK/0.976537
patients	Patienten	NNS	NN		OK/0.973096
.	.	SENT	$.		OK/0.999663

# 0.363915
60	60	CD	CARD		OK/0.978384
You	werden	PP	VAFIN		OK/0.984951
will	__unaligned__	MD	__unaligned__		OK/0.963696
be	gebeten	VB	VVPP		OK/0.982075
asked	gebeten	VVN	VVPP		OK/0.981366
to	gebeten	TO	VVPP		OK/0.918775
a	eine	DT	ART		OK/0.746156
13Kohlenstoff-Harnstoff-Trinklösung	13Kohlenstoff-Harnstoff-Trinklösung	JJ	NN		OK/0.485576
einzuneh-	einzuneh-	NN	VVIZU		OK/0.463252
.	.	SENT	$.		OK/0.993516

# 0.069921
There	Es	RB	NN		OK/0.654682
are	sind	VBP	VAFIN		OK/0.657435
limited	begrenzt	JJ	ADJD		OK/0.986959
data	Daten	NNS	NN		OK/0.994444
on	Daten	IN	NN		OK/0.967659
pharmacokinetics	Pharmakokinetik	NNS	NN		OK/0.961052
,	,	,	$,		OK/0.995606
safety	Unbedenklichkeit	NN	NN		OK/0.806038
and	Unbedenklichkeit	CC	NN		OK/0.964261
efficacy	Unbedenklichkeit	NN	NN		OK/0.979840
of	Wirksamkeit	IN	NN		OK/0.996001
the	von	DT	APPR		OK/0.996950
use	Anwendung	NN	NN		OK/0.990930
of	von	IN	APPR		OK/0.965033
IONSYS	IONSYS	NP	NN		OK/0.956841
in	bei	IN	APPR		OK/0.978765
patients	Patienten	NNS	NN		OK/0.987076
>	>	SYM	$(		OK/0.450254
75	75	CD	CARD		OK/0.715962
years	Jahre	NNS	NN		OK/0.666413
of	__unaligned__	IN	__unaligned__		BAD/0.743718
age	__unaligned__	NN	__unaligned__		BAD/0.756409
is	verfügbar	VBZ	ADJD		BAD/0.967108
available	verfügbar	JJ	ADJD		BAD/0.760536
.	.	SENT	$.		OK/0.991854

# 0.822064
Lansoprazole	Lansoprazol	NP	NN		OK/0.984081
is	wird	VBZ	VAFIN		OK/0.972623
not	nicht	RB	PTKNEG		OK/0.985504
eliminated	eliminiert	VVN	VVPP		OK/0.904187
in	in	IN	APPR		OK/0.948183
relevant	relevantem	JJ	ADJA		OK/0.989172
extent	relevantem	NN	ADJA		OK/0.982867
by	durch	IN	APPR		OK/0.971193
haemodialysis	Hämodialyse	NN	NN		OK/0.991702
.	.	SENT	$.		OK/0.999030

# 0.691537
Compatibility	Verträglichkeit	NP	NN		OK/0.853620
with	mit	IN	APPR		OK/0.952841
Ohrreinigern	Ohrreinigern	NP	NN		OK/0.861831
(	(	(	$(		OK/0.970368
solutions	Lösungen	NNS	NN		OK/0.988286
)	)	)	$(		OK/0.990279
has	wurde	VHZ	VAFIN		OK/0.984738
not	nicht	RB	PTKNEG		OK/0.974763
been	wurde	VBN	VAFIN		OK/0.980916
established	nachgewiesen	VVN	VVPP		OK/0.964628
.	.	SENT	$.		OK/0.997404

# 0.696434
The	Die	DT	ART		OK/0.997336
active	Wirkstoffe	JJ	NN		OK/0.992165
substances	Wirkstoffe	NNS	NN		OK/0.996307
in	in	IN	APPR		OK/0.993842
Icandra	Icandra	NP	NE		OK/0.977709
belong	gehören	VVP	VVFIN		OK/0.827102
to	Gruppe	TO	NN		OK/0.816683
a	einer	DT	ART		OK/0.985601
group	Gruppe	NN	NN		OK/0.996180
of	einer	IN	ART		OK/0.998264
medicines	Arzneimitteln	NNS	NN		OK/0.996736
called	genannt	VVD	VVPP		OK/0.994480
"	"	``	$(		OK/0.997641
oral	Antidiabetika	JJ	NN		OK/0.986908
antidiabetics	Antidiabetika	NNS	NN		OK/0.966467
.	.	SENT	$.		OK/0.999305
"	"	''	$(		OK/0.974484

# 0.660462
Using	Bei	VVG	APPR		OK/0.970411
EVRA	EVRA	NP	NN		OK/0.936496
with	Nahrungsmitteln	IN	NN		OK/0.952696
food	Nahrungsmitteln	NN	NN		OK/0.954008
and	und	CC	KON		OK/0.958261
drink	Getränken	VVP	NN		OK/0.953810
It	Es	PP	PPER		OK/0.995820
is	Es	VBZ	PPER		OK/0.998628
not	nicht	RB	PTKNEG		OK/0.977890
expected	erwarten	VVN	VVINF		OK/0.994585
that	dass	IN/that	KOUS		OK/0.991316
food	Getränke	NN	NN		OK/0.931451
or	oder	CC	KON		OK/0.977529
drink	Getränke	VV	NN		OK/0.938839
the	die	DT	ART		OK/0.998662
mechanism	Wirkungsweise	NN	NN		OK/0.985932
of	Wirkungsweise	IN	NN		OK/0.996984
action	Wirkungsweise	NN	NN		OK/0.998523
of	von	IN	APPR		OK/0.958307
EVRA	EVRA	NP	NN		OK/0.952152
.	.	SENT	$.		OK/0.999330

# 0.080141
-	-	:	$(		OK/0.988548
such	wie	JJ	KOKOM		OK/0.978420
as	wie	IN	KOKOM		OK/0.942293
age	alt	NN	ADJD		BAD/0.416324
you	Sie	PP	PPER		BAD/0.758332
.	.	SENT	$.		BAD/0.910429
−	-	NN	$(		OK/0.388424
if	ob	IN	KOUS		OK/0.384159
you	Sie	PP	PPER		OK/0.560696
take	Sie	VVP	PPER		OK/0.797609
Lamictal	Lamictal	NP	NN		OK/0.968006
with	anderen	IN	PIS		OK/0.990112
other	anderen	JJ	PIS		OK/0.989033
medicines	Arzneimitteln	NNS	NN		OK/0.932479
.	.	SENT	$.		OK/0.983080

# 0.066175
Cases	Fälle	NNS	NN		OK/0.997784
of	Fälle	IN	NN		OK/0.997881
transmission	Übertragung	NN	NN		OK/0.983856
of	__unaligned__	IN	__unaligned__		OK/0.977057
vaccine	Impfvirus	NN	NN		OK/0.995936
virus	__unaligned__	NN	__unaligned__		OK/0.941911
,	__unaligned__	,	__unaligned__		OK/0.404817
this	dieses	DT	PDAT		OK/0.357499
water	ausgeschiedenen	NN	ADJA		OK/0.409555
to	auf	TO	APPR		OK/0.420328
seronegative	seronegative	JJ	ADJA		OK/0.473621
contacts	Kontaktpersonen	NNS	NN		OK/0.492832
have	wurden	VHP	VAFIN		OK/0.665896
been	wurden	VBN	VAFIN		OK/0.761269
observed	beobachtet	VVN	VVPP		OK/0.823236
,	jedoch	,	ADV		OK/0.704823
but	jedoch	CC	ADV		OK/0.446234
without	ohne	IN	APPR		OK/0.862671
clinical	klinische	JJ	ADJA		OK/0.903128
symptoms	Symptome	NNS	NN		OK/0.829616
.	.	SENT	$.		OK/0.998609

# 0.925070
Patients	Patienten	NPS	NN		OK/0.993428
with	mit	IN	APPR		OK/0.984003
normal	normaler	JJ	ADJA		OK/0.968732
renal	Nierenfunktion	JJ	NN		OK/0.970839
function	Nierenfunktion	NN	NN		OK/0.982420
:	:	:	$.		OK/0.991206

# 0.138583
The	In	DT	APPR		OK/0.953691
dose	Dosis	NN	NN		OK/0.988844
and	und	CC	KON		OK/0.995943
frequency	wie	NN	KOKOM		OK/0.984844
of	__unaligned__	IN	__unaligned__		OK/0.994624
administration	__unaligned__	NN	__unaligned__		OK/0.946169
of	__unaligned__	IN	__unaligned__		OK/0.870922
Puregon	Puregon	NP	NN		OK/0.891797
,	,	,	$,		OK/0.869752
depends	hängt	VVZ	VVFIN		OK/0.981864
on	hängt	IN	VVFIN		OK/0.979002
how	hängt	WRB	VVFIN		BAD/0.574777
the	vom	DT	APPRART		BAD/0.582158
indication	Anwendungszweck	NN	NN		BAD/0.682610
(	siehe	(	VVIMP		OK/0.932806
see	siehe	VV	VVIMP		OK/0.996174
above	oben	IN	ADV		OK/0.991557
)	)	)	$(		OK/0.989970
and	sowie	CC	KON		OK/0.744536
the	vom	DT	APPRART		OK/0.707456
patient	__unaligned__	NN	__unaligned__		OK/0.717765
'	__unaligned__	POS	__unaligned__		BAD/0.857284
s	__unaligned__	JJ	__unaligned__		BAD/0.864135
response	Ansprechen	NN	NN		OK/0.996819
to	Ansprechen	TO	NN		OK/0.999478
treatment	Ansprechen	NN	NN		OK/0.987040
.	.	SENT	$.		OK/0.999531

# 0.441514
suggest	auf	VVP	APPR		OK/0.953308
a	__unaligned__	DT	__unaligned__		OK/0.994220
possible	mögliche	JJ	ADJA		OK/0.971032
symptoms	Symptome	NNS	NN		OK/0.984041
may	sein	MD	VAINF		OK/0.631958
be	sein	VB	VAINF		OK/0.678979
prepared	vorbereitet	VVN	VVPP		OK/0.581672
.	.	SENT	$.		OK/0.994646

# 0.611376
The	Die	DT	ART		OK/0.999051
efficacy	Wirksamkeit	NN	NN		OK/0.995554
of	Behandlung	IN	NN		OK/0.989889
treatment	Behandlung	NN	NN		OK/0.996886
with	mit	IN	APPR		OK/0.996707
Xolair	Xolair	NP	NN		OK/0.984745
in	Kombination	IN	NN		OK/0.968747
combination	Kombination	NN	NN		OK/0.988014
with	mit	IN	APPR		OK/0.985873
specific	spezifischer	JJ	ADJA		OK/0.813709
aims	Immuntherapie	NNS	NN		OK/0.722784
has	wurde	VHZ	VAFIN		OK/0.924346
not	nicht	RB	PTKNEG		OK/0.949170
been	wurde	VBN	VAFIN		OK/0.973357
established	nachgewiesen	VVN	VVPP		OK/0.961018
.	.	SENT	$.		OK/0.997257

# 0.313079
In	Im	IN	APPRART		OK/0.889333
the	Im	DT	APPRART		OK/0.815525
rat	Ratten	NN	NN		OK/0.788638
bone	Knochenmark	NN	NN		OK/0.978905
marrow	Knochenmark	NN	NN		OK/0.998103
has	wurde	VHZ	VAFIN		OK/0.996238
been	wurde	VBN	VAFIN		OK/0.995601
observed	beobachtet	VVN	VVPP		OK/0.985228
in	bei	IN	APPR		OK/0.996471
all	allen	DT	PIAT		OK/0.997189
doses	Dosierungen	NNS	NN		OK/0.697989
tested	getesteten	VVD	ADJA		OK/0.627307
,	__unaligned__	,	__unaligned__		OK/0.611915
myelofibrosis	Myelofibrose	NN	NN		OK/0.573151
.	.	SENT	$.		OK/0.994150

# 0.826540
Ciprofloxacin	Ciprofloxacin	NP	NE		OK/0.996384
may	kann	MD	VMFIN		OK/0.991782
worsen	verschlechtern	VV	VVINF		OK/0.980138
the	die	DT	ART		OK/0.996121
symptoms	Symptome	NNS	NN		OK/0.988577
of	die	IN	ART		OK/0.857202
this	dieser	DT	PDAT		OK/0.990097
disease	Krankheit	NN	NN		OK/0.996687
.	.	SENT	$.		OK/0.998848

# 0.399465
2	Weitere	CD	ADJA		OK/0.530425
/	Weitere	SYM	ADJA		OK/0.528776
3	Weitere	CD	ADJA		OK/0.544740
Other	Weitere	JJ	ADJA		OK/0.966384
information	Informationen	NN	NN		OK/0.999018
about	Informationen	IN	NN		OK/0.999528
TRISENOX	TRISENOX	NP	NE		OK/0.990656
:	:	:	$.		OK/0.996188

# 0.954597
Tell	Informieren	VV	NN		OK/0.986004
your	Arzt	PP$	NN		OK/0.997962
doctor	Ihren	NN	PPOSAT		OK/0.999409
if	ob	IN	KOUS		OK/0.997020
you	Sie	PP	PPER		OK/0.999512
are	schwanger	VBP	ADJD		OK/0.999576
pregnant	schwanger	JJ	ADJD		OK/0.997381
or	oder	CC	KON		OK/0.999298
breast-feeding	stillen	VVG	VVINF		OK/0.977059
.	.	SENT	$.		OK/0.999002

# 0.315821
What	Was	WP	PIS		OK/0.987007
GANFORT	GANFORT	NP	NN		OK/0.947072
is	__unaligned__	VBZ	__unaligned__		OK/0.949963
and	und	CC	KON		OK/0.999906
what	wofür	WP	PWAV		OK/0.998484
it	wofür	PP	PWAV		OK/0.989069
is	wofür	VBZ	PWAV		OK/0.989325
used	wofür	VVN	PWAV		OK/0.998965
for	wofür	IN	PWAV		OK/0.998243
2	wofür	CD	PWAV		OK/0.361165
.	ist	SENT	VAFIN		OK/0.658811

# 0.105856
The	Dem	DT	ART		BAD/0.555528
pen	Injektor	NN	NN		BAD/0.799000
is	ist	VBZ	VAFIN		BAD/0.866050
a	eine	DT	ART		BAD/0.843091
manual	Bedienungsanleitung	NN	NN		BAD/0.869356
to	__unaligned__	TO	__unaligned__		BAD/0.811391
instruct	beigelegt	VV	VVPP		BAD/0.793105
patients	Patienten	NNS	NN		OK/0.963857
to	korrekten	TO	ADJA		OK/0.991211
achieve	korrekten	VV	ADJA		OK/0.974128
the	korrekten	DT	ADJA		OK/0.949521
desired	korrekten	VVN	ADJA		OK/0.631105
on	erläutert	IN	VVFIN		OK/0.395644
how	__unaligned__	WRB	__unaligned__		OK/0.445709
to	__unaligned__	TO	__unaligned__		OK/0.463280
use	Gebrauch	VV	NN		OK/0.864962
.	.	SENT	$.		OK/0.995409

# 0.894005
Protein	Proteinbindung	NP	NN		OK/0.960431
binding	Proteinbindung	NN	NN		OK/0.979674
has	wurde	VHZ	VAFIN		OK/0.977264
not	nicht	RB	PTKNEG		OK/0.997554
been	nicht	VBN	PTKNEG		OK/0.962812
determined	bestimmt	VVN	VVPP		OK/0.983408
.	.	SENT	$.		OK/0.999870

# 0.048868
Non-clinical	Nichtklinische	JJ	NN		OK/0.485545
data	Daten	NNS	NN		OK/0.790891
are	Daten	VBP	NN		OK/0.773137
based	basierend	VVN	ADJD		OK/0.964856
on	__unaligned__	IN	__unaligned__		OK/0.933644
conventional	üblichen	JJ	ADJA		OK/0.951883
studies	Studien	NNS	NN		OK/0.972393
of	__unaligned__	IN	__unaligned__		OK/0.896325
safety	Sicherheit	NN	NN		OK/0.954982
,	,	,	$,		OK/0.812680
pharmacology	Pharmakologie	NN	NN		OK/0.939946
,	,	,	$,		OK/0.995496
repeated	wiederholter	JJ	ADJA		OK/0.988256
dose	__unaligned__	NN	__unaligned__		OK/0.951627
toxicity	Toxizität	NN	NN		OK/0.965620
,	,	,	$,		OK/0.939729
genotoxicity	Gentoxizität	NN	NN		OK/0.931136
,	,	,	$,		OK/0.922741
carcinogenic	Kanzerogenität	JJ	NN		OK/0.976794
potential	Kanzerogenität	NN	NN		OK/0.985958
and	und	CC	KON		OK/0.984902
toxicity	Reproduktionstoxizität	NN	NN		OK/0.997780
to	Reproduktionstoxizität	TO	NN		OK/0.949430
reproduction	Reproduktionstoxizität	NN	NN		OK/0.941324
show	zeigen	VV	VVFIN		OK/0.940660
no	keine	DT	PIAT		OK/0.991053
special	besonderen	JJ	ADJA		OK/0.670176
hazard	Menschen	NN	NN		OK/0.522206
for	__unaligned__	IN	__unaligned__		OK/0.618675
humans	__unaligned__	NNS	__unaligned__		OK/0.481591
was	__unaligned__	VBD	__unaligned__		BAD/0.841024
observed	__unaligned__	VVN	__unaligned__		BAD/0.899842
.	.	SENT	$.		OK/0.975983

# 0.477107
Any	verwendetes	DT	ADJA		OK/0.998137
unused	verwendetes	JJ	ADJA		OK/0.999421
product	verwendetes	NN	ADJA		OK/0.996865
or	verwendetes	CC	ADJA		OK/0.889732
waste	verwendetes	NN	ADJA		OK/0.912486
material	verwendetes	NN	ADJA		OK/0.883720
or	oder	CC	KON		BAD/0.768324
Waste	Abfallmaterial	NN	NN		BAD/0.731351
materials	Abfallmaterial	NNS	NN		BAD/0.725905
should	Abfallmaterial	MD	NN		OK/0.995170
be	Abfallmaterial	VB	NN		OK/0.999820
disposed	Abfallmaterial	VVN	NN		OK/0.998624
of	__unaligned__	IN	__unaligned__		OK/0.997728
in	__unaligned__	IN	__unaligned__		OK/0.994611
accordance	nationalen	NN	ADJA		OK/0.998514
with	nationalen	IN	ADJA		OK/0.999068
national	nationalen	JJ	ADJA		OK/0.997504
requirements	Anforderungen	NNS	NN		OK/0.996776
.	.	SENT	$.		OK/0.999305

# 0.832995
Do	dürfen	VVP	VMFIN		OK/0.970993
not	dürfen	RB	VMFIN		OK/0.989797
use	dürfen	VV	VMFIN		OK/0.998098
after	angegebenen	IN	ADJA		OK/0.998827
the	Verfallsdatum	DT	NN		OK/0.998969
expiry	anwenden	NN	VVINF		OK/0.996182
date	Verfallsdatum	NN	NN		OK/0.999288
which	Verfallsdatum	WDT	NN		OK/0.995030
is	Verfallsdatum	VBZ	NN		OK/0.995917
stated	Verfallsdatum	VVN	NN		OK/0.879979
on	Verfallsdatum	IN	NN		OK/0.992125
the	Umkarton	DT	NN		OK/0.999373
carton	Umkarton	NN	NN		OK/0.995098
.	.	SENT	$.		OK/0.999697

# 0.159413
The	Das	DT	ART		OK/0.995026
mean	mittlere	JJ	ADJA		OK/0.997318
volume	Verteilungsvolumen	NN	NN		OK/0.992756
of	Verteilungsvolumen	IN	NN		OK/0.991731
distribution	Verteilungsvolumen	NN	NN		OK/0.968338
at	Steady	IN	NN		OK/0.996945
steady	Steady	JJ	NN		OK/0.994456
state	State	NN	NN		OK/0.936206
for	__unaligned__	IN	__unaligned__		BAD/0.699287
vardenafil	Vardenafil	NN	NE		BAD/0.929756
is	__unaligned__	VBZ	__unaligned__		BAD/0.838714
208	208	CD	CARD		BAD/0.494789
l	l	NN	NN		BAD/0.474373
,	was	,	PRELS		OK/0.874802
indicating	was	VVG	PRELS		OK/0.946961
distribution	Verteilung	NN	NN		OK/0.916539
into	Verteilung	IN	NN		OK/0.968227
the	in	DT	APPR		OK/0.962737
tissues	Verteilung	NNS	NN		OK/0.880614
.	.	SENT	$.		OK/0.999292

# 0.740549
You	Sie	PP	PPER		OK/0.974601
can	können	MD	VMFIN		OK/0.970346
take	__unaligned__	VV	__unaligned__		OK/0.909522
[	[	SYM	$(		OK/0.989152
Invented	Phantasiebezeichnung	JJ	NN		OK/0.998142
name	Phantasiebezeichnung	NN	NN		OK/0.999842
]	Phantasiebezeichnung	SYM	NN		OK/0.990747
with	Mahlzeiten	IN	NN		OK/0.982956
or	Mahlzeiten	CC	NN		OK/0.994303
without	Mahlzeiten	IN	NN		OK/0.884420
food	Mahlzeiten	NN	NN		OK/0.908735
.	.	SENT	$.		OK/0.997510

# 0.985327
How	Wie	NP	KOKOM		OK/0.992939
is	wird	VBZ	VAFIN		OK/0.996075
Luveris	Luveris	NP	NE		OK/0.999469
for	aufbewahrt	IN	VVPP		OK/0.996834
?	?	SENT	$.		OK/0.998978

# 0.099857
Based	Aufgrund	VVN	APPR		OK/0.929849
on	Aufgrund	IN	APPR		OK/0.976091
the	der	DT	ART		OK/0.998932
pharmacokinetics	Pharmakokinetik	NNS	NN		OK/0.931937
and	die	CC	ART		OK/0.509903
the	die	DT	ART		OK/0.946081
terminal	terminale	JJ	ADJA		OK/0.957654
half-life	Halbwertszeit	NN	NN		OK/0.983182
may	kann	MD	VMFIN		OK/0.983479
not	nicht	RB	PTKNEG		OK/0.981382
be	werden	VB	VAINF		OK/0.976495
predictive	__unaligned__	JJ	__unaligned__		OK/0.972905
from	der	IN	ART		OK/0.965521
the	der	DT	ART		OK/0.861928
group	__unaligned__	NN	__unaligned__		OK/0.733995
consisting	__unaligned__	VVG	__unaligned__		BAD/0.906244
of	__unaligned__	IN	__unaligned__		BAD/0.715388
accumulation	Kumulation	NN	NN		BAD/0.656104
and	bzw.	CC	KON		BAD/0.376054
elimination	Elimination	NN	NN		OK/0.998037
of	__unaligned__	IN	__unaligned__		OK/0.997560
voriconazole	Voriconazol	NN	NN		OK/0.997991
.	.	SENT	$.		OK/0.999465

# 0.687221
The	Die	DT	ART		OK/0.996354
bioavailability	Bioverfügbarkeit	NN	NN		OK/0.996751
of	__unaligned__	IN	__unaligned__		OK/0.979597
subcutaneous	subkutan	JJ	ADJD		OK/0.873964
injectable	injiziertem	JJ	ADJA		OK/0.948060
erythropoietin	Erythropoetin	NN	NN		OK/0.985067
is	beträgt	VBZ	VVFIN		OK/0.902938
approximately	ca.	RB	ADV		OK/0.965153
20	20	CD	CARD		OK/0.998820
%	%	NN	NN		OK/0.997917
of	__unaligned__	IN	__unaligned__		OK/0.930440
an	intravenösen	DT	ADJA		OK/0.968331
intravenous	intravenösen	JJ	ADJA		OK/0.990803
dose	Gabe	NN	NN		OK/0.973400
.	.	SENT	$.		OK/0.999800

# 0.913114
Renal	Nierenfunktion	NP	NN		OK/0.949719
impairment	Beeinträchtigung	NN	NN		OK/0.933524
:	:	:	$.		OK/0.998967

# 0.242804
medicines	Arzneimittel	NNS	NN		OK/0.977132
that	Arzneimittel	IN/that	NN		OK/0.944158
you	Sie	PP	PPER		OK/0.951651
are	einnehmen	VBP	VVINF		OK/0.608943
taking	einnehmen	VVG	VVINF		OK/0.579092
at	__unaligned__	IN	__unaligned__		OK/0.411066
the	__unaligned__	DT	__unaligned__		OK/0.460494
same	__unaligned__	JJ	__unaligned__		OK/0.533412
time	__unaligned__	NN	__unaligned__		OK/0.566212
.	.	SENT	$.		OK/0.998275

# 0.228827
Don	Brechen	NP	NN		OK/0.971483
'	Brechen	POS	NN		BAD/0.701701
t	Brechen	NN	NN		BAD/0.622942
stop	Brechen	NN	NN		OK/0.762949
of	__unaligned__	IN	__unaligned__		OK/0.975951
the	den	DT	ART		OK/0.976894
cap	__unaligned__	NN	__unaligned__		OK/0.948317
and	und	CC	KON		OK/0.964107
discard	verwerfen	VV	VVFIN		OK/0.964203
the	Spritze	DT	NN		OK/0.997918
syringe	Spritze	NN	NN		OK/0.998174
and	und	CC	KON		OK/0.999426
needle	Nadel	NN	NN		OK/0.983895
(	(	(	$(		OK/0.988138
setting	bereiten	VVG	VVFIN		OK/0.786961
for	für	IN	APPR		OK/0.910726
a	neue	DT	ADJA		OK/0.959484
new	neue	JJ	ADJA		OK/0.983396
dose	Dosis	NN	NN		OK/0.992224
)	)	)	$(		OK/0.952423
.	.	SENT	$.		OK/0.995671

# 0.295390
The	Die	DT	ART		OK/0.998139
efficacy	Wirksamkeit	NN	NN		OK/0.996979
and	und	CC	KON		OK/0.992468
safety	Unbedenklichkeit	NN	NN		OK/0.975335
of	von	IN	APPR		OK/0.993192
Rapinyl	Rapinyl	NP	NN		OK/0.996574
has	wurde	VHZ	VAFIN		OK/0.995926
been	wurde	VBN	VAFIN		OK/0.999316
studied	untersucht	VVN	VVPP		OK/0.996254
in	bei	IN	APPR		OK/0.984920
patients	Patienten	NNS	NN		OK/0.985784
receiving	Patienten	VVG	NN		OK/0.831053
the	__unaligned__	DT	__unaligned__		OK/0.924797
medicine	Arzneimittel	NN	NN		OK/0.935665
at	Beginn	IN	NN		OK/0.991085
the	der	DT	ART		OK/0.999056
start	Beginn	NN	NN		OK/0.904917
of	der	IN	ART		OK/0.987073
the	der	DT	ART		OK/0.956607
episode	Durchbruchschmerzepisode	NN	NN		OK/0.733860
of	__unaligned__	IN	__unaligned__		OK/0.903249
breakthrough	Durchbruchschmerzepisode	NN	NN		OK/0.989348
pain	Durchbruchschmerzepisode	NN	NN		OK/0.965497
in	anwendeten	IN	VVFIN		BAD/0.762473
patients	__unaligned__	NNS	__unaligned__		BAD/0.659229
.	.	SENT	$.		OK/0.997269

# 0.540668
10	10	CD	CARD		OK/0.994757
/	/	SYM	$(		OK/0.998503
19	19	CD	CARD		OK/0.970173
Accidental	versehentliche	JJ	ADJA		OK/0.924815
injection	Injektion	NN	NN		OK/0.966474
is	gefährlich	VBZ	ADJD		OK/0.964428
dangerous	gefährlich	JJ	ADJD		OK/0.911016
-	-	:	$(		OK/0.946479
see	lesen	VV	VVFIN		OK/0.679117
package	Packungsbeilage	NN	NN		OK/0.937780
insert	__unaligned__	NN	__unaligned__		OK/0.969874
before	vor	IN	APPR		OK/0.983938
use	Anwendung	NN	NN		OK/0.953759
.	.	SENT	$.		OK/0.998960

# 0.212070
As	Als	IN	KOKOM		OK/0.984136
a	Als	DT	KOKOM		OK/0.994095
result	Ergebnis	NN	NN		OK/0.971837
is	wichtiges	VBZ	ADJA		OK/0.876175
shown	zeigte	VVN	VVFIN		OK/0.845957
a	__unaligned__	DT	__unaligned__		OK/0.941326
27.7	27,7	CD	CARD		OK/0.968257
%	%	NN	NN		OK/0.998292
of	__unaligned__	IN	__unaligned__		OK/0.997309
patients	Patienten	NNS	NN		OK/0.997656
and	auch	CC	ADV		OK/0.845886
major	zytogenetische	JJ	ADJA		OK/0.934960
cytogenetic	zytogenetische	JJ	ADJA		OK/0.986776
response	Remission	NN	NN		OK/0.927688
in	bei	IN	APPR		OK/0.959135
20.4	20,4	CD	CARD		OK/0.864506
%	%	NN	NN		OK/0.858199
(	(	(	$(		OK/0.939519
confirmed	bestätigt	VVD	ADJD		OK/0.949755
16	16	CD	CARD		OK/0.998984
%	%	NN	NN		OK/0.997938
)	)	)	$(		OK/0.997401
of	der	IN	ART		OK/0.974546
the	der	DT	ART		OK/0.939223
patients	Patienten	NNS	NN		OK/0.646524
was	war	VBD	VAFIN		BAD/0.811596
complete	komplett	JJ	ADJD		BAD/0.892174
.	.	SENT	$.		OK/0.995818

# 0.934827
What	Welchen	WP	PIAT		OK/0.998472
benefit	Welchen	VVP	PIAT		OK/0.963394
has	Nutzen	VHZ	NN		OK/0.999658
Silgard	Silgard	NP	NE		OK/0.997142
shown	__unaligned__	VVN	__unaligned__		OK/0.996247
during	in	IN	APPR		OK/0.991243
the	__unaligned__	DT	__unaligned__		OK/0.985790
studies	Studien	NNS	NN		OK/0.996980
?	?	SENT	$.		OK/0.998519

# 0.595680
Starlix	Starlix	NP	NN		OK/0.995616
is	wird	VBZ	VAFIN		OK/0.995446
used	angewendet	VVN	VVPP		OK/0.989950
in	in	IN	APPR		OK/0.998822
combination	in	NN	APPR		OK/0.986611
with	mit	IN	APPR		OK/0.999751
metformin	Metformin	NN	NE		OK/0.984689
(	(	(	$(		OK/0.977448
another	anderen	DT	PIAT		OK/0.968353
antidiabetes	Antidiabetikum	NNS	NN		OK/0.883820
medicine	Antidiabetikum	NN	NN		OK/0.894693
)	)	)	$(		OK/0.992336
to	__unaligned__	TO	__unaligned__		OK/0.921054
lower	Blutglukose	JJR	NN		OK/0.929991
blood	Blutglukose	NN	NN		OK/0.967098
glucose	Blutglukose	NN	NN		OK/0.960530
(	(	(	$(		OK/0.996611
sugar	Blutzuckerspiegels	NN	NN		OK/0.980814
)	)	)	$(		OK/0.995784
in	bei	IN	APPR		OK/0.994441
patients	Patienten	NNS	NN		OK/0.999221
whose	deren	WP$	PRELAT		OK/0.997071
diabetes	Diabetes	NN	NN		OK/0.990730
cannot	nicht	MD	PTKNEG		OK/0.993122
be	kann	VB	VMFIN		OK/0.980619
controlled	durch	VVN	APPR		OK/0.967748
by	durch	IN	APPR		OK/0.974653
metformin	Metformin	NN	NE		OK/0.942787
alone	allein	RB	ADV		OK/0.987573
.	.	SENT	$.		OK/0.999212

# 0.640891
Protopic	Protopic	NP	NE		OK/0.994220
contains	enthält	VVZ	VVFIN		OK/0.987426
the	als	DT	KOKOM		OK/0.770385
active	Wirkstoff	JJ	NN		OK/0.814696
substance	Wirkstoff	NN	NN		OK/0.848539
tacrolimus	Tacrolimus	NN	NE		OK/0.974800
,	,	,	$,		OK/0.994722
a	Calcineurin-Inhibitor	DT	NN		OK/0.965677
calcineurin	Calcineurin-Inhibitor	NN	NN		OK/0.953122
inhibitor	Calcineurin-Inhibitor	NN	NN		OK/0.966001
.	.	SENT	$.		OK/0.999057

# 0.863270
If	Wenn	IN	KOUS		OK/0.998411
you	Sie	PP	PPER		OK/0.998152
forget	Einnahme	VVP	NN		OK/0.985718
to	vergessen	TO	VVINF		OK/0.981109
take	vergessen	VV	VVINF		OK/0.998330
ZYPREXA	ZYPREXA	NP	NE		OK/0.995726
Take	Nehmen	VV	VVFIN		OK/0.989827
your	Ihre	PP$	PPOSAT		OK/0.999601
tablets	Tabletten	NNS	NN		OK/0.979280
as	__unaligned__	RB	__unaligned__		OK/0.952585
soon	sobald	RB	KOUS		OK/0.969498
as	__unaligned__	IN	__unaligned__		OK/0.986908
you	Sie	PP	PPER		OK/0.987735
remember	erinnern	VVP	VVINF		OK/0.983068
.	.	SENT	$.		OK/0.999852

# 0.710741
Each	Zonegran-Hartkapsel	DT	NN		OK/0.959415
Zonegran	Zonegran-Hartkapsel	NP	NN		OK/0.906756
hard	Zonegran-Hartkapsel	JJ	NN		OK/0.955020
capsule	Zonegran-Hartkapsel	NN	NN		OK/0.975968
contains	Zonegran-Hartkapsel	VVZ	NN		OK/0.996123
100	100	CD	CARD		OK/0.999545
mg	mg	NN	NN		OK/0.995184
of	__unaligned__	IN	__unaligned__		OK/0.938681
zonisamide	Zonisamid	NN	NN		OK/0.826627
.	.	SENT	$.		OK/0.997327

# 0.275890
These	Diese	DT	PDAT		OK/0.708915
data	Daten	NNS	NN		OK/0.907251
do	__unaligned__	VVP	__unaligned__		OK/0.811993
not	keine	RB	PIAT		OK/0.866255
,	jedoch	,	ADV		OK/0.846994
however	jedoch	RB	ADV		OK/0.814624
,	jedoch	,	ADV		OK/0.968483
recommendations	Empfehlungen	NNS	NN		OK/0.974230
for	für	IN	APPR		OK/0.964534
storage	Aufbewahrung	NN	NN		OK/0.544197
.	.	SENT	$.		OK/0.997057

# 0.529387
Preparations	Lithiumhaltige	NNS	NN		OK/0.941345
containing	Lithiumhaltige	VVG	NN		OK/0.961884
lithium	Lithiumhaltige	NN	NN		OK/0.977300
should	sollten	MD	VMFIN		OK/0.963434
not	nicht	RB	PTKNEG		OK/0.995813
be	sollten	VB	VMFIN		OK/0.987275
taken	eingenommen	VVN	VVPP		OK/0.832291
in	Kombination	IN	NN		OK/0.991358
combination	Kombination	NN	NN		OK/0.982206
with	mit	IN	APPR		OK/0.996467
losartan	Losartan	NN	NE		OK/0.982969
without	ohne	IN	APPR		OK/0.981613
close	enge	JJ	ADJA		OK/0.919067
supervision	ärztliche	NN	ADJA		OK/0.889766
by	__unaligned__	IN	__unaligned__		OK/0.908159
your	__unaligned__	PP$	__unaligned__		OK/0.881235
doctor	__unaligned__	NN	__unaligned__		OK/0.864729
.	.	SENT	$.		OK/0.995745

# 0.833613
197	197	CD	CARD		OK/0.981231
through	Glucosegehalt	IN	NN		OK/0.898079
Ciprofloxacin	Ciprofloxacin	NP	NE		OK/0.998980
Bayer	Bayer	NP	NE		OK/0.998869
solution	Infusionslösung	NN	NN		OK/0.999383
for	Infusionslösung	IN	NN		OK/0.997131
infusion	Infusionslösung	NN	NN		OK/0.997388
contains	enthält	VVZ	VVFIN		OK/0.992406
5	5	CD	CARD		OK/0.995436
g	g	NN	NN		OK/0.999385
of	__unaligned__	IN	__unaligned__		OK/0.994141
glucose	Glucose	NN	NN		OK/0.997848
per	Glucose	IN	NN		OK/0.991417
100	100	CD	CARD		OK/0.999503
ml	ml	NN	NN		OK/0.999531
solution	Infusionslösung	NN	NN		OK/0.992812
for	Infusionslösung	IN	NN		OK/0.977269
infusion	Infusionslösung	NN	NN		OK/0.987966
.	.	SENT	$.		OK/0.999016

# 0.434929
What	Wie	WP	KOKOM		OK/0.975304
ABILIFY	ABILIFY	NP	NE		OK/0.992725
looks	aussieht	VVZ	VVFIN		OK/0.996837
like	aussieht	IN	VVFIN		OK/0.995837
and	und	CC	KON		OK/0.999018
contents	Inhalt	NNS	NN		OK/0.999328
of	Inhalt	IN	NN		OK/0.990913
the	Packung	DT	NN		OK/0.988329
pack	Packung	NN	NN		OK/0.834242
ABILIFY	ABILIFY	NP	NE		OK/0.890930
30	30	CD	CARD		OK/0.994682
mg	mg	NN	NN		OK/0.999143
orodispersible	Schmelztabletten	JJ	NN		OK/0.963046
tablets	Schmelztabletten	NNS	NN		OK/0.966044
are	rund	VBP	ADV		OK/0.941566
round	rund	JJ	ADV		OK/0.954185
and	und	CC	KON		OK/0.997062
pink	rosafarben	JJ	ADJD		OK/0.990348
,	,	,	$,		OK/0.995708
marked	rosafarben	VVN	ADJD		OK/0.983240
with	mit	IN	APPR		OK/0.997346
"	"	``	$(		OK/0.989613
A	A	NP	FM		OK/0.923320
"	"	''	$(		OK/0.953119
over	über	IN	APPR		OK/0.956916
"	"	``	$(		OK/0.979372
643	643	CD	CARD		OK/0.862109
"	"	''	$(		OK/0.986968
on	Seite	IN	NN		OK/0.981886
one	Seite	CD	NN		OK/0.996315
side	Seite	NN	NN		OK/0.997481
and	und	CC	KON		OK/0.999179
"	"	``	$(		OK/0.996581
30	30	CD	CARD		OK/0.986065
"	"	''	$(		OK/0.951095
on	auf	IN	APPR		OK/0.954626
the	auf	DT	APPR		OK/0.936625
other	anderen	JJ	PIS		OK/0.949859
.	.	SENT	$.		OK/0.998878

# 0.056805
Patients	Patienten	NPS	NN		OK/0.996319
receiving	,	VVG	$,		OK/0.954441
immunosuppressive	unter	JJ	APPR		OK/0.953887
regimens	__unaligned__	NNS	__unaligned__		OK/0.979470
involving	__unaligned__	VVG	__unaligned__		OK/0.989511
combinations	__unaligned__	NNS	__unaligned__		OK/0.994941
of	dieser	IN	PDAT		OK/0.966695
these	dieser	DT	PDAT		OK/0.972197
rare	seltenen	JJ	ADJA		OK/0.873087
illness	Erkrankung	NN	NN		BAD/0.748785
,	,	,	$,		BAD/0.754516
are	sind	VBP	VAFIN		BAD/0.697223
not	nicht	RB	PTKNEG		OK/0.828681
able	in	JJ	APPR		BAD/0.595766
to	__unaligned__	TO	__unaligned__		BAD/0.657457
eliminate	zu	VV	PTKZU		BAD/0.955114
Stickstoffabbaustoffe	Stickstoffabbaustoffe	NP	NN		BAD/0.970441
,	,	,	$,		BAD/0.972287
or	wenn	CC	KOUS		BAD/0.956302
has	anreichern	VHZ	VVINF		BAD/0.975330
an	__unaligned__	DT	__unaligned__		BAD/0.962057
affinity	__unaligned__	NN	__unaligned__		BAD/0.838023
for	__unaligned__	IN	__unaligned__		BAD/0.647123
proteins	Proteine	NNS	NN		OK/0.728273
.	.	SENT	$.		OK/0.992312

# 0.341869
ingredients	Bestandteile	NNS	NN		OK/0.974542
of	__unaligned__	IN	__unaligned__		OK/0.989465
the	__unaligned__	DT	__unaligned__		OK/0.986939
capsule	Kapselinhalts	NN	NN		OK/0.966831
contents	Kapselinhalts	NNS	NN		OK/0.974667
:	:	:	$.		OK/0.999673
microcrystalline	Mikrokristalline	JJ	ADJA		OK/0.989816
cellulose	Mikrokristalline	NN	ADJA		OK/0.968613
,	,	,	$,		OK/0.990999
pregelatinised	Maisquellstärke	JJ	NN		OK/0.912863
starch	Maisquellstärke	NN	NN		OK/0.841185
,	,	,	$,		OK/0.907854
silicon	Maisquellstärke	NN	NN		OK/0.868277
dioxide	Maisquellstärke	NN	NN		OK/0.907870
,	Maisquellstärke	,	NN		OK/0.944373
sodium	Natriumdodecylsulfat	NN	NN		OK/0.980635
lauryl	Natriumdodecylsulfat	NN	NN		OK/0.988479
sulphate	Natriumdodecylsulfat	NN	NN		OK/0.989380
,	,	,	$,		OK/0.991761
magnesium	Magnesiumstearat	NN	NN		OK/0.980647
stearate	Magnesiumstearat	NN	NN		OK/0.998243
,	__unaligned__	,	__unaligned__		OK/0.979603
lactose	Lactose-Monohydrat	NN	NE		OK/0.998851
monohydrate	Lactose-Monohydrat	NN	NE		OK/0.990438
,	,	,	$,		OK/0.989156
indigo	Indigokarmin	JJ	NE		OK/0.854983
carmine	Indigokarmin	NN	NE		OK/0.808556
(	(	(	$(		OK/0.962087
E132	E132	NP	NE		OK/0.882501
)	)	)	$(		OK/0.990062
,	,	,	$,		OK/0.995408
titanium	E171	NN	NE		OK/0.893726
dioxide	E171	NN	NE		OK/0.931335
(	E171	(	NE		OK/0.938696
E171	E171	NP	NE		OK/0.994802
)	)	)	$(		OK/0.973871
.	.	SENT	$.		OK/0.999381

# 0.207038
Reproduction	Reproduction	NP	NN		OK/0.992931
is	is	VBZ	ADJA		OK/0.998464
authorised	authorised	VVN	NN		OK/0.992124
provided	provided	VVD	NE		OK/0.991493
the	the	DT	FM		OK/0.997494
source	source	NN	NN		OK/0.998232
is	is	VBZ	ADJA		OK/0.999342
acknowledged	acknowledged.	VVN	NN		OK/0.998540
attaches	bindet	VVZ	VVFIN		OK/0.944750
,	,	,	$,		OK/0.928355
irbesartan	Irbesartan	NN	NE		OK/0.974108
stops	Hormons	VVZ	NN		OK/0.744513
the	__unaligned__	DT	__unaligned__		OK/0.973552
hormone	__unaligned__	NN	__unaligned__		OK/0.965209
having	__unaligned__	VHG	__unaligned__		OK/0.966426
an	__unaligned__	DT	__unaligned__		OK/0.521237
effect	Wirkung	NN	NN		OK/0.974886
,	,	,	$,		OK/0.867113
allowing	__unaligned__	VVG	__unaligned__		OK/0.784293
the	__unaligned__	DT	__unaligned__		OK/0.981251
blood	__unaligned__	NN	__unaligned__		OK/0.991769
vessels	__unaligned__	NNS	__unaligned__		OK/0.961805
to	__unaligned__	TO	__unaligned__		OK/0.918332
widen	erweitern	VV	VVINF		OK/0.800781
.	.	SENT	$.		OK/0.997096

# 0.241133
Do	Nicht	VVP	PTKNEG		OK/0.971626
not	Nicht	RB	PTKNEG		OK/0.987186
shake	heftig	VV	ADJD		OK/0.991170
the	heftig	DT	ADJD		OK/0.998450
vial	heftig	NN	ADJD		OK/0.972911
vigorously	heftig	RB	ADJD		OK/0.883198
as	da	IN	KOUS		OK/0.986253
this	dies	DT	PDS		OK/0.977333
could	__unaligned__	MD	__unaligned__		OK/0.981861
cause	führen	VV	VVINF		OK/0.674115
froth	Schaumbildung	NN	NN		OK/0.677478
to	führen	TO	VVINF		OK/0.728033
form	__unaligned__	VV	__unaligned__		BAD/0.641370
.	.	SENT	$.		OK/0.989138

# 0.089674
7	7	CD	CARD		OK/0.982755
/	/	SYM	$(		OK/0.995454
35	35	CD	CARD		OK/0.993009
The	Der	NP	ART		OK/0.995574
Committee	Ausschuss	NP	NN		OK/0.967641
for	Ausschuss	IN	NN		OK/0.936646
Medicinal	Ausschuss	NP	NN		OK/0.933890
Products	Ausschuss	NPS	NN		OK/0.943357
for	Ausschuss	IN	NN		OK/0.934172
Veterinary	Tierarzneimittel	NP	NN		OK/0.948308
Use	Tierarzneimittel	NP	NN		OK/0.597222
)	hat	)	VAFIN		BAD/0.801483
reduce	__unaligned__	VV	__unaligned__		BAD/0.476943
the	von	DT	APPR		OK/0.955581
absorption	von	NN	APPR		OK/0.974698
of	von	IN	APPR		OK/0.998613
mineral	Mineralöl	NN	NN		OK/0.955839
oil	Mineralöl	NN	NN		OK/0.949988
in	in	IN	APPR		OK/0.997485
Annex	Anhang	NP	NN		OK/0.989198
II	II	NP	CARD		OK/0.986164
of	der	IN	ART		OK/0.995555
Council	Verordnung	NP	NN		OK/0.981906
Regulation	Verordnung	NP	NN		OK/0.988254
(	(	(	$(		OK/0.998612
EEC	EWG	NP	NE		OK/0.989367
)	)	)	$(		OK/0.994609
No	2377	NP	CARD		OK/0.991022
2377	2377	CD	CARD		OK/0.989998
/	/	SYM	$(		OK/0.998248
90	90	CD	CARD		OK/0.989770
in	folgender	IN	ADJA		OK/0.829754
accordance	folgender	NN	ADJA		OK/0.799893
with	folgender	IN	ADJA		OK/0.860729
the	folgender	DT	ADJA		OK/0.925233
following	folgender	VVG	ADJA		OK/0.891180
table	Tabelle	NN	NN		OK/0.950921
are	empfohlen	VBP	VVPP		OK/0.953444
as	__unaligned__	RB	__unaligned__		OK/0.926904
follows	__unaligned__	VVZ	__unaligned__		OK/0.895158
:	:	:	$.		OK/0.995733

# 0.195505
Dafür	Dafür	NP	PAV		OK/0.680147
the	die	DT	ART		OK/0.718813
required	benötigte	VVN	ADJA		OK/0.534083
Produktmenge	Produktmenge	NN	NN		BAD/0.956456
a	einem	DT	ART		BAD/0.934141
parts	Futterbestandteil	NNS	NN		BAD/0.714030
is	wird	VBZ	VAFIN		BAD/0.783936
similar	ähnlicher	JJ	ADJA		BAD/0.841528
appearance	Beschaffenheit	NN	NN		BAD/0.622939
(	(	(	$(		OK/0.996458
e.	z.B.	FW	ADV		OK/0.987392
g	z.B.	NN	ADV		OK/0.987281
.	z.B.	SENT	ADV		OK/0.980670

# 0.313365
Again	Achten	NP	VVFIN		OK/0.651346
,	,	,	$,		OK/0.702866
NOT	NICHT	NP	PTKNEG		OK/0.598315
touching	berühren	VVG	VVINF		OK/0.640862
the	berühren	DT	VVINF		OK/0.964538
needle	berühren	NN	VVINF		OK/0.984015
and	und	CC	KON		OK/0.987590
it	sie	PP	PPER		OK/0.934806
to	__unaligned__	TO	__unaligned__		OK/0.805152
touch	anderen	VV	PIS		OK/0.931176
any	__unaligned__	DT	__unaligned__		OK/0.920472
surface	__unaligned__	NN	__unaligned__		OK/0.876330
.	.	SENT	$.		OK/0.997351

# 0.416405
Opaque	Opake	NP	NN		BAD/0.469486
blisters	Blisterpackungen	NNS	NN		BAD/0.595308
(	(	(	$(		OK/0.991998
PVC	PVC	NP	NE		OK/0.998043
/	/	SYM	$(		OK/0.999785
PE	PE	NN	NE		OK/0.993441
/	/	SYM	$(		OK/0.999210
PVDC	PVDC	NN	NN		OK/0.995406
and	und	CC	KON		OK/0.999254
aluminum	__unaligned__	NN	__unaligned__		OK/0.976331
)	)	)	$(		OK/0.992132
.	.	SENT	$.		OK/0.997726

# 0.360843
-	-	:	$(		OK/0.991862
Autoimmune	Autoimmunhepatitis	NP	NN		OK/0.953399
hepatitis	Autoimmunhepatitis	NP	NN		OK/0.976172
or	oder	CC	KON		OK/0.989866
a	Vorgeschichte	DT	NN		OK/0.891203
history	Vorgeschichte	NN	NN		OK/0.948523
of	Vorgeschichte	IN	NN		OK/0.892055
autoimmune	__unaligned__	JJ	__unaligned__		OK/0.637858
disease	__unaligned__	NN	__unaligned__		OK/0.442538
.	.	SENT	$.		OK/0.984979

# 0.881615
After	Nach	IN	APPR		OK/0.960280
reconstitution	Rekonstitution	NN	NN		OK/0.957488
,	__unaligned__	,	__unaligned__		OK/0.972612
1	1	CD	CARD		OK/0.997083
ml	ml	NN	NN		OK/0.999441
of	Lösung	IN	NN		OK/0.993542
solution	Lösung	NN	NN		OK/0.999155
contains	enthält	VVZ	VVFIN		OK/0.998389
10	10	CD	CARD		OK/0.994042
mg	mg	NN	NN		OK/0.994212
of	__unaligned__	IN	__unaligned__		OK/0.985399
tigecycline	Tigecyclin	NN	NN		OK/0.982737
.	.	SENT	$.		OK/0.999269

# 0.130071
Do	Nicht	VVP	PTKNEG		OK/0.801265
not	Nicht	RB	PTKNEG		OK/0.540534
use	__unaligned__	VV	__unaligned__		OK/0.484240
the	__unaligned__	DT	__unaligned__		OK/0.535015
cursor	gelöstes	NN	ADJA		OK/0.522604
material	verwendetes	NN	ADJA		OK/0.658355
,	,	,	$,		OK/0.729190
empty	leere	JJ	ADJA		OK/0.927492
vials	Glasfläschchen	NNS	NN		OK/0.942942
and	und	CC	KON		OK/0.995707
needles	Nadeln	NNS	NN		OK/0.961014
or	oder	CC	KON		OK/0.977357
Einwegsprit-	Einwegsprit-	NN	TRUNC		OK/0.864550
your	zen	PP$	ADJA		OK/0.906333
should	entsorgen	MD	VVINF		OK/0.882613
be	entsorgen	VB	VVINF		OK/0.918738
disposed	entsorgen	VVN	VVINF		OK/0.951469
of	entsorgen	IN	VVINF		OK/0.700296
properly	ordnungsgemäß	RB	ADJD		OK/0.623556
.	.	SENT	$.		OK/0.999288

# 0.356122
Pull	Ziehen	VV	NN		OK/0.972431
the	den	DT	ART		OK/0.999699
needle	Nadelschutz	NN	NN		OK/0.997654
guard	Nadelschutz	NN	NN		OK/0.990880
from	__unaligned__	IN	__unaligned__		OK/0.981209
the	__unaligned__	DT	__unaligned__		OK/0.993965
syringe	__unaligned__	NN	__unaligned__		OK/0.508189
needle	__unaligned__	NN	__unaligned__		OK/0.642082
and	und	CC	KON		OK/0.961455
check	kontrollieren	NN	VVFIN		OK/0.892360
for	__unaligned__	IN	__unaligned__		OK/0.832001
air	Luftblasen	NN	NN		OK/0.985870
bubbles	Luftblasen	NNS	NN		OK/0.978142
in	in	IN	APPR		OK/0.954430
the	Spritze	DT	NN		OK/0.997202
syringe	Spritze	NN	NN		OK/0.989260
.	.	SENT	$.		OK/0.999718

# 0.130426
Let	Lassen	VVD	NN		BAD/0.837084
not	nicht	RB	PTKNEG		BAD/0.452194
Verwandte	Verwandte	NP	NN		BAD/0.564642
to	__unaligned__	TO	__unaligned__		BAD/0.728129
consider	Freunde	VV	NN		BAD/0.902847
asking	Freunde	VVG	NN		BAD/0.847287
a	__unaligned__	DT	__unaligned__		BAD/0.820796
family	__unaligned__	NN	__unaligned__		BAD/0.781630
member	__unaligned__	NN	__unaligned__		BAD/0.812335
or	oder	CC	KON		OK/0.860088
the	das	DT	ART		OK/0.847895
IONSYS-Gerät	IONSYS-Gerät	NP	NN		OK/0.559209
may	auslösen	MD	VVINF		OK/0.624722
cause	auslösen	VV	VVINF		OK/0.804945
for	für	IN	APPR		OK/0.991348
you	Sie	PP	PPER		OK/0.993493
.	.	SENT	$.		OK/0.994420

# 0.053337
Renal	Niereninsuffizienz	NP	NN		OK/0.993919
impairment	Niereninsuffizienz	NN	NN		OK/0.994431
The	Die	DT	ART		OK/0.999829
pharmacokinetics	Pharmakokinetik	NN	NN		OK/0.991874
of	Pharmakokinetik	IN	NN		OK/0.998816
sitagliptin	Sitagliptin	NN	NN		OK/0.999262
was	wurde	VBD	VAFIN		OK/0.992138
assessed	__unaligned__	VVN	__unaligned__		OK/0.933705
in	in	IN	APPR		OK/0.982343
a	in	DT	APPR		OK/0.744836
open-label	offenen	NN	ADJA		OK/0.637771
study	Studie	NN	NN		OK/0.953374
with	mit	IN	APPR		OK/0.993230
a	reduzierten	DT	ADJA		OK/0.990109
reduced	reduzierten	VVN	ADJA		OK/0.972740
dose	Einzeldosis	NN	NN		OK/0.952942
of	__unaligned__	IN	__unaligned__		OK/0.953380
sitagliptin	Sitagliptin	NN	NN		OK/0.983338
(	(	(	$(		OK/0.995220
50	50	CD	CARD		OK/0.999415
mg	mg	NN	NN		OK/0.999606
)	)	)	$(		OK/0.988512
studied	untersucht	VVN	VVPP		OK/0.879637
,	__unaligned__	,	__unaligned__		OK/0.583493
patients	Patienten	NNS	NN		OK/0.982733
were	wurden	VBD	VAFIN		OK/0.975578
treated	Patienten	VVN	NN		OK/0.935269
in	in	IN	APPR		OK/0.995817
various	verschiedenen	JJ	ADJA		OK/0.885597
stages	Stadien	NNS	NN		OK/0.769703
of	Stadien	IN	NN		OK/0.783210
ALS	Stadien	NN	NN		OK/0.660001
with	mit	IN	APPR		OK/0.875762
varying	__unaligned__	VVG	__unaligned__		OK/0.859044
degrees	__unaligned__	NNS	__unaligned__		OK/0.937623
of	__unaligned__	IN	__unaligned__		OK/0.950359
chronic	chronischen	JJ	ADJA		OK/0.917445
renal	Niereninsuffizienz	JJ	NN		OK/0.663137
insufficiency	Niereninsuffizienz	NN	NN		OK/0.763194
compared	verglichen	VVN	VVPP		OK/0.841723
to	verglichen	TO	VVPP		OK/0.837967
normal	gesunden	JJ	ADJA		OK/0.849368
healthy	gesunden	JJ	ADJA		OK/0.824544
control	Kontrolle	NN	NN		OK/0.694228
subjects	__unaligned__	NNS	__unaligned__		OK/0.679347
.	.	SENT	$.		OK/0.987270

# 0.595669
For	Die	IN	ART		OK/0.990397
a	__unaligned__	DT	__unaligned__		OK/0.995548
full	vollständige	JJ	ADJA		OK/0.997470
list	Auflistung	NN	NN		OK/0.997708
of	Auflistung	IN	NN		OK/0.999370
the	vollständige	DT	ADJA		OK/0.979587
side-effects	__unaligned__	NNS	__unaligned__		OK/0.930965
reported	berichteten	VVD	ADJA		OK/0.911175
with	mit	IN	APPR		OK/0.916949
side	Nebenwirkungen	NN	NN		OK/0.771705
effects	Nebenwirkungen	NNS	NN		OK/0.875935
of	__unaligned__	IN	__unaligned__		OK/0.847265
PROCOMVAX	PROCOMVAX	NP	NN		OK/0.978101
,	__unaligned__	,	__unaligned__		OK/0.986866
see	entnehmen	VVP	VVINF		OK/0.999868
the	entnehmen	DT	VVINF		OK/0.999567
Package	entnehmen	NP	VVINF		OK/0.999109
Leaflet	entnehmen	NP	VVINF		OK/0.955857
.	.	SENT	$.		OK/0.999849

# 0.552818
250	250	CD	CARD		OK/0.992176
mg	mg	NN	NN		OK/0.985965
)	)	)	$(		OK/0.703727
and	und	CC	KON		OK/0.940107
as	als	IN	KOKOM		OK/0.947369
a	als	DT	KOKOM		OK/0.982197
powder	Pulver	NN	NN		OK/0.999545
for	Infusionslösung	IN	NN		OK/0.996801
solution	Infusionslösung	NN	NN		OK/0.977747
for	Infusionslösung	IN	NN		OK/0.910665
infusion	Infusionslösung	NN	NN		OK/0.874432
(	(	(	$(		OK/0.993953
drip	Tropfinfusion	NN	NN		OK/0.988191
into	Vene	IN	NN		OK/0.998133
a	Vene	DT	NN		OK/0.999991
vein	Vene	NN	NN		OK/0.999353
)	)	)	$(		OK/0.989154
.	.	SENT	$.		OK/0.997577

# 0.771242
CYSTAGON	CYSTAGON	NP	NN		OK/0.912340
has	__unaligned__	VHZ	__unaligned__		OK/0.955725
minor	geringen	JJ	ADJA		OK/0.993689
or	mäßigen	CC	ADJA		OK/0.998309
moderate	mäßigen	JJ	ADJA		OK/0.999258
influence	Einfluss	NN	NN		OK/0.999156
on	Einfluss	IN	NN		OK/0.992629
the	die	DT	ART		OK/0.999087
ability	Fähigkeit	NN	NN		OK/0.998037
to	Fähigkeit	TO	NN		OK/0.997175
drive	Maschinen	VV	NN		OK/0.993932
and	Maschinen	CC	NN		OK/0.977718
use	Maschinen	VV	NN		OK/0.988050
machines	Bedienen	NNS	NN		OK/0.994844
CYSTAGON	CYSTAGON	NP	NN		OK/0.945863
may	kann	MD	VMFIN		OK/0.987343
cause	führen	VV	VVINF		OK/0.992852
drowsiness	Schläfrigkeit	NN	NN		OK/0.961284
.	.	SENT	$.		OK/0.997066

# 0.520210
Keep	Die	NP	ART		OK/0.525411
the	__unaligned__	DT	__unaligned__		OK/0.908265
bottle	Flasche	NN	NN		OK/0.990924
.	.	SENT	$.		OK/0.997821

# 0.861856
Read	Lesen	NP	VVFIN		OK/0.991059
all	Lesen	RB	VVFIN		OK/0.993698
of	__unaligned__	IN	__unaligned__		OK/0.994480
this	__unaligned__	DT	__unaligned__		OK/0.974177
leaflet	__unaligned__	NN	__unaligned__		OK/0.880885
.	.	SENT	$.		OK/0.998927

# 0.975404
Ziagen	Ziagen	NP	NN		OK/0.997507
is	ist	VBZ	VAFIN		OK/0.999331
a	ist	DT	VAFIN		OK/0.998439
medicine	Arzneimittel	NN	NN		OK/0.999803
that	Arzneimittel	WDT	NN		OK/0.993961
contains	enthält	VVZ	VVFIN		OK/0.997094
the	den	DT	ART		OK/0.996281
active	Wirkstoff	JJ	NN		OK/0.998590
substance	Wirkstoff	NN	NN		OK/0.996137
abacavir	Abacavir	NN	NN		OK/0.996324
.	.	SENT	$.		OK/0.999983

# 0.738077
Stoffwechselprofil	Stoffwechselprofil	NP	NN		OK/0.804502
tipranavir	Tipranavir	NP	NN		OK/0.785464
:	:	:	$.		OK/0.980023

# 0.415718
Put	Verschließen	VVD	VVFIN		OK/0.812966
the	die	DT	ART		OK/0.995575
bottle	Flasche	NN	NN		OK/0.939401
cap	Flasche	NN	NN		OK/0.958201
back	wieder	RB	ADV		OK/0.709118
on	fest	IN	PTKVZ		OK/0.596559
firmly	fest	RB	PTKVZ		OK/0.673167
.	.	SENT	$.		OK/0.988656

# 0.131965
For	Für	IN	APPR		OK/0.988925
Zometa	Zometa	NP	NE		OK/0.987163
,	__unaligned__	,	__unaligned__		OK/0.931793
the	der	DT	ART		OK/0.941113
Schmerz-Score	Schmerz-Score	NP	NN		OK/0.553670
was	lag	VBD	VVFIN		OK/0.591215
consistently	durchweg	RB	ADV		OK/0.559635
and	und	CC	KON		OK/0.860164
the	die	DT	ART		OK/0.952522
Schmerzverminderung	Schmerzverminderung	NP	NN		OK/0.785061
to	tendenziell	TO	ADJD		OK/0.757015
was	wurde	VBD	VAFIN		OK/0.846343
accompanied	begleitet	VVN	VVPP		OK/0.970391
by	begleitet	IN	VVPP		OK/0.985259
a	__unaligned__	DT	__unaligned__		OK/0.990260
reduction	Reduktion	NN	NN		OK/0.993622
in	Reduktion	IN	NN		OK/0.885911
the	__unaligned__	DT	__unaligned__		OK/0.552712
Schmerzmittel-Scores	Schmerzmittel-Scores	NP	NN		OK/0.536434
.	.	SENT	$.		OK/0.993973

# 0.280564
3	3	CD	CARD		OK/0.997208
weeks	Wochen	NNS	NN		OK/0.999517
after	nach	IN	APPR		OK/0.991430
the	letzten	DT	ADJA		OK/0.954020
last	letzten	JJ	ADJA		OK/0.846022
injection	Injektion	NN	NN		OK/0.768375
has	__unaligned__	VHZ	__unaligned__		BAD/0.774375
been	__unaligned__	VBN	__unaligned__		BAD/0.513325
given	__unaligned__	VVN	__unaligned__		BAD/0.498314
.	.	SENT	$.		OK/0.990085

# 0.215829
Although	Obwohl	IN	KOUS		OK/0.989247
the	die	DT	ART		OK/0.993833
majority	Mehrheit	NN	NN		OK/0.977383
of	Mehrheit	IN	NN		OK/0.956916
patients	Patienten	NNS	NN		OK/0.917793
in	Patienten	IN	NN		OK/0.597183
the	__unaligned__	DT	__unaligned__		OK/0.542534
placebo	Placebogruppe	NN	NN		OK/0.537323
group	Placebogruppe	NN	NN		OK/0.576975
was	Placebogruppe	VBD	NN		OK/0.574228
treated	behandelt	VVN	VVPP		OK/0.932888
with	mit	IN	APPR		OK/0.998731
Betaferon	Betaferon	NP	NN		OK/0.996481
,	__unaligned__	,	__unaligned__		OK/0.881667
there	__unaligned__	EX	__unaligned__		OK/0.940864
was	konnte	VBD	VMFIN		OK/0.982560
no	__unaligned__	DT	__unaligned__		OK/0.946845
prolonged	anhaltender	JJ	ADJA		OK/0.939096
treatment	Behandlungseffekt	NN	NN		OK/0.968030
effect	Behandlungseffekt	NN	NN		OK/0.986613
observed	beobachtet	VVD	VVPP		OK/0.951131
in	im	IN	APPRART		OK/0.998473
the	im	DT	APPRART		OK/0.985420
third	dritten	JJ	ADJA		OK/0.928522
year	Jahr	NN	NN		OK/0.961940
of	der	IN	ART		OK/0.996162
the	der	DT	ART		OK/0.984180
study	Studie	NN	NN		OK/0.987558
.	.	SENT	$.		OK/0.998945

# 0.368423
Shelf	Haltbarkeit	NP	NN		OK/0.992725
life	Haltbarkeit	NN	NN		OK/0.997419
of	des	IN	ART		OK/0.996567
the	des	DT	ART		OK/0.991099
veterinary	Tierarzneimittels	JJ	NN		OK/0.966249
medicinal	Tierarzneimittels	JJ	NN		OK/0.980050
product	Tierarzneimittels	NN	NN		OK/0.979358
as	Verkaufsverpackung	IN	NN		OK/0.904451
packaged	Verkaufsverpackung	VVN	NN		OK/0.986423
for	Verkaufsverpackung	IN	NN		OK/0.955663
sale	Verkaufsverpackung	NN	NN		OK/0.618128
as	unversehrten	IN	ADJA		BAD/0.871075
packaged	unversehrten	VVN	ADJA		BAD/0.975496
for	unversehrten	IN	ADJA		BAD/0.968839
sale	unversehrten	NN	ADJA		BAD/0.908606
:	:	:	$.		OK/0.972198

# 0.952785
Once	Nach	RB	APPR		OK/0.979226
opened	Öffnen	VVD	NN		OK/0.999008
,	Öffnen	,	NN		OK/0.999705
use	Öffnen	NN	NN		OK/0.984967
within	innerhalb	IN	APPR		OK/0.997796
35	35	CD	CARD		OK/0.992613
days	Tagen	NNS	NN		OK/0.997214
.	.	SENT	$.		OK/0.999088

# 0.025262
7	7	CD	CARD		OK/0.973642
the	letzten	DT	ADJA		OK/0.979061
last	letzten	JJ	ADJA		OK/0.972209
30	30	CD	CARD		OK/0.972842
days	Tage	NNS	NN		OK/0.967266
prior	vor	RB	APPR		OK/0.965142
to	vor	TO	APPR		OK/0.945205
study	Studienbeginn	NN	NN		OK/0.703324
entry	Studienbeginn	NN	NN		BAD/0.659961
was	war	VBD	VAFIN		BAD/0.620094
in	__unaligned__	IN	__unaligned__		BAD/0.865379
both	beide	DT	PIAT		OK/0.619968
treatment	Behandlungsgruppen	NN	NN		OK/0.647424
groups	Behandlungsgruppen	NNS	NN		OK/0.733963
with	mit	IN	APPR		OK/0.701651
a	__unaligned__	DT	__unaligned__		OK/0.553179
numerically	numerisch	RB	ADJD		OK/0.539078
higher	numerisch	JJR	ADJD		OK/0.715013
rate	numerisch	NN	ADJD		BAD/0.652470
among	numerisch	IN	ADJD		BAD/0.657307
associated	höheren	VVN	ADJA		OK/0.928285
with	höheren	IN	ADJA		OK/0.850087
a	höheren	DT	ADJA		OK/0.989571
higher	höheren	JJR	ADJA		OK/0.997175
risk	Risiko	NN	NN		OK/0.996094
of	Risiko	IN	NN		OK/0.982925
serious	schwerwiegende	JJ	ADJA		OK/0.991492
bleeding	Blutungsereignisse	NN	NN		OK/0.984323
events	Blutungsereignisse	NNS	NN		OK/0.943738
(	(	(	$(		OK/0.965998
Xigris	Xigris	NP	NE		OK/0.935477
:	:	:	$.		OK/0.978153

# 0.482621
Co-administration	gleichzeitige	NP	ADJA		OK/0.995865
of	gleichzeitige	IN	ADJA		OK/0.960304
ketoconazole	Ketoconazol	NN	NN		OK/0.881444
(	(	(	$(		OK/0.995246
200	200	CD	CARD		OK/0.998198
mg	mg	NN	NN		OK/0.993029
)	)	)	$(		OK/0.996950
,	,	,	$,		OK/0.996201
a	starken	DT	ADJA		OK/0.944581
potent	starken	JJ	ADJA		OK/0.969500
CYP3A4	CYP3A4-Inhibitor	NP	NN		OK/0.953768
inhibitor	CYP3A4-Inhibitor	NN	NN		OK/0.993064
,	__unaligned__	,	__unaligned__		OK/0.980125
with	mit	IN	APPR		OK/0.989301
vardenafil	Vardenafil	NN	NE		OK/0.982070
(	(	(	$(		OK/0.993866
5	5	CD	CARD		OK/0.999070
mg	mg	NN	NN		OK/0.998871
)	)	)	$(		OK/0.997462
resulted	bewirkte	VVN	VVFIN		OK/0.956495
in	eine	IN	ART		OK/0.959135
a	eine	DT	ART		OK/0.964327
10	10-fache	CD	ADJA		OK/0.965827
times	__unaligned__	NNS	__unaligned__		OK/0.986687
increase	Steigerung	NN	NN		OK/0.993665
in	Steigerung	IN	NN		OK/0.966664
vardenafil	Vardenafil-AUC	NP	NE		OK/0.895269
AUC	Vardenafil-AUC	NP	NE		OK/0.972209
and	und	CC	KON		OK/0.994335
a	eine	DT	ART		OK/0.994941
4-fold	4-fache	JJ	ADJA		OK/0.984226
increase	Steigerung	NN	NN		OK/0.994740
in	Steigerung	IN	NN		OK/0.961460
Cmax	Vardenafil-Cmax	NP	NN		OK/0.873765
(	siehe	(	VVIMP		OK/0.995646
see	siehe	VV	VVIMP		OK/0.997931
section	Abschnitt	NN	NN		OK/0.994832
4.4	4.4	CD	CARD		OK/0.992181
)	)	)	$(		OK/0.991904
.	.	SENT	$.		OK/0.995743

# 0.028068
Behandelt	Behandelt	NP	NN		OK/0.543279
may	können	MD	VMFIN		OK/0.593668
be	können	VB	VMFIN		OK/0.619017
infections	Infektionen	NNS	NN		OK/0.940131
such	wie	JJ	KOKOM		OK/0.947128
as	wie	IN	KOKOM		OK/0.958400
impetigo	Impetigo	NN	NN		OK/0.871202
(	(	(	$(		OK/0.987450
a	(	DT	$(		OK/0.989519
bacterial	bakterielle	JJ	ADJA		OK/0.959193
skin	Hautinfektion	NN	NN		OK/0.920885
,	,	,	$,		OK/0.958524
which	__unaligned__	WDT	__unaligned__		OK/0.815414
may	einhergeht	MD	VVFIN		OK/0.735215
be	__unaligned__	VB	__unaligned__		OK/0.825316
associated	__unaligned__	VVN	__unaligned__		OK/0.743962
with	mit	IN	APPR		OK/0.912439
oozing	Krustenbildung	VVG	NN		OK/0.666689
of	__unaligned__	IN	__unaligned__		OK/0.716685
the	den	DT	ART		OK/0.945936
infected	infizierten	VVN	ADJA		OK/0.921665
clean	Hautflächen	JJ	NN		OK/0.904609
)	)	)	$(		OK/0.977276
,	,	,	$,		OK/0.825532
as	sowie	RB	KON		OK/0.966317
well	sowie	RB	KON		OK/0.988060
as	sowie	IN	KON		OK/0.975538
the	__unaligned__	DT	__unaligned__		OK/0.816023
subject	Schnittwunden	NN	NN		OK/0.541250
is	__unaligned__	VBZ	__unaligned__		OK/0.524470
infected	infizierte	VVN	ADJA		OK/0.560306
,	,	,	$,		OK/0.668211
and	und	CC	KON		OK/0.910823
or	genähte	CC	ADJA		OK/0.819148
sutured	__unaligned__	VVN	__unaligned__		OK/0.717305
wounds	__unaligned__	NNS	__unaligned__		OK/0.736914
.	.	SENT	$.		OK/0.994912

# 0.207659
Coversyl	Coversyl	NP	NN		OK/0.918988
and	und	CC	KON		OK/0.995610
associated	Bezeichnungen	JJ	NN		OK/0.916480
names	Bezeichnungen	NNS	NN		OK/0.756424
contain	enthält	VVP	VVFIN		OK/0.760436
perindopril	Perindopril	NN	NE		OK/0.825448
,	,	,	$,		OK/0.975846
a	__unaligned__	DT	__unaligned__		OK/0.923142
potent	hochwirksamen	JJ	ADJA		OK/0.983371
angiotensin	__unaligned__	NP	__unaligned__		OK/0.838237
converting	__unaligned__	VVG	__unaligned__		OK/0.828865
enzyme	ACE-Hemmer	NN	NN		OK/0.901811
inhibitors	ACE-Hemmer	NNS	NN		OK/0.966728
(	(	(	$(		OK/0.988606
ACE-Is	ACE-I	NP	NN		OK/0.901488
)	)	)	$(		OK/0.976444
,	,	,	$,		OK/0.936263
which	__unaligned__	WDT	__unaligned__		OK/0.687654
is	__unaligned__	VBZ	__unaligned__		OK/0.616981
currently	derzeit	RB	ADV		OK/0.952169
indicated	angezeigt	VVN	VVPP		OK/0.974441
for	angezeigt	IN	VVPP		OK/0.999242
the	Behandlung	DT	NN		OK/0.993963
treatment	Behandlung	NN	NN		OK/0.980192
of	Behandlung	IN	NN		OK/0.993899
hypertension	Hypertonie	NN	NN		OK/0.986448
and	und	CC	KON		OK/0.981355
symptomatic	symptomatischer	JJ	ADJA		OK/0.965170
heart	Herzinsuffizienz	NN	NN		OK/0.994954
failure	Herzinsuffizienz	NN	NN		OK/0.993651
.	.	SENT	$.		OK/0.999232

# 0.245941
The	Die	NP	ART		OK/0.997999
Humalog	Humalog	NP	NN		OK/0.907920
BASAL	BASAL	NP	NN		OK/0.873038
physician	Arzt	NN	NN		OK/0.593916
should	muss	MD	VMFIN		OK/0.507945
be	muss	VB	VMFIN		OK/0.428186
consulted	abge-	VVN	TRUNC		BAD/0.923735
when	abge-	WRB	TRUNC		BAD/0.992774
using	abge-	VVG	TRUNC		BAD/0.997040
other	abge-	JJ	TRUNC		BAD/0.986873
medications	abge-	NNS	TRUNC		BAD/0.978084
in	stimmt	IN	VVFIN		BAD/0.934498
addition	abge-	NN	TRUNC		BAD/0.900450
.	.	SENT	$.		OK/0.993504

# 0.947099
What	Wofür	WP	NN		OK/0.997096
is	Wofür	VBZ	NN		OK/0.952583
Emadine	Emadine	NN	NE		OK/0.998264
used	angewendet	VVN	VVPP		OK/0.997485
for	angewendet	IN	VVPP		OK/0.998904
?	?	SENT	$.		OK/0.999320

# 0.091571
If	Wenn	IN	KOUS		OK/0.998396
you	Sie	PP	PPER		OK/0.997869
forget	Einnahme	VVP	NN		OK/0.979141
to	vergessen	TO	VVPP		OK/0.955327
take	vergessen	VV	VVPP		OK/0.953818
ABILIFY	ABILIFY	NP	NE		OK/0.944445
If	Wenn	IN	KOUS		OK/0.993927
you	Sie	PP	PPER		OK/0.999418
forget	vergessen	VVP	VVPP		OK/0.972151
to	vergessen	TO	VVPP		OK/0.922499
take	vergessen	VV	VVPP		OK/0.971825
a	__unaligned__	DT	__unaligned__		OK/0.997612
dose	Dosis	NN	NN		OK/0.995340
,	,	,	$,		OK/0.992103
take	nehmen	VV	VVFIN		OK/0.984969
the	__unaligned__	DT	__unaligned__		OK/0.993337
missed	vergessene	VVN	ADJA		OK/0.990584
dose	Dosis	NN	NN		OK/0.873435
as	denken	RB	VVINF		BAD/0.670650
soon	denken	RB	VVINF		BAD/0.698857
as	denken	IN	VVINF		BAD/0.672791
you	denken	PP	VVINF		BAD/0.748700
remember	denken	VVP	VVINF		BAD/0.825409
,	,	,	$,		OK/0.534876
but	jedoch	CC	ADV		OK/0.607998
not	nicht	RB	PTKNEG		OK/0.763885
in	einem	IN	ART		OK/0.697783
one	__unaligned__	CD	__unaligned__		OK/0.919657
day	Tag	NN	NN		OK/0.884116
to	__unaligned__	TO	__unaligned__		OK/0.843308
make	doppelte	VV	ADJA		OK/0.967157
up	doppelte	RP	ADJA		OK/0.998750
for	doppelte	IN	ADJA		OK/0.994304
a	doppelte	DT	ADJA		OK/0.995605
forgotten	doppelte	JJ	ADJA		OK/0.994610
dose	Dosis	NN	NN		OK/0.988945
.	.	SENT	$.		OK/0.999553

# 0.166393
The	__unaligned__	NP	__unaligned__		OK/0.997883
European	Europäische	NP	ADJA		OK/0.993239
Commission	erteilte	NP	VVFIN		OK/0.878317
to	__unaligned__	TO	__unaligned__		OK/0.888728
BioPartners	BioPartners	NP	NN		OK/0.556219
GmbH	GmbH	NP	NN		OK/0.425067
for	für	IN	APPR		OK/0.578369
the	Europäischen	DT	ADJA		OK/0.713238
European	Europäischen	NP	ADJA		OK/0.611689
Union	Union	NP	NN		OK/0.575703
for	Union	IN	NN		OK/0.559116
Valtropin	Valtropin	NP	NE		OK/0.690480
on	Am	IN	APPRART		OK/0.684332
24	24.	CD	ADJA		OK/0.841327
April	April	NP	NN		OK/0.926096
2006	2006	CD	CARD		OK/0.969187
.	.	SENT	$.		OK/0.999325

# 0.584607
Detailed	Ausführliche	NP	ADJA		OK/0.988248
information	Informationen	NN	NN		OK/0.999728
on	Informationen	IN	NN		OK/0.992245
this	__unaligned__	DT	__unaligned__		OK/0.992780
medicinal	Arzneimittel	JJ	NN		OK/0.999060
product	Arzneimittel	NN	NN		OK/0.999513
is	Website	VBZ	NN		OK/0.981058
available	__unaligned__	JJ	__unaligned__		OK/0.986079
on	__unaligned__	IN	__unaligned__		OK/0.996146
the	Europäischen	DT	ADJA		OK/0.996637
European	Europäischen	NP	ADJA		OK/0.998836
Medicines	Arzneimittel-Agentur	NP	NN		OK/0.999558
Agency	Arzneimittel-Agentur	NP	NN		OK/0.994857
(	(	(	$(		OK/0.999848
EMEA	EMEA	NP	NE		OK/0.999363
)	)	)	$(		OK/0.999176
web	http	NN	NN		OK/0.944974
site	http	NN	NN		OK/0.947216
:	__unaligned__	:	__unaligned__		OK/0.991749
http	http	NN	NN		OK/0.998217
:	:	:	$.		OK/0.999840
/	/	SYM	$(		OK/0.999603
/	/	SYM	$(		OK/0.998043
www.	www.emea.europa.eu	JJ	NN		BAD/0.829964
emea.	www.emea.europa.eu	JJ	NN		BAD/0.839518
europa.	www.emea.europa.eu	JJ	NN		BAD/0.847519
eu	www.emea.europa.eu	NN	NN		BAD/0.822919
/	/	SYM	$(		OK/0.995470
.	.	SENT	$.		OK/0.999798

# 0.882101
Karvezide	Karvezide	NP	NN		OK/0.962261
is	empfohlen	VBZ	VVPP		OK/0.994230
not	nicht	RB	PTKNEG		OK/0.997895
recommended	empfohlen	VVN	VVPP		OK/0.991666
for	für	IN	APPR		OK/0.999145
use	Anwendung	NN	NN		OK/0.999034
in	bei	IN	APPR		OK/0.989873
children	Kindern	NNS	NN		OK/0.998802
and	und	CC	KON		OK/0.999596
adolescents	Jugendlichen	NNS	NN		OK/0.997335
due	aufgrund	JJ	APPR		OK/0.985557
to	aufgrund	TO	APPR		OK/0.998608
a	Fehlens	DT	NN		OK/0.996233
lack	Fehlens	NN	NN		OK/0.991856
of	__unaligned__	IN	__unaligned__		OK/0.991423
data	Daten	NNS	NN		OK/0.995648
on	Daten	IN	NN		OK/0.994165
safety	Unbedenklichkeit	NN	NN		OK/0.995070
and	Unbedenklichkeit	CC	NN		OK/0.993851
efficacy	Wirksamkeit	NN	NN		OK/0.990385
.	.	SENT	$.		OK/0.999363

# 0.905411
Remove	Ziehen	NP	NN		OK/0.968729
the	Ziehen	DT	NN		OK/0.987766
protective	Schutzfolie	JJ	NN		OK/0.986026
seal	__unaligned__	NN	__unaligned__		OK/0.976275
from	ab	IN	PTKVZ		OK/0.974843
a	neuen	DT	ADJA		OK/0.996752
new	neuen	JJ	ADJA		OK/0.999039
needle	Nadel	NN	NN		OK/0.987201
.	.	SENT	$.		OK/0.999338

# 0.773992
Accidental	unbeabsichtigte	NP	ADJA		OK/0.932607
ingestion	unbeabsichtigte	NN	ADJA		OK/0.952531
can	kann	MD	VMFIN		OK/0.981027
be	kann	VB	VMFIN		OK/0.944183
lethal	tödlich	JJ	ADJD		OK/0.895563
for	für	IN	APPR		OK/0.972044
children	Kinder	NNS	NN		OK/0.951225
.	.	SENT	$.		OK/0.995760

# 0.950365
Possible	Mögliche	JJ	ADJA		OK/0.984565
signs	Anzeichen	NNS	NN		OK/0.999423
of	Anzeichen	IN	NN		OK/0.997526
lactic	Laktatazidose	JJ	NN		OK/0.975683
acidosis	Laktatazidose	NN	NN		OK/0.990044
.	:	SENT	$.		OK/0.995625

# 0.085410
One	Eine	NP	ART		BAD/0.425757
Grade	Grad	NP	NN		BAD/0.602094
3	Grad	CD	NN		BAD/0.823312
or	Grad	CC	NN		BAD/0.851878
4	Grad	CD	NN		BAD/0.793636
stomatitis	Stomatitis	NN	NN		BAD/0.668083
has	wurde	VHZ	VAFIN		OK/0.602705
been	wurde	VBN	VAFIN		OK/0.756430
observed	beobachtet	VVN	VVPP		OK/0.859040
in	bei	IN	APPR		OK/0.997022
2	2	CD	CARD		OK/0.995350
%	%	NN	NN		OK/0.998540
of	der	IN	ART		OK/0.996512
the	der	DT	ART		OK/0.996793
patients	Patienten	NNS	NN		OK/0.977695
in	in	IN	APPR		OK/0.987078
the	in	DT	APPR		OK/0.955156
combination	Kombinationstherapiegruppe	NN	NN		OK/0.970252
therapy	Kombinationstherapiegruppe	NN	NN		OK/0.974397
group	Kombinationstherapiegruppe	NN	NN		OK/0.841846
.	.	SENT	$.		OK/0.998138

# 0.583999
Patients	Patienten	NPS	NN		OK/0.997734
with	mit	IN	APPR		OK/0.999394
rare	seltenen	JJ	ADJA		OK/0.995713
hereditary	hereditären	JJ	ADJA		OK/0.988635
problems	hereditären	NNS	ADJA		OK/0.815643
of	hereditären	IN	ADJA		OK/0.782849
galactose	Galactose-Intoleranz	NN	NN		OK/0.987673
intolerance	Galactose-Intoleranz	NN	NN		OK/0.995254
,	,	,	$,		OK/0.997909
the	__unaligned__	DT	__unaligned__		OK/0.934204
Lapp	Galactose-Intoleranz	NP	NN		OK/0.955576
lactase	Galactose-Intoleranz	NN	NN		OK/0.991891
deficiency	Galactose-Intoleranz	NN	NN		OK/0.993709
Lapp-Lactose-Mangel	Lapp-Lactose-Mangel	NP	NN		OK/0.904909
or	oder	CC	KON		OK/0.986040
malabsorption	Galactose-Malabsorption	NN	NN		OK/0.986188
should	sollten	MD	VMFIN		OK/0.996455
not	nicht	RB	PTKNEG		OK/0.992937
take	einnehmen	VV	VVINF		OK/0.996802
this	dieses	DT	PDAT		OK/0.997858
medicine	Arzneimittel	NN	NN		OK/0.988119
.	.	SENT	$.		OK/0.999546

# 0.965241
Each	Jede	DT	PIAT		OK/0.997939
1	1	CD	CARD		OK/0.998528
ml	ml	NN	NN		OK/0.999930
pre-filled	Fertigspritze	JJ	NN		OK/0.997024
syringe	Fertigspritze	NN	NN		OK/0.999183
contains	enthält	VVZ	VVFIN		OK/0.998111
500	500	CD	CARD		OK/0.995286
micrograms	Mikrogramm	NNS	NN		OK/0.994885
darbepoetin	Darbepoetin	NN	NN		OK/0.996840
alfa	alfa	NN	NE		OK/0.996422
(	(	(	$(		OK/0.996873
500	500	CD	CARD		OK/0.998887
micrograms	Mikrogramm	NNS	NN		OK/0.999248
/	/	SYM	$(		OK/0.998790
ml	ml	NN	NN		OK/0.999640
)	)	)	$(		OK/0.997070
.	.	SENT	$.		OK/0.997267

# 0.285556
This	Dieser	DT	PDAT		OK/0.991416
messenger	Botenstoff	NN	NN		OK/0.962266
is	ist	VBZ	VAFIN		OK/0.988872
involved	beteiligt	VVN	VVPP		OK/0.962105
in	beteiligt	IN	VVPP		OK/0.947499
inflammation	Entzündungsgeschehen	NN	NN		OK/0.904067
and	und	CC	KON		OK/0.979657
is	findet	VBZ	VVFIN		OK/0.799866
found	findet	VVN	VVFIN		OK/0.808452
at	hohen	IN	ADJA		OK/0.990167
high	hohen	JJ	ADJA		OK/0.999562
levels	Konzentrationen	NNS	NN		OK/0.995228
in	bei	IN	APPR		OK/0.999164
patients	Patienten	NNS	NN		OK/0.992569
with	mit	IN	APPR		OK/0.919313
the	__unaligned__	DT	__unaligned__		OK/0.785907
diseases	Erkrankungen	NNS	NN		OK/0.498786
,	,	,	$,		OK/0.840927
treated	behandelt	VVN	VVPP		OK/0.979344
with	mit	IN	APPR		OK/0.999276
Remicade	Remicade	NP	NN		OK/0.952089
.	.	SENT	$.		OK/0.993128

# 0.036774
The	Die	DT	ART		OK/0.995649
import	Einfuhr	NN	NN		OK/0.954843
,	Einfuhr	,	NN		OK/0.993705
sale	Einfuhr	NN	NN		OK/0.993558
,	Einfuhr	,	NN		OK/0.994808
supply	Einfuhr	NN	NN		OK/0.973596
and	und	CC	KON		OK/0.999419
/	/	SYM	$(		OK/0.994227
or	oder	CC	KON		OK/0.996586
use	Verwendung	VV	NN		OK/0.966789
of	von	IN	APPR		OK/0.996317
Nobilis	Nobilis	NP	NN		OK/0.951021
IB	4-91	NP	CARD		OK/0.954114
4-91	4-91	CD	CARD		OK/0.948717
in	bestimmten	IN	ADJA		OK/0.969583
certain	bestimmten	JJ	ADJA		OK/0.997631
Member	Mitgliedstaaten	NP	NN		OK/0.998029
States	Mitgliedstaaten	NPS	NN		OK/0.967469
in	im	IN	APPRART		OK/0.908662
the	__unaligned__	DT	__unaligned__		OK/0.806735
innerstaatlicher	innerstaatlicher	NN	ADJA		BAD/0.784142
veterinary	tierärztlicher	NN	ADJA		BAD/0.783849
measures	Maßnahmen	VVZ	NN		BAD/0.709871
the	gesamten	DT	ADJA		BAD/0.842166
whole	Hoheitsgebiet	NN	NN		BAD/0.980604
or	Hoheitsgebiet	CC	NN		BAD/0.981890
part	Hoheitsgebiet	NN	NN		BAD/0.922719
of	Hoheitsgebiet	IN	NN		BAD/0.850588
their	Hoheitsgebiet	PP$	NN		BAD/0.672896
territory	Hoheitsgebiet	NN	NN		OK/0.690841
national	untersagt	JJ	VVPP		OK/0.744897
or	oder	CC	KON		OK/0.931099
national	untersagt	JJ	VVPP		BAD/0.480987
animal	__unaligned__	JJ	__unaligned__		BAD/0.667965
health	__unaligned__	NN	__unaligned__		BAD/0.638366
policy	__unaligned__	NN	__unaligned__		BAD/0.576053
.	.	SENT	$.		OK/0.996992

# 0.057521
The	Der	NP	ART		OK/0.997130
Applicant	Antragsteller	NP	NN		OK/0.992713
concerning	Bezug	VVG	NN		OK/0.936691
the	die	DT	ART		OK/0.982356
analysis	Analyse	NN	NN		OK/0.814528
of	Analyse	IN	NN		OK/0.820129
pain	Schmerzintensitätsdifferenz	NN	NN		BAD/0.616221
intensity	Schmerzintensitätsdifferenz	NN	NN		BAD/0.649777
difference	Schmerzintensitätsdifferenz	NN	NN		BAD/0.525589
(	(	(	$(		OK/0.969654
Pain	Pain	NP	NE		OK/0.917603
Intensity	Intensity	NP	NN		OK/0.885099
Difference	Difference	NP	NE		OK/0.941555
,	,	,	$,		OK/0.974388
PID	PID	NP	NE		OK/0.845562
)	)	)	$(		OK/0.945710
for	für	IN	APPR		OK/0.851323
Rapinyl	Rapinyl	NP	NN		OK/0.908827
compared	Vergleich	VVN	NN		OK/0.975313
to	Vergleich	TO	NN		OK/0.927513
placebo	Placebo	NN	NN		OK/0.761837
after	nach	IN	APPR		OK/0.818687
10	10	CD	CARD		OK/0.900843
minutes	Minuten	NNS	NN		OK/0.891825
in	in	IN	APPR		OK/0.738471
Study	Studie	NP	NN		OK/0.699110
EN3267-005	EN3267-005	NP	VVFIN		OK/0.522362
.	.	SENT	$.		OK/0.987713

# 0.103885
The	Die	DT	ART		OK/0.972874
actual	tatsächliche	JJ	ADJA		OK/0.851280
withdrawal	Wartezeit	NN	NN		OK/0.982563
period	Wartezeit	NN	NN		OK/0.952612
for	für	IN	APPR		OK/0.977576
the	__unaligned__	DT	__unaligned__		OK/0.932443
product	Produkt	NN	NN		OK/0.874111
is	__unaligned__	VBZ	__unaligned__		OK/0.457286
to	__unaligned__	TO	__unaligned__		OK/0.629800
be	muss	VB	VMFIN		OK/0.785488
based	__unaligned__	VVN	__unaligned__		OK/0.807123
on	__unaligned__	IN	__unaligned__		OK/0.852240
the	__unaligned__	DT	__unaligned__		OK/0.900320
residues	Rückstandsmenge	NNS	NN		OK/0.683187
,	jedoch	,	ADV		OK/0.673012
but	jedoch	CC	ADV		OK/0.432099
after	nach	IN	APPR		OK/0.797756
the	__unaligned__	DT	__unaligned__		OK/0.905908
injection	Injektionsstelle	NN	NN		OK/0.920214
site	Injektionsstelle	NN	NN		OK/0.831272
.	.	SENT	$.		OK/0.998976

# 0.967849
How	Wie	NP	KOKOM		OK/0.998754
to	aufzubewahren	TO	VVIZU		OK/0.994794
store	aufzubewahren	VV	VVIZU		OK/0.990209
STOCRIN	STOCRIN	NP	NN		OK/0.978569

# 0.769263
•	•	NN	NN		OK/0.995387
You	Es	PP	PPER		OK/0.961328
may	auftreten	MD	VVINF		OK/0.948919
experience	auftreten	VV	VVINF		OK/0.976206
symptoms	Beschwerden	NNS	NN		OK/0.954903
of	einer	IN	ART		OK/0.990569
neuropathy	Nervenschädigung	NN	NN		OK/0.979895
such	wie	JJ	KOKOM		OK/0.968305
as	wie	IN	KOKOM		OK/0.991694
pain	Schmerzen	NN	NN		OK/0.993698
,	,	,	$,		OK/0.998749
burning	Brennen	NN	NN		OK/0.995257
,	Brennen	,	NN		OK/0.997133
tingling	Kribbeln	VVG	NN		OK/0.998378
,	Benommenheit	,	NN		OK/0.996791
numbness	__unaligned__	NN	__unaligned__		OK/0.967814
and	und	CC	KON		OK/0.998079
/	/	SYM	$(		OK/0.996768
or	oder	CC	KON		OK/0.998243
weakness	Schwäche	NN	NN		OK/0.956363
.	.	SENT	$.		OK/0.998726

# 0.903415
10	11	CD	CARD		OK/0.954169
/	/	SYM	$(		OK/0.996817
16	18	CD	CARD		OK/0.978416
Read	Lesen	NP	NN		OK/0.994135
the	Packungsbeilage	DT	NN		OK/0.989119
package	__unaligned__	NN	__unaligned__		OK/0.999388
leaflet	__unaligned__	NN	__unaligned__		OK/0.998808
before	vor	IN	APPR		OK/0.995252
use	Anwendung	NN	NN		OK/0.985055
.	.	SENT	$.		OK/0.999400

# 0.678541
If	Falls	IN	NN		OK/0.999416
necessary	notwendig	JJ	ADJD		OK/0.994918
,	,	,	$,		OK/0.999075
NovoMix	NovoMix	NP	NN		OK/0.998518
70	70	CD	CARD		OK/0.998322
can	kann	MD	VMFIN		OK/0.992271
be	kann	VB	VMFIN		OK/0.991032
given	verabreicht	VVN	VVPP		OK/0.949275
just	direkt	RB	ADJD		OK/0.871658
after	nach	IN	APPR		OK/0.969424
starting	Beginn	VVG	NN		OK/0.962152
the	der	DT	ART		OK/0.973863
meal	Mahlzeit	NN	NN		OK/0.821093
.	.	SENT	$.		OK/0.993304

# 0.048470
The	Der	DT	ART		OK/0.999155
proportion	Anteil	NN	NN		OK/0.992903
of	Anteil	IN	NN		OK/0.990718
patients	Patienten	NNS	NN		OK/0.961176
at	__unaligned__	IN	__unaligned__		OK/0.486233
12	12	CD	CARD		OK/0.855073
months	Monaten	NNS	NN		OK/0.925961
(	überlebenden	(	ADJA		OK/0.493387
was	betrug	VBD	VVFIN		OK/0.734589
24	24	CD	CARD		OK/0.986434
%	%	NN	NN		OK/0.984479
in	bei	IN	APPR		OK/0.721906
treatment	Behandlung	NN	NN		OK/0.996385
with	mit	IN	APPR		OK/0.997272
DepoCyte	DepoCyte	NN	NN		OK/0.994015
compared	verglichen	VVN	VVPP		OK/0.974127
with	mit	IN	APPR		OK/0.990223
19	19	CD	CARD		OK/0.997912
%	%	NN	NN		OK/0.989782
of	__unaligned__	IN	__unaligned__		OK/0.443059
those	bei	DT	APPR		OK/0.691651
receiving	__unaligned__	VVG	__unaligned__		OK/0.828444
unencapsulated	unverkapseltem	JJ	ADJA		OK/0.706152
cytarabine	Cytarabin	NN	NE		OK/0.621369
.	.	SENT	$.		OK/0.997392

# 0.222348
Film-coated	Filmtablette	NP	NN		OK/0.940749
tablet	Filmtablette	NN	NN		OK/0.915212
Pinkish	Blassrosafarbene	NP	ADJA		OK/0.857698
,	,	,	$,		OK/0.984921
oval	ovale	JJ	ADJA		OK/0.962556
film-coated	Filmtablette	NN	NN		OK/0.995852
tablet	Filmtablette	NN	NN		OK/0.962177
debossed	Prägung	VVN	NN		OK/0.666530
with	Prägung	IN	NN		OK/0.950487
"	"	``	$(		OK/0.996244
SP	SP	NP	NE		OK/0.987085
'	"	''	$(		BAD/0.996624
on	__unaligned__	IN	__unaligned__		BAD/0.761128
one	__unaligned__	CD	__unaligned__		OK/0.992624
side	auf	NN	APPR		OK/0.986262
and	und	CC	KON		OK/0.997318
"	"	``	$(		OK/0.995335
50	50	CD	CARD		OK/0.924675
'	"	''	$(		OK/0.663148
on	auf	IN	APPR		OK/0.708968
the	auf	DT	APPR		OK/0.954281
other	anderen	JJ	PIAT		OK/0.952577
side	Seite	NN	NN		OK/0.965199
.	.	SENT	$.		OK/0.975025

# 0.196279
Using	Bei	VVG	APPR		OK/0.985774
BYETTA	BYETTA	NP	NE		OK/0.930024
with	Nahrungsmitteln	IN	NN		OK/0.902327
food	Nahrungsmitteln	NN	NN		OK/0.828405
and	und	CC	KON		OK/0.801970
drink	Getränken	NN	NN		OK/0.718831
Do	Wenden	VVP	NN		OK/0.450471
not	Wenden	RB	NN		OK/0.585723
use	Wenden	VV	NN		OK/0.913248
BYETTA	BYETTA	NP	NE		OK/0.944624
future	irgendwann	NN	ADV		OK/0.580216
within	innerhalb	IN	ADJD		OK/0.921293
60	60	CD	CARD		OK/0.985214
minutes	Minuten	NNS	NN		OK/0.994405
(	(	(	$(		OK/0.999463
1	1	CD	CARD		OK/0.983223
hour	Stunde	NN	NN		OK/0.977439
)	)	)	$(		OK/0.986189
before	vor	IN	APPR		OK/0.990444
a	dem	DT	ART		OK/0.992196
meal	Essen	NN	NN		OK/0.983836
.	.	SENT	$.		OK/0.999285

# 0.907974
Each	Jede	DT	PIAT		OK/0.998891
capsule	Kapsel	NN	NN		OK/0.995425
contains	enthält	VVZ	VVFIN		OK/0.999757
300	300	CD	CARD		OK/0.999739
mg	mg	NN	NN		OK/0.999483
of	__unaligned__	IN	__unaligned__		OK/0.996808
atazanavir	Atazanavir	NN	NE		OK/0.997161
(	(	(	$(		OK/0.994774
as	Sulfat	IN	NN		OK/0.971326
sulphate	Sulfat	NN	NN		OK/0.944715
)	)	)	$(		OK/0.975964
.	.	SENT	$.		OK/0.993986

# 0.110902
In	In	IN	APPR		OK/0.992779
clinical	klinischen	JJ	ADJA		OK/0.982910
trials	Studien	NNS	NN		OK/0.959216
,	__unaligned__	,	__unaligned__		OK/0.761812
more	mehr	JJR	ADV		OK/0.944637
than	mehr	IN	ADV		OK/0.977225
one	mehr	CD	ADV		OK/0.956595
evaluated	ausgewertet	VVN	VVPP		OK/0.477384
to	__unaligned__	TO	__unaligned__		OK/0.539520
afford	1490	VV	CARD		OK/0.450133
the	__unaligned__	DT	__unaligned__		OK/0.944631
patients	Patienten	NNS	NN		OK/0.959655
in	Patienten	IN	NN		OK/0.604207
whom	denen	WP	PRELS		OK/0.629666
more	mehr	JJR	ADV		OK/0.830804
than	mehr	IN	ADV		OK/0.919333
955	955	CD	CARD		OK/0.856433
treated	behandelt	VVN	VVPP		OK/0.941062
with	mit	IN	APPR		OK/0.995105
InductOs	InductOs	NP	NN		OK/0.928099
.	.	SENT	$.		OK/0.997732

# 0.121606
Absorption	Resorption	NP	NN		OK/0.900119
After	Nach	IN	APPR		OK/0.975509
a	einer	DT	ART		OK/0.995275
single	Einzeldosis	JJ	NN		OK/0.995617
oral	Einzeldosis	JJ	NN		OK/0.997828
dose	Einzeldosis	NN	NN		OK/0.998005
of	__unaligned__	IN	__unaligned__		OK/0.988049
100	100	CD	CARD		OK/0.994623
mg	mg	NN	NN		OK/0.997757
/	/	SYM	$(		OK/0.996823
kg	kg	NN	NN		OK/0.936324
body	Körpergewicht	NN	NN		OK/0.733072
weight	Körpergewicht	NN	NN		OK/0.619567
,	__unaligned__	,	__unaligned__		OK/0.361086
estimated	schätzungsweise	VVN	ADV		OK/0.341674
to	__unaligned__	TO	__unaligned__		OK/0.321357
be	schätzungsweise	VB	ADV		OK/0.294243
approximately	etwa	RB	ADV		OK/0.678156
30	30	CD	CARD		OK/0.964403
%	%	NN	NN		OK/0.996484
of	der	IN	ART		OK/0.996167
the	der	DT	ART		OK/0.992816
absorbed	resorbiert	VVN	VVPP		OK/0.960922
carglumic	Carglumsäure	JJ	NN		OK/0.970373
acid	Carglumsäure	NN	NN		OK/0.999205
.	.	SENT	$.		OK/0.997425

# 0.854839
Very	Sehr	JJ	ADV		OK/0.998981
common	häufige	JJ	ADJA		OK/0.999063
side	Nebenwirkungen	NN	NN		OK/0.994579
effects	Nebenwirkungen	NNS	NN		OK/0.995288
(	(	(	$(		OK/0.996463
affects	betrifft	VVZ	VVFIN		OK/0.960229
more	mehr	JJR	ADV		OK/0.999165
than	mehr	IN	ADV		OK/0.999264
1	1	CD	CARD		OK/0.999176
in	__unaligned__	IN	__unaligned__		OK/0.998618
10	10	CD	CARD		OK/0.998463
patients	Patienten	NNS	NN		OK/0.999017
)	)	)	$(		OK/0.979163
of	von	IN	APPR		OK/0.953201
RILUTEK	RILUTEK	NP	NE		OK/0.936307
are	sind	VBP	VAFIN		OK/0.992894
:	:	:	$.		OK/0.998616

# 0.390689
,	__unaligned__	,	__unaligned__		BAD/0.977954
mental	Störungen	JJ	NN		BAD/0.913208
Säure-Basen-Haushalts	Säure-Basen-Haushalts	NNS	NN		BAD/0.949144
were	wurden	VBD	VAFIN		BAD/0.930146
described	beschrieben	VVN	VVPP		BAD/0.778511
as	beschrieben	IN	VVPP		OK/0.677289
oral	orale	JJ	ADJA		OK/0.951646
carbonic	Carboanhydrasehemmer	JJ	NN		OK/0.945302
anhydrase	Carboanhydrasehemmer	NN	NN		OK/0.965531
inhibitors	Carboanhydrasehemmer	NNS	NN		OK/0.968421
.	.	SENT	$.		OK/0.999075

# 0.719817
EVISTA	EVISTA	NP	NN		OK/0.966327
has	hat	VHZ	VAFIN		OK/0.999435
no	keine	RB	PIAT		OK/0.999240
known	bekannten	VVN	ADJA		OK/0.986342
effects	Auswirkungen	NNS	NN		OK/0.903629
on	auf	IN	APPR		OK/0.986223
the	auf	DT	APPR		OK/0.992338
ability	Fahrtüchtigkeit	NN	NN		OK/0.943808
to	__unaligned__	TO	__unaligned__		OK/0.956240
drive	Maschinen	VV	NN		OK/0.970224
and	Maschinen	CC	NN		OK/0.908797
use	Maschinen	VV	NN		OK/0.965716
machines	Bedienen	NNS	NN		OK/0.984250
.	.	SENT	$.		OK/0.999588

# 0.607645
Oblong	Oblong	NP	NN		OK/0.855336
,	,	,	$,		OK/0.991416
opaque	opak	NN	ADJD		OK/0.958573
,	,	,	$,		OK/0.992942
cream	cremiger	NN	ADJA		OK/0.988990
,	__unaligned__	,	__unaligned__		OK/0.995321
imprinted	Aufdruck	VVN	NN		OK/0.996730
with	Aufdruck	IN	NN		OK/0.980197
GXCC1	GXCC1	NP	NN		OK/0.753091
.	.	SENT	$.		OK/0.998159

# 0.673113
No	keine	NP	PIAT		OK/0.999273
dose	Dosisanpassung	NN	NN		OK/0.999212
adjustment	Dosisanpassung	NN	NN		OK/0.995741
is	erforderlich	VBZ	ADJD		OK/0.993198
necessary	erforderlich	JJ	ADJD		OK/0.981551
in	62	IN	ADJA		OK/0.971680
62	62	CD	ADJA		OK/0.997241
Hepatic	vorzuziehen	JJ	VVIZU		OK/0.987423
impairment	vorzuziehen	NN	VVIZU		OK/0.952855
:	vorzuziehen	:	VVIZU		OK/0.928677
in	Patienten	IN	NN		OK/0.920859
patients	Patienten	NNS	NN		OK/0.994476
with	mit	IN	APPR		OK/0.999604
renal	eingeschränkter	JJ	ADJA		OK/0.999275
impairment	Nierenfunktion	NN	NN		OK/0.991130
whose	__unaligned__	WP$	__unaligned__		OK/0.975510
renal	Nierenfunktion	JJ	NN		OK/0.992783
creatinine	Kreatininclearance	NN	NN		OK/0.996854
clearance	Kreatininclearance	NN	NN		OK/0.951811
is	__unaligned__	VBZ	__unaligned__		OK/0.893447
≥	≥	JJ	ADJD		OK/0.985516
30	30	CD	CARD		OK/0.998078
ml	ml	NN	NN		OK/0.998931
/	/	SYM	$(		OK/0.999296
min	min	NN	VVIMP		OK/0.995419
(	siehe	(	VVIMP		OK/0.999384
see	siehe	VV	VVIMP		OK/0.998334
sections	Abschnitte	NNS	NN		OK/0.997327
4.3	4.3	CD	CARD		OK/0.999386
and	und	CC	KON		OK/0.999963
4.4	4.4	CD	CARD		OK/0.986114
)	)	)	$(		OK/0.983099
.	.	SENT	$.		OK/0.994778

# 0.722683
Hypertension	Hypertonie	NP	NN		OK/0.739096
(	(	(	$(		OK/0.995632
see	siehe	VV	VVIMP		OK/0.992829
section	Abschnitt	NN	NN		OK/0.986148
4.4	4.4	CD	CARD		OK/0.995572
)	)	)	$(		OK/0.999622
:	:	:	$.		OK/0.999492

# 0.187086
Take	Nehmen	VV	VVFIN		OK/0.990864
your	Ihre	PP$	PPOSAT		OK/0.999300
next	nächste	JJ	ADJA		OK/0.962124
capsule	Kapsel	NN	NN		OK/0.838849
at	Zeitpunkt	IN	NN		OK/0.985945
the	Zeitpunkt	DT	NN		OK/0.990323
usual	Zeitpunkt	JJ	NN		OK/0.859594
time	Zeitpunkt	NN	NN		OK/0.855908
,	,	,	$,		OK/0.988117
then	dann	RB	ADV		OK/0.898613
go	fort	VV	PTKVZ		OK/0.520569
on	fort	IN	PTKVZ		OK/0.358741
as	fort	RB	PTKVZ		OK/0.439681
before	fort	RB	PTKVZ		OK/0.549696
.	.	SENT	$.		OK/0.989553

# 0.874832
2	2	CD	CARD		OK/0.928995
/	/	SYM	$(		OK/0.975756
3	3	CD	CARD		OK/0.988497
Why	Warum	WRB	PWAV		OK/0.996702
has	Warum	VHZ	PWAV		OK/0.982235
NovoSeven	NovoSeven	NP	NN		OK/0.984889
been	zugelassen	VBN	VVPP		OK/0.987911
approved	zugelassen	VVN	VVPP		OK/0.990971
?	?	SENT	$.		OK/0.999322

# 0.159280
Common	Häufige	NP	ADJA		OK/0.986988
side	Nebenwirkungen	NN	NN		OK/0.993518
effects	Nebenwirkungen	NNS	NN		OK/0.983185
are	sind	VBP	VAFIN		OK/0.995845
inflammation	Entzündung	NN	NN		OK/0.985311
of	des	IN	ART		OK/0.998679
the	des	DT	ART		OK/0.989323
eye	Auges	NN	NN		OK/0.904492
,	,	,	$,		OK/0.978087
decreased	verminderter	VVD	ADJA		OK/0.984085
intraocular	Augeninnendruck	JJ	NN		OK/0.976562
pressure	__unaligned__	NN	__unaligned__		OK/0.986346
,	,	,	$,		OK/0.991153
severe	schweres	JJ	ADJA		OK/0.834841
or	oder	CC	KON		OK/0.962957
angestrengtes	angestrengtes	NNS	ADJA		OK/0.586157
in	Atmen	IN	NN		OK/0.719277
breathing	Atmen	NN	NN		OK/0.860384
,	__unaligned__	,	__unaligned__		OK/0.902026
shortness	Kurzatmigkeit	NN	NN		OK/0.945055
of	Kurzatmigkeit	IN	NN		OK/0.995390
breath	Kurzatmigkeit	NN	NN		OK/0.997666
,	,	,	$,		OK/0.965435
and	und	CC	KON		OK/0.944191
chills	Schüttelfrost	NNS	NN		OK/0.686764
/	Schüttelfrost	SYM	NN		BAD/0.768743
rigors	Schüttelfrost	NNS	NN		BAD/0.840987
.	.	SENT	$.		OK/0.988358

# 0.486691
The	Die	NP	ART		OK/0.988611
MabCampath	MabCampath-Therapie	NP	NN		OK/0.919215
therapy	MabCampath-Therapie	NN	NN		OK/0.955302
can	kann	MD	VMFIN		OK/0.880547
be	kann	VB	VMFIN		OK/0.745976
administered	kann	VVN	VMFIN		OK/0.714788
after	nach	IN	APPR		OK/0.943901
the	__unaligned__	DT	__unaligned__		OK/0.950082
infection	Infektion	NN	NN		OK/0.942610
is	__unaligned__	VBZ	__unaligned__		OK/0.878546
resolved	Abklingen	VVN	NN		OK/0.854791
.	bzw.	SENT	KON		OK/0.937836

# 0.188905
It	Sie	PP	PPER		OK/0.897271
is	__unaligned__	VBZ	__unaligned__		OK/0.771559
an	__unaligned__	DT	__unaligned__		OK/0.519188
N-vinylpyrrolidone-containing	Hautzellen	JJ	NN		OK/0.416767
polymer	__unaligned__	NN	__unaligned__		OK/0.455134
in	den	IN	ART		OK/0.469794
the	die	DT	ART		OK/0.960219
inflammation	Entzündung	NN	NN		OK/0.943629
,	,	,	$,		OK/0.975324
the	die	DT	ART		OK/0.991735
redness	Rötung	NN	NN		OK/0.957913
and	und	CC	KON		OK/0.998096
itching	Juckreiz	VVG	NN		OK/0.962622
of	der	IN	ART		OK/0.854006
eczema	Ekzems	NN	NN		OK/0.772984
.	.	SENT	$.		OK/0.997645

# 0.954329
Do	Nehmen	VVP	VVFIN		OK/0.995705
not	nicht	RB	PTKNEG		OK/0.998475
take	Nehmen	VV	VVFIN		OK/0.997423
this	dieses	DT	PDAT		OK/0.996770
medicine	Arzneimittel	NN	NN		OK/0.992915
if	wenn	IN	KOUS		OK/0.997109
you	Sie	PP	PPER		OK/0.998225
are	schwanger	VBP	ADJD		OK/0.997538
pregnant	schwanger	JJ	ADJD		OK/0.976766
.	.	SENT	$.		OK/0.999070

# 0.760672
1	1	CD	CARD		OK/0.981263
g	g	NN	NN		OK/0.993081
of	Lösung	IN	NN		OK/0.962619
solution	Lösung	NN	NN		OK/0.995733
(	(	(	$(		OK/0.999613
20	20	CD	CARD		OK/0.999248
drops	Tropfen	NNS	NN		OK/0.995497
)	)	)	$(		OK/0.993994
contains	enthält	VVZ	VVFIN		OK/0.995436
10	10	CD	CARD		OK/0.989069
mg	mg	NN	NN		OK/0.993697
of	__unaligned__	IN	__unaligned__		OK/0.989115
memantine	Memantinhydrochlorid	JJ	NN		OK/0.997284
hydrochloride	Memantinhydrochlorid	NN	NN		OK/0.978571
equivalent	entsprechend	NN	ADJD		OK/0.973911
to	entsprechend	TO	ADJD		OK/0.948585
8.31	8,31	CD	CARD		OK/0.907141
mg	mg	NN	NN		OK/0.990864
memantine	Memantin	NN	NN		OK/0.961940
.	.	SENT	$.		OK/0.999842

# 0.716965
Gentamicin	Gentamicin	NP	NE		OK/0.879562
,	,	,	$,		OK/0.959342
max	max	NN	ADJA		OK/0.879624
..........................................................................................	..........................................................................................	NP	NN		OK/0.905199
34	34	CD	CARD		OK/0.976630
µg	µg	NN	ADJD		OK/0.968577
;	Lösungsmittel	:	NN		OK/0.966174
solvent	Lösungsmittel	JJ	NN		OK/0.973720
:	:	:	$.		OK/0.995174

# 0.358944
Non-clinical	nicht-klinischer	JJ	ADJA		OK/0.682662
data	nicht-klinischer	NNS	ADJA		OK/0.716742
reveal	nicht-klinischer	VVP	ADJA		OK/0.665131
no	nicht-klinischer	DT	ADJA		OK/0.909551
safety	Sicherheit	NN	NN		OK/0.978290
studies	Studien	VVZ	NN		OK/0.749535
special	besondere	JJ	ADJA		OK/0.749927
hazard	__unaligned__	NN	__unaligned__		OK/0.938999
for	__unaligned__	IN	__unaligned__		OK/0.980342
humans	Menschen	NNS	NN		OK/0.953593
(	(	(	$(		OK/0.996894
see	siehe	VV	VVIMP		OK/0.999317
section	Abschnitt	NN	NN		OK/0.997389
4.6	4.6	CD	CARD		OK/0.999222
)	)	)	$(		OK/0.994613
.	.	SENT	$.		OK/0.997261

# 0.757545
There	gibt	RB	VVFIN		OK/0.966957
is	gibt	VBZ	VVFIN		OK/0.881068
limited	eingeschränkte	VVN	ADJA		OK/0.928155
therapeutic	therapeutische	JJ	ADJA		OK/0.973412
experience	Erfahrungen	NN	NN		OK/0.924914
in	bei	IN	APPR		OK/0.998577
patients	Patienten	NNS	NN		OK/0.993540
with	mit	IN	APPR		OK/0.996905
mild	leichter	JJ	ADJD		OK/0.994776
to	moderater	TO	ADJA		OK/0.995578
moderate	moderater	VV	ADJA		OK/0.999497
hepatic	Leberfunktionsstörung	JJ	NN		OK/0.995427
impairment	Leberfunktionsstörung	NN	NN		OK/0.993738
(	siehe	(	VVIMP		OK/0.998163
see	siehe	VV	VVIMP		OK/0.997869
section	Abschnitt	NN	NN		OK/0.994823
4.4	4.4	CD	CARD		OK/0.992179
)	)	)	$(		OK/0.991904
.	.	SENT	$.		OK/0.995743

# 0.108353
Myelo-	Myelo-	NP	TRUNC		OK/0.725565
suppression	suppression	NN	NN		OK/0.901137
occurred	trat	VVD	VVFIN		OK/0.950507
more	häufiger	RBR	ADJD		OK/0.983526
often	häufiger	RB	ADJD		OK/0.984781
in	bei	IN	APPR		OK/0.969557
CML	CML-Patienten	NP	NN		OK/0.541481
patients	__unaligned__	NNS	__unaligned__		OK/0.618359
than	__unaligned__	IN	__unaligned__		OK/0.700185
in	bei	IN	APPR		OK/0.721243
GIST	GIST	NN	NN		OK/0.658854
.	.	SENT	$.		OK/0.990544
This	Dies	DT	PDS		OK/0.984104
is	ist	VBZ	VAFIN		OK/0.973777
probably	wahrscheinlich	RB	ADJD		OK/0.994876
due	auf	JJ	APPR		OK/0.891630
to	__unaligned__	TO	__unaligned__		OK/0.721552
There	erkrankung	RB	NN		OK/0.719272
was	erkrankung	VBD	NN		OK/0.881799
more	erkrankung	JJR	NN		OK/0.891303
myelosuppression	erkrankung	NN	NN		OK/0.799294
seen	erkrankung	VVN	NN		OK/0.652596
.	.	SENT	$.		OK/0.997927

# 0.737816
It	Es	PP	NN		OK/0.986959
is	empfohlen	VBZ	VVPP		OK/0.985981
recommended	empfohlen	VVN	VVPP		OK/0.962513
that	empfohlen	IN/that	VVPP		OK/0.845076
all	alle	DT	PIAT		OK/0.991440
concomitantly	gemeinsam	RB	ADJD		OK/0.972714
eingestallten	eingestallten	JJ	ADJA		OK/0.978279
horses	Pferde	NNS	NN		OK/0.973950
should	impfen	MD	VVINF		OK/0.984150
be	impfen	VB	VVINF		OK/0.985203
vaccinated	impfen	VVN	VVINF		OK/0.957393
.	.	SENT	$.		OK/0.995937

# 0.473067
The	__unaligned__	NP	__unaligned__		OK/0.998267
European	Europäische	NP	ADJA		OK/0.999725
Commission	erteilte	NP	VVFIN		OK/0.997452
granted	Unternehmen	VVD	NN		OK/0.999199
UCB	UCB	NP	NN		OK/0.986615
Pharma	Pharma	NP	NN		OK/0.999042
S.	S.A.	NP	NE		OK/0.979363
A.	S.A.	NP	NE		OK/0.962081
Marketing	Inverkehrbringen	NP	NN		OK/0.992180
Authorisation	Inverkehrbringen	NP	NN		OK/0.948439
for	Inverkehrbringen	IN	NN		OK/0.972573
the	Europäischen	DT	ADJA		OK/0.985307
European	Europäischen	NP	ADJA		OK/0.775692
Union	Union	NP	NN		OK/0.683410
for	Union	IN	NN		OK/0.629992
Vimpat	Vimpat	NP	NN		OK/0.810116
on	Am	IN	APPRART		OK/0.977836
29	29.	CD	ADJA		OK/0.996823
August	August	NP	NN		OK/0.983074
2008	2008	CD	CARD		OK/0.998186
.	.	SENT	$.		OK/0.999755

# 0.741537
Insuman	Insuman	NP	NN		OK/0.997531
Basal	Basal	NP	NN		OK/0.997267
is	ist	VBZ	VAFIN		OK/0.991418
an	allmählichem	DT	ADJA		OK/0.898922
insulin	allmählichem	NN	ADJA		OK/0.952833
preparation	allmählichem	NN	ADJA		OK/0.967618
with	allmählichem	IN	ADJA		OK/0.968167
a	Wirkungseintritt	DT	NN		OK/0.983953
gradual	allmählichem	JJ	ADJA		OK/0.949590
onset	Wirkungseintritt	NN	NN		OK/0.900184
and	und	CC	KON		OK/0.994136
long	langer	JJ	ADJA		OK/0.991961
duration	Wirkdauer	NN	NN		OK/0.999050
of	Wirkdauer	IN	NN		OK/0.999176
action	Wirkdauer	NN	NN		OK/0.991509
.	.	SENT	$.		OK/0.999747

# 0.358991
The	Der	NP	ART		OK/0.998589
Marketing	Zulassungsinhaber	NP	NN		OK/0.993748
Authorisation	Zulassungsinhaber	NP	NN		OK/0.993190
Holder	Zulassungsinhaber	NP	NN		OK/0.950937
,	,	,	$,		OK/0.980656
provided	sofern	VVD	KOUS		OK/0.992940
that	sofern	IN/that	KOUS		OK/0.924019
the	__unaligned__	DT	__unaligned__		OK/0.988142
CHMP	CHMP	NP	ADJA		OK/0.972873
does	nicht	VVZ	PTKNEG		OK/0.714278
not	nicht	RB	PTKNEG		OK/0.909494
anderslautende	anderslautende	NN	ADJA		OK/0.737435
vulnerable	stellt	JJ	VVFIN		OK/0.805540
,	,	,	$,		OK/0.818159
PSUR	PSUR	NP	NN		OK/0.708860
every	alle	DT	PIAT		OK/0.856701
6	6	CD	CARD		OK/0.981572
months	Monate	NNS	NN		OK/0.988538
.	.	SENT	$.		OK/0.999711

# 0.376454
67	67	CD	CARD		OK/0.958450
patients	Patienten	NNS	NN		OK/0.998556
with	mit	IN	APPR		OK/0.990368
high	Bluthochdruck	JJ	NN		OK/0.999017
blood	Bluthochdruck	NN	NN		OK/0.999781
pressure	Bluthochdruck	NN	NN		OK/0.999046
and	und	CC	KON		OK/0.999633
diabetes	Zuckerkrankheit	NN	NN		OK/0.985046
(	(	(	$(		OK/0.996912
type	Typ-2-Diabetes	NN	NN		OK/0.991706
2	Typ-2-Diabetes	CD	NN		OK/0.994092
diabetes	mellitus	NN	VVFIN		OK/0.980084
)	)	)	$(		OK/0.991062
Treatment	Behandlung	NP	NN		OK/0.505973
usually	üblicherweise	RB	ADV		OK/0.952966
starts	beginnt	VVZ	VVFIN		OK/0.991527
with	mit	IN	APPR		OK/0.924318
50	50	CD	CARD		OK/0.993188
mg	mg	NN	NN		OK/0.998935
losartan	Losartan	NN	NE		OK/0.957039
(	(	(	$(		OK/0.997504
one	Tablette	CD	NN		OK/0.997150
tablet	Tablette	NN	NN		OK/0.995493
Cozaar	Cozaar	NP	NN		OK/0.966125
50	50	CD	CARD		OK/0.999484
mg	mg	NN	NN		OK/0.999632
)	)	)	$(		OK/0.996531
once	einmal	IN	ADV		OK/0.993293
a	einmal	DT	ADV		OK/0.992044
day	täglich	NN	ADJD		OK/0.982236
.	.	SENT	$.		OK/0.999165

# 0.451056
This	Dieser	NP	PDAT		OK/0.995753
may	kann	MD	VMFIN		OK/0.990215
be	kann	VB	VMFIN		OK/0.958914
shorter	__unaligned__	JJR	__unaligned__		OK/0.884563
accumulates	ausgiebig	VVZ	ADJD		OK/0.855459
extensively	ausgiebig	RB	ADJD		OK/0.840583
in	bei	IN	APPR		OK/0.667037
heavily	vorbehandelten	RB	ADJA		OK/0.562322
pre-treated	__unaligned__	JJ	__unaligned__		OK/0.757733
patients	Patienten	NNS	NN		OK/0.920339
.	.	SENT	$.		OK/0.999634

# 0.442955
Emtricitabine	Emtricitabin	NP	NE		OK/0.883916
and	und	CC	KON		OK/0.995185
tenofovir	Tenofovir	NP	NE		OK/0.924787
are	werden	VBP	VAFIN		OK/0.809256
eliminated	eliminiert	VVN	VVPP		OK/0.974310
by	eliminiert	IN	VVPP		OK/0.969500
renal	eliminiert	JJ	VVPP		OK/0.985208
excretion	eliminiert	NN	VVPP		OK/0.955217
,	,	,	$,		OK/0.893701
and	und	CC	KON		OK/0.978450
exposure	Exposition	NN	NN		OK/0.997908
to	gegenüber	TO	APPR		OK/0.996637
emtricitabine	Emtricitabin	NN	NE		OK/0.991118
and	und	CC	KON		OK/0.998374
tenofovir	Tenofovir	NN	NE		OK/0.925245
increases	steigt	NNS	VVFIN		OK/0.915969
in	bei	IN	APPR		OK/0.997042
patients	Patienten	NNS	NN		OK/0.984788
with	mit	IN	APPR		OK/0.985515
impaired	Nierenfunktionsstörungen	JJ	NN		OK/0.855713
renal	Nierenfunktionsstörungen	JJ	NN		OK/0.980906
function	Nierenfunktionsstörungen	NN	NN		OK/0.984440
.	.	SENT	$.		OK/0.999385

# 0.435188
A	Eine	NP	ART		OK/0.855446
population	populationspharmakokinetische	NN	ADJA		OK/0.624116
pharmacokinetic	__unaligned__	JJ	__unaligned__		OK/0.690568
analysis	__unaligned__	NN	__unaligned__		OK/0.884741
showed	zeigte	VVD	VVFIN		OK/0.934377
a	eine	DT	ART		OK/0.982151
slightly	leicht	RB	ADJD		OK/0.962312
lower	niedrigere	JJR	ADJA		OK/0.972737
exposure	Exposition	NN	NN		OK/0.992273
to	Exposition	TO	NN		OK/0.964503
paliperidone	Paliperidon	NN	NN		OK/0.981872
in	bei	IN	APPR		OK/0.976283
smokers	Rauchern	NNS	NN		OK/0.969749
compared	Vergleich	VVN	NN		OK/0.967965
with	Vergleich	IN	NN		OK/0.946299
non-smokers	Nichtrauchern	NNS	NN		OK/0.911846
.	.	SENT	$.		OK/0.991949

# 0.832041
Do	Nicht	VVP	PTKNEG		OK/0.993003
not	Nicht	RB	PTKNEG		OK/0.996247
use	anwenden	VV	VVINF		OK/0.999620
in	bei	IN	APPR		OK/0.997018
animals	Tieren	NNS	NN		OK/0.995414
with	mit	IN	APPR		OK/0.994189
known	bekannter	VVN	ADJA		OK/0.997514
hypersensitivity	Überempfindlichkeit	NN	NN		OK/0.999548
to	gegenüber	TO	APPR		OK/0.997717
the	dem	DT	ART		OK/0.998589
active	arzneilich	JJ	ADJD		OK/0.998312
substance	arzneilich	NN	ADJD		OK/0.995532
or	oder	CC	KON		OK/0.999248
to	__unaligned__	TO	__unaligned__		OK/0.993135
any	Bestandteile	DT	NN		OK/0.980210
of	Bestandteile	IN	NN		OK/0.992790
the	Bestandteile	DT	NN		OK/0.993579
excipients	sonstigen	NNS	ADJA		OK/0.887050
.	.	SENT	$.		OK/0.999341

# 0.899162
The	__unaligned__	DT	__unaligned__		OK/0.960357
first	__unaligned__	JJ	__unaligned__		OK/0.982486
dose	Dosis	NN	NN		OK/0.991304
is	wird	VBZ	VAFIN		OK/0.970952
150	150	CD	CARD		OK/0.994636
mg	mg	NN	NN		OK/0.998209
/	/	SYM	$(		OK/0.999756
m2	m2	JJ	ADJD		OK/0.979108
.	.	SENT	$.		OK/0.998293

# 0.638993
Toxicological	Toxikologische	NP	ADJA		OK/0.895542
trials	Prüfungen	NNS	NN		OK/0.965803
with	mit	IN	APPR		OK/0.975110
intramuscular	intramuskulärer	JJ	ADJA		OK/0.996235
administration	Verabreichung	NN	NN		OK/0.988643
of	__unaligned__	IN	__unaligned__		OK/0.974460
single	Einzeldosen	JJ	NN		OK/0.996408
doses	Einzeldosen	NNS	NN		OK/0.979170
have	wurden	VHP	VAFIN		OK/0.987988
been	wurden	VBN	VAFIN		OK/0.986144
carried	durchgeführt	VVN	VVPP		OK/0.961374
out	durchgeführt	RP	VVPP		OK/0.848311
in	Cynomolgus-Affen	IN	NN		OK/0.931525
cynomolgus	Cynomolgus-Affen	NN	NN		OK/0.927378
monkeys	Cynomolgus-Affen	NNS	NN		OK/0.939855
.	.	SENT	$.		OK/0.999235

# 0.305132
The	Die	DT	ART		OK/0.991452
effects	Wirkungen	NNS	NN		OK/0.997208
of	von	IN	APPR		OK/0.999253
Galvus	Galvus	NP	NE		OK/0.991877
were	wurden	VBD	VAFIN		OK/0.985731
first	zunächst	RB	ADV		OK/0.996834
tested	zunächst	VVN	ADV		OK/0.994306
in	Versuchsmodellen	IN	NN		OK/0.997331
experimental	getestet	JJ	VVPP		OK/0.995919
models	Versuchsmodellen	NNS	NN		OK/0.998314
before	Versuchsmodellen	IN	NN		OK/0.999139
being	Versuchsmodellen	VBG	NN		OK/0.992393
studied	Versuchsmodellen	VVN	NN		OK/0.896021
in	Versuchsmodellen	IN	NN		OK/0.894482
three	__unaligned__	CD	__unaligned__		BAD/0.515938
main	an	JJ	APPR		BAD/0.512868
studies	wurden	NNS	VAFIN		BAD/0.642967
involving	untersucht	VVG	VVPP		BAD/0.924139
.	.	SENT	$.		OK/0.998132

# 0.191080
After	Nach	IN	APPR		OK/0.978992
primary	Grundimmunisierung	JJ	NN		OK/0.989338
vaccination	Grundimmunisierung	NN	NN		OK/0.994076
course	Grundimmunisierung	NN	NN		OK/0.982405
95.6	95,6	CD	CARD		OK/0.986497
%	%	NN	NN		OK/0.998086
of	der	IN	ART		OK/0.982218
subjects	Probanden	NNS	NN		OK/0.895678
had	hatten	VHD	VAFIN		OK/0.674767
persistent	Antikörper-Spiegel	JJ	NN		OK/0.549609
lack	__unaligned__	NN	__unaligned__		OK/0.459514
of	__unaligned__	IN	__unaligned__		OK/0.528375
antibody	__unaligned__	NN	__unaligned__		OK/0.769087
production	__unaligned__	NN	__unaligned__		OK/0.842146
of	__unaligned__	IN	__unaligned__		OK/0.913015
at	mindestens	IN	ADV		OK/0.984580
least	mindestens	JJS	ADV		OK/0.965083
0.35	0,35	CD	CARD		OK/0.947380
µg	µg	NN	NN		OK/0.965981
/	/	SYM	$(		OK/0.974950
ml	ml	NN	NN		OK/0.979080
against	gegen	IN	APPR		OK/0.989109
all	alle	DT	PIAT		OK/0.974799
seven	sieben	CD	CARD		OK/0.954222
serotypes	Serotypen	NNS	NN		OK/0.966816
in	in	IN	APPR		OK/0.979476
Prevenar	Prevenar	NP	NE		OK/0.728498
.	.	SENT	$.		OK/0.998852

# 0.908202
Adults	Erwachsene	NNS	NN		OK/0.993116
and	und	CC	KON		OK/0.998208
adolescents	Jugendliche	NNS	NN		OK/0.998922
aged	Alter	VVN	NN		OK/0.974449
13	13	CD	CARD		OK/0.996477
years	Jahren	NNS	NN		OK/0.999407
and	und	CC	KON		OK/0.998359
above	älter	JJ	ADJD		OK/0.944068
:	:	:	$.		OK/0.996812

# 0.928425
Truvada	Truvada	NP	NE		OK/0.989039
is	ist	VBZ	VAFIN		OK/0.999024
supplied	Flaschen	VVN	NN		OK/0.988276
in	in	IN	APPR		OK/0.995831
bottles	Flaschen	NNS	NN		OK/0.986907
containing	Flaschen	VVG	NN		OK/0.991935
30	30	CD	CARD		OK/0.991239
tablets	Tabletten	NNS	NN		OK/0.973754
.	.	SENT	$.		OK/0.998964

# 0.270845
In	In	IN	APPR		OK/0.958166
this	dieser	DT	PDAT		OK/0.991086
study	Studie	NN	NN		OK/0.997447
,	__unaligned__	,	__unaligned__		OK/0.921495
exercise	Belastungsdauer	NN	NN		OK/0.932138
duration	Belastungsdauer	NN	NN		OK/0.911741
was	war	VBD	VAFIN		OK/0.842003
longest	__unaligned__	JJS	__unaligned__		OK/0.411782
in	bei	IN	APPR		OK/0.554139
the	die	DT	PRELS		OK/0.625486
1500	1.500	CD	CARD		OK/0.629026
mg	mg	NN	NN		OK/0.917432
group	__unaligned__	NN	__unaligned__		OK/0.954355
.	.	SENT	$.		OK/0.998945

# 0.389275
as	da	IN	ADV		OK/0.976018
it	__unaligned__	PP	__unaligned__		OK/0.475175
may	können	MD	VMINF		OK/0.830202
have	können	VH	VMINF		OK/0.763722
serious	schwerwiegende	JJ	ADJA		OK/0.956597
side	Nebenwirkungen	NN	NN		OK/0.971062
effects	Nebenwirkungen	NNS	NN		OK/0.939896
.	.	SENT	$.		OK/0.998686

# 0.273895
When	Bei	WRB	APPR		BAD/0.748863
conservative	Ausfällungen	JJ	NN		BAD/0.804170
management	__unaligned__	NN	__unaligned__		BAD/0.611327
of	__unaligned__	IN	__unaligned__		OK/0.709468
reconstituted	rekonstituierte	VVN	ADJA		OK/0.901752
suspension	Suspension	NN	NN		OK/0.995886
should	sollte	MD	VMFIN		OK/0.990389
be	sollte	VB	VMFIN		OK/0.983152
discarded	verworfen	VVN	VVPP		OK/0.988207
.	.	SENT	$.		OK/0.999652

# 0.052402
Pull	Ziehen	VV	NN		OK/0.959253
the	__unaligned__	DT	__unaligned__		OK/0.998687
plunger	Kolben	NN	NN		OK/0.991329
of	dazu	IN	PAV		OK/0.925055
the	der	DT	ART		OK/0.986455
syringe	Applikationsspritze	NN	NN		BAD/0.534946
and	und	CC	KON		BAD/0.526379
both	beide	DT	PIAT		BAD/0.656731
parts	Teile	NNS	NN		BAD/0.700296
,	__unaligned__	,	__unaligned__		OK/0.697855
wash	waschen	VVP	VVFIN		OK/0.798237
the	waschen	DT	VVFIN		OK/0.884564
area	waschen	NN	VVFIN		BAD/0.519468
with	mit	IN	APPR		BAD/0.374204
warmem	warmem	NP	ADJA		BAD/0.555651
Seifenwasser	Seifenwasser	NP	NN		BAD/0.652398
.	.	SENT	$.		OK/0.992187

# 0.054061
Hold	Halten	VVP	VVFIN		OK/0.971086
your	Ihren	PP$	PPOSAT		OK/0.923575
breath	Atem	NN	NN		OK/0.750439
for	__unaligned__	IN	__unaligned__		OK/0.356051
about	etwa	RB	ADV		OK/0.609849
10	10	CD	CARD		OK/0.934623
seconds	Sekunden	NNS	NN		OK/0.902114
or	bzw.	CC	KON		OK/0.570901
for	lange	IN	ADV		OK/0.447617
as	lange	RB	ADV		OK/0.524136
long	lange	JJ	ADV		OK/0.568092
as	lange	IN	ADV		OK/0.616129
you	Ihnen	PP	PPER		OK/0.554193
can	__unaligned__	MD	__unaligned__		OK/0.353540
.	.	SENT	$.		OK/0.979992

# 0.643640
One	Eine	CD	ART		OK/0.710452
Fluconazol-Dosis	Fluconazol-Dosis	NN	NN		OK/0.806460
greater	mehr	JJR	ADV		OK/0.959068
than	mehr	IN	ADV		OK/0.986270
200	200	CD	CARD		OK/0.989249
mg	mg	NN	NN		OK/0.997133
/	/	SYM	$(		OK/0.999780
day	Tag	NN	NN		OK/0.998733
is	empfohlen	VBZ	VVPP		OK/0.980382
not	nicht	RB	PTKNEG		OK/0.988675
recommended	empfohlen	VVN	VVPP		OK/0.985793
.	.	SENT	$.		OK/0.997986

# 0.683204
Please	Bitte	RB	NN		OK/0.998279
follow	befolgen	VV	VVFIN		OK/0.998076
the	befolgen	DT	VVFIN		OK/0.996777
instructions	befolgen	NNS	VVFIN		OK/0.992763
in	in	IN	APPR		OK/0.998652
this	diesem	DT	PDAT		OK/0.993685
section	Abschnitt	NN	NN		OK/0.995461
,	,	,	$,		OK/0.965315
if	wenn	IN	KOUS		OK/0.983310
you	Sie	PP	PPER		OK/0.998552
want	__unaligned__	VVP	__unaligned__		OK/0.992918
to	wollen	TO	VMFIN		OK/0.980140
store	__unaligned__	VV	__unaligned__		OK/0.978289
the	den	DT	ART		OK/0.963583
pen	Pen	NN	NN		OK/0.960995
for	__unaligned__	IN	__unaligned__		OK/0.916445
the	ersten	DT	ADJA		OK/0.957727
first	ersten	JJ	ADJA		OK/0.989357
time	Mal	NN	NN		OK/0.984304
must	verwen-	MD	TRUNC		OK/0.935416
or	oder	CC	KON		OK/0.997168
empty	leere	JJ	ADJA		OK/0.985603
cartridge	Zylinderampulle	NN	NN		OK/0.929858
.	.	SENT	$.		OK/0.996808

# 0.407102
Make	Achten	NP	VVFIN		OK/0.971850
sure	Achten	RB	VVFIN		OK/0.931244
the	__unaligned__	DT	__unaligned__		OK/0.879124
tip	__unaligned__	NN	__unaligned__		OK/0.881936
of	__unaligned__	IN	__unaligned__		OK/0.808888
the	Nadel	DT	NN		OK/0.998105
needle	Nadel	NN	NN		OK/0.906762
with	mit	IN	APPR		OK/0.979831
the	__unaligned__	DT	__unaligned__		OK/0.950488
infant	nichts	NN	PIS		OK/0.615050
.	.	SENT	$.		OK/0.996216

# 0.870132
Which	Gewährleistung	WDT	NN		OK/0.915713
measures	Gewährleistung	NNS	NN		OK/0.997733
are	Gewährleistung	VBP	NN		OK/0.998314
being	Gewährleistung	VBG	NN		OK/0.998540
taken	Gewährleistung	VVN	NN		OK/0.999838
to	Gewährleistung	TO	NN		OK/0.998819
ensure	Gewährleistung	VV	NN		OK/0.994192
the	sicheren	DT	ADJA		OK/0.996976
safe	von	JJ	APPR		OK/0.999553
use	__unaligned__	NN	__unaligned__		OK/0.988506
of	Anwendung	IN	NN		OK/0.997262
ReFacto	ReFacto	NP	NE		OK/0.998983
AF	AF	NP	NN		OK/0.977706
?	?	SENT	$.		OK/0.997792

# 0.796088
Remeron	Remeron	NP	NN		OK/0.993215
15	15	CD	CARD		OK/0.998669
mg	mg	NN	NN		OK/0.999917
film-coated	Filmtabletten	NN	NN		OK/0.996372
tablets	Filmtabletten	NNS	NN		OK/0.999587
contain	enthalten	VVP	VVFIN		OK/0.993690
15	15	CD	CARD		OK/0.998231
mg	mg	NN	NN		OK/0.999406
mirtazapine	Mirtazapin	NN	NE		OK/0.933697
per	pro	IN	APPR		OK/0.868032
film-coated	Filmtablette	NN	NN		OK/0.885946
tablet	Filmtablette	NN	NN		OK/0.967120
.	.	SENT	$.		OK/0.995954

# 0.273079
not	eventuell	RB	ADJD		OK/0.815228
associated	Zusammenhang	VVN	NN		OK/0.819110
with	mit	IN	APPR		OK/0.905825
bleeding	Blutungen	VVG	NN		OK/0.907507
of	die	IN	PRELS		OK/0.799430
the	__unaligned__	DT	__unaligned__		OK/0.946724
skin	Pünktchen	NN	NN		OK/0.958601
as	Pünktchen	IN	NN		OK/0.953783
red	Pünktchen	JJ	NN		OK/0.961213
pinpoint	Pünktchen	NN	NN		OK/0.934797
dots	Pünktchen	NNS	NN		OK/0.811126
under	unter	IN	APPR		OK/0.932367
the	Haut	DT	NN		OK/0.974053
skin	Haut	NN	NN		OK/0.971567
,	,	,	$,		OK/0.928117
and	und	CC	KON		OK/0.992711
/	/	SYM	$(		OK/0.996174
or	oder	CC	KON		OK/0.995821
confusion	Verwirrtheit	NN	NN		OK/0.914427
(	siehe	(	VVIMP		OK/0.998849
see	siehe	VV	VVIMP		OK/0.999649
"	"	``	$(		OK/0.998896
Take	Besondere	VV	ADJA		OK/0.995112
special	Besondere	JJ	ADJA		OK/0.999418
care	Besondere	NN	ADJA		OK/0.999123
with	von	IN	APPR		OK/0.982932
Clopidogrel	Clopidogrel	NP	NE		OK/0.999605
BMS	BMS	NP	NN		OK/0.974726
'	"	''	$(		OK/0.716209
)	)	)	$(		OK/0.956515
.	.	SENT	$.		OK/0.998906

# 0.875716
Insuman	Insuman	NP	NN		OK/0.997669
Comb	Comb	NP	NN		OK/0.999041
50	50	CD	CARD		OK/0.993377
in	in	IN	APPR		OK/0.998703
cartridges	Patronen	NNS	NN		OK/0.996332
for	für	IN	APPR		OK/0.997286
OptiClik	OptiClik	NP	NN		OK/0.996560
has	OptiClik	VHZ	NN		OK/0.996292
been	OptiClik	VBN	NN		OK/0.980900
developed	OptiClik	VVN	NN		OK/0.941178
for	Anwendung	IN	NN		OK/0.974515
use	__unaligned__	NN	__unaligned__		OK/0.991492
with	mit	IN	APPR		OK/0.998488
OptiClik	OptiClik	NP	NN		OK/0.972580
.	.	SENT	$.		OK/0.999405

# 0.014271
The	Das	NP	ART		OK/0.978955
Arzneimittel-Arzneimittel-Wechselwirkungspotential	Arzneimittel-Arzneimittel-Wechselwirkungspotential	NP	NN		OK/0.678406
on	auf	IN	APPR		OK/0.800471
the	__unaligned__	DT	__unaligned__		OK/0.894153
absorbent-unit	Kationen-	NN	TRUNC		OK/0.617451
web	__unaligned__	NN	__unaligned__		OK/0.588494
to	organische	TO	ADJA		OK/0.628760
the	__unaligned__	DT	__unaligned__		OK/0.765194
same	__unaligned__	JJ	__unaligned__		OK/0.887899
renal	__unaligned__	JJ	__unaligned__		OK/0.911387
transporter	Transporter	NN	NN		OK/0.906186
(	(	(	$(		OK/0.875611
"	"	``	$(		OK/0.878094
organic	organic	JJ	NE		OK/0.724884
Indication	cation	NN	NN		OK/0.615269
transporter	transporter	NN	NN		OK/0.541652
,	,	,	$,		OK/0.551084
"	"	''	$(		OK/0.460739
,	,	,	$,		OK/0.495699
between	zwischen	IN	APPR		OK/0.864543
methylnaltrexone	Methylnaltrexonium	NN	NN		OK/0.865976
and	und	CC	KON		OK/0.995733
OCT-Hemmer	OCT-Hemmer	NP	NN		OK/0.967027
was	wurde	VBD	VAFIN		OK/0.991591
studied	untersucht	VVN	VVPP		OK/0.968151
in	untersucht	IN	VVPP		OK/0.974081
18	18	CD	CARD		OK/0.930723
healthy	gesunden	JJ	ADJA		OK/0.875315
subjects	Probanden	NNS	NN		OK/0.934495
.	.	SENT	$.		OK/0.865136
The	Dazu	DT	PAV		OK/0.837418
pharmacokinetic	pharmakokinetische	JJ	ADJA		OK/0.960150
profiles	Profile	NNS	NN		OK/0.908697
of	__unaligned__	IN	__unaligned__		OK/0.751751
methylnaltrexone	Methylnaltrexonium	NN	NN		OK/0.542308
were	wurden	VBD	VAFIN		OK/0.502441
taken	__unaligned__	VVN	__unaligned__		OK/0.489034
before	vor	IN	PTKVZ		OK/0.816391
and	und	CC	KON		OK/0.851691
after	nach	IN	APPR		OK/0.987618
multiple	mehreren	JJ	PIAT		OK/0.988354
doses	Dosen	NNS	NN		OK/0.999642
of	__unaligned__	IN	__unaligned__		OK/0.783835
400	400	CD	CARD		OK/0.988986
mg	mg	NN	NN		OK/0.997914
of	von	IN	APPR		OK/0.997607
cimetidine	Cimetidin	NN	NE		OK/0.951794
.	.	SENT	$.		OK/0.999592

# 0.783860
Excipient	Sonstiger	NP	ADJA		OK/0.978333
:	:	:	$.		OK/0.993963
each	__unaligned__	DT	__unaligned__		OK/0.898654
film-coated	Filmtablette	NN	NN		OK/0.993011
tablet	Filmtablette	NN	NN		OK/0.995886
contains	Jede	VVZ	PIAT		OK/0.917751
249.6	249,6	CD	CARD		OK/0.940930
mg	mg	NN	NN		OK/0.998985
of	__unaligned__	IN	__unaligned__		OK/0.997764
lactose	Lactose-Monohydrat	NN	NN		OK/0.999453
monohydrate	Lactose-Monohydrat	NN	NN		OK/0.997670
.	.	SENT	$.		OK/0.999905

# 0.912963
Do	Nehmen	VVP	VVFIN		OK/0.995311
not	nicht	RB	PTKNEG		OK/0.995439
take	Nehmen	VV	VVFIN		OK/0.998943
one	Morgen	CD	NN		OK/0.996077
tablet	Morgen	NN	NN		OK/0.977446
on	Morgen	IN	NN		OK/0.990230
the	Morgen	DT	NN		OK/0.998213
morning	Morgen	NN	NN		OK/0.995559
to	__unaligned__	TO	__unaligned__		OK/0.985642
make	doppelte	VV	ADJA		OK/0.989380
up	doppelte	RP	ADJA		OK/0.999208
for	doppelte	IN	ADJA		OK/0.994380
a	doppelte	DT	ADJA		OK/0.995614
forgotten	doppelte	JJ	ADJA		OK/0.994612
dose	Dosis	NN	NN		OK/0.988945
.	.	SENT	$.		OK/0.999553

# 0.896288
The	Die	DT	ART		OK/0.997892
concomitant	gleichzeitige	JJ	ADJA		OK/0.991866
use	gleichzeitige	NN	ADJA		OK/0.996951
of	gleichzeitige	IN	ADJA		OK/0.998482
ribavirin	Ribavirin	NN	NN		OK/0.998618
and	und	CC	KON		OK/0.999014
didanosine	Didanosin	NN	NN		OK/0.983200
is	empfohlen	VBZ	VVPP		OK/0.933635
not	nicht	RB	PTKNEG		OK/0.978722
recommended	empfohlen	VVN	VVPP		OK/0.982967
.	.	SENT	$.		OK/0.997854

# 0.504232
Therefore	Daher	RB	PAV		OK/0.994139
,	Daher	,	PAV		OK/0.986706
the	der	DT	ART		OK/0.917240
use	Anwendung	NN	NN		OK/0.973809
of	__unaligned__	IN	__unaligned__		OK/0.991106
Dynastat	Dynastat	NP	NN		OK/0.978164
with	mit	IN	APPR		OK/0.987960
medicinal	Arzneimitteln	JJ	NN		OK/0.964019
products	Arzneimitteln	NNS	NN		OK/0.986529
known	bekannterweise	VVN	VVFIN		OK/0.992041
to	__unaligned__	TO	__unaligned__		OK/0.979503
induce	__unaligned__	VV	__unaligned__		OK/0.972278
are	CYP2C19-Substrate	VBP	NN		OK/0.977946
CYP2C19	CYP2C19-Substrate	NP	NN		OK/0.992197
substrates	CYP2C19-Substrate	NNS	NN		OK/0.963808
(	(	(	$(		OK/0.995055
e.	z.	FW	APPRART		OK/0.985723
g.	B.	FW	NN		OK/0.990211
phenytoin	Phenytoin	NN	NN		OK/0.995637
,	Diazepam	,	NN		OK/0.970992
diazepam	Diazepam	NN	NN		OK/0.943862
,	Diazepam	,	NN		OK/0.947721
or	oder	CC	KON		OK/0.981657
imipramine	Imipramin	NN	NN		OK/0.896113
)	)	)	$(		OK/0.988204
,	,	,	$,		OK/0.987747
caution	Vorsicht	NN	NN		OK/0.992602
should	Vorsicht	MD	NN		OK/0.938644
be	Vorsicht	VB	NN		OK/0.908724
used	Vorsicht	VVN	NN		OK/0.874111
.	.	SENT	$.		OK/0.991024

# 0.777344
combination	Kombination	NN	NN		OK/0.987680
with	mit	IN	APPR		OK/0.998077
insulin	Insulin	NN	NN		OK/0.995324
in	In	IN	APPR		OK/0.997577
clinical	klinischen	JJ	ADJA		OK/0.976450
trials	Prüfungen	NNS	NN		OK/0.985187
an	erhöhte	DT	ADJA		OK/0.987221
increased	erhöhte	VVN	ADJA		OK/0.999789
incidence	Inzidenz	NN	NN		OK/0.998408
of	Inzidenz	IN	NN		OK/0.990591
heart	Herzinsuffizienz	NN	NN		OK/0.989047
failure	Herzinsuffizienz	NN	NN		OK/0.953178
has	beobachtet	VHZ	VVPP		OK/0.879354
been	beobachtet	VBN	VVPP		OK/0.984497
observed	beobachtet	VVN	VVPP		OK/0.991331
when	wenn	WRB	KOUS		OK/0.996604
rosiglitazone	Rosiglitazon	NN	NN		OK/0.997317
was	wurde	VBD	VAFIN		OK/0.986187
used	angewendet	VVN	VVPP		OK/0.998543
in	Kombination	IN	NN		OK/0.997590
combination	Kombination	NN	NN		OK/0.998210
with	mit	IN	APPR		OK/0.997822
insulin	Insulin	NN	NN		OK/0.996643
.	.	SENT	$.		OK/0.999651

# 0.508423
Take	Angstzuständen	VVP	NN		OK/0.739379
special	Angstzuständen	JJ	NN		OK/0.762820
care	Angstzuständen	NN	NN		OK/0.651699
with	und	IN	KON		OK/0.764709
Kaletra	Angstzuständen	NP	NN		OK/0.792802
)	)	)	$(		OK/0.936677
.	.	SENT	$.		OK/0.996085

# 0.403795
92	92	CD	CARD		OK/0.948472
In	In	IN	APPR		OK/0.967330
a	einer	DT	ART		OK/0.921286
clinical	klinischen	JJ	ADJA		OK/0.984026
trial	Studie	NN	NN		OK/0.975081
in	gesunden	IN	ADJA		OK/0.842915
healthy	gesunden	JJ	ADJA		OK/0.973173
subjects	Probanden	NNS	NN		OK/0.994522
,	__unaligned__	,	__unaligned__		OK/0.975056
a	__unaligned__	DT	__unaligned__		OK/0.915402
potent	ein	JJ	ART		OK/0.912434
inhibitor	__unaligned__	NN	__unaligned__		OK/0.914212
of	__unaligned__	IN	__unaligned__		OK/0.972856
CYP2D6	CYP2D6-Inhibitor	NP	NN		OK/0.985313
(	(	(	$(		OK/0.996848
quinidine	Chinidin	NN	NE		OK/0.962549
)	)	)	$(		OK/0.998008
increased	steigerte	VVN	VVFIN		OK/0.972356
aripiprazole	Aripiprazol	NN	NN		OK/0.993323
AUC	AUC	NN	NE		OK/0.996751
by	die	IN	ART		OK/0.886223
107	107	CD	CARD		OK/0.986551
%	%	NN	NN		OK/0.995984
respectively	%	RB	NN		OK/0.987309
,	,	,	$,		OK/0.993125
Cmax	Cmax	NP	NN		OK/0.928113
being	unverändert	VBG	ADJD		OK/0.831720
unchanged	unverändert	JJ	ADJD		OK/0.973721
.	.	SENT	$.		OK/0.999851

# 0.813529
Therefore	Daher	RB	PAV		OK/0.995479
,	Daher	,	PAV		OK/0.995051
you	Sie	PP	PPER		OK/0.989053
should	sollten	MD	VMFIN		OK/0.998764
not	nicht	RB	PTKNEG		OK/0.991151
take	einnehmen	VV	VVINF		OK/0.992384
Januvia	Januvia	NP	NE		OK/0.973322
if	wenn	IN	KOUS		OK/0.995547
you	Sie	PP	PPER		OK/0.991614
are	stillen	VBP	VVINF		OK/0.983062
breast-feeding	stillen	VVG	VVINF		OK/0.998254
or	bzw.	CC	KON		OK/0.985805
plan	wollen	NN	VMFIN		OK/0.966449
to	wollen	TO	VMFIN		OK/0.951598
breast-feed	stillen	VV	VVINF		OK/0.920631
.	.	SENT	$.		OK/0.998948

# 0.104694
Insulin	Human	NP	NE		OK/0.999477
Human	Human	NP	NE		OK/0.999695
Winthrop	Winthrop	NP	NE		OK/0.999907
Comb	Comb	NP	NN		OK/0.999119
25	25	CD	CARD		OK/0.999317
comes	wird	VVZ	VAFIN		OK/0.993779
in	Patronen	IN	NN		OK/0.995308
a	__unaligned__	DT	__unaligned__		OK/0.998417
cartridge	in	NN	APPR		OK/0.873182
sealed	__unaligned__	VVN	__unaligned__		OK/0.980708
in	__unaligned__	IN	__unaligned__		OK/0.976432
a	Patronenhaltern	DT	NN		OK/0.827569
plastic	Patronenhaltern	JJ	NN		OK/0.640801
container	Patronenhaltern	NN	NN		OK/0.590247
,	,	,	$,		OK/0.783728
which	den	WDT	ART		OK/0.764611
is	__unaligned__	VBZ	__unaligned__		OK/0.775623
the	__unaligned__	DT	__unaligned__		OK/0.964354
disposable	auswechselbaren	JJ	ADJA		OK/0.804256
part	;	NN	$.		OK/0.992598
of	__unaligned__	IN	__unaligned__		OK/0.991726
OptiClik	OptiClik	NP	NN		OK/0.596182
,	__unaligned__	,	__unaligned__		OK/0.406353
an	__unaligned__	DT	__unaligned__		OK/0.439761
insulin	__unaligned__	NN	__unaligned__		OK/0.972448
pen	des	NN	ART		OK/0.984057
.	.	SENT	$.		OK/0.999328

# 0.272490
The	Die	DT	ART		OK/0.984187
tmax	tmax	NN	ADJA		OK/0.703093
and	sowie	CC	KON		OK/0.725440
the	die	DT	ART		OK/0.944915
half-life	Halbwertszeit	NN	NN		OK/0.918436
remained	blieben	VVD	VVFIN		OK/0.704191
unchanged	unverändert	JJ	ADJD		OK/0.421033
.	.	SENT	$.		OK/0.998092

# 0.446021
In	In	IN	APPR		OK/0.977812
a	einer	DT	ART		OK/0.983926
second	__unaligned__	JJ	__unaligned__		OK/0.957176
study	Studie	NN	NN		OK/0.996918
,	__unaligned__	,	__unaligned__		OK/0.908138
children	Kinder	NNS	NN		OK/0.997883
aged	Alter	VVD	NN		OK/0.991108
2	2	CD	CARD		OK/0.997099
to	bis	TO	KON		OK/0.998651
15	15	CD	CARD		OK/0.992369
years	Jahren	NNS	NN		OK/0.986628
with	mit	IN	APPR		OK/0.993696
moderate	mittelschwerem	JJ	ADJA		OK/0.992001
to	bis	TO	KON		OK/0.977358
severe	schwerem	JJ	ADJA		OK/0.958348
atopic	atopischen	JJ	ADJA		OK/0.901612
dermatitis	atopischen	NN	ADJA		OK/0.834750
twice	zweimal	RB	ADV		OK/0.974463
daily	täglich	JJ	ADJD		OK/0.995763
for	über	IN	APPR		OK/0.978554
three	drei	CD	CARD		OK/0.998785
weeks	Wochen	NNS	NN		OK/0.996014
of	__unaligned__	IN	__unaligned__		OK/0.985767
0.03	0,03	CD	CARD		OK/0.994522
%	%	NN	NN		OK/0.996794
tacrolimus	Tacrolimussalbe	NN	NN		OK/0.997533
ointment	Tacrolimussalbe	NN	NN		OK/0.998715
,	,	,	$,		OK/0.994504
0.1	0,1	CD	CARD		OK/0.996381
%	%	NN	NN		OK/0.998337
tacrolimus	Tacrolimussalbe	NN	NN		OK/0.993442
ointment	Tacrolimussalbe	NN	NN		OK/0.996776
or	oder	CC	KON		OK/0.998240
1	1	CD	CARD		OK/0.997926
%	%	NN	NN		OK/0.994711
Hydrokortison-Acetat-Salbe	Hydrokortison-Acetat-Salbe	NP	NN		OK/0.739438
.	.	SENT	$.		OK/0.997504

# 0.109633
The	Die	NP	ART		OK/0.883299
Influenza-Diagnose	Influenza-Diagnose	NP	NN		BAD/0.719963
was	konnte	VBD	VMFIN		BAD/0.546302
confirmed	bestätigt	VVN	VVPP		BAD/0.351268
in	bei	IN	APPR		BAD/0.359932
163	163	CD	CARD		BAD/0.332282
out	__unaligned__	RB	__unaligned__		BAD/0.404470
of	__unaligned__	IN	__unaligned__		BAD/0.439263
377	377	CD	CARD		BAD/0.531594
Erstfällen	Erstfällen	NP	NN		BAD/0.594240
.	.	SENT	$.		OK/0.992855

# 0.019015
478	478	CD	CARD		OK/0.859032
of	der	IN	ART		OK/0.910071
the	der	DT	ART		OK/0.940002
enrolled	eingeschlossenen	VVN	ADJA		OK/0.684669
patients	Patienten	NNS	NN		OK/0.881011
(	(	(	$(		OK/0.978866
32	32	CD	CARD		OK/0.997541
%	%	NN	NN		OK/0.996855
)	)	)	$(		OK/0.995646
severe	schwer	JJ	ADJD		OK/0.962479
disease	schwer	NN	ADJD		OK/0.943382
(	(	(	$(		OK/0.973507
CDAI	CDAI	NP	NE		OK/0.975542
score	Score	NN	NE		OK/0.977674
>	>	SYM	$(		BAD/0.815469
300	300	CD	CARD		BAD/0.554353
and	__unaligned__	CC	__unaligned__		BAD/0.644596
concomitant	gleichzeitiger	JJ	ADJA		BAD/0.796998
corticosteroid	__unaligned__	NN	__unaligned__		BAD/0.889265
and	__unaligned__	CC	__unaligned__		BAD/0.970724
/	__unaligned__	SYM	__unaligned__		BAD/0.965432
or	__unaligned__	CC	__unaligned__		BAD/0.933230
taking	Einnahme	VVG	NN		BAD/0.535483
glucocorticoids	Glukokortikoiden	NNS	NN		OK/0.876472
,	__unaligned__	,	__unaligned__		OK/0.766585
and	und	CC	KON		OK/0.989074
/	/	SYM	$(		OK/0.992367
or	oder	CC	KON		OK/0.984669
immunomodulatory	Immunsuppressiva	JJ	NN		OK/0.759400
agents	Immunsuppressiva	NNS	NN		OK/0.687753
,	,	,	$,		BAD/0.619733
these	diese	DT	PDAT		BAD/0.752155
79	__unaligned__	CD	__unaligned__		BAD/0.915074
%	definierten	NN	ADJA		BAD/0.890960
of	__unaligned__	IN	__unaligned__		BAD/0.893753
patients	Patientengruppe	NNS	NN		BAD/0.836924
(	siehe	(	VVIMP		OK/0.955633
see	siehe	VV	VVIMP		OK/0.975878
section	Abschnitt	NN	NN		OK/0.997211
4.1	4.1	CD	CARD		OK/0.995003
)	)	)	$(		OK/0.994050
.	.	SENT	$.		OK/0.997740

# 0.353678
a	Dreimonatspackung	DT	NN		OK/0.953956
3-month	Dreimonatspackung	JJ	NN		OK/0.931760
pack	Dreimonatspackung	NN	NN		OK/0.973611
containing	Dreimonatspackung	VVG	NN		OK/0.968851
42	42	CD	CARD		OK/0.973479
(	(	(	$(		OK/0.983051
3	3	CD	CARD		OK/0.975850
x	×	SYM	XY		OK/0.921368
14	14	CD	CARD		OK/0.913078
)	)	)	$(		OK/0.979010
single	Einzeldosispackungen	JJ	NN		OK/0.903082
packs	Einzeldosispackungen	NNS	NN		OK/0.891076
,	__unaligned__	,	__unaligned__		OK/0.663128
each	__unaligned__	DT	__unaligned__		OK/0.593912
containing	__unaligned__	VVG	__unaligned__		OK/0.578128
:	:	:	$.		OK/0.985179

# 0.230619
Unscrew	Schrauben	NP	VVFIN		BAD/0.655250
the	Schrauben	DT	VVFIN		BAD/0.400862
the	Entnahmevorrichtung	DT	NN		BAD/0.321877
spike	Entnahmevorrichtung	NN	NN		BAD/0.422355
tip	Entnahmevorrichtung	NN	NN		BAD/0.550885
.	.	SENT	$.		OK/0.996267

# 0.640565
Frequently	Oft	NP	ADV		OK/0.855250
with	__unaligned__	IN	__unaligned__		OK/0.920188
1	1	CD	CARD		OK/0.969702
or	oder	CC	KON		OK/0.998187
2	2	CD	CARD		OK/0.983297
leukaphereses	Leukapheresen	NNS	NN		OK/0.906497
on	Leukapheresen	IN	NN		OK/0.962227
days	Tagen	NNS	NN		OK/0.989144
5	5	CD	CARD		OK/0.914168
and	und	CC	KON		OK/0.970975
6	6	CD	CARD		OK/0.933758
.	.	SENT	$.		OK/0.998760

# 0.121068
If	Blutet	IN	NN		OK/0.868278
there	__unaligned__	EX	__unaligned__		OK/0.842925
is	__unaligned__	VBZ	__unaligned__		OK/0.910452
bleeding	__unaligned__	VVG	__unaligned__		OK/0.970038
,	die	,	ART		OK/0.923929
cover	__unaligned__	VV	__unaligned__		OK/0.944079
with	mit	IN	APPR		OK/0.971372
an	__unaligned__	DT	__unaligned__		OK/0.897417
adhesive	__unaligned__	JJ	__unaligned__		OK/0.827176
bandage	__unaligned__	NN	__unaligned__		OK/0.822299
.	.	SENT	$.		OK/0.999284
•	•	NP	ADJA		OK/0.999497
Discard	Entsorgen	NP	NN		OK/0.968458
the	den	DT	ART		OK/0.996279
PegIntron	PegIntron-Injektor	NP	NN		OK/0.991134
pre-filled	PegIntron-Injektor	JJ	NN		OK/0.995635
pen	vorgefüllten	NN	ADJA		OK/0.991565
with	mit	IN	APPR		OK/0.998277
the	__unaligned__	DT	__unaligned__		OK/0.998916
needle	Nadel	NN	NN		OK/0.965762
safely	sicher	RB	ADJD		OK/0.830160
in	in	IN	APPR		OK/0.809103
a	__unaligned__	DT	__unaligned__		OK/0.352566
closed	__unaligned__	JJ	__unaligned__		OK/0.638030
rigid	__unaligned__	JJ	__unaligned__		OK/0.676359
container	__unaligned__	NN	__unaligned__		OK/0.562019
.	.	SENT	$.		OK/0.995867

# 0.987666
Patients	Patienten	NPS	NN		OK/0.998161
with	mit	IN	APPR		OK/0.999172
impaired	eingeschränkter	JJ	ADJA		OK/0.996809
liver	Leberfunktion	NN	NN		OK/0.998229
function	Leberfunktion	NN	NN		OK/0.998399
:	:	:	$.		OK/0.996246

# 0.240567
Duloxetine	Duloxetin	NP	NN		OK/0.891232
normalised	Schmerzschwelle	VVD	NN		OK/0.912738
pain	Schmerzschwelle	NN	NN		OK/0.930310
thresholds	Schmerzschwelle	NNS	NN		OK/0.787184
in	Schmerzschwelle	IN	NN		OK/0.799636
several	Schmerzschwelle	JJ	NN		OK/0.787414
preclinical	präklinischen	JJ	ADJA		OK/0.916954
models	Modellen	NNS	NN		OK/0.603837
of	für	IN	APPR		OK/0.595067
neuropathic	neuropathische	JJ	ADJA		OK/0.627123
and	und	CC	KON		OK/0.916487
inflammatory	entzündliche	JJ	ADJA		OK/0.854454
pain	Schmerzen	NN	NN		OK/0.947053
and	und	CC	KON		OK/0.979024
attenuated	dämpfte	JJ	VVFIN		OK/0.919250
pain	Schmerzverhalten	NN	NN		OK/0.979825
behaviour	für	NN	APPR		OK/0.982126
in	__unaligned__	IN	__unaligned__		OK/0.970792
chronic	chronische	JJ	ADJA		OK/0.951628
pain	Schmerzen	NN	NN		OK/0.982404
.	.	SENT	$.		OK/0.999534

# 0.686351
Norvir	Norvir	NP	NN		OK/0.980423
should	sollte	MD	VMFIN		OK/0.974589
only	nur	RB	ADV		OK/0.998963
be	sollte	VB	VMFIN		OK/0.993275
given	verabreicht	VVN	VVPP		OK/0.916849
by	Ärzten	IN	NN		OK/0.975248
doctors	Ärzten	NNS	NN		OK/0.992082
who	,	WP	$,		OK/0.962036
are	__unaligned__	VBP	__unaligned__		OK/0.982869
experienced	Erfahrung	VVN	NN		OK/0.979571
in	in	IN	APPR		OK/0.997964
the	in	DT	APPR		OK/0.922819
treatment	Behandlung	NN	NN		OK/0.967858
of	Behandlung	IN	NN		OK/0.940432
HIV	HIV-	NP	TRUNC		OK/0.923789
infection	Infektionen	NN	NN		OK/0.983137
.	.	SENT	$.		OK/0.999572

# 0.034045
If	Falls	IN	KOUS		OK/0.972190
you	Sie	PP	PPER		OK/0.995388
see	sehen	VVP	VVINF		OK/0.961057
air	Luftblasen	NN	NN		OK/0.971170
bubbles	Luftblasen	NNS	NN		OK/0.987864
,	,	,	$,		OK/0.991690
pull	ziehen	VVP	VVFIN		OK/0.885942
the	__unaligned__	DT	__unaligned__		OK/0.885014
plunger	Kolben	NN	NN		OK/0.797859
slightly	leicht	RB	ADJD		OK/0.899684
back	zurück	RB	PTKVZ		OK/0.794647
.	.	SENT	$.		OK/0.984332
Tap	Klopfen	VV	VVFIN		OK/0.947333
the	Spritze	DT	NN		OK/0.991918
syringe	Spritze	NN	NN		OK/0.813312
gently	sanft	RB	ADJD		BAD/0.647303
,	,	,	$,		BAD/0.758358
with	__unaligned__	IN	__unaligned__		BAD/0.764621
the	__unaligned__	DT	__unaligned__		BAD/0.425426
needle	die	NN	ART		BAD/0.647384
pointing	nach	VVG	APPR		BAD/0.660327
up	__unaligned__	RP	__unaligned__		OK/0.671656
,	__unaligned__	,	__unaligned__		OK/0.837591
until	bis	IN	KOUS		OK/0.967755
the	die	DT	ART		OK/0.984208
bubbles	Blasen	NNS	NN		OK/0.698087
disappear	verschwinden	VVP	VVINF		OK/0.665417
.	.	SENT	$.		OK/0.998962

# 0.382381
The	Die	DT	ART		OK/0.976493
syringes	Spritzen	NNS	NN		OK/0.828954
have	haben	VHP	VAFIN		OK/0.972771
a	spezielle	DT	ADJA		OK/0.997561
special	spezielle	JJ	ADJA		OK/0.995776
type	spezielle	NN	ADJA		OK/0.808571
of	__unaligned__	IN	__unaligned__		OK/0.809954
markings	Markierungen	NNS	NN		OK/0.626114
for	für	IN	APPR		OK/0.704917
this	diese	DT	PDAT		OK/0.670819
dose	Dosis	NN	NN		OK/0.842153
.	.	SENT	$.		OK/0.997413

# 0.237391
It	Es	PP	NN		OK/0.989882
is	empfiehlt	VBZ	VVFIN		OK/0.979053
recommended	empfiehlt	VVN	VVFIN		OK/0.956934
that	empfiehlt	IN/that	VVFIN		OK/0.360525
the	__unaligned__	DT	__unaligned__		OK/0.498689
symptomatic	symptomatische	JJ	ADJA		OK/0.536868
treatment	symptomatische	NN	ADJA		OK/0.590779
of	der	IN	ART		OK/0.803870
respiratory	respiratorischen	JJ	ADJA		OK/0.809415
and	und	CC	KON		OK/0.948053
haemodynamic	hämodynamischen	JJ	ADJA		OK/0.968081
symptoms	Beschwerden	NNS	NN		OK/0.976856
.	.	SENT	$.		OK/0.999856

# 0.435915
If	Wenn	IN	KOUS		OK/0.985089
after	nach	IN	APPR		OK/0.973066
30	30	CD	CARD		OK/0.997522
minutes	Minuten	NNS	NN		OK/0.993594
,	__unaligned__	,	__unaligned__		OK/0.770882
if	verblieben	IN	VVPP		OK/0.659094
remnants	verblieben	NNS	VVPP		OK/0.860151
from	verblieben	IN	VVPP		OK/0.973332
the	der	DT	ART		OK/0.989544
Effentora	Effentora	NP	NE		OK/0.918489
tablet	Tablette	NN	NN		OK/0.905875
remain	verblieben	VVP	VVPP		OK/0.935670
,	,	,	$,		OK/0.985506
they	diese	PP	PDAT		OK/0.887486
may	können	MD	VMFIN		OK/0.918585
be	können	VB	VMFIN		OK/0.972262
swallowed	geschluckt	VVN	VVPP		OK/0.998551
with	geschluckt	IN	VVPP		OK/0.995977
a	Glas	DT	NN		OK/0.996094
glass	Glas	NN	NN		OK/0.999658
of	Wasser	IN	NN		OK/0.995339
water	Wasser	NN	NN		OK/0.998903
.	.	SENT	$.		OK/0.999060

# 0.259531
Do	Nicht	VVP	PTKNEG		OK/0.880675
not	Nicht	RB	PTKNEG		OK/0.940936
store	lagern	VV	VVINF		OK/0.980744
above	über	IN	APPR		OK/0.981615
30	30	CD	CARD		OK/0.947282
°	oC	SYM	NE		OK/0.877779
C	oC	NP	NE		OK/0.486074
)	__unaligned__	)	__unaligned__		OK/0.334183
.	.	SENT	$.		OK/0.839561

# 0.942832
Ziagen	Ziagen	NP	NN		OK/0.991650
is	ist	VBZ	VAFIN		OK/0.998803
also	auch	RB	ADV		OK/0.992687
available	als	JJ	KOKOM		OK/0.990735
as	__unaligned__	IN	__unaligned__		OK/0.994224
tablets	Tablette	NNS	NN		OK/0.967844
.	.	SENT	$.		OK/0.998741

# 0.852014
Hypersensitivity	Überempfindlichkeit	NP	NN		OK/0.997364
to	gegen	TO	APPR		OK/0.984684
travoprost	Travoprost	NN	NN		OK/0.989383
,	,	,	$,		OK/0.996662
timolol	Timolol	NN	NN		OK/0.962970
or	Bestandteile	CC	NN		OK/0.987678
any	Bestandteile	DT	NN		OK/0.993076
of	Bestandteile	IN	NN		OK/0.977070
the	Bestandteile	DT	NN		OK/0.989246
other	Bestandteile	JJ	NN		OK/0.959584
ingredients	sonstigen	NNS	ADJA		OK/0.958030
.	.	SENT	$.		OK/0.998669

# 0.092017
The	Die	DT	ART		OK/0.994616
solution	Lösung	NN	NN		OK/0.994523
in	in	IN	APPR		OK/0.955336
type	Typ	NN	NN		OK/0.955828
I	I	NP	NN		OK/0.872255
Klarglasflaschen	Klarglasflaschen	NP	NN		BAD/0.756541
,	,	,	$,		BAD/0.666247
these	sen	DT	VVFIN		BAD/0.778460
verschlos-	verschlos-	NN	TRUNC		BAD/0.778771
and	__unaligned__	CC	__unaligned__		BAD/0.481414
plunger	__unaligned__	NN	__unaligned__		OK/0.872547
heads	__unaligned__	NNS	__unaligned__		OK/0.909058
and	und	CC	KON		OK/0.963438
secured	Aluminiumkappen	VVN	NN		OK/0.857811
with	mit	IN	APPR		OK/0.967450
aluminium	__unaligned__	NN	__unaligned__		OK/0.980940
seals	__unaligned__	NNS	__unaligned__		OK/0.834071
Halobutylstopfen	Halobutylstopfen	NP	NN		OK/0.534680
.	.	SENT	$.		OK/0.994336

# 0.159344
One	Ein	CD	ART		OK/0.957472
patient	Patient	NN	NN		OK/0.984442
with	mit	IN	APPR		OK/0.975066
severe	schwerer	JJ	ADJA		OK/0.996040
rheumatoid	rheumatoider	JJ	ADJA		OK/0.993788
arthritis	rheumatoider	NN	ADJA		OK/0.954449
,	,	,	$,		BAD/0.452760
the	die	DT	ART		BAD/0.533172
disease	Krankheit	NN	NN		BAD/0.696050
for	über	IN	APPR		BAD/0.847886
a	eine	DT	ART		OK/0.920226
long	längere	JJ	ADJA		OK/0.921293
time	Zeit	NN	NN		OK/0.939399
may	könnte	MD	VMFIN		OK/0.976068
have	__unaligned__	VH	__unaligned__		OK/0.887310
had	gehabt	VHD	VAPP		OK/0.920594
more	anfälliger	RBR	ADJD		OK/0.931354
sensitive	__unaligned__	JJ	__unaligned__		OK/0.920831
to	__unaligned__	TO	__unaligned__		OK/0.942595
the	__unaligned__	DT	__unaligned__		OK/0.861688
utility	dafür	NN	PAV		OK/0.727645
of	__unaligned__	IN	__unaligned__		OK/0.853966
developing	entwickeln	VVG	VVINF		OK/0.988450
life-threatening	sein	JJ	VAINF		OK/0.993372
lymphoma	Lymphom	NN	NN		OK/0.994795
.	.	SENT	$.		OK/0.999772

# 0.130188
The	Das	DT	ART		OK/0.999343
risk	Risiko	NN	NN		OK/0.999110
of	Risiko	IN	NN		OK/0.999045
hypersensitivity	Überempfindlichkeit	NN	NN		OK/0.988665
were	war	VBD	VAFIN		OK/0.867063
greater	__unaligned__	JJR	__unaligned__		OK/0.838902
in	bei	IN	APPR		OK/0.954934
the	ersten	DT	ADJA		OK/0.993062
first	ersten	JJ	ADJA		OK/0.994640
infusions	Infusionen	NNS	NN		OK/0.977108
and	sowie	CC	KON		OK/0.989582
in	bei	IN	APPR		OK/0.989961
patients	Patienten	NNS	NN		OK/0.978215
receiving	Patienten	VVG	NN		OK/0.776701
TYSABRI	TYSABRI	NP	NN		OK/0.981577
after	nach	IN	APPR		OK/0.983079
a	__unaligned__	DT	__unaligned__		OK/0.771698
short	kurzen	JJ	ADJA		OK/0.951320
initial	anfänglich	JJ	ADJD		OK/0.893625
treatment	Behandlung	NN	NN		OK/0.914720
(	(	(	$(		OK/0.948106
after	zwei	IN	CARD		OK/0.973639
one	zwei	CD	CARD		OK/0.988835
or	oder	CC	KON		OK/0.996506
two	zwei	CD	CARD		OK/0.995220
infusions	Infusionen	NNS	NN		OK/0.984456
)	)	)	$(		OK/0.979912
and	und	CC	KON		OK/0.994442
a	__unaligned__	DT	__unaligned__		OK/0.990616
longer	längeren	RBR	ADJA		OK/0.995158
treatment-free	behandlungsfreien	JJ	ADJA		OK/0.992094
period	Zeitraum	NN	NN		OK/0.996458
(	(	(	$(		OK/0.982309
three	drei	CD	CARD		OK/0.990798
months	Monate	NNS	NN		OK/0.989906
or	oder	CC	KON		OK/0.997134
more	mehr	JJR	ADV		OK/0.968556
)	)	)	$(		OK/0.975203
who	erhielten	WP	VVFIN		OK/0.404227
received	erhielten	VVD	VVFIN		OK/0.663973
again	erneut	RB	ADJD		OK/0.732138
.	.	SENT	$.		OK/0.997679

# 0.287213
For	Die	IN	ART		OK/0.990397
a	__unaligned__	DT	__unaligned__		OK/0.995548
full	vollständige	JJ	ADJA		OK/0.997470
list	Auflistung	NN	NN		OK/0.997702
of	Auflistung	IN	NN		OK/0.999287
the	vollständige	DT	ADJA		OK/0.973294
side-effects	__unaligned__	NNS	__unaligned__		OK/0.899114
reported	berichteten	VVD	ADJA		OK/0.844723
with	mit	IN	APPR		OK/0.801546
side	Nebenwirkungen	NN	NN		BAD/0.601419
effects	Nebenwirkungen	NNS	NN		BAD/0.642489
of	__unaligned__	IN	__unaligned__		BAD/0.673630
Kaletra	Kaletra	NP	NE		OK/0.984840
,	__unaligned__	,	__unaligned__		OK/0.975386
see	entnehmen	VVP	VVINF		OK/0.999840
the	entnehmen	DT	VVINF		OK/0.999566
Package	entnehmen	NP	VVINF		OK/0.999109
Leaflet	entnehmen	NP	VVINF		OK/0.955857
.	.	SENT	$.		OK/0.999849

# 0.515242
Taking	Einnahme	VVG	NN		OK/0.962963
these	dieser	DT	PDAT		OK/0.994781
medicines	Arzneimittel	NNS	NN		OK/0.969045
concomitantly	gleichzeitig	RB	ADJD		OK/0.998987
with	mit	IN	APPR		OK/0.997433
Atripla	Atripla	NP	NE		OK/0.986818
may	kann	MD	VMFIN		OK/0.970401
cause	hervorrufen	VV	VVINF		OK/0.994343
serious	schwere	JJ	ADJA		OK/0.995225
or	oder	CC	KON		OK/0.999829
life-threatening	lebensbedrohliche	JJ	ADJA		OK/0.993507
undesirable	Nebenwirkungen	JJ	NN		OK/0.853911
effects	Nebenwirkungen	NNS	NN		OK/0.973673
,	__unaligned__	,	__unaligned__		OK/0.842956
or	oder	CC	KON		OK/0.973912
the	die	DT	ART		OK/0.903342
effectiveness	Wirksamkeit	NN	NN		OK/0.925862
of	dieser	IN	PDAT		OK/0.961064
these	dieser	DT	PDAT		OK/0.976252
medicines	Arzneimittel	NNS	NN		OK/0.892800
.	.	SENT	$.		OK/0.998707

# 0.275084
At	Zu	IN	APPR		OK/0.978444
the	der	DT	ART		OK/0.961745
beginning	Beginn	NN	NN		OK/0.976325
of	der	IN	ART		OK/0.991493
treatment	Behandlung	NN	NN		OK/0.996582
with	Behandlung	IN	NN		OK/0.935730
Viraferon	Viraferon	NP	NE		OK/0.992520
,	__unaligned__	,	__unaligned__		OK/0.975722
you	Krankheitszeichen	PP	NN		OK/0.987154
may	__unaligned__	MD	__unaligned__		OK/0.979474
experience	__unaligned__	VV	__unaligned__		OK/0.980624
a	__unaligned__	DT	__unaligned__		OK/0.992119
flu-like	grippeähnliche	JJ	ADJA		OK/0.973428
reaction	__unaligned__	NN	__unaligned__		OK/0.952650
caused	verursacht	VVN	VVFIN		OK/0.984008
by	verursacht	IN	VVFIN		OK/0.998738
reaction	__unaligned__	NN	__unaligned__		OK/0.879073
,	__unaligned__	,	__unaligned__		OK/0.833852
with	mit	IN	APPR		OK/0.999634
fever	Fieber	NN	NN		OK/0.997077
,	,	,	$,		OK/0.971136
fatigue	Ermüdung	NN	NN		OK/0.993232
,	,	,	$,		OK/0.999550
headache	Kopfschmerzen	NN	NN		OK/0.988855
,	,	,	$,		OK/0.999628
muscle	Muskelschmerzen	NN	NN		OK/0.997789
pain	Muskelschmerzen	NN	NN		OK/0.998371
,	__unaligned__	,	__unaligned__		OK/0.985287
joint	Gelenkschmerzen	JJ	NN		OK/0.994154
pain	Gelenkschmerzen	NN	NN		OK/0.996705
and	und	CC	KON		OK/0.993392
chills	Schüttelfrost	NNS	NN		OK/0.747111
/	Schüttelfrost	SYM	NN		BAD/0.749561
rigors	Schüttelfrost	NNS	NN		BAD/0.830653
.	.	SENT	$.		OK/0.988497

# 0.926073
General	Allgemein	NP	ADJD		OK/0.959330
at	sensible	IN	ADJA		OK/0.970857
species	Spezies	NNS	NN		OK/0.968601
:	:	:	$.		OK/0.998878

# 0.990359
10	10	CD	CARD		OK/0.998692
Do	Nicht	VVP	PTKNEG		OK/0.997617
not	Nicht	RB	PTKNEG		OK/0.997274
freeze	einfrieren	VV	VVINF		OK/0.997039
.	.	SENT	$.		OK/0.999063

# 0.739601
Caution	geboten	NN	VVPP		OK/0.997829
is	ist	VBZ	VAFIN		OK/0.998138
also	außerdem	RB	ADV		OK/0.993747
the	__unaligned__	DT	__unaligned__		OK/0.979682
concomitant	gleichzeitiger	JJ	ADJA		OK/0.865968
use	Anwendung	NN	NN		OK/0.986276
of	__unaligned__	IN	__unaligned__		OK/0.962908
doxazosin	Doxazosin	NN	NN		OK/0.936846
and	und	CC	KON		OK/0.996216
medicinal	Arzneimitteln	JJ	NN		OK/0.997758
products	Arzneimitteln	NNS	NN		OK/0.991142
which	können	WDT	VMINF		OK/0.987044
may	können	MD	VMINF		OK/0.996537
influence	beeinflussen	VV	VVINF		OK/0.999064
hepatic	Leberstoffwechsel	JJ	NN		OK/0.996586
metabolism	Leberstoffwechsel	NN	NN		OK/0.991356
(	(	(	$(		OK/0.991823
e.	z.	FW	APPR		OK/0.990682
g.	B.	FW	NE		OK/0.995667
cimetidine	Cimetidin	NN	NE		OK/0.986599
)	)	)	$(		OK/0.997332
.	.	SENT	$.		OK/0.996918

# 0.791812
This	Dieses	DT	PDAT		OK/0.987863
medicinal	Dieses	JJ	PDAT		OK/0.990909
product	Dieses	NN	PDAT		OK/0.998720
must	darf	MD	VMFIN		OK/0.997163
not	darf	RB	VMFIN		OK/0.990139
be	darf	VB	VMFIN		OK/0.997662
mixed	gemischt	VVN	VVPP		OK/0.989679
with	mit	IN	APPR		OK/0.957417
acidic	säurehaltigen	JJ	ADJA		OK/0.850240
food	Nahrungsmitteln	NN	NN		OK/0.932163
(	siehe	(	VVIMP		OK/0.994117
see	siehe	VV	VVIMP		OK/0.999503
section	Abschnitt	NN	NN		OK/0.999396
4.2	4.2	CD	CARD		OK/0.997880
)	)	)	$(		OK/0.996742
.	.	SENT	$.		OK/0.997366

# 0.723961
How	Wie	NP	KOKOM		OK/0.988780
do	verabreiche	VVP	VVFIN		OK/0.985065
I	ich	PP	PPER		OK/0.931318
give	mir	VV	PRF		OK/0.784802
my	mir	PP$	PRF		OK/0.910037
injection	Injektion	NN	NN		OK/0.974865
of	mit	IN	APPR		OK/0.968098
Trudexa	Trudexa	NP	NN		OK/0.976502
?	?	SENT	$.		OK/0.998363

# 0.893977
Nervous	Nervensystems	NP	NN		OK/0.981606
system	Nervensystems	NN	NN		OK/0.988523
disorders	Nervensystems	NNS	NN		OK/0.994906
§	§	SYM	NN		OK/0.921571
Very	Sehr	JJ	ADV		OK/0.995434
common	häufig	NN	ADJD		OK/0.998279
:	:	:	$.		OK/0.998323

# 0.397145
9	9	CD	CARD		OK/0.992602
Weight	Gewichtszunahme	NP	NN		OK/0.881457
gain	Gewichtszunahme	NN	NN		OK/0.937416
≥	≥	NN	ADJD		OK/0.994091
7	7	CD	CARD		OK/0.990865
%	%	NN	NN		OK/0.989177
of	Ausgangskörpergewichtes	IN	NN		OK/0.980928
baseline	Ausgangskörpergewichtes	JJ	NN		OK/0.956698
body	Ausgangskörpergewichtes	NN	NN		OK/0.968686
weight	Ausgangskörpergewichtes	NN	NN		OK/0.978030
(	(	(	$(		OK/0.999258
kg	kg	NN	NN		OK/0.995975
)	)	)	$(		OK/0.998902
was	war	VBD	VAFIN		OK/0.974121
very	sehr	RB	ADV		OK/0.966307
common	häufig	JJ	ADJD		OK/0.909578
and	und	CC	KON		OK/0.972318
15	15	CD	CARD		OK/0.995519
%	%	NN	NN		OK/0.998459
of	Ausgangskörpergewichtes	IN	NN		OK/0.989781
baseline	Ausgangskörpergewichtes	JJ	NN		OK/0.955580
body	Ausgangskörpergewichtes	NN	NN		OK/0.956984
weight	Ausgangskörpergewichtes	NN	NN		OK/0.986313
was	war	VBD	VAFIN		OK/0.893528
common	häufig	JJ	ADJD		OK/0.625429
.	.	SENT	$.		OK/0.998245

# 0.358572
It	Es	PP	NN		OK/0.939663
is	Es	VBZ	NN		OK/0.941274
therefore	daher	RB	PAV		OK/0.975875
not	nicht	RB	PTKNEG		OK/0.964340
expected	erwarten	VVN	VVINF		OK/0.947279
to	__unaligned__	TO	__unaligned__		OK/0.834887
expect	Lopinavirspiegel	VV	NN		OK/0.602444
that	Lopinavirspiegel	DT	NN		OK/0.589232
cardiac	Lopinavirspiegel	JJ	NN		OK/0.857677
lopinavir	Lopinavirspiegel	NN	NN		OK/0.878839
levels	Lopinavirspiegel	NNS	NN		OK/0.936490
would	Lopinavirspiegel	MD	NN		OK/0.839475
significantly	signifikant	RB	ADJD		OK/0.878779
higher	höher	RBR	ADJD		OK/0.937995
than	höher	IN	ADJD		OK/0.991545
plasma	Plasmaspiegel	NN	NN		OK/0.997703
levels	Plasmaspiegel	NNS	NN		OK/0.997602
.	.	SENT	$.		OK/0.999345

# 0.356328
For	Die	IN	ART		OK/0.782314
a	__unaligned__	DT	__unaligned__		OK/0.786245
more	vollständige	RBR	ADJA		OK/0.699053
complete	vollständige	JJ	ADJA		OK/0.982912
list	Auflistung	NN	NN		OK/0.996194
of	Auflistung	IN	NN		OK/0.995769
side	Nebenwirkungen	NN	NN		OK/0.992985
effects	Nebenwirkungen	NNS	NN		OK/0.977619
is	__unaligned__	VBZ	__unaligned__		OK/0.643659
available	__unaligned__	JJ	__unaligned__		OK/0.734381
in	__unaligned__	IN	__unaligned__		OK/0.931557
the	__unaligned__	DT	__unaligned__		OK/0.986746
Package	entnehmen	NP	VVINF		OK/0.999624
Leaflet	entnehmen	NP	VVINF		OK/0.960214
.	.	SENT	$.		OK/0.999858

# 0.693988
The	Die	DT	ART		OK/0.999645
majority	Mehrzahl	NN	NN		OK/0.993023
of	dieser	IN	PDAT		OK/0.998086
these	dieser	DT	PDAT		OK/0.996983
symptoms	Symptome	NNS	NN		OK/0.998664
occurred	trat	VVD	VVFIN		OK/0.904120
within	innerhalb	IN	APPR		OK/0.975274
the	ersten	DT	ADJA		OK/0.997332
first	ersten	JJ	ADJA		OK/0.994567
three	drei	CD	CARD		OK/0.974623
days	Tage	NNS	NN		OK/0.966801
after	nach	IN	APPR		OK/0.995633
administration	Verabreichung	NN	NN		OK/0.980543
of	__unaligned__	IN	__unaligned__		OK/0.964038
Aclasta	Aclasta	NP	ADJD		OK/0.837561
.	.	SENT	$.		OK/0.997464

# 0.353742
The	Die	NP	ART		OK/0.990950
Toltrazurilsulfon-Bodenexposition	Toltrazurilsulfon-Bodenexposition	NP	NN		OK/0.869760
was	wurde	VBD	VAFIN		OK/0.961370
assessed	anhand	VVN	APPR		OK/0.905805
in	__unaligned__	IN	__unaligned__		OK/0.601475
a	Gleichungen	DT	NN		OK/0.587768
polynucleotide	zulässiger	NN	ADJA		OK/0.483180
.	.	SENT	$.		OK/0.992603

# 0.736439
Chi	Chi	NP	NE		OK/0.837036
Square	Square	NP	NN		OK/0.829450
tests	Tests	NNS	NN		OK/0.829470
.	.	SENT	$.		OK/0.999350

# 0.536955
For	Bei	IN	APPR		OK/0.978270
patients	Patienten	NNS	NN		OK/0.998636
with	mit	IN	APPR		OK/0.998127
heart	Herzinsuffizienz	NN	NN		OK/0.995102
failure	Herzinsuffizienz	NN	NN		OK/0.978903
,	__unaligned__	,	__unaligned__		OK/0.810058
the	die	DT	ART		OK/0.974346
initial	Initialbehandlung	JJ	NN		OK/0.926496
treatment	__unaligned__	NN	__unaligned__		OK/0.893467
with	mit	IN	APPR		OK/0.994270
Diovan	Diovan	NP	NE		OK/0.960285
should	sollte	MD	VMFIN		OK/0.984061
be	sollte	VB	VMFIN		OK/0.991609
used	Vorsicht	VVN	NN		OK/0.910072
with	Vorsicht	IN	NN		OK/0.929580
caution	Vorsicht	NN	NN		OK/0.864707
.	.	SENT	$.		OK/0.997037

# 0.760444
Caution	geboten	NN	VVPP		OK/0.999301
should	geboten	MD	VVPP		OK/0.999898
be	geboten	VB	VVPP		OK/0.999939
exercised	geboten	VVN	VVPP		OK/0.996978
when	geboten	WRB	VVPP		OK/0.991542
concomitant	gleichzeitiger	JJ	ADJA		OK/0.992074
administration	Verabreichung	NN	NN		OK/0.998814
of	anderer	IN	PIAT		OK/0.992550
other	anderer	JJ	PIAT		OK/0.997334
cytotoxic	Zytostatika	JJ	NN		OK/0.946993
agents	__unaligned__	NNS	__unaligned__		OK/0.958547
,	,	,	$,		OK/0.996731
especially	insbesondere	RB	ADV		OK/0.998662
in	bei	IN	APPR		OK/0.964184
myelotoxischen	myelotoxischen	NN	ADJA		OK/0.855021
substances	Substanzen	NNS	NN		OK/0.964196
.	.	SENT	$.		OK/0.998373

# 0.444349
17	Pharmakotherapeutische	CD	NN		OK/0.885266
Pharmacotherapeutic	Pharmakotherapeutische	NP	NN		OK/0.942215
group	Pharmakotherapeutische	NN	NN		OK/0.918195
:	:	:	$.		OK/0.998254
angiotensin	Angiotensin	NP	NN		OK/0.980065
II	Angiotensin	NP	NN		OK/0.875189
antagonist	__unaligned__	NN	__unaligned__		OK/0.691421
,	,	,	$,		OK/0.989120
plain	rein	RB	ADV		OK/0.968207
,	,	,	$,		OK/0.999208
ATC	ATC	NP	NE		OK/0.995946
code	code	NN	NN		OK/0.992197
:	:	:	$.		OK/0.994109
C09CA04	C09CA04	NN	NE		OK/0.820624
.	.	SENT	$.		OK/0.997847

# 0.674365
Carton	Karton	NP	NN		OK/0.911150
containing	Karton	VVG	NN		OK/0.969780
one	Karton	CD	NN		OK/0.960018
meat	Essbare	NN	ADJA		OK/0.869119
and	Essbare	CC	ADJA		OK/0.853082
offal	Essbare	NN	ADJA		OK/0.808639
:	:	:	$.		OK/0.992124

# 0.849106
Each	Jede	DT	PIAT		OK/0.997030
pack	Packung	NN	NN		OK/0.996395
contains	enthält	VVZ	VVFIN		OK/0.998478
1	1	CD	CARD		OK/0.997499
vial	Durchstechflasche	NN	NN		OK/0.996574
with	mit	IN	APPR		OK/0.994461
3.5	3,5	CD	CARD		OK/0.877201
or	oder	CC	KON		OK/0.987618
5	5	CD	CARD		OK/0.998138
ml	ml	NN	NN		OK/0.999792
solution	Injektionslösung	NN	NN		OK/0.997668
for	Injektionslösung	IN	NN		OK/0.990801
injection	Injektionslösung	NN	NN		OK/0.994995
.	.	SENT	$.		OK/0.999901

# 0.437005
This	Dies	NP	PDS		OK/0.997368
is	ist	VBZ	VAFIN		OK/0.991060
particularly	besonders	RB	ADV		OK/0.994191
important	wichtig	JJ	ADJD		OK/0.974808
in	bei	IN	APPR		OK/0.704060
those	Patienten	DT	NN		BAD/0.889512
who	__unaligned__	WP	__unaligned__		BAD/0.904452
have	__unaligned__	VHP	__unaligned__		BAD/0.944493
reduced	__unaligned__	VVN	__unaligned__		BAD/0.913983
or	Hypoglykämie-Episoden	CC	NN		BAD/0.856106
those	Hypoglykämie-Warnsymptomen	DT	NN		BAD/0.811803
.	.	SENT	$.		OK/0.995207

# 0.640543
A	Unter	DT	APPR		OK/0.877277
variety	verschiedene	NN	ADJA		OK/0.895442
of	__unaligned__	IN	__unaligned__		OK/0.970706
haematological	hämatologische	JJ	ADJA		OK/0.978328
adverse	Nebenwirkungen	JJ	NN		OK/0.992379
reactions	Nebenwirkungen	NNS	NN		OK/0.999711
were	traten	VBD	VVFIN		OK/0.869811
reported	traten	VVN	VVFIN		OK/0.876084
:	:	:	$.		OK/0.997544
thrombocytopenia	Thrombozytopenie	NNS	NN		OK/0.993786
(	(	(	$(		OK/0.998881
27	27	CD	CARD		OK/0.992042
%	%	NN	NN		OK/0.995335
)	)	)	$(		OK/0.998539
,	,	,	$,		OK/0.996185
neutropenia	Neutropenie	NN	NN		OK/0.987016
(	(	(	$(		OK/0.992989
15	15	CD	CARD		OK/0.999553
%	%	NN	NN		OK/0.998148
)	)	)	$(		OK/0.998716
and	und	CC	KON		OK/0.993487
anaemia	Anämie	NN	NN		OK/0.998628
(	(	(	$(		OK/0.996680
13	13	CD	CARD		OK/0.998116
%	%	NN	NN		OK/0.999018
)	)	)	$(		OK/0.992373
.	.	SENT	$.		OK/0.998106

# 0.283130
All	Alle	NP	PIAT		OK/0.944755
of	__unaligned__	IN	__unaligned__		OK/0.962941
these	diese	DT	PDAT		OK/0.976130
patients	Patienten	NNS	NN		OK/0.959347
also	zusätzlich	RB	ADJD		OK/0.768118
had	hatten	VHD	VAFIN		OK/0.841502
medicinal	Arzneimittel	JJ	NN		OK/0.968697
products	Arzneimittel	NNS	NN		OK/0.885135
known	bekannt	VVN	VVPP		OK/0.808514
as	als	IN	KOKOM		OK/0.880164
azathioprine	Azathioprin	NN	NN		OK/0.890672
or	oder	CC	KON		OK/0.972089
mercaptopurine	Mercaptopurin	NN	NN		OK/0.539835
.	.	SENT	$.		OK/0.994562

# 0.058331
If	Falls	IN	NN		OK/0.996924
topotecan	Topotecan	NN	NN		OK/0.981212
is	__unaligned__	VBZ	__unaligned__		OK/0.807319
given	angewendet	VVN	VVPP		BAD/0.673819
to	angewendet	TO	VVPP		BAD/0.619834
pregnant	Schwangerschaft	JJ	NN		OK/0.904215
women	Schwangerschaft	NNS	NN		OK/0.990935
,	,	,	$,		OK/0.984655
or	oder	CC	KON		OK/0.867690
if	falls	IN	KOUS		OK/0.875603
the	Patientin	DT	NN		OK/0.983748
patient	__unaligned__	NN	__unaligned__		OK/0.992429
becomes	schwanger	VVZ	ADJD		OK/0.988869
pregnant	schwanger	JJ	ADJD		OK/0.994411
during	unter	IN	APPR		OK/0.993635
treatment	Therapie	NN	NN		OK/0.935199
,	,	,	$,		OK/0.856949
the	Patientin	DT	NN		OK/0.905748
patient	__unaligned__	NN	__unaligned__		OK/0.656729
must	muss	MD	VMFIN		BAD/0.706613
be	muss	VB	VMFIN		BAD/0.772015
used	vor	VVN	APPR		BAD/0.837705
before	vor	IN	APPR		OK/0.751160
the	möglichen	DT	ADJA		OK/0.875745
potential	möglichen	JJ	ADJA		OK/0.999245
risk	Risiken	NN	NN		OK/0.995460
to	Fetus	TO	NN		OK/0.997764
the	Fetus	DT	NN		OK/0.996498
foetus	Fetus	NN	NN		OK/0.988206
.	.	SENT	$.		OK/0.999950

# 0.727263
This	Dies	NP	PDS		OK/0.995506
may	kann	MD	VMFIN		OK/0.993738
result	zu	VV	APPR		OK/0.952499
in	__unaligned__	IN	__unaligned__		OK/0.980943
decreased	verminderten	VVN	ADJA		OK/0.973472
plasma	Plasmakonzentrationen	NN	NN		OK/0.997222
concentrations	Plasmakonzentrationen	NNS	NN		OK/0.996947
and	und	CC	KON		OK/0.998120
potential	__unaligned__	JJ	__unaligned__		OK/0.955111
decrease	Verringerung	NN	NN		OK/0.954974
efficacy	Wirksamkeit	NN	NN		OK/0.983135
of	__unaligned__	IN	__unaligned__		OK/0.970464
concomitant	verabreichter	JJ	ADJA		OK/0.947189
medicinal	Arzneimittel	JJ	NN		OK/0.984508
products	Arzneimittel	NNS	NN		OK/0.905312
.	.	SENT	$.		OK/0.998964

# 0.338912
Deep	Tiefes	NP	NN		OK/0.851707
,	,	,	$,		OK/0.950313
rapid	Tiefes	JJ	NN		OK/0.926044
breathing	Tiefes	NN	NN		OK/0.937227
,	,	,	$,		OK/0.838501
drowsiness	Tiefes	NN	NN		OK/0.815947
,	,	,	$,		OK/0.844055
and	und	CC	KON		OK/0.952599
non	__unaligned__	JJ	__unaligned__		OK/0.885439
specific	__unaligned__	JJ	__unaligned__		OK/0.744339
symptoms	Symptome	NNS	NN		OK/0.894926
such	wie	JJ	KOKOM		OK/0.989820
as	wie	IN	KOKOM		OK/0.991470
nausea	Übelkeit	NN	NN		OK/0.996158
,	,	,	$,		OK/0.998787
vomiting	Erbrechen	NN	NN		OK/0.988318
and	und	CC	KON		OK/0.995078
stomach	Magenschmerzen	NN	NN		OK/0.983874
pain	Magenschmerzen	NN	NN		OK/0.874735
,	__unaligned__	,	__unaligned__		OK/0.957428
might	können	MD	VMFIN		OK/0.960132
indicate	__unaligned__	VV	__unaligned__		OK/0.920875
the	Entwicklung	DT	NN		OK/0.975696
development	Entwicklung	NN	NN		OK/0.998877
of	Entwicklung	IN	NN		OK/0.993975
lactic	Laktatazidose	JJ	NN		OK/0.989899
acidosis	Laktatazidose	NN	NN		OK/0.980225
.	.	SENT	$.		OK/0.999845

# 0.030055
At	Zu	IN	APPR		OK/0.791377
the	die	DT	ART		BAD/0.622705
dose	Dosis	NN	NN		BAD/0.704877
should	__unaligned__	MD	__unaligned__		BAD/0.759974
be	__unaligned__	VB	__unaligned__		BAD/0.778636
temporarily	__unaligned__	RB	__unaligned__		BAD/0.797653
withheld	__unaligned__	VVN	__unaligned__		BAD/0.832446
until	__unaligned__	IN	__unaligned__		BAD/0.815547
the	__unaligned__	DT	__unaligned__		OK/0.843924
haemoglobin	__unaligned__	NN	__unaligned__		BAD/0.844040
begins	diesem	VVZ	PDAT		BAD/0.872937
to	__unaligned__	TO	__unaligned__		BAD/0.866053
point	angewendeten	NN	ADJA		BAD/0.725998
therapy	angewendeten	NN	ADJA		BAD/0.663005
should	angewendeten	MD	ADJA		OK/0.768676
be	angewendeten	VB	ADJA		OK/0.812876
reinitiated	angewendeten	VVN	ADJA		OK/0.780301
at	,	IN	$,		OK/0.512178
approximately	ca.	RB	ADV		OK/0.888341
25	25	CD	CARD		OK/0.988919
%	%	NN	NN		OK/0.998673
lower	__unaligned__	JJR	__unaligned__		OK/0.986551
than	__unaligned__	IN	__unaligned__		OK/0.967591
the	__unaligned__	DT	__unaligned__		OK/0.967938
previous	__unaligned__	JJ	__unaligned__		OK/0.838221
dose	__unaligned__	NN	__unaligned__		OK/0.783766
,	,	,	$,		BAD/0.948357
resumed	wieder	VVD	ADV		BAD/0.977940
.	.	SENT	$.		OK/0.988533

# 0.405336
During	Innerhalb	IN	APPR		OK/0.952520
the	__unaligned__	DT	__unaligned__		OK/0.890623
night	Nacht	NN	NN		OK/0.915522
dose	Dosis	NN	NN		OK/0.975131
should	sollte	MD	VMFIN		OK/0.914273
be	sollte	VB	VMFIN		OK/0.702480
taken	eingenommen	VVN	VVPP		OK/0.490100
.	.	SENT	$.		OK/0.998366

# 0.811583
Take	Besondere	VVP	ADJA		OK/0.989212
special	Besondere	JJ	ADJA		OK/0.999649
care	Besondere	NN	ADJA		OK/0.998444
with	Vorsicht	IN	NN		OK/0.998792
Viraferon	Viraferon	NP	NN		OK/0.988883
−	−	NN	NN		OK/0.942688
if	wenn	IN	KOUS		OK/0.999525
you	Sie	PP	PPER		OK/0.998794
are	schwanger	VBP	ADJD		OK/0.998903
pregnant	schwanger	JJ	ADJD		OK/0.970555
or	oder	CC	KON		OK/0.998483
intend	beabsichtigen	VVP	VVFIN		OK/0.997513
to	beabsichtigen	TO	VVFIN		OK/0.996947
become	beabsichtigen	VV	VVFIN		OK/0.953080
pregnant	schwanger	JJ	ADJD		OK/0.966051
(	siehe	(	VVIMP		OK/0.993768
see	siehe	VV	VVIMP		OK/0.999137
Pregnancy	Schwangerschaft	NP	NN		OK/0.975983
)	)	)	$(		OK/0.998886
.	.	SENT	$.		OK/0.996139

# 0.329474
In	Bei	IN	APPR		OK/0.963013
pediatric	Kindern	JJ	NN		OK/0.884292
patients	Kindern	NNS	NN		OK/0.950018
(	(	(	$(		OK/0.994530
4	4	CD	CARD		OK/0.995459
to	bis	TO	KON		OK/0.992544
16	16	CD	CARD		OK/0.991933
years	Jahre	NNS	NN		OK/0.969367
of	__unaligned__	IN	__unaligned__		OK/0.802934
age	Jahre	NN	NN		OK/0.817870
)	)	)	$(		OK/0.975892
,	__unaligned__	,	__unaligned__		OK/0.850469
levetiracetam	Levetiracetam	NN	NE		OK/0.991614
efficacy	Wirksamkeit	NN	NN		OK/0.981288
was	wurde	VBD	VAFIN		OK/0.993011
established	Levetiracetam	VVN	NE		OK/0.992599
in	in	IN	APPR		OK/0.997378
a	in	DT	APPR		OK/0.998893
double-blind	doppelblinden	JJ	ADJA		OK/0.995338
,	doppelblinden	,	ADJA		OK/0.983839
placebo-controlled	placebo-kontrollierten	VVN	ADJA		OK/0.991159
study	Studie	NN	NN		OK/0.997798
,	__unaligned__	,	__unaligned__		OK/0.798669
which	__unaligned__	WDT	__unaligned__		OK/0.779747
included	__unaligned__	VVD	__unaligned__		OK/0.785947
198	198	CD	CARD		OK/0.901266
patients	Patienten	NNS	NN		OK/0.998388
and	und	CC	KON		OK/0.998508
had	__unaligned__	VHD	__unaligned__		OK/0.967142
a	einer	DT	ART		OK/0.970424
treatment	Behandlungsdauer	NN	NN		OK/0.991336
duration	Behandlungsdauer	NN	NN		OK/0.998704
of	Behandlungsdauer	IN	NN		OK/0.993403
14	14	CD	CARD		OK/0.996609
weeks	Wochen	NNS	NN		OK/0.996659
.	.	SENT	$.		OK/0.999762

# 0.304594
Plasma	Plasma-Clearance	NP	NN		OK/0.988395
clearance	Plasma-Clearance	NN	NN		OK/0.992101
in	bei	IN	APPR		OK/0.996128
patients	Patienten	NNS	NN		OK/0.996524
with	mit	IN	APPR		OK/0.992581
impaired	beeinträchtigter	JJ	ADJA		OK/0.915001
renal	Nierenfunktion	JJ	NN		OK/0.969305
function	Nierenfunktion	NN	NN		OK/0.990779
(	(	(	$(		OK/0.996278
creatinine	Kreatinin-Clearance	NN	NN		OK/0.998739
clearance	Kreatinin-Clearance	NN	NN		OK/0.997191
41	41	CD	CARD		OK/0.970208
to	__unaligned__	TO	__unaligned__		OK/0.986134
60	60	CD	CARD		OK/0.999876
ml	ml	NN	NN		OK/0.999070
/	/	SYM	$(		OK/0.999781
min	min	NN	NE		OK/0.998808
)	)	)	$(		OK/0.999743
as	Vergleich	IN	NN		OK/0.969415
compared	Vergleich	VVN	NN		OK/0.995081
to	Vergleich	TO	NN		OK/0.993823
a	__unaligned__	DT	__unaligned__		OK/0.920350
control	Kontrollgruppe	NN	NN		OK/0.891722
group	Kontrollgruppe	NN	NN		OK/0.913572
of	__unaligned__	IN	__unaligned__		OK/0.824582
patients	Patienten	NNS	NN		OK/0.979840
to	etwa	TO	ADV		OK/0.850932
about	etwa	RB	ADV		OK/0.953811
67	67	CD	CARD		OK/0.988208
%	%	NN	NN		OK/0.961892
,	__unaligned__	,	__unaligned__		BAD/0.754699
respectively	%	RB	NN		BAD/0.647406
.	.	SENT	$.		OK/0.997732

# 0.332927
Local	Lokale	NP	ADJA		OK/0.754744
Apart	Gewebereaktionen	RB	NN		OK/0.558769
from	Gewebereaktionen	IN	NN		OK/0.704112
an	Gewebereaktionen	DT	NN		OK/0.717402
increase	Gewebereaktionen	NN	NN		OK/0.856853
in	in	IN	APPR		OK/0.929320
abscesses	Abszessen	NNS	NN		OK/0.715610
may	können	MD	VMFIN		OK/0.961847
occur	auftreten	VV	VVINF		OK/0.965950
commonly	häufig	RB	ADJD		OK/0.949795
.	.	SENT	$.		OK/0.998040

# 0.976589
•	•	NP	NN		OK/0.998520
Additional	Zusätzliche	JJ	ADJA		OK/0.981945
information	Informationen	NN	NN		OK/0.993482
:	:	:	$.		OK/0.999491

# 0.554023
IntronA	IntronA	NP	NE		OK/0.964202
may	kann	MD	VMFIN		OK/0.977618
be	kann	VB	VMFIN		OK/0.989693
used	angewendet	VVN	VVPP		OK/0.985374
during	in	IN	APPR		OK/0.990064
the	ersten	DT	ADJA		OK/0.982978
first	ersten	JJ	ADJA		OK/0.936399
twelve	zwölf	NN	CARD		OK/0.850252
months	Monaten	NNS	NN		OK/0.953427
in	Kombination	IN	NN		OK/0.964332
combination	Kombination	NN	NN		OK/0.994425
with	mit	IN	APPR		OK/0.994251
cytarabine	Cytarabin	NN	NE		OK/0.972296
(	(	(	$(		OK/0.998124
an	einem	DT	ART		OK/0.978795
anticancer	Krebsmedikament	NN	NN		OK/0.951629
medicine	Krebsmedikament	NN	NN		OK/0.945159
)	)	)	$(		OK/0.994190
;	;	:	$.		OK/0.997808
•	•	JJ	NN		OK/0.995787
multiple	Myeloms	JJ	NN		OK/0.983096
myeloma	Myeloms	NN	NN		OK/0.942106
(	(	(	$(		OK/0.966334
including	Krebses	VVG	NN		OK/0.888950
bone	Knochenmarks	NN	NN		OK/0.997359
marrow	Knochenmarks	NN	NN		OK/0.992858
)	)	)	$(		OK/0.995954
.	.	SENT	$.		OK/0.999267

# 0.319645
walk	gehen	NN	VVFIN		OK/0.825068
osteonecrosis	Kieferknochennekrosen	NN	NN		OK/0.570984
of	Kieferknochennekrosen	IN	NN		OK/0.615884
the	Kieferknochennekrosen	DT	NN		OK/0.966424
jaw	Kieferknochennekrosen	NN	NN		OK/0.994680
,	Allgemeinen	,	NN		OK/0.997978
generally	Allgemeinen	RB	NN		OK/0.977249
associated	Zahnextraktionen	VVN	NN		OK/0.975612
with	mit	IN	APPR		OK/0.992192
tooth	Zahnextraktionen	NN	NN		OK/0.874671
extraction	Zahnextraktionen	NN	NN		OK/0.739536
and	und	CC	KON		OK/0.993030
/	/	SYM	$(		OK/0.997399
or	oder	CC	KON		OK/0.968941
local	lokalen	JJ	ADJA		OK/0.970570
infection	Infektionen	NN	NN		OK/0.950204
(	(	(	$(		OK/0.998324
including	einschließlich	VVG	APPR		OK/0.999380
osteomyelitis	Osteomyelitis	NN	NN		OK/0.981999
)	)	)	$(		OK/0.994448
.	.	SENT	$.		OK/0.998571

# 0.422439
Non-	Nichtsteroidale	NP	NN		OK/0.801460
steroidal	Nichtsteroidale	JJ	NN		OK/0.773364
antirheumatics	Nichtsteroidale	NNS	NN		OK/0.752706
or	oder	CC	KON		OK/0.942086
estrogens	Estrogene	NNS	NN		OK/0.857032
may	Estrogene	MD	NN		OK/0.915114
reduce	reduzieren	VV	VVFIN		OK/0.948908
the	die	DT	ART		OK/0.995838
antihypertensive	antihypertensive	NN	ADJA		OK/0.995990
effect	Wirkung	NN	NN		OK/0.999681
of	die	IN	ART		OK/0.849676
doxazosin	Doxazosin	NN	NN		OK/0.769326
.	.	SENT	$.		OK/0.997666

# 0.444415
The	Die	DT	ART		OK/0.949899
following	folgenden	VVG	ADJA		OK/0.893299
data	Daten	NNS	NN		OK/0.665915
on	Daten	IN	NN		BAD/0.913906
how	geben	WRB	VVFIN		BAD/0.953664
to	geben	TO	VVFIN		BAD/0.984671
give	geben	VV	VVFIN		BAD/0.998751
the	die	DT	ART		OK/0.989425
frequency	Häufigkeiten	NN	NN		OK/0.901556
of	die	IN	ART		OK/0.989532
adverse	Nebenwirkungen	JJ	NN		OK/0.998587
events	Nebenwirkungen	NNS	NN		OK/0.960462
by	die	IN	PRELS		OK/0.961511
the	Impfstoffs	DT	NN		OK/0.992072
administration	Impfstoffs	NN	NN		OK/0.995792
of	Impfstoffs	IN	NN		OK/0.989978
the	Impfstoffs	DT	NN		OK/0.987300
vaccine	Impfstoffs	NN	NN		OK/0.971772
.	.	SENT	$.		OK/0.999771

# 0.398060
2	Weitere	CD	ADJA		OK/0.530422
/	Weitere	SYM	ADJA		OK/0.528771
3	Weitere	CD	ADJA		OK/0.544733
Other	Weitere	JJ	ADJA		OK/0.966372
information	Informationen	NN	NN		OK/0.998994
about	Informationen	IN	NN		OK/0.997772
BeneFIX	BeneFIX	NP	NE		OK/0.995904
:	:	:	$.		OK/0.988800

# 0.110027
It	Es	PP	NN		OK/0.986767
is	empfohlen	VBZ	VVPP		OK/0.985228
recommended	empfohlen	VVN	VVPP		OK/0.958665
that	empfohlen	IN/that	VVPP		BAD/0.577768
sorafenib	Sorafenib	NN	VVIMP		BAD/0.289766
can	__unaligned__	MD	__unaligned__		BAD/0.512931
be	Mahlzeit	VB	NN		BAD/0.604050
given	__unaligned__	VVN	__unaligned__		BAD/0.716415
without	__unaligned__	IN	__unaligned__		OK/0.783642
regard	__unaligned__	NN	__unaligned__		OK/0.825519
to	__unaligned__	TO	__unaligned__		OK/0.905374
food	unabhängig	NN	ADJD		OK/0.943814
or	oder	CC	KON		OK/0.965051
with	mit	IN	APPR		OK/0.983827
a	einer	DT	ART		OK/0.978941
mild	leicht	JJ	ADJD		OK/0.901601
or	oder	CC	KON		OK/0.995906
moderate	mäßig	JJ	ADJD		OK/0.989495
fat	fettreichen	JJ	ADJA		OK/0.925134
meal	Mahlzeit	NN	NN		OK/0.941698
.	.	SENT	$.		OK/0.996794

# 0.242063
One	Eine	NP	ART		BAD/0.574707
Wachstumshor-	Wachstumshor-	NP	TRUNC		BAD/0.642096
montherapie	montherapie	NN	NN		BAD/0.663691
may	kann	MD	VMFIN		OK/0.804450
reduce	senken	VV	VVINF		OK/0.865832
insulin	Insulin-Sensitivität	NN	NN		OK/0.979847
sensitivity	Insulin-Sensitivität	NN	NN		OK/0.994107
and	und	CC	KON		OK/0.997791
impair	beeinträchtigen	VV	VVINF		OK/0.763488
glucose	Glukosetoleranz	NN	NN		OK/0.869291
tolerance	Glukosetoleranz	NN	NN		OK/0.918185
.	.	SENT	$.		OK/0.998714

# 0.946205
What	Welchen	WP	PIAT		OK/0.998836
benefit	Welchen	VVP	PIAT		OK/0.978762
has	Nutzen	VHZ	NN		OK/0.999311
PritorPlus	PritorPlus	NN	NN		OK/0.994395
shown	__unaligned__	VVN	__unaligned__		OK/0.999119
during	in	IN	APPR		OK/0.988342
the	__unaligned__	DT	__unaligned__		OK/0.984933
studies	Studien	NNS	NN		OK/0.996920
?	?	SENT	$.		OK/0.998517

# 0.195059
One	Eine	NP	ART		OK/0.399255
minute	Minute	NN	NN		OK/0.483341
was	gut	VBD	ADJD		OK/0.549046
well	gut	RB	ADJD		OK/0.602609
umrühren	umrühren	NNS	VVINF		OK/0.492902
,	__unaligned__	,	__unaligned__		OK/0.542669
and	und	CC	KON		OK/0.897713
drink	__unaligned__	VVP	__unaligned__		OK/0.920826
at	__unaligned__	IN	__unaligned__		OK/0.979067
once	__unaligned__	RB	__unaligned__		OK/0.972884
.	.	SENT	$.		OK/0.998769

# 0.788416
EVISTA	EVISTA	NP	NN		OK/0.955995
is	angezeigt	VBZ	VVPP		OK/0.992062
indicated	angezeigt	VVN	VVPP		OK/0.985736
for	angezeigt	IN	VVPP		OK/0.998429
the	Behandlung	DT	NN		OK/0.996853
treatment	Behandlung	NN	NN		OK/0.937970
and	und	CC	KON		OK/0.953994
prevention	Prävention	NN	NN		OK/0.966807
of	__unaligned__	IN	__unaligned__		OK/0.987456
osteoporosis	Osteoporose	NN	NN		OK/0.988945
in	bei	IN	APPR		OK/0.944973
postmenopausal	postmenopausalen	JJ	ADJA		OK/0.977990
women	Frauen	NNS	NN		OK/0.996935
.	.	SENT	$.		OK/0.999799

# 0.202720
Silapo	Silapo	NP	NN		OK/0.980350
has	wurde	VHZ	VAFIN		OK/0.994973
been	wurde	VBN	VAFIN		OK/0.999809
studied	untersucht	VVN	VVPP		OK/0.996503
in	Versuchsmodellen	IN	NN		OK/0.986892
experimental	getestet	JJ	VVPP		OK/0.993073
models	Versuchsmodellen	NNS	NN		OK/0.991519
and	und	CC	KON		OK/0.998411
in	__unaligned__	IN	__unaligned__		OK/0.988110
humans	Menschen	NNS	NN		OK/0.964636
to	nachzuweisen	TO	VVIZU		OK/0.606003
show	nachzuweisen	VV	VVIZU		OK/0.697058
that	dass	IN/that	KOUS		OK/0.827712
it	es	PP	PPER		OK/0.798899
is	es	VBZ	PPER		OK/0.783346
comparable	vergleichbar	JJ	ADJD		OK/0.701331
with	mit	IN	APPR		OK/0.575353
the	mit	DT	APPR		OK/0.981525
reference	Referenzarzneimittel	NN	NN		OK/0.985881
medicine	Referenzarzneimittel	NN	NN		OK/0.972920
,	__unaligned__	,	__unaligned__		OK/0.914066
EPREX	EPREX	NP	NE		OK/0.916966
/	/	SYM	$(		OK/0.951721
ERYPO	ERYPO	NP	NE		OK/0.761309
.	.	SENT	$.		OK/0.996883

# 0.581754
Hepatic	Eingeschränkte	NP	ADJA		OK/0.997753
impairment	Eingeschränkte	NN	ADJA		OK/0.994535
No	Anpassung	DT	NN		OK/0.987548
adjustment	Anpassung	NN	NN		OK/0.989571
of	der	IN	ART		OK/0.999200
the	der	DT	ART		OK/0.997783
initial	Initialdosis	JJ	NN		OK/0.978299
dose	Initialdosis	NN	NN		OK/0.889794
is	erforderlich	VBZ	ADJD		OK/0.832312
required	erforderlich	VVN	ADJD		OK/0.897049
for	__unaligned__	IN	__unaligned__		OK/0.837785
patients	Patienten	NNS	NN		OK/0.996378
with	mit	IN	APPR		OK/0.993986
mild	leicht	JJ	ADJD		OK/0.878285
to	leicht	TO	ADJD		OK/0.908978
severe	stark	JJ	ADJD		OK/0.975941
hepatic	Leberfunktion	JJ	NN		OK/0.997439
impairment	eingeschränkter	NN	ADJA		OK/0.995967
(	siehe	(	VVIMP		OK/0.998940
see	siehe	VV	VVIMP		OK/0.999190
section	Abschnitt	NN	NN		OK/0.999137
5.2	5.2	CD	CARD		OK/0.999799
)	)	)	$(		OK/0.998973
.	.	SENT	$.		OK/0.999067

# 0.240696
A	Ein	DT	ART		OK/0.869439
rise	Hämoglobins	NN	NN		OK/0.693942
in	__unaligned__	IN	__unaligned__		OK/0.660788
haemoglobin	__unaligned__	NN	__unaligned__		OK/0.677752
of	__unaligned__	IN	__unaligned__		OK/0.620023
greater	__unaligned__	JJR	__unaligned__		OK/0.766671
than	als	IN	KOKOM		OK/0.992723
2	2	CD	CARD		OK/0.996355
g	g	NN	NN		OK/0.998068
/	/	SYM	$(		OK/0.999700
dl	dl	NN	NE		OK/0.999707
(	(	(	$(		OK/0.999305
1.25	1,25	CD	CARD		OK/0.998225
mmol	mmol	NN	NN		OK/0.998912
/	/	SYM	$(		OK/0.999403
l	l	NN	NN		OK/0.997379
)	)	)	$(		OK/0.998383
over	Zeitraum	IN	NN		OK/0.918714
a	__unaligned__	DT	__unaligned__		OK/0.987652
four	vier	CD	CARD		OK/0.997284
week	Wochen	NN	NN		OK/0.994869
period	__unaligned__	NN	__unaligned__		OK/0.682672
should	sollte	MD	VMFIN		OK/0.866969
be	vermieden	VB	VVPP		OK/0.819865
avoided	vermieden	VVN	VVPP		OK/0.864126
.	.	SENT	$.		OK/0.998998

# 0.149845
Infections	Infektionen	NNS	NN		OK/0.969938
In	In	IN	APPR		OK/0.989482
the	ersten	DT	ADJA		OK/0.994998
first	ersten	JJ	ADJA		OK/0.991613
12	13	CD	CARD		OK/0.978491
weeks	Wochen	NNS	NN		OK/0.997725
after	nach	IN	APPR		OK/0.981270
treatment	Behandlung	NN	NN		OK/0.810652
with	mit	IN	APPR		OK/0.766458
Zevalin	Zevalin	NP	NN		BAD/0.709168
occurred	kam	VVD	VVFIN		BAD/0.746870
very	sehr	RB	ADV		BAD/0.640569
commonly	häufig	RB	ADJD		BAD/0.643183
in	bei	IN	APPR		BAD/0.500293
patients	Patienten	NNS	NN		BAD/0.417815
with	zu	IN	APPR		BAD/0.601919
infections	Infektionen	NNS	NN		OK/0.971630
.	.	SENT	$.		OK/0.999064

# 0.843006
The	Die	NP	ART		OK/0.996247
Marketing	Inverkehrbringen	NP	NN		OK/0.973597
Authorisation	Inverkehrbringen	NP	NN		OK/0.959046
was	wurde	VBD	VAFIN		OK/0.989454
adopted	__unaligned__	VVN	__unaligned__		OK/0.959961
on	__unaligned__	IN	__unaligned__		OK/0.952244
17	17.	CD	ADJA		OK/0.957545
April	17.	NP	ADJA		OK/0.985165
2008	17.	CD	ADJA		OK/0.996137
.	17.	SENT	ADJA		OK/0.984347

# 0.399227
In	In	IN	APPR		OK/0.990869
the	der	DT	ART		OK/0.982251
study	Studie	NN	NN		OK/0.958024
MN302	MN302	JJ	NN		OK/0.592711
leflunomide	Leflunomid	NN	NN		OK/0.873193
was	war	VBD	VAFIN		OK/0.971392
significantly	signifikant	RB	ADJD		OK/0.884085
less	weniger	RBR	ADV		OK/0.943573
effective	wirksam	JJ	ADJD		OK/0.854232
than	weniger	IN	ADV		OK/0.804941
methotrexate	Methotrexat	NN	NN		OK/0.859126
.	.	SENT	$.		OK/0.999484

# 0.799662
Where	Wohin	WRB	PWAV		OK/0.906635
should	sollen	MD	VMFIN		OK/0.881552
you	Sie	PP	PPER		OK/0.942872
inject	spritzen	VV	VVINF		OK/0.916993
?	?	SENT	$.		OK/0.998386

# 0.659936
Elderly	Ältere	NP	ADJA		OK/0.975184
No	keine	DT	PIAT		OK/0.998128
dose	Dosisanpassung	NN	NN		OK/0.998551
adjustment	Dosisanpassung	NN	NN		OK/0.993898
is	erforderlich	VBZ	ADJD		OK/0.977807
necessary	erforderlich	JJ	ADJD		OK/0.853197
for	Für	IN	APPR		OK/0.851012
elderly	ältere	JJ	ADJA		OK/0.836173
patients	Patienten	NNS	NN		OK/0.792939
.	.	SENT	$.		OK/0.999498

# 0.848053
Investigations	Untersuchungen	NNS	NN		OK/0.938395
elevations	__unaligned__	NNS	__unaligned__		OK/0.964103
of	__unaligned__	IN	__unaligned__		OK/0.999293
hepatic	Lebertransaminasen	JJ	NN		OK/0.999694
transaminases	Lebertransaminasen	NNS	NN		OK/0.991446
and	und	CC	KON		OK/0.998263
alkaline	Phosphatase	JJ	NN		OK/0.982077
phosphatase	Phosphatase	NN	NN		OK/0.932143
.	.	SENT	$.		OK/0.998414

# 0.405013
The	Die	NP	ART		OK/0.985114
recommended	empfohlene	VVD	ADJA		OK/0.986856
in	__unaligned__	IN	__unaligned__		OK/0.953585
section	Abschnitt	NN	NN		OK/0.992867
4.2	4.2	CD	CARD		OK/0.987380
"	"	''	$(		OK/0.994968
and	Art	CC	NN		OK/0.826808
"	"	``	$(		OK/0.819028
It	unbedingt	PP	ADJD		OK/0.701441
is	unbedingt	VBZ	ADJD		OK/0.738684
important	unbedingt	JJ	ADJD		OK/0.809062
to	unbedingt	TO	ADJD		OK/0.698986
use	__unaligned__	VV	__unaligned__		OK/0.755886
infusion	Infusionsgeschwindigkeit	NN	NN		OK/0.825540
.	.	SENT	$.		OK/0.998540

# 0.121884
This	Dadurch	NP	PAV		OK/0.954511
in	__unaligned__	IN	__unaligned__		OK/0.980410
turn	__unaligned__	NN	__unaligned__		OK/0.955386
stimulates	wiederum	VVZ	ADV		OK/0.945037
the	deren	DT	PDAT		OK/0.943879
speedy	Neurotransmittern	JJ	NN		BAD/0.712844
recovery	__unaligned__	NN	__unaligned__		BAD/0.689537
of	__unaligned__	IN	__unaligned__		BAD/0.710595
the	__unaligned__	DT	__unaligned__		BAD/0.522443
infected	Freisetzung	JJ	NN		BAD/0.538028
cells	__unaligned__	NNS	__unaligned__		BAD/0.567517
,	einschließlich	,	APPR		BAD/0.447020
and	und	CC	KON		OK/0.960373
consequently	damit	RB	PAV		OK/0.795597
maintaining	__unaligned__	VVG	__unaligned__		OK/0.680288
Rückenmarksignalisierung	Rückenmarksignalisierung	NP	NN		OK/0.827789
pain	Schmerz	NN	NN		OK/0.940364
.	.	SENT	$.		OK/0.995850

# 0.087633
Excipients	Sonstige	NP	ADJA		OK/0.922942
:	:	:	$.		OK/0.986059
glycine	Glycin	NN	NE		OK/0.952703
,	Dinatriumhydrogenphosphat	,	NE		OK/0.984221
disodium	Dinatriumhydrogenphosphat	NN	NE		OK/0.920670
phosphate	Dinatriumhydrogenphosphat	NN	NE		OK/0.979822
anhydrous	Dinatriumhydrogenphosphat	JJ	NE		OK/0.817124
,	,	,	$,		OK/0.868765
sodium	Natriumdihydrogenphosphat	NN	NN		OK/0.588178
dihydrogen	Natriumdihydrogenphosphat	NN	NN		OK/0.508658
phosphate	Natriumdihydrogenphosphat	NN	NN		OK/0.865649
monohydrate	Natriumdihydrogenphosphat	NN	NN		BAD/0.650119
,	__unaligned__	,	__unaligned__		BAD/0.478780
and	und	CC	KON		OK/0.947159
human	Albuminlösung	JJ	NN		OK/0.957145
albumin	Albuminlösung	NN	NN		OK/0.990443
solution	Albuminlösung	NN	NN		OK/0.994821
One	Eine	CD	ART		OK/0.967155
ampoule	Ampulle	NN	NN		OK/0.985066
of	Ampulle	IN	NN		OK/0.978507
solvent	Ampulle	NN	NN		OK/0.959790
contains	enthält	VVZ	VVFIN		OK/0.992884
1	1	CD	CARD		OK/0.999376
ml	ml	NN	NN		OK/0.997381
of	für	IN	APPR		OK/0.853758
water	Injektionszwecke	NN	NN		OK/0.861129
for	Injektionszwecke	IN	NN		OK/0.893129
injections	Injektionszwecke	NNS	NN		OK/0.909256
.	.	SENT	$.		OK/0.997583

# 0.826149
1	1	CD	CARD		OK/0.999058
%	%	NN	NN		OK/0.999386
)	)	)	$(		OK/0.997786
;	;	:	$.		OK/0.996857
Administration	Verabreichungsort	NP	NN		OK/0.963714
Site	Verabreichungsort	NP	NN		OK/0.907702
Conditions	Verabreichungsort	NPS	NN		OK/0.918002
Fatigue	Abgeschlagenheit	NP	NN		OK/0.955299
/	/	SYM	$(		OK/0.997777
weakness	Schwäche	NN	NN		OK/0.981106
(	(	(	$(		OK/0.997961
G3	G3	NP	NN		OK/0.997794
/	/	SYM	$(		OK/0.998942
4	4	CD	CARD		OK/0.996383
:	:	:	$.		OK/0.997226

# 0.777556
sichelähnliche	sichelähnliche	NN	ADJA		OK/0.845192
outwards	annehmen	NNS	VVINF		OK/0.824845
)	)	)	$(		OK/0.954918
.	.	SENT	$.		OK/0.994948

# 0.200870
In	In	IN	APPR		OK/0.981465
these	diesen	DT	PDAT		OK/0.996812
studies	Studien	NNS	NN		OK/0.998841
were	lagen	VBD	VVFIN		OK/0.714553
1.503	1.503	CD	CARD		OK/0.621668
infants	Kindern	NNS	NN		OK/0.520972
had	anti-HBs-Ergebnisse	VHD	NN		OK/0.510753
anti-HBs	anti-HBs-Ergebnisse	NNS	NN		OK/0.592901
results	anti-HBs-Ergebnisse	NNS	NN		OK/0.602802
available	anti-HBs-Ergebnisse	JJ	NN		OK/0.840277
following	anti-HBs-Ergebnisse	VVG	NN		OK/0.964074
the	ersten	DT	ADJA		OK/0.998164
first	ersten	JJ	ADJA		OK/0.993463
two	zwei	CD	CARD		OK/0.996952
doses	Dosen	NNS	NN		OK/0.996801
of	__unaligned__	IN	__unaligned__		OK/0.895237
PROCOMVAX	PROCOMVAX	NP	NE		OK/0.948852
,	,	,	$,		OK/0.921565
1.309	1.309	CD	CARD		OK/0.785629
after	nach	IN	APPR		OK/0.993569
the	__unaligned__	DT	__unaligned__		OK/0.993374
third	dritten	JJ	ADJA		OK/0.920751
dose	Dosis	NN	NN		OK/0.988456
.	.	SENT	$.		OK/0.999898

# 0.416601
the	die	DT	ART		OK/0.609389
vaccines	Impfstoffe	NNS	NN		OK/0.542882
sites	Stellen	NNS	NN		OK/0.569503
should	__unaligned__	MD	__unaligned__		OK/0.837126
be	injiziert	VB	VVPP		OK/0.919156
injected	injiziert	VVN	VVPP		OK/0.916686
.	.	SENT	$.		OK/0.998952

# 0.662021
•	•	NP	NN		OK/0.997611
a	durchstechsicheren	DT	ADJA		OK/0.971501
puncture-proof	durchstechsicheren	JJ	ADJA		OK/0.901086
container	durchstechsicheren	NN	ADJA		OK/0.881132
for	für	IN	APPR		OK/0.913375
safe	sichere	JJ	ADJA		OK/0.954576
disposal	Entsorgung	NN	NN		OK/0.956893
of	der	IN	ART		OK/0.995778
the	der	DT	ART		OK/0.997706
syringes	Spritzen	NNS	NN		OK/0.840849
.	.	SENT	$.		OK/0.999525

# 0.462516
The	Die	DT	ART		OK/0.991082
maximum	maximalen	JJ	ADJA		OK/0.997745
plasma	Plasmakonzentrationen	NN	NN		OK/0.992921
concentrations	Plasmakonzentrationen	NNS	NN		OK/0.998042
of	des	IN	ART		OK/0.995118
the	des	DT	ART		OK/0.987348
single	einzigen	JJ	ADJA		OK/0.898095
active	Metaboliten	JJ	NN		OK/0.947708
metabolite	Metaboliten	NN	NN		OK/0.977845
of	__unaligned__	IN	__unaligned__		OK/0.961036
ramipril	Ramipril	NN	NE		OK/0.973666
,	,	,	$,		OK/0.965367
ramiprilat	Ramiprilat	NP	NE		OK/0.814682
,	,	,	$,		OK/0.879717
has	erreicht	VHZ	VVPP		OK/0.741369
reached	erreicht	VVN	VVPP		OK/0.912958
within	innerhalb	IN	ADJD		OK/0.994925
2	2	CD	CARD		OK/0.997825
-	-	:	$(		OK/0.994079
4	4	CD	CARD		OK/0.995490
hours	Stunden	NNS	NN		OK/0.990137
after	nach	IN	APPR		OK/0.998146
taking	Einnahme	VVG	NN		OK/0.909842
ramipril	Ramipril	NN	NE		OK/0.930513
.	.	SENT	$.		OK/0.996448

# 0.508436
If	Wenn	IN	KOUS		OK/0.865681
the	die	DT	ART		OK/0.982974
solution	Lösung	NN	NN		OK/0.995685
is	Lösung	VBZ	NN		OK/0.934351
cloudy	trübe	JJ	VVFIN		OK/0.975326
or	oder	CC	KON		OK/0.999479
contains	enthält	VVZ	VVFIN		OK/0.941682
particles	Partikel	NNS	NN		OK/0.931368
in	__unaligned__	IN	__unaligned__		OK/0.880597
it	__unaligned__	PP	__unaligned__		OK/0.770194
,	,	,	$,		OK/0.984672
you	Sie	PP	PPER		OK/0.996368
must	dürfen	MD	VMFIN		OK/0.993427
not	nicht	RB	PTKNEG		OK/0.997969
use	verwenden	VV	VVINF		OK/0.989886
it	verwenden	PP	VVINF		OK/0.895562
.	.	SENT	$.		OK/0.998147

# 0.637500
Ciprofloxacin	Ciprofloxacin	NP	NE		OK/0.994759
inhibits	hemmt	VVZ	VVFIN		OK/0.975183
DNA-gyrase	DNA-Gyrase	NP	NN		OK/0.840796
,	was	,	PRELS		OK/0.991741
which	__unaligned__	WDT	__unaligned__		OK/0.937399
results	führt	VVZ	VVFIN		OK/0.980895
in	führt	IN	VVFIN		OK/0.990452
the	der	DT	ART		OK/0.971475
inhibition	Hemmung	NN	NN		OK/0.900825
of	der	IN	ART		OK/0.967035
the	der	DT	ART		OK/0.981873
synthesis	DNA-Synthese	NN	NN		OK/0.919923
.	.	SENT	$.		OK/0.999233

# 0.986263
Instructions	Hinweise	NNS	NN		OK/0.998078
for	Hinweise	IN	NN		OK/0.995976
administration	Impfstoffes	NN	NN		OK/0.999375
of	Impfstoffes	IN	NN		OK/0.998822
the	Impfstoffes	DT	NN		OK/0.999343
vaccine	Impfstoffes	NN	NN		OK/0.994496
:	:	:	$.		OK/0.999558

# 0.945841
Pregnancy	Schwangerschaft	NP	NN		OK/0.978284
(	(	(	$(		OK/0.999624
see	siehe	VV	VVIMP		OK/0.980726
section	Abschnitt	NN	NN		OK/0.984708
4.3	4.3	CD	CARD		OK/0.994571
)	)	)	$(		OK/0.999973
:	:	:	$.		OK/0.999637

# 0.096575
Neutropenia	Neutropenie	NP	NN		OK/0.985119
lasted	hielt	VVD	VVFIN		OK/0.971176
for	für	IN	APPR		OK/0.987298
>	>	SYM	$(		BAD/0.587956
7	7	CD	CARD		OK/0.959934
days	Tage	NNS	NN		OK/0.998367
in	bei	IN	APPR		OK/0.983181
41	41	CD	CARD		OK/0.996227
%	%	NN	NN		OK/0.991494
and	und	CC	KON		OK/0.963431
that	__unaligned__	IN/that	__unaligned__		BAD/0.730049
of	für	IN	APPR		BAD/0.515170
30	30	CD	CARD		BAD/0.413375
-	-	:	$(		BAD/0.457135
35	35	CD	CARD		OK/0.844755
days	Tage	NNS	NN		OK/0.990611
in	bei	IN	APPR		OK/0.972765
8	8	CD	CARD		OK/0.998343
%	%	NN	NN		OK/0.999113
of	der	IN	ART		OK/0.995461
the	der	DT	ART		OK/0.987080
patients	Patienten	NNS	NN		OK/0.945136
.	.	SENT	$.		OK/0.999735

# 0.421093
Do	dürfen	VVP	VMFIN		OK/0.968775
not	dürfen	RB	VMFIN		OK/0.984975
use	dürfen	VV	VMFIN		OK/0.995208
PRODUCT	HANDELSNAME	NN	NN		OK/0.989719
NAME	HANDELSNAME	JJ	NN		OK/0.987501
20	20	CD	CARD		OK/0.976698
mg	mg	NN	NN		OK/0.978765
if	wenn	IN	KOUS		OK/0.999059
you	Sie	PP	PPER		OK/0.999678
notice	bemerken	VVP	VVINF		OK/0.997165
any	bemerken	DT	VVINF		OK/0.999302
visible	sichtbare	JJ	ADJA		OK/0.935586
sign	Qualitätsminderung	NN	NN		OK/0.593502
of	Qualitätsminderung	IN	NN		OK/0.630025
deterioration	Qualitätsminderung	NN	NN		OK/0.595411
.	.	SENT	$.		OK/0.996085

# 0.669347
Insulatard	Insulatard	NP	NN		OK/0.977309
is	ist	VBZ	VAFIN		OK/0.960121
an	Isophan-	DT	TRUNC		OK/0.790303
isophane	Isophan-	NN	TRUNC		OK/0.924624
insulin	Isophan-	NN	TRUNC		OK/0.978771
suspension	Isophan-	NN	TRUNC		OK/0.977709
(	(	(	$(		OK/0.990179
NPH	NPH	NP	NE		OK/0.944566
)	)	)	$(		OK/0.978345
insulin	__unaligned__	NN	__unaligned__		OK/0.937563
.	.	SENT	$.		OK/0.999790

# 0.709355
Angiotensin	Angiotensin	NP	NN		OK/0.989454
II	Angiotensin	NP	NN		OK/0.997751
is	ist	VBZ	VAFIN		OK/0.965297
a	starker	DT	ADJA		OK/0.963136
potent	starker	JJ	ADJA		OK/0.982816
vasoconstrictor	Vasokonstriktor	NN	NN		OK/0.920506
is	__unaligned__	VBZ	__unaligned__		OK/0.960028
a	__unaligned__	DT	__unaligned__		OK/0.967919
photosensitising	ein	VVG	ART		OK/0.876772
agent	__unaligned__	NN	__unaligned__		OK/0.955372
(	(	(	$(		OK/0.986187
a	(	DT	$(		OK/0.997267
blood	Blutgefäße	NN	NN		OK/0.998305
vessels	Blutgefäße	NNS	NN		OK/0.980070
)	)	)	$(		OK/0.974069
.	.	SENT	$.		OK/0.997323

# 0.157510
Actraphane	Actraphane	NP	NN		OK/0.990582
is	normalerweise	VBZ	ADV		OK/0.979911
usually	normalerweise	RB	ADV		OK/0.999150
given	wird	VVN	VAFIN		OK/0.984460
once	einmal	RB	ADV		OK/0.998530
or	oder	CC	KON		OK/0.999064
twice	zweimal	RB	ADV		OK/0.997983
a	täglich	DT	ADJD		OK/0.999619
day	täglich	NN	ADJD		OK/0.994695
when	wenn	WRB	KOUS		OK/0.984957
a	eine	DT	ART		OK/0.999312
rapid	schnelle	JJ	ADJA		OK/0.987854
initial	initiale	JJ	ADJA		OK/0.957439
effect	__unaligned__	NN	__unaligned__		BAD/0.585904
together	__unaligned__	RB	__unaligned__		BAD/0.685381
with	zusammen	IN	ADV		BAD/0.673917
a	__unaligned__	DT	__unaligned__		BAD/0.681162
more	__unaligned__	RBR	__unaligned__		BAD/0.868681
prolonged	anhaltenden	JJ	ADJA		BAD/0.810239
effect	__unaligned__	NN	__unaligned__		BAD/0.619043
is	__unaligned__	VBZ	__unaligned__		BAD/0.632281
desired	__unaligned__	VVN	__unaligned__		BAD/0.448911
.	.	SENT	$.		OK/0.995915

# 0.738190
Caution	Vorsicht	NN	NN		OK/0.992836
must	Vorsicht	MD	NN		OK/0.993135
be	Vorsicht	VB	NN		OK/0.995937
exercised	Vorsicht	VVN	NN		OK/0.983672
when	Vorsicht	WRB	NN		OK/0.982703
prescribing	Verordnung	VVG	NN		OK/0.928979
to	__unaligned__	TO	__unaligned__		OK/0.864991
older	ältere	JJR	ADJA		OK/0.834281
patients	Patienten	NNS	NN		OK/0.883948
.	.	SENT	$.		OK/0.999574

# 0.104865
Fresenius	Fresenius	NP	NN		OK/0.871883
Kabi	Kabi	NP	NN		OK/0.781167
Nederland	Nederland	NP	NE		OK/0.282596
B.V.	B.V.	NP	NE		OK/0.363623
,	__unaligned__	,	__unaligned__		OK/0.505215
Postbus	Postbus	NP	NN		OK/0.619733
2379	2379	CD	CARD		OK/0.694742
solution	2379	NN	CARD		OK/0.746271
for	2379	IN	CARD		OK/0.760338
infusion	NL-5202	NN	NN		OK/0.843102
NL-5202	NL-5202	NP	NN		OK/0.783487
CJ	CJ	NP	NE		OK/0.872270
's	CJ	POS	NE		OK/0.883708
Hertogenbosch	Hertogenbosch	NP	NE		OK/0.903937
,	,	,	$,		OK/0.933375
Netherlands	Niederlande	NP	NE		OK/0.842231
Tel-No	Tel-No	NP	NE		OK/0.806781
.	.	SENT	$.		OK/0.900947
:	:	:	$.		OK/0.993399

# 0.160465
For	Bei	IN	APPR		OK/0.902614
oral	oraler	JJ	ADJA		OK/0.948298
administration	__unaligned__	NN	__unaligned__		OK/0.940492
of	__unaligned__	IN	__unaligned__		OK/0.802915
2	2	CD	CARD		OK/0.991334
to	bis	TO	KON		OK/0.984712
4	4	CD	CARD		OK/0.961580
mg	mg	NN	NN		OK/0.996686
/	/	SYM	$(		OK/0.998835
kg	kg	NN	NN		OK/0.980070
verhielt	verhielt	NN	VVFIN		OK/0.336068
the	die	DT	ART		OK/0.440590
extent	Resorption	NN	NN		OK/0.422017
of	Resorption	IN	NN		OK/0.694698
absorption	Resorption	NN	NN		OK/0.877878
.	.	SENT	$.		OK/0.901598

# 0.199367
Oral	__unaligned__	NP	__unaligned__		OK/0.585616
use	__unaligned__	NN	__unaligned__		OK/0.601549
Swallow	Als	NP	KOKOM		OK/0.822320
whole	__unaligned__	NN	__unaligned__		OK/0.876318
,	zerkauen	,	VVINF		OK/0.791718
do	zerkauen	VVP	VVINF		OK/0.786346
not	nicht	RB	PTKNEG		OK/0.971163
chew	zerkauen	VV	VVINF		OK/0.875219
,	,	,	$,		OK/0.955413
divide	zerkauen	VV	VVINF		OK/0.915981
or	zerdrücken	CC	VVFIN		OK/0.987562
crush	zerdrücken	VV	VVFIN		OK/0.991191
Read	Packungsbeilage	VV	NN		OK/0.997752
the	Packungsbeilage	DT	NN		OK/0.994356
package	Packungsbeilage	NN	NN		OK/0.998348
leaflet	Packungsbeilage	NN	NN		OK/0.989977
before	beachten	IN	VVINF		OK/0.659868
use	beachten	NN	VVINF		OK/0.669253
.	.	SENT	$.		OK/0.995313

# 0.015626
7	7	CD	CARD		OK/0.677212
have	__unaligned__	VHP	__unaligned__		OK/0.309719
a	__unaligned__	DT	__unaligned__		OK/0.502141
narrow	Zytochrom	JJ	NN		OK/0.260489
therapeutic	__unaligned__	JJ	__unaligned__		OK/0.589209
P450-abhängige	P450-abhängige	NP	ADJA		OK/0.420892
Lebermischfunktions-Oxidase	Lebermischfunktions-Oxidase	NN	NN		OK/0.617094
.	.	SENT	$.		OK/0.874538
The	Die	DT	ART		OK/0.861465
principal	wichtigste	JJ	ADJA		OK/0.557213
Stoffwechselbahn	Stoffwechselbahn	NP	NN		OK/0.562470
,	,	,	$,		OK/0.774528
N-demethylierung	N-demethylierung	NP	NN		OK/0.677512
,	,	,	$,		OK/0.934700
primarily	allem	RB	PIS		OK/0.941690
mediated	vermittelt	VVN	VVPP		OK/0.949067
by	__unaligned__	IN	__unaligned__		OK/0.420115
CYP3A	CYP3A	NP	NE		OK/0.799963
.	.	SENT	$.		OK/0.999007

# 0.439053
Elimination	Elimination	NP	NN		OK/0.997664
Renal	renale	NP	ADJA		OK/0.990864
clearance	Clearance	NN	NN		OK/0.998969
of	von	IN	APPR		OK/0.998616
metformin	Metformin	NN	NE		OK/0.998701
is	__unaligned__	VBZ	__unaligned__		OK/0.995479
>	>	SYM	$(		BAD/0.931485
400	400	CD	CARD		OK/0.975445
ml	ml	NN	NN		OK/0.998620
/	/	SYM	$(		OK/0.999431
min	min	NN	ADJD		OK/0.994059
,	__unaligned__	,	__unaligned__		OK/0.864258
indicating	auf	VVG	APPR		OK/0.830121
that	__unaligned__	IN/that	__unaligned__		OK/0.896747
metformin	__unaligned__	NN	__unaligned__		OK/0.976101
is	__unaligned__	VBZ	__unaligned__		OK/0.983979
eliminated	glomeruläre	VVN	ADJA		OK/0.763505
by	glomeruläre	IN	ADJA		OK/0.870919
glomerular	glomeruläre	JJ	ADJA		OK/0.900138
filtration	glomeruläre	NN	ADJA		OK/0.831330
and	und	CC	KON		OK/0.938041
tubular	tubuläre	JJ	ADJA		OK/0.991138
secretion	tubuläre	NN	ADJA		OK/0.992091
.	.	SENT	$.		OK/0.998232

# 0.388364
Depending	Je	VVG	ADV		OK/0.985782
on	Je	IN	ADV		OK/0.960089
how	Je	WRB	ADV		OK/0.900696
your	Ihre	PP$	PPOSAT		OK/0.909794
anaemia	Anämie	NN	NN		OK/0.876519
responds	anspricht	VVZ	VVFIN		OK/0.804264
,	,	,	$,		OK/0.929274
the	die	DT	ART		OK/0.995029
dose	Dosis	NN	NN		OK/0.999267
may	kann	MD	VMFIN		OK/0.990351
be	kann	VB	VMFIN		OK/0.965423
adjusted	angepasst	VVN	VVPP		OK/0.986729
approximately	etwa	RB	ADV		OK/0.955440
every	alle	DT	PIAT		OK/0.998172
four	vier	CD	CARD		OK/0.998669
weeks	Wochen	NNS	NN		OK/0.997124
until	bis	IN	KOUS		OK/0.788687
your	Ihr	PP$	PPOSAT		OK/0.968063
condition	__unaligned__	NN	__unaligned__		OK/0.961552
is	__unaligned__	VBZ	__unaligned__		OK/0.807941
controlled	Kontrolle	VVN	NN		OK/0.818278
.	.	SENT	$.		OK/0.997692

# 0.500998
These	Diese	DT	PDAT		OK/0.985085
effects	Effekte	NNS	NN		OK/0.989146
have	wurden	VHP	VAFIN		OK/0.993462
been	wurden	VBN	VAFIN		OK/0.969135
observed	beobachtet	VVN	VVPP		OK/0.897385
similar	__unaligned__	JJ	__unaligned__		OK/0.921863
to	der	TO	ART		OK/0.687718
the	der	DT	ART		OK/0.882173
expected	erwartenden	VVN	ADJA		OK/0.740138
clinical	klinischen	JJ	ADJA		OK/0.967813
exposure	Exposition	NN	NN		OK/0.981495
.	.	SENT	$.		OK/0.998953

# 0.164120
In	In	IN	APPR		OK/0.877254
very	sehr	RB	ADV		OK/0.994740
rare	seltenen	JJ	ADJA		OK/0.978935
cases	Fällen	NNS	NN		OK/0.916842
there	__unaligned__	EX	__unaligned__		OK/0.851361
has	monate-	VHZ	TRUNC		OK/0.836812
been	__unaligned__	VBN	__unaligned__		OK/0.918278
subcutaneous	jahrelanger	JJ	ADJA		OK/0.937196
treatment	Therapie	NN	NN		OK/0.995426
with	mit	IN	APPR		OK/0.998908
other	anderen	JJ	PIS		OK/0.999439
products	Erythropoetin-haltigen	NNS	ADJA		OK/0.948500
containing	__unaligned__	VVG	__unaligned__		OK/0.823062
Pure	Erythroblastopenie	NP	NN		OK/0.998354
Red	Erythroblastopenie	NP	NN		OK/0.998309
Cell	Erythroblastopenie	NP	NN		OK/0.996991
Aplasia	Erythroblastopenie	NP	NN		OK/0.989708
(	(	(	$(		OK/0.809801
PRCA	PRCA	NP	NE		OK/0.989037
)	)	)	$(		OK/0.979670
and	auch	CC	ADV		OK/0.660099
may	__unaligned__	MD	__unaligned__		OK/0.582838
not	__unaligned__	RB	__unaligned__		OK/0.542685
be	__unaligned__	VB	__unaligned__		OK/0.652487
treated	__unaligned__	VVN	__unaligned__		OK/0.830180
with	__unaligned__	IN	__unaligned__		OK/0.940957
Retacrit	Retacrit	NP	NE		OK/0.929972
cannot	auszuschließen	MD	VVIZU		OK/0.949033
be	auszuschließen	VB	VVIZU		OK/0.981083
excluded	auszuschließen	VVN	VVIZU		OK/0.971587
.	.	SENT	$.		OK/0.999112

# 0.334509
Overdose	Überdosierung	NP	NN		OK/0.974996
may	kann	MD	VMFIN		OK/0.879811
cause	kann	VV	VMFIN		OK/0.846938
a	Abfall	DT	NN		OK/0.973885
fall	Abfall	NN	NN		OK/0.860504
in	Abfall	IN	NN		OK/0.923318
blood	Blutdrucks	NN	NN		OK/0.992499
pressure	Blutdrucks	NN	NN		OK/0.990502
,	,	,	$,		OK/0.998317
palpitations	Herzklopfen	NNS	NN		OK/0.984952
,	__unaligned__	,	__unaligned__		OK/0.959363
or	oder	CC	KON		OK/0.985093
-rasen	-rasen	NN	ADJA		OK/0.778780
(	(	(	$(		OK/0.967538
palpitations	Palpitationen	NNS	NN		OK/0.940617
)	)	)	$(		OK/0.996736
,	,	,	$,		OK/0.986294
slow	langsamen	JJ	ADJA		OK/0.975827
heart	Puls	NN	NN		OK/0.911585
beat	Puls	NN	NN		OK/0.891617
,	,	,	$,		OK/0.990727
changes	Veränderung	NNS	NN		OK/0.948491
in	Veränderung	IN	NN		OK/0.998535
blood	Blutwerten	NN	NN		OK/0.998808
count	__unaligned__	NN	__unaligned__		OK/0.998100
and	und	CC	KON		OK/0.958409
cause	verursachen	NN	VVINF		OK/0.848848
.	.	SENT	$.		OK/0.998447

# 0.212834
It	Es	PP	PPER		OK/0.960949
can	kann	MD	VMFIN		OK/0.959930
be	kann	VB	VMFIN		OK/0.994643
given	intravenös	VVN	ADJD		OK/0.996612
intravenously	intravenös	RB	ADJD		OK/0.997933
(	(	(	$(		OK/0.980963
into	Vene	IN	NN		OK/0.997916
a	Vene	DT	NN		OK/0.999944
vein	Vene	NN	NN		OK/0.998995
)	)	)	$(		OK/0.985792
,	jedoch	,	ADV		OK/0.862989
but	jedoch	CC	ADV		BAD/0.573696
only	nur	RB	ADV		BAD/0.499212
or	Fachpersonal	CC	NN		BAD/0.688067
health	Fachpersonal	NN	NN		OK/0.998461
care	Fachpersonal	NN	NN		OK/0.998500
professional	Fachpersonal	JJ	NN		OK/0.690977
.	.	SENT	$.		OK/0.992639

# 0.754128
Insert	Stechen	NP	NN		OK/0.990712
the	Stechen	DT	NN		OK/0.999697
needle	Stechen	NN	NN		OK/0.998583
into	Stechen	IN	NN		OK/0.997854
the	Stechen	DT	NN		OK/0.993503
skin	Haut	NN	NN		OK/0.986239
and	und	CC	KON		OK/0.993890
push	drücken	VV	VVFIN		OK/0.930475
in	den	IN	ART		OK/0.945476
the	den	DT	ART		OK/0.989166
injection	Injektionsknopf	NN	NN		OK/0.998943
button	Injektionsknopf	NN	NN		OK/0.995390
is	__unaligned__	VBZ	__unaligned__		OK/0.945165
in	in	IN	APPR		OK/0.922522
the	den	DT	ART		OK/0.961306
pen	Injektor	NN	NN		OK/0.947233
.	.	SENT	$.		OK/0.998279

# 0.825848
Important	Wichtige	JJ	ADJA		OK/0.996095
information	Informationen	NN	NN		OK/0.999674
about	Wichtige	IN	ADJA		OK/0.997764
some	bestimmte	DT	ADJA		OK/0.965297
of	Bestandteile	IN	NN		OK/0.968498
the	Bestandteile	DT	NN		OK/0.969321
ingredients	Bestandteile	NNS	NN		OK/0.984684
of	Bestandteile	IN	NN		OK/0.996952
Azomyr	Azomyr	NP	NN		OK/0.997890
Azomyr	Azomyr	NP	NN		OK/0.994269
oral	Einnehmen	JJ	NN		OK/0.999832
solution	Lösung	NN	NN		OK/0.999958
contains	enthält	VVZ	VVFIN		OK/0.984650
sorbitol	Sorbitol	NN	NE		OK/0.911773
.	.	SENT	$.		OK/0.999594

# 0.069911
This	Das	DT	ART		OK/0.997368
medicinal	Arzneimittel	JJ	NN		OK/0.996555
product	Arzneimittel	NN	NN		OK/0.980495
should	ist	MD	VAFIN		OK/0.812739
be	verabreichen	VB	VVINF		OK/0.905337
administered	verabreichen	VVN	VVINF		OK/0.886898
using	mittels	VVG	APPR		OK/0.838798
a	__unaligned__	DT	__unaligned__		OK/0.802427
Verneblertyps	Verneblertyps	NP	NN		OK/0.596545
with	mit	IN	APPR		OK/0.736945
Dosierfunktion	Dosierfunktion	NP	NN		OK/0.509860
,	,	,	$,		OK/0.543060
has	unterbunden	VHZ	VVPP		OK/0.518908
been	unterbunden	VBN	VVPP		OK/0.627863
delivered	unterbunden	VVN	VVPP		OK/0.544885
,	,	,	$,		OK/0.709028
released	freigesetzt	VVN	VVPP		OK/0.657150
as	sobald	IN	KOUS		OK/0.971147
soon	sobald	RB	KOUS		OK/0.929818
as	sobald	IN	KOUS		OK/0.914847
the	korrekte	DT	ADJA		OK/0.938993
correct	korrekte	JJ	ADJA		OK/0.943926
dose	Dosis	NN	NN		OK/0.956014
has	wurde	VHZ	VAFIN		OK/0.792830
been	wurde	VBN	VAFIN		OK/0.893745
delivered	__unaligned__	VVN	__unaligned__		OK/0.656838
.	.	SENT	$.		OK/0.977853

# 0.010361
119	119	NP	CARD		OK/0.934562
National	zuständigen	NP	ADJA		OK/0.873828
Competent	zuständigen	NP	ADJA		OK/0.605587
Authorities	Behörden	NP	NN		OK/0.332588
(	__unaligned__	(	__unaligned__		OK/0.304583
National	koordiniert	NP	VVFIN		OK/0.356518
Competent	koordiniert	NP	VVFIN		OK/0.379539
Authorities	koordiniert	NP	VVFIN		OK/0.406828
,	__unaligned__	,	__unaligned__		OK/0.721291
coordinated	koordiniert	VVN	VVFIN		OK/0.697208
by	durch	IN	APPR		OK/0.966201
the	den	DT	ART		OK/0.998373
Reference	Referenzmitgliedstaat	NP	NN		OK/0.977587
Member	Referenzmitgliedstaat	NP	NN		OK/0.997925
State	Referenzmitgliedstaat	NP	NN		OK/0.995355
,	,	,	$,		OK/0.998973
shall	__unaligned__	MD	__unaligned__		OK/0.999014
ensure	sicher	VV	ADJD		OK/0.986650
that	dass	IN/that	KOUS		OK/0.993933
the	folgenden	DT	ADJA		OK/0.995673
following	folgenden	VVG	ADJA		OK/0.973658
conditions	Bedingungen	NNS	NN		OK/0.925870
are	Bedingungen	VBP	NN		OK/0.731975
fulfilled	__unaligned__	VVN	__unaligned__		OK/0.731077
by	__unaligned__	IN	__unaligned__		OK/0.844584
the	__unaligned__	DT	__unaligned__		OK/0.947897
Marketing	Inhabern	NP	NN		OK/0.953910
Authorisation	Inhabern	NN	NN		OK/0.950881
Holders	Inhabern	NNS	NN		OK/0.918399
(	__unaligned__	(	__unaligned__		BAD/0.736833
marketing	Inverkehrbringen	NN	NN		BAD/0.608861
authorisation	Genehmigung	NN	NN		BAD/0.624812
for	für	IN	APPR		BAD/0.654022
the	für	DT	APPR		BAD/0.782733
medicinal	__unaligned__	JJ	__unaligned__		BAD/0.947039
product	__unaligned__	NN	__unaligned__		BAD/0.904089
described	__unaligned__	VVN	__unaligned__		BAD/0.763473
below	werden	IN	VAINF		BAD/0.692883
are	__unaligned__	VBP	__unaligned__		BAD/0.741456
implemented	__unaligned__	VVN	__unaligned__		BAD/0.681574
:	:	:	$.		OK/0.725751

# 0.067567
The	Der	DT	ART		OK/0.980325
MAH	Inhaber	NP	NN		OK/0.744959
marketing	Inverkehrbringen	NN	NN		OK/0.598419
authorisation	Genehmigung	NN	NN		OK/0.622347
prior	vor	RB	APPR		OK/0.742309
to	__unaligned__	TO	__unaligned__		OK/0.772339
the	der	DT	ART		OK/0.748238
launch	Markteinführung	NN	NN		OK/0.482242
of	__unaligned__	IN	__unaligned__		OK/0.567019
the	in	DT	APPR		OK/0.907198
Übereinkunft	Übereinkunft	NP	NN		OK/0.859079
agreed	__unaligned__	VVD	__unaligned__		OK/0.900761
with	mit	IN	APPR		OK/0.962573
the	zuständigen	DT	ADJA		OK/0.908008
competent	zuständigen	JJ	ADJA		OK/0.702256
authorities	Behörden	NNS	NN		OK/0.970162
in	der	IN	ART		OK/0.969036
the	der	DT	ART		OK/0.918326
Mitgliedsländer	Mitgliedsländer	NP	NN		BAD/0.671087
has	umsetzen	VHZ	VVINF		BAD/0.771442
any	Folgendes	DT	NN		BAD/0.926206
of	Folgendes	IN	NN		BAD/0.873562
the	Folgendes	DT	NN		OK/0.877613
following	Folgendes	NN	NN		OK/0.919582
:	:	:	$.		OK/0.997468

# 0.507236
2	2	CD	CARD		OK/0.708275
/	/	SYM	$(		OK/0.627423
3	3	CD	CARD		OK/0.675917
This	Diese	DT	PDAT		OK/0.975360
summary	Zusammenfassung	NN	NN		OK/0.997288
was	zuletzt	VBD	ADV		OK/0.999639
last	zuletzt	RB	ADV		OK/0.999287
updated	aktualisiert	VVN	VVPP		OK/0.999144
in	06-2008	IN	CARD		OK/0.988352
June	06-2008	NP	CARD		OK/0.945379
2008	06-2008	CD	CARD		OK/0.968600
.	.	SENT	$.		OK/0.998739

# 0.729075
Do	Sie	VVP	PPER		OK/0.958159
not	nicht	RB	PTKNEG		OK/0.963280
inject	doppelte	VV	ADJA		OK/0.919388
a	__unaligned__	DT	__unaligned__		OK/0.996894
double	__unaligned__	JJ	__unaligned__		OK/0.994265
dose	Dosis	NN	NN		OK/0.999058
to	__unaligned__	TO	__unaligned__		OK/0.997115
make	nachzuholen	VV	VVIZU		OK/0.994152
up	nachzuholen	RP	VVIZU		OK/0.997076
for	__unaligned__	IN	__unaligned__		OK/0.976058
a	eine	DT	ART		OK/0.990321
forgotten	vergessene	JJ	ADJA		OK/0.993495
individual	vergessene	JJ	ADJA		OK/0.914828
dose	vergessene	NN	ADJA		OK/0.888034
.	.	SENT	$.		OK/0.999168

# 0.245938
Exelon	Exelon	NP	NN		OK/0.986271
may	kann	MD	VMFIN		OK/0.918910
cause	kann	VV	VMFIN		OK/0.920487
dizziness	Schwindel	NN	NN		OK/0.999601
and	oder	CC	KON		OK/0.977010
somnolence	Schläfrigkeit	NN	NN		OK/0.974018
,	,	,	$,		OK/0.936102
particularly	allem	RB	PIS		OK/0.759582
at	Beginn	IN	NN		OK/0.985155
the	der	DT	ART		OK/0.999893
start	Beginn	NN	NN		OK/0.985555
of	der	IN	ART		OK/0.999299
treatment	Behandlung	NN	NN		OK/0.990542
,	der	,	ART		OK/0.744846
or	oder	CC	KON		OK/0.731177
when	bei	WRB	APPR		OK/0.740895
increasing	Dosissteigerung	VVG	NN		OK/0.613797
the	__unaligned__	DT	__unaligned__		OK/0.709794
dose	Dosissteigerung	NN	NN		OK/0.609431
.	.	SENT	$.		OK/0.999110

# 0.253155
Discontinuation	Absetzen	NP	NN		OK/0.966914
of	Absetzen	IN	NN		OK/0.994243
risperidone	Risperidon	NN	NE		OK/0.983754
may	kann	MD	VMFIN		OK/0.994653
be	kann	VB	VMFIN		OK/0.996319
required	erforderlich	VVN	ADJD		OK/0.984626
•	•	JJ	VVFIN		OK/0.999761
fever	Fieber	NN	NN		OK/0.996996
,	,	,	$,		OK/0.998011
severe	schwere	JJ	ADJA		OK/0.993007
muscle	Muskelsteifheit	NN	NN		OK/0.992788
stiffness	Muskelsteifheit	NN	NN		OK/0.929719
,	,	,	$,		OK/0.988817
sweating	Schweißausbrüche	VVG	NN		OK/0.825088
or	oder	CC	KON		OK/0.961992
Bewusstseinsminderung	Bewusstseinsminderung	NP	NN		OK/0.826728
(	(	(	$(		OK/0.985572
a	(	DT	$(		OK/0.982257
disease	Erkrankung	NN	NN		OK/0.968003
"	"	``	$(		OK/0.759693
Neuroleptic	Neuroleptisches	NP	ADJA		OK/0.691123
Malignant	Malignes	NP	NN		OK/0.587667
Syndrome	Malignes	NP	NN		OK/0.523419
)	)	)	$(		OK/0.816934
.	.	SENT	$.		OK/0.989390

# 0.486363
104	104	CD	CARD		OK/0.981030
/	/	SYM	$(		OK/0.999074
125	129	CD	CARD		OK/0.998248
contamination	Verunreinigungen	NN	NN		OK/0.986467
during	während	IN	APPR		OK/0.984498
withdrawal	Entnahme	NN	NN		OK/0.938378
should	vermeiden	MD	VVINF		OK/0.697291
be	vermeiden	VB	VVINF		OK/0.615036
avoided	vermeiden	VVN	VVINF		OK/0.598385
.	.	SENT	$.		OK/0.996115

# 0.481745
rash	Ausschlag	NN	NN		OK/0.966557
(	(	(	$(		OK/0.995957
11.6	11,6	CD	CARD		OK/0.997241
%	%	NN	NN		OK/0.997720
)	)	)	$(		OK/0.998900
,	,	,	$,		OK/0.998303
dizziness	Schwindel	NN	NN		OK/0.993449
(	(	(	$(		OK/0.995031
8.5	8,5	CD	CARD		OK/0.989395
%	%	NN	NN		OK/0.997180
)	)	)	$(		OK/0.999051
,	,	,	$,		OK/0.998827
nausea	Übelkeit	NN	NN		OK/0.992016
(	(	(	$(		OK/0.971383
8.0	8,0	CD	CARD		OK/0.993088
%	%	NN	NN		OK/0.997910
)	)	)	$(		OK/0.998603
,	,	,	$,		OK/0.992117
headache	Kopfschmerzen	NN	NN		OK/0.782359
(	(	(	$(		OK/0.996895
5.7	5,7	CD	CARD		OK/0.991171
%	%	NN	NN		OK/0.996420
)	)	)	$(		OK/0.996105
and	und	CC	KON		OK/0.997770
fatigue	Müdigkeit	VV	NN		OK/0.929615
(	(	(	$(		OK/0.996229
5.5	5,5	CD	CARD		OK/0.998474
%	%	NN	NN		OK/0.996257
)	)	)	$(		OK/0.998186
.	.	SENT	$.		OK/0.962890
The	Die	DT	ART		OK/0.996185
most	ausgeprägtesten	RBS	ADJA		OK/0.979157
notable	ausgeprägtesten	JJ	ADJA		OK/0.965999
adverse	Nebenwirkungen	JJ	NN		OK/0.979151
reactions	ausgeprägtesten	NNS	ADJA		OK/0.986036
associated	ausgeprägtesten	VVN	ADJA		OK/0.957463
with	mit	IN	APPR		OK/0.951160
efavirenz	Efavirenz	NN	NE		OK/0.972334
are	sind	VBP	VAFIN		OK/0.979883
rash	Ausschläge	JJ	NN		OK/0.976987
and	und	CC	KON		OK/0.998409
nervous	Nervensystem	JJ	NN		OK/0.997639
system	Nervensystem	NN	NN		OK/0.988288
symptoms	Symptome	NNS	NN		OK/0.960739
(	siehe	(	VVIMP		OK/0.994926
see	siehe	VV	VVIMP		OK/0.996132
section	Abschnitt	NN	NN		OK/0.994561
4.4	4.4	CD	CARD		OK/0.992127
)	)	)	$(		OK/0.991894
.	.	SENT	$.		OK/0.995742

# 0.850496
119	119	CD	CARD		OK/0.983898
patients	Patienten	NNS	NN		OK/0.999312
received	erhielten	VVD	VVFIN		OK/0.986410
anidulafungin	Anidulafungin	NN	NE		OK/0.921855
over	Zeitraum	IN	NN		OK/0.975404
a	Zeitraum	DT	NN		OK/0.989939
period	Zeitraum	NN	NN		OK/0.977753
of	__unaligned__	IN	__unaligned__		OK/0.993591
≥	≥	JJ	ADJA		OK/0.992791
14	14	CD	CARD		OK/0.983521
days	Tagen	NNS	NN		OK/0.993847
.	.	SENT	$.		OK/0.999646

# 0.613678
The	Die	DT	ART		OK/0.993847
hard	Hartkapseln	JJ	NN		OK/0.989810
capsules	Hartkapseln	NNS	NN		OK/0.985085
have	haben	VHP	VAFIN		OK/0.975568
an	opak	DT	ADJD		OK/0.999741
opaque	opak	JJ	ADJD		OK/0.998760
white	weißes	JJ	ADJA		OK/0.997849
body	Unterteil	NN	NN		OK/0.957898
,	,	,	$,		OK/0.994451
an	opak	DT	ADJD		OK/0.987225
opaque	opak	JJ	ADJD		OK/0.998653
orange	oranges	NN	ADJA		OK/0.987307
cap	Oberteil	NN	NN		OK/0.977083
,	__unaligned__	,	__unaligned__		OK/0.945517
and	und	CC	KON		OK/0.991595
are	__unaligned__	VBP	__unaligned__		OK/0.968261
imprinted	__unaligned__	VVN	__unaligned__		OK/0.945523
with	mit	IN	APPR		OK/0.901798
black	schwarzer	JJ	ADJA		OK/0.862555
ink	schwarzer	NN	ADJA		OK/0.805284
.	.	SENT	$.		OK/0.998628

# 0.698554
181	181	NP	CARD		OK/0.809618
Neupro	Neupro	NP	NN		OK/0.962451
is	ist	VBZ	VAFIN		OK/0.989339
available	__unaligned__	JJ	__unaligned__		OK/0.942536
in	__unaligned__	IN	__unaligned__		OK/0.971828
the	folgenden	DT	ADJA		OK/0.992089
following	folgenden	VVG	ADJA		OK/0.975648
pack	Packungsgrößen	NN	NN		OK/0.974614
sizes	Packungsgrößen	NNS	NN		OK/0.956465
:	:	:	$.		OK/0.998983

# 0.968328
What	Wofür	WP	NN		OK/0.996741
is	Wofür	VBZ	NN		OK/0.976647
RoActemra	RoActemra	NP	NE		OK/0.999478
used	angewendet	VVD	VVPP		OK/0.995792
for	angewendet	IN	VVPP		OK/0.998103
?	?	SENT	$.		OK/0.999301

# 0.821231
Blister	Blisterpackung	NP	NN		OK/0.973638
with	mit	IN	APPR		OK/0.991716
14	14	CD	CARD		OK/0.998218
,	,	,	$,		OK/0.997213
28	28	CD	CARD		OK/0.998453
,	,	,	$,		OK/0.999551
30	30	CD	CARD		OK/0.998553
,	,	,	$,		OK/0.999657
56	56	CD	CARD		OK/0.995516
,	,	,	$,		OK/0.988791
84	84	CD	CARD		OK/0.995463
,	,	,	$,		OK/0.998706
90	90	CD	CARD		OK/0.998429
or	oder	CC	KON		OK/0.999787
98	98	CD	CARD		OK/0.992782
tablets	Tabletten	NNS	NN		OK/0.998326
or	oder	CC	KON		OK/0.995909
perforated	Einzeldosen-Blisterpackung	JJ	NN		OK/0.972217
unit	perforierte	NN	ADJA		OK/0.951966
dose	perforierte	NN	ADJA		OK/0.984016
blisters	perforierte	NNS	ADJA		OK/0.946993
with	mit	IN	APPR		OK/0.993808
28	28	CD	CARD		OK/0.998161
x	x	NN	ADJA		OK/0.998287
1	1	CD	CARD		OK/0.996645
tablets	Tablette	NNS	NN		OK/0.994723
.	.	SENT	$.		OK/0.999534

# 0.162889
Tell	Informieren	VV	NN		OK/0.986466
your	Arzt	PP$	NN		OK/0.999387
doctor	Ihren	NN	PPOSAT		OK/0.999233
if	wenn	IN	KOUS		OK/0.997108
you	Sie	PP	PPER		OK/0.997836
have	Sie	VHP	PPER		OK/0.982778
excessive	übermäßigen	JJ	ADJA		OK/0.931365
thirst	Durst	NN	NN		OK/0.886437
,	__unaligned__	,	__unaligned__		OK/0.858118
or	oder	CC	KON		OK/0.889269
higher	häufiger	JJR	ADJA		OK/0.602200
and	und	CC	KON		OK/0.587876
a	__unaligned__	DT	__unaligned__		OK/0.540628
larger	größere	JJR	ADJA		OK/0.531417
amounts	Mengen	NNS	NN		OK/0.736709
of	__unaligned__	IN	__unaligned__		OK/0.414841
wasserlassen	wasserlassen	NP	VVINF		OK/0.569949
.	.	SENT	$.		OK/0.993914

# 0.061562
All	Alle	NP	PIAT		OK/0.941492
physicians	Ärzte	NNS	NN		OK/0.574676
who	Ärzte	WP	NN		BAD/0.790050
prescribe	verordnen	VVP	VVINF		BAD/0.821871
Tysabri	Tysabri	NP	NN		BAD/0.800925
must	müssen	MD	VMFIN		OK/0.500305
be	müssen	VB	VMFIN		OK/0.516442
familiar	vertraut	JJ	VVPP		OK/0.502573
with	vertraut	IN	VVPP		OK/0.584638
the	der	DT	ART		OK/0.886125
Physician	Arztinformation	NP	NN		OK/0.740978
Information	Managementleitlinien	NP	NN		OK/0.815363
and	und	CC	KON		OK/0.973141
Management	__unaligned__	NP	__unaligned__		OK/0.899987
.	.	SENT	$.		OK/0.999067

# 0.499664
107	107	CD	CARD		OK/0.942698
The	Die	DT	ART		OK/0.974192
plastic	Plastikflasche	NN	NN		OK/0.930551
bottle	Plastikflasche	NN	NN		OK/0.950211
comes	Plastikflasche	VVZ	NN		OK/0.885594
with	kindersicheren	IN	ADJA		OK/0.973124
a	kindersicheren	DT	ADJA		OK/0.999456
child	kindersicheren	NN	ADJA		OK/0.998334
resistant	kindersicheren	JJ	ADJA		OK/0.983480
cap	kindersicheren	NN	ADJA		OK/0.975625
and	__unaligned__	CC	__unaligned__		OK/0.806351
should	__unaligned__	MD	__unaligned__		OK/0.815575
be	__unaligned__	VB	__unaligned__		OK/0.788902
opened	__unaligned__	VVN	__unaligned__		OK/0.796756
as	folgt	RB	VVFIN		OK/0.974184
follows	folgt	VVZ	VVFIN		OK/0.982921
:	:	:	$.		OK/0.999646

# 0.036024
Patients	Patienten	NPS	NN		OK/0.613109
must	müssen	MD	VMFIN		OK/0.619833
be	müssen	VB	VMFIN		OK/0.663087
instructed	angewiesen	VVN	ADJD		OK/0.554747
to	angewiesen	TO	ADJD		BAD/0.790309
complete	komplette	VV	ADJA		BAD/0.777924
the	die	DT	ART		OK/0.850055
amount	Menge	NN	NN		OK/0.869954
of	__unaligned__	IN	__unaligned__		OK/0.892651
STELARA	STELARA	NP	NE		OK/0.602457
as	__unaligned__	RB	__unaligned__		BAD/0.716357
reflected	__unaligned__	VVD	__unaligned__		BAD/0.929956
in	den	IN	ART		BAD/0.926439
the	den	DT	ART		OK/0.850580
instructions	Anweisungen	NNS	NN		OK/0.933851
provided	Anweisungen	VVN	NN		OK/0.831173
in	in	IN	APPR		OK/0.911707
the	in	DT	APPR		OK/0.920556
package	Packungsbeilage	NN	NN		OK/0.915432
leaflet	Packungsbeilage	NN	NN		OK/0.837041
.	.	SENT	$.		OK/0.996862

# 0.820022
34	34	CD	CARD		OK/0.995636
the	Behandlung	DT	NN		OK/0.997955
treatment	Behandlung	NN	NN		OK/0.996850
and	und	CC	KON		OK/0.986442
prevention	__unaligned__	NN	__unaligned__		OK/0.959031
of	__unaligned__	IN	__unaligned__		OK/0.979495
flea	Flohbefall	NN	NN		OK/0.991782
infestations	Flohbefall	NNS	NN		OK/0.991137
Pyriprole	Pyriprol	NP	NN		OK/0.998663
kills	tötet	VVZ	VVFIN		OK/0.990897
fleas	Flöhe	NNS	NN		OK/0.978669
within	innerhalb	IN	APPR		OK/0.995981
24	24	CD	CARD		OK/0.998805
hours	Stunden	NNS	NN		OK/0.995211
after	Stunden	IN	NN		OK/0.934293
treatment	Behandlung	NN	NN		OK/0.960230
.	.	SENT	$.		OK/0.991438

# 0.667164
Do	dürfen	VVP	VMFIN		OK/0.955595
not	dürfen	RB	VMFIN		OK/0.956309
use	dürfen	VV	VMFIN		OK/0.958988
this	Arzneimittel	DT	NN		OK/0.978297
medicine	Arzneimittel	NN	NN		OK/0.984761
after	nach	IN	APPR		OK/0.979995
the	__unaligned__	DT	__unaligned__		OK/0.996645
expiry	Verfallsdatum	NN	NN		OK/0.995596
date	Verfallsdatum	NN	NN		OK/0.998315
which	__unaligned__	WDT	__unaligned__		OK/0.986901
is	__unaligned__	VBZ	__unaligned__		OK/0.995020
stated	auf	VVN	APPR		OK/0.979830
on	__unaligned__	IN	__unaligned__		OK/0.963180
the	dem	DT	ART		OK/0.991867
carton	Umkarton	NN	NN		OK/0.926264
,	,	,	$,		OK/0.975498
the	angegebenen	DT	ADJA		OK/0.882283
bottle	__unaligned__	NN	__unaligned__		OK/0.931801
.	.	SENT	$.		OK/0.998118

# 0.457822
•	•	NN	ADJA		OK/0.998965
antibiotics	Antibiotika	NNS	NN		OK/0.982288
and	und	CC	KON		OK/0.998607
antiviral	antivirale	JJ	ADJA		OK/0.984333
medicines	Medikamente	NNS	NN		OK/0.972255
may	können	MD	VMFIN		OK/0.989003
be	können	VB	VMFIN		OK/0.933680
given	verabreicht	VVN	VVPP		OK/0.934241
to	Ihnen	TO	PPER		OK/0.852918
you	Ihnen	PP	PPER		OK/0.854641
,	,	,	$,		OK/0.878826
you	Sie	PP	PPER		OK/0.761470
are	__unaligned__	VBP	__unaligned__		OK/0.705893
also	zusätzlich	RB	ADJD		OK/0.816114
taking	__unaligned__	VVG	__unaligned__		OK/0.784563
before	vor	IN	APPR		OK/0.984951
infections	Infektionen	NNS	NN		OK/0.993101
.	.	SENT	$.		OK/0.999352

# 0.182646
If	Wenn	IN	KOUS		OK/0.997194
you	Sie	PP	PPER		OK/0.997184
take	Sie	VVP	PPER		OK/0.991905
Prialt	Prialt	NN	NN		OK/0.998406
together	zusammen	RB	ADV		OK/0.920413
with	mit	IN	APPR		OK/0.988029
certain	bestimmten	JJ	ADJA		OK/0.994091
other	anderen	JJ	PIAT		OK/0.973654
painkillers	Schmerzmitteln	NNS	NN		OK/0.820423
may	kann	MD	VMFIN		OK/0.833589
experience	es	VV	PPER		OK/0.608971
drowsiness	Schläfrigkeit	NN	NN		OK/0.581506
may	kommen	MD	VVINF		OK/0.283830
occur	kommen	VV	VVINF		OK/0.386422
.	.	SENT	$.		OK/0.982907

# 0.517506
Treatment	Behandlung	NP	NN		OK/0.996186
with	mit	IN	APPR		OK/0.997440
Protopic	Protopic	NP	NE		OK/0.996333
should	soll	MD	VMFIN		OK/0.996949
only	nur	RB	ADV		OK/0.998248
be	soll	VB	VMFIN		OK/0.985832
initiated	eingeleitet	VVN	VVPP		OK/0.976142
by	Ärzten	IN	NN		OK/0.987625
physicians	Ärzten	NNS	NN		OK/0.998601
with	Ärzten	IN	NN		OK/0.980934
experience	Erfahrung	NN	NN		OK/0.989251
in	in	IN	APPR		OK/0.999268
the	der	DT	ART		OK/0.999438
diagnosis	Diagnose	NN	NN		OK/0.992454
and	und	CC	KON		OK/0.999264
treatment	Behandlung	NN	NN		OK/0.984381
of	Behandlung	IN	NN		OK/0.953111
atopic	Dermatitis	JJ	NN		OK/0.643166
dermatitis	Dermatitis	NN	NN		OK/0.633939
.	.	SENT	$.		OK/0.997212

# 0.655718
Your	Ihr	PP$	PPOSAT		OK/0.997955
doctor	Arzt	NN	NN		OK/0.997491
will	wird	MD	VAFIN		OK/0.997716
decide	entscheiden	VV	VVINF		OK/0.979030
the	die	DT	ART		OK/0.962024
duration	Dauer	NN	NN		OK/0.752373
of	Dauer	IN	NN		OK/0.723603
treatment	Behandlung	NN	NN		OK/0.935059
.	.	SENT	$.		OK/0.990055

# 0.824915
For	Zur	IN	APPRART		OK/0.948502
Kurzzeit-Behandlung	Kurzzeit-Behandlung	NP	NN		OK/0.913118
postoperative	postoperativen	JJ	ADJA		OK/0.862451
pain	Schmerzen	NN	NN		OK/0.988167
.	.	SENT	$.		OK/0.999815

# 0.499766
Do	Nicht	VVP	PTKNEG		OK/0.968925
not	Nicht	RB	PTKNEG		OK/0.967242
use	__unaligned__	VV	__unaligned__		OK/0.979894
in	bei	IN	APPR		OK/0.993711
animals	Tieren	NNS	NN		OK/0.988910
with	mit	IN	APPR		OK/0.980394
stomach	Magen-	NN	TRUNC		OK/0.988690
/	/	SYM	$(		OK/0.986524
Darmgeschwüren	Darmgeschwüren	NP	NN		OK/0.926872
,	,	,	$,		OK/0.975104
high-grade	hochgradigen	JJ	ADJA		OK/0.908744
renal	Nierenfunktionsstörungen	JJ	NN		OK/0.993851
impairment	Nierenfunktionsstörungen	NN	NN		OK/0.994080
,	,	,	$,		OK/0.993380
clotting	Blutgerinnungsstörungen	VVG	NN		OK/0.961177
disorders	Blutgerinnungsstörungen	NNS	NN		OK/0.995600
or	oder	CC	KON		OK/0.997194
severe	schweren	JJ	ADJA		OK/0.912955
their	Kreislaufstörungen	PP$	NN		OK/0.844369
use	anwenden	NN	VVINF		OK/0.830951
(	(	(	$(		OK/0.912478
hypovolemia	Hypovolämie	NN	NN		OK/0.846981
)	)	)	$(		OK/0.967790
.	.	SENT	$.		OK/0.995822

# 0.317034
advice	Beratung	NN	NN		OK/0.971199
,	,	,	$,		OK/0.983419
you	Sie	PP	PPER		OK/0.997004
should	sollten	MD	VMFIN		OK/0.986046
tell	Ihren	VV	PPOSAT		OK/0.969367
your	Ihren	PP$	PPOSAT		OK/0.991616
doctor	Arzt	NN	NN		OK/0.986431
,	__unaligned__	,	__unaligned__		OK/0.959865
nurse	Apotheker	NN	NN		OK/0.997550
or	Apotheker	CC	NN		OK/0.999165
pharmacist	Apotheker	NN	NN		OK/0.999040
for	__unaligned__	IN	__unaligned__		OK/0.925128
ask	befragen	VV	VVINF		BAD/0.488425
in	die	IN	ART		BAD/0.626360
Detailinformationen	Detailinformationen	NP	NN		BAD/0.680017
.	.	SENT	$.		OK/0.989739

# 0.064081
The	Der	DT	ART		OK/0.984976
effect	Einfluss	NN	NN		OK/0.997380
of	von	IN	APPR		OK/0.999778
age	Alter	NN	NN		OK/0.998323
,	,	,	$,		OK/0.939278
gender	Geschlecht	NN	NN		OK/0.820801
,	__unaligned__	,	__unaligned__		OK/0.415967
or	oder	CC	KON		OK/0.934160
smoking	Rauchen	NN	NN		OK/0.882418
on	auf	IN	APPR		OK/0.916995
olanzapine	Olanzapin-Clearance	JJ	NN		OK/0.899296
clearance	Olanzapin-Clearance	NN	NN		OK/0.849841
and	__unaligned__	CC	__unaligned__		BAD/0.697741
half-life	__unaligned__	NN	__unaligned__		BAD/0.478231
is	gering	VBZ	ADJD		BAD/0.654332
small	__unaligned__	JJ	__unaligned__		BAD/0.632169
in	__unaligned__	IN	__unaligned__		BAD/0.969615
comparison	__unaligned__	NN	__unaligned__		BAD/0.921836
with	mit	IN	APPR		OK/0.941156
the	der	DT	ART		OK/0.842451
degree	__unaligned__	NN	__unaligned__		OK/0.883193
of	__unaligned__	IN	__unaligned__		OK/0.860868
variation	__unaligned__	NN	__unaligned__		OK/0.845334
between	zwischen	IN	APPR		OK/0.996908
individual	einzelnen	JJ	ADJA		OK/0.992470
variation	Schwankungsbreite	NN	NN		OK/0.943638
between	Schwankungsbreite	IN	NN		OK/0.982464
individuals	Personen	NNS	NN		OK/0.901472
.	.	SENT	$.		OK/0.999638

# 0.567032
The	Die	DT	ART		OK/0.991913
solution	Lösung	NN	NN		OK/0.984824
is	wird	VBZ	VAFIN		OK/0.937806
slowly	langsam	RB	ADJD		OK/0.968672
after	nach	IN	APPR		OK/0.913806
reconstitution	Rekonstitution	NN	NN		OK/0.873117
and	und	CC	KON		OK/0.997582
dilution	Verdünnung	NN	NN		OK/0.986017
,	__unaligned__	,	__unaligned__		OK/0.907358
given	infundiert	VVN	VVFIN		OK/0.935594
an	infundiert	DT	VVFIN		OK/0.977137
intravenous	intravenös	JJ	ADJD		OK/0.993090
infusion	infundiert	NN	VVFIN		OK/0.983871
over	über	IN	APPR		OK/0.986432
approximately	ca.	RB	ADV		OK/0.982530
1	1	CD	CARD		OK/0.848331
hour	Stunde	NN	NN		OK/0.924696
.	.	SENT	$.		OK/0.997734

# 0.408600
Hypoaesthesia	Hypästhesie	NP	NN		OK/0.744956
(	(	(	$(		OK/0.953292
decreased	herabgesetzte	VVN	ADJA		OK/0.959140
sensation	Berührungsempfindlichkeit	NN	NN		OK/0.974950
)	)	)	$(		OK/0.989266
;	;	:	$.		OK/0.997822
diarrhoea	Durchfall	NN	NN		OK/0.942149
(	(	(	$(		OK/0.886489
softened	weicher	JJ	ADJA		OK/0.674702
or	oder	CC	KON		OK/0.986664
watery	wässriger	JJ	ADJA		OK/0.944422
stools	Stuhl	NNS	NN		OK/0.953685
)	)	)	$(		OK/0.918784
.	.	SENT	$.		OK/0.976536

# 0.742066
Bridion	Bridion	NP	NN		OK/0.957722
is	ist	VBZ	VAFIN		OK/0.990272
a	eine	DT	ART		OK/0.992804
solution	Injektionslösung	NN	NN		OK/0.994711
for	Injektionslösung	IN	NN		OK/0.993438
injection	Injektionslösung	NN	NN		OK/0.994375
that	__unaligned__	WDT	__unaligned__		OK/0.937349
contains	__unaligned__	VVZ	__unaligned__		OK/0.928024
the	die	DT	PRELS		OK/0.936055
active	Wirkstoff	JJ	NN		OK/0.905647
substance	Wirkstoff	NN	NN		OK/0.980271
sugammadex	Sugammadex	NN	NN		OK/0.973651
(	(	(	$(		OK/0.999314
100	100	CD	CARD		OK/0.994115
mg	mg	NN	NN		OK/0.993812
/	/	SYM	$(		OK/0.992626
ml	ml	NN	NN		OK/0.999016
)	)	)	$(		OK/0.997011
.	.	SENT	$.		OK/0.997262

# 0.417860
The	Die	DT	ART		OK/0.915914
following	folgenden	VVG	ADJA		OK/0.878314
substances	__unaligned__	NNS	__unaligned__		OK/0.836531
contained	__unaligned__	VVN	__unaligned__		OK/0.841305
in	im	IN	APPRART		OK/0.948880
the	__unaligned__	DT	__unaligned__		OK/0.959413
final	Endprodukt	JJ	NN		OK/0.863075
steps	befindlichen	NNS	ADJA		OK/0.866817
included	__unaligned__	VVN	__unaligned__		OK/0.950097
in	in	IN	APPR		OK/0.999787
Annex	Anhang	NP	NN		OK/0.997057
II	II	NP	CARD		OK/0.995244
of	__unaligned__	IN	__unaligned__		OK/0.994689
Council	Verordnung	NP	NN		OK/0.993100
Regulation	Verordnung	NP	NN		OK/0.990319
(	(	(	$(		OK/0.998684
EEC	EWG	NP	NE		OK/0.989387
)	)	)	$(		OK/0.994612
No	2377	NP	CARD		OK/0.991024
2377	2377	CD	CARD		OK/0.990005
/	/	SYM	$(		OK/0.998273
90	90	CD	CARD		OK/0.990338
in	folgender	IN	ADJA		OK/0.840819
accordance	folgender	NN	ADJA		OK/0.818071
with	folgender	IN	ADJA		OK/0.886400
the	folgender	DT	ADJA		OK/0.962151
following	folgender	VVG	ADJA		OK/0.971135
table	Tabelle	NN	NN		OK/0.988073
:	:	:	$.		OK/0.997136

# 0.402886
NeoRecormon	NeoRecormon	NP	NN		OK/0.978455
should	sollte	MD	VMFIN		OK/0.966144
be	sollte	VB	VMFIN		OK/0.941291
administered	__unaligned__	VVN	__unaligned__		OK/0.925663
either	entweder	RB	KON		OK/0.996492
subcutaneously	subkutan	RB	ADJD		OK/0.989718
or	oder	CC	KON		OK/0.996521
intravenously	intravenös	RB	ADJD		OK/0.927222
in	__unaligned__	IN	__unaligned__		OK/0.894057
order	,	NN	$,		OK/0.935445
to	erhöhen	TO	VVINF		OK/0.927254
increase	erhöhen	VV	VVINF		OK/0.749760
haemoglobin	Hämoglobin	NN	NN		OK/0.656674
to	auf	TO	APPR		OK/0.650607
not	nicht	RB	PTKNEG		OK/0.937951
greater	mehr	JJR	ADV		OK/0.979040
than	mehr	IN	ADV		OK/0.989661
12	12	CD	CARD		OK/0.990238
g	g	NN	NN		OK/0.978619
/	/	SYM	$(		OK/0.999528
dl	dl	NN	NE		OK/0.999436
(	(	(	$(		OK/0.998617
7.5	7,5	CD	CARD		OK/0.995397
mmol	mmol	NN	NN		OK/0.998161
/	/	SYM	$(		OK/0.998753
l	l	NN	NN		OK/0.994404
)	)	)	$(		OK/0.996891
.	.	SENT	$.		OK/0.998150

# 0.200044
13	13	CD	CARD		OK/0.971314
normal	__unaligned__	JJ	__unaligned__		OK/0.974811
donors	__unaligned__	NNS	__unaligned__		OK/0.945836
,	__unaligned__	,	__unaligned__		OK/0.938520
pulmonary	pulmonale	JJ	ADJA		OK/0.991035
adverse	unerwünschte	JJ	ADJA		OK/0.993781
events	Ereignisse	NNS	NN		OK/0.979128
(	(	(	$(		OK/0.980715
haemoptysis	Hämoptyse	NN	NN		OK/0.936113
,	,	,	$,		OK/0.986689
pulmonary	pulmonale	JJ	ADJA		OK/0.970980
haemorrhage	Hämorrhagie	NN	NN		OK/0.991332
,	,	,	$,		OK/0.964805
pulmonary	Lungeninfiltrate	JJ	NN		OK/0.980149
infiltrates	Lungeninfiltrate	NNS	NN		OK/0.959800
,	,	,	$,		OK/0.960640
dyspnoea	Dyspnoe	NN	NN		OK/0.971747
and	und	CC	KON		OK/0.999128
hypoxia	Hypoxie	NN	NN		OK/0.984884
)	)	)	$(		OK/0.995098
have	berichtet	VHP	VVFIN		BAD/0.579293
been	berichtet	VBN	VVFIN		BAD/0.530470
reported	berichtet	VVN	VVFIN		OK/0.885762
very	sehr	RB	ADV		OK/0.989414
rarely	selten	RB	ADJD		OK/0.992819
in	__unaligned__	IN	__unaligned__		OK/0.984960
post	__unaligned__	NN	__unaligned__		OK/0.917494
marketing	__unaligned__	NN	__unaligned__		OK/0.913741
experience	über	NN	APPR		OK/0.835043
(	siehe	(	VVIMP		OK/0.998625
see	siehe	VV	VVIMP		OK/0.997356
section	Abschnitt	NN	NN		OK/0.994745
4.4	4.4	CD	CARD		OK/0.992164
)	)	)	$(		OK/0.991901
.	.	SENT	$.		OK/0.995742

# 0.098340
427	427	CD	CARD		OK/0.717348
(	(	(	$(		OK/0.992243
92	92	CD	CARD		OK/0.995074
%	%	NN	NN		OK/0.998566
)	)	)	$(		OK/0.992845
patients	Patienten	NNS	NN		OK/0.881872
were	KRAS-Status	VBD	NN		OK/0.491172
evaluable	KRAS-Status	JJ	NN		OK/0.374503
for	KRAS-Status	IN	NN		OK/0.486700
KRAS	KRAS-Status	NP	NN		OK/0.835849
status	KRAS-Status	NN	NN		OK/0.899272
of	KRAS-Status	IN	NN		OK/0.833840
which	KRAS-Status	WDT	NN		OK/0.577980
184	184	CD	CARD		OK/0.467904
had	wiesen	VHD	VVFIN		OK/0.793550
mutations	Mutationen	NNS	NN		OK/0.979129
.	.	SENT	$.		OK/0.996577

# 0.472585
,	__unaligned__	,	__unaligned__		BAD/0.967662
mental	Störungen	JJ	NN		BAD/0.856982
Fetthaushalts	Fetthaushalts	NP	NN		BAD/0.845595
should	sollten	MD	VMFIN		OK/0.796025
be	sollten	VB	VMFIN		OK/0.959697
treated	behandelt	VVN	VVPP		OK/0.877427
depending	je	VVG	ADV		OK/0.898217
on	je	IN	ADV		OK/0.990404
the	__unaligned__	DT	__unaligned__		OK/0.998937
clinical	klinischer	JJ	ADJA		OK/0.943785
trials	__unaligned__	NNS	__unaligned__		OK/0.916737
.	.	SENT	$.		OK/0.996746

# 0.874203
Furthermore	Darüber	RB	PAV		OK/0.987465
will	entscheidet	MD	VVFIN		OK/0.971815
be	entscheidet	VB	VVFIN		OK/0.943845
decided	entscheidet	VVN	VVFIN		OK/0.934709
by	__unaligned__	IN	__unaligned__		OK/0.967551
your	Ihr	PP$	PPOSAT		OK/0.995696
doctor	Arzt	NN	NN		OK/0.992085
.	.	SENT	$.		OK/0.998712

# 0.183490
If	Falls	IN	KOUS		OK/0.979600
you	Sie	PP	PPER		OK/0.971560
weigh	wiegen	VVP	VVFIN		OK/0.833760
less	weniger	JJR	ADV		OK/0.972170
than	als	IN	KOKOM		OK/0.993290
in	in	IN	APPR		OK/0.997932
the	in	DT	APPR		OK/0.988367
corresponding	entsprechenden	JJ	ADJA		OK/0.896858
FLD	Zeile	NN	NN		OK/0.881236
for	für	IN	APPR		OK/0.933595
your	Ihre	PP$	PPOSAT		OK/0.993641
body	__unaligned__	NN	__unaligned__		OK/0.989660
size	Körpergröße	NN	NN		OK/0.896142
,	,	,	$,		OK/0.967221
do	nehmen	VVP	VVFIN		BAD/0.750010
not	nehmen	RB	VVFIN		BAD/0.653856
take	nehmen	VV	VVFIN		OK/0.689049
alli	alli	NNS	ADJD		OK/0.716380
.	.	SENT	$.		OK/0.995118

# 0.231534
Zeitweilig	Zeitweilig	NP	NN		OK/0.901193
injection	Injektionsstelle	NN	NN		OK/0.945151
site	Injektionsstelle	NN	NN		OK/0.933562
may	kann	MD	VMFIN		OK/0.990389
be	kann	VB	VMFIN		OK/0.942197
a	__unaligned__	DT	__unaligned__		OK/0.969633
small	kleiner	JJ	ADJA		OK/0.957132
percentage	__unaligned__	NN	__unaligned__		OK/0.908295
(	(	(	$(		OK/0.993609
up	zu	RB	APPR		OK/0.992828
to	bis	TO	KON		OK/0.974069
2	2	CD	CARD		BAD/0.702212
and	)	CC	$(		BAD/0.799268
,	,	,	$,		OK/0.635869
within	innerhalb	IN	APPR		OK/0.908583
1	1	CD	CARD		OK/0.994032
to	1	TO	CARD		OK/0.965762
4	4	CD	CARD		OK/0.992804
weeks	Wochen	NNS	NN		OK/0.954747
.	..	SENT	ADJA		OK/0.954817

# 0.306768
The	Die	NP	ART		OK/0.979715
Hauptfrage	Hauptfrage	NP	NN		OK/0.747473
during	während	IN	APPR		OK/0.817179
this	dieses	DT	PDAT		OK/0.869904
procedure	Verfahrens	NN	NN		OK/0.695612
was	bestand	VBD	VVFIN		OK/0.580877
whether	ob	IN	KOUS		OK/0.899081
the	die	DT	ART		OK/0.973193
strength	Stärke	NN	NN		OK/0.961370
of	von	IN	APPR		OK/0.986807
5	5	CD	CARD		OK/0.989189
mg	mg	NN	NN		OK/0.977119
is	empfohlene	VBZ	ADJA		OK/0.797747
the	die	DT	ART		OK/0.996086
recommended	empfohlene	JJ	ADJA		OK/0.992922
starting	Anfangsdosis	VVG	NN		OK/0.998433
dose	Anfangsdosis	NN	NN		OK/0.998938
for	für	IN	APPR		OK/0.998230
all	sämtliche	DT	PIAT		OK/0.959520
patients	Patienten	NNS	NN		OK/0.974065
.	.	SENT	$.		OK/0.999778

# 0.744009
If	Wenn	IN	KOUS		OK/0.995445
not	nicht	RB	PTKNEG		OK/0.962575
used	benutzt	VVN	VVPP		OK/0.892815
during	innerhalb	IN	APPR		OK/0.844825
these	dieser	DT	PDAT		OK/0.915971
30	30	CD	CARD		OK/0.968318
days	Tage	NNS	NN		OK/0.981852
,	,	,	$,		OK/0.994829
the	Lösung	DT	NN		OK/0.979598
solution	Lösung	NN	NN		OK/0.996287
should	muss	MD	VMFIN		OK/0.992900
be	muss	VB	VMFIN		OK/0.996338
discarded	verworfen	VVN	VVPP		OK/0.986758
.	.	SENT	$.		OK/0.999537

# 0.986168
What	Was	WP	PIS		OK/0.999352
is	Was	VBZ	PIS		OK/0.995603
Protopic	Protopic	JJ	NE		OK/0.990123
?	?	SENT	$.		OK/0.999851

# 0.201973
As	Da	IN	ADV		OK/0.939200
it	nicht	PP	PTKNEG		OK/0.669402
is	nicht	VBZ	PTKNEG		OK/0.916415
not	nicht	RB	PTKNEG		OK/0.959922
Protein-gebunden	Protein-gebunden	NP	NN		OK/0.916237
stavudine	Stavudin	NP	NE		OK/0.959822
is	ist	VBZ	VAFIN		OK/0.981146
not	nicht	RB	PTKNEG		OK/0.676004
expected	erwarten	VVN	VVINF		OK/0.627694
to	__unaligned__	TO	__unaligned__		BAD/0.746879
affect	__unaligned__	VV	__unaligned__		BAD/0.940245
the	die	DT	ART		OK/0.987139
pharmacokinetics	Pharmakokinetik	NN	NN		OK/0.996827
of	Pharmakokinetik	IN	NN		OK/0.995156
Protein-gebundenen	Protein-gebundenen	NP	ADJA		OK/0.971988
affected	beeinträchtigt	VVD	VVPP		OK/0.980338
.	.	SENT	$.		OK/0.999258

# 0.994708
How	Wie	NP	KOKOM		OK/0.997844
is	wird	VBZ	VAFIN		OK/0.998482
Actrapid	Actrapid	NP	NN		OK/0.999243
used	angewendet	VVD	VVPP		OK/0.999253
?	?	SENT	$.		OK/0.999703

# 0.439488
In	In	IN	APPR		OK/0.939572
clinical	klinischen	JJ	ADJA		OK/0.969525
studies	Phase-III-Studien	NNS	NN		OK/0.881454
of	von	IN	APPR		OK/0.918147
six	6	CD	CARD		OK/0.943246
to	6	TO	CARD		OK/0.863769
12	12	CD	CARD		OK/0.983234
months	Monaten	NNS	NN		OK/0.948273
,	die	,	ART		OK/0.878287
the	__unaligned__	DT	__unaligned__		OK/0.819978
duration	Dauer	NN	NN		OK/0.887071
of	Dauer	IN	NN		OK/0.873198
conjunctival	Hyperämie	JJ	NN		OK/0.779262
hyperaemia	Hyperämie	NN	NN		OK/0.857875
time	Zeit	NN	NN		OK/0.959707
.	.	SENT	$.		OK/0.999143

# 0.083376
13	13	CD	CARD		OK/0.977474
should	__unaligned__	MD	__unaligned__		OK/0.899673
be	__unaligned__	VB	__unaligned__		OK/0.805266
administered	__unaligned__	VVN	__unaligned__		OK/0.778605
within	innerhalb	IN	APPR		OK/0.997665
8	8	CD	CARD		OK/0.994835
hours	Stunden	NNS	NN		OK/0.974440
to	verwendet	TO	VVPP		OK/0.366949
measure	__unaligned__	VV	__unaligned__		OK/0.402241
compliance	Einhaltung	NN	NN		OK/0.654794
In-use	Lagerungszeiten	NN	NN		OK/0.739632
storage	__unaligned__	NN	__unaligned__		OK/0.915895
times	__unaligned__	NNS	__unaligned__		OK/0.808029
and	und	CC	KON		OK/0.965471
conditions	bedingungen	NNS	NN		OK/0.933063
prior	der	RB	ART		OK/0.778968
to	vor	TO	APPR		OK/0.663807
use	Verwendung	VV	NN		OK/0.761805
are	liegen	VBP	VVFIN		OK/0.872180
the	Verantwortung	DT	NN		OK/0.955892
responsibility	Anwenders	NN	NN		OK/0.815456
of	Verantwortung	IN	NN		OK/0.941502
the	Verantwortung	DT	NN		OK/0.976605
user	Verantwortung	NN	NN		OK/0.930055
.	.	SENT	$.		OK/0.999656

# 0.240011
Rosiglitazone	Rosiglitazon	NP	NN		OK/0.956937
does	nicht	VVZ	PTKNEG		OK/0.549534
not	nicht	RB	PTKNEG		OK/0.702997
Insulin-Sekretion	Insulin-Sekretion	NN	NN		OK/0.532038
from	aus	IN	APPR		OK/0.925206
the	__unaligned__	DT	__unaligned__		OK/0.937608
pancreas	Pankreas	NN	NN		OK/0.849115
did	induzierte	VVD	VVFIN		OK/0.856488
not	keine	RB	PIAT		OK/0.970275
stimulate	__unaligned__	VV	__unaligned__		OK/0.862283
pancreatic	__unaligned__	JJ	__unaligned__		OK/0.919927
insulin	__unaligned__	NN	__unaligned__		OK/0.970908
secretion	__unaligned__	NN	__unaligned__		OK/0.996455
or	__unaligned__	CC	__unaligned__		OK/0.954155
induce	__unaligned__	VV	__unaligned__		OK/0.972852
hypoglycaemia	Hypoglykämie	NN	NN		OK/0.993901
in	Ratten	IN	NN		OK/0.993253
rats	Ratten	NNS	NN		OK/0.999798
and	und	CC	KON		OK/0.983399
mice	Mäusen	NNS	NN		OK/0.966356
.	.	SENT	$.		OK/0.997763

# 0.041026
There	Es	RB	NN		BAD/0.505206
have	Es	VHP	NN		BAD/0.565932
been	wurde	VBN	VAFIN		BAD/0.788597
a	__unaligned__	DT	__unaligned__		BAD/0.871345
number	__unaligned__	NN	__unaligned__		BAD/0.834162
of	__unaligned__	IN	__unaligned__		BAD/0.595364
symptoms	Symptomen	NNS	NN		OK/0.694397
reported	berichtet	VVN	VVFIN		OK/0.769157
were	waren	VBD	VAFIN		OK/0.842114
possibly	möglicherweise	RB	ADV		OK/0.824318
histamininduziert	histamininduziert	JJ	ADJD		OK/0.671767
,	;	,	$.		OK/0.896352
including	darunter	VVG	PAV		OK/0.957588
reports	Berichte	NNS	NN		OK/0.992490
of	über	IN	APPR		OK/0.986237
rash	Hautausschlag	NN	NN		OK/0.940712
,	,	,	$,		OK/0.974558
swelling	Schwellung	VVG	NN		OK/0.998880
of	von	IN	APPR		OK/0.988089
the	von	DT	APPR		OK/0.997972
face	Gesicht	NN	NN		OK/0.996157
,	Gesicht	,	NN		OK/0.949902
lips	Gesicht	NNS	NN		OK/0.969357
and	und	CC	KON		OK/0.999636
/	/	SYM	$(		OK/0.999111
or	oder	CC	KON		OK/0.998239
lips	Lippen	NNS	NN		OK/0.959412
,	,	,	$,		OK/0.999471
itching	Juckreiz	VVG	NN		OK/0.997893
,	Juckreiz	,	NN		OK/0.914019
warmth	Wärmegefühl	NN	NN		OK/0.867871
or	oder	CC	KON		OK/0.945379
multi-piece	Atemstörungen	NN	NN		OK/0.599292
.	.	SENT	$.		OK/0.995225

# 0.331511
Push	Bewegen	VVP	NN		OK/0.774359
the	die	DT	ART		OK/0.933107
some	einige	DT	PIAT		OK/0.525012
circles	kreisenden	NNS	ADJA		OK/0.511331
,	,	,	$,		OK/0.704085
to	__unaligned__	TO	__unaligned__		OK/0.975852
dissolve	um	VV	KOUI		OK/0.977395
the	__unaligned__	DT	__unaligned__		OK/0.989205
powder	Pulver	NN	NN		OK/0.968932
(	siehe	(	VVIMP		OK/0.997109
see	siehe	VV	VVIMP		OK/0.999549
Diagram	Abb	NP	VVFIN		OK/0.992600
8	8	CD	CARD		OK/0.996833
)	)	)	$(		OK/0.996241
.	.	SENT	$.		OK/0.998262

# 0.276149
Interactions	Wechselwirkungen	NNS	NN		OK/0.990398
of	gleichzeitigen	IN	ADJA		OK/0.973617
concomitant	gleichzeitigen	JJ	ADJA		OK/0.975980
doses	Gaben	NNS	NN		OK/0.980253
of	__unaligned__	IN	__unaligned__		OK/0.998613
lansoprazole	Lansoprazol	NN	NN		OK/0.996592
and	und	CC	KON		OK/0.993421
NSAIDs	NSARs	NNS	NN		OK/0.954461
could	konnten	MD	VMFIN		OK/0.804145
be	konnten	VB	VMFIN		OK/0.817495
demonstrated	belegt	VVN	VVPP		OK/0.956363
in	in	IN	APPR		OK/0.968109
a	Reihe	DT	NN		OK/0.944365
number	__unaligned__	NN	__unaligned__		OK/0.891078
of	__unaligned__	IN	__unaligned__		OK/0.974708
clinical	klinischer	JJ	ADJA		OK/0.975997
studies	Studien	NNS	NN		OK/0.994044
,	,	,	$,		BAD/0.711357
nor	noch	CC	ADV		BAD/0.996359
due	durch	JJ	APPR		BAD/0.972007
to	__unaligned__	TO	__unaligned__		BAD/0.926599
the	__unaligned__	DT	__unaligned__		BAD/0.837660
extensive	umfassende	JJ	ADJA		BAD/0.855321
clinical	klinische	JJ	ADJA		OK/0.903687
experience	Erfahrungen	NN	NN		OK/0.872507
.	.	SENT	$.		OK/0.999407

# 0.405894
Before	Vor	IN	APPR		OK/0.893277
treatment	Behandlung	NN	NN		OK/0.925184
,	__unaligned__	,	__unaligned__		OK/0.938744
an	übermäßigen	DT	ADJA		OK/0.988377
excessive	übermäßigen	JJ	ADJA		OK/0.988250
hair	Haarwuchs	NN	NN		OK/0.952945
at	__unaligned__	IN	__unaligned__		OK/0.945332
the	__unaligned__	DT	__unaligned__		OK/0.930779
treatment	__unaligned__	NN	__unaligned__		OK/0.871418
site	an	NN	APPR		BAD/0.643272
.	.	SENT	$.		OK/0.995834

# 0.494548
●	●	NP	ADJA		OK/0.997610
Make	sicher	VVP	ADJD		OK/0.996519
sure	sicher	RB	ADJD		OK/0.998619
that	dass	IN/that	KOUS		OK/0.998605
the	das	DT	ART		OK/0.999369
powder	Pulver	NN	NN		OK/0.998863
is	vollständig	VBZ	ADJD		OK/0.992990
completely	vollständig	RB	ADJD		OK/0.993422
dissolved	vollständig	VVN	ADJD		OK/0.952716
,	,	,	$,		OK/0.922889
and	und	CC	KON		OK/0.976215
wait	warten	VV	VVFIN		OK/0.970348
until	bis	IN	KOUS		OK/0.976115
all	alle	DT	PIAT		OK/0.957929
air	Luftbläschen	NN	NN		OK/0.972154
bubbles	Luftbläschen	NNS	NN		OK/0.979982
,	,	,	$,		OK/0.987089
may	eventuell	MD	ADJD		OK/0.789629
have	haben	VH	VAFIN		OK/0.754252
disappeared	verschwunden	VVN	VVPP		OK/0.679994
.	.	SENT	$.		OK/0.997239

# 0.292239
Intake	Nahrungsaufnahme	NP	NN		OK/0.574423
of	__unaligned__	IN	__unaligned__		OK/0.652005
food	Nahrungsaufnahme	NN	NN		OK/0.962753
reduces	vermindert	VVZ	VVFIN		OK/0.984976
the	die	DT	ART		OK/0.999276
bioavailability	Bioverfügbarkeit	NN	NN		OK/0.998377
of	die	IN	ART		OK/0.986812
lansoprazole	Lansoprazol	NN	NN		OK/0.974788
:	__unaligned__	:	__unaligned__		OK/0.890289
it	empfohlen	PP	VVPP		OK/0.799427
is	empfohlen	VBZ	VVPP		OK/0.937257
recommended	empfohlen	VVN	VVPP		OK/0.953129
to	__unaligned__	TO	__unaligned__		OK/0.961858
take	,	VV	$,		OK/0.942179
lansoprazole	Lansoprazol	NN	NN		OK/0.989645
before	vor	IN	APPR		OK/0.982786
the	den	DT	ART		OK/0.950547
meal	einzunehmen	NN	VVIZU		OK/0.792062
.	.	SENT	$.		OK/0.994779

# 0.802655
What	Was	WP	PWS		OK/0.999139
you	müssen	PP	VMFIN		OK/0.995218
should	müssen	MD	VMFIN		OK/0.994307
know	__unaligned__	VV	__unaligned__		OK/0.998481
before	vor	IN	APPR		OK/0.997406
you	Sie	PP	PPER		OK/0.998455
take	Einnahme	VVP	NN		OK/0.996186
INVEGA	INVEGA	NP	NE		OK/0.999359
3	3.	CD	ADJA		OK/0.992016
.	__unaligned__	SENT	__unaligned__		OK/0.979828
How	Wie	WRB	PWAV		OK/0.993130
to	__unaligned__	TO	__unaligned__		OK/0.999120
take	__unaligned__	VV	__unaligned__		OK/0.998214
INVEGA	INVEGA	NP	NE		OK/0.998487
4	einzunehmen	CD	VVIZU		OK/0.848260
.	?	SENT	$.		OK/0.979632

# 0.204238
With	Mit	IN	APPR		OK/0.904193
a	einer	DT	ART		OK/0.957788
lower-fat	fettreduzierten	JJ	ADJA		OK/0.505530
diet	fettreduzierten	NN	ADJA		OK/0.830803
may	können	MD	VMFIN		OK/0.830389
increase	können	VV	VMFIN		OK/0.842403
these	diese	DT	PDAT		OK/0.871290
effects	Effekte	NNS	NN		OK/0.939862
you	Sie	PP	PPER		OK/0.948680
should	vermeiden	MD	VVINF		OK/0.828130
be	vermeiden	VB	VVINF		OK/0.836382
made	vermeiden	VVN	VVINF		BAD/0.772592
as	vermeiden	IN	VVINF		BAD/0.825108
provided	vermeiden	VVN	VVINF		BAD/0.836395
.	.	SENT	$.		OK/0.990910

# 0.074199
The	Die	NP	ART		OK/0.999536
European	Europäische	NP	ADJA		OK/0.997773
Medicines	Arzneimittel-Agentur	NP	NN		OK/0.997907
Agency	Arzneimittel-Agentur	NP	NN		OK/0.997366
(	(	(	$(		OK/0.999859
EMEA	EMEA	NP	NE		OK/0.999103
)	)	)	$(		OK/0.996181
will	wird	MD	VAFIN		OK/0.924928
review	__unaligned__	VV	__unaligned__		OK/0.669469
any	__unaligned__	DT	__unaligned__		OK/0.673417
new	neuen	JJ	ADJA		OK/0.956099
information	Informationen	NN	NN		OK/0.634163
that	prüfen	WDT	VVINF		OK/0.472809
may	prüfen	MD	VVINF		OK/0.379131
become	__unaligned__	VV	__unaligned__		OK/0.356714
available	__unaligned__	JJ	__unaligned__		OK/0.406034
,	,	,	$,		OK/0.512179
and	und	CC	KON		OK/0.504109
this	__unaligned__	DT	__unaligned__		OK/0.584449
summary	vorliegende	NN	ADJA		OK/0.690606
will	wird	MD	VAFIN		OK/0.980905
be	aktualisiert	VB	VVPP		OK/0.951027
updated	aktualisiert	VVN	VVPP		OK/0.902608
as	aktualisiert	IN	VVPP		OK/0.842842
necessary	aktualisiert	JJ	VVPP		OK/0.845566
.	.	SENT	$.		OK/0.998084

# 0.941974
315	315	CD	CARD		OK/0.970274
could	anregen	MD	VVINF		OK/0.993739
stimulate	__unaligned__	VV	__unaligned__		OK/0.971243
.	.	SENT	$.		OK/0.999406

# 0.947634
Do	Nicht	VVP	PTKNEG		OK/0.992911
not	Nicht	RB	PTKNEG		OK/0.995753
use	anwenden	VV	VVINF		OK/0.997483
during	Trächtigkeit	IN	NN		OK/0.987891
pregnancy	Trächtigkeit	NN	NN		OK/0.965196
.	.	SENT	$.		OK/0.999145

# 0.057299
12	12	CD	CARD		OK/0.925443
*	*	SYM	XY		OK/0.965470
Within	Innerhalb	IN	ADJD		OK/0.986302
60	60	CD	CARD		OK/0.999205
days	Tagen	NNS	NN		OK/0.998053
of	Erreichen	IN	NN		OK/0.928753
or	__unaligned__	CC	__unaligned__		OK/0.925969
risk	__unaligned__	NN	__unaligned__		OK/0.789466
minimisation	__unaligned__	NN	__unaligned__		OK/0.446044
)	__unaligned__	)	__unaligned__		BAD/0.927967
milestone	Meilensteins	NN	NN		BAD/0.910644
being	Meilensteins	VBG	NN		BAD/0.820146
reached	Meilensteins	VVN	NN		OK/0.542914
(	(	(	$(		OK/0.805418
pharmacovigilance	Arzneimittelüberwachung	NN	NN		OK/0.817648
or	oder	CC	KON		OK/0.995505
risk	Risikominimierung	NN	NN		OK/0.938766
minimisation	Risikominimierung	NN	NN		OK/0.870622
)	)	)	$(		OK/0.963914
.	.	SENT	$.		OK/0.956456
*	*	SYM	XY		OK/0.962771
At	Anforderung	IN	NN		OK/0.914863
the	Anforderung	DT	NN		OK/0.871300
request	Anforderung	NN	NN		OK/0.688399
of	Anforderung	IN	NN		OK/0.742175
the	Anforderung	DT	NN		OK/0.973849
EMEA	EMEA	NP	NN		OK/0.967781
.	.	SENT	$.		OK/0.999609

# 0.479498
For	Zur	IN	APPRART		OK/0.960082
intravenous	intravenösen	JJ	ADJA		OK/0.997261
infusion	Infusion	NN	NN		OK/0.993053
will	wird	MD	VAFIN		OK/0.960148
be	__unaligned__	VB	__unaligned__		OK/0.891685
diluted	verdünnt	VVN	VVPP		OK/0.775082
after	nach	IN	APPR		OK/0.754048
bolus	Bolusdosis	NN	NN		OK/0.914466
dose	Bolusdosis	NN	NN		OK/0.996911
of	__unaligned__	IN	__unaligned__		OK/0.980236
TRACTOCILE	TRACTOCILE	NP	VVFIN		OK/0.980306
7.5	7,5	CD	CARD		OK/0.997055
mg	mg	NN	NN		OK/0.999264
/	/	SYM	$(		OK/0.997337
ml	ml	JJ	NN		OK/0.999648
concentrate	Konzentrat	NN	NN		OK/0.998658
for	Infusionslösung	IN	NN		OK/0.996166
solution	Infusionslösung	NN	NN		OK/0.981804
for	Infusionslösung	IN	NN		OK/0.968405
infusion	Infusionslösung	NN	NN		OK/0.966602
in	in	IN	APPR		OK/0.964210
any	__unaligned__	DT	__unaligned__		OK/0.852674
of	__unaligned__	IN	__unaligned__		OK/0.956335
the	folgenden	DT	ADJA		OK/0.991081
following	folgenden	VVG	ADJA		OK/0.972513
solutions	Lösungen	NNS	NN		OK/0.987396
:	:	:	$.		OK/0.996289

# 0.518401
Dose	verabreichende	NP	ADJA		OK/0.998704
to	verabreichende	TO	ADJA		OK/0.997857
be	verabreichende	VB	ADJA		OK/0.995742
administered	verabreichende	VVN	ADJA		OK/0.988207
Rebetol	Rebetol	NP	NN		OK/0.942525
oral	Einnehmen	JJ	NN		OK/0.988914
solution	Lösung	NN	NN		OK/0.998972
is	wird	VBZ	VAFIN		OK/0.997578
supplied	angeboten	VVN	VVPP		OK/0.996888
in	angeboten	IN	VVPP		OK/0.995349
a	angeboten	DT	VVPP		OK/0.916686
concentration	__unaligned__	NN	__unaligned__		OK/0.829643
of	__unaligned__	IN	__unaligned__		OK/0.593987
40	40	CD	CARD		OK/0.911444
mg	mg	NN	NN		OK/0.975760
/	/	SYM	$(		OK/0.997708
ml	ml	NN	NN		OK/0.993847
.	.	SENT	$.		OK/0.999736

# 0.766212
40	40	CD	CARD		OK/0.997137
After	Nach	IN	APPR		OK/0.996318
discontinuation	Absetzen	NN	NN		OK/0.999101
of	Absetzen	IN	NN		OK/0.991557
short-term	Langzeit-Therapie	JJ	NN		OK/0.988022
and	Kurzzeit-	CC	TRUNC		OK/0.992222
long-term	Kurzzeit-	JJ	TRUNC		OK/0.995892
treatment	Langzeit-Therapie	NN	NN		OK/0.996728
with	von	IN	APPR		OK/0.989184
pregabalin	Pregabalin	NN	NN		OK/0.999013
withdrawal	Entzugssymptome	NN	NN		OK/0.986841
symptoms	Entzugssymptome	NNS	NN		OK/0.989452
have	Entzugssymptome	VHP	NN		OK/0.942308
been	beobachtet	VBN	VVPP		OK/0.888427
observed	beobachtet	VVN	VVPP		OK/0.975279
in	bei	IN	APPR		OK/0.988363
some	einigen	DT	PIAT		OK/0.959134
patients	Patienten	NNS	NN		OK/0.960297
.	.	SENT	$.		OK/0.999658

# 0.582579
The	Die	DT	ART		OK/0.997444
mean	mittlere	JJ	ADJA		OK/0.914386
half-life	Halbwertszeit	NN	NN		OK/0.885457
ranged	lag	VVN	VVFIN		OK/0.792701
from	zwischen	IN	APPR		OK/0.821831
5.5	5,5	CD	CARD		OK/0.902390
h	h	NN	NN		OK/0.965777
(	(	(	$(		OK/0.994368
women	Frauen	NNS	NN		OK/0.994800
)	)	)	$(		OK/0.995884
and	und	CC	KON		OK/0.987216
6.0	6,0	CD	CARD		OK/0.899515
h	h	NN	NN		OK/0.945992
(	(	(	$(		OK/0.947395
men	Männer	NNS	NN		OK/0.986116
)	)	)	$(		OK/0.993499
.	.	SENT	$.		OK/0.998982

# 0.543689
No	keine	NP	PIAT		OK/0.999270
dose	Dosisanpassung	NN	NN		OK/0.999113
adjustment	Dosisanpassung	NN	NN		OK/0.991687
is	erforderlich	VBZ	ADJD		OK/0.991008
required	erforderlich	VVN	ADJD		OK/0.987914
to	__unaligned__	TO	__unaligned__		OK/0.870143
17	17	CD	CARD		OK/0.989395
Hepatic	vorzuziehen	JJ	VVIZU		OK/0.923438
impairment	vorzuziehen	NN	VVIZU		OK/0.864643
:	vorzuziehen	:	VVIZU		OK/0.876789
in	Patienten	IN	NN		OK/0.891558
patients	Patienten	NNS	NN		OK/0.992977
with	mit	IN	APPR		OK/0.999586
renal	eingeschränkter	JJ	ADJA		OK/0.999275
impairment	Nierenfunktion	NN	NN		OK/0.991130
whose	__unaligned__	WP$	__unaligned__		OK/0.975510
renal	Nierenfunktion	JJ	NN		OK/0.992783
creatinine	Kreatininclearance	NN	NN		OK/0.996854
clearance	Kreatininclearance	NN	NN		OK/0.951811
is	__unaligned__	VBZ	__unaligned__		OK/0.893447
≥	≥	JJ	ADJD		OK/0.985516
30	30	CD	CARD		OK/0.998078
ml	ml	NN	NN		OK/0.998931
/	/	SYM	$(		OK/0.999296
min	min	NN	VVIMP		OK/0.995419
(	siehe	(	VVIMP		OK/0.999384
see	siehe	VV	VVIMP		OK/0.998334
sections	Abschnitte	NNS	NN		OK/0.997327
4.3	4.3	CD	CARD		OK/0.999386
and	und	CC	KON		OK/0.999963
4.4	4.4	CD	CARD		OK/0.986114
)	)	)	$(		OK/0.983099
.	.	SENT	$.		OK/0.994778

# 0.494267
If	Wenn	IN	KOUS		OK/0.986587
you	Sie	PP	PPER		OK/0.962790
are	befürchten	VBP	VVINF		OK/0.899093
concerned	befürchten	VVN	VVINF		OK/0.864353
that	dass	IN/that	KOUS		OK/0.983589
you	Sie	PP	PPER		OK/0.984619
miss	versäumt	VVP	VVPP		OK/0.977668
a	versäumt	DT	VVPP		OK/0.993589
dose	versäumt	NN	VVPP		OK/0.996113
of	__unaligned__	IN	__unaligned__		OK/0.984740
INVANZ	INVANZ	NP	NE		OK/0.970878
,	,	,	$,		OK/0.994658
you	Sie	PP	PPER		OK/0.990485
should	Sie	MD	PPER		OK/0.993413
contact	wenden	VV	VVFIN		OK/0.994339
your	Arzt	PP$	NN		OK/0.999387
doctor	Ihren	NN	PPOSAT		OK/0.985150
or	Fachkraft	CC	NN		OK/0.967507
another	Fachkraft	DT	NN		OK/0.989509
healthcare	Fachkraft	NN	NN		OK/0.815035
professional	Fachkraft	NN	NN		OK/0.708138
.	.	SENT	$.		OK/0.992482

# 0.939309
bradycardia	Bradykardie	NN	NN		OK/0.986819
,	,	,	$,		OK/0.989658
tachycardia	Tachykardie	NN	NN		OK/0.994516
,	Tachykardie	,	NN		OK/0.973308
palpitations	Palpitationen	NNS	NN		OK/0.980961
Common	Häufig	JJ	ADJD		OK/0.997595
:	:	:	$.		OK/0.999605

# 0.854330
264	264	CD	CARD		OK/0.940184
The	Den	DT	ART		OK/0.994391
pen	Pen	NN	NN		OK/0.986577
containing	__unaligned__	VVG	__unaligned__		OK/0.974927
a	__unaligned__	DT	__unaligned__		OK/0.997719
cartridge	Patrone	NN	NN		OK/0.996229
must	eingelegter	MD	ADJA		OK/0.992482
not	eingelegter	RB	ADJA		OK/0.988618
be	eingelegter	VB	ADJA		OK/0.998058
stored	eingelegter	VVN	ADJA		OK/0.990678
in	im	IN	APPRART		OK/0.996908
the	im	DT	APPRART		OK/0.990084
refrigerator	Kühlschrank	NN	NN		OK/0.977923
.	.	SENT	$.		OK/0.998034

# 0.371034
In	Bei	IN	APPR		OK/0.893077
juvenile	__unaligned__	JJ	__unaligned__		OK/0.948591
rats	Ratten	NNS	NN		OK/0.964668
the	__unaligned__	DT	__unaligned__		OK/0.997228
types	__unaligned__	NNS	__unaligned__		OK/0.985180
of	die	IN	ART		OK/0.991413
toxicity	Toxizität	NN	NN		OK/0.987627
do	qualitativ	VVP	ADJD		OK/0.668970
not	nicht	RB	PTKNEG		OK/0.991460
differ	qualitativ	VV	ADJD		OK/0.958219
qualitatively	qualitativ	RB	ADJD		OK/0.998914
from	qualitativ	IN	ADJD		OK/0.997658
those	qualitativ	DT	ADJD		OK/0.993551
observed	qualitativ	VVN	ADJD		OK/0.995414
in	bei	IN	APPR		OK/0.996725
adult	adulten	JJ	ADJA		OK/0.966790
rats	__unaligned__	NNS	__unaligned__		OK/0.691518
.	.	SENT	$.		OK/0.984027

# 0.436986
73	73	NP	CARD		OK/0.939229
Bondronat	Bondronat	NP	NN		OK/0.981074
is	ist	VBZ	VAFIN		OK/0.994292
available	Packungen	JJ	NN		OK/0.994006
in	Packungen	IN	NN		OK/0.990692
packs	Packungen	NNS	NN		OK/0.951746
of	Packungen	IN	NN		OK/0.991511
1	1	CD	CARD		OK/0.998266
,	,	,	$,		OK/0.999821
5	5	CD	CARD		OK/0.992836
and	und	CC	KON		OK/0.998658
10	10	CD	CARD		OK/0.998548
vials	Durchstechflaschen	NNS	NN		OK/0.991889
(	(	(	$(		OK/0.951692
6-ml-Durchstechflasche	6-ml-Durchstechflasche	JJ	NN		OK/0.799255
in	__unaligned__	IN	__unaligned__		OK/0.733677
a	Glas	DT	NN		OK/0.773926
glass	Glas	NN	NN		OK/0.977962
vial	__unaligned__	NN	__unaligned__		OK/0.761576
)	)	)	$(		OK/0.971139
.	.	SENT	$.		OK/0.995325

# 0.890681
No	keine	NP	PIAT		OK/0.999273
dose	Dosisanpassung	NN	NN		OK/0.999214
adjustment	Dosisanpassung	NN	NN		OK/0.995816
is	erforderlich	VBZ	ADJD		OK/0.993862
necessary	erforderlich	JJ	ADJD		OK/0.982527
based	Aufgrund	VVN	APPR		OK/0.973867
on	__unaligned__	IN	__unaligned__		OK/0.979547
gender	Geschlecht	NN	NN		OK/0.998036
or	oder	CC	KON		OK/0.990568
race	ethnischer	NN	ADJA		OK/0.953534
(	siehe	(	VVIMP		OK/0.997221
see	siehe	VV	VVIMP		OK/0.998327
section	Abschnitt	NN	NN		OK/0.999111
5.2	5.2	CD	CARD		OK/0.999798
)	)	)	$(		OK/0.998973
.	.	SENT	$.		OK/0.999067

# 0.822091
Entacapone	Entacapon	NP	NN		OK/0.987271
belongs	gehört	VVZ	VVFIN		OK/0.998373
to	gehört	TO	VVFIN		OK/0.997551
a	neuen	DT	ADJA		OK/0.998390
new	neuen	JJ	ADJA		OK/0.989434
therapeutic	therapeutischen	JJ	ADJA		OK/0.941357
class	Klasse	NN	NN		OK/0.965231
,	,	,	$,		OK/0.975132
the	den	DT	ART		OK/0.960473
(	(	(	$(		OK/0.995659
COMT	COMT	NP	NE		OK/0.982937
)	)	)	$(		OK/0.978331
inhibitors	Hemmern	NNS	NN		OK/0.965251
.	.	SENT	$.		OK/0.999547

# 0.792310
Store	Originalbehältnis	NP	NN		OK/0.990049
in	Originalbehältnis	IN	NN		OK/0.993183
the	Originalbehältnis	DT	NN		OK/0.999257
original	Originalbehältnis	JJ	NN		OK/0.982942
container	Originalbehältnis	NN	NN		OK/0.943136
in	den	IN	ART		OK/0.998145
order	schützen	NN	VVINF		OK/0.995823
to	schützen	TO	VVINF		OK/0.994931
protect	schützen	VV	VVINF		OK/0.997572
from	schützen	IN	VVINF		OK/0.899053
light	schützen	NN	VVINF		OK/0.909454
.	.	SENT	$.		OK/0.997705

# 0.774281
How	Wie	NP	KOKOM		OK/0.999103
to	__unaligned__	TO	__unaligned__		OK/0.996187
use	__unaligned__	VV	__unaligned__		OK/0.997410
INTANZA	INTANZA	NP	NE		OK/0.994284
4	anzuwenden	CD	VVIZU		OK/0.797052
.	?	SENT	$.		OK/0.890757

# 0.980131
Why	Warum	NP	PWAV		OK/0.999649
has	Warum	VHZ	PWAV		OK/0.994914
Beromun	Beromun	NP	NE		OK/0.989674
been	zugelassen	VBN	VVPP		OK/0.996312
approved	zugelassen	VVN	VVPP		OK/0.997415
?	?	SENT	$.		OK/0.999441

# 0.455698
What	Was	WP	PWS		OK/0.999139
you	müssen	PP	VMFIN		OK/0.995217
should	müssen	MD	VMFIN		OK/0.994300
know	__unaligned__	VV	__unaligned__		OK/0.998441
before	vor	IN	APPR		OK/0.996577
you	Sie	PP	PPER		OK/0.988434
take	Einnahme	VVP	NN		OK/0.995544
Efexor	Efexor	NP	ADJD		OK/0.969827
3	3.	CD	ADJA		OK/0.506824
.	__unaligned__	SENT	__unaligned__		OK/0.590556

# 0.679661
8	8	CD	CARD		OK/0.994954
The	Die	DT	ART		OK/0.998931
incidence	Häufigkeit	NN	NN		OK/0.970881
of	__unaligned__	IN	__unaligned__		OK/0.992693
low	erniedrigten	JJ	ADJA		OK/0.942293
haemoglobin	Hämoglobinwertes	NN	NN		OK/0.953339
levels	__unaligned__	NNS	__unaligned__		OK/0.978132
(	(	(	$(		OK/0.997426
anaemia	Anämie	NN	NN		OK/0.997217
)	)	)	$(		OK/0.996561
was	war	VBD	VAFIN		OK/0.875727
higher	höher	JJR	ADJD		OK/0.959517
than	unter	IN	APPR		OK/0.969986
10	10	CD	CARD		OK/0.989771
mg	mg	NN	NN		OK/0.994523
Volibris	Volibris	NP	NN		OK/0.910682
.	.	SENT	$.		OK/0.999273

# 0.652459
Gently	Bewegen	NP	NN		OK/0.903125
move	__unaligned__	VV	__unaligned__		OK/0.934911
the	__unaligned__	DT	__unaligned__		OK/0.994523
vial	Durchstechflasche	NN	NN		OK/0.994781
in	__unaligned__	IN	__unaligned__		OK/0.905424
circles	kreisenden	NNS	ADJA		OK/0.844570
,	,	,	$,		OK/0.906306
to	__unaligned__	TO	__unaligned__		OK/0.990856
dissolve	um	VV	KOUI		OK/0.982500
the	__unaligned__	DT	__unaligned__		OK/0.990178
powder	Pulver	NN	NN		OK/0.969388
(	siehe	(	VVIMP		OK/0.997118
see	siehe	VV	VVIMP		OK/0.999410
Diagram	Abb	NP	VVFIN		OK/0.976756
6	6	CD	CARD		OK/0.993684
)	)	)	$(		OK/0.995148
.	.	SENT	$.		OK/0.998609

# 0.940444
The	Das	DT	ART		OK/0.999145
potential	mögliche	JJ	ADJA		OK/0.996721
risk	Risiko	NN	NN		OK/0.991198
for	für	IN	APPR		OK/0.985369
humans	Menschen	NNS	NN		OK/0.984819
is	bekannt	VBZ	ADJD		OK/0.991133
unknown	bekannt	JJ	ADJD		OK/0.977815
.	.	SENT	$.		OK/0.997910

# 0.899958
In	Bei	IN	APPR		OK/0.966965
animals	Tieren	NNS	NN		OK/0.982268
,	__unaligned__	,	__unaligned__		OK/0.952319
glimepiride	Glimepirid	NN	NN		OK/0.988669
is	Muttermilch	VBZ	NN		OK/0.998802
excreted	Muttermilch	VVN	NN		OK/0.996088
in	Muttermilch	IN	NN		OK/0.991864
milk	Muttermilch	NN	NN		OK/0.991060
.	.	SENT	$.		OK/0.999874

# 0.107633
This	Dies	NP	PDS		OK/0.995046
means	bedeutet	VVZ	VVFIN		OK/0.993706
that	dass	IN/that	KOUS		OK/0.999399
Olanzapine	Olanzapin	NP	NE		OK/0.991559
Mylan	Mylan	NP	NE		OK/0.904782
"	"	''	$(		OK/0.935145
reference	Referenzarzneimittel	NN	NN		OK/0.974179
medicine	Referenzarzneimittel	NN	NN		OK/0.981455
'	__unaligned__	POS	__unaligned__		BAD/0.994287
already	bereits	RB	ADV		OK/0.399949
authorised	__unaligned__	VVN	__unaligned__		OK/0.712695
in	__unaligned__	IN	__unaligned__		OK/0.972184
the	Europäischen	DT	ADJA		OK/0.980800
European	Europäischen	NP	ADJA		OK/0.982565
Union	Union	NP	NN		OK/0.980071
(	(	(	$(		OK/0.998312
EU	EU	NP	NE		OK/0.995924
)	)	)	$(		OK/0.990195
called	zugelassenen	VVD	ADJA		OK/0.437448
Zyprexa	Zyprexa	NP	NN		OK/0.615892
is	__unaligned__	VBZ	__unaligned__		BAD/0.981030
similar	ähnlich	JJ	ADJD		BAD/0.946581
to	ähnlich	TO	ADJD		BAD/0.870235
.	.	SENT	$.		OK/0.974033

# 0.901212
Olanzapine	Olanzapin	NP	NN		OK/0.996917
orodispersible	Schmelztablette	JJ	NN		OK/0.996832
tablets	Schmelztablette	NNS	NN		OK/0.971865
may	kann	MD	VMFIN		OK/0.992575
be	kann	VB	VMFIN		OK/0.990351
used	angewendet	VVN	VVPP		OK/0.996555
as	Alternative	IN	NN		OK/0.994800
an	Alternative	DT	NN		OK/0.998864
alternative	Alternative	NN	NN		OK/0.996730
to	Alternative	TO	NN		OK/0.980432
olanzapine	Olanzapin	JJ	NE		OK/0.983093
coated	Filmtabletten	JJ	NN		OK/0.977603
tablets	Filmtabletten	NNS	NN		OK/0.997355
.	.	SENT	$.		OK/0.999873

# 0.826727
injection	Injektionsstelle	NN	NN		OK/0.981862
site	Injektionsstelle	NN	NN		OK/0.972971
adverse	Nebenwirkungen	JJ	NN		OK/0.988779
events	Nebenwirkungen	NNS	NN		OK/0.968126
The	Die	DT	ART		OK/0.999370
most	häufigsten	RBS	ADJA		OK/0.994160
commonly	berichtete	RB	ADJA		OK/0.971649
reported	berichtete	VVN	ADJA		OK/0.985231
side	Nebenwirkung	NN	NN		OK/0.980202
effect	Nebenwirkung	NN	NN		OK/0.941401
at	Injektionsstelle	IN	NN		OK/0.998219
the	Injektionsstelle	DT	NN		OK/0.999878
injection	Injektionsstelle	NN	NN		OK/0.999224
site	Injektionsstelle	NN	NN		OK/0.995922
pain	Schmerz	NN	NN		OK/0.989196
.	.	SENT	$.		OK/0.998650

# 0.947565
No	keine	NP	PIAT		OK/0.998548
dosage	Anpassung	NN	NN		OK/0.994577
adjustment	Anpassung	NN	NN		OK/0.994435
is	notwendig	VBZ	ADJD		OK/0.996291
necessary	notwendig	JJ	ADJD		OK/0.967673
in	diesen	IN	PDAT		OK/0.996847
these	diesen	DT	PDAT		OK/0.999698
patients	Patienten	NNS	NN		OK/0.993433
.	.	SENT	$.		OK/0.999885

# 0.509642
If	Wenn	IN	KOUS		OK/0.999053
you	Sie	PP	PPER		OK/0.998995
have	haben	VHP	VAFIN		OK/0.992269
epilepsy	Epilepsie	NN	NN		OK/0.988203
,	,	,	$,		OK/0.996107
talk	sprechen	VV	VVFIN		OK/0.971105
to	sprechen	TO	VVFIN		OK/0.967928
your	Ihrem	PP$	PPOSAT		OK/0.999054
doctor	Arzt	NN	NN		OK/0.998515
about	__unaligned__	IN	__unaligned__		OK/0.574477
the	die	DT	ART		OK/0.992735
ability	Fähigkeit	NN	NN		OK/0.999142
to	Fähigkeit	TO	NN		OK/0.997257
drive	Maschinen	VV	NN		OK/0.993753
and	Maschinen	CC	NN		OK/0.976004
use	Maschinen	VV	NN		OK/0.983593
machines	Bedienen	NNS	NN		OK/0.988279
.	.	SENT	$.		OK/0.999626

# 0.801167
The	Die	DT	ART		OK/0.998052
dose	Dosis	NN	NN		OK/0.999149
can	kann	MD	VMFIN		OK/0.997963
be	kann	VB	VMFIN		OK/0.981432
given	__unaligned__	VVN	__unaligned__		OK/0.817214
without	__unaligned__	IN	__unaligned__		OK/0.989373
a	Mahlzeit	DT	NN		OK/0.992209
meal	Mahlzeit	NN	NN		OK/0.996995
.	.	SENT	$.		OK/0.996134

# 0.301249
Due	Wegen	NP	APPR		OK/0.991666
to	Wegen	TO	APPR		OK/0.993069
the	Wegen	DT	APPR		OK/0.991147
limited	begrenzten	JJ	ADJA		OK/0.978983
data	Daten	NNS	NN		OK/0.974354
from	Daten	IN	NN		OK/0.903260
this	dieser	DT	PDAT		OK/0.821332
study	Studie	NN	NN		OK/0.876242
,	__unaligned__	,	__unaligned__		OK/0.409686
no	keine	DT	PIAT		OK/0.805629
definitive	abschließende	JJ	ADJA		OK/0.865971
conclusion	Schlussfolgerung	NN	NN		OK/0.882071
can	kann	MD	VMFIN		OK/0.958002
be	werden	VB	VAINF		OK/0.966369
drawn	gezogen	VVN	VVPP		OK/0.953321
.	.	SENT	$.		OK/0.998627

# 0.858744
For	Auflistung	IN	NN		OK/0.938579
a	Auflistung	DT	NN		OK/0.929857
full	Auflistung	JJ	NN		OK/0.991291
list	Auflistung	NN	NN		OK/0.998681
of	Auflistung	IN	NN		OK/0.999155
excipients	sonstigen	NNS	ADJA		OK/0.982422
,	6.1	,	CARD		OK/0.978435
see	6.1	VV	CARD		OK/0.988677
section	Abschnitt	NN	NN		OK/0.998159
6.1	6.1	CD	CARD		OK/0.993551
.	.	SENT	$.		OK/0.999817

# 0.668656
In	Im	IN	APPRART		OK/0.997768
case	Falle	NN	NN		OK/0.951820
of	Falle	IN	NN		OK/0.919425
jaundice	Gelbsucht	NN	NN		OK/0.903211
treatment	abzubrechen	NN	VVIZU		OK/0.893449
should	abzubrechen	MD	VVIZU		OK/0.900608
be	abzubrechen	VB	VVIZU		OK/0.873571
discontinued	abzubrechen	VVN	VVIZU		OK/0.818258
.	.	SENT	$.		OK/0.994901

# 0.432127
The	Der	DT	ART		OK/0.997047
pH	pH-Wert	NN	NN		OK/0.975533
may	sofern	MD	KOUS		OK/0.913447
have	,	VH	$,		OK/0.537608
been	__unaligned__	VBN	__unaligned__		OK/0.523904
adjusted	__unaligned__	VVN	__unaligned__		OK/0.978140
with	mit	IN	APPR		OK/0.997873
sodium	Natriumhydroxid	NN	NN		OK/0.999075
hydroxide	Natriumhydroxid	NN	NN		OK/0.981936
and	und	CC	KON		OK/0.999736
/	/	SYM	$(		OK/0.999456
or	oder	CC	KON		OK/0.978494
hydrochloric	Salzsäure	JJ	NN		OK/0.994163
acid	Salzsäure	NN	NN		OK/0.997098
.	.	SENT	$.		OK/0.999951

# 0.441874
Clear	Klare	NP	NN		OK/0.917452
or	oder	CC	KON		OK/0.983992
slightly	leicht	RB	ADJD		OK/0.889485
opaleszierende	opaleszierende	JJ	ADJA		BAD/0.590131
.	.	SENT	$.		OK/0.994605

# 0.653786
Therefore	Daher	RB	PAV		OK/0.996538
,	Daher	,	PAV		OK/0.997563
your	Ihr	PP$	PPOSAT		OK/0.987079
haemoglobin	Hämoglobinwert	NN	NN		OK/0.997612
level	Hämoglobinwert	NN	NN		OK/0.995194
and	und	CC	KON		OK/0.995919
your	Ihr	PP$	PPOSAT		OK/0.990137
blood	Blutdruck	NN	NN		OK/0.994737
pressure	Blutdruck	NN	NN		OK/0.985965
should	sorgfältig	MD	ADJD		OK/0.908704
be	sorgfältig	VB	ADJD		OK/0.831035
carefully	sorgfältig	RB	ADJD		OK/0.757556
monitored	überwacht	VVN	VVPP		OK/0.808528
.	.	SENT	$.		OK/0.997217

# 0.038390
ADVATE	ADVATE	NP	NN		OK/0.992699
contains	enthält	VVZ	VVFIN		OK/0.995830
no	keine	DT	PIAT		OK/0.992036
inactive	pharmakologisch	JJ	ADJD		OK/0.854122
,	__unaligned__	,	__unaligned__		OK/0.675652
von	__unaligned__	NP	__unaligned__		OK/0.643915
Willebrand	wirksamen	NP	ADJA		OK/0.593209
factor	__unaligned__	NN	__unaligned__		OK/0.795080
and	und	CC	KON		OK/0.915660
is	__unaligned__	VBZ	__unaligned__		OK/0.451134
therefore	daher	RB	PAV		OK/0.753031
not	nicht	RB	PTKNEG		OK/0.800578
indicated	für	VVN	APPR		BAD/0.822395
in	__unaligned__	IN	__unaligned__		BAD/0.807450
von	von-Willebrand-Jürgens-Syndroms	NP	NN		BAD/0.808765
Willebrand	von-Willebrand-Jürgens-Syndroms	NP	NN		BAD/0.602391
's	von-Willebrand-Jürgens-Syndroms	POS	NN		BAD/0.470221
disease	von-Willebrand-Jürgens-Syndroms	NN	NN		OK/0.747626
.	.	SENT	$.		OK/0.983442

# 0.376380
The	Die	DT	ART		OK/0.993012
outside	__unaligned__	NN	__unaligned__		OK/0.975727
of	__unaligned__	IN	__unaligned__		OK/0.984716
the	__unaligned__	DT	__unaligned__		OK/0.991108
backing	__unaligned__	NN	__unaligned__		OK/0.957764
layer	__unaligned__	NN	__unaligned__		OK/0.981961
is	__unaligned__	VBZ	__unaligned__		OK/0.978400
beige	__unaligned__	JJ	__unaligned__		OK/0.941430
and	und	CC	KON		OK/0.982066
labelled	beigefarben	VVN	ADJD		OK/0.861577
with	mit	IN	APPR		OK/0.882006
"	"	``	$(		OK/0.804616
Prometax	Prometax	NN	NN		OK/0.911355
,	,	,	$,		OK/0.922658
"	"	''	$(		OK/0.849669
"	"	``	$(		OK/0.893635
9.5	9.5	CD	CARD		OK/0.941397
mg	mg	NN	NN		OK/0.964736
/	/	SYM	$(		OK/0.957955
24	24	CD	CARD		OK/0.977473
h	h	NN	NN		OK/0.978056
"	"	''	$(		OK/0.985684
and	und	CC	KON		OK/0.980375
"	"	``	$(		OK/0.910766
BHDI	BHDI	NP	NE		OK/0.810626
.	.	SENT	$.		OK/0.996861
"	"	``	$(		OK/0.973340

# 0.451613
The	Die	DT	ART		OK/0.987663
lowest	niedrigste	JJS	ADJA		OK/0.990058
effective	wirksame	JJ	ADJA		OK/0.992708
maintenance	Erhaltungsdosis	NN	NN		OK/0.991179
dose	Erhaltungsdosis	NN	NN		OK/0.998148
of	__unaligned__	IN	__unaligned__		OK/0.726904
80	80	CD	CARD		OK/0.699228
mg	mg	NN	NN		OK/0.588852
degarelix	Degarelix	NN	NE		OK/0.607337
.	.	SENT	$.		OK/0.977541

# 0.212817
Pregnancy	__unaligned__	NP	__unaligned__		BAD/0.513022
and	__unaligned__	CC	__unaligned__		BAD/0.570467
breast-feeding	__unaligned__	VVG	__unaligned__		BAD/0.510129
Ask	Fragen	NP	NN		OK/0.977125
your	Arzt	PP$	NN		OK/0.995984
doctor	Ihren	NN	PPOSAT		OK/0.998642
for	Rat	IN	NN		OK/0.993820
advice	Rat	NN	NN		OK/0.999556
before	Rat	IN	NN		OK/0.751850
taking	Rat	VVG	NN		OK/0.743263
any	Rat	DT	NN		OK/0.749405
medicine	Rat	NN	NN		OK/0.759606
.	.	SENT	$.		OK/0.998870

# 0.350170
The	Die	DT	ART		OK/0.997713
clinical	klinische	JJ	ADJA		OK/0.999196
relevance	Relevanz	NN	NN		OK/0.997489
of	dieser	IN	PDAT		OK/0.977932
this	dieser	DT	PDAT		OK/0.989476
decreased	verringerten	VVN	ADJA		OK/0.950186
susceptibility	Empfindlichkeit	NN	NN		OK/0.687434
was	wurde	VBD	VAFIN		BAD/0.799631
not	noch	RB	ADV		BAD/0.840007
yet	noch	RB	ADV		BAD/0.915021
fully	völlig	RB	ADJD		BAD/0.913814
understood	erforscht	VVN	VVPP		BAD/0.939222
.	.	SENT	$.		OK/0.845005

# 0.765736
Please	Bitte	RB	NN		OK/0.999268
read	lesen	VVD	VVFIN		OK/0.995672
the	folgende	DT	ADJA		OK/0.999877
following	folgende	VVG	ADJA		OK/0.998222
instructions	Bedienungsanleitung	NNS	NN		OK/0.993284
before	vor	IN	APPR		OK/0.998460
using	der	VVG	ART		OK/0.991309
your	__unaligned__	PP$	__unaligned__		OK/0.978312
Levemir	Levemir	NP	NE		OK/0.989117
InnoLet	InnoLet	NP	NE		OK/0.885165
carefully	sorgfältig	RB	ADJD		BAD/0.916038
.	.	SENT	$.		OK/0.994140

# 0.007032
As	Als	IN	KOKOM		OK/0.709883
Minor	__unaligned__	NP	__unaligned__		OK/0.537020
metabolites	Nebenmetaboliten	NNS	NN		OK/0.506611
identified	__unaligned__	VVN	__unaligned__		OK/0.398857
were	wurden	VBD	VAFIN		OK/0.515741
a	__unaligned__	DT	__unaligned__		OK/0.419979
diol	__unaligned__	NN	__unaligned__		OK/0.380470
,	,	,	$,		OK/0.531765
Isopropen	Isopropen	NN	NN		OK/0.238139
and	und	CC	KON		OK/0.733865
nateglinide	Acylglucuronid	NN	NN		OK/0.516983
;	Acylglucuronid	:	NN		OK/0.558391
only	Acylglucuronid	RB	NN		OK/0.625940
.	.	SENT	$.		OK/0.906344
Only	Nur	RB	ADV		OK/0.901720
the	der	DT	ART		OK/0.981637
Nebenmetabolit	Nebenmetabolit	NP	NN		BAD/0.319328
Isopropen	Isopropen	NN	NN		BAD/0.438834
has	verfügt	VHZ	VVFIN		BAD/0.624327
similar	ähnliche	JJ	ADJA		BAD/0.574839
activity	Aktivität	NN	NN		BAD/0.785619
to	__unaligned__	TO	__unaligned__		BAD/0.774510
nateglinide	Nateglinid	NN	NN		BAD/0.819740
.	.	SENT	$.		OK/0.993312

# 0.416484
It	Es	PP	PPER		OK/0.984847
has	gezeigt	VHZ	VVPP		OK/0.984974
been	gezeigt	VBN	VVPP		OK/0.993191
shown	gezeigt	VVN	VVPP		OK/0.998142
that	dass	IN/that	KOUS		OK/0.982826
ivabradine	Ivabradin	NN	NE		OK/0.989188
did	keinen	VVD	PIAT		OK/0.991451
not	keinen	RB	PIAT		OK/0.989164
affect	Einfluss	VV	NN		OK/0.996581
the	den	DT	ART		OK/0.997743
metabolism	Metabolismus	NN	NN		OK/0.994895
and	und	CC	KON		OK/0.997204
plasma	Plasmakonzentrationen	NN	NN		OK/0.998296
concentrations	Plasmakonzentrationen	NNS	NN		OK/0.998247
of	anderer	IN	PIAT		OK/0.996210
other	anderer	JJ	PIAT		OK/0.999591
CYP3A4	CYP3A4-Substrate	NP	NN		OK/0.979545
substrates	CYP3A4-Substrate	NNS	NN		OK/0.968149
(	(	(	$(		OK/0.963618
mild	schwache	JJ	ADJA		OK/0.543005
,	,	,	$,		OK/0.674828
moderate	mäßige	JJ	ADJA		OK/0.800361
and	und	CC	KON		OK/0.975921
severe	starke	JJ	ADJA		OK/0.938867
)	)	)	$(		OK/0.973593
.	.	SENT	$.		OK/0.996906

# 0.326597
If	Sofern	IN	KOUS		OK/0.988818
heparin	Heparin	NN	NN		OK/0.994429
has	wurde	VHZ	VAFIN		OK/0.963900
been	wurde	VBN	VAFIN		OK/0.915543
administered	__unaligned__	VVN	__unaligned__		OK/0.835327
within	innerhalb	IN	APPR		OK/0.995616
4	4	CD	CARD		OK/0.995922
hours	Stunden	NNS	NN		OK/0.992398
before	vor	IN	APPR		OK/0.993150
the	der	DT	ART		OK/0.995687
start	Beginn	NN	NN		OK/0.868979
of	der	IN	ART		OK/0.982572
a	der	DT	ART		OK/0.987862
bleeding	Blutung	VVG	NN		OK/0.973219
episode	Blutung	NN	NN		OK/0.763275
,	,	,	$,		OK/0.843370
the	die	DT	ART		OK/0.952807
administration	Gabe	NN	NN		OK/0.933139
of	Gabe	IN	NN		OK/0.859022
protamine	Protamin	NN	NN		OK/0.758500
should	erwogen	MD	VVPP		OK/0.813187
be	erwogen	VB	VVPP		OK/0.932315
considered	erwogen	VVN	VVPP		OK/0.887490
.	.	SENT	$.		OK/0.995952

# 0.603110
In	Bei	IN	APPR		OK/0.930249
deterioration	Verschlechterung	NN	NN		OK/0.975969
of	Verschlechterung	IN	NN		OK/0.979149
cardiac	Herzfunktion	JJ	NN		OK/0.981630
function	__unaligned__	NN	__unaligned__		OK/0.975687
,	__unaligned__	,	__unaligned__		OK/0.795233
pioglitazone	Pioglitazon	NN	NN		OK/0.792877
should	muss	MD	VMFIN		OK/0.805298
be	abgesetzt	VB	VVPP		OK/0.912547
discontinued	abgesetzt	VVN	VVPP		OK/0.940723
.	.	SENT	$.		OK/0.995386

# 0.726865
The	Die	DT	ART		OK/0.997715
clinical	klinische	JJ	ADJA		OK/0.999222
relevance	Relevanz	NN	NN		OK/0.998460
of	dieser	IN	PDAT		OK/0.997161
these	dieser	DT	PDAT		OK/0.996640
findings	Ergebnisse	NNS	NN		OK/0.984240
has	nicht	VHZ	PTKNEG		OK/0.814394
not	nicht	RB	PTKNEG		OK/0.933999
been	nicht	VBN	PTKNEG		OK/0.904013
established	bekannt	VVN	ADJD		OK/0.985131
in	Patienten	IN	NN		OK/0.976292
patients	Patienten	NNS	NN		OK/0.998549
with	mit	IN	APPR		OK/0.997629
high	Bluthochdruck	JJ	NN		OK/0.999186
blood	Bluthochdruck	NN	NN		OK/0.999045
pressure	Bluthochdruck	NN	NN		OK/0.991457
.	.	SENT	$.		OK/0.999910

# 0.050320
15	15	CD	CARD		OK/0.985036
A	Bei	DT	APPR		OK/0.921959
negative	negative	JJ	ADJA		OK/0.976462
effect	Auswirkungen	NN	NN		OK/0.978359
of	__unaligned__	IN	__unaligned__		OK/0.983502
tacrolimus	__unaligned__	NN	__unaligned__		OK/0.893089
on	__unaligned__	IN	__unaligned__		OK/0.912726
male	männliche	JJ	ADJA		OK/0.976893
fertility	Fertilität	NN	NN		OK/0.985267
,	,	,	$,		OK/0.993669
such	wie	JJ	KOKOM		OK/0.792299
as	wie	IN	KOKOM		OK/0.884783
decreased	verminderte	VVN	ADJA		OK/0.744991
number	Anzahl	NN	NN		OK/0.824808
and	und	CC	KON		OK/0.992295
size	__unaligned__	NN	__unaligned__		OK/0.711187
of	__unaligned__	IN	__unaligned__		OK/0.616078
sperm	Spermien	NN	NN		OK/0.400468
motility	Motilität	NN	NN		OK/0.201348
have	,	VHP	$,		OK/0.175350
been	beobachtet	VBN	VVPP		OK/0.461925
observed	beobachtet	VVN	VVPP		OK/0.685376
.	.	SENT	$.		OK/0.991885

# 0.008534
Since	Da	IN	ADV		OK/0.977801
hinged	zweiwertige	VVN	ADJA		OK/0.601303
in	bilden	IN	VVINF		OK/0.496206
gastrointestinal	gastrointestinal	JJ	ADJD		OK/0.606135
and	mit	CC	APPR		OK/0.664491
oral	oralen	JJ	ADJA		OK/0.797243
tetracyclines	Tetrazyklinen	NNS	NN		OK/0.668284
and	und	CC	KON		OK/0.866793
quinolones	Chinolonen	NNS	NN		BAD/0.580825
may	können	MD	VMINF		BAD/0.661203
be	können	VB	VMINF		BAD/0.844081
of	__unaligned__	IN	__unaligned__		OK/0.466560
sufficient	__unaligned__	JJ	__unaligned__		OK/0.541221
and	und	CC	KON		OK/0.807784
may	verringern	MD	VVINF		BAD/0.675563
reduce	verringern	VV	VVINF		OK/0.781514
the	verringern	DT	VVINF		OK/0.950786
absorption	Resorption	NN	NN		OK/0.968999
is	wird	VBZ	VAFIN		OK/0.948415
impaired	Resorption	VVN	NN		OK/0.885654
,	,	,	$,		OK/0.991434
co-administration	gleichzeitige	NN	ADJA		OK/0.990737
of	gleichzeitige	IN	ADJA		OK/0.961888
strontium	Strontiumranelat	NN	NN		OK/0.755302
ranelate	Strontiumranelat	NN	NN		OK/0.652463
with	mit	IN	APPR		OK/0.975232
these	diesen	DT	PDAT		OK/0.992771
medicinal	Arzneimitteln	JJ	NN		OK/0.990092
products	Arzneimitteln	NNS	NN		OK/0.961891
is	__unaligned__	VBZ	__unaligned__		OK/0.814619
not	nicht	RB	PTKNEG		OK/0.868784
recommended	empfohlen	VVN	VVPP		OK/0.951882
.	.	SENT	$.		OK/0.996394

# 0.808813
The	Das	DT	ART		OK/0.995359
powder	Pulver	NN	NN		OK/0.998550
is	abgefüllt	VBZ	VVPP		OK/0.998837
presented	abgefüllt	VVN	VVPP		OK/0.991114
in	abgefüllt	IN	VVPP		OK/0.982174
3	3	CD	CARD		OK/0.999177
ml	ml	NN	NN		OK/0.996777
ampoules	Ampullen	NNS	NN		OK/0.894269
neutral	farblosem	JJ	ADJA		OK/0.919128
colourless	__unaligned__	JJ	__unaligned__		OK/0.976877
glass	Glas	NN	NN		OK/0.989696
(	(	(	$(		OK/0.994351
type	Typ	NN	NN		OK/0.995324
I	__unaligned__	NN	__unaligned__		OK/0.985156
)	)	)	$(		OK/0.995857
.	.	SENT	$.		OK/0.997173

# 0.144599
The	Der	DT	ART		OK/0.993119
mechanism	Mechanismus	NN	NN		OK/0.991895
of	der	IN	ART		OK/0.987556
the	der	DT	ART		OK/0.968910
hepatotoxicity	Lebertoxizität	NN	NN		OK/0.887558
is	nicht	VBZ	PTKNEG		OK/0.908009
not	nicht	RB	PTKNEG		OK/0.991624
fully	vollständig	RB	ADJD		OK/0.994065
studied	untersucht	VVN	VVPP		OK/0.933663
,	__unaligned__	,	__unaligned__		OK/0.640753
and	und	CC	KON		OK/0.879230
may	möglicherweise	MD	ADV		OK/0.793593
vary	variieren	VV	VVINF		OK/0.674755
with	variieren	IN	VVINF		OK/0.524757
the	den	DT	ART		OK/0.698335
Biovector	Endothelin-Antagonisten	NP	NN		OK/0.380157
.	.	SENT	$.		OK/0.993516

# 0.101982
It	Es	PP	PPER		OK/0.635907
should	sollte	MD	VMFIN		OK/0.656818
be	sollte	VB	VMFIN		OK/0.849591
Mindestintervall	Mindestintervall	NP	NN		OK/0.921973
8	8	CD	CARD		OK/0.996833
weeks	Wochen	NNS	NN		OK/0.992121
before	eingehalten	IN	VVPP		BAD/0.745700
commencement	eingehalten	NN	VVPP		BAD/0.857577
of	__unaligned__	IN	__unaligned__		BAD/0.911558
treatment	__unaligned__	NN	__unaligned__		BAD/0.998478
to	erreichen	TO	VVINF		BAD/0.980234
achieve	erreichen	VV	VVINF		BAD/0.956893
an	ausreichende	DT	ADJA		BAD/0.929595
adequate	ausreichende	JJ	ADJA		OK/0.490787
recovery	Erholung	NN	NN		OK/0.391850
of	der	IN	ART		OK/0.513774
adequate	Knochenmarkfunktion	JJ	NN		OK/0.730644
bone	Knochenmarkfunktion	NN	NN		OK/0.991952
marrow	Knochenmarkfunktion	NN	NN		OK/0.995981
function	Knochenmarkfunktion	NN	NN		OK/0.964900
.	.	SENT	$.		OK/0.998823

# 0.396463
disorders	Gastrointestinaltrakts	NNS	NN		OK/0.977890
:	:	:	$.		OK/0.879569
Gastrointestinal	Blähungen.	JJ	NN		OK/0.640474
disorders	__unaligned__	NNS	__unaligned__		OK/0.630596
:	__unaligned__	:	__unaligned__		OK/0.549076
eructation	Aufstoßen	NN	NN		OK/0.663169
,	,	,	$,		OK/0.913918
constipation	Verstopfung	NN	NN		OK/0.924289
,	Verstopfung	,	NN		OK/0.997190
acute	akute	JJ	ADJA		OK/0.998315
pancreatitis	Pankreatitis	NN	NN		OK/0.985854
(	siehe	(	VVIMP		OK/0.999806
see	siehe	VV	VVIMP		OK/0.999301
section	Abschnitt	NN	NN		OK/0.995038
4.4	4.4	CD	CARD		OK/0.992222
)	)	)	$(		OK/0.991912
.	.	SENT	$.		OK/0.995744

# 0.113340
If	Sollten	IN	VVFIN		OK/0.993338
blisters	Blasen	NNS	NN		OK/0.936988
may	sein	MD	VAINF		OK/0.968821
be	sein	VB	VAINF		OK/0.983512
present	__unaligned__	JJ	__unaligned__		OK/0.893517
,	,	,	$,		OK/0.915326
tippen	tippen	VV	VVFIN		OK/0.801724
slightly	leicht	RB	ADJD		OK/0.835022
with	mit	IN	APPR		OK/0.884547
your	Ihrem	PP$	PPOSAT		OK/0.935473
finger	Finger	NN	NN		OK/0.847727
until	bis	IN	KOUS		OK/0.836685
all	__unaligned__	PDT	__unaligned__		OK/0.741066
the	die	DT	ART		OK/0.851579
air	Luftblasen	NN	NN		OK/0.828287
bubbles	Luftblasen	NNS	NN		OK/0.975675
rise	aufsteigen	VVP	VVINF		OK/0.961279
to	__unaligned__	TO	__unaligned__		OK/0.936081
the	__unaligned__	DT	__unaligned__		OK/0.841310
top	__unaligned__	NN	__unaligned__		OK/0.410765
of	__unaligned__	IN	__unaligned__		OK/0.534329
the	__unaligned__	DT	__unaligned__		OK/0.846846
syringe	__unaligned__	NN	__unaligned__		OK/0.654050
.	.	SENT	$.		OK/0.991621

# 0.700818
It	Es	PP	NN		OK/0.988911
is	empfohlen	VBZ	VVPP		OK/0.993630
recommended	empfohlen	VVN	VVPP		OK/0.995510
that	dass	IN/that	KOUS		OK/0.991733
HIV	HIV-infizierte	NP	ADJA		OK/0.996334
infected	HIV-infizierte	JJ	ADJA		OK/0.990977
women	Frauen	NNS	NN		OK/0.986674
do	__unaligned__	VVP	__unaligned__		OK/0.865772
not	__unaligned__	RB	__unaligned__		OK/0.915687
breast-feed	stillen	VV	VVINF		OK/0.976281
their	ihre	PP$	PPOSAT		OK/0.998778
infants	Kinder	NNS	NN		OK/0.997595
under	Umständen	IN	NN		OK/0.988104
any	Umständen	DT	NN		OK/0.996792
circumstances	Umständen	NNS	NN		OK/0.994246
in	__unaligned__	IN	__unaligned__		OK/0.989388
order	,	NN	$,		OK/0.920042
to	sollen	TO	VMFIN		OK/0.996704
avoid	zu	VV	PTKZU		OK/0.997911
transmission	Übertragung	NN	NN		OK/0.999449
of	__unaligned__	IN	__unaligned__		OK/0.968906
HIV	HIV	NP	NE		OK/0.998670
.	.	SENT	$.		OK/0.999046

# 0.369590
81	81	CD	CARD		OK/0.994299
%	%	NN	NN		OK/0.989762
(	(	(	$(		OK/0.994824
30	30	CD	CARD		OK/0.996205
/	/	SYM	$(		OK/0.992281
37	37	CD	CARD		OK/0.924951
)	)	)	$(		OK/0.990357
in	bei	IN	APPR		OK/0.988536
invasive	invasiver	JJ	ADJA		OK/0.993534
candidiasis	Candidiasis	NN	NN		OK/0.987186
,	,	,	$,		OK/0.990169
50	50	CD	CARD		OK/0.997269
%	%	NN	NN		OK/0.996992
(	(	(	$(		OK/0.989735
5	5	CD	CARD		OK/0.994254
/	/	SYM	$(		OK/0.999558
10	10	CD	CARD		OK/0.995496
)	)	)	$(		OK/0.998814
in	bei	IN	APPR		OK/0.978757
invasive	invasiver	JJ	ADJA		OK/0.971672
aspergillosis	Aspergillose	NN	NN		OK/0.971707
,	__unaligned__	,	__unaligned__		OK/0.890751
and	und	CC	KON		OK/0.990587
100	100	CD	CARD		OK/0.990598
%	%	NN	NN		OK/0.974082
(	(	(	$(		OK/0.988608
1	1	CD	CARD		OK/0.997664
/	/	SYM	$(		OK/0.998909
1	1	CD	CARD		OK/0.995580
)	)	)	$(		OK/0.999011
in	bei	IN	APPR		OK/0.948296
esophageal	Candidiasis	JJ	NN		OK/0.813841
candidiasis	Candidiasis	NN	NN		OK/0.542371
.	.	SENT	$.		OK/0.990315

# 0.735326
There	Es	EX	NN		OK/0.971088
are	Es	VBP	NN		OK/0.966856
no	keine	DT	PIAT		OK/0.993365
apparent	offensichtlichen	JJ	ADJA		OK/0.868180
age-related	altersbezogenen	JJ	ADJA		OK/0.822456
effects	Wirkungen	NNS	NN		OK/0.979836
on	Wirkungen	IN	NN		OK/0.997999
the	die	DT	ART		OK/0.999383
pharmacokinetics	Pharmakokinetik	NN	NN		OK/0.995783
of	Pharmakokinetik	IN	NN		OK/0.997183
ViraferonPeg	ViraferonPeg	NP	NN		OK/0.983265
.	.	SENT	$.		OK/0.998745

# 0.409009
The	Gepufferte	DT	NN		OK/0.836014
pharmaceutical	Darreichungsform	JJ	NE		OK/0.612861
form	Darreichungsform	NN	NE		OK/0.764027
of	__unaligned__	IN	__unaligned__		OK/0.927724
indinavir	Indinavir	NN	NN		OK/0.948189
and	und	CC	KON		OK/0.996573
didanosine	Didanosin	NN	NN		OK/0.970240
has	wurde	VHZ	VAFIN		OK/0.866282
not	nicht	RB	PTKNEG		OK/0.916023
been	wurde	VBN	VAFIN		OK/0.850449
performed	durchgeführt	VVN	VVPP		OK/0.853196
.	.	SENT	$.		OK/0.998870

# 0.152390
Potential	Mögliche	JJ	ADJA		OK/0.992164
interactions	Wechselwirkungen	NNS	NN		OK/0.992924
affecting	Mögliche	VVG	ADJA		OK/0.939414
olanzapine	Olanzapin	NN	NN		OK/0.996131
Since	Da	IN	ADV		OK/0.982868
olanzapine	Olanzapin	NN	NN		OK/0.983824
is	__unaligned__	VBZ	__unaligned__		OK/0.988852
metabolised	metabolisiert	VVN	ADJD		OK/0.998728
by	metabolisiert	IN	ADJD		OK/0.978697
CYP1A2	1A2	NP	NN		OK/0.974426
,	,	,	$,		OK/0.996048
substances	__unaligned__	NNS	__unaligned__		OK/0.993183
that	__unaligned__	WDT	__unaligned__		OK/0.914343
may	beeinflussen	MD	VVFIN		OK/0.825978
affect	beeinflussen	VV	VVFIN		OK/0.518991
or	__unaligned__	CC	__unaligned__		BAD/0.833059
inhibit	__unaligned__	VV	__unaligned__		BAD/0.905835
this	dieses	DT	PDAT		OK/0.600942
isoenzyme	Isoenzym	NN	NN		OK/0.765547
may	möglicherweise	MD	ADV		OK/0.901465
inhibit	hemmen	VV	VVFIN		OK/0.971910
the	die	DT	ART		OK/0.998673
pharmacokinetics	Pharmakokinetik	NN	NN		OK/0.987233
of	Pharmakokinetik	IN	NN		OK/0.995558
olanzapine	Olanzapin	NN	NE		OK/0.997657
.	.	SENT	$.		OK/0.999720

# 0.618784
The	Die	NP	ART		OK/0.996199
results	Ergebnisse	NNS	NN		OK/0.981733
showed	zeigten	VVD	VVFIN		OK/0.925263
that	zeigten	IN/that	VVFIN		OK/0.691054
the	der	DT	ART		OK/0.980115
active	Metabolit	JJ	NN		OK/0.962294
metabolite	Metabolit	NN	NN		OK/0.964257
is	aus	VBZ	APPR		OK/0.991463
losartan	Losartan	JJ	NE		OK/0.979160
in	in	IN	APPR		OK/0.998912
all	allen	DT	PIAT		OK/0.999013
age	Altersgruppen	NN	NN		OK/0.995206
groups	Altersgruppen	NNS	NN		OK/0.982571
.	.	SENT	$.		OK/0.998839

# 0.465521
In	Bei	IN	APPR		OK/0.941803
patients	Patienten	NNS	NN		OK/0.959017
with	mit	IN	APPR		OK/0.971979
grade	Grad	NN	NN		OK/0.767105
3	3	CD	CARD		OK/0.764906
or	oder	CC	KON		OK/0.917262
4	4	CD	CARD		OK/0.923557
diarrhoea	Diarrhöe	NN	NN		OK/0.876711
,	__unaligned__	,	__unaligned__		OK/0.972360
the	die	DT	ART		OK/0.990338
dose	Dosis	NN	NN		OK/0.993600
should	sollte	MD	VMFIN		OK/0.996978
be	sollte	VB	VMFIN		OK/0.990861
reduced	reduziert	VVN	VVPP		OK/0.985815
for	für	IN	APPR		OK/0.998664
subsequent	Behandlungszyklen	JJ	NN		OK/0.953371
courses	Behandlungszyklen	NNS	NN		OK/0.930513
0.4	0,4	CD	CARD		OK/0.964348
mg	mg	NN	NN		OK/0.979495
/	/	SYM	$(		OK/0.995649
m2	²	NN	ADJA		OK/0.961387
/	/	SYM	$(		OK/0.998958
day	Tag	NN	NN		OK/0.996158
(	(	(	$(		OK/0.999073
see	siehe	VV	VVIMP		OK/0.995588
section	Abschnitt	NN	NN		OK/0.985430
4.4	4.4	CD	CARD		OK/0.990319
)	)	)	$(		OK/0.991545
.	.	SENT	$.		OK/0.995703

# 0.645992
SonoVue	SonoVue	NP	NN		OK/0.995188
should	darf	MD	VMFIN		OK/0.976957
not	darf	RB	VMFIN		OK/0.977561
be	darf	VB	VMFIN		OK/0.998941
used	darf	VVN	VMFIN		OK/0.996412
in	bei	IN	APPR		OK/0.988086
people	Patienten	NNS	NN		OK/0.998030
who	die	WP	PRELS		OK/0.998316
may	möglicherweise	MD	ADV		OK/0.998415
be	überempfindlich	VB	ADJD		OK/0.999781
hypersensitive	überempfindlich	JJ	ADJD		OK/0.997903
(	(	(	$(		OK/0.999595
allergic	allergisch	JJ	ADJD		OK/0.999271
)	)	)	$(		OK/0.999948
to	gegen	TO	APPR		OK/0.991102
sulphur	Schwefelhexafluorid	NN	NN		OK/0.874378
hexafluoride	Schwefelhexafluorid	NN	NN		OK/0.744139
or	oder	CC	KON		OK/0.996278
to	oder	TO	KON		OK/0.960338
any	Bestandteile	DT	NN		OK/0.995074
of	Bestandteile	IN	NN		OK/0.998026
the	Bestandteile	DT	NN		OK/0.994895
other	anderen	JJ	PIAT		OK/0.996274
ingredients	Bestandteile	NNS	NN		OK/0.994041
.	.	SENT	$.		OK/0.999732

# 0.413635
The	Die	DT	ART		OK/0.983142
period	Wachstumsphase	NN	NN		OK/0.576842
depends	hängt	VVZ	VVFIN		OK/0.965017
on	hängt	IN	VVFIN		OK/0.988997
the	Wachstumsphase	DT	NN		OK/0.944382
breed	Wachstumsphase	NN	NN		OK/0.807368
dog	Hundes	NN	NN		OK/0.761902
.	.	SENT	$.		OK/0.991470

# 0.928141
Tasigna	Tasigna	NP	NE		OK/0.991612
should	darf	MD	VMFIN		OK/0.986144
not	nicht	RB	PTKNEG		OK/0.997881
be	darf	VB	VMFIN		OK/0.998214
used	angewendet	VVN	VVPP		OK/0.999632
in	bei	IN	APPR		OK/0.996888
people	Patienten	NNS	NN		OK/0.998708
who	die	WP	PRELS		OK/0.998353
may	möglicherweise	MD	ADV		OK/0.998417
be	überempfindlich	VB	ADJD		OK/0.999781
hypersensitive	überempfindlich	JJ	ADJD		OK/0.997903
(	(	(	$(		OK/0.999594
allergic	allergisch	JJ	ADJD		OK/0.999212
)	)	)	$(		OK/0.999942
to	auf	TO	APPR		OK/0.985661
nilotinib	Nilotinib	NN	NE		OK/0.993556
or	oder	CC	KON		OK/0.997858
any	Bestandteile	DT	NN		OK/0.996081
of	Bestandteile	IN	NN		OK/0.997180
the	Bestandteile	DT	NN		OK/0.994769
other	anderen	JJ	PIAT		OK/0.996261
ingredients	Bestandteile	NNS	NN		OK/0.994039
.	.	SENT	$.		OK/0.999732

# 0.052743
The	Die	DT	ART		OK/0.996213
two	beiden	CD	PIAT		OK/0.994649
regimens	__unaligned__	NNS	__unaligned__		OK/0.849669
resulted	__unaligned__	VVN	__unaligned__		OK/0.730975
in	der	IN	ART		OK/0.981986
exposures	Exposition	NNS	NN		OK/0.962565
on	Tag	IN	NN		OK/0.976636
Day	Tag	NP	NN		OK/0.988143
3	3	CD	CARD		OK/0.980979
which	die	WDT	PRELS		OK/0.983301
is	ungefähr	VBZ	ADJD		OK/0.924745
approximately	ungefähr	RB	ADJD		OK/0.992758
1.5	1,5-	CD	CARD		OK/0.933762
and	und	CC	KON		OK/0.985897
3X	__unaligned__	JJ	__unaligned__		OK/0.959750
times	höher	NNS	ADJD		OK/0.942743
higher	höher	JJR	ADJD		OK/0.996595
than	höher	IN	ADJD		OK/0.998285
those	diejenigen	DT	PDS		OK/0.984289
reported	__unaligned__	VVN	__unaligned__		OK/0.968578
with	mit	IN	APPR		OK/0.983134
recommended	empfohlenen	VVN	ADJA		OK/0.969058
once	einmal	IN	ADV		OK/0.859455
daily	einmal	JJ	ADV		OK/0.852831
or	oder	CC	KON		OK/0.996022
twice	zweimal	RB	ADV		OK/0.990115
daily	täglichen	JJ	ADJA		OK/0.984270
with	__unaligned__	IN	__unaligned__		OK/0.974469
lopinavir	Lopinavir	NP	NN		OK/0.994165
/	/	SYM	$(		OK/0.997426
ritonavir	Ritonavir	NN	NE		OK/0.969810
dose	Dosis	NN	NN		OK/0.919536
in	bei	IN	APPR		OK/0.672736
steady	konstanten	JJ	ADJA		OK/0.479379
Wirkstoffspiegeln	Wirkstoffspiegeln	NP	NN		OK/0.461317
seen	beobachtet	VVN	VVPP		OK/0.418421
with	__unaligned__	IN	__unaligned__		BAD/0.861331
either	__unaligned__	DT	__unaligned__		BAD/0.876745
active	__unaligned__	JJ	__unaligned__		OK/0.770542
substance	__unaligned__	NN	__unaligned__		OK/0.839153
alone	__unaligned__	RB	__unaligned__		OK/0.849347
.	.	SENT	$.		OK/0.994982

# 0.974440
What	Was	WP	PIS		OK/0.999359
is	Was	VBZ	PIS		OK/0.996345
Viracept	Viracept	JJ	NN		OK/0.977191
?	?	SENT	$.		OK/0.999649

# 0.532448
Renal	Nierenfunktion	NP	NN		OK/0.991356
function	Nierenfunktion	VVP	NN		OK/0.970052
It	Es	PP	PPER		OK/0.967230
is	bekannt	VBZ	ADJD		OK/0.985920
known	bekannt	VVN	ADJD		OK/0.985429
that	dass	IN/that	KOUS		OK/0.985294
metformin	Metformin	NN	NE		OK/0.968093
and	und	CC	KON		OK/0.971849
sitagliptin	Sitagliptin	NN	NE		OK/0.792346
hauptäschlich	hauptäschlich	NN	ADJD		OK/0.621128
excreted	ausgeschieden	VVN	VVPP		OK/0.959655
through	ausgeschieden	IN	VVPP		OK/0.992136
the	__unaligned__	DT	__unaligned__		OK/0.999694
kidneys	__unaligned__	NNS	__unaligned__		OK/0.980560
.	.	SENT	$.		OK/0.999769

# 0.079826
Data	Daten	NP	NN		OK/0.923212
from	Daten	IN	NN		OK/0.931124
elderly	älteren	JJ	ADJA		OK/0.994723
patients	Patienten	NNS	NN		OK/0.995371
treated	Patienten	VVN	NN		OK/0.961092
with	mit	IN	APPR		OK/0.993233
ViraferonPeg	ViraferonPeg	NP	NN		OK/0.665007
treated	behandelt	VVN	VVPP		OK/0.404104
with	behandelt	IN	VVPP		OK/0.380432
no	keinen	DT	PIAT		OK/0.945451
evidence	Hinweis	NN	NN		OK/0.973636
that	dass	IN/that	KOUS		OK/0.983334
no	__unaligned__	DT	__unaligned__		BAD/0.582387
alteration	eine	NN	ART		BAD/0.857895
in	__unaligned__	IN	__unaligned__		BAD/0.876872
ViraferonPeg	ViraferonPeg-	NP	TRUNC		BAD/0.732029
dose	Dosis	NN	NN		OK/0.824692
is	notwendig	VBZ	ADJD		OK/0.821658
necessary	notwendig	JJ	ADJD		OK/0.892296
based	Alters	VVN	NN		OK/0.963294
on	Alters	IN	NN		OK/0.995408
age	Alters	NN	NN		OK/0.991162
(	siehe	(	VVIMP		OK/0.997545
see	siehe	VV	VVIMP		OK/0.995392
section	Abschnitt	NN	NN		OK/0.999024
5.2	5.2	CD	CARD		OK/0.999798
)	)	)	$(		OK/0.998973
.	.	SENT	$.		OK/0.999067

# 0.159406
,	,	,	$,		BAD/0.855045
polyoxyl	Macrogolglycerolricinoleat	NN	NN		BAD/0.853020
35	Macrogolglycerolricinoleat	CD	NN		BAD/0.725229
castor	Macrogolglycerolricinoleat	NN	NN		BAD/0.706691
oil	Macrogolglycerolricinoleat	NN	NN		BAD/0.567307
,	__unaligned__	,	__unaligned__		BAD/0.383958
citric	Citronensäure	JJ	NN		OK/0.911642
acid	Citronensäure	NN	NN		OK/0.987478
(	(	(	$(		OK/0.998194
anhydrous	wasserfrei	JJ	ADJD		OK/0.983158
)	)	)	$(		OK/0.994045
and	und	CC	KON		OK/0.997446
ethanol	Ethanol	NN	NN		OK/0.760209
(	(	(	$(		OK/0.985272
approximately	ca.	RB	ADV		OK/0.947160
392	392	CD	CARD		OK/0.955304
mg	mg	NN	NN		OK/0.992672
/	/	SYM	$(		OK/0.995029
ml	ml	NN	NN		OK/0.999083
)	)	)	$(		OK/0.997017
.	.	SENT	$.		OK/0.997263

# 0.034567
60	60	CD	CARD		OK/0.994339
liver	Leberfunktionstest	NN	NN		OK/0.984394
function	Leberfunktionstest	NN	NN		OK/0.970141
test	Leberfunktionstest	NN	NN		OK/0.919761
,	,	,	$,		OK/0.977863
liver	einer	NN	ART		OK/0.860546
function	__unaligned__	NN	__unaligned__		OK/0.968049
test	__unaligned__	NN	__unaligned__		OK/0.985012
abnormalities	__unaligned__	NNS	__unaligned__		OK/0.937286
suggestive	__unaligned__	JJ	__unaligned__		OK/0.993688
of	Anzeichen	IN	NN		OK/0.998872
hepatic	Leberfunktionsstörung	JJ	NN		OK/0.994048
impairment	Leberfunktionsstörung	NN	NN		OK/0.963576
,	__unaligned__	,	__unaligned__		OK/0.446764
which	__unaligned__	WDT	__unaligned__		OK/0.528539
may	können	MD	VMFIN		OK/0.899486
be	können	VB	VMFIN		OK/0.886703
accompanied	begleitet	VVN	VVPP		OK/0.942475
by	begleitet	IN	VVPP		OK/0.893706
morphologic	morphologischen	JJ	ADJA		OK/0.829583
changes	Veränderungen	NNS	NN		OK/0.970866
in	Veränderungen	IN	NN		OK/0.991722
liver	Leberbiopsie	NN	NN		OK/0.901426
biopsy	Leberbiopsie	NN	NN		OK/0.786913
.	.	SENT	$.		OK/0.871705
which	__unaligned__	WDT	__unaligned__		OK/0.888426
may	möglicherweise	MD	ADV		OK/0.740669
be	möglicherweise	VB	ADV		OK/0.490958
lebensbedrohliches	lebensbedrohliches	NNS	ADJA		BAD/0.903870
ovarian	Überstimulationssyndrom	JJ	NN		OK/0.982940
hyperstimulation	Überstimulationssyndrom	NN	NN		OK/0.998190
syndrome	Überstimulationssyndrom	NN	NN		OK/0.987646
may	auftreten	MD	VVINF		OK/0.561663
occur	auftreten	VV	VVINF		OK/0.560145
.	.	SENT	$.		OK/0.995558

# 0.260598
Growth	Wachstumshormon	NP	NN		OK/0.997958
hormone	Wachstumshormon	NN	NN		OK/0.998452
increases	__unaligned__	VVZ	__unaligned__		OK/0.992387
the	die	DT	ART		OK/0.997406
workload	vergrößert	NN	VVFIN		OK/0.613064
on	__unaligned__	IN	__unaligned__		OK/0.706726
the	__unaligned__	DT	__unaligned__		OK/0.948098
organs	Organe	NNS	NN		OK/0.867550
,	,	,	$,		OK/0.988656
including	einschließlich	VVG	APPR		OK/0.999589
the	__unaligned__	DT	__unaligned__		OK/0.994788
kidneys	Nieren	NNS	NN		OK/0.945572
,	__unaligned__	,	__unaligned__		OK/0.951750
and	und	CC	KON		OK/0.982596
to	erhöht	TO	VVFIN		OK/0.654453
increase	erhöht	VV	VVFIN		OK/0.631610
the	__unaligned__	DT	__unaligned__		OK/0.791028
quantity	Menge	NN	NN		OK/0.953428
of	__unaligned__	IN	__unaligned__		OK/0.986637
red	roten	JJ	ADJA		OK/0.994411
blood	roten	NN	ADJA		OK/0.994174
cells	roten	NNS	ADJA		OK/0.990372
.	.	SENT	$.		OK/0.999798

# 0.307621
Toremifene	Toremifen	NP	NN		OK/0.963182
has	keinen	VHZ	PIAT		OK/0.994016
no	keinen	DT	PIAT		OK/0.976078
influence	Einfluß	NN	NN		OK/0.953188
on	auf	IN	APPR		OK/0.961296
the	auf	DT	APPR		OK/0.996726
ability	Verkehrstüchtigkeit	NN	NN		OK/0.991183
to	__unaligned__	TO	__unaligned__		OK/0.982689
drive	und	VV	KON		OK/0.820997
or	__unaligned__	CC	__unaligned__		OK/0.462116
to	__unaligned__	TO	__unaligned__		OK/0.404419
use	Maschinen	VV	NN		OK/0.905693
machines	Bedienen	NNS	NN		OK/0.960933
.	.	SENT	$.		OK/0.999366

# 0.772796
The	Die	NP	ART		OK/0.981919
recommended	empfohlene	VVD	ADJA		OK/0.993537
starting	Initialdosis	VVG	NN		OK/0.997191
dose	Initialdosis	NN	NN		OK/0.998076
is	liegt	VBZ	VVFIN		OK/0.981500
0.4	0,4-0,8	CD	CARD		OK/0.962028
-	0,4-0,8	:	CARD		OK/0.875022
0.8	0,4-0,8	CD	CARD		OK/0.937665
g	g	NN	NN		OK/0.972578
/	/	SYM	$(		OK/0.999126
kg	kg	NN	NN		OK/0.999643
followed	gefolgt	VVN	ADJD		OK/0.986891
by	gefolgt	IN	ADJD		OK/0.991174
at	mindestens	IN	ADV		OK/0.999603
least	mindestens	JJS	ADV		OK/0.998959
0.2	0,2	CD	CARD		OK/0.991405
g	g	NN	NN		OK/0.994362
/	/	SYM	$(		OK/0.995835
kg	kg	NN	NN		OK/0.998159
every	alle	DT	PIAT		OK/0.994827
three	drei	CD	CARD		OK/0.998388
weeks	Wochen	NNS	NN		OK/0.992084
.	.	SENT	$.		OK/0.999296

# 0.115597
In	In	IN	APPR		OK/0.984229
exceptional	Ausnahmefällen	JJ	NN		OK/0.956363
cases	Ausnahmefällen	NNS	NN		OK/0.946373
,	,	,	$,		OK/0.877344
adults	Erwachsene	NNS	NN		OK/0.875406
may	können	MD	VMFIN		OK/0.852641
be	__unaligned__	VB	__unaligned__		OK/0.849053
a	raschen	DT	ADJA		OK/0.989220
rapid	raschen	JJ	ADJA		OK/0.993084
protection	einen	NN	ART		OK/0.983469
Antritt	Antritt	NP	NN		OK/0.802494
a	einer	DT	ART		OK/0.908958
travelling	Reise	VVG	NN		OK/0.710316
,	,	,	$,		OK/0.858373
the	__unaligned__	DT	__unaligned__		BAD/0.858737
need	benötigen	NN	VVFIN		BAD/0.902244
to	__unaligned__	TO	__unaligned__		BAD/0.676481
receive	erhalten	VV	VVPP		BAD/0.551500
three	drei	CD	CARD		OK/0.838832
injections	Injektionen	NNS	NN		OK/0.870272
over	von	IN	APPR		OK/0.772542
three	drei	CD	CARD		OK/0.994414
weeks	Wochen	NNS	NN		OK/0.990963
.	.	SENT	$.		OK/0.999274

# 0.979871
29	29.	CD	ADJA		OK/0.992199
August	August	NP	NN		OK/0.993587
1996	1996	CD	CARD		OK/0.996586
Date	Datum	NN	NN		OK/0.999440
of	Datum	IN	NN		OK/0.999974
last	Datum	JJ	NN		OK/0.997964
renewal	Datum	NN	NN		OK/0.998369
:	:	:	$.		OK/0.999566

# 0.371138
The	Die	DT	ART		OK/0.971260
Targretin-Dosis	Targretin-Dosis	NN	NN		BAD/0.629173
depends	hängt	VVZ	VVFIN		OK/0.962085
on	hängt	IN	VVFIN		OK/0.994356
the	der	DT	ART		OK/0.996973
patient	des	NN	ART		OK/0.995965
's	__unaligned__	POS	__unaligned__		OK/0.996947
body	Körperoberfläche	NN	NN		OK/0.981728
surface	__unaligned__	NN	__unaligned__		OK/0.897185
area	__unaligned__	NN	__unaligned__		OK/0.915223
in	in	IN	APPR		OK/0.969167
square	Quadratmetern	JJ	NN		OK/0.883772
meter	Quadratmetern	NN	NN		OK/0.800633
(	(	(	$(		OK/0.993371
m2	m2	NN	NE		OK/0.976809
)	)	)	$(		OK/0.985571
.	.	SENT	$.		OK/0.995319

# 0.028742
By	Bis	IN	APPR		OK/0.948877
day	Tag	NN	NN		OK/0.994675
60	60	CD	CARD		OK/0.977755
of	die	IN	ART		OK/0.917894
the	__unaligned__	DT	__unaligned__		OK/0.811383
CMD	CMD	NP	NN		BAD/0.749989
(	(	(	$(		BAD/0.469972
v	CMD	NN	NN		BAD/0.864577
)	CMD	)	NN		BAD/0.794214
could	konnte	MD	VMFIN		BAD/0.933919
not	konnte	RB	VMFIN		BAD/0.937584
be	konnte	VB	VMFIN		OK/0.330904
able	Einigung	JJ	NN		OK/0.459031
to	Einigung	TO	NN		OK/0.563193
reach	Einigung	VV	NN		OK/0.672719
an	Einigung	DT	NN		OK/0.817733
agreement	Einigung	NN	NN		OK/0.918965
in	dieser	IN	PDAT		OK/0.940892
this	dieser	DT	PDAT		OK/0.994502
matter	Angelegenheit	NN	NN		OK/0.959836
,	,	,	$,		OK/0.995400
since	da	IN	KOUS		OK/0.991538
France	Frankreich	NP	NE		OK/0.900737
and	und	CC	KON		OK/0.963001
Italy	Italien	NP	NE		OK/0.920011
have	an	VHP	APPR		OK/0.772525
concerns	Bedenken	NNS	NN		OK/0.729010
festhielten	festhielten	NNS	VVFIN		BAD/0.866584
.	.	SENT	$.		OK/0.987204

# 0.339309
M1	M1	NP	NE		OK/0.816029
and	und	CC	KON		OK/0.957330
M3	__unaligned__	NP	__unaligned__		OK/0.780325
have	haben	VHP	VAFIN		OK/0.903219
an	offenen	DT	ADJA		OK/0.968188
open	offenen	JJ	ADJA		OK/0.952499
Beta-Lactonring	Beta-Lactonring	NN	NN		OK/0.863607
and	und	CC	KON		OK/0.994280
activity	Aktivität	NN	NN		OK/0.970641
(	(	(	$(		OK/0.995393
1,000	1.000-	CD	CARD		OK/0.978908
to	1.000-	TO	CARD		OK/0.972542
vs.	bzw.	IN	KON		OK/0.785758
2.500-fach	2.500-fach	JJ	NN		OK/0.664902
)	)	)	$(		OK/0.930529
.	.	SENT	$.		OK/0.993292

# 0.868362
Treatment	Behandlung	NP	NN		OK/0.992255
of	Behandlung	IN	NN		OK/0.991263
stomach	Magengeschwüren	NN	NN		OK/0.996268
ulcers	Magengeschwüren	NNS	NN		OK/0.989576
The	Die	DT	ART		OK/0.997234
recommended	empfohlene	JJ	ADJA		OK/0.998374
dose	Dosierung	NN	NN		OK/0.994219
is	beträgt	VBZ	VVFIN		OK/0.989137
1	1	CD	CARD		OK/0.985300
capsule	Kapsel	NN	NN		OK/0.991675
once	einmal	IN	ADV		OK/0.999421
daily	täglich	JJ	ADJD		OK/0.999892
(	(	(	$(		OK/0.988429
equivalent	entsprechend	NN	ADJD		OK/0.979638
to	entsprechend	TO	ADJD		OK/0.993054
30	30	CD	CARD		OK/0.999190
mg	mg	NN	NN		OK/0.999068
lansoprazole	Lansoprazol	NN	NN		OK/0.994499
)	)	)	$(		OK/0.997437
for	für	IN	APPR		OK/0.972329
4	4	CD	CARD		OK/0.996162
weeks	Wochen	NNS	NN		OK/0.992295
.	.	SENT	$.		OK/0.999418

# 0.694304
Co-administration	gleichzeitige	NP	ADJA		OK/0.995932
of	gleichzeitige	IN	ADJA		OK/0.972170
Invirase	Invirase	NP	NN		OK/0.979813
/	/	SYM	$(		OK/0.970600
ritonavir	Ritonavir	NN	NE		OK/0.980799
with	und	IN	KON		OK/0.925433
midazolam	Midazolam	NN	NE		OK/0.932091
is	kontraindiziert	VBZ	ADJD		OK/0.911672
contraindicated	kontraindiziert	VVN	ADJD		OK/0.820772
(	(	(	$(		OK/0.998386
see	siehe	VV	VVIMP		OK/0.997164
section	Abschnitt	NN	NN		OK/0.987918
4.3	4.3	CD	CARD		OK/0.990370
)	)	)	$(		OK/0.999435
.	.	SENT	$.		OK/0.997513

# 0.268553
Ask	Fragen	NP	NN		OK/0.992033
your	Ihren	PP$	PPOSAT		OK/0.995034
doctor	Arzt	NN	NN		OK/0.952798
if	wenn	IN	KOUS		OK/0.991848
you	Sie	PP	PPER		OK/0.879854
are	Sie	VBP	PPER		BAD/0.650017
older	darüber	JJR	PAV		BAD/0.625357
Whilst	Zweifel	IN	NN		BAD/0.592630
,	,	,	$,		OK/0.860631
if	ob	IN	KOUS		OK/0.871205
any	__unaligned__	DT	__unaligned__		OK/0.995738
of	__unaligned__	IN	__unaligned__		OK/0.998832
these	zutrifft	DT	VVFIN		OK/0.995810
applies	zutrifft	VVZ	VVFIN		OK/0.997313
to	zutrifft	TO	VVFIN		OK/0.993059
you	Ihnen	PP	PPER		OK/0.973211
.	.	SENT	$.		OK/0.993622

# 0.490934
This	Dies	NP	PDS		OK/0.987543
corresponds	entspricht	VVZ	VVFIN		OK/0.966770
to	entspricht	TO	VVFIN		OK/0.940407
the	dem	DT	ART		OK/0.885671
contents	Inhalt	NNS	NN		OK/0.771163
of	einer	IN	ART		OK/0.982471
one	einer	CD	ART		OK/0.887868
syringe	Spritze	NN	NN		OK/0.956387
for	für	IN	APPR		OK/0.949222
a	mit	DT	APPR		OK/0.987318
500	500	CD	CARD		OK/0.998939
kg	kg	NN	NN		OK/0.991618
horse	Pferd	NN	NN		OK/0.786687
.	.	SENT	$.		OK/0.996025

# 0.880169
Each	Jede	DT	PIAT		OK/0.993925
Präparatstärke	Präparatstärke	NP	NN		OK/0.962507
is	ist	VBZ	VAFIN		OK/0.998129
available	Packungen	JJ	NN		OK/0.993203
in	Packungen	IN	NN		OK/0.991860
packs	Packungen	NNS	NN		OK/0.963272
of	Packungen	IN	NN		OK/0.986640
10	10	CD	CARD		OK/0.988904
,	,	,	$,		OK/0.997956
20	20	CD	CARD		OK/0.990905
and	und	CC	KON		OK/0.998065
100	100	CD	CARD		OK/0.994754
tablets	Tabletten	NNS	NN		OK/0.990984
.	.	SENT	$.		OK/0.999113

# 0.436499
From	Aus	IN	APPR		OK/0.995582
a	mikrobiologischer	DT	ADJA		OK/0.999466
microbiological	mikrobiologischer	JJ	ADJA		OK/0.996565
point	mikrobiologischer	NN	ADJA		OK/0.993971
of	Sicht	IN	NN		OK/0.998043
view	Sicht	NN	NN		OK/0.994483
,	Sicht	,	NN		OK/0.954645
the	Sicht	DT	NN		OK/0.984493
product	das	NN	ART		OK/0.993863
should	muss	MD	VMFIN		OK/0.990060
be	muss	VB	VMFIN		OK/0.996688
used	verwendet	VVN	VVPP		OK/0.867778
immediately	unverzüglich	RB	ADJD		OK/0.921306
,	,	,	$,		OK/0.947293
unless	sofern	IN	KOUS		OK/0.973076
2,6-diisopropylphenol	beim	JJ	APPRART		OK/0.903833
cannot	ausgeschlossen	MD	VVPP		OK/0.805223
exclude	__unaligned__	VV	__unaligned__		OK/0.758070
the	__unaligned__	DT	__unaligned__		OK/0.924693
risk	Risiko	NN	NN		OK/0.982897
of	Risiko	IN	NN		OK/0.952614
microbiological	mikrobiologischen	JJ	ADJA		OK/0.880172
care	Kontaminierung	NN	NN		OK/0.840560
.	.	SENT	$.		OK/0.998104

# 0.221388
Check	Sprechen	NP	VVFIN		OK/0.842474
,	__unaligned__	,	__unaligned__		OK/0.754923
if	Bedarf	IN	NN		OK/0.703627
needed	Bedarf	VVN	NN		OK/0.480452
,	__unaligned__	,	__unaligned__		OK/0.410394
check	__unaligned__	NN	__unaligned__		OK/0.316614
with	mit	IN	APPR		OK/0.762159
your	Ihrem	PP$	PPOSAT		OK/0.984766
doctor	Arzt	NN	NN		OK/0.997857
or	Apotheker	CC	NN		OK/0.997561
pharmacist	Apotheker	NN	NN		OK/0.999765
.	.	SENT	$.		OK/0.999872

# 0.970948
How	Wie	NP	KOKOM		OK/0.998767
does	wirkt	VVZ	VVFIN		OK/0.996503
Galvus	Galvus	NP	NE		OK/0.999210
work	__unaligned__	NN	__unaligned__		OK/0.975821
?	?	SENT	$.		OK/0.999866

# 0.014086
Pregabalin	Pregabalin	NP	NN		OK/0.861669
,	,	,	$,		OK/0.979671
the	der	DT	ART		OK/0.983419
active	Wirkstoff	JJ	NN		OK/0.992857
ingredient	Wirkstoff	NN	NN		OK/0.993221
in	in	IN	APPR		OK/0.995287
Lyrica	Lyrica	NP	NE		OK/0.728004
,	,	,	$,		BAD/0.623911
is	__unaligned__	VBZ	__unaligned__		BAD/0.746326
structurally	verwandt	RB	VVPP		BAD/0.597708
related	verwandt	VVN	VVPP		BAD/0.531889
to	__unaligned__	TO	__unaligned__		BAD/0.617364
effects	von	NNS	APPR		BAD/0.667614
on	__unaligned__	IN	__unaligned__		BAD/0.576093
back	her	RB	APZR		OK/0.760535
to	Struktur	TO	NN		OK/0.815018
identical	__unaligned__	JJ	__unaligned__		OK/0.858985
with	mit	IN	APPR		OK/0.976062
the	__unaligned__	DT	__unaligned__		OK/0.983811
body	körpereigenen	NN	ADJA		OK/0.893455
's	körpereigenen	POS	ADJA		OK/0.905244
own	körpereigenen	JJ	ADJA		OK/0.876697
the	__unaligned__	DT	__unaligned__		OK/0.846133
neurotransmitter	Neurotransmitter	NN	NN		OK/0.738980
GABA	GABA	NP	NE		OK/0.828264
(	(	(	$(		OK/0.874932
gamma-	Gamma-Aminobuttersäure	NN	NN		OK/0.626805
aminobutyric	__unaligned__	NN	__unaligned__		OK/0.580678
acid	__unaligned__	NN	__unaligned__		OK/0.504996
)	)	)	$(		OK/0.975210
,	,	,	$,		OK/0.997606
however	jedoch	RB	ADV		OK/0.973652
,	jedoch	,	ADV		OK/0.994436
shows	zeigt	VVZ	VVFIN		OK/0.931296
fully	völlig	RB	ADJD		OK/0.958067
other	andere	JJ	PIS		OK/0.788558
biologic	biologische	JJ	ADJA		OK/0.858640
effects	Wirkungen	NNS	NN		OK/0.953869
.	.	SENT	$.		OK/0.997111

# 0.108003
If	Wenn	IN	KOUS		OK/0.998076
you	Sie	PP	PPER		OK/0.995395
usemore	größere	VVZ	ADJA		OK/0.981329
Nifedipine	Nifedipine	NP	ADJA		OK/0.927681
Pharmamatch	Pharmamatch	NP	NN		OK/0.990159
retard	retard	VV	NE		OK/0.678105
tablets	__unaligned__	NNS	__unaligned__		OK/0.985029
than	als	IN	KOUS		OK/0.993348
you	Sie	PP	PPER		OK/0.989750
should	sollten	MD	VMFIN		OK/0.954145
If	Wenn	IN	KOUS		OK/0.995727
you	Sie	PP	PPER		OK/0.995065
usemore	größere	VVZ	ADJA		OK/0.981202
Nifedipine	Nifedipine	NP	ADJA		OK/0.927579
Pharmamatch	Pharmamatch	NP	NN		OK/0.990119
retard	retard	VV	NE		OK/0.676978
tablets	__unaligned__	NNS	__unaligned__		OK/0.983253
than	als	IN	KOUS		OK/0.987735
you	Sie	PP	PPER		OK/0.952846
were	__unaligned__	VBD	__unaligned__		OK/0.777510
told	__unaligned__	VVN	__unaligned__		OK/0.551018
to	__unaligned__	TO	__unaligned__		OK/0.357915
,	,	,	$,		OK/0.587627
contact	__unaligned__	VV	__unaligned__		OK/0.653772
your	Arzt	PP$	NN		OK/0.972503
doctor	Ihren	NN	PPOSAT		OK/0.998818
or	Apotheker	CC	NN		OK/0.999632
pharmacist	Apotheker	NN	NN		OK/0.999644
immediately	sofort	RB	ADV		OK/0.997957
.	.	SENT	$.		OK/0.998864

# 0.891645
Ziagen	Ziagen	NP	NN		OK/0.982332
should	sollte	MD	VMFIN		OK/0.998954
not	nicht	RB	PTKNEG		OK/0.995184
be	sollte	VB	VMFIN		OK/0.978572
given	verabreicht	VVN	VVPP		OK/0.961983
to	verabreicht	TO	VVPP		OK/0.979581
patients	Patienten	NNS	NN		OK/0.998372
with	mit	IN	APPR		OK/0.996452
endstage	Endstadium	JJ	NN		OK/0.984238
renal	Endstadium	JJ	NN		OK/0.996903
disease	Endstadium	NN	NN		OK/0.996095
(	siehe	(	VVIMP		OK/0.995138
see	siehe	VV	VVIMP		OK/0.997815
section	Abschnitt	NN	NN		OK/0.999096
5.2	5.2	CD	CARD		OK/0.999798
)	)	)	$(		OK/0.998973
.	.	SENT	$.		OK/0.999067

# 0.047546
If	Falls	IN	NN		OK/0.993877
the	die	DT	ART		OK/0.989846
incidence	__unaligned__	NN	__unaligned__		OK/0.974560
of	der	IN	ART		OK/0.996446
elevations	Erhöhung	NNS	NN		OK/0.960077
of	der	IN	ART		OK/0.993717
ALT	ALT	NP	ADJA		OK/0.982853
(	(	(	$(		OK/0.990415
SGPT	SGPT	NP	NN		OK/0.938442
)	)	)	$(		OK/0.996114
values	Werte	NNS	NN		OK/0.961951
>	über	SYM	APPR		BAD/0.960654
2	2fachen	CD	NN		BAD/0.661811
times	__unaligned__	NNS	__unaligned__		BAD/0.558452
the	__unaligned__	DT	__unaligned__		OK/0.784820
ULN	oberen	NP	ADJA		OK/0.726945
,	__unaligned__	,	__unaligned__		OK/0.724219
transaminase	__unaligned__	NN	__unaligned__		OK/0.703145
levels	Normwerte	NNS	NN		OK/0.776849
persistiert	persistiert	NN	VVFIN		OK/0.794322
or	oder	CC	KON		OK/0.996282
greater	mehr	JJR	ADV		OK/0.996857
than	mehr	IN	ADV		OK/0.973490
3	3fache	CD	ADJA		OK/0.980452
times	__unaligned__	NNS	__unaligned__		OK/0.994470
upper	__unaligned__	JJ	__unaligned__		OK/0.990997
limit	__unaligned__	NN	__unaligned__		OK/0.981735
of	__unaligned__	IN	__unaligned__		OK/0.713445
normal	Normgrenze	JJ	NN		OK/0.508417
,	,	,	$,		OK/0.486320
must	muss	MD	VMFIN		OK/0.683335
be	muss	VB	VMFIN		OK/0.950114
discontinued	abgesetzt	VVN	VVPP		OK/0.939023
and	und	CC	KON		OK/0.985220
leflunomide	Leflunomid	NN	NN		OK/0.980392
washout	Auswaschmaßnahmen	NNS	NN		OK/0.955057
procedure	Auswaschmaßnahmen	NN	NN		OK/0.917321
initiated	eingeleitet	VVD	VVPP		OK/0.773236
.	.	SENT	$.		OK/0.999631

# 0.384680
In	In	IN	APPR		OK/0.998677
some	einigen	DT	PIAT		OK/0.998553
cases	Fällen	NNS	NN		OK/0.997483
,	Fällen	,	NN		OK/0.895942
and	und	CC	KON		OK/0.997559
especially	insbesondere	RB	ADV		OK/0.998267
in	bei	IN	APPR		OK/0.982392
younger	jüngeren	JJR	ADJA		OK/0.995962
patients	Patienten	NNS	NN		OK/0.994023
,	__unaligned__	,	__unaligned__		OK/0.842300
it	es	PP	PPER		OK/0.950229
is	es	VBZ	PPER		OK/0.942663
necessary	erforderlich	JJ	ADJD		OK/0.975228
to	__unaligned__	TO	__unaligned__		OK/0.944290
administer	zu	VV	PTKZU		OK/0.644695
the	die	DT	ART		OK/0.864965
doses	Dosen	NNS	NN		OK/0.982975
more	kürzeren	RBR	ADJA		OK/0.984698
frequent	__unaligned__	JJ	__unaligned__		OK/0.949288
or	oder	CC	KON		OK/0.968803
higher	höheren	JJR	ADJA		OK/0.965838
amounts	Mengen	NNS	NN		OK/0.920454
.	.	SENT	$.		OK/0.989098

# 0.361057
A	Insgesamt	DT	ADV		OK/0.827056
total	Insgesamt	NN	ADV		OK/0.905957
of	__unaligned__	IN	__unaligned__		OK/0.857813
716	716	CD	CARD		OK/0.608848
patients	Patienten	NNS	NN		OK/0.926983
in	in	IN	APPR		OK/0.987781
this	diese	DT	PDAT		OK/0.953985
study	Studie	NN	NN		OK/0.994285
(	(	(	$(		OK/0.991403
sham	Scheininjektion	NN	NN		OK/0.954650
238	238	CD	CARD		OK/0.976260
;	;	:	$.		OK/0.999327
Lucentis	Lucentis	NP	NN		OK/0.997488
0.3	0,3	CD	CARD		OK/0.986519
mg	mg	NN	NN		OK/0.998568
,	__unaligned__	,	__unaligned__		OK/0.914148
238	238	CD	CARD		OK/0.965061
;	__unaligned__	:	__unaligned__		OK/0.982827
Lucentis	Lucentis	NP	NN		OK/0.997831
0.5	0,5	CD	CARD		OK/0.978447
mg	mg	NN	NN		OK/0.999234
,	__unaligned__	,	__unaligned__		OK/0.922970
240	240	CD	CARD		OK/0.937938
)	)	)	$(		OK/0.986447
.	.	SENT	$.		OK/0.998290

# 0.082087
Common	Häufig	NP	ADJD		OK/0.967188
reports	über	VVZ	APPR		OK/0.998528
of	__unaligned__	IN	__unaligned__		OK/0.998764
redness	Rötung	NN	NN		OK/0.959386
and	und	CC	KON		OK/0.998616
/	/	SYM	$(		OK/0.997223
or	oder	CC	KON		OK/0.984543
induration	Verhärtung	NN	NN		OK/0.684007
and	bzw.	CC	KON		OK/0.781805
swelling	Schwellung	NN	NN		OK/0.962636
/	/	SYM	$(		OK/0.970457
pain	Schmerzen	NN	NN		OK/0.997068
at	Injektionsstelle	IN	NN		OK/0.992467
the	der	DT	ART		OK/0.998409
site	Injektionsstelle	NN	NN		OK/0.971736
of	der	IN	ART		OK/0.997323
injection	Injektionsstelle	NN	NN		OK/0.998153
,	,	,	$,		OK/0.994290
fever	Fieber	NN	NN		OK/0.985714
equal	__unaligned__	JJ	__unaligned__		OK/0.847483
to	__unaligned__	TO	__unaligned__		OK/0.875572
or	__unaligned__	CC	__unaligned__		OK/0.727224
greater	__unaligned__	JJR	__unaligned__		OK/0.889200
than	von	IN	APPR		OK/0.803446
38	38	CD	CARD		OK/0.732014
°	°	SYM	NN		OK/0.813368
C	°	NP	NN		OK/0.818862
or	oder	CC	KON		OK/0.914726
higher	höher	JJR	ADJD		OK/0.723897
,	Reizbarkeit	,	NN		OK/0.919868
irritability	Reizbarkeit	NN	NN		OK/0.993314
,	Reizbarkeit	,	NN		OK/0.998795
somnolence	__unaligned__	NN	__unaligned__		OK/0.994173
(	__unaligned__	(	__unaligned__		OK/0.973357
sleepiness	Schläfrigkeit	NN	NN		OK/0.978137
)	__unaligned__	)	__unaligned__		OK/0.966011
,	,	,	$,		OK/0.992331
loss	Appetitverlust	NN	NN		OK/0.996795
of	Appetitverlust	IN	NN		OK/0.987659
appetite	Appetitverlust	NN	NN		OK/0.923999
,	,	,	$,		OK/0.977101
sleeplessness	Schlaflosigkeit	NN	NN		OK/0.860343
,	Schlaflosigkeit	,	NN		OK/0.798380
diarrhoea	Durchfall	NN	NN		OK/0.805707
and	und	CC	KON		OK/0.759993
vomiting	Erbrechen	NN	NN		OK/0.718438
have	berichtet	VHP	VVPP		OK/0.724761
been	berichtet	VBN	VVPP		OK/0.805182
reported	berichtet	VVN	VVPP		OK/0.820049
.	.	SENT	$.		OK/0.997212

# 0.236879
In	In	IN	APPR		OK/0.979631
Osteoporose-Behandlungsstudien	Osteoporose-Behandlungsstudien	NP	NN		OK/0.948644
OPTRUMA	OPTRUMA	NP	NN		OK/0.967598
was	war	VBD	VAFIN		OK/0.920679
seen	bei	VVN	APPR		OK/0.532475
in	bei	IN	APPR		OK/0.987069
patients	Patientinnen	NNS	NN		OK/0.937707
in	Patientinnen	IN	NN		OK/0.690724
the	__unaligned__	DT	__unaligned__		OK/0.682808
study	__unaligned__	NN	__unaligned__		OK/0.699401
,	__unaligned__	,	__unaligned__		BAD/0.918307
significantly	signifikant	RB	ADJD		BAD/0.892926
.	.	SENT	$.		OK/0.987720

# 0.093274
Based	Auf	VVN	APPR		OK/0.876331
on	Auf	IN	APPR		OK/0.984363
the	der	DT	ART		OK/0.994260
analysis	Analyse	NN	NN		OK/0.833166
of	Analyse	IN	NN		OK/0.722048
Leberbiopsien	Leberbiopsien	NP	NN		BAD/0.785543
,	,	,	$,		OK/0.936528
male	männlichen	JJ	ADJA		OK/0.985776
patients	Patienten	NNS	NN		OK/0.997555
with	mit	IN	APPR		OK/0.977624
Fabry	Fabry-Syndrom	NP	NN		OK/0.637112
Disease	Fabry-Syndrom	NP	NN		OK/0.575856
before	vor	IN	PTKVZ		OK/0.755878
and	und	CC	KON		OK/0.817721
after	nach	IN	APPR		OK/0.999103
administration	Anwendung	NN	NN		OK/0.994066
of	Anwendung	IN	NN		OK/0.985848
withdrawal	entnommen	NN	VVPP		OK/0.991044
,	,	,	$,		OK/0.980463
Gewebe-Halbwertzeit	Gewebe-Halbwertzeit	NP	NN		OK/0.892558
is	geschätzt	VBZ	VVPP		OK/0.988931
estimated	geschätzt	VVN	VVPP		OK/0.998644
to	geschätzt	TO	VVPP		OK/0.992780
be	geschätzt	VB	VVPP		OK/0.964896
greater	__unaligned__	JJR	__unaligned__		OK/0.944191
than	über	IN	APPR		OK/0.928707
24	24	CD	CARD		OK/0.947042
hours	Stunden	NNS	NN		OK/0.979389
,	,	,	$,		OK/0.921415
and	und	CC	KON		OK/0.990979
the	die	DT	ART		OK/0.993881
hepatic	hepatische	JJ	ADJA		OK/0.973334
uptake	__unaligned__	NN	__unaligned__		OK/0.941126
of	des	IN	ART		OK/0.997401
the	des	DT	ART		OK/0.995112
enzyme	Enzyms	NN	NN		OK/0.768650
is	wird	VBZ	VAFIN		OK/0.965279
estimated	geschätzt	VVN	VVPP		OK/0.996053
to	geschätzt	TO	VVPP		OK/0.993719
be	geschätzt	VB	VVPP		OK/0.990026
10	10	CD	CARD		OK/0.983609
%	%	NN	NN		OK/0.996093
of	verabreichten	IN	ADJA		OK/0.996368
the	verabreichten	DT	ADJA		OK/0.998307
administered	verabreichten	VVN	ADJA		OK/0.997257
dose	Dosis	NN	NN		OK/0.996429
.	.	SENT	$.		OK/0.998999

# 0.482554
These	Diese	DT	PDAT		OK/0.991924
side	Nebenwirkungen	NN	NN		OK/0.992178
effects	Nebenwirkungen	NNS	NN		OK/0.987893
likely	betreffen	JJ	VVFIN		OK/0.771519
to	__unaligned__	TO	__unaligned__		OK/0.741297
affect	betreffen	VV	VVFIN		OK/0.720843
between	zwischen	IN	APPR		OK/0.987332
1	1	CD	CARD		OK/0.997793
and	und	CC	KON		OK/0.999099
10	10	CD	CARD		OK/0.981527
in	__unaligned__	IN	__unaligned__		OK/0.819296
every	jeweils	DT	ADV		OK/0.887118
100	100	CD	CARD		OK/0.972864
patients	Patienten	NNS	NN		OK/0.978813
.	.	SENT	$.		OK/0.999759

# 0.963644
For	Die	IN	ART		OK/0.988819
a	Auflistung	DT	NN		OK/0.991553
full	Auflistung	JJ	NN		OK/0.996826
list	Auflistung	NN	NN		OK/0.998871
of	Auflistung	IN	NN		OK/0.998985
excipients	sonstigen	NNS	ADJA		OK/0.993240
,	__unaligned__	,	__unaligned__		OK/0.995166
see	siehe	VV	ADV		OK/0.999474
section	Abschnitt	NN	NN		OK/0.998716
6.1	6.1	CD	CARD		OK/0.997374
.	.	SENT	$.		OK/0.999837

# 0.304923
The	Der	DT	ART		OK/0.999172
proportion	Anteil	NN	NN		OK/0.993634
of	Anteil	IN	NN		OK/0.995077
patients	Patienten	NNS	NN		OK/0.995015
who	Patienten	WP	NN		OK/0.963618
had	UACR	VHD	NN		OK/0.900786
UACR	UACR	NP	NN		OK/0.880951
reduced	reduziert	VVN	VVPP		OK/0.895059
at	mindestens	IN	ADV		OK/0.974653
least	mindestens	JJS	ADV		OK/0.977485
50	50	CD	CARD		OK/0.996275
%	%	NN	NN		OK/0.998308
from	__unaligned__	IN	__unaligned__		OK/0.790051
baseline	__unaligned__	NN	__unaligned__		OK/0.703991
,	,	,	$,		OK/0.728438
from	__unaligned__	IN	__unaligned__		OK/0.799918
baseline	__unaligned__	NN	__unaligned__		OK/0.957604
to	__unaligned__	TO	__unaligned__		OK/0.829177
endpoint	__unaligned__	NN	__unaligned__		OK/0.756559
was	betrug	VBD	VVFIN		OK/0.776194
24.7	24,7	CD	CARD		OK/0.885357
%	%	NN	NN		OK/0.980442
and	und	CC	KON		OK/0.997050
12.5	12,5	CD	ADJA		OK/0.992464
%	%	NN	NN		OK/0.997641
for	__unaligned__	IN	__unaligned__		OK/0.967381
Rasilez	Rasilez	NP	NE		OK/0.989017
with	__unaligned__	IN	__unaligned__		OK/0.993705
placebo	Placebo	NN	NN		OK/0.999331
.	.	SENT	$.		OK/0.999493

# 0.901214
Method	Art	NP	NN		OK/0.989576
of	Art	IN	NN		OK/0.991253
administration	Art	NN	NN		OK/0.991948
Rebif	Rebif	NP	NE		OK/0.998376
is	wird	VBZ	VAFIN		OK/0.996716
intended	subkutan	VVN	ADJD		OK/0.997142
for	__unaligned__	IN	__unaligned__		OK/0.982611
subcutaneous	subkutan	JJ	ADJD		OK/0.988604
(	(	(	$(		OK/0.999681
under	unter	IN	APPR		OK/0.997015
the	Haut	DT	NN		OK/0.996064
skin	Haut	NN	NN		OK/0.996482
)	)	)	$(		OK/0.996133
injection	injiziert	NN	VVPP		OK/0.962894
.	.	SENT	$.		OK/0.999352

# 0.142439
In	An	IN	APPR		OK/0.791046
rats	Ratten	NNS	NN		OK/0.904522
,	__unaligned__	,	__unaligned__		OK/0.933333
a	__unaligned__	DT	__unaligned__		OK/0.862251
two-year	zweijährige	JJ	ADJA		OK/0.807516
carcinogenicity	Kanzerogenitätsstudie	NN	NN		OK/0.944300
study	Kanzerogenitätsstudie	NN	NN		OK/0.958311
of	__unaligned__	IN	__unaligned__		OK/0.915657
male	__unaligned__	JJ	__unaligned__		OK/0.980459
rats	__unaligned__	NNS	__unaligned__		OK/0.865384
at	__unaligned__	IN	__unaligned__		OK/0.545675
oral	oralen	JJ	ADJA		OK/0.970858
doses	Dosen	NNS	NN		OK/0.992855
up	zu	RB	APPR		OK/0.988281
to	bis	TO	KON		OK/0.949224
900	900	CD	CARD		OK/0.922300
mg	mg	NN	NN		OK/0.999237
/	/	SYM	$(		OK/0.998746
kg	kg	NN	NN		OK/0.992495
(	(	(	$(		OK/0.981057
approximately	etwa	RB	ADV		OK/0.910391
200	200fache	CD	ADJA		OK/0.901782
times	das	NNS	ART		OK/0.888110
human	Exposition	JJ	NN		OK/0.858070
exposure	Exposition	NN	NN		OK/0.829273
at	empfohlenen	IN	ADJA		OK/0.751931
the	empfohlenen	DT	ADJA		OK/0.702998
maximum	Höchstdosis	JJ	NN		OK/0.962713
recommended	Höchstdosis	JJ	NN		OK/0.930328
dose	Höchstdosis	NN	NN		OK/0.983408
)	)	)	$(		OK/0.991090
.	.	SENT	$.		OK/0.998654

# 0.038909
Ingredients	Kapselhülle	NP	NN		OK/0.833820
of	__unaligned__	IN	__unaligned__		OK/0.886947
the	__unaligned__	DT	__unaligned__		OK/0.948729
capsule	Kapselhülle	NN	NN		OK/0.943451
shell	Kapselhülle	NN	NN		OK/0.962683
:	:	:	$.		OK/0.997043
gelatin	Gelatine	NN	NN		OK/0.505646
Indigo	Indigocarmin	NP	NE		OK/0.525915
Carmine	Indigocarmin	NP	NE		OK/0.422403
(	(	(	$(		OK/0.839929
E132	Indigocarmin	NP	NE		OK/0.706278
)	)	)	$(		OK/0.959441
yellow	Eisenoxidhydrat	JJ	NN		OK/0.872893
iron	Eisenoxidhydrat	NN	NN		OK/0.946897
oxide	Eisenoxidhydrat	NN	NN		OK/0.991432
(	(	(	$(		OK/0.999588
E	E	NP	NN		OK/0.995130
172	172	CD	CARD		OK/0.985346
)	)	)	$(		OK/0.999758
Red	-oxid	NP	NN		OK/0.957474
iron	-oxid	NN	NN		OK/0.995583
oxide	-oxid	NN	NN		OK/0.997497
(	(	(	$(		OK/0.999718
E	E	NP	NN		OK/0.996995
172	172	CD	CARD		OK/0.996869
)	)	)	$(		OK/0.999808
Titanium	Titandioxid	NP	NN		OK/0.989180
dioxide	Titandioxid	NN	NN		OK/0.996195
(	(	(	$(		OK/0.995805
E	E	NP	NN		OK/0.998243
171	171	CD	CARD		OK/0.996781
)	)	)	$(		OK/0.996515
Yellow	Eisen	JJ	NN		OK/0.837938
iron	Eisen	NN	NN		OK/0.949313
oxide	Eisen	NN	NN		OK/0.815936
(	Eisen	(	NN		OK/0.655906
E172	II	NP	NE		OK/0.651713
)	__unaligned__	)	__unaligned__		OK/0.487939
,	__unaligned__	,	__unaligned__		OK/0.570854
black	-oxid	JJ	NN		OK/0.964194
iron	-oxid	NN	NN		OK/0.992835
oxide	-oxid	NN	NN		OK/0.955852
(	(	(	$(		OK/0.995784
E172	-oxid	NP	NN		OK/0.841772
)	)	)	$(		OK/0.995591
potassium	Kaliumhydroxid	NN	NN		OK/0.957576
hydroxide	Kaliumhydroxid	NN	NN		OK/0.958948
shellac	Schellack	NN	NN		OK/0.935849
.	.	SENT	$.		OK/0.999388

# 0.056956
The	Der	DT	ART		OK/0.963886
mechanism	Mechanismus	NN	NN		OK/0.968153
underlying	zugrunde	VVG	ADV		OK/0.938826
this	diesem	DT	PDAT		OK/0.979062
event	Ereignis	NN	NN		OK/0.851968
is	,	VBZ	$,		OK/0.867920
not	nicht	RB	PTKNEG		OK/0.980407
known	bekannt	VVN	ADJD		OK/0.983175
;	;	:	$.		OK/0.986504
however	jedoch	RB	ADV		OK/0.972158
,	jedoch	,	ADV		OK/0.992234
on	eine	IN	ART		OK/0.967186
autonomic	autonome	JJ	ADJA		OK/0.885110
neuropathy	Neuropathie	NN	NN		OK/0.978871
,	,	,	$,		OK/0.964680
one	__unaligned__	CD	__unaligned__		OK/0.855604
of	__unaligned__	IN	__unaligned__		OK/0.573869
the	__unaligned__	DT	__unaligned__		OK/0.429007
factors	__unaligned__	NNS	__unaligned__		BAD/0.918460
that	__unaligned__	WDT	__unaligned__		BAD/0.990432
may	könnte	MD	VMFIN		BAD/0.964983
be	sein	VB	VAINF		BAD/0.937717
of	der	IN	ART		BAD/0.725340
help	beiträgt	NN	VVFIN		BAD/0.691863
to	beiträgt	TO	VVFIN		BAD/0.475423
slow	beiträgt	VV	VVFIN		BAD/0.353984
.	.	SENT	$.		OK/0.990045

# 0.509907
Plasma	Plasmaproteinbindung	NP	NN		OK/0.922615
protein	vernachlässigen	NN	VVINF		OK/0.896133
binding	vernachlässigen	NN	VVINF		OK/0.846752
is	vernachlässigen	VBZ	VVINF		OK/0.614459
negligible	vernachlässigen	JJ	VVINF		OK/0.617166
.	.	SENT	$.		OK/0.996015

# 0.742708
Hellgrüne	Hellgrüne	NP	NN		OK/0.919320
,	,	,	$,		OK/0.992439
oval	ovale	JJ	ADJA		OK/0.996608
film-coated	Filmtabletten	NN	NN		OK/0.997195
tablets	Filmtabletten	NNS	NN		OK/0.999948
imprinted	Aufdruck	VVN	NN		OK/0.999402
with	Aufdruck	IN	NN		OK/0.999013
"	"	``	$(		OK/0.994565
Amgen	AMGEN	NP	NN		OK/0.964029
"	"	''	$(		OK/0.982203
on	__unaligned__	IN	__unaligned__		OK/0.986518
one	__unaligned__	CD	__unaligned__		OK/0.998199
side	auf	NN	APPR		OK/0.988328
and	und	CC	KON		OK/0.998904
"	"	``	$(		OK/0.997948
90	90	CD	CARD		OK/0.989132
"	"	''	$(		OK/0.971203
on	auf	IN	APPR		OK/0.969333
the	auf	DT	APPR		OK/0.965475
other	anderen	JJ	PIAT		OK/0.957875
side	Seite	NN	NN		OK/0.967194
.	.	SENT	$.		OK/0.975678

# 0.515353
There	liegen	RB	VVFIN		OK/0.998735
is	Es	VBZ	NN		OK/0.995529
no	keine	DT	PIAT		OK/0.999758
experience	Erfahrungen	NN	NN		OK/0.976067
of	Überdosierung	IN	NN		OK/0.972559
overdose	Überdosierung	NN	NN		OK/0.868813
with	mit	IN	APPR		OK/0.857075
<	Name	SYM	NN		BAD/0.859317
Invented	Phantasiebezeichnung	JJ	NN		OK/0.852189
Name	Name	NN	NN		OK/0.864882
>	Name	SYM	NN		BAD/0.982147
.	.	SENT	$.		OK/0.998228

# 0.738282
This	Das	NP	PDS		OK/0.992612
means	bedeutet	VVZ	VVFIN		OK/0.994712
that	bedeutet	IN/that	VVFIN		OK/0.992094
because	aufgrund	IN	APPR		OK/0.990973
the	__unaligned__	DT	__unaligned__		OK/0.997458
disease	Seltenheit	NN	NN		OK/0.986820
is	__unaligned__	VBZ	__unaligned__		OK/0.965812
rare	__unaligned__	JJ	__unaligned__		OK/0.970241
,	,	,	$,		OK/0.990252
it	__unaligned__	PP	__unaligned__		OK/0.952103
has	__unaligned__	VHZ	__unaligned__		OK/0.989341
not	nicht	RB	PTKNEG		OK/0.998104
been	__unaligned__	VBN	__unaligned__		OK/0.967488
possible	möglich	JJ	ADJD		OK/0.991738
to	__unaligned__	TO	__unaligned__		OK/0.977886
obtain	vollständige	VV	ADJA		OK/0.960889
complete	vollständige	JJ	ADJA		OK/0.998192
information	Informationen	NN	NN		OK/0.999865
on	Informationen	IN	NN		OK/0.973785
this	diesem	DT	PDAT		OK/0.981673
medicinal	Arzneimittel	JJ	NN		OK/0.988785
product	Arzneimittel	NN	NN		OK/0.960702
.	.	SENT	$.		OK/0.998426

# 0.964208
What	Welche	WP	PIAT		OK/0.996298
is	Risiken	VBZ	NN		OK/0.997215
the	Risiken	DT	NN		OK/0.999962
risk	Risiken	NN	NN		OK/0.999577
associated	Risiken	VVN	NN		OK/0.995418
with	mit	IN	APPR		OK/0.999060
DuoTrav	DuoTrav	NP	NE		OK/0.983104
?	?	SENT	$.		OK/0.988548

# 0.639985
After	Nach	IN	APPR		OK/0.986228
a	4-wöchigen	DT	ADJA		OK/0.983393
4	4-wöchigen	CD	ADJA		OK/0.965613
week	4-wöchigen	NN	ADJA		OK/0.971067
induction	Einleitungstherapie	NN	NN		OK/0.986893
period	__unaligned__	NN	__unaligned__		OK/0.970595
with	mit	IN	APPR		OK/0.992469
Tracleer	Tracleer	NP	ADJD		OK/0.912258
62.5	62,5	CD	CARD		OK/0.922546
mg	mg	NN	NN		OK/0.974454
twice	zweimal	RB	ADV		OK/0.999483
daily	täglich	RB	ADJD		OK/0.995885
was	betrug	VBD	VVFIN		OK/0.951951
also	untersuchte	RB	ADJA		OK/0.916587
looked	untersuchte	VVN	ADJA		OK/0.916713
at	untersuchte	IN	ADJA		OK/0.970357
both	beiden	DT	PIAT		OK/0.993549
studies	Studien	NNS	NN		OK/0.999151
,	__unaligned__	,	__unaligned__		OK/0.987897
the	__unaligned__	DT	__unaligned__		OK/0.985430
maintenance	Erhaltungsdosis	NN	NN		OK/0.994781
dose	Erhaltungsdosis	NN	NN		OK/0.999342
of	__unaligned__	IN	__unaligned__		OK/0.988290
125	125	CD	CARD		OK/0.995232
mg	mg	NN	NN		OK/0.994479
twice	zweimal	RB	ADV		OK/0.998855
daily	täglich	JJ	ADJD		OK/0.993882
.	.	SENT	$.		OK/0.994192

# 0.811854
In	Bei	IN	APPR		OK/0.989436
children	Kindern	NNS	NN		OK/0.984259
,	die	,	ART		OK/0.887044
infusion	Infusionsdauer	NN	NN		OK/0.964130
time	Infusionsdauer	NN	NN		OK/0.949009
is	__unaligned__	VBZ	__unaligned__		OK/0.953570
60	60	CD	CARD		OK/0.997816
minutes	Minuten	NNS	NN		OK/0.987877
.	.	SENT	$.		OK/0.999536

# 0.188668
Women	Frauen	NP	NN		OK/0.999587
of	gebärfähigen	IN	ADJA		OK/0.998619
childbearing	gebärfähigen	NN	ADJA		OK/0.979097
potential	gebärfähigen	NN	ADJA		OK/0.714427
must	schwangerschaftsverhütende	MD	ADJA		OK/0.718297
use	schwangerschaftsverhütende	VV	ADJA		OK/0.767953
contraceptive	schwangerschaftsverhütende	JJ	ADJA		OK/0.933533
measures	schwangerschaftsverhütende	NNS	ADJA		OK/0.972278
during	während	IN	APPR		OK/0.968299
treatment	Behandlung	NN	NN		OK/0.939213
.	Behandlung	SENT	NN		OK/0.518801
Sulfoamino	Methoden	NP	NN		OK/0.408447
use	anwenden	NN	VVINF		OK/0.733291
immediately	umgehend	RB	ADJD		OK/0.792922
and	und	CC	KON		OK/0.969531
tell	informieren	VV	VVINF		OK/0.917203
their	ihren	PP$	PPOSAT		OK/0.996524
doctor	Arzt	NN	NN		OK/0.995990
if	falls	IN	KOUS		OK/0.993983
they	sie	PP	PPER		OK/0.994381
become	schwanger	VVP	ADJD		OK/0.974852
pregnant	schwanger	JJ	ADJD		OK/0.984747
.	.	SENT	$.		OK/0.998952

# 0.174366
83	83	CD	CARD		OK/0.968222
In	Bei	IN	APPR		OK/0.856053
patients	Patienten	NNS	NN		OK/0.998665
with	mit	IN	APPR		OK/0.997791
chronic	chronischer	JJ	ADJA		OK/0.998511
renal	Niereninsuffizienz	JJ	NN		OK/0.998758
failure	Niereninsuffizienz	NN	NN		OK/0.993257
,	__unaligned__	,	__unaligned__		OK/0.870507
maintenance	Erhaltungstherapie	NN	NN		OK/0.594689
haemoglobin	__unaligned__	NN	__unaligned__		OK/0.863523
concentration	__unaligned__	NN	__unaligned__		OK/0.870253
should	sollte	MD	VMFIN		OK/0.987855
not	nicht	RB	PTKNEG		OK/0.994259
exceed	überschritten	VV	VVPP		OK/0.930822
the	Obergrenze	DT	NN		OK/0.808811
upper	Obergrenze	JJ	NN		OK/0.475425
limit	Obergrenze	NN	NN		OK/0.764509
of	Obergrenze	IN	NN		OK/0.813333
the	Obergrenze	DT	NN		OK/0.920834
target	Hämoglobin-Zielkonzentration	NN	NN		OK/0.955526
haemoglobin	Hämoglobin-Zielkonzentration	NN	NN		OK/0.997209
concentration	Hämoglobin-Zielkonzentration	NN	NN		OK/0.980661
recommended	empfohlene	VVN	ADJA		OK/0.974216
in	__unaligned__	IN	__unaligned__		OK/0.921064
section	Abschnitt	NN	NN		OK/0.987493
4.2	4.2	CD	CARD		OK/0.984535
.	.	SENT	$.		OK/0.999710

# 0.033758
In	Bei	IN	APPR		OK/0.901946
yew	assistierten	NN	ADJA		OK/0.782514
there	besteht	EX	VVFIN		OK/0.895412
is	ein	VBZ	ART		OK/0.839657
a	höheres	DT	ADJA		OK/0.902020
higher	höheres	JJR	ADJA		OK/0.982921
risk	Risiko	NN	NN		OK/0.973571
for	__unaligned__	IN	__unaligned__		BAD/0.792849
the	Entwicklung	DT	NN		OK/0.585326
development	Entwicklung	NN	NN		OK/0.718645
of	Entwicklung	IN	NN		OK/0.568227
OHSS	OHSS	NP	NN		OK/0.509999
is	,	VBZ	$,		OK/0.363736
increased	__unaligned__	VVN	__unaligned__		OK/0.507494
by	__unaligned__	IN	__unaligned__		OK/0.898963
a	__unaligned__	DT	__unaligned__		OK/0.980748
serum	__unaligned__	NN	__unaligned__		OK/0.974090
estradiol	__unaligned__	NN	__unaligned__		OK/0.995210
level	__unaligned__	NN	__unaligned__		OK/0.944494
>	als	SYM	KOKOM		OK/0.711934
3000	3000	CD	CARD		OK/0.803988
pg	pg	NN	NN		OK/0.911774
/	/	SYM	$(		OK/0.998708
ml	ml	NN	NN		OK/0.996699
(	(	(	$(		OK/0.989814
11000	11000	CD	CARD		OK/0.903600
pmol	pmol	NN	NN		OK/0.949485
/	/	SYM	$(		OK/0.993171
l	l	NN	NN		OK/0.996161
)	)	)	$(		OK/0.995805
and	und	CC	KON		OK/0.999156
20	20	CD	CARD		OK/0.988052
or	oder	CC	KON		OK/0.997624
more	mehr	JJR	PIAT		OK/0.966156
follicles	Follikel	NNS	NN		OK/0.987219
of	mit	IN	APPR		OK/0.977549
11	12	CD	CARD		OK/0.979424
mm	mm	NN	NN		OK/0.974356
or	oder	CC	KON		OK/0.998220
more	mehr	JJR	ADV		OK/0.940185
in	mehr	IN	ADV		OK/0.923378
diameter	vorliegen	NN	VVINF		OK/0.734511
.	.	SENT	$.		OK/0.993805

# 0.516450
Active	Pro	NP	APPR		OK/0.829024
substances	Pro	NNS	APPR		OK/0.872713
:	Pro	:	APPR		OK/0.628330
per	Pro	IN	APPR		OK/0.872927
dose	Dosis	NN	NN		OK/0.995764
of	__unaligned__	IN	__unaligned__		OK/0.992339
2	2	CD	CARD		OK/0.998075
ml	ml	NN	NN		OK/0.926892
:	:	:	$.		OK/0.997532

# 0.091113
In	Bei	IN	APPR		OK/0.889895
the	__unaligned__	DT	__unaligned__		OK/0.959189
combination	Kombination	NN	NN		OK/0.980458
of	__unaligned__	IN	__unaligned__		OK/0.831255
the	beiden	DT	PIAT		OK/0.957623
two	beiden	CD	PIAT		OK/0.957002
medicines	Arzneimittel	NNS	NN		OK/0.943017
are	Arzneimittel	VBP	NN		OK/0.866229
still	dennoch	RB	ADV		OK/0.883117
should	sollte	MD	VMFIN		OK/0.590530
be	sollte	VB	VMFIN		BAD/0.863572
the	ein	DT	ART		BAD/0.851207
monitoring	Monitoring	NN	NN		BAD/0.528589
of	__unaligned__	IN	__unaligned__		BAD/0.603534
the	auf	DT	APPR		BAD/0.525561
Methotrexat-bedingte	Methotrexat-bedingte	NP	ADJA		BAD/0.506067
toxicity	Toxizität	NN	NN		OK/0.936480
may	gezogen	MD	VVPP		OK/0.923950
be	gezogen	VB	VVPP		OK/0.983026
considered	gezogen	VVN	VVPP		OK/0.961612
.	.	SENT	$.		OK/0.999635

# 0.301625
-	-	:	$(		OK/0.985702
Carefully	gebrauchten	RB	ADJA		OK/0.911958
dispose	gebrauchten	VV	ADJA		OK/0.971692
of	__unaligned__	IN	__unaligned__		OK/0.991473
used	gebrauchten	VVN	ADJA		OK/0.985231
syringes	Spritzen	NNS	NN		OK/0.986433
always	immer	RB	ADV		OK/0.969579
in	in	IN	APPR		OK/0.892493
the	vorgesehenen	DT	ADJA		OK/0.411967
proper	Abfallbehälter	JJ	NN		OK/0.595848
disposal	Abfallbehälter	NN	NN		OK/0.907853
unit	Abfallbehälter	NN	NN		OK/0.823081
.	.	SENT	$.		OK/0.999244

# 0.054884
In	In	IN	APPR		OK/0.993767
13	13	CD	CARD		OK/0.985154
clinical	klinischen	JJ	ADJA		OK/0.995767
trials	Studien	NNS	NN		OK/0.983668
with	mit	IN	APPR		OK/0.977871
696	696	CD	CARD		OK/0.778176
patients	Patienten	NNS	NN		OK/0.757892
were	wurde	VBD	VAFIN		BAD/0.791823
on	__unaligned__	IN	__unaligned__		BAD/0.866046
Emadine	Emadine	NP	NE		OK/0.653159
for	__unaligned__	IN	__unaligned__		OK/0.729872
up	zu	IN	APPR		OK/0.985402
to	zu	TO	APPR		OK/0.989581
42	42	CD	CARD		OK/0.997572
days	Tage	NNS	NN		OK/0.979338
within	bis	IN	APPR		OK/0.920400
one	bis	CD	APPR		OK/0.887217
to	bis	TO	APPR		OK/0.903279
four	vier	CD	CARD		OK/0.931237
times	mal	NNS	ADV		OK/0.907415
daily	täglich	JJ	ADJD		BAD/0.508678
in	in	IN	APPR		BAD/0.696069
both	beide	DT	PIAT		BAD/0.598658
eyes	Augen	NNS	NN		BAD/0.474663
.	.	SENT	$.		OK/0.983286

# 0.557274
7	7	CD	CARD		OK/0.997145
,	,	,	$,		OK/0.997609
10	10	CD	CARD		OK/0.993852
,	,	,	$,		OK/0.997374
14	14	CD	CARD		OK/0.991226
,	,	,	$,		OK/0.992622
15	15	CD	CARD		OK/0.991853
,	,	,	$,		OK/0.995552
20	20	CD	CARD		OK/0.987638
,	__unaligned__	,	__unaligned__		OK/0.637913
28	28	CD	CARD		OK/0.971833
,	,	,	$,		OK/0.998851
30	30	CD	CARD		OK/0.997025
,	,	,	$,		OK/0.999708
50	50	CD	CARD		OK/0.989103
,	,	,	$,		OK/0.999340
56	56	CD	CARD		OK/0.995472
,	,	,	$,		OK/0.988776
84	84	CD	CARD		OK/0.995449
,	,	,	$,		OK/0.998613
90	90	CD	CARD		OK/0.998766
,	,	,	$,		OK/0.999230
98	98	CD	CARD		OK/0.989585
or	oder	CC	KON		OK/0.998896
280	280	CD	CARD		OK/0.985522
tablets	Tabletten	NNS	NN		OK/0.958301
.	.	SENT	$.		OK/0.999237

# 0.908924
with	mit	IN	APPR		OK/0.941625
serotonergic	__unaligned__	JJ	__unaligned__		OK/0.946052
medicinal	Arzneimittel	JJ	NN		OK/0.998180
products	Arzneimittel	NNS	NN		OK/0.992667
:	:	:	$.		OK/0.998426

# 0.655967
From	Von	IN	APPR		OK/0.895149
dehydration	Dehydratation	NN	NN		OK/0.948017
and	und	CC	KON		OK/0.993055
pulmonary	Lungenödemen	JJ	NN		OK/0.979383
oedema	Lungenödemen	NN	NN		OK/0.971896
have	berichtet	VHP	VVPP		OK/0.820524
been	berichtet	VBN	VVPP		OK/0.878583
reported	berichtet	VVN	VVPP		OK/0.904047
rarely	selten	RB	ADJD		OK/0.945179
.	.	SENT	$.		OK/0.998814

# 0.022753
adverse	Nebenwirkungen	JJ	NN		OK/0.940266
reactions	Nebenwirkungen	NNS	NN		OK/0.719719
may	möglicherweise	MD	ADV		BAD/0.840477
be	möglicherweise	VB	ADV		BAD/0.966124
related	Zusammenhang	VVN	NN		BAD/0.858398
to	Zusammenhang	TO	NN		BAD/0.718754
Entecavir-Behandlung	Entecavir-Behandlung	NP	NN		BAD/0.799811
considered	stehend	VVN	ADJD		BAD/0.954919
at	stehend	IN	ADJD		BAD/0.830857
least	stehend	JJS	ADJD		BAD/0.660675
possibly	stehend	RB	ADJD		BAD/0.467134
related	stehend	VVN	ADJD		BAD/0.377776
to	stehend	TO	ADJD		BAD/0.312820
,	,	,	$,		BAD/0.417291
16440	anatomischen	CD	ADJA		BAD/0.703645
,	__unaligned__	,	__unaligned__		BAD/0.661520
by	Systemorganklassen	IN	NN		OK/0.975359
system	Systemorganklassen	NN	NN		OK/0.999040
organ	Systemorganklassen	NN	NN		OK/0.999665
class	Systemorganklassen	NN	NN		OK/0.997941
(	(	(	$(		OK/0.992721
SOC	SOC	NP	NE		OK/0.865267
)	)	)	$(		OK/0.881479
are	aufgelistet	VBP	VVPP		OK/0.483329
listed	aufgelistet	VVN	VVPP		OK/0.490721
below	aufgelistet	IN	VVPP		OK/0.491599
:	:	:	$.		OK/0.969941

# 0.321528
The	Die	DT	ART		OK/0.973361
sedation	Sedierung	NN	NN		OK/0.898853
beEinflusste	beEinflusste	NN	VVFIN		OK/0.597558
adverse	Paarungsverhalten	JJ	NN		OK/0.653238
effects	__unaligned__	NNS	__unaligned__		OK/0.484779
on	__unaligned__	IN	__unaligned__		OK/0.488430
male	männlicher	JJ	ADJA		OK/0.945364
rats	Ratten	NNS	NN		OK/0.943789
.	.	SENT	$.		OK/0.998355

# 0.936298
The	Die	DT	ART		OK/0.999040
usual	übliche	JJ	ADJA		OK/0.996577
dose	Dosis	NN	NN		OK/0.999078
of	von	IN	APPR		OK/0.999163
Paxene	Paxene	NP	NN		OK/0.996394
is	ist	VBZ	VAFIN		OK/0.988204
100	100	CD	CARD		OK/0.977211
mg	mg	NN	NN		OK/0.990284
/	/	SYM	$(		OK/0.998564
m2	²	JJ	ADJA		OK/0.985512
of	__unaligned__	IN	__unaligned__		OK/0.998690
body	Körperoberfläche	NN	NN		OK/0.998052
surface	Körperoberfläche	NN	NN		OK/0.998774
area	Körperoberfläche	NN	NN		OK/0.998040
.	.	SENT	$.		OK/0.999471

# 0.266111
After	Nach	IN	APPR		OK/0.891681
use	Anwendung	NN	NN		OK/0.717071
the	Pflaster	DT	NN		OK/0.761340
patch	Pflaster	NN	NN		OK/0.681622
still	noch	RB	ADV		OK/0.493284
Wirkstoffanteile	Wirkstoffanteile	NP	NN		OK/0.357543
.	.	SENT	$.		OK/0.993844

# 0.395037
2	Weitere	CD	ADJA		OK/0.530552
/	Weitere	SYM	ADJA		OK/0.528952
3	Weitere	CD	ADJA		OK/0.544985
Other	Weitere	JJ	ADJA		OK/0.966846
information	Informationen	NN	NN		OK/0.999890
about	Informationen	IN	NN		OK/0.998833
RILUTEK	RILUTEK	NP	NE		OK/0.977717
:	:	:	$.		OK/0.997375

# 0.412135
46	46	CD	CARD		OK/0.936312
•	•	NN	NN		OK/0.976282
are	allergisch	VBP	ADJD		OK/0.525607
allergic	allergisch	JJ	ADJD		OK/0.830032
(	(	(	$(		OK/0.999970
hypersensitive	überempfindlich	JJ	ADJD		OK/0.995239
)	gegen	)	APPR		OK/0.983246
to	gegen	TO	APPR		OK/0.998881
any	__unaligned__	DT	__unaligned__		OK/0.983101
of	der	IN	ART		OK/0.992406
the	der	DT	ART		OK/0.997476
active	Wirkstoffe	JJ	NN		OK/0.994240
substances	Wirkstoffe	NNS	NN		OK/0.994524
or	oder	CC	KON		OK/0.996373
any	Bestandteile	DT	NN		OK/0.998525
of	Bestandteile	IN	NN		OK/0.987825
the	Bestandteile	DT	NN		OK/0.993160
other	Bestandteile	JJ	NN		OK/0.976503
ingredients	sonstigen	NNS	ADJA		OK/0.979573
of	Bestandteile	IN	NN		OK/0.956063
Cervarix	Cervarix	NP	NE		OK/0.943671
.	.	SENT	$.		OK/0.997072

# 0.123060
until	Bis	IN	APPR		OK/0.672512
they	an	PP	APPR		BAD/0.675630
are	__unaligned__	VBP	__unaligned__		BAD/0.890998
dispensed	__unaligned__	VVN	__unaligned__		BAD/0.910804
to	__unaligned__	TO	__unaligned__		BAD/0.959971
the	__unaligned__	DT	__unaligned__		BAD/0.829831
patient	den	NN	ART		BAD/0.842148
in	__unaligned__	IN	__unaligned__		BAD/0.565822
a	Kühlschrank	DT	NN		OK/0.817008
refrigerator	Kühlschrank	NN	NN		OK/0.950411
.	.	SENT	$.		OK/0.995614

# 0.308256
In	In	IN	APPR		OK/0.950311
a	einer	DT	ART		OK/0.837822
placebo-controlled	Placebo-kontrollierten	VVN	ADJA		OK/0.834398
26-week	Langzeitstudie	JJ	NN		OK/0.769490
,	__unaligned__	,	__unaligned__		OK/0.856961
the	die	DT	ART		OK/0.990424
incidence	Inzidenz	NN	NN		OK/0.995961
of	Inzidenz	IN	NN		OK/0.973920
EPS	EPS	NP	NN		OK/0.782868
was	__unaligned__	VBD	__unaligned__		OK/0.765062
19	19	CD	CARD		OK/0.989593
%	%	NN	NN		OK/0.990124
for	Aripiprazol-Behandlung	IN	NN		OK/0.863898
aripiprazole-treated	Aripiprazol-Behandlung	JJ	NN		OK/0.844127
patients	Aripiprazol-Behandlung	NNS	NN		OK/0.850864
and	und	CC	KON		OK/0.946663
13.1	13,1	CD	CARD		OK/0.937696
%	%	NN	NN		OK/0.996578
in	__unaligned__	IN	__unaligned__		OK/0.908629
the	__unaligned__	DT	__unaligned__		OK/0.933689
patients	Patienten	NNS	NN		OK/0.999218
adding	__unaligned__	VVG	__unaligned__		OK/0.993871
placebo	Placebo	NN	NN		OK/0.998378
.	.	SENT	$.		OK/0.999617

# 0.471740
Reproduction	Reproduktionsstudien	NP	NN		OK/0.974920
studies	Reproduktionsstudien	NNS	NN		OK/0.972652
with	mit	IN	APPR		OK/0.920496
ViraferonPeg	ViraferonPeg	NP	NN		OK/0.633514
have	wurden	VHP	VAFIN		OK/0.671978
not	nicht	RB	PTKNEG		OK/0.780013
been	nicht	VBN	PTKNEG		OK/0.730293
performed	durchgeführt	VVN	VVPP		OK/0.849238
.	.	SENT	$.		OK/0.999493

# 0.252161
The	Die	DT	ART		OK/0.945787
number	Zahl	NN	NN		OK/0.861808
of	Zahl	IN	NN		OK/0.947611
sporadic	auftretenden	JJ	ADJA		OK/0.934502
resistance	Resistenzen	NN	NN		OK/0.867653
may	kann	MD	VMFIN		OK/0.773701
be	kann	VB	VMFIN		OK/0.637562
higher	höher	JJR	ADJD		OK/0.685261
and	und	CC	KON		OK/0.636408
in	bei	IN	APPR		OK/0.692569
immunsuppri-	immunsuppri-	NN	TRUNC		OK/0.554273
mierten	mierten	NN	ADJA		OK/0.553487
patients	Patienten	NNS	NN		OK/0.825812
.	.	SENT	$.		OK/0.999352

# 0.086352
,	,	,	$,		OK/0.461505
Transfusion	fresh	NP	NE		OK/0.502456
)	)	)	$(		OK/0.850725
and	und	CC	KON		OK/0.859724
Thrombozytenkonzentraten	Thrombozytenkonzentraten	NP	NN		BAD/0.539212
should	erwogen	MD	VVPP		BAD/0.494903
be	erwogen	VB	VVPP		BAD/0.587654
considered	erwogen	VVN	VVPP		BAD/0.694693
with	__unaligned__	IN	__unaligned__		BAD/0.806765
clinical	klinische	JJ	ADJA		OK/0.924168
and	und	CC	KON		OK/0.996163
laboratory	labormedizinische	NN	ADJA		OK/0.937455
reassessment	labormedizinische	NN	ADJA		OK/0.819443
after	labormedizinische	IN	ADJA		OK/0.876994
each	jeder	DT	PIAT		OK/0.931388
administration	Gabe	NN	NN		OK/0.942172
.	.	SENT	$.		OK/0.997781

# 0.072939
Losartan	Losartan	NP	NE		OK/0.974829
had	hat	VHD	VAFIN		OK/0.989450
no	keine	DT	PIAT		OK/0.998768
effect	Wirkung	NN	NN		OK/0.974603
on	Wirkung	IN	NN		OK/0.946205
the	__unaligned__	DT	__unaligned__		OK/0.692472
autonomic	autonomen	JJ	ADJA		OK/0.322508
reflexes	Reflexe	NNS	NN		OK/0.314005
and	und	CC	KON		OK/0.563881
no	keinen	DT	PIAT		OK/0.570099
sustained	anhaltenden	JJ	ADJA		OK/0.547955
effect	Effekt	NN	NN		OK/0.893880
on	Effekt	IN	NN		OK/0.888586
norepinephrine	Noradrenalin	NN	NE		OK/0.434714
in	im	IN	APPRART		OK/0.938537
the	im	DT	APPRART		OK/0.905645
plasma	Plasma	NN	NN		OK/0.944168
.	.	SENT	$.		OK/0.998207

# 0.442814
Efficacy	Wirksamkeit	NP	NN		OK/0.710663
was	hätte	VBD	VAFIN		BAD/0.917603
to	__unaligned__	TO	__unaligned__		BAD/0.948516
be	__unaligned__	VB	__unaligned__		BAD/0.954151
explored	untersucht	VVN	VVPP		BAD/0.973220
at	niedrigsten	IN	ADJA		BAD/0.914129
the	niedrigsten	DT	ADJA		OK/0.844336
lowest	niedrigsten	JJS	ADJA		OK/0.974105
recommended	empfohlenen	JJ	ADJA		OK/0.987799
dose	Dosis	NN	NN		OK/0.966425
.	.	SENT	$.		OK/0.998141

# 0.382133
One	Eine	NP	ART		OK/0.531698
sudden	plötzliche	JJ	ADJA		OK/0.774568
and	und	CC	KON		OK/0.999557
increasing	zunehmende	VVG	ADJA		OK/0.933701
worsening	Verschlechterung	NN	NN		OK/0.989728
is	ist	VBZ	VAFIN		OK/0.992000
potentially	potentiell	RB	ADJD		OK/0.956522
life-threatening	lebensbedrohlich	JJ	ADJD		OK/0.909978
and	und	CC	KON		OK/0.959536
the	Patient	DT	NN		OK/0.991863
patient	Patient	NN	NN		OK/0.986563
should	sollte	MD	VMFIN		OK/0.978796
undergo	dringend	VV	ADJD		OK/0.946972
urgent	dringend	JJ	ADJD		OK/0.952368
medical	dringend	JJ	ADJD		OK/0.977502
assessment	dringend	NN	ADJD		OK/0.989353
.	.	SENT	$.		OK/0.998117

# 0.917600
How	Wie	NP	KOKOM		OK/0.991091
does	wirkt	VVZ	VVFIN		OK/0.964519
OPTISON	OPTISON	NP	NN		OK/0.998530
work	__unaligned__	NN	__unaligned__		OK/0.955203
?	?	SENT	$.		OK/0.999766

# 0.026764
For	Für	IN	APPR		OK/0.647100
the	den	DT	ART		OK/0.583072
daily	über	JJ	APPR		OK/0.571208
for	Jahr	IN	NN		OK/0.593414
1	Jahr	CD	NN		OK/0.564774
year	Jahr	NN	NN		OK/0.668074
hinausgehenden	hinausgehenden	NN	ADJA		OK/0.444751
No	keine	DT	PIAT		OK/0.540563
data	Daten	NNS	NN		OK/0.920977
are	Daten	VBP	NN		OK/0.668838
available	Daten	JJ	NN		OK/0.961444
on	Daten	IN	NN		OK/0.983660
the	zu	DT	APPR		OK/0.950824
Rezidivraten	Rezidivraten	NN	NN		OK/0.933834
and	und	CC	KON		OK/0.968996
additional	weiteren	JJ	ADJA		OK/0.741037
lead	__unaligned__	NN	__unaligned__		OK/0.487367
to	__unaligned__	TO	__unaligned__		OK/0.602098
the	Entwicklung	DT	NN		OK/0.652433
development	Entwicklung	NN	NN		OK/0.765847
of	Entwicklung	IN	NN		OK/0.823029
therapy	__unaligned__	NN	__unaligned__		BAD/0.614587
.	.	SENT	$.		OK/0.984494

# 0.115451
Major	Starke	NP	ADJA		OK/0.710045
bleeding	Blutungen	NN	NN		OK/0.747584
were	waren	VBD	VAFIN		OK/0.630245
also	ebenfalls	RB	ADV		OK/0.895378
very	sehr	RB	ADV		OK/0.967483
common	häufig	JJ	ADJD		OK/0.963838
(	(	(	$(		OK/0.998175
>	>	SYM	$(		BAD/0.677215
1	1	CD	CARD		OK/0.992356
/	/	SYM	$(		OK/0.999580
10	10	CD	CARD		OK/0.997293
)	)	)	$(		OK/0.998515
and	und	CC	KON		OK/0.989939
have	wurden	VHP	VAFIN		OK/0.858115
been	wurden	VBN	VAFIN		OK/0.795303
described	beschrieben	VVN	VVPP		OK/0.876525
more	häufiger	RBR	ADJD		OK/0.872317
frequently	häufiger	RB	ADJD		OK/0.758442
with	häufiger	IN	ADJD		OK/0.785520
eptifibatide	Eptifibatid	NN	ADJD		OK/0.654551
than	als	IN	KOKOM		OK/0.825426
with	__unaligned__	IN	__unaligned__		OK/0.965775
placebo	Placebo	NN	NN		OK/0.997604
(	(	(	$(		OK/0.996645
10.8	10,8	CD	CARD		OK/0.996436
%	%	NN	NN		OK/0.994937
versus	gegenüber	IN	APPR		OK/0.947366
9.3	9,3	CD	CARD		OK/0.961006
%	%	NN	NN		OK/0.990734
,	__unaligned__	,	__unaligned__		OK/0.862378
respectively	%	RB	NN		OK/0.864443
)	)	)	$(		OK/0.992261
.	.	SENT	$.		OK/0.995700

# 0.273335
Viani	Viani	NP	NN		OK/0.972478
should	darf	MD	VMFIN		OK/0.987716
not	nicht	RB	PTKNEG		OK/0.997978
be	darf	VB	VMFIN		OK/0.998460
used	angewendet	VVN	VVPP		OK/0.988184
if	wenn	IN	KOUS		OK/0.989864
you	Sie	PP	PPER		OK/0.997629
are	allergisch	VBP	ADJD		OK/0.958836
allergic	allergisch	JJ	ADJD		OK/0.706186
(	allergisch	(	ADJD		OK/0.999194
hypersensitive	überempfindlich	JJ	ADJD		OK/0.990512
)	gegen	)	APPR		OK/0.972031
to	__unaligned__	TO	__unaligned__		OK/0.976621
salmeterol	Salmeterolxinafoat	NN	NN		OK/0.877389
xinafoate	Salmeterolxinafoat	NNS	NN		OK/0.867251
,	,	,	$,		OK/0.989902
fluticasone	Fluticasonpropionat	NN	NN		OK/0.974481
propionate	Fluticasonpropionat	NN	NN		OK/0.942826
or	oder	CC	KON		OK/0.864587
to	__unaligned__	TO	__unaligned__		OK/0.704439
the	__unaligned__	DT	__unaligned__		OK/0.774218
excipient	Bestandteil	NN	NN		OK/0.704833
Norflurane	Norfluran	NP	NE		OK/0.908212
(	Norfluran	(	NE		OK/0.968939
HFA	Norfluran	NP	NE		OK/0.968224
134a	Norfluran	NP	NE		OK/0.939763
)	)	)	$(		OK/0.979562
.	.	SENT	$.		OK/0.996621

# 0.266403
based	konventionellen	VVN	ADJA		OK/0.918366
on	konventionellen	IN	ADJA		OK/0.924955
conventional	konventionellen	JJ	ADJA		OK/0.995136
studies	Studien	NNS	NN		OK/0.998025
of	__unaligned__	IN	__unaligned__		OK/0.990977
safety	Sicherheitspharmakologie	NN	NN		OK/0.992981
pharmacology	Sicherheitspharmakologie	NN	NN		OK/0.984338
,	,	,	$,		OK/0.994494
genotoxicity	Genotoxizität	NN	NN		OK/0.974349
and	und	CC	KON		OK/0.951182
carcinogenic	kanzerogenen	JJ	ADJA		OK/0.977566
potential	Potential	NN	NN		OK/0.991963
of	__unaligned__	IN	__unaligned__		BAD/0.453245
Preclinical	präklinischen	JJ	ADJA		BAD/0.537037
data	Gefahren	NNS	NN		BAD/0.645842
reveal	Gefahren	VVP	NN		BAD/0.635160
no	Gefahren	DT	NN		OK/0.988137
special	Gefahren	JJ	NN		OK/0.996640
hazard	besonderen	NN	ADJA		OK/0.996807
for	Gefahren	IN	NN		OK/0.998629
humans	Gefahren	NNS	NN		OK/0.995522
.	.	SENT	$.		OK/0.999533

# 0.359793
Marked	Deutliche	NP	ADJA		OK/0.939631
elevations	Erhöhung	NNS	NN		OK/0.958814
in	Erhöhung	IN	NN		OK/0.986606
Cyclosporin-	Cyclosporin-	NP	TRUNC		OK/0.754801
A	A	NP	NN		OK/0.705834
(	(	(	$(		OK/0.891969
CsA	CsA	NP	NE		OK/0.811385
)	)	)	$(		OK/0.984538
levels	-Spiegel	NNS	NN		OK/0.964718
in	bei	IN	APPR		OK/0.996681
patients	Patienten	NNS	NN		OK/0.994109
receiving	Patienten	VVG	NN		OK/0.803924
PIs	PIs	NP	NE		OK/0.858333
,	,	,	$,		OK/0.936996
incl.	einschl	JJ	VVFIN		OK/0.874430
indinavir	Indinavir	NN	NE		OK/0.921967
.	.	SENT	$.		OK/0.999732

# 0.309754
Your	Ihr	PP$	PPOSAT		OK/0.991896
doctor	Arzt	NN	NN		OK/0.993616
will	Arzt	MD	NN		OK/0.953408
tell	Ihnen	VV	PPER		BAD/0.851743
you	Ihnen	PP	PPER		BAD/0.848446
how	geben	WRB	VVINF		BAD/0.978243
to	geben	TO	VVINF		BAD/0.993264
give	geben	VV	VVINF		BAD/0.997183
a	__unaligned__	DT	__unaligned__		BAD/0.979116
loading	Initialdosis	NN	NN		BAD/0.970749
dose	Initialdosis	NN	NN		OK/0.898234
of	__unaligned__	IN	__unaligned__		OK/0.837775
6	6	CD	CARD		OK/0.989713
mg	mg	NN	NN		OK/0.984170
Erwachsenem	Erwachsenem	NN	NN		OK/0.818952
usually	üblicherweise	RB	ADV		OK/0.825783
at	Zeitpunkt	IN	NN		OK/0.941528
the	__unaligned__	DT	__unaligned__		OK/0.906606
time	__unaligned__	NN	__unaligned__		OK/0.924556
of	__unaligned__	IN	__unaligned__		OK/0.898400
Nierentransplantations-	Nierentransplantations-	NP	TRUNC		OK/0.736340
surgery	Operation	NN	NN		OK/0.967356
.	.	SENT	$.		OK/0.998091

# 0.206169
A	Einige	NP	PIAT		OK/0.924567
few	Einige	JJ	PIAT		OK/0.928820
patients	Patienten	NNS	NN		OK/0.996031
who	denen	WP	PRELS		OK/0.944676
have	hypoglykämische	VHP	ADJA		OK/0.968480
experienced	hypoglykämische	VVN	ADJA		OK/0.974682
hypoglycaemic	hypoglykämische	JJ	ADJA		OK/0.891326
reactions	Reaktionen	NNS	NN		OK/0.949251
after	hypoglykämische	IN	ADJA		OK/0.969467
transfer	tierischem	NN	ADJA		OK/0.924615
from	__unaligned__	IN	__unaligned__		OK/0.938016
animal	__unaligned__	JJ	__unaligned__		OK/0.904969
source	__unaligned__	NN	__unaligned__		OK/0.799950
insulin	Insulin	NN	NN		OK/0.945112
have	auftraten	VHP	VVFIN		OK/0.907402
reported	berichteten	VVN	VVFIN		OK/0.864347
that	dass	IN/that	KOUS		OK/0.748900
early	frühen	JJ	ADJA		OK/0.887155
warning	Warnsymptome	NN	NN		OK/0.976396
symptoms	Warnsymptome	NNS	NN		OK/0.965984
of	__unaligned__	IN	__unaligned__		OK/0.929000
hypoglycaemia	Hypoglykämie	NN	NN		OK/0.969324
different	ausgeprägt	JJ	ADJD		OK/0.788550
or	ausgeprägt	CC	ADJD		OK/0.835804
less	ausgeprägt	RBR	ADJD		OK/0.920103
pronounced	ausgeprägt	JJ	ADJD		OK/0.953312
than	als	IN	KOKOM		OK/0.966685
prophylaxis	__unaligned__	NN	__unaligned__		OK/0.889892
or	oder	CC	KON		OK/0.959244
with	ihrem	IN	PPOSAT		OK/0.880457
their	__unaligned__	PP$	__unaligned__		OK/0.974286
previous	__unaligned__	JJ	__unaligned__		OK/0.944629
insulin	Insulin	NN	NN		OK/0.972219
.	.	SENT	$.		OK/0.999453

# 0.289185
Caution	Vorsicht	NN	NN		OK/0.998503
should	Vorsicht	MD	NN		OK/0.984950
be	Vorsicht	VB	NN		OK/0.961418
taken	__unaligned__	VVN	__unaligned__		OK/0.751455
in	bei	IN	APPR		OK/0.935332
HIV-positive	HIV-positiven	JJ	ADJA		OK/0.892606
subjects	__unaligned__	NNS	__unaligned__		OK/0.903146
co-infected	mit	VVN	APPR		OK/0.711634
with	__unaligned__	IN	__unaligned__		OK/0.853253
HCV	HCV	NP	NE		OK/0.948538
patients	Patienten	NNS	NN		OK/0.988929
receiving	Patienten	VVG	NN		OK/0.865395
treatment	Behandlung	NN	NN		OK/0.994879
with	mit	IN	APPR		OK/0.982660
Nukleosid-Reverse-	Nukleosid-Reverse-	NP	TRUNC		OK/0.960405
(	(	(	$(		OK/0.994974
NRTIs	NRTI	NP	NE		OK/0.972324
)	)	)	$(		OK/0.992766
(	(	(	$(		OK/0.992556
especially	insbesondere	RB	ADV		OK/0.993667
ddI	ddI	NN	NE		OK/0.885848
and	und	CC	KON		OK/0.995278
d4T	d4T	NN	NE		OK/0.937743
)	)	)	$(		OK/0.983584
and	sowie	CC	KON		OK/0.973431
associated	__unaligned__	VVN	__unaligned__		OK/0.912198
interferon	Interferon	NN	NN		OK/0.999691
alfa-2b	alfa-2b	NN	ADJA		OK/0.995957
/	/	SYM	$(		OK/0.998418
ribavirin	Ribavirin-	NN	TRUNC		OK/0.975338
treatment	Behandlung	NN	NN		OK/0.990425
.	.	SENT	$.		OK/0.993878

# 0.252020
Sanohex	Sanohex	NP	NE		OK/0.997979
is	wird	VBZ	VAFIN		OK/0.995003
used	angewendet	VVN	VVPP		OK/0.995708
to	angewendet	TO	VVPP		OK/0.962734
treat	angewendet	VV	VVPP		OK/0.976994
breathing	Atembeschwerden	NN	NN		OK/0.988214
difficulties	Atembeschwerden	NNS	NN		OK/0.926880
caused	verursacht	VVN	VVPP		OK/0.863076
by	verursacht	IN	VVPP		OK/0.833125
asthma	Asthma	NN	NN		OK/0.863080
and	und	CC	KON		OK/0.961970
chronisch-	chronisch-	NN	TRUNC		OK/0.823967
,	__unaligned__	,	__unaligned__		OK/0.701691
chronic	Lungenerkrankung	JJ	NN		OK/0.522681
obstructive	Lungenerkrankung	JJ	NN		OK/0.488485
pulmonary	Lungenerkrankung	JJ	NN		OK/0.973181
disease	Lungenerkrankung	NN	NN		OK/0.985147
(	(	(	$(		OK/0.931598
COPD	COPD	NN	NE		OK/0.872577
)	)	)	$(		OK/0.978725
.	.	SENT	$.		OK/0.996785

# 0.137942
abnormally	ungewöhnlich	RB	ADJD		OK/0.923931
large	starker	JJ	ADJA		OK/0.911983
excitability	Erregbarkeit	NN	NN		OK/0.738587
and	und	CC	KON		OK/0.939466
Gefühle	Gefühle	NP	NN		OK/0.838580
)	)	)	$(		OK/0.977148
,	,	,	$,		OK/0.996161
talk	sprechen	NN	VVFIN		OK/0.989969
to	sprechen	TO	VVFIN		OK/0.975887
your	Ihrem	PP$	PPOSAT		OK/0.999472
doctor	Arzt	NN	NN		OK/0.998549
before	bevor	IN	KOUS		OK/0.994546
you	Sie	PP	PPER		OK/0.998340
start	beginnen	VVP	VVFIN		OK/0.984334
to	einzunehmen	TO	VVIZU		OK/0.922831
take	einzunehmen	VV	VVIZU		OK/0.485276
the	das	DT	ART		OK/0.923843
medicines	Arzneimittel	NNS	NN		OK/0.945433
and	bzw.	CC	KON		OK/0.938334
continue	weiterhin	VVP	ADV		OK/0.898945
to	__unaligned__	TO	__unaligned__		OK/0.837800
take	einnehmen	VV	VVINF		OK/0.863612
this	__unaligned__	DT	__unaligned__		BAD/0.717530
medicine	__unaligned__	NN	__unaligned__		BAD/0.768794
.	.	SENT	$.		OK/0.986849

# 0.537838
Pregnancy	Schwangerschaft	NP	NN		OK/0.998626
and	und	CC	KON		OK/0.999632
breast-feeding	Stillzeit	VVG	NN		OK/0.994073
Ask	Fragen	NP	VVFIN		OK/0.998643
your	Arzt	PP$	NN		OK/0.992870
doctor	Ihren	NN	PPOSAT		OK/0.988328
before	vor	IN	APPR		OK/0.985402
using	Anwendung	VVG	NN		OK/0.991774
Viani	Viani	NP	NN		OK/0.954353
for	Rat	IN	NN		OK/0.993766
advice	Rat	NN	NN		OK/0.999138
before	Rat	IN	NN		OK/0.761630
taking	Rat	VVG	NN		OK/0.757943
any	Rat	DT	NN		OK/0.770811
medicine	Rat	NN	NN		OK/0.780364
if	wenn	IN	KOUS		OK/0.997643
you	Sie	PP	PPER		OK/0.998434
are	schwanger	VBP	ADJD		OK/0.999450
pregnant	schwanger	JJ	ADJD		OK/0.999479
or	oder	CC	KON		OK/0.999924
breast	stillen	NN	VVINF		OK/0.979880
feeding	stillen	NN	VVINF		OK/0.977754
.	.	SENT	$.		OK/0.999546

# 0.485148
Dose	Dosistitration	NP	NN		OK/0.952436
titration	Dosistitration	NN	NN		OK/0.763611
and	und	CC	KON		OK/0.742920
maintenance	Erhaltungstherapie	NN	NN		OK/0.928020
therapy	Erhaltungstherapie	NN	NN		OK/0.984126
The	Das	DT	ART		OK/0.986172
patch	Pflaster	NN	NN		OK/0.994458
should	sollte	MD	VMFIN		OK/0.969804
be	sollte	VB	VMFIN		OK/0.906228
applied	Pflaster	VVN	NN		OK/0.865876
every	alle	DT	PIS		OK/0.929213
72	72	CD	CARD		OK/0.886715
hours	Stunden	NNS	NN		OK/0.870563
.	.	SENT	$.		OK/0.998615

# 0.403983
medicinal	Arzneimittel	JJ	NN		OK/0.729402
products	Arzneimittel	NNS	NN		OK/0.870513
for	__unaligned__	IN	__unaligned__		OK/0.977276
parenteral	parenteralen	JJ	ADJA		OK/0.988590
administration	Anwendung	NN	NN		OK/0.913673
should	sollten	MD	VMFIN		OK/0.969550
be	sollten	VB	VMFIN		OK/0.894080
checked	überprüft	VVN	VVPP		OK/0.810136
before	vor	IN	APPR		OK/0.964129
visible	sichtbare	JJ	ADJA		OK/0.959618
foreign	Fremdpartikel	JJ	NN		OK/0.923594
particles	Fremdpartikel	NNS	NN		OK/0.969784
and	und	CC	KON		OK/0.999438
discoloration	Verfärbung	NN	NN		OK/0.987676
prior	Verfärbung	RB	NN		OK/0.987581
to	__unaligned__	TO	__unaligned__		OK/0.984246
administration	__unaligned__	NN	__unaligned__		OK/0.865274
.	.	SENT	$.		OK/0.993372

# 0.853113
For	Zur	IN	APPRART		OK/0.957942
intramuscular	intramuskulären	JJ	ADJA		OK/0.949904
use	Anwendung	NN	NN		OK/0.883082
.	.	SENT	$.		OK/0.997674

# 0.325847
The	Der	DT	ART		OK/0.994766
contents	Inhalt	NNS	NN		OK/0.980616
of	Inhalt	IN	NN		OK/0.965989
RotaTeq-Röhrchens	RotaTeq-Röhrchens	NP	NN		OK/0.899312
is	wird	VBZ	VAFIN		OK/0.932901
given	gegeben	VVN	VVPP		OK/0.866741
when	__unaligned__	WRB	__unaligned__		OK/0.789215
the	__unaligned__	DT	__unaligned__		OK/0.551492
baby	Säugling	NN	NN		OK/0.455703
is	__unaligned__	VBZ	__unaligned__		OK/0.601225
directly	direkt	RB	ADJD		OK/0.803179
in	in	IN	APPR		OK/0.937573
the	den	DT	ART		OK/0.998307
mouth	Mund	NN	NN		OK/0.983761
.	.	SENT	$.		OK/0.999214

# 0.004338
In	In	IN	APPR		OK/0.885824
each	jeder	DT	PIS		OK/0.916395
of	der	IN	ART		OK/0.907396
the	__unaligned__	DT	__unaligned__		OK/0.840915
studies	Feldstudien	NNS	NN		OK/0.820306
were	wurden	VBD	VAFIN		OK/0.787871
animals	Tiere	NNS	NN		OK/0.974959
of	verschiedener	IN	ADJA		OK/0.993948
various	verschiedener	JJ	ADJA		OK/0.997191
breeds	Rassen	NNS	NN		OK/0.967905
,	,	,	$,		OK/0.954008
these	Alters-	DT	TRUNC		OK/0.883645
two	__unaligned__	CD	__unaligned__		OK/0.771960
weight	Gewichtsgruppen	NN	NN		OK/0.563536
of	die	IN	PRELS		OK/0.536172
the	__unaligned__	DT	__unaligned__		OK/0.452143
prosthesis	__unaligned__	NN	__unaligned__		BAD/0.915155
(	Wege	(	NN		BAD/0.947872
10	__unaligned__	CD	__unaligned__		BAD/0.936624
)	__unaligned__	)	__unaligned__		BAD/0.825197
with	mit	IN	APPR		OK/0.909580
secondary	parasitären	JJ	ADJA		OK/0.860248
gastrointestinal	gastrointestinalen	JJ	ADJA		OK/0.807196
specified	Rund-	JJ	TRUNC		OK/0.799496
roundworms	Rund-	NNS	TRUNC		OK/0.983493
and	und	CC	KON		OK/0.992653
tapeworms	Bandwürmer	NNS	NN		OK/0.809531
in	__unaligned__	IN	__unaligned__		OK/0.663122
patients	__unaligned__	NNS	__unaligned__		OK/0.403740
infected	infiziert	VVN	VVPP		OK/0.833751
with	infiziert	IN	VVPP		OK/0.534558
either	entweder	DT	KON		OK/0.904577
Profender	Profender	NP	NN		OK/0.781918
or	oder	CC	KON		OK/0.992663
any	anderen	DT	PIS		OK/0.987991
other	anderen	JJ	PIS		OK/0.992014
approved	zugelassenen	VVN	ADJA		BAD/0.666530
for	für	IN	APPR		BAD/0.915564
this	diese	DT	PDAT		BAD/0.910461
indication	Indikation	NN	NN		BAD/0.757431
in	__unaligned__	IN	__unaligned__		BAD/0.907979
the	Europäischen	DT	ADJA		BAD/0.642751
European	Europäischen	NP	ADJA		BAD/0.669586
Union	Union	NP	NN		BAD/0.831122
are	__unaligned__	VBP	__unaligned__		BAD/0.876829
treated	behandelt	VVN	VVPP		BAD/0.624659
.	.	SENT	$.		OK/0.996284

# 0.418456
12	12	CD	CARD		OK/0.943119
After	Nach	IN	APPR		OK/0.963901
delivery	Geburt	NN	NN		OK/0.950011
,	Geburt	,	NN		OK/0.997294
insulin	Insulinbedarf	NN	NN		OK/0.996710
requirements	Insulinbedarf	NNS	NN		OK/0.997245
return	Insulinbedarf	VVP	NN		OK/0.943853
rapidly	kurzer	RB	ADJA		OK/0.977084
to	kurzer	TO	ADJA		OK/0.926629
pre-pregnancy	kurzer	NN	ADJA		OK/0.945557
values	Werte	NNS	NN		OK/0.912593
,	,	,	$,		BAD/0.615347
.	.	SENT	$.		OK/0.992792

# 0.243430
The	Das	DT	ART		OK/0.999289
risk	Risiko	NN	NN		OK/0.996745
of	Risiko	IN	NN		OK/0.982051
intussusception	Invagination	NN	NN		OK/0.918478
has	wurde	VHZ	VAFIN		OK/0.967638
been	wurde	VBN	VAFIN		OK/0.998051
studied	untersucht	VVN	VVPP		OK/0.998844
in	__unaligned__	IN	__unaligned__		OK/0.970122
a	großen	DT	ADJA		OK/0.994607
large	einer	JJ	ART		OK/0.975570
number	__unaligned__	NN	__unaligned__		OK/0.956459
of	__unaligned__	IN	__unaligned__		OK/0.986961
long-term	Sicherheitsstudie	JJ	NN		OK/0.995171
safety	Sicherheitsstudie	NN	NN		OK/0.990970
study	Sicherheitsstudie	NN	NN		OK/0.989517
with	mit	IN	APPR		OK/0.983866
63.225	63.225	CD	CARD		OK/0.790754
volunteers	Probanden	NNS	NN		OK/0.655339
in	in	IN	APPR		OK/0.620728
Lateinamerika	Lateinamerika	NP	NE		OK/0.446817
and	und	CC	KON		OK/0.865243
Finland	Finnland	NP	NE		OK/0.709474
.	.	SENT	$.		OK/0.996671

# 0.098466
(	__unaligned__	(	__unaligned__		OK/0.517049
e.	Atropin	FW	NN		OK/0.602420
g.	B.	FW	NN		OK/0.656830
atropine	Atropin	NN	NN		OK/0.682362
,	,	,	$,		OK/0.900640
biperiden	Biperiden	NP	NN		OK/0.791113
)	)	)	$(		OK/0.946253
may	können	MD	VMFIN		OK/0.992058
increase	erhöhen	VV	VVINF		OK/0.953671
the	erhöhen	DT	VVINF		OK/0.946872
bioavailability	Bioverfügbarkeit	NN	NN		OK/0.991351
of	__unaligned__	IN	__unaligned__		OK/0.939640
thiazide-type	thiazidartigen	NN	ADJA		OK/0.745161
diuretics	Diuretika	NNS	NN		OK/0.941628
by	__unaligned__	IN	__unaligned__		OK/0.800209
decreasing	__unaligned__	VVG	__unaligned__		OK/0.876392
gastrointestinal	__unaligned__	JJ	__unaligned__		OK/0.984199
motility	__unaligned__	NN	__unaligned__		OK/0.948663
and	und	CC	KON		OK/0.989195
stomach	Magenentleerung	VV	NN		OK/0.965011
emptying	Magenentleerung	VVG	NN		OK/0.912607
rate	Magenentleerung	NN	NN		OK/0.891978
from	Magen-Darm-Motilität	IN	NN		OK/0.742613
Mucor	Magen-Darm-Motilität	NP	NN		OK/0.712852
miehei	Magen-Darm-Motilität	NP	NN		OK/0.642953
.	.	SENT	$.		OK/0.995580

# 0.855058
Adverse	Unerwünschte	JJ	ADJA		OK/0.934772
effects	Auswirkungen	NNS	NN		OK/0.985812
on	Auswirkungen	IN	NN		OK/0.998809
cognitive	kognitive	JJ	ADJA		OK/0.992901
function	kognitive	NN	ADJA		OK/0.973073
have	wurden	VHP	VAFIN		OK/0.998590
not	nicht	RB	PTKNEG		OK/0.983551
been	wurden	VBN	VAFIN		OK/0.984638
observed	beobachtet	VVN	VVPP		OK/0.968434
.	.	SENT	$.		OK/0.999172

# 0.424911
Patients	Triglycerid-Serumspiegel	NPS	NN		OK/0.739177
with	__unaligned__	IN	__unaligned__		OK/0.906471
this	__unaligned__	DT	__unaligned__		OK/0.948543
medical	__unaligned__	JJ	__unaligned__		OK/0.988761
history	__unaligned__	NN	__unaligned__		OK/0.998610
should	sollten	MD	VMFIN		OK/0.988072
have	Raloxifen-Gabe	VH	NN		OK/0.895793
serum	Raloxifen-Gabe	NN	NN		OK/0.963539
triglycerides	Raloxifen-Gabe	NNS	NN		OK/0.975706
monitored	Raloxifen-Gabe	VVD	NN		OK/0.935322
when	Raloxifen-Gabe	WRB	NN		OK/0.889494
taking	Raloxifen-Gabe	VVG	NN		OK/0.902957
raloxifene	Raloxifen-Gabe	NN	NN		OK/0.729485
.	.	SENT	$.		OK/0.997695

# 0.561087
The	Das	DT	ART		OK/0.973650
disintegration	Ansatzstück	NN	NN		OK/0.794271
of	__unaligned__	IN	__unaligned__		OK/0.834192
the	Spritze	DT	NN		OK/0.941736
syringe	Spritze	NN	NN		OK/0.887603
taking	__unaligned__	VVG	__unaligned__		OK/0.913614
care	__unaligned__	NN	__unaligned__		OK/0.963007
not	nicht	RB	PTKNEG		OK/0.993437
to	berühren	TO	VVINF		OK/0.926290
touch	berühren	VV	VVINF		OK/0.927362
the	__unaligned__	DT	__unaligned__		OK/0.995195
needle	berühren	NN	VVINF		OK/0.938986
.	.	SENT	$.		OK/0.998808

# 0.470273
This	Diese	DT	PDAT		OK/0.964687
activity	Aktivität	NN	NN		OK/0.990300
could	könnte	MD	VMFIN		OK/0.998597
increase	erhöhen	VV	VVINF		OK/0.902487
the	erhöhen	DT	VVINF		OK/0.984700
risk	Risiko	NN	NN		OK/0.990232
of	Risiko	IN	NN		OK/0.817495
Purin-Nukleosid-	Purin-Nukleosid-	NP	ADJA		OK/0.698730
analogues	Analoga	NNS	NN		OK/0.717428
(	(	(	$(		OK/0.997054
e.	z.B.	FW	ADV		OK/0.969129
g.	z.B.	FW	ADV		OK/0.959134
didanosine	Didanosin	NN	NN		OK/0.990172
or	oder	CC	KON		OK/0.986744
abacavir	Abacavir	NN	NN		OK/0.993968
)	)	)	$(		OK/0.999081
induced	induzierten	VVN	ADJA		OK/0.999271
by	induzierten	IN	ADJA		OK/0.949166
lactic	Laktatazidose	JJ	NN		OK/0.986521
acidosis	Laktatazidose	NN	NN		OK/0.991707
.	.	SENT	$.		OK/0.999883

# 0.698539
8	8	CD	CARD		OK/0.997696
/	/	SYM	$(		OK/0.993729
24	24	CD	CARD		OK/0.991680
patients	Patienten	NNS	NN		OK/0.997479
with	mit	IN	APPR		OK/0.985554
Diabetic	autonomer	NP	ADJA		OK/0.918487
Autonomic	autonomer	NP	ADJA		OK/0.905448
Neuropathy	autonomer	NP	ADJA		OK/0.919092
Doxazosin	Doxazosin	NP	NN		OK/0.947537
should	Vorsicht	MD	NN		OK/0.955770
be	Vorsicht	VB	NN		OK/0.984376
administered	Vorsicht	VVN	NN		OK/0.978634
with	Vorsicht	IN	NN		OK/0.944477
caution	Vorsicht	NN	NN		OK/0.900146
.	.	SENT	$.		OK/0.997681

# 0.628629
Whenever	Sofern	WRB	KOUS		OK/0.847879
possible	möglich	JJ	ADJD		OK/0.942458
,	,	,	$,		OK/0.989974
fluoroquinolones	Fluorochinolone	NNS	NN		OK/0.956226
should	sollten	MD	VMFIN		OK/0.974180
only	nur	RB	ADV		OK/0.998917
be	nur	VB	ADV		OK/0.984638
used	verwendet	VVN	VVPP		OK/0.947753
based	Grundlage	VVN	NN		OK/0.955684
on	Grundlage	IN	NN		OK/0.958727
susceptibility	Antibiogramm	NN	NN		OK/0.956473
testing	__unaligned__	NN	__unaligned__		OK/0.871154
.	.	SENT	$.		OK/0.998036

# 0.610099
Barbara	Barbara	NP	NE		OK/0.838522
van	van	NP	NE		OK/0.831973
Zwieten-Boot	Zwieten-Boot	NP	NN		OK/0.840821
and	und	CC	KON		OK/0.931525
Dr	Dr.	NP	NN		OK/0.903145
Tomas	Tomas	NP	NE		OK/0.887358
Salmonson	Salmonson	NP	NE		OK/0.852707
.	.	SENT	$.		OK/0.997990

# 0.722638
This	Diese	DT	PDAT		OK/0.996662
summary	Zusammenfassung	NN	NN		OK/0.996720
was	wurde	VBD	VAFIN		OK/0.999108
last	08-2008	RB	CARD		OK/0.998170
updated	08-2008	VVN	CARD		OK/0.990160
in	08-2008	IN	CARD		OK/0.949510
08-2008	08-2008	CD	CARD		OK/0.735829
.	.	SENT	$.		OK/0.997049

# 0.559857
Adverse	Nebenwirkungen	JJ	NN		OK/0.990647
events	Nebenwirkungen	NNS	NN		OK/0.974619
associated	Zusammenhang	VVN	NN		OK/0.993603
with	mit	IN	APPR		OK/0.983764
Dukoral	Dukoral	NP	NN		OK/0.851776
are	sind	VBP	VAFIN		OK/0.676222
rare	selten	JJ	ADJD		OK/0.641404
.	.	SENT	$.		OK/0.997655

# 0.776915
This	Diese	NP	PDS		OK/0.989525
can	können	MD	VMFIN		OK/0.956977
usually	üblicherweise	RB	ADV		OK/0.961028
be	behandelt	VB	VVPP		OK/0.909991
treated	behandelt	VVN	VVPP		OK/0.842639
by	__unaligned__	IN	__unaligned__		OK/0.991885
your	Ihrem	PP$	PPOSAT		OK/0.997967
doctor	Arzt	NN	NN		OK/0.986569
.	.	SENT	$.		OK/0.997307

# 0.845628
There	gibt	RB	VVFIN		OK/0.989055
is	gibt	VBZ	VVFIN		OK/0.965277
limited	wenige	JJ	PIAT		OK/0.998966
information	Informationen	NN	NN		OK/0.996504
on	Informationen	IN	NN		OK/0.965742
the	die	DT	ART		OK/0.997903
use	Anwendung	NN	NN		OK/0.994618
of	die	IN	ART		OK/0.992329
ritonavir	Ritonavir	NN	NE		OK/0.984834
(	(	(	$(		OK/0.995620
the	der	DT	ART		OK/0.996238
active	Wirkstoff	JJ	NN		OK/0.993552
ingredient	Wirkstoff	NN	NN		OK/0.995693
in	der	IN	ART		OK/0.983652
Norvir	Norvir	NP	NE		OK/0.995929
)	)	)	$(		OK/0.993218
during	während	IN	APPR		OK/0.988041
pregnancy	Schwangerschaft	NN	NN		OK/0.988372
.	.	SENT	$.		OK/0.991368

# 0.118304
For	Bei	IN	APPR		OK/0.945028
each	jedem	DT	PIAT		OK/0.941968
patient	jedem	NN	PIAT		OK/0.547717
,	jedem	,	PIAT		OK/0.811170
unexplained	ungeklärten	JJ	ADJA		OK/0.695539
vaginal	ungeklärten	JJ	ADJA		OK/0.367306
haemoglobin	Hämoglobin-	NN	TRUNC		OK/0.876876
or	oder	CC	KON		OK/0.997907
blood	Blutdruckabfall	NN	NN		OK/0.989576
pressure	Blutdruckabfall	NN	NN		OK/0.991889
should	sollte	MD	VMFIN		OK/0.989132
be	sollte	VB	VMFIN		OK/0.924147
Blutungsquelle	Blutungsquelle	NP	NN		OK/0.861407
should	__unaligned__	MD	__unaligned__		OK/0.851785
be	__unaligned__	VB	__unaligned__		OK/0.707420
investigated	__unaligned__	VVN	__unaligned__		OK/0.629120
.	.	SENT	$.		OK/0.994450

# 0.192659
Continued	Fortsetzung	JJ	NN		OK/0.877226
therapy	Therapie	NN	NN		OK/0.979609
for	__unaligned__	IN	__unaligned__		OK/0.873623
up	zu	IN	APPR		OK/0.982067
to	bis	TO	KON		OK/0.994124
24	24	CD	CARD		OK/0.995116
months	Monate	NNS	NN		OK/0.976322
in	in	IN	APPR		OK/0.936092
an	offenen	DT	ADJA		OK/0.776595
open-label	offenen	NN	ADJA		OK/0.708133
study	Studie	NN	NN		OK/0.838495
of	Verlängerung	IN	NN		OK/0.872649
a	kontinuierliche	DT	ADJA		OK/0.993869
continuous	kontinuierliche	JJ	ADJA		OK/0.970576
resulted	bewirkte	VVN	VVFIN		OK/0.964410
in	__unaligned__	IN	__unaligned__		OK/0.971358
an	Zunahme	DT	NN		OK/0.569234
increase	Zunahme	NN	NN		OK/0.760083
in	Zunahme	IN	NN		OK/0.620638
BMD	BMD	NP	NN		OK/0.747024
.	.	SENT	$.		OK/0.997914

# 0.311686
If	Wenn	IN	KOUS		OK/0.996427
your	Ihr	PP$	PPOSAT		OK/0.990508
Blutzuckerspie-	Blutzuckerspie-	NN	NN		OK/0.841635
;	gel	:	VVFIN		OK/0.662693
decreased	gel	VVN	VVFIN		OK/0.642447
phosphates	gel	NNS	VVFIN		OK/0.677879
is	__unaligned__	VBZ	__unaligned__		OK/0.620628
falling	__unaligned__	VVG	__unaligned__		OK/0.704566
too	zu	RB	APPR		OK/0.801475
much	__unaligned__	RB	__unaligned__		OK/0.962461
you	Sie	PP	PPER		OK/0.976061
may	können	MD	VMFIN		OK/0.980446
become	werden	VV	VAINF		OK/0.844334
unconscious	bewusstlos	JJ	ADJD		OK/0.807912
.	.	SENT	$.		OK/0.990963

# 0.849711
Some	einigen	DT	PIAT		OK/0.992240
patients	Patienten	NNS	NN		OK/0.998871
experienced	trat	JJ	VVFIN		OK/0.982559
haematuria	Hämaturie	NN	ADJA		OK/0.883114
/	/	SYM	$(		OK/0.965722
proteinuria	Proteinurie	NN	NN		OK/0.969569
.	.	SENT	$.		OK/0.997674

# 0.523546
The	Die	DT	ART		OK/0.999611
most	häufigsten	RBS	ADJA		OK/0.998057
common	häufigsten	JJ	ADJA		OK/0.998736
side	Nebenwirkungen	NN	NN		OK/0.994910
effects	Nebenwirkungen	NNS	NN		OK/0.998551
with	von	IN	APPR		OK/0.988439
Comtan	Comtan	NP	NN		OK/0.992009
(	(	(	$(		OK/0.999706
seen	beobachtet	VVN	VVFIN		OK/0.998274
in	bei	IN	APPR		OK/0.969897
between	__unaligned__	IN	__unaligned__		OK/0.989078
1	1	CD	CARD		OK/0.991904
and	__unaligned__	CC	__unaligned__		OK/0.989934
10	10	CD	CARD		OK/0.998603
patients	Patienten	NNS	NN		OK/0.998176
in	Patienten	IN	NN		OK/0.987560
100	100	CD	CARD		OK/0.993663
)	)	)	$(		OK/0.978901
are	__unaligned__	VBP	__unaligned__		OK/0.888900
dyskinesia	Dyskinesie	NNS	NN		OK/0.902800
(	(	(	$(		OK/0.989202
uncontrollable	Störungen	JJ	NN		OK/0.974254
movements	__unaligned__	NNS	__unaligned__		OK/0.937488
)	)	)	$(		OK/0.985272
,	,	,	$,		OK/0.994664
nausea	Nausea	NN	NE		OK/0.986359
(	Nausea	(	NE		OK/0.976828
feeling	Nausea	VVG	NE		OK/0.986882
sick	Nausea	JJ	NE		OK/0.978625
)	)	)	$(		OK/0.996628
and	und	CC	KON		OK/0.992164
harmless	harmlose	JJ	ADJA		OK/0.838085
urine	harmlose	NN	ADJA		OK/0.917663
discoloration	harmlose	NN	ADJA		OK/0.889748
.	.	SENT	$.		OK/0.999362

# 0.724217
Clofarabine	Clofarabin	NP	NE		OK/0.953892
was	war	VBD	VAFIN		OK/0.980580
teratogenic	teratogen	JJ	VVFIN		OK/0.798072
in	Ratten	IN	NN		OK/0.988496
rats	Ratten	NNS	NN		OK/0.998654
and	und	CC	KON		OK/0.996133
rabbits	Kaninchen	NNS	NN		OK/0.947939
.	.	SENT	$.		OK/0.996148

# 0.941271
Procoralan	Procoralan	NP	NN		OK/0.989892
contains	enthält	VVZ	VVFIN		OK/0.993916
the	den	DT	ART		OK/0.999077
active	arzneilich	JJ	ADJD		OK/0.999101
substance	arzneilich	NN	ADJD		OK/0.999331
ivabradine	Ivabradin	NN	NE		OK/0.998428
is	__unaligned__	VBZ	__unaligned__		OK/0.996019
available	Stärken	JJ	NN		OK/0.989475
in	Stärken	IN	NN		OK/0.997648
strengths	Stärken	NNS	NN		OK/0.998518
of	Stärken	IN	NN		OK/0.998626
5	5	CD	CARD		OK/0.993536
mg	mg	NN	NN		OK/0.998663
or	oder	CC	KON		OK/0.995564
7.5	7,5	CD	CARD		OK/0.990897
mg	mg	NN	NN		OK/0.994700
.	.	SENT	$.		OK/0.999616

# 0.972933
.	.	SENT	$.		OK/0.972933

# 0.979407
What	Wofür	WP	NN		OK/0.999387
is	Wofür	VBZ	NN		OK/0.982230
Protopy	Protopy	NN	NN		OK/0.999284
used	angewendet	VVN	VVPP		OK/0.998909
for	angewendet	IN	VVPP		OK/0.999637
?	?	SENT	$.		OK/0.999337

# 0.472032
persisted	hielt	VVD	VVFIN		OK/0.931630
to	bis	TO	KON		OK/0.987930
completion	Abschluss	NN	NN		OK/0.994026
of	der	IN	ART		OK/0.998117
the	der	DT	ART		OK/0.974888
study	Studie	NN	NN		OK/0.984005
,	__unaligned__	,	__unaligned__		OK/0.547267
at	Woche	IN	NN		OK/0.803212
week	Woche	NN	NN		OK/0.899432
24	24	CD	CARD		OK/0.964676
.	.	SENT	$.		OK/0.998912

# 0.525694
Parahydroxybenzoates	Parahydroxybenzoate	NP	NN		OK/0.885771
may	können	MD	VMFIN		OK/0.927157
cause	verursachen	VV	VVINF		OK/0.921939
allergic	allergische	JJ	ADJA		OK/0.983561
reactions	Reaktionen	NNS	NN		OK/0.984520
(	(	(	$(		OK/0.996989
possibly	möglicherweise	RB	ADV		OK/0.731246
delayed	verzögert	VVN	VVPP		OK/0.695843
)	)	)	$(		OK/0.932839
.	.	SENT	$.		OK/0.979468

# 0.022830
Such	Solche	JJ	PIAT		OK/0.982753
methods	Methoden	NNS	NN		OK/0.975406
must	müssen	MD	VMFIN		OK/0.995366
take	müssen	VV	VMFIN		OK/0.984123
appropriate	ausreichende	JJ	ADJA		OK/0.984286
precision	Präzision	NN	NN		OK/0.935502
and	und	CC	KON		OK/0.949525
a	um	DT	KOUI		BAD/0.874362
processor	Richtigkeit	NN	NN		BAD/0.979380
(	__unaligned__	(	__unaligned__		BAD/0.963059
22	__unaligned__	CD	__unaligned__		BAD/0.920342
)	__unaligned__	)	__unaligned__		BAD/0.799886
to	__unaligned__	TO	__unaligned__		BAD/0.797401
show	zeigen	VV	VVINF		BAD/0.571599
the	__unaligned__	DT	__unaligned__		BAD/0.600967
HER2	HER2-Überexpression	NP	NN		BAD/0.661620
and	und	CC	KON		OK/0.661842
must	müssen	MD	VMFIN		OK/0.861525
be	müssen	VB	VMFIN		OK/0.921784
able	in	JJ	APPR		OK/0.906186
to	__unaligned__	TO	__unaligned__		OK/0.891052
discriminate	__unaligned__	VV	__unaligned__		OK/0.718866
between	zwischen	IN	APPR		OK/0.987933
moderate	mäßiger	JJ	ADJD		OK/0.978368
(	(	(	$(		OK/0.988745
with	mit	IN	APPR		OK/0.998079
2	2	CD	CARD		OK/0.998697
+	+	SYM	KON		OK/0.990838
)	)	)	$(		OK/0.993117
and	und	CC	KON		OK/0.992668
severe	starker	JJ	ADJA		OK/0.893280
(	(	(	$(		OK/0.937893
agrees	übereinstimmend	VVZ	ADJD		OK/0.745603
to	__unaligned__	TO	__unaligned__		OK/0.724046
discriminate	unterscheiden	VV	VVINF		BAD/0.763645
with	mit	IN	APPR		OK/0.738889
3	3	CD	CARD		OK/0.984624
+	+	SYM	KON		OK/0.988338
)	)	)	$(		OK/0.991094
levels	Überexpression	NNS	NN		OK/0.822802
of	von	IN	APPR		OK/0.975513
overexpression	Überexpression	NN	NN		OK/0.971137
of	von	IN	APPR		OK/0.971570
HER2	HER2	NP	ADJD		OK/0.946217
.	.	SENT	$.		OK/0.999433

# 0.881641
2	2	CD	CARD		OK/0.929121
/	/	SYM	$(		OK/0.975955
3	3	CD	CARD		OK/0.988983
Why	Warum	WRB	PWAV		OK/0.998458
has	Warum	VHZ	PWAV		OK/0.989202
Tysabri	Tysabri	NP	NE		OK/0.981116
been	zugelassen	VBN	VVPP		OK/0.992425
approved	zugelassen	VVN	VVPP		OK/0.992832
?	?	SENT	$.		OK/0.999356

# 0.583671
11	11	CD	CARD		OK/0.987815
,	,	,	$,		OK/0.993376
34	34	CD	CARD		OK/0.977352
)	)	)	$(		OK/0.980504
in	in	IN	APPR		OK/0.901904
the	to-treat	DT	NN		OK/0.847605
intent-to-treat	intent-	JJ	TRUNC		OK/0.667657
analysis	-Analyse	NN	NN		OK/0.740743
.	.	SENT	$.		OK/0.994374

# 0.565381
12	12	CD	CARD		OK/0.890625
Keep	Die	VV	ART		OK/0.734840
the	__unaligned__	DT	__unaligned__		OK/0.997068
vial	Durchstechflasche	NN	NN		OK/0.993902
in	im	IN	APPRART		OK/0.999410
the	im	DT	APPRART		OK/0.998307
outer	Umkarton	JJ	NN		OK/0.993049
carton	Umkarton	NN	NN		OK/0.992376
in	den	IN	ART		OK/0.998995
order	schützen	NN	VVINF		OK/0.977520
to	schützen	TO	VVINF		OK/0.964520
protect	schützen	VV	VVINF		OK/0.955773
it	__unaligned__	PP	__unaligned__		OK/0.855738
from	schützen	IN	VVINF		OK/0.970014
light	schützen	NN	VVINF		OK/0.962476
.	.	SENT	$.		OK/0.998733

# 0.051405
Alternatively	Alternativ	RB	ADJD		OK/0.964032
,	,	,	$,		OK/0.998880
e.	z.B.	FW	ADV		OK/0.992176
g.	z.B.	FW	ADV		OK/0.960332
in	im	IN	APPRART		OK/0.989008
case	Falle	NN	NN		OK/0.856854
of	Falle	IN	NN		OK/0.664423
higher	stärkerer	JJR	ADJA		OK/0.657044
bleeding	Blutungen	NN	NN		OK/0.857617
,	,	,	$,		OK/0.897369
TachoSil	TachoSil	NP	NN		OK/0.837856
can	kann	MD	VMFIN		OK/0.904514
be	kann	VB	VMFIN		OK/0.934716
given	__unaligned__	VVN	__unaligned__		OK/0.724065
without	ohne	IN	APPR		OK/0.877792
Vorbefeuchten	Vorbefeuchten	NP	NN		OK/0.536346
,	,	,	$,		OK/0.775415
for	für	IN	APPR		OK/0.720378
3-5	3-5	CD	CARD		OK/0.856265
minutes	Minuten	NNS	NN		OK/0.940439
,	,	,	$,		OK/0.868299
to	die	TO	ART		OK/0.840947
the	die	DT	ART		OK/0.914053
body	__unaligned__	NN	__unaligned__		OK/0.846888
(	__unaligned__	(	__unaligned__		OK/0.540392
2	__unaligned__	CD	__unaligned__		OK/0.421287
)	__unaligned__	)	__unaligned__		OK/0.468576
.	.	SENT	$.		OK/0.887847

# 0.940569
How	Wie	NP	KOKOM		OK/0.993438
to	einzunehmen	TO	VVIZU		OK/0.977074
take	einzunehmen	VV	VVIZU		OK/0.971207
Thymanax	Thymanax	NP	NN		OK/0.985494
?	?	SENT	$.		OK/0.990614

# 0.967605
What	Wofür	WP	NN		OK/0.997592
is	Wofür	VBZ	NN		OK/0.985350
Xarelto	Xarelto	NN	NE		OK/0.997213
used	angewendet	VVN	VVPP		OK/0.991700
for	angewendet	IN	VVPP		OK/0.992129
?	?	SENT	$.		OK/0.999162

# 0.497154
Therefore	Daher	RB	PAV		OK/0.993483
,	Daher	,	PAV		OK/0.969480
during	während	IN	APPR		OK/0.931734
treatment	Behandlung	NN	NN		OK/0.953583
,	__unaligned__	,	__unaligned__		OK/0.949677
monitoring	Überwachung	VVG	NN		OK/0.982951
of	Überwachung	IN	NN		OK/0.916949
Digoxin-Konzentration	Digoxin-Konzentration	NN	NN		OK/0.769274
with	mit	IN	APPR		OK/0.971766
lenalidomide	Lenalidomid	NN	NN		OK/0.866396
is	angezeigt	VBZ	VVPP		OK/0.818934
indicated	angezeigt	VVN	VVPP		OK/0.798156
.	.	SENT	$.		OK/0.998496

# 0.195023
Treatment	Behandlung	NP	NN		OK/0.984072
with	mit	IN	APPR		OK/0.885528
<	Name	SYM	NN		BAD/0.856671
Invented	Phantasiebezeichnung	JJ	NN		OK/0.883904
Name	Name	NN	NN		OK/0.914225
>	Name	SYM	NN		BAD/0.880665
should	sollte	MD	VMFIN		OK/0.980950
be	sollte	VB	VMFIN		OK/0.994827
initiated	eingeleitet	VVN	VVPP		OK/0.992682
by	Ärzten	IN	NN		OK/0.994943
physicians	Ärzten	NNS	NN		OK/0.998852
with	Ärzten	IN	NN		OK/0.981034
experience	Erfahrung	NN	NN		OK/0.989271
in	in	IN	APPR		OK/0.999269
the	der	DT	ART		OK/0.999438
diagnosis	Diagnose	NN	NN		OK/0.992426
and	und	CC	KON		OK/0.999132
treatment	Behandlung	NN	NN		OK/0.976612
of	Behandlung	IN	NN		OK/0.912832
atopic	atopischen	JJ	ADJA		BAD/0.539288
dermatitis	atopischen	NN	ADJA		BAD/0.545570
.	.	SENT	$.		OK/0.987534

# 0.581825
Patients	Patienten	NPS	NN		OK/0.985338
who	Patienten	WP	NN		OK/0.945696
were	vorhergegangene	VBD	ADJA		OK/0.798429
non-responders	vorhergegangene	NNS	ADJA		OK/0.855225
to	__unaligned__	TO	__unaligned__		OK/0.888826
previous	vorhergegangene	JJ	ADJA		OK/0.902031
treatment	Behandlung	NN	NN		OK/0.980249
with	mit	IN	APPR		OK/0.982836
pegylated	pegyliertem	JJ	ADJA		OK/0.923229
interferon	Interferon	NN	NN		OK/0.998588
alfa-2b	alfa-	NN	TRUNC		OK/0.993659
/	/	SYM	$(		OK/0.994190
ribavirin	Ribavirin	NN	NN		OK/0.990727
treatment	abgebrochen	NN	VVPP		OK/0.995793
due	wegen	JJ	APPR		OK/0.996788
to	wegen	TO	APPR		OK/0.996240
haematological	hämatologischer	JJ	ADJA		OK/0.972336
toxicity	Toxizität	NN	NN		OK/0.989553
were	waren	VBD	VAFIN		OK/0.991755
excluded	ausgeschlossen	VVN	VVPP		OK/0.995510
from	aus	IN	APPR		OK/0.994887
this	dieser	DT	PDAT		OK/0.989132
study	Studie	NN	NN		OK/0.969992
.	.	SENT	$.		OK/0.997649

# 0.602446
The	Die	DT	ART		OK/0.995814
use	Anwendung	NN	NN		OK/0.997413
of	von	IN	APPR		OK/0.992468
premedicants	Prämedikationen	NNS	NN		OK/0.948449
does	Prämedikationen	VVZ	NN		OK/0.977977
not	Prämedikationen	RB	NN		OK/0.995227
affect	Prämedikationen	VV	NN		OK/0.971906
the	die	DT	ART		OK/0.951020
required	Narkoseeinleitung	JJ	NN		OK/0.812965
Sevofluran-	Sevofluran-	NP	TRUNC		OK/0.680269
.	.	SENT	$.		OK/0.991193

# 0.334660
The	Die	DT	ART		OK/0.877457
sample	Probenröhrchen	NN	NN		OK/0.509179
tube	__unaligned__	NN	__unaligned__		OK/0.667556
should	müssen	MD	VMFIN		OK/0.758112
be	müssen	VB	VMFIN		OK/0.906855
in	in	IN	APPR		OK/0.967599
the	in	DT	APPR		OK/0.990322
original	Originalverpackung	JJ	NN		OK/0.978881
packaging	__unaligned__	NN	__unaligned__		OK/0.969987
,	__unaligned__	,	__unaligned__		OK/0.976266
to	__unaligned__	TO	__unaligned__		OK/0.950134
a	qualifizierten	DT	ADJA		OK/0.974672
qualified	qualifizierten	JJ	ADJA		OK/0.961157
laboratory	Labor	NN	NN		OK/0.914005
for	__unaligned__	IN	__unaligned__		OK/0.857459
analysis	Analyse	NN	NN		OK/0.935520
.	.	SENT	$.		OK/0.999072

# 0.422182
In	Beim	IN	APPRART		OK/0.998225
humans	Beim	NNS	APPRART		OK/0.999317
,	__unaligned__	,	__unaligned__		OK/0.989432
there	__unaligned__	EX	__unaligned__		OK/0.819308
were	wurden	VBD	VAFIN		OK/0.769187
no	keine	DT	PIAT		OK/0.956902
metabolites	Metaboliten	NNS	NN		OK/0.779135
have	identifiziert	VHP	VVPP		OK/0.718392
been	identifiziert	VBN	VVPP		OK/0.824939
identified	identifiziert	VVN	VVPP		OK/0.964316
so	bisher	RB	ADV		OK/0.936294
far	bisher	RB	ADV		OK/0.839906
.	.	SENT	$.		OK/0.994314

# 0.153553
In	Bei	IN	APPR		OK/0.519920
dogs	Hunden	NNS	NN		OK/0.428747
and	und	CC	KON		OK/0.745611
rats	Ratten	NNS	NN		OK/0.779331
were	beobachtet	VBD	VVPP		BAD/0.874794
observed	beobachtet	VVN	VVPP		OK/0.738582
after	nach	IN	APPR		OK/0.993834
administration	Applikation	NN	NN		OK/0.989983
of	__unaligned__	IN	__unaligned__		OK/0.977377
high	hoher	JJ	ADJA		OK/0.988901
doses	Dosen	NNS	NN		OK/0.998986
of	__unaligned__	IN	__unaligned__		OK/0.826930
RISPERDAL	RISPERDAL	NP	NN		OK/0.989059
CONSTA	CONSTA	NP	NE		OK/0.992685
local	lokale	JJ	ADJA		OK/0.968015
irritation	Irritationen	NN	NN		OK/0.972513
at	Injektionsstelle	IN	NN		OK/0.989464
the	Injektionsstelle	DT	NN		OK/0.999842
site	Injektionsstelle	NN	NN		OK/0.996235
of	__unaligned__	IN	__unaligned__		OK/0.979513
the	Injektionsstelle	DT	NN		OK/0.996857
injection	Injektionsstelle	NN	NN		OK/0.973377
.	.	SENT	$.		OK/0.999700

# 0.263138
The	Die	DT	ART		OK/0.907155
adverse	Nebenwirkungen	JJ	NN		OK/0.988804
reactions	Nebenwirkungen	NNS	NN		OK/0.997272
listed	aufgelisteten	VVN	ADJA		OK/0.980047
above	oben	IN	ADV		OK/0.965671
in	bei	IN	APPR		OK/0.935400
patients	Patienten	NNS	NN		OK/0.839497
who	Patienten	WP	NN		OK/0.646462
have	__unaligned__	VHP	__unaligned__		OK/0.382170
a	__unaligned__	DT	__unaligned__		OK/0.664325
poor	schlechten	JJ	ADJA		OK/0.654043
performance	Allgemeinzustand	NN	NN		OK/0.938741
status	Allgemeinzustand	NN	NN		OK/0.969305
(	siehe	(	VVIMP		OK/0.999026
see	siehe	VV	VVIMP		OK/0.998230
section	Abschnitt	NN	NN		OK/0.994877
4.4	4.4	CD	CARD		OK/0.992190
)	)	)	$(		OK/0.991906
.	.	SENT	$.		OK/0.995743

# 0.020585
Any	Jede	DT	PIAT		OK/0.728698
person	Person	NN	NN		OK/0.952020
intending	__unaligned__	VVG	__unaligned__		OK/0.942812
to	__unaligned__	TO	__unaligned__		OK/0.939072
import	die	VV	PRELS		OK/0.918025
,	,	,	$,		OK/0.920585
sell	Absicht	VV	NN		OK/0.644628
the	__unaligned__	DT	__unaligned__		OK/0.982212
veterinary	Tierarzneimittel	JJ	NN		OK/0.980409
medicinal	Tierarzneimittel	JJ	NN		OK/0.982764
product	Tierarzneimittel	NN	NN		OK/0.986011
import	verkaufen	NN	VVINF		OK/0.942838
,	,	,	$,		OK/0.983277
sell	verkaufen	VV	VVINF		OK/0.935459
,	,	,	$,		OK/0.982183
supply	verkaufen	VV	VVINF		OK/0.931225
and	und	CC	KON		OK/0.998610
/	/	SYM	$(		OK/0.993632
or	oder	CC	KON		OK/0.996377
use	anzuwenden	VV	VVIZU		OK/0.944970
the	__unaligned__	DT	__unaligned__		OK/0.932468
veterinary	__unaligned__	JJ	__unaligned__		BAD/0.757077
medicinal	__unaligned__	JJ	__unaligned__		BAD/0.641269
product	__unaligned__	NN	__unaligned__		BAD/0.566535
must	muß	MD	VMFIN		BAD/0.475573
consult	sich	VV	PRF		BAD/0.459275
the	__unaligned__	DT	__unaligned__		OK/0.774253
relevant	__unaligned__	JJ	__unaligned__		OK/0.890076
to	dem	TO	ART		OK/0.792555
the	dem	DT	ART		OK/0.960735
import	Einfuhr	NN	NN		OK/0.951941
,	,	,	$,		OK/0.993220
sale	Verkauf	NN	NN		OK/0.980804
,	Verkauf	,	NN		OK/0.988412
supply	Verkauf	NN	NN		OK/0.969151
and	und	CC	KON		OK/0.999419
/	/	SYM	$(		OK/0.996773
or	oder	CC	KON		OK/0.996866
use	Anwendung	VV	NN		OK/0.988672
of	__unaligned__	IN	__unaligned__		OK/0.986598
national	nationalen	JJ	ADJA		OK/0.721570
policies	geltenden	NNS	ADJA		OK/0.504874
.	.	SENT	$.		OK/0.965671

# 0.823040
-	-	:	$(		OK/0.964850
The	Der	DT	ART		OK/0.998407
active	Wirkstoff	JJ	NN		OK/0.995141
substance	Wirkstoff	NN	NN		OK/0.995268
is	Wirkstoff	VBZ	NN		OK/0.980629
ganirelix	Ganirelix	NN	NE		OK/0.952997
(	(	(	$(		OK/0.996882
0.25	0,25	CD	CARD		OK/0.996068
mg	mg	NN	NN		OK/0.998767
)	)	)	$(		OK/0.998316
in	in	IN	APPR		OK/0.962335
0.5	0,5	CD	CARD		OK/0.989450
ml	ml	NN	NN		OK/0.993765
of	Lösung	IN	NN		OK/0.962849
solution	Lösung	NN	NN		OK/0.988115
.	.	SENT	$.		OK/0.999566

# 0.891798
The	Die	DT	ART		OK/0.995279
infusion	Infusion	NN	NN		OK/0.988639
should	sollte	MD	VMFIN		OK/0.965046
be	sollte	VB	VMFIN		OK/0.995730
administered	verabreicht	VVN	VVPP		OK/0.993169
over	über	IN	APPR		OK/0.984618
at	mindestens	IN	ADV		OK/0.978681
least	mindestens	JJS	ADV		OK/0.971531
30	30	CD	CARD		OK/0.995837
minutes	Minuten	NNS	NN		OK/0.988767
.	.	SENT	$.		OK/0.999215

# 0.512069
Each	Jede	DT	PIAT		OK/0.996748
pack	Packung	NN	NN		OK/0.992914
of	Packung	IN	NN		OK/0.991366
Convenia	Convenia	NP	NE		OK/0.973873
contains	enthält	VVZ	VVFIN		OK/0.966652
two	zwei	CD	CARD		OK/0.996363
vials	Durchstechflaschen	NNS	NN		OK/0.981186
,	,	,	$,		OK/0.932035
one	__unaligned__	CD	__unaligned__		OK/0.722350
containing	__unaligned__	VVG	__unaligned__		OK/0.735766
the	__unaligned__	DT	__unaligned__		OK/0.858203
powder	Pulver	NN	NN		OK/0.911547
,	,	,	$,		OK/0.876113
and	und	CC	KON		OK/0.994777
the	die	DT	ART		OK/0.987030
other	andere	JJ	PIS		OK/0.988679
with	mit	IN	APPR		OK/0.997586
the	__unaligned__	DT	__unaligned__		OK/0.994464
diluent	Verdünnungsmittel	NN	NN		OK/0.951949
.	.	SENT	$.		OK/0.998534

# 0.514288
To	Zur	TO	APPRART		OK/0.958855
maintain	Aufrechterhaltung	VV	NN		OK/0.991425
the	Aufrechterhaltung	DT	NN		OK/0.993417
effect	Wirkung	NN	NN		OK/0.986971
of	Wirkung	IN	NN		OK/0.916499
the	Wirkung	DT	NN		OK/0.951361
treatment	Behandlung	NN	NN		OK/0.935943
is	__unaligned__	VBZ	__unaligned__		OK/0.668911
undertaken	__unaligned__	VVN	__unaligned__		OK/0.731322
every	alle	DT	PIAT		OK/0.793488
6	6	CD	CARD		OK/0.913996
months	Monate	NNS	NN		OK/0.974058
.	.	SENT	$.		OK/0.999603

# 0.262960
Follow	Folgen	NP	NN		OK/0.926243
them	Folgen	PP	NN		OK/0.915982
exactly	genau	RB	ADJD		OK/0.924550
and	und	CC	KON		OK/0.987762
visit	Ih-	VV	NN		OK/0.774736
your	Sie	PP$	PPER		OK/0.649247
diabetes	__unaligned__	NN	__unaligned__		OK/0.662039
clinic	behandelnden	NN	ADJA		OK/0.481432
regularly	regelmäßig	RB	ADJD		OK/0.859488
.	.	SENT	$.		OK/0.989107
•	•	NN	NN		OK/0.999886
If	Falls	IN	KOUS		OK/0.985881
you	Sie	PP	PPER		OK/0.988101
change	Insulinart	VVP	NN		OK/0.913614
(	(	(	$(		OK/0.944172
e.	z.	FW	APPRART		OK/0.902199
g	z.	NN	APPRART		OK/0.883149
.	z.	SENT	APPRART		OK/0.953763

# 0.153429
too	zu	RB	APPR		OK/0.443252
negative	negativen	JJ	ADJA		OK/0.834339
results	Ergebnisse	NNS	NN		OK/0.784849
,	,	,	$,		OK/0.993163
especially	Tuberkulin-Hauttests	RB	NN		OK/0.959904
in	bei	IN	APPR		OK/0.953152
patients	bei	NNS	APPR		OK/0.947467
who	,	WP	$,		OK/0.960669
are	__unaligned__	VBP	__unaligned__		OK/0.854525
severely	__unaligned__	RB	__unaligned__		BAD/0.571645
ill	schwer	JJ	ADJD		BAD/0.834679
.	.	SENT	$.		OK/0.994922

# 0.372129
Some	einigen	RB	PIAT		OK/0.992296
of	der	IN	ART		OK/0.994138
the	der	DT	ART		OK/0.987501
patients	Patienten	NNS	NN		OK/0.954492
was	war	VBD	VAFIN		OK/0.862742
an	__unaligned__	DT	__unaligned__		OK/0.652940
intervention	Intervention	NN	NN		OK/0.874235
by	mittels	IN	APPR		OK/0.961208
a	Diuretikum	DT	NN		OK/0.979208
majority	__unaligned__	NN	__unaligned__		OK/0.983518
of	Aufnahme	IN	NN		OK/0.913709
the	des	DT	ART		OK/0.970656
Flüssigkeitshaushalts	Flüssigkeitshaushalts	NP	NN		OK/0.802994
or	oder	CC	KON		OK/0.989359
congestive	dekompensierten	JJ	ADJA		OK/0.985265
heart	Herzinsuffizienz	NN	NN		OK/0.996076
failure	Herzinsuffizienz	NN	NN		OK/0.941634
is	erforderlich	VBZ	ADJD		OK/0.869575
required	erforderlich	VVN	ADJD		OK/0.904397
.	.	SENT	$.		OK/0.999194

# 0.290157
feeling	Übelkeitsgefühl	NN	NN		OK/0.964617
sick	Übelkeitsgefühl	NN	NN		OK/0.977834
and	und	CC	KON		OK/0.998715
nausea	Übelkeit	NN	NN		OK/0.948551
(	Übelkeit	(	NN		BAD/0.522716
feeling	Übelkeit	VVG	NN		BAD/0.606286
sick	Übelkeit	JJ	NN		BAD/0.697803
)	Übelkeit	)	NN		BAD/0.644447
,	,	,	$,		OK/0.991623
vomiting	Erbrechen	NN	NN		OK/0.991838
,	Verstopfung	,	NN		OK/0.994596
constipation	Verstopfung	NN	NN		OK/0.983830
and	und	CC	KON		OK/0.997495
diarrhoea	Durchfall	NN	NN		OK/0.885447
.	.	SENT	$.		OK/0.993657

# 0.052596
M98-863	M98-863	NP	NN		OK/0.905048
is	ist	VBZ	VAFIN		OK/0.942760
a	randomisierte	DT	ADJA		OK/0.885364
randomised	randomisierte	VVN	ADJA		OK/0.903665
,	,	,	$,		OK/0.955833
double-blind	doppelblinde	JJ	ADJA		OK/0.802497
trial	Studie	NN	NN		BAD/0.515501
of	__unaligned__	IN	__unaligned__		BAD/0.714459
653	653	CD	CARD		BAD/0.822815
antiretroviral	antiretroviral	JJ	NN		OK/0.631795
naïve	naiven	NN	ADJA		OK/0.820322
patients	Patienten	NNS	NN		OK/0.969573
receiving	Patienten	VVG	NN		OK/0.898426
Kaletra	Kaletra	NP	NE		OK/0.995346
(	(	(	$(		OK/0.899665
400	400	CD	CARD		OK/0.990855
/	/	SYM	$(		OK/0.998647
100	100	CD	CARD		OK/0.996171
mg	mg	NN	NN		OK/0.979455
twice	2x	RB	VVFIN		OK/0.968254
daily	täglich	JJ	ADJD		OK/0.985469
)	)	)	$(		OK/0.989450
compared	mit	VVN	APPR		OK/0.901111
to	__unaligned__	TO	__unaligned__		OK/0.964941
nelfinavir	Nelfinavir	NP	NE		OK/0.980232
(	(	(	$(		OK/0.997874
750	750	CD	CARD		OK/0.993895
mg	mg	NN	NN		OK/0.998524
three	3x	CD	VVFIN		OK/0.968992
times	3x	NNS	VVFIN		OK/0.992409
daily	täglich	RB	ADJD		OK/0.994528
)	)	)	$(		OK/0.998624
plus	plus	CC	ADV		OK/0.876608
NRTIs	NRTI	NP	NN		OK/0.865674
compared	verglich	VVD	VVFIN		OK/0.627364
.	.	SENT	$.		OK/0.992126

# 0.992639
How	Wie	NP	KOKOM		OK/0.996787
is	wird	VBZ	VAFIN		OK/0.997968
Viracept	Viracept	RB	NN		OK/0.999015
used	angewendet	VVN	VVPP		OK/0.998927
?	?	SENT	$.		OK/0.999606

# 0.229200
Breakpoints	Breakpoints	NP	NN		OK/0.816020
The	Die	NP	ART		OK/0.921064
EUCAST	EUCAST	NP	NN		OK/0.681758
(	(	(	$(		OK/0.991102
European	European	NP	NE		OK/0.989397
Committee	Committee	NP	NE		OK/0.964218
on	on	IN	ADJA		OK/0.970476
Antimicrobial	Antimicrobial	NP	NN		OK/0.962609
Susceptibility	Susceptibility	NP	NE		OK/0.884416
Testing	Testing	NP	NN		OK/0.803599
Breakpoints	Breakpoints	NP	NN		OK/0.758773
above	Breakpoints	IN	NN		OK/0.733713
the	__unaligned__	DT	__unaligned__		OK/0.714067
minimum	__unaligned__	JJ	__unaligned__		OK/0.648309
inhibitory	__unaligned__	JJ	__unaligned__		OK/0.789168
concentrations	__unaligned__	NNS	__unaligned__		OK/0.790483
(	(	(	$(		OK/0.995217
MIC	MHK	JJ	NN		OK/0.989768
)	)	)	$(		OK/0.991186
are	__unaligned__	VBP	__unaligned__		OK/0.973438
as	folgt	RB	VVFIN		OK/0.975672
follows	folgt	VVZ	VVFIN		OK/0.965863
:	:	:	$.		OK/0.999511

# 0.907834
anaemia	Anämie	NN	NN		OK/0.998596
,	,	,	$,		OK/0.976860
neutropenia	Neutropenie	NN	NN		OK/0.979983
and	und	CC	KON		OK/0.994398
leucopenia	Leukopenie	NN	NN		OK/0.961503
Uncommon	Gelegentlich	NN	ADJD		OK/0.964671
:	:	:	$.		OK/0.999002

# 0.264865
During	Während	IN	APPR		OK/0.993144
the	ersten	DT	ADJA		OK/0.991192
first	ersten	JJ	ADJA		OK/0.730509
absorbent	21-tägigen	NN	ADJA		BAD/0.689758
and	die	CC	ART		BAD/0.839223
the	Behandlung	DT	NN		OK/0.741566
quantity	Futtermenge	NN	NN		OK/0.965840
of	__unaligned__	IN	__unaligned__		OK/0.984445
daily	__unaligned__	JJ	__unaligned__		OK/0.979339
animal	Tieres	NN	NN		OK/0.976153
may	kann	MD	VMFIN		OK/0.983511
remain	bleiben	VV	VVINF		OK/0.994480
unchanged	unverändert	JJ	ADJD		OK/0.975648
.	.	SENT	$.		OK/0.999792

# 0.199252
In	In	IN	APPR		OK/0.995373
both	beiden	DT	PIAT		OK/0.991710
trials	Studien	NNS	NN		OK/0.961841
,	__unaligned__	,	__unaligned__		OK/0.851839
concomitant	Begleitmedikation	JJ	NN		OK/0.739805
AEDs	Begleitmedikation	NNS	NN		OK/0.729233
are	__unaligned__	VBP	__unaligned__		OK/0.530628
on	__unaligned__	IN	__unaligned__		OK/0.359093
stable	stabilen	JJ	ADJA		OK/0.717292
doses	Dosen	NNS	NN		OK/0.840335
of	__unaligned__	IN	__unaligned__		OK/0.879979
folic	Folsäure	JJ	NN		OK/0.979274
acid	Folsäure	NN	NN		OK/0.976252
,	,	,	$,		OK/0.988344
oral	oralen	JJ	ADJA		OK/0.993368
corticosteroids	Kortikosteroiden	NNS	NN		OK/0.972893
(	(	(	$(		OK/0.996469
≤	≤	NN	NE		OK/0.997918
10	10	CD	CARD		OK/0.998815
mg	mg	NN	NN		OK/0.998229
/	/	SYM	$(		OK/0.999535
day	Tag	NN	NN		OK/0.999038
)	)	)	$(		OK/0.982306
and	und	CC	KON		OK/0.998941
/	/	SYM	$(		OK/0.990128
or	oder	CC	KON		OK/0.994213
non-steroidal	Antiphlogistika	NN	NN		OK/0.866020
anti-inflammatory	Antiphlogistika	JJ	NN		OK/0.903238
drugs	Antiphlogistika	NNS	NN		OK/0.952458
(	(	(	$(		OK/0.990410
NSAIDs	NSAIDs	NP	NE		OK/0.996099
)	)	)	$(		OK/0.991480
.	.	SENT	$.		OK/0.996564

# 0.604992
medicinal	Arzneimittel	JJ	NN		OK/0.962315
products	Arzneimittel	NNS	NN		OK/0.980786
on	auf	IN	APPR		OK/0.986921
special	spezielle	JJ	ADJA		OK/0.992631
and	und	CC	KON		OK/0.997114
restricted	eingeschränkte	JJ	ADJA		OK/0.915070
medical	ärztliche	JJ	ADJA		OK/0.965489
prescription	Verschreibung	NN	NN		OK/0.992766
(	(	(	$(		OK/0.830071
See	siehe	NP	VVIMP		OK/0.868503
Annex	Anhang	NP	NN		OK/0.933597
I	I	NP	FM		OK/0.876211
:	:	:	$.		OK/0.926868

# 0.234917
The	Die	DT	ART		OK/0.969473
metabolites	Metaboliten	NNS	NN		OK/0.915606
are	Metaboliten	VBP	NN		OK/0.785819
eliminated	eliminiert	VVN	VVPP		OK/0.980196
by	eliminiert	IN	VVPP		OK/0.962947
plasma	Plasma	NN	NN		OK/0.989010
and	und	CC	KON		OK/0.990893
urine	Urin	NN	NN		OK/0.971521
in	in	IN	APPR		OK/0.987237
2	2	CD	CARD		OK/0.952782
phases	Phasen	NNS	NN		OK/0.788757
,	,	,	$,		OK/0.863855
with	__unaligned__	IN	__unaligned__		OK/0.825849
half-lives	Halbwertszeiten	NNS	NN		OK/0.896384
of	__unaligned__	IN	__unaligned__		OK/0.908103
approximately	ca.	RB	ADV		OK/0.989734
2	2	CD	CARD		OK/0.997876
to	__unaligned__	TO	__unaligned__		OK/0.971513
5	5	CD	CARD		OK/0.980464
hours	Stunden	NNS	NN		OK/0.987308
(	(	(	$(		OK/0.992457
plasma	Plasma	NN	NN		OK/0.982348
)	)	)	$(		OK/0.990006
and	bzw.	CC	KON		OK/0.945964
2	2	CD	CARD		OK/0.964576
and	und	CC	KON		OK/0.989526
18	18	CD	CARD		OK/0.989261
hours	Stunden	NNS	NN		OK/0.974637
(	(	(	$(		OK/0.995500
urine	Urin	NN	NN		OK/0.930907
)	)	)	$(		OK/0.939456
were	wurden	VBD	VAFIN		OK/0.634744
calculated	berechnet	VVN	VVPP		OK/0.801976
.	.	SENT	$.		OK/0.998473

# 0.164986
(	__unaligned__	(	__unaligned__		OK/0.811763
e.	B.	FW	NN		OK/0.789092
g.	B.	FW	NN		OK/0.810911
hepatic	Leber-	JJ	TRUNC		OK/0.990446
or	oder	CC	KON		OK/0.998355
renal	Nierenfunktion	JJ	NN		OK/0.985079
function	Nierenfunktion	NN	NN		OK/0.987026
or	oder	CC	KON		OK/0.994457
certain	bestimmten	JJ	ADJA		OK/0.997087
drug	Arzneimittelwechselwirkungen	NN	NN		OK/0.982685
interactions	Arzneimittelwechselwirkungen	NNS	NN		OK/0.959460
that	bestimmten	WDT	ADJA		OK/0.899756
may	erhöhen	MD	VVINF		OK/0.979411
increase	erhöhen	VV	VVINF		OK/0.994550
risperidone	Risperidon-	NN	ADJA		OK/0.943399
plasma	Plasmakonzentrationen	NN	NN		OK/0.991753
concentrations	Plasmakonzentrationen	NNS	NN		OK/0.995031
(	(	(	$(		OK/0.999386
see	siehe	VV	VVIMP		OK/0.998758
section	Abschnitt	NN	NN		OK/0.999261
4.5	4.5	CD	CARD		OK/0.999584
)	)	)	$(		OK/0.999646
,	,	,	$,		OK/0.992286
it	kann	PP	VMFIN		OK/0.362372
may	kann	MD	VMFIN		OK/0.662459
be	sein	VB	VAINF		OK/0.743518
appropriate	angemessen	JJ	VVPP		OK/0.755843
to	reduzieren	TO	VVINF		OK/0.932917
reduce	reduzieren	VV	VVINF		OK/0.994006
the	__unaligned__	DT	__unaligned__		OK/0.987048
dose	Dosis	NN	NN		OK/0.995250
to	__unaligned__	TO	__unaligned__		OK/0.981299
12.5	12,5	CD	CARD		OK/0.989373
mg	mg	NN	NN		OK/0.994904
.	.	SENT	$.		OK/0.999534

# 0.759309
The	Die	DT	ART		OK/0.997859
ointment	Salbe	NN	NN		OK/0.985105
should	darf	MD	VMFIN		OK/0.877090
not	nicht	RB	PTKNEG		OK/0.989489
be	darf	VB	VMFIN		OK/0.983987
used	angewendet	VVN	VVPP		OK/0.991102
during	in	IN	APPR		OK/0.993219
the	__unaligned__	DT	__unaligned__		OK/0.997671
nose	Nase	NN	NN		OK/0.960919
,	,	,	$,		OK/0.991226
mouth	Mund	NN	NN		OK/0.953923
or	oder	CC	KON		OK/0.977192
eyes	Augen	NNS	NN		OK/0.975502
.	.	SENT	$.		OK/0.998543

# 0.200011
More	Mehr	JJR	ADV		OK/0.998273
than	Mehr	IN	ADV		OK/0.997215
98	98	CD	CARD		OK/0.989276
%	%	NN	NN		OK/0.999622
of	der	IN	ART		OK/0.996574
the	der	DT	ART		OK/0.973898
women	Frauen	NNS	NN		OK/0.647221
were	waren	VBD	VAFIN		OK/0.433517
still	noch	RB	ADV		OK/0.419189
observed	__unaligned__	VVN	__unaligned__		BAD/0.953326
at	Zeitpunkt	IN	NN		BAD/0.948466
this	diesem	DT	PDAT		BAD/0.955263
time	Zeitpunkt	NN	NN		BAD/0.957079
seropositive	seropositiv	JJ	ADJD		BAD/0.929932
for	für	IN	APPR		BAD/0.827966
both	beide	DT	PIAT		BAD/0.801296
antigens	Antigene	NNS	NN		BAD/0.813900
.	.	SENT	$.		OK/0.987755

# 0.889930
Read	Lesen	NP	VVFIN		OK/0.991121
all	Lesen	RB	VVFIN		OK/0.993987
of	__unaligned__	IN	__unaligned__		OK/0.996245
this	__unaligned__	DT	__unaligned__		OK/0.992138
leaflet	__unaligned__	NN	__unaligned__		OK/0.967018
carefully	sorgfältig	RB	ADJD		OK/0.997287
before	bevor	IN	KOUS		OK/0.995734
you	Sie	PP	PPER		OK/0.998275
start	__unaligned__	VVP	__unaligned__		OK/0.991119
using	Anwendung	VVG	NN		OK/0.989770
this	dieses	DT	PDAT		OK/0.994655
medicine	beginnen	NN	VVINF		OK/0.994305
.	.	SENT	$.		OK/0.998103
Keep	Heben	VV	VVFIN		OK/0.984966
this	Heben	DT	VVFIN		OK/0.994426
leaflet	Packungsbeilage	NN	NN		OK/0.988495
.	.	SENT	$.		OK/0.998683

# 0.071385
Adverse	Nebenwirkungen	JJ	NN		OK/0.979772
reactions	Nebenwirkungen	NNS	NN		OK/0.838401
with	__unaligned__	IN	__unaligned__		OK/0.871377
suspected	vermutlich	JJ	ADV		OK/0.861756
(	(	(	$(		OK/0.891251
at	zumindest	IN	ADV		OK/0.864362
least	zumindest	JJS	ADV		OK/0.838730
possibly	möglicherweise	RB	ADV		BAD/0.470398
related	mit	VVN	APPR		BAD/0.643088
to	der	TO	ART		BAD/0.719041
treatment	Behandlung	NN	NN		BAD/0.698832
are	__unaligned__	VBP	__unaligned__		BAD/0.756045
listed	in	VVN	APPR		BAD/0.804387
below	__unaligned__	IN	__unaligned__		BAD/0.792396
by	__unaligned__	IN	__unaligned__		BAD/0.938195
body	__unaligned__	NN	__unaligned__		BAD/0.837657
system	__unaligned__	NN	__unaligned__		BAD/0.773246
are	gegliedert	VBP	VVPP		OK/0.932074
presented	__unaligned__	VVN	__unaligned__		OK/0.958246
below	__unaligned__	IN	__unaligned__		OK/0.952323
by	__unaligned__	IN	__unaligned__		OK/0.971408
system	__unaligned__	NN	__unaligned__		OK/0.952287
organ	__unaligned__	NN	__unaligned__		OK/0.907828
class	Organsystem	NN	NN		OK/0.782691
and	und	CC	KON		OK/0.804890
absolute	absoluter	JJ	ADJA		OK/0.852397
frequency	Häufigkeit	NN	NN		OK/0.845858
.	.	SENT	$.		OK/0.997182

# 0.250641
The	Der	NP	ART		OK/0.995140
Applicant	Antragsteller	NP	NN		OK/0.955670
also	auch	RB	ADV		OK/0.972777
exposure	Expositionsdaten	NN	NN		OK/0.952356
has	zufolge	VHZ	APPO		OK/0.735017
been	__unaligned__	VBN	__unaligned__		OK/0.659052
reported	__unaligned__	VVN	__unaligned__		OK/0.679043
in	__unaligned__	IN	__unaligned__		OK/0.714103
a	insgesamt	DT	ADV		OK/0.758858
total	__unaligned__	NN	__unaligned__		OK/0.969997
of	__unaligned__	IN	__unaligned__		OK/0.945290
around	etwa	RB	ADV		OK/0.862856
143	143	CD	CARD		OK/0.785164
589	589	CD	CARD		OK/0.875793
injections	Injektionen	NNS	NN		OK/0.945997
were	wurden	VBD	VAFIN		OK/0.747873
administered	an	VVN	APPR		OK/0.825370
to	__unaligned__	TO	__unaligned__		OK/0.891071
patients	Patienten	NNS	NN		OK/0.920024
.	.	SENT	$.		OK/0.999615

# 0.927312
04	04	CD	CARD		OK/0.953560
October	Oktober	NP	NN		OK/0.995643
1996	1996	CD	CARD		OK/0.994830
Date	Datum	NN	NN		OK/0.999615
of	Datum	IN	NN		OK/0.999934
last	Datum	JJ	NN		OK/0.986394
renewal	Verlängerung	NN	NN		OK/0.990046
:	:	:	$.		OK/0.999412

# 0.204165
Currently	Derzeit	RB	ADV		OK/0.836864
there	Derzeit	EX	ADV		OK/0.826576
are	liegen	VBP	VVFIN		BAD/0.622597
no	keine	DT	PIAT		BAD/0.366782
formal	offiziellen	JJ	ADJA		BAD/0.621285
Kanzerogenitätsdaten	Kanzerogenitätsdaten	NN	NN		BAD/0.612568
.	.	SENT	$.		OK/0.989396

# 0.072403
Please	Bitte	RB	NN		OK/0.987596
consult	nehmen	VV	VVFIN		OK/0.776933
your	__unaligned__	PP$	__unaligned__		OK/0.789484
doctor	__unaligned__	NN	__unaligned__		OK/0.889759
before	Rücksprache	IN	NN		OK/0.948859
taking	__unaligned__	VVG	__unaligned__		OK/0.935961
Revlimid	Revlimid	NP	NN		OK/0.957945
,	,	,	$,		OK/0.959304
consult	Ihrem	VV	PPOSAT		OK/0.691904
your	Arzt	PP$	NN		OK/0.798943
doctor	Arzt	NN	NN		OK/0.735171
if	wenn	IN	KOUS		OK/0.849400
you	Ihnen	PP	PPER		OK/0.756738
have	Ihnen	VHP	PPER		OK/0.448546
been	__unaligned__	VBN	__unaligned__		OK/0.406122
told	__unaligned__	VVN	__unaligned__		OK/0.305109
by	__unaligned__	IN	__unaligned__		OK/0.338222
your	__unaligned__	PP$	__unaligned__		OK/0.662633
doctor	__unaligned__	NN	__unaligned__		OK/0.679830
that	dass	IN/that	KOUS		OK/0.801369
you	Sie	PP	PPER		OK/0.895372
.	.	SENT	$.		OK/0.957072

# 0.369965
The	Der	DT	ART		OK/0.998659
doctor	Arzt	NN	NN		OK/0.959887
may	kann	MD	VMFIN		OK/0.912581
temporarily	vorübergehend	RB	ADJD		OK/0.892147
to	die	TO	ART		OK/0.812042
the	die	DT	ART		OK/0.946334
infusion	Infusion	NN	NN		OK/0.959196
(	(	(	$(		OK/0.960810
for	für	IN	APPR		OK/0.985847
5	5	CD	CARD		OK/0.975399
-	-	:	$(		OK/0.984177
10	10	CD	CARD		OK/0.982964
min	Min	NN	NE		OK/0.975115
)	)	)	$(		OK/0.988278
until	bis	IN	KOUS		OK/0.983165
the	die	DT	ART		OK/0.993739
solid	weggehen	JJ	VVINF		OK/0.845589
symptoms	Symptome	NNS	NN		OK/0.944680
,	,	,	$,		OK/0.850427
and	und	CC	KON		OK/0.896169
then	dann	RB	ADV		OK/0.876819
continue	fortsetzen	VV	VVINF		OK/0.831127
with	fortsetzen	IN	VVINF		OK/0.797643
the	die	DT	ART		OK/0.989185
infusion	Infusion	NN	NN		OK/0.975040
.	.	SENT	$.		OK/0.999072

# 0.364843
The	Die	NP	ART		OK/0.991218
results	Ergebnisse	NNS	NN		OK/0.982147
demonstrated	Mehrfach-Dosis-Studie	VVD	NN		OK/0.928615
a	__unaligned__	DT	__unaligned__		OK/0.887920
multiple-dose	P450-Substraten	JJ	NN		OK/0.902139
probe	P450-Substraten	NN	NN		OK/0.930321
study	P450-Substraten	NN	NN		OK/0.967749
assessing	P450-Substraten	VVG	NN		OK/0.946840
P450	P450-Substraten	JJ	NN		OK/0.992783
substrates	P450-Substraten	NNS	NN		OK/0.999138
in	bei	IN	APPR		OK/0.981944
chronic	chronischer	JJ	ADJA		OK/0.997165
hepatitis	Hepatitis	NP	NN		OK/0.999871
C	Hepatitis	NP	NN		OK/0.971265
patients	Patienten	NNS	NN		OK/0.961482
receiving	die	VVG	PRELS		OK/0.850427
once	einmal	IN	ADV		OK/0.964410
weekly	wöchentlich	JJ	ADJD		OK/0.989149
ViraferonPeg	ViraferonPeg	NP	NN		OK/0.974613
(	(	(	$(		OK/0.991800
1.5	1,5	CD	CARD		OK/0.959171
µg	μg	NN	NN		OK/0.986295
/	/	SYM	$(		OK/0.999608
kg	kg	NN	NN		OK/0.997748
)	)	)	$(		OK/0.998179
for	über	IN	APPR		OK/0.921154
4	4	CD	CARD		OK/0.995735
weeks	Wochen	NNS	NN		OK/0.992983
demonstrated	zeigten	VVD	VVFIN		OK/0.919657
an	__unaligned__	DT	__unaligned__		OK/0.760888
increase	__unaligned__	NN	__unaligned__		OK/0.883777
in	bei	IN	APPR		OK/0.993073
activity	__unaligned__	NN	__unaligned__		OK/0.976098
of	__unaligned__	IN	__unaligned__		OK/0.962898
CYP2D6	CYP2D6	NP	NE		OK/0.997452
and	und	CC	KON		OK/0.998580
CYP2C8	CYP2C8	NP	NE		OK/0.998740
/	/	SYM	$(		OK/0.999687
9	9.	CD	ADJA		OK/0.990168
.	9.	SENT	ADJA		OK/0.994626

# 0.514774
In	In	IN	APPR		OK/0.998363
vitro	vitro-	NN	TRUNC		OK/0.992501
studies	Studien	NNS	NN		OK/0.999624
indicate	zeigen	VVP	VVINF		OK/0.998248
that	dass	IN/that	KOUS		OK/0.997938
irbesartan	Irbesartan	NN	NE		OK/0.999323
is	überwiegend	VBZ	ADJD		OK/0.970830
primarily	überwiegend	RB	ADJD		OK/0.997215
oxidised	Cytochrom-P450-Enzym	VVN	NN		OK/0.967023
by	Cytochrom-P450-Enzym	IN	NN		OK/0.966264
the	Cytochrom-P450-Enzym	DT	NN		OK/0.983068
cytochrome	Cytochrom-P450-Enzym	NN	NN		OK/0.983599
P450	Cytochrom-P450-Enzym	NN	NN		OK/0.996429
enzyme	Cytochrom-P450-Enzym	NN	NN		OK/0.987381
CYP2C9	CYP2C9	NP	NN		OK/0.960653
;	;	:	$.		OK/0.994750
isoenzyme	Isoenzym	NP	NN		OK/0.995935
CYP3A4	CYP3A4	NP	NE		OK/0.975443
has	vernachlässigbaren	VHZ	ADJA		OK/0.723327
negligible	vernachlässigbaren	JJ	ADJA		OK/0.694986
effect	Effekt	NN	NN		OK/0.754088
.	.	SENT	$.		OK/0.999353

# 0.579921
PVC	PVC	NP	NN		OK/0.996884
/	/	SYM	$(		OK/0.999429
PVDC	PVDC-Blisterpackung	NN	NN		OK/0.953950
blister	PVDC-Blisterpackung	NN	NN		OK/0.982323
sealed	PVDC-Blisterpackung	VVN	NN		OK/0.956890
with	mit	IN	APPR		OK/0.984475
an	Aluminiumfolie	DT	NN		OK/0.719788
aluminium	Aluminiumfolie	NN	NN		OK/0.973709
foil	Aluminiumfolie	NN	NN		OK/0.860818
.	.	SENT	$.		OK/0.998549

# 0.389619
In	Bei	IN	APPR		OK/0.840389
high-risk	Hochrisikopatienten	JJ	NN		OK/0.746204
patients	Hochrisikopatienten	NNS	NN		OK/0.794195
should	sollte	MD	VMFIN		OK/0.902126
be	sollte	VB	VMFIN		OK/0.873615
administered	sollte	VVN	VMFIN		OK/0.847338
,	,	,	$,		OK/0.894010
if	wenn	IN	KOUS		OK/0.933006
clinically	klinisch	RB	ADJD		OK/0.968210
indicated	angezeigt	VVN	VVPP		OK/0.963030
,	,	,	$,		OK/0.961584
electrocardiogram	EKG-Überwachung	NN	NN		OK/0.808295
monitoring	EKG-Überwachung	NN	NN		OK/0.744324
.	.	SENT	$.		OK/0.995920

# 0.537183
Pregnancy	Schwangerschaft	NP	NN		OK/0.997525
Data	Daten	NP	NN		OK/0.974279
on	Daten	IN	NN		OK/0.966908
a	__unaligned__	DT	__unaligned__		OK/0.982990
very	sehr	RB	ADV		OK/0.997371
limited	begrenzte	JJ	ADJA		OK/0.993537
number	Anzahl	NN	NN		OK/0.986451
of	Anzahl	IN	NN		OK/0.979406
exposed	exponierten	JJ	ADJA		OK/0.833961
pregnancies	Schwangerschaften	NNS	NN		OK/0.991792
indicate	exponierten	VVP	ADJA		OK/0.981625
no	exponierten	DT	ADJA		OK/0.990089
adverse	Schwangerschaften	JJ	NN		OK/0.996054
event	Schwangerschaften	NN	NN		OK/0.950426
of	__unaligned__	IN	__unaligned__		OK/0.992072
adverse	Nebenwirkungen	JJ	NN		OK/0.995873
effect	von	NN	APPR		OK/0.997465
of	__unaligned__	IN	__unaligned__		OK/0.970169
febuxostat	Febuxostat	NN	NN		OK/0.947740
on	auf	IN	APPR		OK/0.957855
pregnancy	Schwangerschaft	NN	NN		OK/0.988492
or	oder	CC	KON		OK/0.947291
on	Gesundheit	IN	NN		OK/0.960675
the	Gesundheit	DT	NN		OK/0.993848
health	Gesundheit	NN	NN		OK/0.989199
of	__unaligned__	IN	__unaligned__		OK/0.998141
the	Fetus	DT	NN		OK/0.999345
foetus	Fetus	NN	NN		OK/0.983700
/	/	SYM	$(		OK/0.999504
newborn	Neugeborenen	JJ	NN		OK/0.994919
child	Neugeborenen	NN	NN		OK/0.911780
.	.	SENT	$.		OK/0.999578

# 0.560647
How	Wie	NP	KOKOM		OK/0.999150
to	__unaligned__	TO	__unaligned__		OK/0.997863
use	__unaligned__	VV	__unaligned__		OK/0.985464
Humalog	Humalog	NP	NN		OK/0.998805
Mix25	Mix25	NP	NN		OK/0.997148
4	anzuwenden	CD	VVIZU		BAD/0.762255
.	?	SENT	$.		OK/0.808361

# 0.687121
Like	Wie	IN	KOKOM		OK/0.998482
all	alle	DT	PIAT		OK/0.998878
medicines	Arzneimittel	NNS	NN		OK/0.999603
,	__unaligned__	,	__unaligned__		OK/0.995790
PRODUCT	HANDELSNAME	NN	NN		OK/0.996081
NAME	HANDELSNAME	NP	NN		OK/0.996513
20	20	CD	CARD		OK/0.973259
mg	mg	NN	NN		OK/0.986012
can	__unaligned__	MD	__unaligned__		OK/0.976287
cause	__unaligned__	VV	__unaligned__		OK/0.967260
side	Nebenwirkungen	NN	NN		OK/0.989881
effects	Nebenwirkungen	NNS	NN		OK/0.998914
,	,	,	$,		OK/0.998921
although	aber	IN	ADV		OK/0.998973
not	nicht	RB	PTKNEG		OK/0.997467
every	__unaligned__	DT	__unaligned__		OK/0.816076
body	__unaligned__	NN	__unaligned__		OK/0.806951
gets	__unaligned__	VVZ	__unaligned__		OK/0.994595
them	__unaligned__	PP	__unaligned__		OK/0.997743
.	.	SENT	$.		OK/0.999293

# 0.066118
If	Bei	IN	APPR		OK/0.710761
normal	normalen	JJ	ADJA		OK/0.852190
or	oder	CC	KON		OK/0.969570
decreased	erniedrigten	VVN	ADJA		OK/0.831438
values	__unaligned__	NNS	__unaligned__		OK/0.996320
for	__unaligned__	IN	__unaligned__		OK/0.961760
glycated	__unaligned__	JJ	__unaligned__		OK/0.898836
haemoglobin	Hämoglobin	NN	NN		OK/0.872856
must	muss	MD	VMFIN		BAD/0.599161
be	muss	VB	VMFIN		BAD/0.973370
sent	__unaligned__	VVN	__unaligned__		BAD/0.979376
to	an	TO	APPR		BAD/0.924792
the	__unaligned__	DT	__unaligned__		OK/0.458892
possibility	__unaligned__	NN	__unaligned__		OK/0.518154
of	__unaligned__	IN	__unaligned__		OK/0.725162
recurrent	__unaligned__	JJ	__unaligned__		OK/0.928762
,	__unaligned__	,	__unaligned__		OK/0.961285
unrecognised	unerkannte	JJ	ADJA		OK/0.850948
(	(	(	$(		OK/0.997814
especially	insbesondere	RB	ADV		OK/0.995775
nocturnal	nächtliche	JJ	ADJA		OK/0.917215
)	)	)	$(		OK/0.997267
episodes	Hypoglykämien	NNS	NN		OK/0.977450
of	__unaligned__	IN	__unaligned__		OK/0.954110
hypoglycaemia	__unaligned__	NN	__unaligned__		OK/0.964650
.	.	SENT	$.		OK/0.998877

# 0.751379
If	Wenn	IN	KOUS		OK/0.999225
reconstituted	rekonstituiertes	VVN	ADJA		OK/0.961961
azacitidine	Azacitidin	NN	NN		OK/0.990066
with	mit	IN	APPR		OK/0.997289
the	Haut	DT	NN		OK/0.995817
skin	Haut	NN	NN		OK/0.967480
areas	gerät	NNS	VVFIN		OK/0.934556
,	,	,	$,		OK/0.976084
the	betroffene	DT	ADJA		OK/0.945429
area	__unaligned__	NN	__unaligned__		OK/0.961995
should	muss	MD	VMFIN		OK/0.955464
be	muss	VB	VMFIN		OK/0.979207
immediately	unverzüglich	RB	ADJD		OK/0.995624
and	und	CC	KON		OK/0.999296
thoroughly	gründlich	RB	ADJD		OK/0.999364
with	mit	IN	APPR		OK/0.996814
soap	Seife	NN	NN		OK/0.998667
and	Seife	CC	NN		OK/0.959517
water	Seife	NN	NN		OK/0.990355
.	.	SENT	$.		OK/0.997781

# 0.870184
The	Die	DT	ART		OK/0.994903
mean	mittlere	JJ	ADJA		OK/0.997719
duration	Behandlungsdauer	NN	NN		OK/0.981484
of	Behandlungsdauer	IN	NN		OK/0.998633
exposure	mit	NN	APPR		OK/0.990820
to	__unaligned__	TO	__unaligned__		OK/0.999669
fondaparinux	Fondaparinux	NN	NN		OK/0.987933
was	betrug	VBD	VVFIN		OK/0.926401
6.2	6,2	CD	CARD		OK/0.947769
days	Tage	NNS	NN		OK/0.992196
.	.	SENT	$.		OK/0.999632

# 0.597278
Treatment	Behandlung	NP	NN		OK/0.999189
should	sollte	MD	VMFIN		OK/0.995703
be	sollte	VB	VMFIN		OK/0.926600
initiated	__unaligned__	VVN	__unaligned__		OK/0.692096
according	entsprechend	VVG	ADJD		OK/0.907020
to	__unaligned__	TO	__unaligned__		OK/0.840340
the	den	DT	ART		OK/0.921867
symptoms	Symptomen	NNS	NN		OK/0.966828
.	.	SENT	$.		OK/0.999783

# 0.708732
see	Abschnitt	VVP	NN		OK/0.890610
section	Abschnitt	NN	NN		OK/0.985728
5.1	5.1	CD	CARD		OK/0.997926
for	__unaligned__	IN	__unaligned__		OK/0.993711
more	weitere	JJR	ADJA		OK/0.998785
information	Informationen	NN	NN		OK/0.999790
about	Informationen	IN	NN		OK/0.997802
dose-related	dosisabhängige	JJ	ADJA		OK/0.979009
reactions	Reaktionen	NNS	NN		OK/0.934371
to	auf	TO	APPR		OK/0.868009
etoricoxib	Etoricoxib	NN	NE		OK/0.871303
.	.	SENT	$.		OK/0.997860

# 0.096163
46	46	CD	CARD		OK/0.965792
In	Bei	IN	APPR		OK/0.924791
smoking	Rauchern	NN	NN		OK/0.919439
subjects	Rauchern	NNS	NN		OK/0.955022
with	mit	IN	APPR		OK/0.989562
mild	leichter	JJ	ADJA		OK/0.997758
hepatic	Leberfunktionseinschränkung	JJ	NN		OK/0.997835
dysfunction	Leberfunktionseinschränkung	NN	NN		OK/0.997342
,	__unaligned__	,	__unaligned__		OK/0.947872
mean	mittlere	JJ	ADJA		OK/0.987316
elimination	Eliminationshalbwertszeit	NN	NN		OK/0.991541
half-life	Eliminationshalbwertszeit	NN	NN		OK/0.996543
(	(	(	$(		OK/0.993501
39.3	39,3	CD	CARD		OK/0.921033
hr	Std	NN	NE		OK/0.924351
)	)	)	$(		OK/0.975499
was	Std	VBD	NE		OK/0.804778
prolonged	Std	JJ	NE		OK/0.786690
and	und	CC	KON		OK/0.958149
clearance	Clearance	NN	NN		OK/0.981153
(	(	(	$(		OK/0.993157
18.0	18,0	CD	CARD		OK/0.956777
l	l	NN	NN		OK/0.991376
/	/	SYM	$(		OK/0.996833
hr	Std	NN	NE		OK/0.977924
)	)	)	$(		OK/0.992373
was	Std	VBD	NE		OK/0.891039
reduced	rauchenden	VVN	ADJA		OK/0.920923
analogous	__unaligned__	JJ	__unaligned__		OK/0.848734
to	Vergleich	TO	NN		OK/0.855303
non-smoking	__unaligned__	VVG	__unaligned__		OK/0.679153
healthy	gesunden	JJ	ADJA		OK/0.941220
subjects	Probanden	NNS	NN		OK/0.939735
(	(	(	$(		OK/0.888868
48.8	48,8	CD	CARD		OK/0.743201
hr	Std	NN	NN		OK/0.774934
and	bzw.	CC	KON		OK/0.841431
14.1	14,1	CD	CARD		OK/0.867303
l	l	NN	NN		OK/0.975248
/	/	SYM	$(		OK/0.993973
hr	Std	NN	NE		OK/0.957222
,	,	,	$,		OK/0.887032
respectively	)	RB	$(		OK/0.575498
)	__unaligned__	)	__unaligned__		OK/0.663684
.	.	SENT	$.		OK/0.962886

# 0.430752
22	22	NP	CARD		OK/0.982696
These	Wirkungen	DT	NN		OK/0.962068
effects	Wirkungen	NNS	NN		OK/0.998703
were	waren	VBD	VAFIN		OK/0.987057
independent	unabhängig	JJ	ADJD		OK/0.971395
of	__unaligned__	IN	__unaligned__		OK/0.951534
pioglitazone	__unaligned__	NN	__unaligned__		OK/0.939113
's	__unaligned__	POS	__unaligned__		OK/0.916502
effects	__unaligned__	NNS	__unaligned__		OK/0.836908
on	auf	IN	APPR		OK/0.785431
blood	Blutzuckerspiegel	NN	NN		OK/0.995409
sugar	Blutzuckerspiegel	NN	NN		OK/0.998492
levels	Blutzuckerspiegel	NNS	NN		OK/0.971406
were	waren	VBD	VAFIN		OK/0.880059
statistically	statistisch	RB	ADJD		OK/0.913676
significant	statistisch	JJ	ADJD		OK/0.930093
different	ausgeprägt	JJ	VVPP		OK/0.826222
to	__unaligned__	TO	__unaligned__		OK/0.855096
glibenclamide	Glibenclamid	NN	ADJD		OK/0.848735
.	.	SENT	$.		OK/0.998645

# 0.084902
Studies	Studien	NPS	NN		OK/0.996818
in	Ratten	IN	NN		OK/0.998372
rats	Ratten	NNS	NN		OK/0.984315
indicated	__unaligned__	VVD	__unaligned__		OK/0.823884
that	dass	DT	KOUS		OK/0.981621
uptake	Aufnahme	NN	NN		OK/0.987931
into	__unaligned__	IN	__unaligned__		OK/0.952609
brain	__unaligned__	NN	__unaligned__		OK/0.944003
tissue	__unaligned__	NN	__unaligned__		OK/0.831419
was	war	VBD	VAFIN		OK/0.813067
limited	beschränkt	VVN	VVPP		OK/0.965421
,	__unaligned__	,	__unaligned__		OK/0.978680
distribution	Verteilung	NN	NN		OK/0.911267
into	__unaligned__	IN	__unaligned__		OK/0.857330
and	und	CC	KON		OK/0.919479
out	__unaligned__	IN	__unaligned__		OK/0.741904
of	__unaligned__	IN	__unaligned__		OK/0.857090
uptake	lymphatischen	NN	ADJA		OK/0.912905
into	__unaligned__	IN	__unaligned__		OK/0.889642
brain	__unaligned__	NN	__unaligned__		OK/0.885186
tissue	__unaligned__	NN	__unaligned__		OK/0.764827
was	erfolgte	VBD	VVFIN		OK/0.628025
rapid	schnell	JJ	ADJD		OK/0.599534
,	__unaligned__	,	__unaligned__		OK/0.738832
and	und	CC	KON		OK/0.897031
excretion	Exkretion	NN	NN		OK/0.917287
into	Exkretion	IN	NN		OK/0.956652
the	die	DT	ART		OK/0.999845
milk	in	NN	APPR		OK/0.994941
of	die	IN	ART		OK/0.967353
lactating	säugender	VVG	ADJA		OK/0.992230
rats	Ratten	NNS	NN		OK/0.998456
was	war	VBD	VAFIN		OK/0.938629
extensive	stark	JJ	ADJD		BAD/0.551746
.	.	SENT	$.		OK/0.998578

# 0.277359
With	Mit	IN	APPR		OK/0.844961
TYSABRI	TYSABRI	NP	NN		OK/0.947904
have	wurden	VHP	VAFIN		OK/0.482693
been	wurden	VBN	VAFIN		OK/0.389761
associated	assoziiert	VVN	VVFIN		OK/0.842627
with	assoziiert	IN	VVFIN		OK/0.908998
hypersensitivity	Überempfindlichkeitsreaktionen	NN	NN		OK/0.978778
reactions	Überempfindlichkeitsreaktionen	NNS	NN		OK/0.992507
,	einschließlich	,	APPR		OK/0.988287
including	einschließlich	VVG	APPR		OK/0.997493
severe	schwerer	JJ	ADJA		OK/0.979866
systemic	systemischer	JJ	ADJA		OK/0.996138
reactions	Reaktionen	NNS	NN		OK/0.986145
(	siehe	(	VVIMP		OK/0.999182
see	siehe	VV	VVIMP		OK/0.993970
section	Abschnitt	NN	NN		OK/0.988324
4.8	4.8	CD	CARD		OK/0.992692
)	)	)	$(		OK/0.992358
.	.	SENT	$.		OK/0.998348

# 0.179597
Upon	gemeinsamer	IN	ADJA		BAD/0.748270
co-administration	gemeinsamer	NN	ADJA		BAD/0.802837
with	mit	IN	APPR		BAD/0.837693
efavirenz	Efavirenz	NP	NE		BAD/0.488991
,	__unaligned__	,	__unaligned__		BAD/0.485181
a	tägliche	DT	ADJA		BAD/0.403581
daily	tägliche	JJ	ADJA		OK/0.983478
dose	Dosis	NN	NN		OK/0.989107
of	__unaligned__	IN	__unaligned__		OK/0.992234
rifabutin	Rifabutin	NN	NE		OK/0.937085
should	sollte	MD	VMFIN		OK/0.975322
be	sollte	VB	VMFIN		OK/0.961921
increased	um	VVN	APPR		OK/0.810456
by	__unaligned__	IN	__unaligned__		OK/0.960403
50	50	CD	CARD		OK/0.996443
%	%	NN	NN		OK/0.992767
.	.	SENT	$.		OK/0.999716

# 0.698050
b	b	SYM	ADJA		OK/0.931293
)	)	)	$(		OK/0.927980
Tabellarische	Tabellarische	NP	ADJA		OK/0.759563
list	Aufstellung	NN	NN		OK/0.839975
side	Nebenwirkungen	NN	NN		OK/0.980274
effects	Nebenwirkungen	NNS	NN		OK/0.991794
:	:	:	$.		OK/0.998596

# 0.435647
Patients	Patientinnen	NPS	NN		OK/0.996921
with	mit	IN	APPR		OK/0.999809
diabetes	Diabetes	NN	NN		OK/0.996561
should	sollten	MD	VMFIN		OK/0.944327
continue	unbedingt	VV	ADJD		OK/0.811814
to	__unaligned__	TO	__unaligned__		OK/0.940663
seek	ärztlichen	VV	ADJA		OK/0.995401
medical	ärztlichen	JJ	ADJA		OK/0.993740
advice	Rat	NN	NN		OK/0.991359
if	wenn	IN	KOUS		OK/0.953712
pregnancy	Schwangerschaft	NN	NN		OK/0.987775
is	wird	VBZ	VAFIN		OK/0.968136
planned	geplant	VVN	VVPP		OK/0.971596
or	oder	CC	KON		OK/0.764711
has	eingetreten	VHZ	VVPP		OK/0.745939
not	__unaligned__	RB	__unaligned__		OK/0.731326
been	__unaligned__	VBN	__unaligned__		OK/0.892151
achieved	__unaligned__	VVN	__unaligned__		OK/0.889443
.	.	SENT	$.		OK/0.999504

# 0.041533
When	Bei	WRB	APPR		OK/0.782903
used	__unaligned__	VVN	__unaligned__		OK/0.984608
as	unterstützende	IN	ADJA		OK/0.996897
supportive	unterstützende	JJ	ADJA		OK/0.968757
aid	Präventionsstrategie	NN	NN		OK/0.890737
in	der	IN	ART		OK/0.916763
the	__unaligned__	DT	__unaligned__		OK/0.821159
prevention	__unaligned__	NN	__unaligned__		BAD/0.549742
strategy	im	NN	APPRART		BAD/0.724512
(	(	(	$(		BAD/0.638540
in	in	IN	APPR		BAD/0.584620
the	__unaligned__	DT	__unaligned__		BAD/0.613167
disease	__unaligned__	NN	__unaligned__		BAD/0.697336
is	__unaligned__	VBZ	__unaligned__		BAD/0.735975
present	Beständen	JJ	NN		BAD/0.682515
in	in	IN	APPR		OK/0.724562
which	denen	WDT	PRELS		OK/0.829571
a	eine	DT	ART		OK/0.938605
transovarielle	transovarielle	NN	ADJA		OK/0.978025
transmission	Übertragung	NN	NN		OK/0.984324
of	__unaligned__	IN	__unaligned__		OK/0.906856
Mycoplasma	gallisepticum	NP	ADJD		OK/0.887121
gallisepticum	gallisepticum	NN	ADJD		OK/0.683958
are	wahrscheinlich	VBP	ADJD		OK/0.899353
likely	wahrscheinlich	JJ	ADJD		OK/0.858380
to	wahrscheinlich	TO	ADJD		OK/0.860094
become	__unaligned__	VV	__unaligned__		OK/0.970435
these	__unaligned__	DT	__unaligned__		OK/0.994468
)	)	)	$(		OK/0.997998
:	:	:	$.		OK/0.999313

# 0.046557
In	In	IN	APPR		OK/0.961992
a	einer	DT	ART		OK/0.899399
study	Studie	NN	NN		OK/0.992441
of	__unaligned__	IN	__unaligned__		OK/0.947622
booster	Auffrischimpfung	NN	NN		OK/0.986738
vaccination	Auffrischimpfung	NN	NN		OK/0.660742
with	__unaligned__	IN	__unaligned__		OK/0.392104
Menitorix	__unaligned__	NP	__unaligned__		OK/0.372698
or	__unaligned__	CC	__unaligned__		OK/0.394903
with	mit	IN	APPR		OK/0.829961
other	__unaligned__	JJ	__unaligned__		OK/0.946674
Hib	Hib	NP	NE		OK/0.935008
and	und	CC	KON		OK/0.961669
MenC	MenC	NP	NE		OK/0.819135
,	__unaligned__	,	__unaligned__		OK/0.637038
Menitorix	Menitorix	NP	NN		OK/0.645941
was	wurde	VBD	VAFIN		OK/0.723903
(	(	(	$(		OK/0.810091
in	in	IN	APPR		OK/0.890623
kontralaterale	kontralaterale	JJ	ADJA		OK/0.769832
thighs	Oberschenkel	NNS	NN		OK/0.788312
)	)	)	$(		OK/0.981956
with	mit	IN	APPR		OK/0.985817
the	ersten	DT	ADJA		OK/0.997311
first	ersten	JJ	ADJA		OK/0.996700
dose	Dosis	NN	NN		OK/0.939422
of	eines	IN	ART		OK/0.801396
Masern-Mumps-Röteln-	Masern-Mumps-Röteln-	NP	TRUNC		OK/0.765846
three	Kombinationsimpfstoffes	CD	NN		OK/0.829330
dose	__unaligned__	NN	__unaligned__		OK/0.719502
combined	__unaligned__	JJ	__unaligned__		OK/0.893518
vaccine	__unaligned__	NN	__unaligned__		OK/0.934558
.	.	SENT	$.		OK/0.999431

# 0.178385
If	Falls	IN	KOUS		OK/0.958994
you	Sie	PP	PPER		OK/0.991103
notice	bemerken	VVP	VVINF		OK/0.984837
your	Ihrer	PP$	PPOSAT		OK/0.998062
skin	Haut	NN	NN		OK/0.996957
at	Injektionsstelle	IN	NN		OK/0.998512
the	Injektionsstelle	DT	NN		OK/0.999746
injection	Injektionsstelle	NN	NN		OK/0.998582
site	Injektionsstelle	NN	NN		OK/0.952302
can	Verdickungen	MD	NN		OK/0.896424
report	berichten	VV	VVFIN		OK/0.894287
,	,	,	$,		OK/0.904937
tell	Ihrem	VV	PPOSAT		OK/0.938056
your	Arzt	PP$	NN		OK/0.982465
doctor	Arzt	NN	NN		OK/0.996408
or	oder	CC	KON		OK/0.994213
diabetes	Diabetesberaterin	NN	NN		OK/0.980090
nurse	Diabetesberaterin	NN	NN		OK/0.978419
because	Diabetesberaterin	IN	NN		OK/0.951508
these	diese	DT	PDAT		OK/0.989476
reactions	Reaktionen	NNS	NN		OK/0.977282
,	,	,	$,		BAD/0.709012
or	__unaligned__	CC	__unaligned__		BAD/0.762739
they	__unaligned__	PP	__unaligned__		BAD/0.857404
may	können	MD	VMFIN		OK/0.832852
change	sich	VV	PRF		OK/0.628703
the	__unaligned__	DT	__unaligned__		OK/0.809178
absorption	die	NN	ART		OK/0.832340
of	__unaligned__	IN	__unaligned__		OK/0.983367
your	Ihres	PP$	PPOSAT		OK/0.990842
insulin	Insulins	NN	NN		OK/0.988111
if	wenn	IN	KOUS		OK/0.997613
you	Sie	PP	PPER		OK/0.987965
inject	injizieren	VVP	VVINF		OK/0.990014
in	Stelle	IN	NN		OK/0.995696
such	solche	PDT	PIAT		OK/0.987786
a	__unaligned__	DT	__unaligned__		OK/0.931724
site	__unaligned__	NN	__unaligned__		OK/0.784149
.	.	SENT	$.		OK/0.998358

# 0.773537
This	Diese	DT	PDAT		OK/0.995530
combination	Kombination	NN	NN		OK/0.993597
should	sollte	MD	VMFIN		OK/0.993601
be	sollte	VB	VMFIN		OK/0.961936
used	Vorsicht	VVN	NN		OK/0.889551
with	Vorsicht	IN	NN		OK/0.919659
caution	Vorsicht	NN	NN		OK/0.857818
.	.	SENT	$.		OK/0.996912

# 0.237763
If	Wenn	IN	KOUS		OK/0.998988
an	eine	DT	ART		OK/0.978150
adverse	Nebenwirkung	JJ	NN		OK/0.995907
event	Nebenwirkung	NN	NN		OK/0.786866
occurs	auftritt	VVZ	VVFIN		OK/0.603097
at	Injektionsstelle	IN	NN		OK/0.995917
the	Injektionsstelle	DT	NN		OK/0.999578
injection	Injektionsstelle	NN	NN		OK/0.999708
site	Injektionsstelle	NN	NN		OK/0.973344
,	,	,	$,		OK/0.879334
appropriate	angemessene	JJ	ADJA		OK/0.957902
measures	Maßnahmen	NNS	NN		OK/0.888135
should	sollten	MD	VMFIN		OK/0.987041
be	sollten	VB	VMFIN		OK/0.848392
treated	werden	VVN	VAINF		OK/0.598980
with	werden	IN	VAINF		OK/0.648553
antidepressants	__unaligned__	NNS	__unaligned__		OK/0.733371
.	.	SENT	$.		OK/0.996483

# 0.369344
Reproductive	Geschlechtsorgane	NP	NN		OK/0.986161
system	Geschlechtsorgane	NN	NN		OK/0.908336
and	Geschlechtsorgane	CC	NN		OK/0.893340
breast	Geschlechtsorgane	NN	NN		OK/0.402441
disorders	Geschlechtsorgane	NNS	NN		OK/0.659337
:	:	:	$.		OK/0.899908

# 0.922762
Keep	Reich-	VV	TRUNC		OK/0.988734
out	Reich-	RP	TRUNC		OK/0.990242
of	Reich-	IN	TRUNC		OK/0.990365
the	Reich-	DT	TRUNC		OK/0.996796
reach	Reich-	NN	TRUNC		OK/0.975599
and	und	CC	KON		OK/0.998723
sight	Sichtweite	NN	NN		OK/0.978455
of	Sichtweite	IN	NN		OK/0.996748
children	Kindern	NNS	NN		OK/0.995965
.	.	SENT	$.		OK/0.998880

# 0.860036
Lantus	Lantus	NP	NN		OK/0.992810
100	100	CD	CARD		OK/0.982664
Units	Einheiten	NNS	NN		OK/0.961212
/	/	SYM	$(		OK/0.989774
ml	ml	JJ	NN		OK/0.999896
solution	Injektionslösung	NN	NN		OK/0.997857
for	Injektionslösung	IN	NN		OK/0.992673
injection	Injektionslösung	NN	NN		OK/0.998330
in	Fertigpen	IN	NN		OK/0.991419
a	Fertigpen	DT	NN		OK/0.998381
pre-filled	Fertigpen	JJ	NN		OK/0.998065
pen	Fertigpen	NN	NN		OK/0.993168
,	,	,	$,		OK/0.997418
OptiSet	OptiSet	NP	NN		OK/0.987477
,	,	,	$,		OK/0.984953
is	klare	VBZ	ADJA		OK/0.999110
a	klare	DT	ADJA		OK/0.999563
clear	klare	JJ	ADJA		OK/0.999544
,	,	,	$,		OK/0.999769
colourless	farblose	JJ	ADJA		OK/0.994392
and	und	CC	KON		OK/0.998833
waterlike	farblose	JJ	ADJA		OK/0.974788
solution	farblose	NN	ADJA		OK/0.988827
.	.	SENT	$.		OK/0.999665

# 0.573803
Studies	Studien	NPS	NN		OK/0.990394
with	mit	IN	APPR		OK/0.997293
high	hohen	JJ	ADJA		OK/0.993407
intravenous	intravenösen	JJ	ADJA		OK/0.991011
doses	Dosen	NNS	NN		OK/0.996952
of	__unaligned__	IN	__unaligned__		OK/0.989588
Phenylacetate	Phenylacetat	NP	NN		OK/0.977411
have	haben	VHP	VAFIN		OK/0.980119
shown	gezeigt	VVN	VVPP		OK/0.996321
that	dass	IN/that	KOUS		OK/0.989351
the	die	DT	ART		OK/0.982404
pharmacokinetics	Pharmakokinetik	NNS	NN		OK/0.620759
.	.	SENT	$.		OK/0.997214

# 0.458893
If	Falls	IN	NN		OK/0.998259
the	die	DT	ART		OK/0.998860
pandemic	pandemische	JJ	ADJA		OK/0.910026
situation	Situation	NN	NN		OK/0.944951
allows	pandemische	VVZ	ADJA		OK/0.928564
,	,	,	$,		OK/0.993206
immunisation	__unaligned__	NN	__unaligned__		OK/0.880498
shall	__unaligned__	MD	__unaligned__		OK/0.828238
this	dies	DT	PDS		OK/0.970769
vaccination	Immunisierung	NN	NN		OK/0.969094
in	bei	IN	APPR		OK/0.992022
patients	Patienten	NNS	NN		OK/0.998778
with	mit	IN	APPR		OK/0.999467
severe	schweren	JJ	ADJA		OK/0.986583
febrile	fieberhaften	JJ	ADJA		OK/0.880380
illness	fieberhaften	NN	ADJA		OK/0.716665
or	oder	CC	KON		OK/0.939549
acute	akuten	JJ	ADJA		OK/0.965661
infections	Infektionen	NNS	NN		OK/0.992360
.	.	SENT	$.		OK/0.999006

# 0.388248
2	Weitere	CD	ADJA		OK/0.530505
/	Weitere	SYM	ADJA		OK/0.528888
3	Weitere	CD	ADJA		OK/0.544895
Other	Weitere	JJ	ADJA		OK/0.966677
information	Informationen	NN	NN		OK/0.999571
about	Informationen	IN	NN		OK/0.998106
OptiMARK	OptiMARK	NP	NN		OK/0.962002
:	:	:	$.		OK/0.995063

# 0.333891
Treatment	Behandlung	NP	NN		OK/0.987682
may	kann	MD	VMFIN		OK/0.997510
be	kann	VB	VMFIN		OK/0.986743
initiated	begonnen	VVN	VVPP		OK/0.961372
before	bevor	IN	KOUS		OK/0.841012
Kulturergebnisse	Kulturergebnisse	NP	NN		BAD/0.784962
are	__unaligned__	VBP	__unaligned__		BAD/0.833118
available	vorliegen	JJ	VVINF		BAD/0.622012
and	und	CC	KON		OK/0.963183
may	kann	MD	VMFIN		OK/0.966934
be	kann	VB	VMFIN		OK/0.957431
adjusted	entsprechend	VVN	ADJD		OK/0.997331
to	__unaligned__	TO	__unaligned__		OK/0.964395
explain	nach	VV	APPR		OK/0.923778
their	deren	PP$	PDAT		OK/0.977898
availability	Verfügbarkeit	NN	NN		OK/0.940856
.	.	SENT	$.		OK/0.999802

# 0.576717
Therefore	Daher	RB	PAV		OK/0.993149
,	Daher	,	PAV		OK/0.976355
considered	betrachtet	VVN	VVPP		BAD/0.756105
in	bei	IN	APPR		BAD/0.810648
the	__unaligned__	DT	__unaligned__		OK/0.981833
evaluation	Beurteilung	NN	NN		OK/0.977326
of	Beurteilung	IN	NN		OK/0.989826
the	Beurteilung	DT	NN		OK/0.999095
pharmacokinetics	Pharmakokinetik	NN	NN		OK/0.996751
of	Pharmakokinetik	IN	NN		OK/0.996049
a	einzelne	DT	ADJA		OK/0.965707
active	Wirkstoff	JJ	NN		OK/0.930731
substance	Wirkstoff	NN	NN		OK/0.902999
.	.	SENT	$.		OK/0.999566

# 0.181200
Even	Auch	RB	ADV		OK/0.977550
resolved	Enzymwerterhöhungen	VVD	NN		OK/0.862628
2	Enzymwerterhöhungen	CD	NN		OK/0.703906
in	in	IN	APPR		OK/0.948925
2	2	CD	CARD		OK/0.924117
cases	Fällen	NNS	NN		OK/0.752840
with	__unaligned__	IN	__unaligned__		BAD/0.834636
continuation	__unaligned__	NN	__unaligned__		BAD/0.601886
of	beider	IN	PIAT		OK/0.903073
both	beider	DT	PIAT		OK/0.962397
drugs	Arzneimittel	NNS	NN		OK/0.876396
and	und	CC	KON		OK/0.997772
3	3	CD	CARD		OK/0.993360
after	nach	IN	APPR		OK/0.988337
discontinuation	Absetzen	NN	NN		OK/0.929655
of	Absetzen	IN	NN		OK/0.871759
leflunomide	Leflunomid	NN	NN		OK/0.907625
.	.	SENT	$.		OK/0.999357

# 0.863354
Aclasta	Aclasta	NP	NN		OK/0.984553
should	darf	MD	VMFIN		OK/0.984335
not	nicht	RB	PTKNEG		OK/0.987583
be	darf	VB	VMFIN		OK/0.997816
mixed	gemischt	VVN	VVPP		OK/0.989874
with	mit	IN	APPR		OK/0.988265
other	anderen	JJ	PIS		OK/0.988396
medicinal	Arzneimitteln	JJ	NN		OK/0.989485
products	Arzneimitteln	NNS	NN		OK/0.992577
or	oder	CC	KON		OK/0.991876
intravenous	intravenösen	JJ	ADJA		OK/0.935149
.	.	SENT	$.		OK/0.998617

# 0.579136
Typical	Typische	JJ	ADJA		OK/0.988385
adverse	Typische	JJ	ADJA		OK/0.999415
drug	Typische	NN	ADJA		OK/0.997685
reactions	Typische	NNS	ADJA		OK/0.991512
of	__unaligned__	IN	__unaligned__		OK/0.917744
NSAIDs	NSAIDs	NNS	NE		OK/0.975509
such	wie	JJ	KOKOM		OK/0.966356
as	wie	IN	KOKOM		OK/0.973478
loss	Appetitlosigkeit	NN	NN		OK/0.998191
of	Appetitlosigkeit	IN	NN		OK/0.999570
appetite	Appetitlosigkeit	NN	NN		OK/0.999447
,	Erbrechen	,	NN		OK/0.985760
vomiting	Erbrechen	NN	NN		OK/0.976638
,	,	,	$,		OK/0.994183
diarrhoea	Durchfall	NN	NN		OK/0.974139
,	,	,	$,		OK/0.993922
faecal	okkultes	JJ	ADJA		OK/0.984567
occult	okkultes	JJ	ADJA		OK/0.988539
blood	Blut	NN	NN		OK/0.983050
,	,	,	$,		OK/0.987119
apathy	Apathie	NN	NN		OK/0.983042
and	und	CC	KON		OK/0.993780
renal	Nierenversagen	JJ	NN		OK/0.999048
failure	Nierenversagen	NN	NN		OK/0.998510
have	__unaligned__	VHP	__unaligned__		OK/0.988567
occasionally	__unaligned__	RB	__unaligned__		OK/0.950904
been	berichtet	VBN	VVPP		OK/0.958490
reported	berichtet	VVN	VVPP		OK/0.952440
in	__unaligned__	IN	__unaligned__		OK/0.947257
35	35	CD	CARD		OK/0.977030
/	/	SYM	$(		OK/0.990425
34	38	CD	CARD		OK/0.876659
.	.	SENT	$.		OK/0.998374

# 0.606835
25	25	CD	CARD		OK/0.991143
discontinuation	Absetzen	NN	NN		OK/0.999009
of	Absetzen	IN	NN		OK/0.994940
the	rekonstituierten	DT	ADJA		OK/0.997180
reconstituted	rekonstituierten	VVN	ADJA		OK/0.992527
suspension	Suspension	NN	NN		OK/0.988723
may	__unaligned__	MD	__unaligned__		BAD/0.752317
occur	möglich	VV	ADJD		BAD/0.674162
.	.	SENT	$.		OK/0.987704

# 0.217186
After	Nach	IN	APPR		OK/0.988671
a	einer	DT	ART		OK/0.957940
major	Hüftoperation	JJ	NN		OK/0.548387
hip	__unaligned__	NN	__unaligned__		OK/0.633687
surgery	__unaligned__	NN	__unaligned__		OK/0.675611
,	__unaligned__	,	__unaligned__		OK/0.861553
you	Sie	PP	PPER		OK/0.960348
will	gewöhnlich	MD	ADJD		OK/0.952425
usually	gewöhnlich	RB	ADJD		OK/0.992459
take	nehmen	VV	VVFIN		OK/0.968104
the	die	DT	ART		OK/0.962983
tablets	Tabletten	NNS	NN		OK/0.942832
for	__unaligned__	IN	__unaligned__		OK/0.510708
5	5	CD	CARD		OK/0.942102
weeks	Wochen	NNS	NN		OK/0.986595
.	.	SENT	$.		OK/0.999267

# 0.672004
This	Diese	NP	PDAT		OK/0.989737
may	__unaligned__	MD	__unaligned__		OK/0.945535
occur	Symptome	VV	NN		OK/0.961065
,	__unaligned__	,	__unaligned__		OK/0.776701
which	__unaligned__	WDT	__unaligned__		OK/0.778836
may	können	MD	VMFIN		OK/0.956708
effects	Effekte	NNS	NN		OK/0.996011
symptoms	Expositions-Symptome	NNS	NN		OK/0.978317
.	.	SENT	$.		OK/0.999135

# 0.576495
Treatment	Behandlung	NP	NN		OK/0.999264
should	sollte	MD	VMFIN		OK/0.998793
normally	normalerweise	RB	ADV		OK/0.998062
not	nicht	RB	PTKNEG		OK/0.937490
be	__unaligned__	VB	__unaligned__		OK/0.992648
started	begonnen	VVN	VVPP		OK/0.990784
if	wenn	IN	KOUS		OK/0.986043
the	die	DT	ART		OK/0.928982
BL	GPT-Spiegel	NP	NN		OK/0.729583
10	10-Fachen	CD	NN		OK/0.738297
X	10-Fachen	NP	NN		OK/0.876675
ULN	10-Fachen	NP	NN		OK/0.877318
.	.	SENT	$.		OK/0.999490

# 0.382940
CANCIDAS	CANCIDAS	NP	NE		OK/0.988757
should	sollte	MD	VMFIN		OK/0.993775
be	sollte	VB	VMFIN		OK/0.995882
administered	einmal	VVN	ADV		OK/0.991167
once	einmal	RB	ADV		OK/0.984038
daily	täglich	JJ	ADJD		OK/0.974575
by	langsame	IN	ADJA		OK/0.819457
slow	langsame	JJ	ADJA		OK/0.939420
intravenous	intravenöse	JJ	ADJA		OK/0.994450
infusion	Infusion	NN	NN		OK/0.996076
over	Infusion	IN	NN		OK/0.970806
approximately	ca.	RB	ADV		OK/0.969809
1	einstündige	CD	ADJA		BAD/0.708597
hour	einstündige	NN	ADJA		BAD/0.557966
.	.	SENT	$.		OK/0.986221

# 0.196576
2.5	2,5	CD	CARD		OK/0.998908
%	%	NN	NN		OK/0.997540
(	(	(	$(		OK/0.961097
17	17	CD	CARD		OK/0.990051
/	/	SYM	$(		OK/0.984907
685	685	CD	CARD		OK/0.900725
subjects	Personen	NNS	NN		OK/0.854796
)	)	)	$(		OK/0.929422
,	__unaligned__	,	__unaligned__		OK/0.554581
compared	Vergleich	VVN	NN		OK/0.766843
to	Vergleich	TO	NN		OK/0.898589
0.9	0,9	CD	CARD		OK/0.978405
%	%	NN	NN		OK/0.982291
(	(	(	$(		OK/0.973932
6	6	CD	CARD		OK/0.969345
/	/	SYM	$(		OK/0.871941
679	679	CD	CARD		OK/0.846274
subjects	Personen	NNS	NN		OK/0.752690
)	)	)	$(		OK/0.748188
on	__unaligned__	IN	__unaligned__		OK/0.549069
placebo	Plazebo	NN	NN		OK/0.927487
.	.	SENT	$.		OK/0.996998

# 0.892216
Lantus	Lantus	NP	NN		OK/0.992810
100	100	CD	CARD		OK/0.982664
Units	Einheiten	NNS	NN		OK/0.961212
/	/	SYM	$(		OK/0.989775
ml	ml	JJ	NN		OK/0.999897
solution	Injektionslösung	NN	NN		OK/0.998082
for	Injektionslösung	IN	NN		OK/0.996490
injection	Injektionslösung	NN	NN		OK/0.998198
in	Patrone	IN	NN		OK/0.991323
a	Patrone	DT	NN		OK/0.999901
cartridge	Patrone	NN	NN		OK/0.999612
is	klare	VBZ	ADJA		OK/0.998390
a	klare	DT	ADJA		OK/0.999298
clear	klare	JJ	ADJA		OK/0.999540
,	,	,	$,		OK/0.999769
colourless	farblose	JJ	ADJA		OK/0.994392
and	und	CC	KON		OK/0.998833
waterlike	farblose	JJ	ADJA		OK/0.974788
solution	farblose	NN	ADJA		OK/0.988827
.	.	SENT	$.		OK/0.999665

# 0.359476
situation	Fall	NN	NN		OK/0.945120
,	__unaligned__	,	__unaligned__		OK/0.967165
the	das	DT	ART		OK/0.996651
benefit	Nutzen-Risiko-Verhältnis	NN	NN		OK/0.986838
/	Nutzen-Risiko-Verhältnis	SYM	NN		OK/0.998735
risk	Nutzen-Risiko-Verhältnis	NN	NN		OK/0.998054
balance	Nutzen-Risiko-Verhältnis	NN	NN		OK/0.982986
of	das	IN	ART		OK/0.971383
Trudexa	Trudexa-Therapie	NP	NN		OK/0.988037
very	sehr	RB	ADV		OK/0.964266
carefully	sorgfältig	RB	ADJD		BAD/0.452828
considered	abgewogen	VVN	VVPP		BAD/0.775411
.	.	SENT	$.		OK/0.993243

# 0.683395
59	59	NP	CARD		OK/0.951276
Tevagrastim	Tevagrastim	NP	NN		OK/0.848996
and	und	CC	KON		OK/0.973543
bone	Knochenmarktransplantation	NN	NN		OK/0.999614
marrow	Knochenmarktransplantation	NN	NN		OK/0.998231
transplantation	Knochenmarktransplantation	NN	NN		OK/0.991346
The	Die	DT	ART		OK/0.999590
usual	übliche	JJ	ADJA		OK/0.972187
starting	Anfangsdosis	VVG	NN		OK/0.999511
dose	Anfangsdosis	NN	NN		OK/0.999918
is	beträgt	VBZ	VVFIN		OK/0.998976
1	1	CD	CARD		OK/0.972289
million	Million	CD	NN		OK/0.990672
international	internationale	JJ	ADJA		OK/0.984976
units	Einheiten	NNS	NN		OK/0.993879
(	(	(	$(		OK/0.995131
MIU	Mio.	NP	NE		OK/0.987832
)	)	)	$(		OK/0.999555
per	pro	IN	APPR		OK/0.995122
kilogram	Kilogramm	NN	NN		OK/0.974471
of	__unaligned__	IN	__unaligned__		OK/0.947731
bodyweight	pro	NN	APPR		OK/0.978864
each	pro	DT	APPR		OK/0.973305
day	Tag	NN	NN		OK/0.992692
.	.	SENT	$.		OK/0.999831

# 0.346628
The	Die	DT	ART		OK/0.961009
histopatological	histopathologischen	JJ	ADJA		OK/0.820690
findings	Ergebnisse	NNS	NN		OK/0.951254
in	__unaligned__	IN	__unaligned__		OK/0.797956
Knochenmarkuntersuchungen	Knochenmarkuntersuchungen	NP	NN		OK/0.612894
showed	zeigten	VVD	VVFIN		OK/0.919471
no	keine	DT	PIAT		OK/0.936205
significant	nennenswerten	JJ	ADJA		OK/0.908850
changes	Veränderungen	NNS	NN		OK/0.949281
would	wären	MD	VAFIN		OK/0.838106
be	wären	VB	VAFIN		OK/0.834808
caused	__unaligned__	VVN	__unaligned__		OK/0.894833
by	__unaligned__	IN	__unaligned__		OK/0.932829
the	Behandlung	DT	NN		OK/0.951511
treatment	Behandlung	NN	NN		OK/0.983015
.	.	SENT	$.		OK/0.997840

# 0.171496
Less	Weniger	RBR	ADV		OK/0.945139
commonly	häufig	RB	ADJD		OK/0.992101
,	__unaligned__	,	__unaligned__		OK/0.978770
and	auch	CC	ADV		OK/0.984659
there	kam	EX	VVFIN		OK/0.948689
was	kam	VBD	VVFIN		OK/0.766500
a	geringfügigen	DT	ADJA		OK/0.665752
slight	geringfügigen	JJ	ADJA		OK/0.543200
addition	an	NN	APPR		OK/0.546984
to	__unaligned__	TO	__unaligned__		OK/0.859469
what	__unaligned__	WP	__unaligned__		OK/0.974145
is	__unaligned__	VBZ	__unaligned__		OK/0.973467
stated	__unaligned__	VVN	__unaligned__		OK/0.984994
in	__unaligned__	IN	__unaligned__		OK/0.975924
other	anderen	JJ	PIS		OK/0.975803
mucous	Schleimhautblutungen	JJ	NN		OK/0.833787
membrane	Schleimhautblutungen	NN	NN		OK/0.783823
,	,	,	$,		OK/0.890086
such	wie	JJ	KOUS		OK/0.823666
as	wie	IN	KOUS		OK/0.896926
gingival	Zahnfleischbluten	JJ	NN		OK/0.879540
bleeding	Zahnfleischbluten	NN	NN		OK/0.935569
or	oder	CC	KON		OK/0.948527
vaginal	Vaginalblutungen	JJ	NN		OK/0.747588
bleeding	__unaligned__	NN	__unaligned__		OK/0.927666
.	.	SENT	$.		OK/0.998909

# 0.339798
Evra	Evra	NP	NN		OK/0.803107
is	Evra	VBZ	NN		OK/0.756859
a	Evra	DT	NN		OK/0.830315
patch	Pflasterversion	NN	NN		OK/0.776872
"	"	``	$(		OK/0.855193
the	kombinierten	DT	ADJA		OK/0.856523
pill	Pille	NN	NN		OK/0.680866
'	__unaligned__	POS	__unaligned__		OK/0.600355
(	(	(	$(		OK/0.885838
combined	__unaligned__	JJ	__unaligned__		OK/0.956212
oral	__unaligned__	JJ	__unaligned__		OK/0.988643
contraceptive	oralen	JJ	ADJA		OK/0.971964
pill	__unaligned__	NN	__unaligned__		OK/0.959258
)	)	)	$(		OK/0.987608
.	.	SENT	$.		OK/0.997167

# 0.156358
Patients	Patienten	NPS	NN		OK/0.988236
,	,	,	$,		OK/0.968110
whose	deren	WP$	PRELAT		OK/0.959452
blood	Blutzuckereinstellung	NN	NN		OK/0.995132
glucose	Blutzuckereinstellung	NN	NN		OK/0.999367
control	Blutzuckereinstellung	NN	NN		OK/0.990041
is	__unaligned__	VBZ	__unaligned__		OK/0.977327
greatly	__unaligned__	RB	__unaligned__		OK/0.994365
improved	__unaligned__	JJ	__unaligned__		OK/0.985833
e.	__unaligned__	FW	__unaligned__		OK/0.595885
g.	__unaligned__	FW	__unaligned__		OK/0.646802
by	durch	IN	APPR		OK/0.982906
intensified	intensivierte	JJ	ADJA		OK/0.979765
insulin	Insulintherapie	NN	NN		OK/0.960074
therapy	Insulintherapie	NN	NN		OK/0.985612
is	deutlich	VBZ	ADJD		OK/0.971632
markedly	deutlich	RB	ADJD		OK/0.982552
improved	verbessert	VVN	VVPP		OK/0.874389
,	,	,	$,		OK/0.957709
may	können	MD	VMFIN		OK/0.927428
experience	wahrnehmen	VV	VVINF		OK/0.766783
a	__unaligned__	DT	__unaligned__		OK/0.902190
change	Hypoglykämie-Warnsymptome	NN	NN		OK/0.876920
in	__unaligned__	IN	__unaligned__		OK/0.841957
their	__unaligned__	PP$	__unaligned__		OK/0.724083
usual	__unaligned__	JJ	__unaligned__		OK/0.928621
warning	__unaligned__	NN	__unaligned__		OK/0.984847
of	__unaligned__	IN	__unaligned__		OK/0.958850
hypoglycaemia	__unaligned__	NN	__unaligned__		OK/0.813810
and	und	CC	KON		OK/0.880092
should	sollten	MD	VMFIN		OK/0.977462
be	sollten	VB	VMFIN		OK/0.967481
advised	dementsprechend	VVN	ADJD		OK/0.958469
accordingly	dementsprechend	RB	ADJD		OK/0.911023
.	.	SENT	$.		OK/0.998668

# 0.741706
Also	Auch	RB	ADV		OK/0.997343
,	__unaligned__	,	__unaligned__		OK/0.991729
the	der	DT	ART		OK/0.956831
effect	Einfluss	NN	NN		OK/0.959953
of	der	IN	ART		OK/0.987188
food	Nahrungsmitteln	NN	NN		OK/0.939265
on	auf	IN	APPR		OK/0.919195
the	auf	DT	APPR		OK/0.999485
rate	Ausmaß	NN	NN		OK/0.988101
and	Ausmaß	CC	NN		OK/0.995943
extent	Ausmaß	NN	NN		OK/0.998950
of	Ausmaß	IN	NN		OK/0.977431
absorption	Absorption	NN	NN		OK/0.905365
.	.	SENT	$.		OK/0.995546

# 0.463381
It	Es	PP	NN		OK/0.969691
is	Es	VBZ	NN		OK/0.946088
noted	sei	VVN	VAFIN		OK/0.967825
that	__unaligned__	IN/that	__unaligned__		OK/0.970969
in	in	IN	APPR		OK/0.979948
the	Mehrheit	DT	NN		OK/0.984706
majority	Mehrheit	NN	NN		OK/0.987390
of	Mehrheit	IN	NN		OK/0.912169
those	solcher	DT	PIAT		OK/0.943622
reports	Berichte	NNS	NN		OK/0.982332
,	__unaligned__	,	__unaligned__		OK/0.950847
tuberculosis	Tuberkulose	NN	NN		OK/0.879410
was	war	VBD	VAFIN		OK/0.867921
extra-pulmonary	extrapulmonär	NN	ADJD		OK/0.789148
,	,	,	$,		OK/0.990854
i.	h.	FW	VVFIN		OK/0.987140
e.	d.	FW	PDS		OK/0.925852
It	disseminiert	PP	ADJD		BAD/0.950846
should	__unaligned__	MD	__unaligned__		BAD/0.947864
be	__unaligned__	VB	__unaligned__		BAD/0.958880
noted	__unaligned__	VVN	__unaligned__		BAD/0.968872
.	.	SENT	$.		OK/0.980962

# 0.741564
-	-	:	$(		OK/0.997734
if	wenn	IN	KOUS		OK/0.998807
you	Sie	PP	PPER		OK/0.999491
have	haben	VHP	VAINF		OK/0.973143
monoclonal	Gammopathie	NN	NN		OK/0.847740
gammopathy	Gammopathie	NN	NN		OK/0.773091
.	.	SENT	$.		OK/0.998833

# 0.235042
October	Oktober	NP	NN		OK/0.983179
2006	2006	CD	CARD		OK/0.994620
The	Der	DT	ART		OK/0.998683
Reference	Referenzmitgliedstaat	NP	NN		OK/0.986599
Member	Referenzmitgliedstaat	NP	NN		OK/0.998739
State	Referenzmitgliedstaat	NP	NN		OK/0.998088
was	war	VBD	VAFIN		OK/0.998711
United	Vereinigte	NP	ADJA		OK/0.994441
Kingdom	Königreich	NP	NN		OK/0.985640
and	und	CC	KON		OK/0.966062
the	betroffenen	DT	ADJA		OK/0.907617
Concerned	betroffenen	NP	ADJA		OK/0.981606
Member	Mitgliedstaaten	NP	NN		OK/0.998319
States	Mitgliedstaaten	NPS	NN		OK/0.997942
were	waren	VBD	VAFIN		OK/0.947410
Belgium	Belgien	NP	NE		OK/0.929366
,	,	,	$,		OK/0.937465
Greece	Griechenland	NP	NE		OK/0.750985
,	,	,	$,		OK/0.851035
Ireland	Irland	NP	NE		OK/0.695083
,	,	,	$,		OK/0.829934
Poland	Polen	NP	NE		OK/0.670707
and	und	CC	KON		OK/0.875514
Spain	Spanien	NP	NE		OK/0.590674
.	.	SENT	$.		OK/0.994538

# 0.176340
Both	Beide	DT	PIAT		OK/0.941378
patient	Therapieregimes	NN	NN		OK/0.672124
were	wurden	VBD	VAFIN		OK/0.272612
collected	__unaligned__	VVN	__unaligned__		OK/0.578604
every	alle	DT	PIAT		OK/0.888621
3	3	CD	CARD		OK/0.981027
weeks	Wochen	NNS	NN		OK/0.993210
for	über	IN	APPR		OK/0.878465
6	6	CD	CARD		OK/0.873394
cycles	Zyklen	NNS	NN		OK/0.914019
,	__unaligned__	,	__unaligned__		OK/0.822941
once	einmal	RB	ADV		OK/0.876803
.	.	SENT	$.		OK/0.999104

# 0.786697
Protein	Proteinbindung	NP	NN		OK/0.959646
binding	Proteinbindung	NN	NN		OK/0.962741
is	beträgt	VBZ	VVFIN		OK/0.863291
in	vitro	IN	NE		OK/0.916827
vitro	vitro	NN	NE		OK/0.962169
approximately	etwa	RB	ADV		OK/0.979891
60	60	CD	CARD		OK/0.999439
%	%	NN	NN		OK/0.999938
to	bis	TO	APPR		OK/0.997018
70	70	CD	CARD		OK/0.997117
%	%	NN	NN		OK/0.989332
.	.	SENT	$.		OK/0.999762

# 0.387504
Patients	Patienten	NPS	NN		OK/0.998939
with	mit	IN	APPR		OK/0.997437
pre-existing	vorbestehender	VVG	ADJA		OK/0.962158
liver	Leberfunktion	NN	NN		OK/0.907367
dysfunction	__unaligned__	NN	__unaligned__		OK/0.992921
,	__unaligned__	,	__unaligned__		OK/0.982153
including	einschließlich	VVG	APPR		OK/0.994616
chronic	chronisch-aktiven	JJ	ADJA		OK/0.947793
active	chronisch-aktiven	JJ	ADJA		OK/0.955142
hepatitis	Hepatitis	NN	NN		OK/0.973965
,	__unaligned__	,	__unaligned__		OK/0.900864
have	zeigen	VHP	VVFIN		OK/0.952593
an	erhöhte	DT	ADJA		OK/0.988033
increased	erhöhte	VVN	ADJA		OK/0.998266
frequency	Häufigkeit	NN	NN		OK/0.996459
of	Häufigkeit	IN	NN		OK/0.999187
liver	Leberfunktionsstörungen	JJR	NN		OK/0.991028
function	__unaligned__	NN	__unaligned__		OK/0.989126
abnormalities	__unaligned__	NNS	__unaligned__		OK/0.965502
during	unter	IN	APPR		OK/0.991591
combination	antiretroviralen	NN	ADJA		OK/0.990430
antiretroviral	__unaligned__	JJ	__unaligned__		OK/0.881513
therapy	Kombinationstherapie	NN	NN		OK/0.892415
and	und	CC	KON		OK/0.746626
should	sollten	MD	VMFIN		OK/0.993536
be	sollten	VB	VMFIN		OK/0.992003
monitored	überwacht	VVN	VVPP		OK/0.993173
according	__unaligned__	VVG	__unaligned__		OK/0.947968
to	__unaligned__	TO	__unaligned__		OK/0.957654
standard	Praxis	JJ	NN		OK/0.858895
practice	Praxis	NN	NN		OK/0.953271
.	.	SENT	$.		OK/0.998428

# 0.249809
This	Das	DT	ART		OK/0.997385
medicinal	Arzneimittel	JJ	NN		OK/0.996764
product	Arzneimittel	NN	NN		OK/0.957160
should	darf	MD	VMFIN		OK/0.833470
be	nicht	VB	PTKNEG		OK/0.992984
disposed	__unaligned__	VVN	__unaligned__		OK/0.998678
of	__unaligned__	IN	__unaligned__		OK/0.996804
in	im	IN	APPRART		OK/0.990992
accordance	entsorgt	NN	VVPP		OK/0.495654
with	entsorgt	IN	VVPP		OK/0.568162
local	entsorgt	JJ	VVPP		OK/0.464113
requirements	entsorgt	NNS	VVPP		OK/0.500704
.	.	SENT	$.		OK/0.995905

# 0.501606
The	Die	DT	ART		OK/0.995894
colour	Farbe	NN	NN		OK/0.963461
of	von	IN	APPR		OK/0.973612
the	rekonstituierten	DT	ADJA		OK/0.994390
reconstituted	rekonstituierten	VVN	ADJA		OK/0.982624
Cubicin-Lösungen	Cubicin-Lösungen	NP	NN		OK/0.920610
may	kann	MD	VMFIN		OK/0.863617
be	kann	VB	VMFIN		OK/0.894501
pale	blassgelb	JJ	ADJD		OK/0.956553
yellow	blassgelb	NN	ADJD		OK/0.991291
to	bis	TO	KON		OK/0.916612
hellbraun	hellbraun	NN	ADJD		OK/0.662591
.	.	SENT	$.		OK/0.996454

# 0.565999
Complete	komplette	JJ	ADJA		OK/0.901397
washout	Auswaschphase	NNS	NN		OK/0.865669
will	dauert	MD	VVFIN		OK/0.677518
normally	normalerweise	RB	ADV		OK/0.971033
last	dauert	VV	VVFIN		OK/0.891216
for	dauert	IN	VVFIN		OK/0.997749
11	11	CD	CARD		OK/0.995752
days	Tage	NNS	NN		OK/0.965304
.	.	SENT	$.		OK/0.999503

# 0.232603
In	In	IN	APPR		OK/0.958491
an	Analyse	DT	NN		OK/0.959583
analysis	Analyse	NN	NN		OK/0.970614
of	__unaligned__	IN	__unaligned__		OK/0.806247
Mehrfachereignissen	Mehrfachereignissen	NP	NN		OK/0.541397
Zometa	Zometa	NP	NE		OK/0.759635
reduced	verringerte	VVD	VVFIN		OK/0.745384
the	__unaligned__	DT	__unaligned__		OK/0.932273
risk	Risiko	NN	NN		OK/0.947416
of	Risiko	IN	NN		OK/0.947456
experiencing	SRE	VVG	NN		OK/0.916232
and	s	CC	NN		OK/0.965382
41	41	CD	CARD		OK/0.996374
%	%	NN	NN		OK/0.997127
(	(	(	$(		OK/0.997774
hazard	Risiko-Verhältnis	NN	NN		OK/0.979014
ratio	Risiko-Verhältnis	NN	NN		OK/0.926448
of	__unaligned__	IN	__unaligned__		OK/0.765403
0.59	0,59	CD	CARD		OK/0.659195
,	,	,	$,		OK/0.958683
p	p	NN	NE		OK/0.985314
=	=	SYM	$(		OK/0.987836
0.019	0,019	LS	CARD		OK/0.979493
)	)	)	$(		OK/0.998281
compared	Vergleich	VVN	NN		OK/0.992504
to	Vergleich	TO	NN		OK/0.998642
placebo	Plazebo	NN	NN		OK/0.991243
.	.	SENT	$.		OK/0.999054

# 0.415223
There	Es	EX	NN		OK/0.867753
were	bestanden	VBD	VVFIN		OK/0.892045
no	keine	DT	PIAT		OK/0.996275
differences	Unterschiede	NNS	NN		OK/0.958987
were	Unterschiede	VBD	NN		BAD/0.929051
observed	__unaligned__	VVN	__unaligned__		BAD/0.862093
for	__unaligned__	IN	__unaligned__		BAD/0.864570
EVISTA	EVISTA-	NP	TRUNC		BAD/0.748073
.	bzw.	SENT	KON		OK/0.820251

# 0.010708
Dosage	__unaligned__	NP	__unaligned__		OK/0.918573
adjustment	Dosisanpassung	NN	NN		OK/0.991934
:	:	:	$.		OK/0.985073
−	−	NN	NN		OK/0.790329
Each	Jeder	DT	PIAT		OK/0.645387
aPTT-Wert	aPTT-Wert	NN	NN		OK/0.366534
outside	außerhalb	IN	APPR		OK/0.882726
the	__unaligned__	DT	__unaligned__		OK/0.887697
target	Zielbereiches	NN	NN		OK/0.897997
range	Zielbereiches	NN	NN		OK/0.569647
immediately	sofort	RB	ADV		OK/0.446856
the	,	DT	$,		OK/0.454017
dose	Dosisanpassungen	NN	NN		OK/0.571787
adjustments	Dosisanpassungen	NNS	NN		OK/0.896768
should	erfolgen	MD	VVINF		BAD/0.585505
be	erfolgen	VB	VVINF		BAD/0.645779
performed	erfolgen	VVN	VVINF		BAD/0.720523
before	bevor	RB	KOUS		OK/0.860137
,	,	,	$,		OK/0.996379
unless	sei	IN	VAFIN		OK/0.992210
there	es	EX	PPER		OK/0.997684
is	__unaligned__	VBZ	__unaligned__		OK/0.993639
an	dringender	DT	ADJD		OK/0.985450
individual	__unaligned__	JJ	__unaligned__		OK/0.995159
clinical	klinischer	JJ	ADJA		OK/0.973343
Handlungsbedarf	Handlungsbedarf	NP	NN		OK/0.852838
.	.	SENT	$.		OK/0.994816
-	−	:	ADJD		OK/0.776995
If	Liegt	IN	VVFIN		OK/0.717952
the	der	DT	ART		OK/0.854768
again	erneut	RB	ADJD		OK/0.790264
confirmed	aPTT-Wert	VVN	NN		OK/0.926581
aPTT	aPTT-Wert	NN	NN		OK/0.925439
value	aPTT-Wert	NN	NN		OK/0.978467
is	__unaligned__	VBZ	__unaligned__		OK/0.985851
above	__unaligned__	IN	__unaligned__		OK/0.942579
the	des	DT	ART		OK/0.951444
target	Zielbereiches	NN	NN		OK/0.873304
range	Zielbereiches	NN	NN		OK/0.861936
,	,	,	$,		OK/0.828682
the	die	DT	ART		OK/0.941408
infusion	Infusion	NN	NN		OK/0.970458
should	sollte	MD	VMFIN		OK/0.836167
be	sollte	VB	VMFIN		OK/0.972539
discontinued	unterbrochen	VVN	VVPP		OK/0.955451
for	für	IN	APPR		OK/0.993050
two	zwei	CD	CARD		OK/0.989655
hours	Stunden	NNS	NN		OK/0.976635
.	.	SENT	$.		OK/0.998233

# 0.919669
comparison	Vergleich	NN	NN		OK/0.992982
is	basiert	VBZ	VVFIN		OK/0.998982
based	basiert	VVN	VVFIN		OK/0.998874
on	basiert	IN	VVFIN		OK/0.993546
historical	historischen	JJ	ADJA		OK/0.978971
controls	Kontrollen	NNS	NN		OK/0.939842
.	.	SENT	$.		OK/0.996019

# 0.388248
2	Weitere	CD	ADJA		OK/0.530505
/	Weitere	SYM	ADJA		OK/0.528888
3	Weitere	CD	ADJA		OK/0.544895
Other	Weitere	JJ	ADJA		OK/0.966677
information	Informationen	NN	NN		OK/0.999571
about	Informationen	IN	NN		OK/0.998106
Cortavance	Cortavance	NP	NE		OK/0.962002
:	:	:	$.		OK/0.995063

# 0.287953
Do	Verwenden	VVP	VVFIN		OK/0.797303
not	Verwenden	RB	VVFIN		OK/0.802172
use	Verwenden	VV	VVFIN		OK/0.948863
extruded	graduierte	VVN	ADJA		OK/0.837527
syringe	Spritze	NN	NN		OK/0.986770
equipped	__unaligned__	VVN	__unaligned__		OK/0.458404
with	__unaligned__	IN	__unaligned__		OK/0.778950
a	__unaligned__	DT	__unaligned__		OK/0.916299
needle	Nadel	NN	NN		OK/0.968907
.	.	SENT	$.		OK/0.999298

# 0.245049
The	Der	NP	ART		OK/0.998268
Committee	Ausschuss	NP	NN		OK/0.989700
for	Ausschuss	IN	NN		OK/0.990518
Medicinal	Ausschuss	NP	NN		OK/0.997580
Products	Humanarzneimittel	NPS	NN		OK/0.998138
for	Ausschuss	IN	NN		OK/0.997242
Human	Humanarzneimittel	NP	NN		OK/0.998991
Use	Humanarzneimittel	NP	NN		OK/0.991686
(	(	(	$(		OK/0.999617
CHMP	CHMP	NP	NE		OK/0.999167
)	)	)	$(		OK/0.998729
concluded	Schluss	VVD	NN		OK/0.987393
that	gelangte	IN/that	VVFIN		OK/0.910204
the	__unaligned__	DT	__unaligned__		OK/0.982379
efficacy	Wirksamkeit	NN	NN		OK/0.999195
of	Wirksamkeit	IN	NN		OK/0.997194
Tysabri	Tysabri	NP	NE		OK/0.984287
in	die	IN	ART		OK/0.977478
relapses	Krankheitsschübe	NNS	NN		OK/0.882853
was	war	VBD	VAFIN		OK/0.792130
absorbed	__unaligned__	VVN	__unaligned__		OK/0.641984
and	auch	CC	ADV		OK/0.346852
disability	Behinderung	NN	NN		OK/0.548962
been	nachgewiesen	VBN	VVPP		OK/0.916587
clearly	eindeutig	RB	ADJD		OK/0.923008
established	nachgewiesen	VVN	VVPP		OK/0.954457
.	.	SENT	$.		OK/0.994199

# 0.783625
Take	Nehmen	VV	VVFIN		OK/0.958087
the	die	DT	ART		OK/0.998588
pack	Packung	NN	NN		OK/0.950764
with	mit	IN	PTKVZ		OK/0.984756
you	Sie	PP	PPER		OK/0.993372
and	und	CC	KON		OK/0.996206
show	zeigen	VV	VVFIN		OK/0.968966
it	sie	PP	PPER		OK/0.954724
to	__unaligned__	TO	__unaligned__		OK/0.910379
your	Arzt	PP$	NN		OK/0.990494
doctor	Arzt	NN	NN		OK/0.986308
.	.	SENT	$.		OK/0.997402

# 0.121353
-	-	:	$(		OK/0.968812
Increased	Erhöhte	JJ	ADJA		OK/0.971619
sensitivity	Empfindlichkeit	NN	NN		OK/0.967620
of	der	IN	ART		OK/0.997030
the	der	DT	ART		OK/0.974657
skin	Haut	NN	NN		OK/0.983308
to	gegenüber	TO	APPR		OK/0.972833
sunlight	Sonnenlicht	NN	NN		OK/0.907334
.	.	SENT	$.		OK/0.997400
You	Sie	PP	PPER		OK/0.997709
should	sollten	MD	VMFIN		OK/0.999348
not	nicht	RB	PTKNEG		OK/0.992688
last	__unaligned__	VV	__unaligned__		OK/0.506741
long	lange	RB	ADV		OK/0.893214
to	der	TO	ART		OK/0.899183
strong	__unaligned__	JJ	__unaligned__		OK/0.939918
sunlight	Sonnenlicht	NN	NN		OK/0.823119
,	,	,	$,		OK/0.962085
sunlamps	Höhensonne	NNS	NN		OK/0.873898
or	oder	CC	KON		OK/0.989880
other	anderen	JJ	PIAT		OK/0.979090
sources	__unaligned__	NNS	__unaligned__		OK/0.768503
of	__unaligned__	IN	__unaligned__		OK/0.625245
UV	__unaligned__	NP	__unaligned__		OK/0.570809
radiation	__unaligned__	NN	__unaligned__		OK/0.497980
.	.	SENT	$.		OK/0.986953

# 0.047582
After	Nach	IN	APPR		OK/0.994225
52	52	CD	CARD		OK/0.997082
weeks	Wochen	NNS	NN		OK/0.996791
of	Behandlung	IN	NN		OK/0.968202
treatment	Behandlung	NN	NN		OK/0.758072
,	__unaligned__	,	__unaligned__		OK/0.394752
had	wiesen	VHD	VVFIN		OK/0.438411
all	alle	DT	PIAT		OK/0.755801
12	12	CD	CARD		OK/0.773617
patients	Patienten	NNS	NN		OK/0.987922
with	mit	IN	APPR		OK/0.996500
erhebbarenMeßergebnissen	erhebbarenMeßergebnissen	NN	NN		OK/0.851435
decrease	Abnahme	NN	NN		OK/0.758649
in	Abnahme	IN	NN		OK/0.670171
LVM	LVM	NP	NN		OK/0.497108
from	Ausgangswert	IN	NN		OK/0.533686
baseline	Ausgangswert	NN	NN		OK/0.332164
,	,	,	$,		OK/0.481704
and	und	CC	KON		OK/0.528185
6	6	CD	CARD		OK/0.575877
of	__unaligned__	IN	__unaligned__		OK/0.635298
12	12	CD	CARD		OK/0.974320
patients	Patienten	NNS	NN		OK/0.993447
showed	zeigten	VVD	VVFIN		OK/0.991928
values	Werte	NNS	NN		OK/0.996697
within	Normbereich	IN	NN		OK/0.982125
normal	Normbereich	JJ	NN		OK/0.989790
range	Normbereich	NN	NN		OK/0.992488
.	.	SENT	$.		OK/0.998499

# 0.964617
What	Wofür	WP	NN		OK/0.987370
is	Wofür	VBZ	NN		OK/0.977769
Yondelis	Yondelis	NP	NE		OK/0.997016
used	angewendet	VVD	VVPP		OK/0.998743
for	angewendet	IN	VVPP		OK/0.997627
?	?	SENT	$.		OK/0.999290

# 0.299804
Posology	Dosierung	NP	NN		OK/0.697819
The	Das	DT	ART		OK/0.969093
recommended	empfohlene	JJ	ADJA		OK/0.995078
dosage	Dosierungsschema	NN	NN		OK/0.986511
regimen	Dosierungsschema	NN	NN		OK/0.966564
of	für	IN	APPR		OK/0.963675
Aldurazyme	Aldurazyme	NP	NN		OK/0.980090
is	ist	VBZ	VAFIN		OK/0.866883
100	100	CD	CARD		OK/0.655491
U	E	NN	NN		OK/0.636045
/	/	SYM	$(		OK/0.862872
kg	kg	NN	NN		OK/0.845257
body	Körpergewicht	NN	NN		OK/0.943693
weight	Körpergewicht	NN	NN		OK/0.991952
administered	verabreicht	VVN	VVFIN		OK/0.948843
once	einmal	IN	ADV		OK/0.992863
every	wöchentlich	DT	ADJD		OK/0.998755
week	wöchentlich	NN	ADJD		OK/0.975047
as	intravenöse	IN	ADJA		OK/0.942543
an	intravenöse	DT	ADJA		OK/0.989094
intravenous	intravenöse	JJ	ADJA		OK/0.999619
infusion	Infusion	NN	NN		OK/0.996557
.	.	SENT	$.		OK/0.999878

# 0.794244
•	●	NP	ADJA		OK/0.997756
Hyperglycaemia	Hyperglykämie	NP	NN		OK/0.985670
(	(	(	$(		OK/0.999974
high	hoher	JJ	ADJA		OK/0.999344
blood	Blutzucker	NN	NN		OK/0.999887
sugar	Blutzucker	NN	NN		OK/0.998044
)	)	)	$(		OK/0.997169
means	bedeutet	VVZ	VVFIN		OK/0.933868
there	__unaligned__	EX	__unaligned__		OK/0.964840
is	__unaligned__	VBZ	__unaligned__		OK/0.931494
too	viel	RB	PIAT		OK/0.951436
much	viel	JJ	PIAT		OK/0.966083
sugar	Zucker	NN	NN		OK/0.984418
in	im	IN	APPRART		OK/0.995019
the	im	DT	APPRART		OK/0.989157
blood	Blut	NN	NN		OK/0.972856
.	.	SENT	$.		OK/0.999142

# 0.413051
491	491	CD	CARD		OK/0.702555
Look	Schauen	NN	NN		OK/0.571968
at	Schauen	IN	NN		OK/0.639088
the	Schauen	DT	NN		OK/0.882014
cartridge	Schauen	NN	NN		OK/0.894346
before	Schauen	IN	NN		OK/0.897469
you	Sie	PP	PPER		OK/0.970648
use	Gebrauch	VVP	NN		OK/0.998296
it	__unaligned__	PP	__unaligned__		OK/0.901294
.	.	SENT	$.		OK/0.998664

# 0.051467
The	Der	DT	ART		OK/0.990928
effect	Effekt	NN	NN		OK/0.991649
of	von	IN	APPR		OK/0.987581
Temsirolimus	Temsirolimus	NP	NN		OK/0.765805
is	beruht	VBZ	VVFIN		OK/0.675058
due	beruht	JJ	VVFIN		OK/0.473290
to	__unaligned__	TO	__unaligned__		OK/0.331691
suggest	darauf	VV	PAV		OK/0.351549
that	darauf	IN/that	PAV		OK/0.525790
it	es	PP	PPER		OK/0.582125
is	es	VBZ	PPER		OK/0.607779
a	in	DT	APPR		OK/0.565688
complex	__unaligned__	NN	__unaligned__		OK/0.266935
with	mit	IN	APPR		OK/0.862685
FKBP-12	FKBP-12	NP	NN		OK/0.783638
and	und	CC	KON		OK/0.873903
mTOR	mTOR	NN	NN		OK/0.779431
.	.	SENT	$.		OK/0.998054

# 0.634238
How	Wie	NP	KOKOM		OK/0.961851
do	wenden	VVP	VVFIN		OK/0.925240
you	Sie	PP	PPER		OK/0.952395
or	oder	CC	KON		OK/0.984844
the	die	DT	ART		OK/0.911673
person	Person	NN	NN		OK/0.865030
injecting	spritzt	VVG	VVFIN		OK/0.870977
you	Sie	PP	PPER		OK/0.938207
,	,	,	$,		OK/0.964254
use	spritzt	VV	VVFIN		OK/0.984445
an	Aranesp-Fertigspritze	DT	NN		OK/0.975288
Aranesp	Aranesp-Fertigspritze	NP	NN		OK/0.973539
pre-filled	Aranesp-Fertigspritze	JJ	NN		OK/0.970591
syringe	Aranesp-Fertigspritze	NN	NN		OK/0.947056
?	?	SENT	$.		OK/0.997211

# 0.095716
AUC	AUC	NP	NE		OK/0.990808
:	:	:	$.		OK/0.992190
↓	↓	NN	ADJA		OK/0.981346
60	60	CD	CARD		OK/0.999334
%	%	NN	NN		OK/0.998028
(	(	(	$(		OK/0.996901
↓	↓	NN	ADJD		OK/0.975709
54	54	CD	CARD		OK/0.987576
to	__unaligned__	TO	__unaligned__		OK/0.984951
↓	↓	NP	NN		OK/0.929275
74	74	CD	CARD		OK/0.970347
)	)	)	$(		OK/0.999410
Cmax	Cmax	NP	NN		OK/0.992571
:	:	:	$.		OK/0.999566
↓	↓	NN	ADJA		OK/0.991834
70	70	CD	CARD		OK/0.999285
%	%	NN	NN		OK/0.995800
(	(	(	$(		OK/0.978543
↓	↓	NN	NN		OK/0.980331
55	58	CD	CARD		OK/0.959890
to	__unaligned__	TO	__unaligned__		OK/0.893063
↓	↓	NP	ADJD		OK/0.948187
78	85	CD	CARD		OK/0.900596
)	)	)	$(		OK/0.977587
(	(	(	$(		OK/0.988355
CYP3A4	CYP3A4	NP	NN		OK/0.984435
induction	Induktion	NN	NN		OK/0.965004
)	)	)	$(		OK/0.984515
Co-administration	gleichzeitige	NN	ADJA		OK/0.949298
of	gleichzeitige	IN	ADJA		OK/0.968196
efavirenz	Efavirenz	NN	NE		OK/0.942594
with	mit	IN	APPR		OK/0.990894
atorvastatin	Atorvastatin	NN	NN		OK/0.975531
,	,	,	$,		OK/0.943886
pravastatin	Pravastatin	NN	NN		OK/0.883878
,	,	,	$,		OK/0.912411
or	oder	CC	KON		OK/0.941039
simvastatin	Simvastatin	NN	NN		OK/0.935755
did	beeinflusste	VVD	VVFIN		OK/0.661694
not	beeinflusste	RB	VVFIN		OK/0.551324
affect	beeinflusste	VV	VVFIN		OK/0.842704
AUC	AUC	NP	NE		OK/0.929834
and	die	CC	ART		BAD/0.667732
Cmax	Cmax-Werte	NP	NN		OK/0.755832
of	__unaligned__	IN	__unaligned__		OK/0.803728
efavirenz	Efavirenz	NP	NE		OK/0.990536
.	.	SENT	$.		OK/0.999687

# 0.617334
During	Während	IN	APPR		OK/0.998964
long-term	Langzeitbehandlung	JJ	NN		OK/0.998367
treatment	Langzeitbehandlung	NN	NN		OK/0.980194
with	mit	IN	APPR		OK/0.994383
Stalevo	Stalevo	NP	NE		OK/0.955586
,	__unaligned__	,	__unaligned__		OK/0.890600
your	Ihr	PP$	PPOSAT		OK/0.893355
doctor	Arzt	NN	NN		OK/0.982657
will	Arzt	MD	NN		OK/0.991606
experience	bei	VV	APPR		OK/0.983836
some	einige	DT	PIAT		OK/0.962989
laboratory	Laboruntersuchungen	NN	NN		OK/0.854979
tests	Laboruntersuchungen	NNS	NN		OK/0.796583
regularly	regelmäßig	RB	ADJD		OK/0.973611
.	.	SENT	$.		OK/0.998518

# 0.054592
lamotrigine	Lamotrigin	NN	NN		OK/0.894156
is	__unaligned__	VBZ	__unaligned__		OK/0.826322
currently	derzeit	RB	ADV		OK/0.986865
not	nicht	RB	PTKNEG		OK/0.997726
known	bekannt	JJ	ADJD		OK/0.998170
(	siehe	(	VVIMP		OK/0.997537
see	siehe	VV	VVIMP		OK/0.999560
section	Abschnitt	NN	NN		OK/0.999737
4.5	4.5	CD	CARD		OK/0.999585
)	)	)	$(		OK/0.999228
,	,	,	$,		OK/0.977634
the	das	DT	ART		OK/0.831568
regimen	Behandlungsschema	NN	NN		OK/0.586783
should	sollte	MD	VMFIN		OK/0.731880
be	sollte	VB	VMFIN		OK/0.942767
used	angewendet	VVN	VVPP		OK/0.877414
are	__unaligned__	VBP	__unaligned__		BAD/0.574352
recommended	empfohlen	VVN	VVPP		BAD/0.656409
for	für	IN	APPR		BAD/0.713113
lamotrigine	__unaligned__	NN	__unaligned__		BAD/0.709242
with	mit	IN	APPR		OK/0.861637
concurrent	gleichzeitige	JJ	ADJA		OK/0.367674
valproate	Valproat	NNS	NE		OK/0.592172
.	.	SENT	$.		OK/0.996928

# 0.287187
In	Darüber	IN	PAV		OK/0.995874
addition	Darüber	NN	PAV		OK/0.993743
,	hinaus	,	ADV		OK/0.999883
co-administration	gleichzeitige	NN	ADJA		OK/0.997197
of	gleichzeitige	IN	ADJA		OK/0.993310
phenytoin	Phenytoin	NN	NN		OK/0.995154
and	und	CC	KON		OK/0.999408
lopinavir	Lopinavir	NNS	NN		OK/0.992889
/	/	SYM	$(		OK/0.998195
ritonavir	Ritonavir	NN	NE		OK/0.990100
resulted	führte	VVN	VVFIN		OK/0.967331
in	führte	IN	VVFIN		OK/0.985761
a	__unaligned__	DT	__unaligned__		OK/0.964353
moderate	moderaten	JJ	ADJA		OK/0.956605
decrease	Abfall	NN	NN		OK/0.934929
in	Abfall	IN	NN		OK/0.796728
phenytoin	Phenytoin	NN	NN		OK/0.684633
is	__unaligned__	VBZ	__unaligned__		OK/0.375636
estimated	Steady-State-Konzentrationen	VVN	NN		OK/0.478116
.	.	SENT	$.		OK/0.992421

# 0.033245
It	Außerdem	PP	ADV		OK/0.944311
was	wurde	VBD	VAFIN		OK/0.965912
also	Außerdem	RB	ADV		OK/0.984275
shown	gezeigt	VVN	VVPP		OK/0.967261
that	dass	IN/that	KOUS		OK/0.949267
atosiban	Atosiban	NN	NN		OK/0.905862
is	__unaligned__	VBZ	__unaligned__		BAD/0.733944
involved	an	VVN	APPR		BAD/0.612458
in	__unaligned__	IN	__unaligned__		BAD/0.552052
the	den	DT	ART		BAD/0.394414
Vasopressin-Rezeptor	Vasopressin-Rezeptor	NN	NE		BAD/0.712990
them	und	PP	KON		BAD/0.716107
to	__unaligned__	TO	__unaligned__		OK/0.578018
the	Wirkung	DT	NN		OK/0.732108
effect	Wirkung	NN	NN		OK/0.870082
of	Wirkung	IN	NN		OK/0.767885
the	__unaligned__	DT	__unaligned__		OK/0.673191
U-shape	Vasopressin	NN	NE		BAD/0.657570
.	.	SENT	$.		OK/0.991593

# 0.233373
In	Bei	IN	APPR		OK/0.993257
case	versehentlichem	NN	ADJA		OK/0.982952
of	Haut-	IN	TRUNC		OK/0.969988
accidental	versehentlichem	JJ	ADJA		OK/0.913751
contact	versehentlichem	NN	ADJA		BAD/0.591163
(	oder	(	KON		BAD/0.898457
skin	__unaligned__	NN	__unaligned__		BAD/0.670961
,	__unaligned__	,	__unaligned__		OK/0.857451
wash	abspülen	VVP	VVINF		OK/0.730005
immediately	sofort	RB	ADV		OK/0.963211
with	mit	IN	APPR		OK/0.982733
copious	reichlich	JJ	PIAT		OK/0.993848
amounts	reichlich	NNS	PIAT		OK/0.998230
of	reichlich	IN	PIAT		OK/0.997709
water	reichlich	NN	PIAT		OK/0.997091
.	.	SENT	$.		OK/0.999368

# 0.319008
7	7	CD	CARD		OK/0.992395
hours	Stunden	NNS	NN		OK/0.998779
is	__unaligned__	VBZ	__unaligned__		OK/0.960090
stated	Etikett	VVN	NN		OK/0.990401
on	Etikett	IN	NN		OK/0.997524
the	Etikett	DT	NN		OK/0.999509
label	Etikett	NN	NN		OK/0.993811
after	angegebenen	IN	ADJA		OK/0.666947
the	__unaligned__	DT	__unaligned__		OK/0.986341
reference	Kalibriertermin	NN	NN		OK/0.843998
time	Kalibriertermin	NN	NN		OK/0.825234
(	(	(	$(		OK/0.991026
35	35	CD	CARD		OK/0.970076
hours	Stunden	NNS	NN		OK/0.942601
from	ab	IN	APPR		OK/0.788174
the	ab	DT	APPR		OK/0.967600
end	Ende	NN	NN		OK/0.976400
of	ab	IN	APPR		OK/0.983916
manufacture	__unaligned__	NN	__unaligned__		OK/0.840497
)	)	)	$(		OK/0.971592
.	.	SENT	$.		OK/0.996080

# 0.572685
Tell	Informieren	VV	NN		OK/0.986592
your	Arzt	PP$	NN		OK/0.999777
doctor	Ihren	NN	PPOSAT		OK/0.999936
or	Apotheker	CC	NN		OK/0.999477
pharmacist	Apotheker	NN	NN		OK/0.999650
if	wenn	IN	KOUS		OK/0.999637
you	Sie	PP	PPER		OK/0.998238
are	schwanger	VBP	ADJD		OK/0.999422
pregnant	schwanger	JJ	ADJD		OK/0.998246
or	oder	CC	KON		OK/0.999361
think	vermuten	VVP	VVFIN		OK/0.983141
that	dass	IN/that	KOUS		OK/0.998103
you	Sie	PP	PPER		OK/0.999296
are	schwanger	VBP	ADJD		OK/0.989395
pregnant	schwanger	JJ	ADJD		OK/0.941655
,	__unaligned__	,	__unaligned__		OK/0.881447
or	__unaligned__	CC	__unaligned__		OK/0.895831
might	könnten	MD	VMFIN		OK/0.860899
get	__unaligned__	VV	__unaligned__		OK/0.846319
pregnant	__unaligned__	JJ	__unaligned__		OK/0.835463
,	__unaligned__	,	__unaligned__		OK/0.830619
if	wenn	IN	KOUS		OK/0.991253
you	Sie	PP	PPER		OK/0.975761
are	stillen	VBP	VVINF		OK/0.959673
breast-feeding	stillen	VVG	VVINF		OK/0.967970
.	.	SENT	$.		OK/0.999152

# 0.435985
Anticholinergic	Anticholinerge	NP	NN		OK/0.980140
agents	Substanzen	NNS	NN		OK/0.990408
(	(	(	$(		OK/0.992981
e.	z.	FW	APPRART		OK/0.972753
g.	B.	FW	NN		OK/0.964902
atropine	Atropin	NN	NN		OK/0.897483
,	,	,	$,		OK/0.960591
biperiden	Biperiden	NP	NN		OK/0.833823
)	)	)	$(		OK/0.955058
may	können	MD	VMFIN		OK/0.991723
increase	erhöhen	VV	VVINF		OK/0.978684
the	die	DT	ART		OK/0.991853
bioavailability	Bioverfügbarkeit	NN	NN		OK/0.996657
of	die	IN	ART		OK/0.978286
thiazide	Thiaziddiuretika	NN	NE		OK/0.991869
diuretics	Thiaziddiuretika	NNS	NE		OK/0.997988
by	__unaligned__	IN	__unaligned__		OK/0.946697
decreasing	__unaligned__	VVG	__unaligned__		OK/0.840487
gastrointestinal	gastrointestinalen	JJ	ADJA		OK/0.950213
motility	Motilität	NN	NN		OK/0.887111
and	und	CC	KON		OK/0.980786
stomach	Magenentleerung	VV	NN		OK/0.963342
emptying	Magenentleerung	VVG	NN		OK/0.919303
rate	Magenentleerung	NN	NN		OK/0.867499
.	.	SENT	$.		OK/0.997939

# 0.142726
Inhibition	Hemmung	NP	NN		OK/0.952103
of	Hemmung	IN	NN		OK/0.966147
COMT	COMT	NP	NN		OK/0.848726
in	in	IN	APPR		OK/0.845973
red	roten	JJ	ADJA		OK/0.953188
blood	roten	NN	ADJA		OK/0.977548
cells	roten	NNS	ADJA		OK/0.945831
correlate	korreliert	VVP	VVFIN		OK/0.785737
closely	eng	RB	ADJD		OK/0.769727
with	mit	IN	APPR		OK/0.940214
the	den	DT	ART		OK/0.935723
plasma	Plasmakonzentrationen	NN	NN		OK/0.916028
concentrations	Plasmakonzentrationen	NNS	NN		OK/0.956008
of	__unaligned__	IN	__unaligned__		OK/0.964959
entacapone	Entacapon	NN	NN		OK/0.840032
and	und	CC	KON		OK/0.989719
shows	zeigt	VVZ	VVFIN		OK/0.989932
the	die	DT	ART		OK/0.989132
reversibility	Reversibilität	NN	NN		BAD/0.593125
of	der	IN	ART		BAD/0.460491
the	__unaligned__	DT	__unaligned__		BAD/0.453056
COMT-Hemmung	COMT-Hemmung	NP	NN		BAD/0.685583
.	.	SENT	$.		OK/0.991249

# 0.381028
Pregnancy	Schwangerschaft	NP	NN		OK/0.997651
:	:	:	$.		OK/0.996060
there	liegen	EX	VVFIN		OK/0.620831
are	liegen	VBP	VVFIN		OK/0.616026
no	keine	RB	PIAT		OK/0.967718
adequate	hinreichenden	JJ	ADJA		OK/0.963493
or	oder	CC	KON		OK/0.993107
well-controlled	gut	JJ	ADJD		OK/0.880172
studies	Studien	NNS	NN		OK/0.998309
of	__unaligned__	IN	__unaligned__		OK/0.923619
Atripla	Atripla	NP	NE		OK/0.990657
or	oder	CC	KON		OK/0.983835
its	seinen	PP$	PPOSAT		OK/0.978046
components	Komponenten	NNS	NN		OK/0.986134
in	bei	IN	APPR		OK/0.913603
pregnant	Schwangeren	JJ	NN		OK/0.970792
women	Schwangeren	NNS	NN		OK/0.985957
.	.	SENT	$.		OK/0.999889

# 0.796651
ZYPREXA	ZYPREXA	NP	NN		OK/0.995661
VELOTAB	VELOTAB	NP	NN		OK/0.996548
5	5	CD	CARD		OK/0.999537
mg	mg	NN	NN		OK/0.995685
,	,	,	$,		OK/0.984345
10	10	CD	CARD		OK/0.992673
mg	mg	NN	NN		OK/0.960604
,	,	,	$,		OK/0.901219
15	15	CD	CARD		OK/0.997617
mg	mg	NN	NN		OK/0.994934
and	und	CC	KON		OK/0.999305
20	20	CD	CARD		OK/0.996772
mg	mg	NN	NN		OK/0.995423
are	sind	VBP	VAFIN		OK/0.986773
available	Packungen	JJ	NN		OK/0.987956
in	Packungen	IN	NN		OK/0.993706
packs	Packungen	NNS	NN		OK/0.985092
of	Packungen	IN	NN		OK/0.992000
28	28	CD	CARD		OK/0.992902
,	,	,	$,		OK/0.998258
35	35	CD	CARD		OK/0.994794
,	,	,	$,		OK/0.999039
56	56	CD	CARD		OK/0.999309
or	oder	CC	KON		OK/0.999139
70	70	CD	CARD		OK/0.994846
tablets	Tabletten	NNS	NN		OK/0.990784
.	.	SENT	$.		OK/0.999458

# 0.556682
The	Die	DT	ART		OK/0.979940
following	folgenden	VVG	ADJA		OK/0.978696
treatment	Behandlungsschemata	NN	NN		OK/0.989836
regimens	Behandlungsschemata	NNS	NN		OK/0.982761
for	für	IN	APPR		OK/0.978027
induction	Induktions-	NN	TRUNC		OK/0.964315
,	,	,	$,		OK/0.965299
Konsolidierungs-	Konsolidierungs-	NP	TRUNC		OK/0.739157
and	und	CC	KON		OK/0.951568
maintenance	Erhaltungstherapie	NN	NN		OK/0.986087
therapy	Erhaltungstherapie	NN	NN		OK/0.996534
is	empfohlen	VBZ	VVPP		OK/0.846909
recommended	empfohlen	VVN	VVPP		OK/0.916693
.	.	SENT	$.		OK/0.994012

# 0.169622
White	Weiße	NP	NN		OK/0.993667
,	,	,	$,		OK/0.999793
round	runde	NN	ADJA		OK/0.996261
,	,	,	$,		OK/0.983080
flat	__unaligned__	RB	__unaligned__		OK/0.975617
,	__unaligned__	,	__unaligned__		OK/0.966048
HDPE	HDPE	NP	NN		OK/0.777130
bottles	Flaschen	NNS	NN		OK/0.945211
with	mit	IN	APPR		OK/0.987172
a	mit	DT	APPR		OK/0.954681
white	weißen	NN	ADJA		OK/0.973881
,	,	,	$,		OK/0.868168
Polypropylen-Verschluß	Polypropylen-Verschluß	NP	NN		OK/0.782034
30	30	CD	CARD		OK/0.989850
film-coated	Filmtabletten	NN	NN		OK/0.993822
tablets	Filmtabletten	NNS	NN		OK/0.999138
with	mit	IN	APPR		OK/0.998761
two	zwei	CD	CARD		OK/0.994846
1-Gramm-Trockenmittelbehältnissen	1-Gramm-Trockenmittelbehältnissen	NP	NN		OK/0.866166
or	oder	CC	KON		OK/0.973811
90	90	CD	CARD		OK/0.994242
film-coated	Filmtabletten	NN	NN		OK/0.996088
tablets	Filmtabletten	NNS	NN		OK/0.998971
with	mit	IN	APPR		OK/0.994335
a	__unaligned__	DT	__unaligned__		OK/0.832521
1-Gramm-	1-Gramm-	JJ	TRUNC		OK/0.473112
Trockenmittelbehältnis	Trockenmittelbehältnis	NP	NN		OK/0.416739
.	.	SENT	$.		OK/0.992981

# 0.675544
DULOXETINE	DULOXETINE	NP	NN		OK/0.963804
BOEHRINGER	BOEHRINGER	NP	NE		OK/0.944251
INGELHEIM	INGELHEIM	NP	NE		OK/0.879316
40	40	CD	CARD		OK/0.829316
mg	mg	NN	NN		OK/0.941213
is	ist	VBZ	VAFIN		OK/0.998873
available	Packungen	JJ	NN		OK/0.996270
in	Packungen	IN	NN		OK/0.994922
packs	Packungen	NNS	NN		OK/0.985813
of	Packungen	IN	NN		OK/0.993208
28	28	CD	CARD		OK/0.998851
,	,	,	$,		OK/0.999770
56	56	CD	CARD		OK/0.999764
,	,	,	$,		OK/0.999511
98	98	CD	CARD		OK/0.998731
,	,	,	$,		OK/0.994722
140	140	CD	CARD		OK/0.982010
and	und	CC	KON		OK/0.998023
196	196	CD	CARD		OK/0.962422
(	(	(	$(		OK/0.996425
2	2	CD	CARD		OK/0.997929
x	x	SYM	ADJA		OK/0.998738
98	98	CD	CARD		OK/0.997242
)	)	)	$(		OK/0.998295
capsules	Hartkapseln	NNS	NN		OK/0.967391
.	.	SENT	$.		OK/0.996827

# 0.372062
In	Bei	IN	APPR		OK/0.985509
healthy	gesunden	JJ	ADJA		OK/0.991689
subjects	Freiwilligen	NNS	NN		OK/0.997283
,	__unaligned__	,	__unaligned__		OK/0.908168
there	fanden	EX	VVFIN		OK/0.921070
were	fanden	VBD	VVFIN		OK/0.873818
no	geschlechtsspezifische	DT	ADJA		OK/0.846895
differences	Unterschiede	NNS	NN		OK/0.991667
in	Unterschiede	IN	NN		OK/0.873373
the	__unaligned__	DT	__unaligned__		OK/0.937679
pharmacokinetic	pharmakokinetischen	JJ	ADJA		OK/0.835980
parameters	Parameter	NNS	NN		OK/0.884293
of	__unaligned__	IN	__unaligned__		OK/0.920798
phenylbutyrate	Phenylbutyrat	NNS	NN		OK/0.865951
and	und	CC	KON		OK/0.942029
phenylacetate	Phenylacetat	JJ	NN		OK/0.747297
(	(	(	$(		OK/0.989828
AUC	AUC	NP	NE		OK/0.998683
and	und	CC	KON		OK/0.996946
Cmax	Cmax	NP	NE		OK/0.990842
approx	ca.	NP	ADV		OK/0.983330
.	ca.	SENT	ADV		OK/0.999917

# 0.899000
12	hämodialysierbar	CD	ADJD		OK/0.909592
haemodialysis	hämodialysierbar	NN	ADJD		OK/0.962538
.	.	SENT	$.		OK/0.999164

# 0.800238
Do	dürfen	VVP	VMFIN		OK/0.962976
not	dürfen	RB	VMFIN		OK/0.972361
use	dürfen	VV	VMFIN		OK/0.990293
Rotarix	Rotarix	NP	NN		OK/0.985988
after	nach	IN	APPR		OK/0.967090
the	Verfalldatum	DT	NN		OK/0.967308
expiry	angegebenen	NN	ADJA		OK/0.944609
date	Verfalldatum	NN	NN		OK/0.942616
which	Verfalldatum	WDT	NN		OK/0.975664
is	Verfalldatum	VBZ	NN		OK/0.979203
stated	Verfalldatum	VVN	NN		OK/0.989003
on	Verfalldatum	IN	NN		OK/0.996219
the	Umkarton	DT	NN		OK/0.996735
carton	Umkarton	NN	NN		OK/0.995410
.	.	SENT	$.		OK/0.999700

# 0.366939
The	Die	DT	ART		OK/0.996794
bottle	Flasche	NN	NN		OK/0.996990
should	darf	MD	VMFIN		OK/0.983765
not	nicht	RB	PTKNEG		OK/0.994799
be	darf	VB	VMFIN		OK/0.973911
filtered	abgekühlt	VVN	VVPP		OK/0.945761
pulse	__unaligned__	NN	__unaligned__		OK/0.946456
rate	unter	NN	APPR		OK/0.960130
as	da	IN	KOUS		OK/0.993560
this	dies	DT	PDS		OK/0.971751
may	kann	MD	VMFIN		OK/0.976031
interfere	beeinträchtigen	VV	VVINF		OK/0.921873
with	beeinträchtigen	IN	VVINF		OK/0.836807
the	den	DT	ART		OK/0.930698
Markierungsvorgang	Markierungsvorgang	NP	NN		OK/0.496909
.	.	SENT	$.		OK/0.994685

# 0.450083
Please	Bitte	RB	NN		OK/0.997262
read	lesen	VVD	VVFIN		OK/0.964132
the	__unaligned__	DT	__unaligned__		OK/0.999384
instructions	Anleitung	NNS	NN		OK/0.999409
carefully	sorgfältig	RB	ADJD		OK/0.997018
and	und	CC	KON		OK/0.995729
follow	befolgen	VV	VVFIN		OK/0.983375
them	__unaligned__	PP	__unaligned__		OK/0.967006
step	__unaligned__	VV	__unaligned__		OK/0.954181
by	__unaligned__	IN	__unaligned__		OK/0.885118
the	für	DT	APPR		OK/0.765412
issue	Punkt	NN	NN		BAD/0.739683
.	.	SENT	$.		OK/0.984384

# 0.533495
au	ug	FW	ADJA		OK/0.755586
Each	Jede	DT	PIAT		OK/0.996369
ampoule	Ampulle	NN	NN		OK/0.998333
contains	enthält	VVZ	VVFIN		OK/0.998531
100	100	CD	CARD		OK/0.999229
IU	I.E.	NP	NE		OK/0.995934
(	(	(	$(		OK/0.993978
15	15	CD	CARD		OK/0.998832
micrograms	Mikrogramm	NNS	NN		OK/0.983331
in	in	IN	APPR		OK/0.999240
1.0	1	CD	CARD		OK/0.993998
ml	ml	NN	NN		OK/0.993268
)	)	)	$(		OK/0.992270
of	Lachs-Calcitonin	IN	NN		OK/0.879925
recombinant	Lachs-Calcitonin	JJ	NN		OK/0.904452
salmon	Lachs-Calcitonin	NN	NN		OK/0.865818
calcitonin	Lachs-Calcitonin	NN	NN		OK/0.841957
.	.	SENT	$.		OK/0.997867

# 0.473997
There	Es	RB	NN		OK/0.799055
is	Es	VBZ	NN		OK/0.850374
no	kein	DT	PIAT		OK/0.984451
reason	Grund	NN	NN		OK/0.950656
for	für	IN	APPR		OK/0.999050
dose	Dosisanpassung	NN	NN		OK/0.918302
adjustment	Dosisanpassung	NN	NN		OK/0.957159
of	__unaligned__	IN	__unaligned__		OK/0.953650
Myfenax	Myfenax	NP	NN		OK/0.986636
after	nach	IN	APPR		OK/0.989611
basis	Herztransplantatabstoßung	NN	NN		OK/0.733397
.	.	SENT	$.		OK/0.996597

# 0.835817
Meloxicam	Meloxicam	NP	NN		OK/0.990898
acts	wirkt	VVZ	VVFIN		OK/0.999219
by	wirkt	IN	VVFIN		OK/0.988245
inhibition	Hemmung	NN	NN		OK/0.991957
of	__unaligned__	IN	__unaligned__		OK/0.960889
prostaglandin	Prostaglandinsynthese	NN	NN		OK/0.888304
synthesis	Prostaglandinsynthese	NN	NN		OK/0.917535
.	.	SENT	$.		OK/0.999471

# 0.678882
The	Die	DT	ART		OK/0.985145
reversibility	Reversibilität	NN	NN		OK/0.754318
of	dieser	IN	PDAT		OK/0.918871
this	dieser	DT	PDAT		OK/0.986902
effect	Wirkung	NN	NN		OK/0.995318
is	bekannt	VBZ	ADJD		OK/0.945790
unknown	bekannt	JJ	ADJD		OK/0.940485
.	.	SENT	$.		OK/0.996370

# 0.172897
Particular	Besondere	NP	ADJA		OK/0.965603
caution	Vorsicht	NN	NN		OK/0.996293
should	Vorsicht	MD	NN		OK/0.987021
be	Vorsicht	VB	NN		OK/0.996315
used	Vorsicht	VVN	NN		OK/0.997239
in	bei	IN	APPR		OK/0.990998
patients	Patienten	NNS	NN		OK/0.992231
who	,	WP	$,		OK/0.987242
previously	früher	RB	ADV		OK/0.972342
had	früher	VHD	ADV		OK/0.961826
an	allergische	DT	ADJA		OK/0.998448
allergic	allergische	JJ	ADJA		OK/0.998275
reaction	allergische	NN	ADJA		OK/0.959317
to	auf	TO	APPR		OK/0.922092
penicillins	Penicilline	NNS	NN		OK/0.646263
,	__unaligned__	,	__unaligned__		OK/0.694535
or	andere	CC	PIS		OK/0.910177
other	andere	JJ	PIS		OK/0.918133
beta-lactams	Betalaktame	NNS	NN		OK/0.882360
are	Betalaktame	VBP	NN		OK/0.902117
known	ist	VVN	VAFIN		OK/0.960008
to	__unaligned__	TO	__unaligned__		OK/0.805291
have	aufgetreten	VH	VVPP		OK/0.448158
occurred	aufgetreten	VVN	VVPP		OK/0.457716
.	.	SENT	$.		OK/0.956872

# 0.037736
From	Von	IN	APPR		OK/0.896683
19	19	CD	CARD		OK/0.920140
patients	Patienten	NNS	NN		OK/0.901432
in	bei	IN	APPR		OK/0.424695
whom	denen	WP	PRELS		OK/0.480500
phenotypic	phänotypische	JJ	ADJA		OK/0.574580
and	und	CC	KON		OK/0.843093
genotypic	genotypische	JJ	ADJA		OK/0.761561
studies	Untersuchungen	NNS	NN		OK/0.757286
performed	durchgeführt	VVN	VVPP		OK/0.596713
in	__unaligned__	IN	__unaligned__		OK/0.320139
clinical	klinischen	JJ	ADJA		OK/0.938481
isolates	Isolaten	NNS	NN		OK/0.930958
were	wurden	VBD	VAFIN		OK/0.945296
9	9	CD	CARD		OK/0.967939
patients	Patienten	NNS	NN		OK/0.917117
showed	zeigten	VVD	VVFIN		OK/0.588693
reduced	reduzierte	VVN	ADJA		OK/0.790702
susceptibility	Empfindlichkeit	NN	NN		OK/0.773533
(	(	(	$(		OK/0.923468
5-	5-	CD	TRUNC		OK/0.838034
to	__unaligned__	TO	__unaligned__		OK/0.901915
93-fach	93-fach	VV	NN		OK/0.933545
)	)	)	$(		OK/0.992533
versus	gegenüber	CC	APPR		OK/0.992202
nelfinavir	Nelfinavir	NN	NE		OK/0.910784
in	vitro	IN	NE		OK/0.994430
vitro	vitro	NN	NE		OK/0.992355
.	.	SENT	$.		OK/0.998796

# 0.490713
Special	Spezielle	JJ	ADJA		OK/0.969942
footnotes	Anmerkungen	NNS	NN		OK/0.957981
and	und	CC	KON		OK/0.995130
special	besondere	JJ	ADJA		OK/0.994441
precautions	Vorsichtsmaßnahmen	NNS	NN		OK/0.996986
with	Hinblick	IN	NN		OK/0.992436
regard	Hinblick	NN	NN		OK/0.996934
to	Hinblick	TO	NN		OK/0.994854
meningitis	Meningitis	NN	NN		OK/0.875069
,	,	,	$,		OK/0.853562
increases	Erhöhungen	NNS	NN		OK/0.952570
in	Erhöhungen	IN	NN		OK/0.994429
creatine	Kreatinkinase	NN	NN		OK/0.982345
kinase	Kreatinkinase	NN	NN		OK/0.998479
and	und	CC	KON		OK/0.992884
adverse	unerwünschte	JJ	ADJA		OK/0.997646
events	Ereignisse	NNS	NN		OK/0.979704
on	auf	IN	APPR		OK/0.866233
the	das	DT	ART		OK/0.968378
central	ZNS	JJ	NN		OK/0.990454
nervous	ZNS	JJ	NN		OK/0.991698
system	ZNS	NN	NN		OK/0.993487
can	finden	MD	VVFIN		OK/0.990073
be	finden	VB	VVFIN		OK/0.952974
found	finden	VVN	VVFIN		OK/0.894413
in	im	IN	APPRART		OK/0.861422
section	Abschnitt	NN	NN		OK/0.961568
4.4	4.4	CD	CARD		OK/0.962066
.	.	SENT	$.		OK/0.999588

# 0.184916
thrombolytics	Thrombolytika	NNS	NN		OK/0.888177
:	:	:	$.		OK/0.995694
the	Die	DT	ART		OK/0.996744
safety	Unbedenklichkeit	NN	NN		OK/0.995818
of	__unaligned__	IN	__unaligned__		OK/0.946086
the	__unaligned__	DT	__unaligned__		OK/0.992393
concomitant	gleichzeitigen	JJ	ADJA		OK/0.969792
administration	Gabe	NN	NN		OK/0.996222
of	Gabe	IN	NN		OK/0.953102
clopidogrel	Clopidogrel	NN	NE		OK/0.930143
,	,	,	$,		OK/0.862236
Thrombolytics	fibrin-	NP	TRUNC		OK/0.742742
:	fibrin-	:	TRUNC		OK/0.800514
fibrin	fibrinspezifisch	NN	ADJD		OK/0.863460
or	oder	CC	KON		OK/0.972473
non-fibrin	__unaligned__	JJ	__unaligned__		OK/0.762763
specific	__unaligned__	JJ	__unaligned__		OK/0.562979
thrombolytic	__unaligned__	JJ	__unaligned__		OK/0.504055
agents	__unaligned__	NNS	__unaligned__		OK/0.603116
and	und	CC	KON		OK/0.825112
heparins	__unaligned__	NNS	__unaligned__		OK/0.864165
was	wurde	VBD	VAFIN		OK/0.990459
evaluated	untersucht	VVN	VVPP		OK/0.985366
in	bei	IN	APPR		OK/0.996128
patients	Patienten	NNS	NN		OK/0.996589
with	mit	IN	APPR		OK/0.999293
acute	akutem	JJ	ADJA		OK/0.993309
myocardial	Herzinfarkt	JJ	NN		OK/0.989850
infarction	Herzinfarkt	NN	NN		OK/0.903750
.	.	SENT	$.		OK/0.998773

# 0.286499
38	38	NP	CARD		OK/0.939936
have	untersucht	VHP	VVFIN		OK/0.727043
been	untersucht	VBN	VVFIN		OK/0.804768
investigated	untersucht	VVN	VVFIN		OK/0.895101
to	__unaligned__	TO	__unaligned__		OK/0.863937
date	__unaligned__	VV	__unaligned__		OK/0.730186
(	(	(	$(		OK/0.902734
reported	CCyR	VVN	NN		OK/0.779057
)	)	)	$(		OK/0.959539
.	.	SENT	$.		OK/0.942641
Further	Weitere	JJR	ADJA		OK/0.867833
efficacy	Wirksamkeit	NN	NN		OK/0.956640
results	Ergebnisse	NNS	NN		OK/0.972370
are	Ergebnisse	VBP	NN		OK/0.937662
reported	Ergebnisse	VVN	NN		OK/0.810157
in	Tabelle	IN	NN		OK/0.993508
Table	Tabelle	NP	NN		OK/0.994092
5	5	CD	CARD		OK/0.941044
.	.	SENT	$.		OK/0.997942

# 0.801791
Hepatic	Eingeschränkte	NP	ADJA		OK/0.998405
impairment	Eingeschränkte	NN	ADJA		OK/0.995695
:	:	:	$.		OK/0.998552
in	Patienten	IN	NN		OK/0.958502
patients	Patienten	NNS	NN		OK/0.996762
with	mit	IN	APPR		OK/0.996926
mild	leichter	JJ	ADJD		OK/0.998706
to	mittelschwerer	TO	ADJA		OK/0.998150
moderate	mittelschwerer	JJ	ADJA		OK/0.999431
cirrhosis	Leberzirrhose	NN	NN		OK/0.995155
,	die	,	ART		OK/0.993104
the	die	DT	ART		OK/0.999619
pharmacokinetic	Pharmakokinetik	JJ	NN		OK/0.970445
parameters	__unaligned__	NNS	__unaligned__		OK/0.980785
of	__unaligned__	IN	__unaligned__		OK/0.997901
irbesartan	Irbesartan	NN	NE		OK/0.995533
are	wesentlich	VBP	ADJD		OK/0.964369
not	nicht	RB	PTKNEG		OK/0.999457
significantly	wesentlich	RB	ADJD		OK/0.989642
altered	verändert	VVN	VVPP		OK/0.932395
.	.	SENT	$.		OK/0.998665

# 0.014044
The	Die	DT	ART		OK/0.993993
type	Art	NN	NN		OK/0.938902
of	Art	IN	NN		OK/0.891839
evidence-based	verwendeten	JJ	ADJA		BAD/0.388055
,	__unaligned__	,	__unaligned__		BAD/0.554704
N-N-dimethylformamid	Gerätes	NP	NN		BAD/0.568427
,	sowie	,	KON		BAD/0.608128
and	sowie	CC	KON		BAD/0.389319
duration	Dauer	NN	NN		BAD/0.485317
of	Dauer	IN	NN		BAD/0.617174
605A	Beleuchtung	NP	NN		BAD/0.860222
)	__unaligned__	)	__unaligned__		BAD/0.837418
is	__unaligned__	VBZ	__unaligned__		OK/0.457871
used	__unaligned__	VVN	__unaligned__		OK/0.618720
for	__unaligned__	IN	__unaligned__		OK/0.790790
depend	hängen	VV	VVFIN		OK/0.844218
on	hängen	IN	VVFIN		OK/0.917843
how	wie	WRB	KOKOM		OK/0.982549
long	lang	RB	ADJD		OK/0.989455
the	der	DT	ART		OK/0.985522
heparinized	erkrankte	JJ	ADJA		BAD/0.500108
gullet	Speiseröhre	NN	NN		BAD/0.554448
.	.	SENT	$.		OK/0.993312

# 0.876622
Irbesartan	Irbesartan	NP	NE		OK/0.994896
BMS	BMS	NP	NN		OK/0.998577
belongs	gehört	VVZ	VVFIN		OK/0.997908
to	gehört	TO	VVFIN		OK/0.998827
a	gehört	DT	VVFIN		OK/0.999457
class	gehört	NN	VVFIN		OK/0.999051
of	gehört	IN	VVFIN		OK/0.997869
medicines	Arzneimitteln	NNS	NN		OK/0.999479
known	bekannt	VVN	VVPP		OK/0.998619
as	__unaligned__	IN	__unaligned__		OK/0.993955
angiotensin-II	Angiotensin-II-	NP	TRUNC		OK/0.974221
receptor	__unaligned__	NN	__unaligned__		OK/0.904908
antagonists	__unaligned__	NNS	__unaligned__		OK/0.993158
.	.	SENT	$.		OK/0.993410

# 0.825892
Do	Sie	VVP	PPER		OK/0.948806
not	Öffnen	RB	VVFIN		OK/0.991108
open	Öffnen	VV	VVFIN		OK/0.993426
the	die	DT	ART		OK/0.994917
blister	Blisterpackung	NN	NN		OK/0.991316
until	__unaligned__	IN	__unaligned__		OK/0.928903
ready	nur	JJ	ADV		OK/0.958670
to	vor	TO	APPR		OK/0.987619
administer	__unaligned__	VV	__unaligned__		OK/0.965236
.	.	SENT	$.		OK/0.999121

# 0.712782
The	Die	DT	ART		OK/0.984412
following	folgenden	VVG	ADJA		OK/0.973097
adverse	unerwünschten	JJ	ADJA		OK/0.996140
events	unerwünschten	NNS	ADJA		OK/0.966524
with	mit	IN	APPR		OK/0.982327
possible	möglicher	JJ	ADJA		OK/0.942037
clinical	klinischer	JJ	ADJA		OK/0.979177
relevance	Relevanz	NN	NN		OK/0.959983
have	wurden	VHP	VAFIN		OK/0.899122
been	wurden	VBN	VAFIN		OK/0.938777
observed	beobachtet	VVN	VVPP		OK/0.941755
in	in	IN	APPR		OK/0.979366
animal	Tierstudien	JJ	NN		OK/0.977698
studies	Tierstudien	NNS	NN		OK/0.966482
:	:	:	$.		OK/0.998199

# 0.484217
The	Das	DT	ART		OK/0.999402
most	häufigsten	RBS	ADJA		OK/0.995412
frequently	häufigsten	RB	ADJA		OK/0.994846
observed	beobachtete	VVN	ADJA		OK/0.992054
symptoms	Symptom	NNS	NN		OK/0.991482
was	war	VBD	VAFIN		OK/0.993990
redness	Hautrötung	NN	NN		OK/0.988671
of	Hautrötung	IN	NN		OK/0.997577
the	Hautrötung	DT	NN		OK/0.994954
skin	Hautrötung	NN	NN		OK/0.970051
,	,	,	$,		OK/0.950996
on	überwiegenden	IN	ADJA		OK/0.938627
the	__unaligned__	DT	__unaligned__		OK/0.976192
majority	Mehrzahl	NN	NN		OK/0.986023
of	Fälle	IN	NN		OK/0.993133
cases	Fälle	NNS	NN		OK/0.989376
within	innerhalb	IN	APPR		OK/0.997648
24	24	CD	CARD		OK/0.984142
hours	Stunden	NNS	NN		OK/0.893951
abklang	abklang	NN	VVFIN		BAD/0.692555
.	.	SENT	$.		OK/0.988237

# 0.334202
Wunddrainage	Wunddrainage	NP	NN		OK/0.877052
)	)	)	$(		OK/0.990953
than	als	IN	KOKOM		OK/0.991860
in	bei	IN	APPR		OK/0.936317
subsequent	InductOs-Patienten	JJ	NN		OK/0.868963
interventions	__unaligned__	NNS	__unaligned__		OK/0.569020
,	,	,	$,		OK/0.614264
not	nicht	RB	PTKNEG		OK/0.874605
previously	__unaligned__	RB	__unaligned__		OK/0.901206
treated	behandelt	VVN	VVPP		OK/0.994300
with	mit	IN	APPR		OK/0.999924
non-steroidal	__unaligned__	NN	__unaligned__		OK/0.976895
anti-inflammatory	Entzündungshemmern	JJ	NN		OK/0.835070
medicines	Entzündungshemmern	NNS	NN		OK/0.853444
.	.	SENT	$.		OK/0.984225

# 0.625835
Known	Bekannte	VVN	ADJA		OK/0.984735
hypersensitivity	Überempfindlichkeit	NN	NN		OK/0.997481
to	gegen	TO	APPR		OK/0.994925
the	den	DT	ART		OK/0.999620
active	Wirkstoff	JJ	NN		OK/0.995009
substance	Wirkstoff	NN	NN		OK/0.990403
,	,	,	$,		OK/0.970318
to	__unaligned__	TO	__unaligned__		OK/0.887117
hamster	Hamsterproteine	NN	NN		OK/0.817802
proteins	Hamsterproteine	NNS	NN		OK/0.874757
or	oder	CC	KON		OK/0.998472
to	oder	TO	KON		OK/0.953734
any	Bestandteile	DT	NN		OK/0.994438
of	Bestandteile	IN	NN		OK/0.996892
the	Bestandteile	DT	NN		OK/0.994238
excipients	sonstigen	NNS	ADJA		OK/0.887520
.	.	SENT	$.		OK/0.999344

# 0.047882
The	Die	DT	ART		OK/0.996436
ingredients	Bestandteile	NNS	NN		OK/0.988548
of	__unaligned__	IN	__unaligned__		OK/0.998051
Cozaar	Cozaar	NP	NN		OK/0.997719
Comp	Comp	NP	NN		OK/0.910802
to	wirken	TO	VVFIN		BAD/0.478447
the	__unaligned__	DT	__unaligned__		BAD/0.533681
proximal	antihypertensiv	JJ	ADJD		BAD/0.870659
end	__unaligned__	NN	__unaligned__		BAD/0.941937
of	__unaligned__	IN	__unaligned__		BAD/0.877911
the	__unaligned__	DT	__unaligned__		BAD/0.648942
additive	additiv	NN	ADJD		BAD/0.788370
,	,	,	$,		BAD/0.583858
and	die	CC	ART		BAD/0.585856
greater	stärker	JJR	ADJD		BAD/0.464917
reductions	Blutdrucksenkung	NNS	NN		BAD/0.492366
in	Blutdrucksenkung	IN	NN		OK/0.991437
blood	Blutdrucksenkung	NN	NN		OK/0.998547
pressure	Blutdrucksenkung	NN	NN		OK/0.990603
as	als	RB	KOKOM		OK/0.972691
compared	__unaligned__	VVN	__unaligned__		OK/0.940976
to	__unaligned__	TO	__unaligned__		OK/0.943674
the	__unaligned__	DT	__unaligned__		OK/0.945323
administration	Gabe	NN	NN		OK/0.884446
of	Gabe	IN	NN		OK/0.687808
either	__unaligned__	DT	__unaligned__		OK/0.763226
of	__unaligned__	IN	__unaligned__		OK/0.889835
its	__unaligned__	PP$	__unaligned__		OK/0.872887
components	Einzelbestandteile	NNS	NN		OK/0.910418
.	.	SENT	$.		OK/0.993782

# 0.258789
If	Falls	IN	NN		OK/0.997541
side	Nebenwirkungen	NN	NN		OK/0.998680
effects	Nebenwirkungen	NNS	NN		OK/0.997047
that	die	WDT	PRELS		OK/0.993570
affect	betreffen	VVP	VVFIN		OK/0.986363
the	__unaligned__	DT	__unaligned__		OK/0.971295
central	Zentralnervensystem	JJ	NN		OK/0.997219
nervous	Zentralnervensystem	JJ	NN		OK/0.997929
system	Zentralnervensystem	NN	NN		OK/0.995114
,	,	,	$,		OK/0.996199
such	wie	JJ	KOKOM		OK/0.961916
as	wie	IN	KOKOM		OK/0.985260
dizziness	Schwindel	NN	NN		OK/0.983719
,	,	,	$,		OK/0.979103
may	auftreten	MD	VVINF		OK/0.489791
occur	auftreten	VV	VVINF		OK/0.602344
,	,	,	$,		OK/0.836256
it	es	PP	PPER		OK/0.931976
is	es	VBZ	PPER		OK/0.897043
verboten	verboten	JJ	VVPP		OK/0.843123
,	,	,	$,		OK/0.788042
drive	__unaligned__	VV	__unaligned__		OK/0.799433
or	__unaligned__	CC	__unaligned__		OK/0.811664
operate	Fahrzeug	VV	NN		OK/0.845511
machinery	bedienen	NN	VVINF		OK/0.973270
.	.	SENT	$.		OK/0.997469

# 0.540108
PVC	PVC-Blister	NP	NN		OK/0.949775
inward	Grüne	RB	NN		OK/0.921149
and	und	CC	KON		OK/0.991249
with	Aluminiumfolie	IN	NN		OK/0.958990
aluminium	__unaligned__	NN	__unaligned__		OK/0.999534
foil	__unaligned__	NN	__unaligned__		OK/0.995056
backing	__unaligned__	NN	__unaligned__		OK/0.952378
in	in	IN	APPR		OK/0.981149
a	__unaligned__	DT	__unaligned__		OK/0.883226
cartons	Faltschachteln	NNS	NN		OK/0.657772
.	.	SENT	$.		OK/0.991828

# 0.170032
After	Nach	IN	APPR		OK/0.868078
training	Schulung	NN	NN		OK/0.682577
,	__unaligned__	,	__unaligned__		OK/0.901266
doctors	sachgemäßen	NNS	ADJA		OK/0.958050
subcutaneous	subkutanen	JJ	ADJA		OK/0.985301
injection	Injektionstechnik	NN	NN		OK/0.999258
technique	Injektionstechnik	NN	NN		OK/0.996287
,	__unaligned__	,	__unaligned__		OK/0.929903
patients	Patienten	NNS	NN		OK/0.968193
may	können	MD	VMFIN		OK/0.944848
inject	injizieren	VV	VVINF		OK/0.894680
STELARA	STELARA	NP	NE		OK/0.938408
yourself	selbst	PP	ADV		OK/0.892121
if	wenn	IN	KOUS		OK/0.893762
the	__unaligned__	DT	__unaligned__		OK/0.845400
treating	behandelnde	VVG	ADJA		OK/0.724990
physician	behandelnde	NN	ADJA		OK/0.564126
determines	__unaligned__	VVZ	__unaligned__		OK/0.484624
that	__unaligned__	IN/that	__unaligned__		OK/0.536611
this	dies	DT	PDS		OK/0.825186
is	__unaligned__	VBZ	__unaligned__		OK/0.916839
appropriate	__unaligned__	JJ	__unaligned__		OK/0.854979
.	.	SENT	$.		OK/0.998221

# 0.073817
The	Die	DT	ART		OK/0.973162
good	gute	JJ	ADJA		OK/0.950148
tolerability	Verträglichkeit	NN	NN		OK/0.854737
has	belegt	VHZ	VVPP		OK/0.870246
been	belegt	VBN	VVPP		OK/0.959094
shown	belegt	VVN	VVPP		OK/0.981525
in	in	IN	APPR		OK/0.999279
a	in	DT	APPR		OK/0.972666
clinical	klinischen	JJ	ADJA		OK/0.994894
trial	Studie	NN	NN		OK/0.956155
,	,	,	$,		OK/0.799146
in	in	IN	APPR		OK/0.545256
which	in	WDT	APPR		OK/0.461260
the	__unaligned__	DT	__unaligned__		OK/0.531323
re-administration	wiederholte	NN	ADJA		OK/0.415473
,	die	,	ART		OK/0.331845
the	die	DT	ART		OK/0.394528
daily	tägliche	JJ	ADJA		OK/0.793074
intake	Einnahme	NN	NN		OK/0.891241
of	__unaligned__	IN	__unaligned__		OK/0.990272
2	4	CD	CARD		OK/0.993854
g	g	NN	NN		OK/0.976215
strontium	Strontiumranelat	NN	NN		OK/0.770367
ranelate	Strontiumranelat	NN	NN		OK/0.858265
more	über	JJR	APPR		OK/0.972858
than	über	IN	APPR		OK/0.951549
25	25	CD	CARD		OK/0.951416
days	Tage	NNS	NN		OK/0.990712
in	gesunden	IN	ADJA		OK/0.980829
healthy	gesunden	JJ	ADJA		OK/0.995636
postmenopausal	postmenopausalen	JJ	ADJA		OK/0.997957
women	Frauen	NNS	NN		OK/0.993163
has	untersucht	VHZ	VVPP		OK/0.949141
not	untersucht	RB	VVPP		OK/0.925571
been	untersucht	VBN	VVPP		OK/0.957179
studied	untersucht	VVN	VVPP		OK/0.959073
.	.	SENT	$.		OK/0.999377

# 0.517332
Celecoxib	Celecoxib	NP	NE		OK/0.977415
can	kann	MD	VMFIN		OK/0.994683
be	kann	VB	VMFIN		OK/0.996997
used	zusammen	VVN	ADV		OK/0.978071
with	mit	IN	APPR		OK/0.997499
low-dose	dosierter	NN	ADJA		OK/0.959007
acetylsalicylic	Acetylsalicylsäure	JJ	NN		OK/0.978668
acid	Acetylsalicylsäure	NN	NN		OK/0.959806
used	angewendet	VVN	VVPP		BAD/0.855420
,	,	,	$,		OK/0.907893
but	aber	CC	KON		OK/0.968783
is	Celecoxib	VBZ	VVIMP		OK/0.843002
not	kein	RB	PIAT		OK/0.889068
a	Ersatz	DT	NN		OK/0.988004
substitute	Ersatz	NN	NN		OK/0.978042
for	für	IN	APPR		OK/0.987726
acetylsalicylic	Acetylsalicylsäure	JJ	NN		OK/0.994444
acid	Acetylsalicylsäure	NN	NN		OK/0.998042
for	zur	IN	APPRART		OK/0.986961
cardiovascular	kardiovaskulären	JJ	ADJA		OK/0.992832
prophylaxis	Prophylaxe	NN	NN		OK/0.981830
.	.	SENT	$.		OK/0.999467

# 0.127283
The	Das	DT	ART		OK/0.886359
product	Produkt	NN	NN		OK/0.650852
before	vor	IN	APPR		BAD/0.853890
administration	Verabreichung	NN	NN		BAD/0.920977
,	__unaligned__	,	__unaligned__		BAD/0.891679
in	bei	IN	APPR		BAD/0.832740
the	__unaligned__	DT	__unaligned__		BAD/0.671562
manufacture	__unaligned__	NN	__unaligned__		BAD/0.737166
of	__unaligned__	IN	__unaligned__		BAD/0.653508
2-8	auftauen	CD	VVINF		BAD/0.602705
°	__unaligned__	SYM	__unaligned__		BAD/0.641597
C	__unaligned__	NP	__unaligned__		BAD/0.559196
(	__unaligned__	(	__unaligned__		BAD/0.706583
refrigerator	__unaligned__	NN	__unaligned__		BAD/0.808633
)	__unaligned__	)	__unaligned__		BAD/0.802670
.	.	SENT	$.		OK/0.902963

# 0.194184
th	el	NN	NE		BAD/0.527301
au	ug	FW	ADJD		BAD/0.588547
As	Wie	IN	KOKOM		OK/0.941433
with	anderen	IN	PIS		OK/0.987242
other	anderen	JJ	PIS		OK/0.986631
used	Insulinprodukten	VVN	NN		OK/0.582083
in	__unaligned__	IN	__unaligned__		OK/0.571830
the	die	DT	ART		OK/0.947712
hypoglycaemia	Hypoglykämie	NN	NN		OK/0.973133
in	im	IN	APPRART		OK/0.986847
general	Allgemeinen	NN	NN		OK/0.996496
the	im	DT	APPRART		OK/0.983997
most	häufigsten	RBS	ADJA		OK/0.995598
common	häufigsten	JJ	ADJA		OK/0.991356
undesirable	Nebenwirkung	JJ	NN		OK/0.955290
effects	__unaligned__	NNS	__unaligned__		OK/0.939176
.	.	SENT	$.		OK/0.998796

# 0.884926
2	2	CD	CARD		OK/0.928920
/	/	SYM	$(		OK/0.975637
3	3	CD	CARD		OK/0.988207
Why	Warum	WRB	PWAV		OK/0.995653
has	Warum	VHZ	PWAV		OK/0.988055
Temodal	Temodal	NP	NN		OK/0.994957
been	zugelassen	VBN	VVPP		OK/0.989592
approved	zugelassen	VVN	VVPP		OK/0.992006
?	?	SENT	$.		OK/0.999341

# 0.341650
In	Bei	IN	APPR		OK/0.997618
case	versehentlicher	NN	ADJA		OK/0.996388
of	versehentlicher	IN	ADJA		OK/0.998593
accidental	versehentlicher	JJ	ADJA		OK/0.998922
self-injection	Selbstinjektion	NN	NN		OK/0.982854
,	,	,	$,		OK/0.746541
ingestion	Einnahme	NN	NN		OK/0.848033
or	oder	CC	KON		OK/0.996845
spillage	Hautexposition	NN	NN		OK/0.901156
onto	Hautexposition	IN	NN		OK/0.841029
skin	Hautexposition	NN	NN		OK/0.911621
,	__unaligned__	,	__unaligned__		OK/0.955512
seek	Arzt	VV	NN		OK/0.746722
medical	__unaligned__	JJ	__unaligned__		OK/0.753472
advice	__unaligned__	NN	__unaligned__		OK/0.898311
immediately	__unaligned__	RB	__unaligned__		OK/0.940536
and	und	CC	KON		OK/0.996555
show	__unaligned__	VV	__unaligned__		OK/0.946991
the	Packungsbeilage	DT	NN		OK/0.991172
package	Packungsbeilage	NN	NN		OK/0.995862
leaflet	Packungsbeilage	NN	NN		OK/0.947502
or	oder	CC	KON		OK/0.992995
the	Etikett	DT	NN		OK/0.998883
label	Etikett	NN	NN		OK/0.999848
to	__unaligned__	TO	__unaligned__		OK/0.976864
the	__unaligned__	DT	__unaligned__		OK/0.997537
physician	vorzuzeigen	NN	VVIZU		OK/0.990587
.	.	SENT	$.		OK/0.999443

# 0.312605
The	Ein	NP	ART		OK/0.909994
necroses	Hirudin	VVZ	NE		OK/0.921182
attaches	bindet	VVZ	VVFIN		OK/0.961388
to	Molekül	TO	NN		OK/0.917767
thrombin	Thrombin	NN	NN		OK/0.942206
and	und	CC	KON		OK/0.733066
mixtures	thrombogene	NNS	ADJA		BAD/0.910881
thereof	__unaligned__	RB	__unaligned__		BAD/0.931721
,	__unaligned__	,	__unaligned__		BAD/0.776277
the	die	DT	ART		OK/0.925862
effect	Wirkung	NN	NN		OK/0.929767
of	Wirkung	IN	NN		OK/0.942596
the	die	DT	ART		OK/0.993277
infusion	Thrombins	NN	NN		OK/0.832401
.	.	SENT	$.		OK/0.998094

# 0.662500
Fentanyl	Fentanyl	NP	NN		OK/0.958248
should	sollte	MD	VMFIN		OK/0.993529
be	__unaligned__	VB	__unaligned__		OK/0.996222
used	angewendet	VVN	VVPP		OK/0.988398
during	während	IN	APPR		OK/0.995710
pregnancy	Schwangerschaft	NN	NN		OK/0.997678
only	nur	RB	ADV		OK/0.764077
if	wenn	IN	KOUS		OK/0.984432
it	es	PP	PPER		OK/0.990678
is	es	VBZ	PPER		OK/0.998163
clearly	unbedingt	RB	ADJD		OK/0.963271
necessary	erforderlich	JJ	ADJD		OK/0.946437
.	.	SENT	$.		OK/0.999648

# 0.622280
Hypotension	Hypotonie	NP	NN		OK/0.844079
may	kann	MD	VMFIN		OK/0.990591
occur	auftreten	VV	VVFIN		OK/0.958362
at	Behandlungsbeginn	IN	NN		OK/0.997731
the	Behandlungsbeginn	DT	NN		OK/0.998140
beginning	Behandlungsbeginn	NN	NN		OK/0.999547
of	__unaligned__	IN	__unaligned__		OK/0.993793
treatment	__unaligned__	NN	__unaligned__		OK/0.975776
,	,	,	$,		OK/0.996932
especially	besonders	RB	ADV		OK/0.992088
if	wenn	IN	KOUS		OK/0.983624
pramipexole	Pramipexol	NN	NN		OK/0.990323
is	__unaligned__	VBZ	__unaligned__		OK/0.937884
titrated	Dosistitration	VVN	NN		OK/0.914886
too	schnell	RB	ADJD		OK/0.885589
fast	schnell	RB	ADJD		OK/0.899262
.	.	SENT	$.		OK/0.998542

# 0.437036
In	Bei	IN	APPR		OK/0.943409
107	107	CD	CARD		OK/0.979577
patients	Patienten	NNS	NN		OK/0.994776
treated	Patienten	VVN	NN		OK/0.990862
with	mit	IN	APPR		OK/0.998691
CRIXIVAN	CRIXIVAN	NP	NE		OK/0.992648
alone	allein	RB	ADV		OK/0.982726
or	oder	CC	KON		OK/0.982661
in	Kombination	IN	NN		OK/0.960487
combination	Kombination	NN	NN		OK/0.992330
for	für	IN	APPR		OK/0.990611
up	zu	IN	APPR		OK/0.996223
to	bis	TO	KON		OK/0.998558
48	48	CD	CARD		OK/0.997717
weeks	Wochen	NNS	NN		OK/0.998688
,	,	,	$,		OK/0.994585
was	war	VBD	VAFIN		OK/0.968386
similar	ähnlich	JJ	ADJD		OK/0.986099
to	ähnlich	TO	ADJD		OK/0.911301
that	ähnlich	DT	ADJD		OK/0.596207
of	__unaligned__	IN	__unaligned__		OK/0.692536
the	das	DT	ART		OK/0.860226
overall	allgemeine	JJ	ADJA		OK/0.929997
safety	Sicherheitsprofil	NN	NN		OK/0.955692
.	.	SENT	$.		OK/0.997017

# 0.150055
29	29	NP	CARD		OK/0.996455
Dose	Dosisabhängige	NP	NN		OK/0.981592
related	Dosisabhängige	VVD	NN		OK/0.958128
asymptomatic	asymptomatische	JJ	ADJA		OK/0.859468
prolongations	PR-Intervalls	NNS	NN		OK/0.783429
in	PR-Intervalls	IN	NN		OK/0.973243
PR	PR-Intervalls	NP	NN		OK/0.982645
interval	PR-Intervalls	NN	NN		OK/0.947341
have	__unaligned__	VHP	__unaligned__		OK/0.791699
been	__unaligned__	VBN	__unaligned__		OK/0.753661
seen	wurden	VVN	VAFIN		OK/0.562895
in	in	IN	APPR		OK/0.630207
clinical	klinischen	JJ	ADJA		OK/0.680484
trials	Studien	NNS	NN		OK/0.746312
with	mit	IN	APPR		OK/0.889661
REYATAZ	REYATAZ	NP	NE		OK/0.742182
have	beobachtet	VHP	VVPP		OK/0.547983
been	beobachtet	VBN	VVPP		OK/0.557405
observed	beobachtet	VVN	VVPP		OK/0.673997
.	.	SENT	$.		OK/0.991616

# 0.281746
These	Diese	DT	PDAT		OK/0.896318
IgG	IgG-Antikörper	NP	NN		OK/0.892257
antibodies	IgG-Antikörper	NNS	NN		OK/0.982375
to	IgG-Antikörper	TO	NN		OK/0.833845
did	schienen	VVD	VVFIN		OK/0.485929
after	nach	IN	APPR		OK/0.617497
approximately	etwa	RB	ADV		OK/0.721767
3	__unaligned__	CD	__unaligned__		OK/0.738566
to	__unaligned__	TO	__unaligned__		OK/0.878581
12	3-12	CD	CARD		OK/0.913652
months	Monaten	NNS	NN		OK/0.938614
of	__unaligned__	IN	__unaligned__		OK/0.862676
treatment	Behandlungszeit	NN	NN		OK/0.888796
.	.	SENT	$.		OK/0.996918

# 0.366510
On	Am	IN	APPRART		OK/0.935752
28	28	CD	CARD		OK/0.999684
July	Juli	NP	NN		OK/0.994714
2002	2002	CD	CARD		OK/0.969707
The	__unaligned__	DT	__unaligned__		OK/0.992197
European	Europäische	NP	ADJA		OK/0.999859
Commission	erteilte	NP	VVFIN		OK/0.992152
granted	Unternehmen	VVD	NN		OK/0.978594
the	Europäischen	DT	ADJA		OK/0.613378
European	Europäischen	NP	ADJA		OK/0.720849
Union	Union	NP	NN		OK/0.808899
for	Union	IN	NN		OK/0.726417
TopoTarget	TopoTarget	NP	NN		OK/0.853401
A	A	NP	FM		OK/0.944991
/	/	SYM	$(		OK/0.987794
S	S	NP	NN		OK/0.939206
for	für	IN	APPR		OK/0.978035
Savene	Savene	NP	NN		OK/0.917140
.	.	SENT	$.		OK/0.999642

# 0.271685
The	Die	DT	ART		OK/0.983780
synthesis	Synthese	NN	NN		OK/0.950717
of	__unaligned__	IN	__unaligned__		OK/0.973124
5-ALA	5-ALA	NP	NN		OK/0.933113
is	wird	VBZ	VAFIN		OK/0.941587
given	wird	VVN	VAFIN		OK/0.627627
through	über	IN	APPR		OK/0.914651
a	__unaligned__	DT	__unaligned__		OK/0.930786
similar	Pool	JJ	NN		OK/0.970333
intracellular	intrazellulären	JJ	ADJA		OK/0.986516
free	freiem	NN	ADJA		OK/0.974887
identified	Häm	VVN	NE		OK/0.925897
by	durch	IN	APPR		OK/0.987403
a	negativen	DT	ADJA		OK/0.893120
negative	negativen	JJ	ADJA		OK/0.805739
Feedback-Mechanismus	Feedback-Mechanismus	NP	NN		BAD/0.745633
.	.	SENT	$.		OK/0.996080

# 0.984390
What	Wofür	WP	NN		OK/0.998379
is	Wofür	VBZ	NN		OK/0.990129
Pandemrix	Pandemrix	NN	NE		OK/0.999235
used	angewendet	VVN	VVPP		OK/0.996793
for	angewendet	IN	VVPP		OK/0.999715
?	?	SENT	$.		OK/0.999339

# 0.949662
Each	Jede	DT	PIAT		OK/0.997980
0.5	0,5	CD	CARD		OK/0.994966
ml	ml	NN	NN		OK/0.999530
pre-filled	Fertigspritze	JJ	NN		OK/0.995516
syringe	Fertigspritze	NN	NN		OK/0.999501
contains	enthält	VVZ	VVFIN		OK/0.997995
100	100	CD	CARD		OK/0.996670
micrograms	Mikrogramm	NNS	NN		OK/0.993635
darbepoetin	Darbepoetin	NN	NN		OK/0.986227
alfa	alfa	NN	NE		OK/0.995653
(	(	(	$(		OK/0.995099
200	200	CD	CARD		OK/0.998934
micrograms	Mikrogramm	NNS	NN		OK/0.999508
/	/	SYM	$(		OK/0.997618
ml	ml	NN	NN		OK/0.999626
)	)	)	$(		OK/0.997069
.	.	SENT	$.		OK/0.997267

# 0.114042
In	In	IN	APPR		OK/0.972473
the	der	DT	ART		OK/0.971291
maintenance	Erhaltungsphase	NN	NN		OK/0.858376
phase	Erhaltungsphase	NN	NN		OK/0.864220
on	__unaligned__	IN	__unaligned__		BAD/0.730881
the	der	DT	ART		BAD/0.237926
basis	__unaligned__	NN	__unaligned__		BAD/0.564296
of	__unaligned__	IN	__unaligned__		BAD/0.756841
serum	Serumcalciumspiegel	NN	NN		OK/0.875355
calcium	__unaligned__	NN	__unaligned__		OK/0.975421
levels	__unaligned__	NNS	__unaligned__		OK/0.862989
should	muss	MD	VMFIN		OK/0.938977
be	__unaligned__	VB	__unaligned__		OK/0.987952
monitored	__unaligned__	VVN	__unaligned__		OK/0.977943
every	alle	DT	PIAT		OK/0.998752
2-3	2-3	CD	CARD		OK/0.987271
months	Monate	NNS	NN		OK/0.978194
.	.	SENT	$.		OK/0.999647

# 0.418275
Serious	Schwerwiegende	NP	NN		OK/0.985667
cardiovascular	kardiovaskuläre	JJ	ADJA		OK/0.994743
events	Ereignisse	NNS	NN		OK/0.997910
,	,	,	$,		OK/0.997281
including	einschließlich	VVG	APPR		OK/0.996803
myocardial	Herzinfarkt	JJ	NN		OK/0.996498
infarction	Herzinfarkt	NN	NN		OK/0.956111
,	,	,	$,		OK/0.986829
unstable	instabile	JJ	ADJA		OK/0.995299
angina	pectoris	NN	ADJA		OK/0.997810
,	plötzlicher	,	ADJA		OK/0.955760
sudden	plötzlicher	JJ	ADJA		OK/0.918966
cardiac	Herztod	JJ	NN		OK/0.967543
death	Herztod	NN	NN		OK/0.993024
,	,	,	$,		OK/0.987074
ventricular	ventrikuläre	JJ	ADJA		OK/0.983700
arrhythmia	Arrhythmie	NN	NN		OK/0.988868
,	,	,	$,		OK/0.989083
cerebrovascular	zerebrovaskuläre	JJ	ADJA		OK/0.944041
haemorrhage	Blutung	NN	NN		OK/0.989673
,	,	,	$,		OK/0.953334
transient	Attacke	JJ	NN		OK/0.974174
ischaemic	Attacke	JJ	NN		OK/0.977991
attack	Attacke	NN	NN		OK/0.978779
,	,	,	$,		OK/0.996719
hypertension	Hypertonie	NN	NN		OK/0.994510
and	und	CC	KON		OK/0.998090
hypotension	Hypotonie	NN	NN		OK/0.955771
have	gemeldet	VHP	VVPP		OK/0.970236
been	gemeldet	VBN	VVPP		OK/0.971954
reported	gemeldet	VVN	VVPP		OK/0.953489
from	__unaligned__	IN	__unaligned__		OK/0.765098
post-marketing	Markteinführung	NN	NN		OK/0.968806
experience	Markteinführung	NN	NN		OK/0.963344
in	im	IN	APPRART		OK/0.984537
temporal	zeitlichen	JJ	ADJA		OK/0.946592
association	zeitlichen	NN	ADJA		OK/0.950104
with	mit	IN	APPR		OK/0.991229
the	dem	DT	ART		OK/0.989502
use	Gebrauch	NN	NN		OK/0.994783
of	__unaligned__	IN	__unaligned__		OK/0.987773
VIAGRA	VIAGRA	NP	NE		OK/0.966419
.	.	SENT	$.		OK/0.999627

# 0.281564
In	Bei	IN	APPR		OK/0.971509
the	__unaligned__	DT	__unaligned__		OK/0.990030
unlikely	__unaligned__	JJ	__unaligned__		OK/0.977554
event	__unaligned__	NN	__unaligned__		OK/0.960971
of	__unaligned__	IN	__unaligned__		OK/0.950379
skin	Hautkontakt	NN	NN		OK/0.983028
contact	__unaligned__	NN	__unaligned__		OK/0.995610
with	mit	IN	APPR		OK/0.979722
thoroughly	Flascheninhalt	RB	NN		OK/0.860176
cleanse	Flascheninhalt	VV	NN		OK/0.611027
the	die	DT	ART		OK/0.874175
exposed	betroffene	VVN	ADJA		OK/0.489761
area	betroffene	NN	ADJA		OK/0.716006
immediately	sofort	RB	ADV		OK/0.924442
.	.	SENT	$.		OK/0.997131

# 0.634678
Acute	Akute	NP	ADJA		OK/0.991969
hypersensitivity	Überempfindlichkeitsreaktionen	NN	NN		OK/0.976890
reactions	Überempfindlichkeitsreaktionen	NNS	NN		OK/0.997229
(	(	(	$(		OK/0.999814
e.	z.B.	FW	ADV		OK/0.970108
g	z.B.	NN	ADV		OK/0.952729
.	z.B.	SENT	ADV		OK/0.919900
,	Urtikaria	,	NE		OK/0.963211
urticaria	Urtikaria	NN	NE		OK/0.987557
,	,	,	$,		OK/0.999555
angioedema	Angioödem	NP	NE		OK/0.985618
,	Angioödem	,	NE		OK/0.937402
bronchoconstriction	Bronchokonstriktion	NN	NN		OK/0.956828
,	,	,	$,		OK/0.988671
anaphylaxis	Anaphylaxie	NN	ADJA		OK/0.984449
)	)	)	$(		OK/0.998746
have	wurden	VHP	VAFIN		OK/0.967622
been	wurden	VBN	VAFIN		OK/0.985537
observed	beobachtet	VVN	VVPP		OK/0.989475
rarely	selten	RB	ADJD		OK/0.959119
during	__unaligned__	IN	__unaligned__		OK/0.895001
interferon	Interferon	NN	NN		OK/0.998708
alfa-2b	alfa-2b	NN	VVFIN		OK/0.989096
therapy	Behandlung	NN	NN		OK/0.987206
.	.	SENT	$.		OK/0.997729

# 0.307806
Since	Da	IN	ADV		OK/0.993578
no	keine	DT	PIAT		OK/0.996104
studies	Verträglichkeitsstudien	NNS	NN		OK/0.995823
were	wurden	VBD	VAFIN		OK/0.963898
conducted	durchgeführt	VVN	VVPP		OK/0.986739
,	,	,	$,		OK/0.983478
this	dieses	DT	PDAT		OK/0.999556
medicinal	Arzneimittel	JJ	NN		OK/0.998104
product	__unaligned__	NN	__unaligned__		OK/0.994667
must	darf	MD	VMFIN		OK/0.984174
not	nicht	RB	PTKNEG		OK/0.994684
be	__unaligned__	VB	__unaligned__		OK/0.937813
mixed	anderen	VVN	PIS		OK/0.824936
with	mit	IN	APPR		OK/0.984865
other	anderen	JJ	PIS		OK/0.994913
medicinal	Arzneimitteln	JJ	NN		OK/0.984599
products	Arzneimitteln	NNS	NN		OK/0.998608
except	außer	IN	APPR		OK/0.995053
those	außer	DT	APPR		OK/0.991865
mentioned	außer	VVN	APPR		OK/0.954187
in	__unaligned__	IN	__unaligned__		OK/0.740905
6.6.	6.6.	CD	CARD		BAD/0.730938
listed	aufgeführten	VVN	ADJA		BAD/0.743423
.	.	SENT	$.		OK/0.975232

# 0.811588
•	•	JJ	ADJA		OK/0.997588
Experience	Erfahrungen	NN	NN		OK/0.920425
with	mit	IN	APPR		OK/0.994126
hepatitis	Hepatitis-B-Impfstoffen	NP	NN		OK/0.991689
B	Hepatitis-B-Impfstoffen	NP	NN		OK/0.954353
vaccines	Hepatitis-B-Impfstoffen	NNS	NN		OK/0.900100
:	:	:	$.		OK/0.987707

# 0.941028
What	Welchen	WP	PIAT		OK/0.998932
benefit	Welchen	VVP	PIAT		OK/0.982837
has	Nutzen	VHZ	NN		OK/0.998476
Avastin	Avastin	NP	NN		OK/0.997057
shown	__unaligned__	VVN	__unaligned__		OK/0.992719
during	in	IN	APPR		OK/0.980133
the	__unaligned__	DT	__unaligned__		OK/0.982509
studies	Studien	NNS	NN		OK/0.996753
?	?	SENT	$.		OK/0.998509

# 0.818133
However	Allerdings	RB	ADV		OK/0.974395
,	Allerdings	,	ADV		OK/0.990137
losartan	Losartan	NN	NE		OK/0.956896
,	,	,	$,		OK/0.999468
as	wie	RB	KOKOM		OK/0.993651
with	andere	IN	PIS		OK/0.989710
other	andere	JJ	PIS		OK/0.993881
blood	blutdrucksenkende	NN	ADJA		OK/0.996065
pressure	blutdrucksenkende	NN	ADJA		OK/0.996236
lowering	blutdrucksenkende	VVG	ADJA		OK/0.984866
medicinal	Arzneimittel	JJ	NN		OK/0.998350
products	Arzneimittel	NNS	NN		OK/0.992040
,	,	,	$,		OK/0.979811
dizziness	Schwindel	NN	NN		OK/0.995963
or	oder	CC	KON		OK/0.998163
tiredness	Müdigkeit	NN	NN		OK/0.991725
in	bei	IN	APPR		OK/0.995559
some	einigen	DT	PIAT		OK/0.997878
individuals	Personen	NNS	NN		OK/0.952918
.	.	SENT	$.		OK/0.999530

# 0.580595
Cisplatin	Cisplatin	NP	NN		OK/0.884214
has	wurde	VHZ	VAFIN		OK/0.893823
been	wurde	VBN	VAFIN		OK/0.917304
used	eingesetzt	VVN	VVPP		OK/0.922003
at	Dosierungen	IN	NN		OK/0.779371
doses	Dosierungen	NNS	NN		OK/0.965999
of	__unaligned__	IN	__unaligned__		OK/0.956605
lipopeptide	75-100	NN	CARD		OK/0.930959
mg	mg	NN	NN		OK/0.967598
/	/	SYM	$(		OK/0.999092
m2	m2	JJ	VVFIN		OK/0.993379
once	einmal	IN	ADV		OK/0.984864
every	alle	DT	PIAT		OK/0.981237
3	3	CD	CARD		OK/0.992411
weeks	Wochen	NNS	NN		OK/0.989887
.	.	SENT	$.		OK/0.999180

# 0.140528
The	Der	DT	ART		OK/0.923709
pulse	Puls	NN	NN		BAD/0.485099
rate	__unaligned__	NN	__unaligned__		BAD/0.688723
should	sollte	MD	VMFIN		BAD/0.790003
be	sollte	VB	VMFIN		BAD/0.823231
determined	__unaligned__	VVN	__unaligned__		BAD/0.933608
before	vor	IN	APPR		BAD/0.858308
and	und	CC	KON		BAD/0.887240
during	während	IN	KOUS		OK/0.535936
administration	Verabreichung	NN	NN		OK/0.723172
of	von	IN	APPR		OK/0.983501
ADVATE	ADVATE	NN	NN		OK/0.958245
.	.	SENT	$.		OK/0.996084

# 0.275621
LUMIGAN	LUMIGAN	NP	NN		OK/0.955747
should	sollte	MD	VMFIN		OK/0.971373
be	sollte	VB	VMFIN		OK/0.990282
used	angewendet	VVN	VVPP		OK/0.938702
in	in	IN	APPR		OK/0.988269
pregnancy	Schwangerschaft	NN	NN		OK/0.967614
only	nur	RB	ADV		OK/0.485220
if	Indikationsstellung	IN	NN		OK/0.510415
clearly	__unaligned__	RB	__unaligned__		OK/0.472279
needed	__unaligned__	VVN	__unaligned__		OK/0.511108
.	.	SENT	$.		OK/0.996429

# 0.875161
21	21	CD	CARD		OK/0.970641
As	Wie	IN	KOKOM		OK/0.975280
with	__unaligned__	IN	__unaligned__		OK/0.993161
any	jeder	DT	PIAT		OK/0.998465
insulin	Insulintherapie	NN	NN		OK/0.999075
therapy	__unaligned__	NN	__unaligned__		OK/0.998678
,	__unaligned__	,	__unaligned__		OK/0.988057
injection	Injektionsstelle	NN	NN		OK/0.996964
site	Injektionsstelle	NN	NN		OK/0.997373
reactions	Reaktionen	NNS	NN		OK/0.998939
may	können	MD	VMFIN		OK/0.996824
occur	auftreten	VV	VVFIN		OK/0.997826
and	__unaligned__	CC	__unaligned__		OK/0.979840
include	B.	VV	NN		OK/0.987797
pain	Schmerzen	NN	NN		OK/0.996762
,	Juckreiz	,	NN		OK/0.998837
itching	Juckreiz	VVG	NN		OK/0.999083
,	Juckreiz	,	NN		OK/0.991340
hives	Nesselsucht	NNS	NN		OK/0.996928
,	,	,	$,		OK/0.999020
swelling	Schwellungen	VVG	NN		OK/0.995226
and	und	CC	KON		OK/0.990138
inflammation	Entzündungen	NN	NN		OK/0.996501
.	.	SENT	$.		OK/0.999835

# 0.296143
take	einnehmen	VV	VVINF		BAD/0.480757
this	__unaligned__	DT	__unaligned__		BAD/0.821648
medicine	__unaligned__	NN	__unaligned__		BAD/0.864735
.	.	SENT	$.		OK/0.991415
This	Dies	DT	PDS		OK/0.995158
is	ist	VBZ	VAFIN		OK/0.995893
a	ist	DT	VAFIN		OK/0.995606
group	__unaligned__	NN	__unaligned__		OK/0.998270
of	__unaligned__	IN	__unaligned__		OK/0.987104
medicines	Arzneimitteln	NNS	NN		OK/0.992254
(	(	(	$(		OK/0.986621
"	"	``	$(		OK/0.995625
nitrates	Nitrate	NNS	NN		OK/0.971442
"	"	''	$(		OK/0.978994
)	)	)	$(		OK/0.990372
,	,	,	$,		OK/0.987220
which	__unaligned__	WDT	__unaligned__		OK/0.896552
are	werden	VBP	VAINF		OK/0.933295
used	werden	VVN	VAINF		OK/0.938474
for	Behandlung	IN	NN		OK/0.974276
the	Behandlung	DT	NN		OK/0.983128
treatment	Behandlung	NN	NN		OK/0.995715
of	von	IN	APPR		OK/0.999581
angina	pectoris	NN	NE		OK/0.987578
(	(	(	$(		OK/0.997153
a	(	DT	$(		OK/0.991907
type	Art	NN	NN		OK/0.987175
of	von	IN	APPR		OK/0.960285
"	"	``	$(		OK/0.937517
chest	Herzschmerzen	NN	NN		OK/0.979552
pain	Herzschmerzen	NN	NN		OK/0.985685
"	"	''	$(		OK/0.973349
)	)	)	$(		OK/0.991743
.	.	SENT	$.		OK/0.997386

# 0.579825
Wipe	Wischen	NP	NN		OK/0.993378
the	Wischen	DT	NN		OK/0.987122
air	überschüssige	NN	ADJA		OK/0.939581
ointment	Salbe	NN	NN		OK/0.961007
carefully	vorsichtig	RB	ADJD		OK/0.610596
.	.	SENT	$.		OK/0.993042

# 0.765515
Taking	blutigen	VVG	ADJA		OK/0.822412
other	oder	JJ	KON		OK/0.887828
medicines	__unaligned__	NNS	__unaligned__		OK/0.947650
and	und	CC	KON		OK/0.997485
diarrhoea	Durchfall	NN	NN		OK/0.971084
.	.	SENT	$.		OK/0.997452

# 0.621352
Treatment	Behandlungsfehler	NP	NN		OK/0.975080
failure	Behandlungsfehler	NN	NN		OK/0.930719
can	können	MD	VMFIN		OK/0.960171
occur	__unaligned__	VV	__unaligned__		OK/0.990718
as	Folge	IN	NN		OK/0.996807
a	Folge	DT	NN		OK/0.995456
consequence	Folge	NN	NN		OK/0.985892
of	Folge	IN	NN		OK/0.997920
human	Blutgerinnungsfaktor	JJ	NN		OK/0.981984
coagulation	Blutgerinnungsfaktor	NN	NN		OK/0.996706
factor	Blutgerinnungsfaktor	NN	NN		OK/0.999008
IX	IX	NP	CARD		OK/0.957285
adsorption	__unaligned__	NN	__unaligned__		OK/0.861956
to	der	TO	ART		OK/0.879184
adsorption	__unaligned__	NN	__unaligned__		OK/0.899182
to	einiger	TO	PIAT		OK/0.853766
occur	auftreten	VV	VVINF		OK/0.921869
.	.	SENT	$.		OK/0.999194

# 0.552323
Patients	Patienten	NPS	NN		OK/0.997735
with	mit	IN	APPR		OK/0.999401
rare	seltenen	JJ	ADJA		OK/0.996097
hereditary	hereditären	JJ	ADJA		OK/0.992385
problems	hereditären	NNS	ADJA		OK/0.885989
of	hereditären	IN	ADJA		OK/0.881939
fructose	Fructose-Intoleranz	NN	NN		OK/0.989073
intolerance	Fructose-Intoleranz	NN	NN		OK/0.990292
,	,	,	$,		OK/0.982436
galactose	Galactose-Intoleranz	NN	NN		OK/0.930737
intolerance	Galactose-Intoleranz	NN	NN		OK/0.984665
,	,	,	$,		OK/0.997261
the	__unaligned__	DT	__unaligned__		OK/0.933969
Lapp	Galactose-Intoleranz	NP	NN		OK/0.955746
lactase	Galactose-Intoleranz	NN	NN		OK/0.992468
deficiency	Galactose-Intoleranz	NN	NN		OK/0.993045
,	,	,	$,		OK/0.992109
glucose-galactose	Glucose-Galactose-Malabsorption	JJ	NN		OK/0.971277
malabsorption	Glucose-Galactose-Malabsorption	NN	NN		OK/0.987227
or	oder	CC	KON		OK/0.986443
sucrase-isomaltase	Sucrase-Isomaltase-Insuffizienz	NN	NN		OK/0.860357
insufficiency	Sucrase-Isomaltase-Insuffizienz	NN	NN		OK/0.922663
should	sollten	MD	VMFIN		OK/0.983576
not	nicht	RB	PTKNEG		OK/0.996783
take	einnehmen	VV	VVINF		OK/0.997134
this	dieses	DT	PDAT		OK/0.997880
medicine	Arzneimittel	NN	NN		OK/0.988125
.	.	SENT	$.		OK/0.999546

# 0.641182
In	Außerdem	IN	ADV		OK/0.968011
addition	Außerdem	NN	ADV		OK/0.998686
,	__unaligned__	,	__unaligned__		OK/0.996842
the	die	DT	ART		OK/0.962238
quality	Schlafqualität	NN	NN		OK/0.961880
of	__unaligned__	IN	__unaligned__		OK/0.971316
sleep	__unaligned__	NN	__unaligned__		OK/0.870584
and	und	CC	KON		OK/0.989902
the	der	DT	ART		OK/0.972550
morning	morgendliche	NN	ADJA		OK/0.920998
Wachheitsgrad	Wachheitsgrad	NP	NN		OK/0.866559
significantly	signifikant	RB	ADJD		OK/0.984289
taking	unter	VVG	APPR		OK/0.985618
Circadin	Circadin	NP	NE		OK/0.973741
compared	Vergleich	VVN	NN		OK/0.991581
to	Vergleich	TO	NN		OK/0.999206
placebo	Plazebo	NN	NN		OK/0.991375
.	.	SENT	$.		OK/0.999057

# 0.321680
If	Falls	IN	NN		OK/0.996293
your	Ihr	PP$	PPOSAT		OK/0.999729
doctor	Arzt	NN	NN		OK/0.996055
may	__unaligned__	MD	__unaligned__		OK/0.662410
increase	erhöht	VV	VVPP		OK/0.929857
the	die	DT	ART		OK/0.990359
dose	Dosis	NN	NN		OK/0.992419
of	dieser	IN	PDAT		OK/0.973338
these	dieser	DT	PDAT		OK/0.952503
Lebertest	Lebertest	NN	NN		OK/0.774770
should	muss	MD	VMFIN		OK/0.583867
take	__unaligned__	VV	__unaligned__		OK/0.877280
place	__unaligned__	NN	__unaligned__		OK/0.898908
before	vor	IN	APPR		OK/0.971615
increasing	Dosiserhöhung	VVG	NN		OK/0.940243
the	der	DT	ART		OK/0.998441
dose	Dosiserhöhung	NN	NN		OK/0.988841
and	und	CC	KON		OK/0.997496
periodically	regelmäßig	RB	ADJD		OK/0.991499
thereafter	danach	RB	PAV		OK/0.994080
.	.	SENT	$.		OK/0.999533

# 0.086550
Table	Tabelle	NP	NN		OK/0.961537
1	5	CD	CARD		OK/0.929302
shows	zeigt	VVZ	VVFIN		OK/0.947246
the	__unaligned__	DT	__unaligned__		OK/0.920994
virologic	virologische	JJ	ADJA		BAD/0.655105
,	,	,	$,		BAD/0.581141
biochemical	biochemische	JJ	ADJA		BAD/0.560752
and	und	CC	KON		BAD/0.364631
serological	serologische	JJ	ADJA		BAD/0.570522
Verlaufsparameter	Verlaufsparameter	NP	NN		BAD/0.697292
and	und	CC	KON		OK/0.861926
Table	Tabelle	NP	NN		OK/0.764859
6	6	CD	CARD		OK/0.744643
of	das	IN	ART		BAD/0.802430
the	__unaligned__	DT	__unaligned__		OK/0.901726
histological	histologische	JJ	ADJA		OK/0.963500
response	Ansprechen	NN	NN		OK/0.988040
.	.	SENT	$.		OK/0.999953

# 0.670469
In	In	IN	APPR		OK/0.976741
a	einer	DT	ART		OK/0.980225
similar	ähnlichen	JJ	ADJA		OK/0.990705
patient	Patientenpopulation	NN	NN		OK/0.985249
population	Patientenpopulation	NN	NN		OK/0.967765
over	über	IN	APPR		OK/0.932917
120	120	CD	CARD		OK/0.992154
weeks	Wochen	NNS	NN		OK/0.998294
persistent	andauernde	JJ	ADJA		OK/0.935410
antiretroviral	antiretrovirale	JJ	ADJA		OK/0.967640
response	Antwort	NN	NN		OK/0.895702
was	wurde	VBD	VAFIN		OK/0.935733
demonstrated	gezeigt	VVN	VVPP		OK/0.980997
in	bei	IN	APPR		OK/0.992527
approximately	ca.	RB	ADV		OK/0.993996
70	70	CD	CARD		OK/0.998450
%	%	NN	NN		OK/0.999498
of	der	IN	ART		OK/0.994553
the	der	DT	ART		OK/0.986813
patients	Patienten	NNS	NN		OK/0.944975
.	.	SENT	$.		OK/0.999734

# 0.481873
Concomitant	gleichzeitige	NP	ADJA		OK/0.998054
administration	gleichzeitige	NN	ADJA		OK/0.998672
of	gleichzeitige	IN	ADJA		OK/0.999595
CYP3A4	CYP3A4-Inhibitoren	NP	NN		OK/0.999461
inhibitors	CYP3A4-Inhibitoren	NNS	NN		OK/0.997368
will	CYP3A4-Inhibitoren	MD	NN		OK/0.985172
lead	CYP3A4-Inhibitoren	VV	NN		OK/0.982139
to	__unaligned__	TO	__unaligned__		OK/0.962063
increased	erhöhten	VVN	ADJA		OK/0.914518
exposure	Exposition	NN	NN		BAD/0.709616
of	__unaligned__	IN	__unaligned__		BAD/0.730218
rimonabant	Rimonabant	NN	VVFIN		BAD/0.700640
.	.	SENT	$.		OK/0.976600

# 0.158140
Zie-	Zie-	NP	TRUNC		BAD/0.599870
Do	hen	VVP	VVFIN		BAD/0.646657
not	hen	RB	VVFIN		BAD/0.734724
throw	hen	VV	VVFIN		BAD/0.697932
away	hen	RB	VVFIN		BAD/0.618226
,	__unaligned__	,	__unaligned__		OK/0.676573
then	dann	RB	ADV		OK/0.852151
the	Nadel	DT	NN		OK/0.943316
needle	Nadel	NN	NN		OK/0.854995
from	aus	IN	APPR		OK/0.945185
the	Haut	DT	NN		OK/0.963704
skin	Haut	NN	NN		OK/0.960728
.	.	SENT	$.		OK/0.999509

# 0.389530
In	In	IN	APPR		OK/0.953947
the	der	DT	ART		OK/0.976098
other	anderen	JJ	PIAT		OK/0.970618
study	Studie	NN	NN		OK/0.984327
the	die	DT	ART		OK/0.918537
objective	__unaligned__	JJ	__unaligned__		OK/0.869468
response	__unaligned__	NN	__unaligned__		OK/0.980881
rate	__unaligned__	NN	__unaligned__		OK/0.885196
was	betrug	VBD	VVFIN		OK/0.908354
increased	Zunahme	VVN	NN		OK/0.938784
7.1	7,1	CD	CARD		OK/0.963833
cm	cm	NN	NN		OK/0.909853
for	für	IN	APPR		OK/0.937838
OPTISON	OPTISON	NP	NN		OK/0.867235
and	und	CC	KON		OK/0.989712
3.1	3,1	CD	CARD		OK/0.995971
cm	cm	NN	NN		OK/0.987853
for	für	IN	APPR		OK/0.998460
the	das	DT	ART		OK/0.995565
contact	Referenzmittel	NN	NN		OK/0.790985
surface	Referenzmittel	NN	NN		OK/0.771257
.	.	SENT	$.		OK/0.997920

# 0.792126
This	Dies	NP	PDS		OK/0.997690
may	kann	MD	VMFIN		OK/0.991999
mean	__unaligned__	VV	__unaligned__		OK/0.874577
that	dass	IN/that	KOUS		OK/0.872302
an	Infektion	DT	NN		OK/0.944577
infection	Infektion	NN	NN		OK/0.981727
.	.	SENT	$.		OK/0.968835

# 0.967777
CELSENTRI	CELSENTRI	NP	NN		OK/0.997895
is	ist	VBZ	VAFIN		OK/0.996624
a	ist	DT	VAFIN		OK/0.996255
medicine	Arzneimittel	NN	NN		OK/0.999788
that	Arzneimittel	WDT	NN		OK/0.993952
contains	enthält	VVZ	VVFIN		OK/0.997052
the	den	DT	ART		OK/0.995797
active	Wirkstoff	JJ	NN		OK/0.994374
substance	Wirkstoff	NN	NN		OK/0.996813
maraviroc	Maraviroc	NN	NE		OK/0.995773
.	.	SENT	$.		OK/0.999929

# 0.171828
In	Bei	IN	APPR		OK/0.839422
38	38	CD	CARD		OK/0.915314
%	%	NN	NN		OK/0.987642
of	der	IN	ART		OK/0.993784
the	der	DT	ART		OK/0.996297
patients	Patienten	NNS	NN		OK/0.995687
included	__unaligned__	VVD	__unaligned__		OK/0.931086
in	in	IN	APPR		OK/0.991727
this	diese	DT	PDAT		OK/0.956740
study	Studie	NN	NN		OK/0.923674
were	lagen	VBD	VVFIN		OK/0.819545
enrolled	eingeschlossenen	VVN	ADJA		OK/0.545490
45	45	CD	CARD		BAD/0.876395
patients	BCR-ABL-Mutationen	NNS	NN		BAD/0.924389
harboring	__unaligned__	VVG	__unaligned__		BAD/0.924839
a	__unaligned__	DT	__unaligned__		BAD/0.841469
variety	verschiedene	NN	ADJA		BAD/0.726383
of	__unaligned__	IN	__unaligned__		BAD/0.761978
available	vor	JJ	PTKVZ		BAD/0.753183
.	.	SENT	$.		OK/0.932385

# 0.454666
Body	Körpergewicht	NP	NN		OK/0.779588
weight	Körpergewicht	NN	NN		OK/0.659943
<	unter	SYM	APPR		BAD/0.912459
60	60	CD	CARD		OK/0.874545
kg	kg	NN	NN		OK/0.876461
.	.	SENT	$.		OK/0.997452

# 0.661284
subjects	Infizierte	NNS	ADJA		OK/0.903077
,	,	,	$,		OK/0.944957
31	Länge	CD	NN		OK/0.948441
cm	cm	NN	NN		OK/0.990889
or	cm	CC	NN		OK/0.996344
birefringent	Gesamtfläche	JJ	NN		OK/0.979538
>	>	SYM	$(		OK/0.793958
100	100	CD	CARD		OK/0.984782
cm2	cm2	NN	NN		OK/0.966018
.	.	SENT	$.		OK/0.997965

# 0.225909
Hold	Halten	VVP	VVFIN		OK/0.977024
the	Halten	DT	VVFIN		OK/0.992326
Reco-Pen	Reco-Pen	NN	NN		OK/0.981604
of	der	IN	ART		OK/0.986044
the	__unaligned__	DT	__unaligned__		OK/0.986232
needle	Kanüle	NN	NN		BAD/0.385264
,	,	,	$,		BAD/0.497482
insert	stechen	VV	VVFIN		BAD/0.815551
the	__unaligned__	DT	__unaligned__		BAD/0.786010
needle	__unaligned__	NN	__unaligned__		BAD/0.970407
with	und	IN	KON		BAD/0.976113
a	__unaligned__	DT	__unaligned__		BAD/0.970231
quick	__unaligned__	JJ	__unaligned__		BAD/0.968168
,	__unaligned__	,	__unaligned__		BAD/0.949506
firm	kräftig	JJ	ADJD		BAD/0.914122
action	kräftig	NN	ADJD		BAD/0.865513
.	.	SENT	$.		OK/0.970049

# 0.068720
As	Infolge	IN	NN		OK/0.972728
a	Infolge	DT	NN		OK/0.994037
consequence	Infolge	NN	NN		OK/0.946319
of	dieser	IN	PDAT		OK/0.989596
these	dieser	DT	PDAT		OK/0.979362
receptors	Bindung	NNS	NN		OK/0.926622
and	die	CC	ART		BAD/0.784936
cannot	nicht	MD	PTKNEG		BAD/0.794125
be	kann	VB	VMFIN		BAD/0.674032
longer	länger	RBR	ADJD		BAD/0.399917
that	__unaligned__	IN/that	__unaligned__		BAD/0.487943
the	die	DT	PRELS		BAD/0.315152
magnetostatic	Nachrichten	NN	NN		BAD/0.585315
for	für	IN	APPR		OK/0.872826
growth	__unaligned__	NN	__unaligned__		OK/0.898429
,	,	,	$,		OK/0.953825
progression	Fortschreiten	NN	NN		OK/0.958124
,	__unaligned__	,	__unaligned__		OK/0.856145
triazolopyridinyl	weiteres	NN	ADJA		OK/0.714447
and	und	CC	KON		OK/0.907407
their	ihre	PP$	PPOSAT		OK/0.895814
spread	Ausbreitung	NN	NN		OK/0.825881
.	.	SENT	$.		OK/0.997971

# 0.551746
For	Die	IN	ART		OK/0.990397
a	__unaligned__	DT	__unaligned__		OK/0.995548
full	vollständige	JJ	ADJA		OK/0.997470
list	Auflistung	NN	NN		OK/0.997708
of	Auflistung	IN	NN		OK/0.999367
the	vollständige	DT	ADJA		OK/0.979392
side-effects	__unaligned__	NNS	__unaligned__		OK/0.929978
reported	berichteten	VVD	ADJA		OK/0.909115
with	mit	IN	APPR		OK/0.913372
side	Nebenwirkungen	NN	NN		OK/0.760139
effects	Nebenwirkungen	NNS	NN		OK/0.859865
of	__unaligned__	IN	__unaligned__		OK/0.769312
CoAprovel	CoAprovel	NP	NN		OK/0.982087
,	__unaligned__	,	__unaligned__		OK/0.998141
see	entnehmen	VVP	VVINF		OK/0.999955
the	entnehmen	DT	VVINF		OK/0.999568
Package	entnehmen	NP	VVINF		OK/0.999109
Leaflet	entnehmen	NP	VVINF		OK/0.955857
.	.	SENT	$.		OK/0.999849

# 0.963989
The	Die	DT	ART		OK/0.995778
tablets	Tabletten	NNS	NN		OK/0.998482
should	müssen	MD	VMFIN		OK/0.981548
be	müssen	VB	VMFIN		OK/0.997493
swallowed	geschluckt	VVN	VVPP		OK/0.990065
whole	geschluckt	RP	VVPP		OK/0.997249
.	.	SENT	$.		OK/0.999823

# 0.876176
-	-	:	$(		OK/0.996490
If	Wenn	IN	KOUS		OK/0.998882
you	Sie	PP	PPER		OK/0.997655
have	Sie	VHP	PPER		OK/0.997833
any	Fragen	DT	NN		OK/0.994313
further	Fragen	JJR	NN		OK/0.999677
questions	Fragen	NNS	NN		OK/0.994709
,	,	,	$,		OK/0.999741
ask	wenden	VV	VVFIN		OK/0.932034
your	Arzt	PP$	NN		OK/0.996613
doctor	Ihren	NN	PPOSAT		OK/0.989629
or	oder	CC	KON		OK/0.989544
your	__unaligned__	PP$	__unaligned__		OK/0.982244
pharmacist	Apotheker	NN	NN		OK/0.987282
.	.	SENT	$.		OK/0.999200

# 0.089888
The	Die	DT	ART		OK/0.957703
radiation	Strahlenexposition	NN	NN		OK/0.522210
to	__unaligned__	TO	__unaligned__		OK/0.438435
an	durchschnittlichen	DT	ADJA		OK/0.558238
average	durchschnittlichen	JJ	ADJA		OK/0.852942
adult	erwachsenen	NN	ADJA		OK/0.928562
patients	Patienten	NNS	NN		OK/0.997450
(	(	(	$(		OK/0.997693
70	70	CD	CARD		OK/0.997071
kg	kg	NN	NN		OK/0.998598
)	)	)	$(		OK/0.997604
from	__unaligned__	IN	__unaligned__		OK/0.976884
an	__unaligned__	DT	__unaligned__		OK/0.975941
intravenous	intravenöser	JJ	ADJA		OK/0.985231
injection	Injektion	NN	NN		OK/0.958227
of	von	IN	APPR		OK/0.906811
ioflupane	Ioflupan	NN	ADJA		OK/0.627627
(	Ioflupan	(	ADJA		OK/0.515776
123I	123I	NP	NE		OK/0.588638
)	)	)	$(		OK/0.936326
in	folgender	IN	ADJA		OK/0.666181
accordance	folgender	NN	ADJA		OK/0.726853
with	folgender	IN	ADJA		OK/0.829161
the	folgender	DT	ADJA		OK/0.924101
following	folgender	VVG	ADJA		OK/0.911559
table	Tabelle	NN	NN		OK/0.960373
.	.	SENT	$.		OK/0.998488

# 0.038541
For	Die	IN	ART		OK/0.990397
a	__unaligned__	DT	__unaligned__		OK/0.995548
full	vollständige	JJ	ADJA		OK/0.997467
list	Auflistung	NN	NN		OK/0.997670
of	Auflistung	IN	NN		OK/0.998868
the	vollständige	DT	ADJA		OK/0.941379
side-effects	__unaligned__	NNS	__unaligned__		OK/0.737568
reported	berichteten	VVN	ADJA		BAD/0.492317
with	mit	IN	APPR		BAD/0.668688
Cyanokit	Cyanokit	JJ	NN		BAD/0.459708
hypersensitive	__unaligned__	JJ	__unaligned__		BAD/0.607759
(	zu	(	PTKZU		BAD/0.644787
allergic	__unaligned__	JJ	__unaligned__		BAD/0.609567
)	__unaligned__	)	__unaligned__		BAD/0.572928
to	__unaligned__	TO	__unaligned__		BAD/0.653589
ribavirin	__unaligned__	NN	__unaligned__		BAD/0.716774
or	der	CC	ART		BAD/0.713429
any	__unaligned__	DT	__unaligned__		BAD/0.704614
of	__unaligned__	IN	__unaligned__		BAD/0.688486
the	entnehmen	DT	VVINF		OK/0.971292
other	entnehmen	JJ	VVINF		BAD/0.713498
ingredients	entnehmen	NNS	VVINF		BAD/0.707848
.	.	SENT	$.		OK/0.997022

# 0.292125
Follow	Befolgen	NP	VVFIN		OK/0.797772
carefully	sorgfältig	RB	ADJD		OK/0.739906
all	alle	DT	PIAT		OK/0.921012
instructions	Anweisungen	NNS	NN		OK/0.794633
that	__unaligned__	IN/that	__unaligned__		OK/0.469659
your	Ihr	PP$	PPOSAT		OK/0.803664
doctor	Arzt	NN	NN		OK/0.957238
has	hat	VHZ	VAFIN		OK/0.974302
given	gegeben	VVN	VVPP		OK/0.959591
you	Ihnen	PP	PPER		OK/0.886184
.	.	SENT	$.		OK/0.937482

# 0.911500
What	Welchen	WP	PIAT		OK/0.998628
benefit	Welchen	VVP	PIAT		OK/0.970005
has	Nutzen	VHZ	NN		OK/0.998546
TORISEL	TORISEL	NP	NE		OK/0.998091
shown	__unaligned__	VVN	__unaligned__		OK/0.978941
during	in	IN	APPR		OK/0.967332
the	__unaligned__	DT	__unaligned__		OK/0.978729
studies	Studien	NNS	NN		OK/0.996491
?	?	SENT	$.		OK/0.998496

# 0.457562
(	(	(	$(		OK/0.989961
as	3,375	RB	CARD		OK/0.935493
3.375	Mononatriumibandronat	CD	NN		OK/0.975299
mg	mg	NN	NN		OK/0.986173
ibandronic	__unaligned__	JJ	__unaligned__		OK/0.880609
acid	__unaligned__	NN	__unaligned__		OK/0.917524
,	__unaligned__	,	__unaligned__		OK/0.860652
monosodium	__unaligned__	NN	__unaligned__		OK/0.851435
salt	__unaligned__	NN	__unaligned__		OK/0.829189
,	H2O	,	NN		OK/0.883836
monohydrate	H2O	NN	NN		OK/0.664530
)	)	)	$(		OK/0.964503
.	.	SENT	$.		OK/0.997479

# 0.188286
Vardenafildosis	Vardenafildosis	NP	NN		OK/0.978774
should	darf	MD	VMFIN		OK/0.988080
not	nicht	RB	PTKNEG		OK/0.997101
exceed	überschreiten	VV	VVINF		OK/0.986468
a	Maximum	DT	NN		OK/0.953590
maximum	Maximum	NN	NN		OK/0.943372
of	von	IN	APPR		OK/0.949799
2.5	2,5	CD	CARD		OK/0.998794
mg	mg	NN	NN		OK/0.998139
in	in	IN	APPR		OK/0.940495
a	in	DT	APPR		OK/0.992518
time	Zeitraum	NN	NN		OK/0.962207
period	Zeitraum	NN	NN		OK/0.963153
after	72-Stunden	IN	ADJA		OK/0.810761
a	__unaligned__	DT	__unaligned__		OK/0.566703
single	__unaligned__	NN	__unaligned__		OK/0.328566
is	__unaligned__	VBZ	__unaligned__		BAD/0.974669
taken	__unaligned__	VVN	__unaligned__		BAD/0.924185
in	bei	IN	APPR		OK/0.977590
combination	Kombination	NN	NN		OK/0.996147
with	mit	IN	APPR		OK/0.997277
a	__unaligned__	DT	__unaligned__		OK/0.958393
boosted	geboosteten	VVN	ADJA		OK/0.934909
protease	Proteasehemmer	NN	NN		OK/0.984867
inhibitor	Proteasehemmer	NN	NN		OK/0.984138
.	.	SENT	$.		OK/0.998668

# 0.129410
The	Die	DT	ART		OK/0.983214
data	Daten	NNS	NN		OK/0.932835
presented	vorgelegten	VVN	ADJA		OK/0.789441
showed	zeigten	VVD	VVFIN		OK/0.971708
no	keinen	DT	PIAT		OK/0.996327
evidence	eindeutigen	NN	ADJA		OK/0.964654
of	__unaligned__	IN	__unaligned__		OK/0.910490
Zusammen-	Zusammen-	NP	TRUNC		OK/0.652487
increase	von	NN	APPR		OK/0.594737
in	der	IN	ART		OK/0.778544
numbers	__unaligned__	NNS	__unaligned__		OK/0.916497
of	__unaligned__	IN	__unaligned__		OK/0.956031
patients	hang	NNS	VVFIN		OK/0.953898
with	mit	IN	APPR		OK/0.969239
CTCL	hang	NP	VVFIN		OK/0.754720
,	oder	,	KON		OK/0.506400
relative	__unaligned__	JJ	__unaligned__		OK/0.846974
to	__unaligned__	TO	__unaligned__		OK/0.930885
what	__unaligned__	WP	__unaligned__		OK/0.990020
would	__unaligned__	MD	__unaligned__		OK/0.957438
be	__unaligned__	VB	__unaligned__		OK/0.788059
expected	__unaligned__	VVN	__unaligned__		OK/0.722437
.	.	SENT	$.		OK/0.998001

# 0.627734
Examine	Kontrollieren	NP	VVFIN		OK/0.984496
the	Kontrollieren	DT	VVFIN		OK/0.996271
solution	Kontrollieren	NN	VVFIN		OK/0.988957
prior	vor	RB	APPR		OK/0.988334
to	vor	TO	APPR		OK/0.977730
administration	Anwendung	NN	NN		OK/0.992163
,	__unaligned__	,	__unaligned__		OK/0.993217
the	die	DT	ART		OK/0.990841
reconstituted	__unaligned__	VVN	__unaligned__		OK/0.987691
solution	__unaligned__	NN	__unaligned__		OK/0.985911
prior	__unaligned__	RB	__unaligned__		OK/0.965018
to	__unaligned__	TO	__unaligned__		OK/0.977242
administration	__unaligned__	NN	__unaligned__		OK/0.839663
:	:	:	$.		OK/0.902770
do	wenden	VVP	VVFIN		OK/0.905833
not	nicht	RB	PTKNEG		OK/0.988336
use	__unaligned__	VV	__unaligned__		OK/0.940230
if	wenn	IN	KOUS		OK/0.994123
or	oder	CC	KON		OK/0.991830
contains	__unaligned__	VVZ	__unaligned__		OK/0.957886
particles	__unaligned__	NNS	__unaligned__		OK/0.985587
.	.	SENT	$.		OK/0.998023

# 0.639417
Apidra	Apidra	NP	NN		OK/0.971188
is	wird	VBZ	VAFIN		OK/0.999343
used	angewendet	VVN	VVPP		OK/0.999763
to	angewendet	TO	VVPP		OK/0.967325
treat	angewendet	VV	VVPP		OK/0.982767
adults	Erwachsenen	NNS	NN		OK/0.995806
,	,	,	$,		OK/0.978522
adolescents	Jugendlichen	NNS	NN		OK/0.987758
and	und	CC	KON		OK/0.999038
children	Kindern	NNS	NN		OK/0.996257
aged	ab	VVN	APPR		OK/0.992759
six	sechs	CD	CARD		OK/0.989078
years	Jahren	NNS	NN		OK/0.998673
or	__unaligned__	CC	__unaligned__		OK/0.980285
older	Jahren	JJR	NN		OK/0.991622
with	mit	IN	APPR		OK/0.997644
diabetes	Diabetes	NN	NN		OK/0.984952
who	die	WP	PRELS		OK/0.894740
need	benötigen	VVP	VVFIN		OK/0.762417
treatment	Behandlung	NN	NN		OK/0.992111
with	mit	IN	APPR		OK/0.995679
insulin	Insulin	NN	NN		OK/0.997442
.	.	SENT	$.		OK/0.999660

# 0.118518
The	Der	DT	ART		OK/0.999513
vaccine	Impfstoff	NN	NN		OK/0.999214
contains	enthält	VVZ	VVFIN		OK/0.996717
transdermal	nicht-toxisches	JJ	ADJA		OK/0.930026
undercoat	rekombinantes	NN	ADJA		OK/0.689944
have	Derivat	VHP	NN		OK/0.523738
distant	Toxins	JJ	NN		OK/0.464553
P.	P.	NP	NE		OK/0.399565
multocida	multocida	NN	ADJA		OK/0.454128
and	und	CC	KON		OK/0.807553
inactivated	inaktivierte	VVD	ADJA		OK/0.681264
B.	B.	NP	NN		OK/0.609033
bronchiseptica-Zellen	bronchiseptica-Zellen	NP	VVFIN		OK/0.414093
.	.	SENT	$.		OK/0.957641

# 0.277456
Except	Außer	IN	APPR		OK/0.972243
for	Außer	IN	APPR		OK/0.974191
hypertrophy	Hypertrophie	NN	NN		OK/0.959304
of	der	IN	ART		OK/0.968887
the	der	DT	ART		OK/0.940138
hepatocytes	Hepatozyten	NNS	NN		BAD/0.617222
,	__unaligned__	,	__unaligned__		BAD/0.608576
no	keine	DT	PIAT		BAD/0.522146
other	weiteren	JJ	ADJA		BAD/0.472654
changes	Veränderungen	NNS	NN		OK/0.989027
were	wurden	VBD	VAFIN		OK/0.991073
observed	beobachtet	VVN	VVPP		OK/0.956513
.	.	SENT	$.		OK/0.998944

# 0.076399
(	__unaligned__	(	__unaligned__		BAD/0.941851
b	__unaligned__	LS	__unaligned__		BAD/0.806590
)	WÄHREND	)	VVFIN		BAD/0.930408
the	die	DT	ART		OK/0.758047
vaccination	Impfung	NN	NN		OK/0.911672
,	,	,	$,		OK/0.983158
•	•	NP	NN		OK/0.995310
Your	Ihr	PP$	PPOSAT		OK/0.997706
doctor	Arzt	NN	NN		OK/0.996522
and	und	CC	KON		OK/0.994744
his	seine	PP$	PPOSAT		OK/0.957661
staff	Mitarbeiter	NN	NN		OK/0.842033
take	achten	VV	VVINF		BAD/0.597693
care	achten	NN	VVINF		BAD/0.481381
not	nicht	RB	PTKNEG		BAD/0.582946
to	__unaligned__	TO	__unaligned__		BAD/0.955199
give	Ihnen	VV	PPER		BAD/0.995021
you	Ihnen	PP	PPER		BAD/0.979690
Optaflu	Optaflu	NP	VVFIN		BAD/0.949422
into	__unaligned__	IN	__unaligned__		OK/0.593360
a	__unaligned__	DT	__unaligned__		OK/0.789720
vein	Blutgefäß	NN	NN		OK/0.678592
.	.	SENT	$.		OK/0.996478

# 0.868154
How	Wie	NP	KOKOM		OK/0.994884
much	viel	RB	ADV		OK/0.977630
should	sollten	MD	VMFIN		OK/0.984261
you	Sie	PP	PPER		OK/0.894230
take	einnehmen	VV	VVINF		OK/0.975676
?	?	SENT	$.		OK/0.998941

# 0.496523
Therefore	Daher	RB	PAV		OK/0.996033
treatment	__unaligned__	NN	__unaligned__		OK/0.995790
is	__unaligned__	VBZ	__unaligned__		OK/0.844003
intended	ist	VVN	VAFIN		OK/0.805506
to	__unaligned__	TO	__unaligned__		OK/0.737125
be	__unaligned__	VB	__unaligned__		OK/0.734166
administered	__unaligned__	VVN	__unaligned__		OK/0.694078
by	durch	IN	APPR		OK/0.836733
a	durch	DT	APPR		OK/0.971591
healthcare	Fachpersonal	NN	NN		OK/0.977667
provider	Fachpersonal	NN	NN		OK/0.944552
(	siehe	(	VVIMP		OK/0.995392
see	siehe	VV	VVIMP		OK/0.998940
section	Abschnitt	NN	NN		OK/0.999811
6.6	6.6	CD	CARD		OK/0.998290
)	)	)	$(		OK/0.997048
.	.	SENT	$.		OK/0.998611

# 0.128622
Cattle	Rind	NNS	NN		OK/0.949907
:	:	:	$.		OK/0.997937
A	Zur	DT	APPRART		OK/0.986228
single	einmaligen	JJ	ADJA		OK/0.993283
subcutaneous	subkutanen	JJ	ADJA		OK/0.994762
(	__unaligned__	(	__unaligned__		OK/0.991836
cattle	__unaligned__	NNS	__unaligned__		OK/0.986367
)	in	)	APPR		OK/0.530375
injection	Injektion	NN	NN		OK/0.778180
of	__unaligned__	IN	__unaligned__		OK/0.695284
2.5	2,5	CD	CARD		OK/0.994804
mg	mg	NN	NN		OK/0.999360
tulathromycin	Tulathromycin	NN	NE		OK/0.963007
/	/	SYM	$(		OK/0.996559
kg	kg	NN	NN		OK/0.991110
body	Körpergewicht	NN	NN		OK/0.960891
weight	Körpergewicht	NN	NN		OK/0.970554
(	__unaligned__	(	__unaligned__		BAD/0.926352
equivalent	entsprechend	NN	ADJD		OK/0.903413
to	entsprechend	TO	ADJD		OK/0.985615
1	1	CD	CARD		OK/0.999192
ml	ml	NN	NN		OK/0.997514
/	pro	SYM	APPR		OK/0.929357
40	40	CD	CARD		OK/0.961382
kg	kg	NN	NN		OK/0.967752
body	Körpergewicht	NN	NN		OK/0.988081
weight	Körpergewicht	NN	NN		OK/0.965394
)	__unaligned__	)	__unaligned__		BAD/0.663629
.	.	SENT	$.		OK/0.825601

# 0.445939
Alternatively	Alternativ	RB	ADJD		OK/0.984332
,	Alternativ	,	ADJD		OK/0.949379
in	bei	IN	APPR		OK/0.942978
metastatic	metastasiertem	JJ	ADJA		OK/0.995924
breast	Brustkrebs	NN	NN		OK/0.995205
cancer	Brustkrebs	NN	NN		OK/0.996523
,	__unaligned__	,	__unaligned__		OK/0.845538
Herceptin	Herceptin	NP	ADJD		OK/0.944509
is	__unaligned__	VBZ	__unaligned__		OK/0.708826
also	auch	RB	ADV		OK/0.688006
given	verabreicht	VVN	VVPP		OK/0.684561
every	alle	DT	PIAT		OK/0.876753
3	3	CD	CARD		OK/0.976501
weeks	Wochen	NNS	NN		OK/0.986190
.	.	SENT	$.		OK/0.999100

# 0.935167
1	1	CD	CARD		OK/0.997349
vial	Durchstechflasche	NN	NN		OK/0.998924
of	__unaligned__	IN	__unaligned__		OK/0.986898
powder	Pulver	NN	NN		OK/0.998170
for	für	IN	APPR		OK/0.998308
concentrate	Konzentrat	NN	NN		OK/0.998882
for	Infusionslösung	IN	NN		OK/0.997392
solution	Infusionslösung	NN	NN		OK/0.983370
for	Infusionslösung	IN	NN		OK/0.972978
infusion	Infusionslösung	NN	NN		OK/0.987069
.	.	SENT	$.		OK/0.998994

# 0.460330
Information	Informationen	NP	NN		OK/0.989507
on	Informationen	IN	NN		OK/0.519686
pre-treatment	Vorbehandlung	NN	NN		OK/0.860140
,	__unaligned__	,	__unaligned__		OK/0.991587
see	siehe	VV	ADV		OK/0.972895
section	Abschnitt	NN	NN		OK/0.994522
4.4	4.4	CD	CARD		OK/0.998069
and	und	CC	KON		OK/0.997737
further	weitere	JJR	ADJA		OK/0.984918
instructions	Anleitungen	NNS	NN		OK/0.936324
,	__unaligned__	,	__unaligned__		OK/0.987957
see	siehe	VV	ADV		OK/0.996604
section	Abschnitt	NN	NN		OK/0.999340
6.6	6.6	CD	CARD		OK/0.998478
.	.	SENT	$.		OK/0.999858

# 0.625443
The	Die	DT	ART		OK/0.981601
medicines	Arzneimittel	NNS	NN		OK/0.935437
were	wurden	VBD	VAFIN		OK/0.888300
added	zusätzlich	VVN	ADJD		OK/0.758573
to	zusätzlich	TO	ADJD		OK/0.748774
ciclosporin	Ciclosporin	NN	NN		OK/0.934007
and	und	CC	KON		OK/0.994397
corticosteroids	Kortikosteroiden	NNS	NN		OK/0.946733
.	.	SENT	$.		OK/0.999740

# 0.220073
Entecavir	Entecavir	NP	NN		OK/0.796034
's	__unaligned__	POS	__unaligned__		OK/0.662922
ability	beeinträchtigt	NN	VVFIN		OK/0.902605
to	__unaligned__	TO	__unaligned__		OK/0.701631
interferes	Virusenzyms	VVZ	NN		OK/0.873612
activity	Aktivität	NN	NN		OK/0.960086
,	der	,	ART		OK/0.985146
DNA	__unaligned__	NN	__unaligned__		OK/0.798721
polymerase	__unaligned__	NN	__unaligned__		OK/0.758615
,	,	,	$,		OK/0.840139
which	Bildung	WDT	NN		OK/0.732764
is	__unaligned__	VBZ	__unaligned__		OK/0.838851
involved	__unaligned__	VVN	__unaligned__		OK/0.765782
in	bei	IN	APPR		OK/0.980528
the	der	DT	ART		OK/0.976161
formation	__unaligned__	NN	__unaligned__		OK/0.957615
of	__unaligned__	IN	__unaligned__		OK/0.967973
viral	__unaligned__	JJ	__unaligned__		OK/0.998054
DNA	__unaligned__	NN	__unaligned__		OK/0.971319
.	.	SENT	$.		OK/0.997922

# 0.501032
The	Die	DT	ART		OK/0.995753
recommended	empfohlene	JJ	ADJA		OK/0.998236
dose	empfohlene	NN	ADJA		OK/0.995718
of	__unaligned__	IN	__unaligned__		OK/0.974700
Avastin	Avastin	NP	NN		OK/0.977502
is	beträgt	VBZ	VVFIN		OK/0.993098
10	10	CD	CARD		OK/0.996164
mg	mg	NN	NN		OK/0.999016
/	/	SYM	$(		OK/0.996584
kg	kg	NN	NN		OK/0.997956
of	__unaligned__	IN	__unaligned__		OK/0.984565
body	Körpergewicht	NN	NN		OK/0.996725
weight	Körpergewicht	NN	NN		OK/0.993011
given	einmal	VVN	ADV		OK/0.879960
once	einmal	IN	ADV		OK/0.979443
every	alle	DT	PIAT		OK/0.987479
2	2	CD	CARD		OK/0.997044
weeks	Wochen	NNS	NN		OK/0.997186
or	oder	CC	KON		OK/0.991754
15	15	CD	CARD		OK/0.997616
mg	mg	NN	NN		OK/0.999579
/	/	SYM	$(		OK/0.998889
kg	kg	NN	NN		OK/0.998100
of	__unaligned__	IN	__unaligned__		OK/0.984609
body	Körpergewicht	NN	NN		OK/0.996710
weight	Körpergewicht	NN	NN		OK/0.992800
given	einmal	VVN	ADV		OK/0.875455
once	einmal	IN	ADV		OK/0.973104
every	alle	DT	PIAT		OK/0.943401
3	3	CD	CARD		OK/0.993877
weeks	Wochen	NNS	NN		OK/0.982705
as	intravenöse	IN	ADJA		OK/0.779907
an	intravenöse	DT	ADJA		OK/0.981048
intravenous	intravenöse	JJ	ADJA		OK/0.999539
infusion	Infusion	NN	NN		OK/0.996548
.	.	SENT	$.		OK/0.999878

# 0.512369
By	Durch	IN	APPR		OK/0.895972
blocking	Durch	VVG	APPR		OK/0.828260
these	dieser	DT	PDAT		OK/0.852497
enzymes	Enzyme	NNS	NN		OK/0.802933
,	__unaligned__	,	__unaligned__		OK/0.938980
Sutent	Sutent	NP	ADJD		OK/0.927454
may	kann	MD	VMFIN		OK/0.926070
reduce	verringern	VV	VVINF		OK/0.951684
the	verringern	DT	VVINF		OK/0.975840
growth	Wachstum	NN	NN		OK/0.996010
and	und	CC	KON		OK/0.996135
spread	Ausbreitung	NN	NN		OK/0.849602
of	der	IN	ART		OK/0.913283
cancer	Krebszellen	NN	NN		OK/0.981228
cells	Krebszellen	NNS	NN		OK/0.994251
.	.	SENT	$.		OK/0.998697

# 0.430750
Ciprofloxacin	Ciprofloxacin	NP	NE		OK/0.987902
Hikma	Hikma	NP	NE		OK/0.968762
has	hat	VHZ	VAFIN		OK/0.966610
only	nur	RB	ADV		OK/0.940973
mild	leichte	JJ	ADJA		OK/0.959819
or	oder	CC	KON		OK/0.998547
moderate	mittelschwere	JJ	ADJA		OK/0.994842
on	Auswirkungen	IN	NN		OK/0.994619
the	__unaligned__	DT	__unaligned__		OK/0.965853
effects	__unaligned__	NNS	__unaligned__		OK/0.596526
on	__unaligned__	IN	__unaligned__		OK/0.571639
the	die	DT	ART		OK/0.987395
ability	Fähigkeit	NN	NN		OK/0.998188
to	Fähigkeit	TO	NN		OK/0.997173
drive	Maschinen	VV	NN		OK/0.993738
and	Maschinen	CC	NN		OK/0.975998
use	Maschinen	VV	NN		OK/0.983591
machines	Bedienen	NNS	NN		OK/0.988279
.	.	SENT	$.		OK/0.999626

# 0.966499
Each	Jede	DT	PIAT		OK/0.997633
infusion	Infusion	NN	NN		OK/0.994412
contains	enthält	VVZ	VVFIN		OK/0.989436
up	zu	RP	APPR		OK/0.998766
to	zu	TO	APPR		OK/0.995673
21	21	CD	CARD		OK/0.998772
g	g	NN	NN		OK/0.989048
.	.	SENT	$.		OK/0.999353

# 0.199945
There	Es	EX	NN		OK/0.979103
are	Es	VBP	NN		OK/0.988411
no	keine	DT	PIAT		OK/0.999457
adequate	ausreichenden	JJ	ADJA		OK/0.998350
data	Daten	NNS	NN		OK/0.992527
from	Daten	IN	NN		OK/0.787027
the	von	DT	APPR		OK/0.943874
use	Anwendung	NN	NN		OK/0.991078
of	von	IN	APPR		OK/0.986884
efavirenz	Efavirenz	NN	NE		OK/0.954839
with	mit	IN	APPR		OK/0.991976
low	niedrig	JJ	ADJD		OK/0.945731
dose	dosiertem	NN	ADJA		OK/0.636829
ritonavir	Ritonavir	NN	NN		OK/0.980173
(	(	(	$(		OK/0.995810
100	100	CD	CARD		OK/0.996677
mg	mg	NN	NN		OK/0.994163
,	,	,	$,		OK/0.995804
once	einmal	RB	ADV		OK/0.993488
or	oder	CC	KON		OK/0.999221
twice	zweimal	RB	ADV		OK/0.996457
daily	täglich	JJ	ADJD		OK/0.989627
)	)	)	$(		OK/0.989927
is	Verfügung	VBZ	NN		BAD/0.673866
available	Verfügung	JJ	NN		BAD/0.479815
.	.	SENT	$.		OK/0.997470

# 0.628633
Use	Die	NP	ART		OK/0.867311
in	bei	IN	APPR		OK/0.998567
paediatric	pädiatrischen	JJ	ADJA		OK/0.998243
patients	Patienten	NNS	NN		OK/0.998271
aged	Alter	VVD	NN		OK/0.985255
2	2	CD	CARD		OK/0.998545
to	bis	TO	APPR		OK/0.994645
<	<	SYM	$(		BAD/0.888422
12	12	CD	CARD		OK/0.998043
years	Jahren	NNS	NN		OK/0.999151
of	__unaligned__	IN	__unaligned__		OK/0.994864
age	Jahren	NN	NN		OK/0.996121
with	mit	IN	APPR		OK/0.995847
hepatic	Leber-	JJ	TRUNC		OK/0.997887
or	oder	CC	KON		OK/0.991710
renal	Niereninsuffizienz	JJ	NN		OK/0.972497
insufficiency	Niereninsuffizienz	NN	NN		OK/0.982929
has	untersucht	VHZ	ADJD		OK/0.982187
not	nicht	RB	PTKNEG		OK/0.997935
been	untersucht	VBN	ADJD		OK/0.983693
studied	untersucht	VVN	ADJD		OK/0.932950
(	(	(	$(		OK/0.996493
see	siehe	VV	VVIMP		OK/0.990518
section	Abschnitt	NN	NN		OK/0.988146
4.8	4.8	CD	CARD		OK/0.996386
and	und	CC	KON		OK/0.994342
section	Abschnitt	NN	NN		OK/0.996903
5.2	5.2	CD	CARD		OK/0.998914
)	)	)	$(		OK/0.998941
.	.	SENT	$.		OK/0.999066

# 0.369600
In	Ferner	IN	NN		OK/0.892637
addition	Ferner	NN	NN		OK/0.940214
,	__unaligned__	,	__unaligned__		OK/0.983932
she	es	PP	PPER		OK/0.885983
should	sollte	MD	VMFIN		OK/0.996172
not	nicht	RB	PTKNEG		OK/0.997086
be	__unaligned__	VB	__unaligned__		OK/0.979721
used	angewendet	VVN	VVPP		OK/0.988163
in	bei	IN	APPR		OK/0.993717
people	Personen	NNS	NN		OK/0.998058
in	bei	IN	APPR		OK/0.792930
whom	denen	WP	PRELS		OK/0.880954
after	nach	IN	APPR		OK/0.939541
Hepatitis	Hepatitis-B-Impfstoffs	NP	NN		OK/0.862934
B	Hepatitis-B-Impfstoffs	NP	NN		OK/0.954021
vaccine	Hepatitis-B-Impfstoffs	NN	NN		OK/0.974905
as	Hepatitis-B-Impfstoffs	IN	NN		OK/0.937822
a	__unaligned__	DT	__unaligned__		OK/0.862611
function	__unaligned__	NN	__unaligned__		OK/0.916031
of	__unaligned__	IN	__unaligned__		OK/0.977305
an	allergische	DT	ADJA		OK/0.994275
allergic	allergische	JJ	ADJA		OK/0.999082
reaction	allergische	NN	ADJA		OK/0.985378
occurred	aufgetreten	VVD	VVPP		OK/0.871684
.	.	SENT	$.		OK/0.995161

# 0.356863
Based	Basierend	VVN	ADJD		OK/0.988413
on	Basierend	IN	ADJD		OK/0.983354
the	den	DT	ART		OK/0.999217
reported	berichteten	VVN	ADJA		OK/0.956128
adverse	Nebenwirkungen	JJ	NN		OK/0.856481
reactions	Nebenwirkungen	NNS	NN		OK/0.937033
is	ist	VBZ	VAFIN		OK/0.972894
not	nicht	RB	PTKNEG		OK/0.828221
expected	erwarten	VVN	VVINF		OK/0.971851
that	dass	IN/that	KOUS		OK/0.989818
Doribax	Doribax	NP	NE		OK/0.935840
is	__unaligned__	VBZ	__unaligned__		OK/0.684104
affecting	die	VVG	ART		OK/0.641375
the	__unaligned__	DT	__unaligned__		OK/0.996827
ability	Verkehrstüchtigkeit	NN	NN		OK/0.968140
to	Fähigkeit	TO	NN		OK/0.990142
drive	Maschinen	VV	NN		OK/0.996406
and	Maschinen	CC	NN		OK/0.986144
use	Maschinen	VV	NN		OK/0.982932
machines	Maschinen	NNS	NN		OK/0.933177
.	.	SENT	$.		OK/0.998624

# 0.399488
Up	Bisher	NP	ADV		OK/0.983198
to	__unaligned__	TO	__unaligned__		OK/0.965222
now	Bisher	RB	ADV		OK/0.767349
there	Bisher	EX	ADV		OK/0.767314
were	wurde	VBD	VAFIN		OK/0.659988
only	nur	RB	ADV		OK/0.827611
a	geringe	DT	ADJA		OK/0.989466
small	geringe	JJ	ADJA		OK/0.985970
number	Anzahl	NN	NN		OK/0.996601
of	Anzahl	IN	NN		OK/0.998880
patients	Patienten	NNS	NN		OK/0.995084
with	mit	IN	APPR		OK/0.992316
late-onset	Verlaufsform	NN	NN		OK/0.901153
disease	Verlaufsform	NN	NN		OK/0.904802
(	siehe	(	VVIMP		OK/0.975522
see	siehe	VV	VVIMP		OK/0.998715
section	Abschnitt	NN	NN		OK/0.999755
5.1	5.1	CD	CARD		OK/0.999448
)	)	)	$(		OK/0.996188
were	__unaligned__	VBD	__unaligned__		OK/0.944037
treated	behandelt	VVN	VVPP		OK/0.995605
with	mit	IN	APPR		OK/0.997353
Myozyme	Myozyme	NP	NE		OK/0.893227
.	.	SENT	$.		OK/0.992592

# 0.264541
This	Dies	NP	PDS		OK/0.989623
is	ist	VBZ	VAFIN		OK/0.972062
probably	wahrscheinlich	RB	ADJD		OK/0.997344
due	auf	JJ	APPR		OK/0.961062
to	__unaligned__	TO	__unaligned__		OK/0.898602
the	das	DT	ART		OK/0.526695
less	Vorkommen	RBR	NN		BAD/0.991829
effective	__unaligned__	JJ	__unaligned__		BAD/0.986425
in	__unaligned__	IN	__unaligned__		BAD/0.990258
lowering	__unaligned__	VVG	__unaligned__		BAD/0.996146
blood	häufigere	NN	ADJA		BAD/0.966842
pressure	__unaligned__	NN	__unaligned__		BAD/0.974633
in	__unaligned__	IN	__unaligned__		BAD/0.994962
Niedrig-Renin-Status	Niedrig-Renin-Status	NP	NN		BAD/0.991276
in	bei	IN	APPR		OK/0.940557
the	__unaligned__	DT	__unaligned__		OK/0.994189
black	schwarzen	JJ	ADJA		OK/0.983388
population	Bevölkerung	NN	NN		OK/0.762881
are	zurückzuführen	VBP	VVIZU		BAD/0.944293
due	zurückzuführen	JJ	VVIZU		BAD/0.980462
to	zurückzuführen	TO	VVIZU		BAD/0.974567
treatment	__unaligned__	NN	__unaligned__		BAD/0.934547
(	siehe	(	VVIMP		OK/0.951883
see	siehe	VV	VVIMP		OK/0.997639
section	Abschnitt	NN	NN		OK/0.999749
5.1	5.1	CD	CARD		OK/0.999689
)	)	)	$(		OK/0.998397
.	.	SENT	$.		OK/0.997281

# 0.956685
How	Wie	NP	KOKOM		OK/0.997789
is	wird	VBZ	VAFIN		OK/0.962535
Evoltra	Evoltra	NP	NN		OK/0.999496
used	angewendet	VVD	VVPP		OK/0.995508
?	?	SENT	$.		OK/0.999419

# 0.274841
If	Wenn	IN	KOUS		OK/0.999469
necessary	nötig	JJ	ADJD		OK/0.992754
,	der	,	ART		OK/0.994813
the	der	DT	ART		OK/0.989002
doctor	Arzt	NN	NN		OK/0.976182
if	__unaligned__	IN	__unaligned__		OK/0.849399
the	die	DT	ART		OK/0.896717
A	A	NP	NN		OK/0.682513
bständen	bständen	NN	VVFIN		BAD/0.656418
increase	steigern	NN	VVINF		BAD/0.742354
.	.	SENT	$.		OK/0.951124

# 0.106716
This	Dadurch	NP	PAV		OK/0.914474
helps	sinkt	VVZ	VVFIN		BAD/0.553428
to	sinkt	TO	VVFIN		BAD/0.613995
reduce	Dadurch	VV	PAV		BAD/0.493444
the	__unaligned__	DT	__unaligned__		BAD/0.439482
pressure	__unaligned__	NN	__unaligned__		BAD/0.774883
inside	__unaligned__	IN	__unaligned__		BAD/0.799193
the	__unaligned__	DT	__unaligned__		BAD/0.490230
eye	__unaligned__	NN	__unaligned__		BAD/0.427626
.	.	SENT	$.		OK/0.972674

# 0.491848
Other	Weitere	JJ	ADJA		OK/0.990669
special	Patientengruppen	JJ	NN		OK/0.989823
populations	Patientengruppen	NNS	NN		OK/0.970624
No	keine	DT	PIAT		OK/0.992053
dose	Dosierungsanpassung	NN	NN		OK/0.989186
adjustment	Dosierungsanpassung	NN	NN		OK/0.980645
according	nach	VVG	APPR		OK/0.979563
to	__unaligned__	TO	__unaligned__		OK/0.996164
sex	Geschlecht	NN	NN		OK/0.929711
,	Zugehörigkeit	,	NN		OK/0.985632
race	ethnischer	NN	ADJA		OK/0.987696
,	Zugehörigkeit	,	NN		OK/0.922225
or	oder	CC	KON		OK/0.987970
Body	Body	NP	NE		OK/0.958991
Mass	Mass	NP	NN		OK/0.954883
Index	Body	NP	NE		OK/0.951515
(	(	(	$(		OK/0.996218
BMI	BMI	NP	NN		OK/0.992879
)	)	)	$(		OK/0.997432
is	erforderlich	VBZ	ADJD		OK/0.716170
required	erforderlich	VVN	ADJD		OK/0.817654
.	.	SENT	$.		OK/0.998626

# 0.120635
The	Der	NP	ART		OK/0.981522
MAH	Zulassungsinhaber	NP	NN		OK/0.742223
shall	Studienprogramm	MD	NN		OK/0.701317
complete	abzuschließen	VV	VVIZU		OK/0.706640
the	Ergebnisse	DT	NN		OK/0.978689
study	__unaligned__	NN	__unaligned__		OK/0.625039
and	für	CC	APPR		BAD/0.949972
additional	Bewertungsbericht	JJ	NN		BAD/0.971564
pharmacovigilance	Bewertungsbericht	NN	NN		BAD/0.960452
activities	Bewertungsbericht	NNS	NN		BAD/0.962143
detailed	Bewertungsbericht	VVN	NN		BAD/0.964734
in	__unaligned__	IN	__unaligned__		BAD/0.937970
the	__unaligned__	DT	__unaligned__		BAD/0.475881
Pharmacovigilance	den	NN	ART		BAD/0.880071
has	Nutzen-Risiko-Verhältnisses	VHZ	NN		BAD/0.984468
been	__unaligned__	VBN	__unaligned__		BAD/0.876947
given	__unaligned__	VVN	__unaligned__		BAD/0.802857
.	.	SENT	$.		OK/0.984346

# 0.917112
Insulin	Human	NP	NE		OK/0.999477
Human	Human	NP	NE		OK/0.999691
Winthrop	Winthrop	NP	NE		OK/0.999915
Basal	Basal	NP	NN		OK/0.999141
is	gibt	VBZ	VVFIN		OK/0.994729
supplied	gibt	VVN	VVFIN		OK/0.974410
in	in	IN	APPR		OK/0.998915
vials	Durchstechflaschen	NNS	NN		OK/0.997379
containing	Durchstechflaschen	VVG	NN		OK/0.982455
5	5	CD	CARD		OK/0.999122
ml	ml	NN	NN		OK/0.998817
suspension	Suspension	NN	NN		OK/0.996877
(	(	(	$(		OK/0.998743
500	500	CD	CARD		OK/0.998532
IU	I.E.	NP	NE		OK/0.987858
)	)	)	$(		OK/0.980208
.	.	SENT	$.		OK/0.997136

# 0.457805
Some	Einige	DT	PIAT		OK/0.995197
cases	Fälle	NNS	NN		OK/0.995541
have	Fälle	VHP	NN		OK/0.988707
had	nahmen	VHN	VVFIN		OK/0.807252
fatal	tödlichen	JJ	ADJA		OK/0.887666
outcome	tödlichen	NN	ADJA		OK/0.524581
.	.	SENT	$.		OK/0.999169

# 0.689842
If	Wenn	IN	KOUS		OK/0.995838
you	Sie	PP	PPER		OK/0.977766
stop	abbrechen	VVP	VVINF		OK/0.993352
using	abbrechen	VVG	VVINF		OK/0.991129
the	der	DT	ART		OK/0.999356
initial	ursprüngliche	NN	ADJA		OK/0.987024
can	kann	MD	VMFIN		OK/0.980487
result	__unaligned__	VV	__unaligned__		OK/0.778510
within	innerhalb	IN	APPR		OK/0.982514
2	2	CD	CARD		OK/0.991776
months	Monaten	NNS	NN		OK/0.985108
come	wieder	VVN	ADV		OK/0.951651
back	wieder	RB	ADV		OK/0.972107
.	.	SENT	$.		OK/0.999421

# 0.612893
Please	Bitte	RB	NN		OK/0.998874
speak	sprechen	VVP	VVFIN		OK/0.979643
with	mit	IN	APPR		OK/0.975965
your	Ihrem	PP$	PPOSAT		OK/0.972372
doctor	Arzt	NN	NN		OK/0.962050
if	falls	IN	KOUS		OK/0.996838
you	Sie	PP	PPER		OK/0.999622
notice	bemerken	VVP	VVINF		OK/0.993893
any	bemerken	DT	VVINF		OK/0.997731
changes	Veränderungen	NNS	NN		OK/0.998582
in	Veränderungen	IN	NN		OK/0.996032
your	Ihrer	PP$	PPOSAT		OK/0.992303
body	__unaligned__	NN	__unaligned__		OK/0.991326
shape	Körperform	NN	NN		OK/0.930513
due	durch	JJ	APPR		OK/0.811334
to	__unaligned__	TO	__unaligned__		OK/0.775823
a	eine	DT	ART		OK/0.987755
fat	Fettumverteilung	JJ	NN		OK/0.975489
redistribution	Fettumverteilung	NN	NN		OK/0.940335
.	.	SENT	$.		OK/0.999312

# 0.811245
189	189	CD	CARD		OK/0.815765
Very	Sehr	JJ	ADV		OK/0.991895
common	häufig	JJ	ADJD		OK/0.996342
:	:	:	$.		OK/0.998217

# 0.872803
Your	Ihr	PP$	PPOSAT		OK/0.960385
Actraphane	Actraphane	NP	NN		OK/0.992750
30	30	CD	CARD		OK/0.999433
InnoLet	InnoLet	NN	NN		OK/0.998634
is	__unaligned__	VBZ	__unaligned__		OK/0.958102
designed	__unaligned__	VVN	__unaligned__		OK/0.987142
to	__unaligned__	TO	__unaligned__		OK/0.984440
work	__unaligned__	VV	__unaligned__		OK/0.996065
accurately	genaue	RB	ADJA		OK/0.998136
and	und	CC	KON		OK/0.998517
safely	Funktionsweise	RB	NN		OK/0.974481
.	.	SENT	$.		OK/0.999197

# 0.364033
What	Was	WP	PIS		OK/0.997325
Ferriprox	Ferriprox	NP	TRUNC		OK/0.945399
is	__unaligned__	VBZ	__unaligned__		OK/0.816863
and	und	CC	KON		OK/0.998836
what	wofür	WP	PWAV		OK/0.998428
it	wofür	PP	PWAV		OK/0.989055
is	wofür	VBZ	PWAV		OK/0.989328
used	wofür	VVN	PWAV		OK/0.998989
for	wofür	IN	PWAV		OK/0.998951
2	wofür	CD	PWAV		BAD/0.629941
.	__unaligned__	SENT	__unaligned__		BAD/0.485450

# 0.494451
There	Es	RB	NN		OK/0.709950
was	wurde	VBD	VAFIN		OK/0.737598
,	jedoch	,	ADV		OK/0.924465
however	jedoch	RB	ADV		OK/0.948030
,	jedoch	,	ADV		OK/0.977730
a	__unaligned__	DT	__unaligned__		OK/0.946533
need	notwendig	NN	ADJD		OK/0.940565
to	befunden	TO	VVPP		OK/0.981005
further	__unaligned__	RBR	__unaligned__		OK/0.956430
evaluate	genauer	VV	ADJD		OK/0.957791
the	__unaligned__	DT	__unaligned__		OK/0.989368
benefit	Nutzen-Risiko-Verhältnis	NN	NN		OK/0.998685
/	Nutzen-Risiko-Verhältnis	SYM	NN		OK/0.999025
risk	Nutzen-Risiko-Verhältnis	NN	NN		OK/0.998968
balance	Nutzen-Risiko-Verhältnis	NN	NN		OK/0.995584
of	__unaligned__	IN	__unaligned__		OK/0.993542
some	einiger	DT	PIAT		OK/0.993981
non-selective	nichtselektiver	JJ	ADJA		OK/0.976695
NSAIDs	NSAID	NN	NN		OK/0.968131
including	einschließlich	VVG	APPR		OK/0.994737
piroxicam	Piroxicam	NN	NE		OK/0.952733
.	.	SENT	$.		OK/0.999677

# 0.271782
In	Bei	IN	APPR		OK/0.995463
children	Kindern	NNS	NN		OK/0.993777
(	(	(	$(		OK/0.995217
2	2-12	CD	CARD		OK/0.996058
-	__unaligned__	:	__unaligned__		OK/0.993362
12	2-12	CD	CARD		OK/0.997759
years	Jahre	NNS	NN		OK/0.997808
of	__unaligned__	IN	__unaligned__		OK/0.958617
age	Jahre	NN	NN		OK/0.957884
)	)	)	$(		OK/0.996655
will	wird	MD	VAFIN		OK/0.945777
start	begonnen	VV	VVPP		OK/0.788046
with	mit	IN	APPR		OK/0.956230
a	geringeren	DT	ADJA		OK/0.866109
lower	geringeren	JJR	ADJA		OK/0.895652
dose	Dosis	NN	NN		OK/0.994154
and	und	CC	KON		OK/0.984943
increased	gesteigert	VVN	VVPP		OK/0.865648
to	__unaligned__	TO	__unaligned__		OK/0.603079
maximal	maximalen	JJ	ADJA		OK/0.485191
dose	Dosis	NN	NN		OK/0.938436
according	entsprechend	VVG	ADJD		OK/0.980584
to	__unaligned__	TO	__unaligned__		OK/0.998977
body	Körperoberfläche	NN	NN		OK/0.998736
surface	Körperoberfläche	NN	NN		OK/0.998847
area	Körperoberfläche	NN	NN		OK/0.998045
.	.	SENT	$.		OK/0.999471

# 0.302418
The	Die	DT	ART		OK/0.976189
woman	Anwenderin	NN	NN		OK/0.899041
is	ist	VBZ	VAFIN		OK/0.957828
not	nicht	RB	PTKNEG		OK/0.656701
safely	sicher	RB	ADJD		OK/0.797092
protected	geschützt	VVN	VVPP		OK/0.697333
prior	vor	RB	APPR		OK/0.581548
to	vor	TO	APPR		OK/0.515799
pregnancy	Schwangerschaft	NN	NN		OK/0.688097
.	.	SENT	$.		OK/0.894961

# 0.354078
er	I	NNS	NN		BAD/0.704155
In	__unaligned__	IN	__unaligned__		OK/0.777673
the	__unaligned__	DT	__unaligned__		OK/0.955463
five	fünf	CD	CARD		OK/0.980115
large	großen	JJ	ADJA		OK/0.981862
controlled	kontrollierten	JJ	ADJA		OK/0.962280
studies	Studien	NNS	NN		OK/0.966116
involving	insgesamt	VVG	ADV		OK/0.998157
a	insgesamt	DT	ADV		OK/0.999291
total	insgesamt	NN	ADV		OK/0.992518
of	insgesamt	IN	ADV		OK/0.993301
2833	2833	CD	CARD		OK/0.873414
patients	Patienten	NNS	NN		OK/0.982312
,	,	,	$,		OK/0.944000
and	und	CC	KON		OK/0.993190
one	Tumorprogression	CD	NN		OK/0.986649
was	wurde	VBD	VAFIN		OK/0.988002
studied	untersucht	VVN	VVPP		OK/0.971703
.	.	SENT	$.		OK/0.999539

# 0.476617
The	Die	DT	ART		OK/0.984281
uptake	Aufnahme	NN	NN		OK/0.706154
of	Aufnahme	IN	NN		OK/0.937238
bexarotene	Bexaroten	NN	NN		OK/0.942905
due	durch	JJ	APPR		OK/0.944244
to	__unaligned__	TO	__unaligned__		OK/0.905266
organs	Organe	NNS	NN		OK/0.826392
or	oder	CC	KON		OK/0.982092
tissues	Gewebe	NNS	NN		OK/0.882452
has	untersucht	VHZ	VVPP		OK/0.982249
not	nicht	RB	PTKNEG		OK/0.965350
been	untersucht	VBN	VVPP		OK/0.992654
studied	untersucht	VVN	VVPP		OK/0.988679
.	.	SENT	$.		OK/0.999646

# 0.127298
In	Bei	IN	APPR		OK/0.466923
patients	leichten	NNS	ADJA		OK/0.559167
with	leichten	IN	ADJA		OK/0.631990
mild	leichten	JJ	ADJA		OK/0.969825
to	bis	TO	KON		OK/0.991149
moderate	mittelschweren	JJ	ADJA		OK/0.993432
type	Gaucher-Krankheit	NN	NN		OK/0.998935
1	Gaucher-Krankheit	CD	NN		OK/0.997936
Gaucher	Gaucher-Krankheit	NP	NN		OK/0.998495
disease	Gaucher-Krankheit	NN	NN		OK/0.997244
,	__unaligned__	,	__unaligned__		OK/0.901298
the	die	DT	ART		OK/0.920825
effectiveness	Wirksamkeit	NN	NN		OK/0.973922
of	die	IN	ART		OK/0.958535
Zavesca	Zavesca	NP	NE		OK/0.993525
has	wurde	VHZ	VAFIN		OK/0.976876
been	wurde	VBN	VAFIN		OK/0.997778
studied	untersucht	VVN	VVPP		OK/0.997975
in	__unaligned__	IN	__unaligned__		OK/0.993881
one	Hauptstudie	CD	NN		OK/0.999566
main	Hauptstudie	JJ	NN		OK/0.998169
study	Hauptstudie	NN	NN		OK/0.996009
involving	Hauptstudie	VVG	NN		OK/0.993035
28	28	CD	CARD		OK/0.998980
patients	Patienten	NNS	NN		OK/0.993640
undergoing	sich	VVG	PRF		OK/0.755799
ERT	EET	NN	ADJA		OK/0.879133
could	konnten	MD	VMFIN		OK/0.908244
not	nicht	RB	PTKNEG		OK/0.786101
be	__unaligned__	VB	__unaligned__		OK/0.661466
undergoing	unterziehen	VVG	VVINF		OK/0.657935
or	oder	CC	KON		OK/0.934120
•	wollten	NN	VMFIN		OK/0.858729
.	.	SENT	$.		OK/0.996283

# 0.961209
Like	Wie	IN	KOKOM		OK/0.998481
all	alle	DT	PIAT		OK/0.998864
medicines	Arzneimittel	NNS	NN		OK/0.999266
,	__unaligned__	,	__unaligned__		OK/0.989953
Livensa	Livensa	NP	NN		OK/0.994253
can	__unaligned__	MD	__unaligned__		OK/0.997036
have	haben	VH	VAFIN		OK/0.999288
side	Nebenwirkungen	NN	NN		OK/0.997576
effects	Nebenwirkungen	NNS	NN		OK/0.996381
,	,	,	$,		OK/0.996955
although	die	IN	PRELS		OK/0.996337
not	nicht	RB	PTKNEG		OK/0.999488
everybody	bei	NN	APPR		OK/0.995789
gets	__unaligned__	VVZ	__unaligned__		OK/0.999476
them	__unaligned__	PP	__unaligned__		OK/0.998633
.	.	SENT	$.		OK/0.999314

# 0.019303
The	Die	DT	ART		OK/0.998225
efficacy	Wirksamkeit	NN	NN		OK/0.996692
of	__unaligned__	IN	__unaligned__		OK/0.965219
buprenorphine	Buprenorphin	NN	NN		OK/0.988627
8	8	CD	CARD		OK/0.941715
mg	mg	NN	NN		OK/0.882193
daily	täglich	NN	ADJD		OK/0.889508
was	entsprach	VBD	VVFIN		OK/0.582127
similar	entsprach	JJ	VVFIN		OK/0.653802
to	entsprach	TO	VVFIN		OK/0.391162
that	entsprach	WDT	VVFIN		OK/0.300974
observed	entsprach	VVD	VVFIN		OK/0.255554
in	der	IN	ART		OK/0.396352
moderate	moderaten	JJ	ADJA		OK/0.520082
doses	Dosierung	NNS	NN		OK/0.507855
of	des	IN	ART		OK/0.631523
active	Verumkontrollpräparats	JJ	NN		OK/0.524893
control	Verumkontrollpräparats	NN	NN		OK/0.426846
,	__unaligned__	,	__unaligned__		OK/0.370240
to	__unaligned__	TO	__unaligned__		OK/0.314278
establish	Äquivalenz	VV	NN		OK/0.384323
equivalence	Äquivalenz	NN	NN		OK/0.500842
was	wurde	VBD	VAFIN		OK/0.526557
,	jedoch	,	ADV		OK/0.751641
however	jedoch	RB	ADV		OK/0.860071
,	jedoch	,	ADV		OK/0.952306
have	belegt	VHP	VVPP		OK/0.970663
not	nicht	RB	PTKNEG		OK/0.994300
been	belegt	VBN	VVPP		OK/0.994058
established	belegt	VVN	VVPP		OK/0.966837
.	.	SENT	$.		OK/0.999205

# 0.934845
What	Welchen	WP	PIAT		OK/0.998759
benefit	Welchen	VVP	PIAT		OK/0.975534
has	Nutzen	VHZ	NN		OK/0.999179
Fosavance	Fosavance	NP	NN		OK/0.990574
shown	__unaligned__	VVN	__unaligned__		OK/0.997185
during	in	IN	APPR		OK/0.984095
the	__unaligned__	DT	__unaligned__		OK/0.983679
studies	Studien	NNS	NN		OK/0.996834
?	?	SENT	$.		OK/0.998512

# 0.820216
Similar	Vergleichbare	JJ	ADJA		OK/0.934105
results	Ergebnisse	NNS	NN		OK/0.976866
were	wurden	VBD	VAFIN		OK/0.989999
seen	beobachtet	VVN	VVPP		OK/0.931330
in	bei	IN	APPR		OK/0.987111
HIV-1	HIV-1	JJ	ADJA		OK/0.972557
infected	infizierten	JJ	ADJA		OK/0.981215
children	Kindern	NNS	NN		OK/0.979782
.	.	SENT	$.		OK/0.999091

# 0.087644
Plasma	Plasma-Konzentrationen	NP	NN		OK/0.950726
concentrations	__unaligned__	NNS	__unaligned__		OK/0.936297
of	__unaligned__	IN	__unaligned__		OK/0.855564
non-response	__unaligned__	NN	__unaligned__		OK/0.643012
are	von	VBP	APPR		OK/0.491986
excluded	__unaligned__	VVN	__unaligned__		OK/0.370321
,	,	,	$,		OK/0.407578
and	__unaligned__	CC	__unaligned__		OK/0.249013
the	__unaligned__	DT	__unaligned__		OK/0.373003
patient	Wirkstoffen	NN	NN		OK/0.476896
is	__unaligned__	VBZ	__unaligned__		OK/0.923588
primarily	erster	RB	ADJA		OK/0.997947
metabolised	metabolisiert	VVN	ADJD		OK/0.997860
by	metabolisiert	IN	ADJD		OK/0.994280
CYP2C9	CYP2C9	NP	NN		OK/0.980191
,	,	,	$,		OK/0.863688
may	können	MD	VMFIN		OK/0.923760
be	können	VB	VMFIN		OK/0.939305
increased	erhöht	VVN	VVPP		OK/0.973196
when	gleichzeitiger	WRB	ADJA		OK/0.939955
co-administered	gleichzeitiger	JJ	ADJA		OK/0.951660
with	gleichzeitiger	IN	ADJA		OK/0.953560
sitaxentan	Sitaxentan-Natrium	NN	NN		OK/0.976081
sodium	Sitaxentan-Natrium	NN	NN		OK/0.972890
.	.	SENT	$.		OK/0.994960

# 0.327632
What	Was	WP	PIS		OK/0.998158
Levemir	Levemir	NP	NE		OK/0.986712
is	__unaligned__	VBZ	__unaligned__		OK/0.960250
and	und	CC	KON		OK/0.999304
what	wofür	WP	PWAV		OK/0.998453
it	wofür	PP	PWAV		OK/0.989061
is	wofür	VBZ	PWAV		OK/0.989323
used	wofür	VVN	PWAV		OK/0.998964
for	wofür	IN	PWAV		OK/0.998243
2	wofür	CD	PWAV		OK/0.361165
.	ist	SENT	VAFIN		OK/0.658811

# 0.869852
-	-	:	$(		OK/0.990275
Women	Frauen	NNS	NN		OK/0.989744
who	Frauen	WP	NN		OK/0.987038
are	Stillende	VBP	ADJA		OK/0.942223
breast-feeding	Stillende	VVG	ADJA		OK/0.905302
.	.	SENT	$.		OK/0.996705

# 0.193263
au	ug	FW	ADJD		BAD/0.757826
The	Die	DT	ART		OK/0.977930
vials	Durchstechflaschen	NNS	NN		OK/0.994928
are	sind	VBP	VAFIN		OK/0.993415
made	__unaligned__	VVN	__unaligned__		OK/0.974002
from	aus	IN	APPR		OK/0.978705
type	Glasart	NN	NN		OK/0.994441
1	Glasart	CD	NN		OK/0.986470
glass	Glasart	NN	NN		OK/0.993983
with	mit	IN	APPR		OK/0.983500
a	__unaligned__	DT	__unaligned__		OK/0.899149
cysteine-free	überzogenen	JJ	ADJA		BAD/0.460506
Gummiverschlüssen	Gummiverschlüssen	NP	NN		BAD/0.544537
27a	Fluorpolymer	NP	NN		BAD/0.616676
)	Fluorpolymer	)	NN		BAD/0.737287
.	.	SENT	$.		OK/0.962204

# 0.132700
Oral	Suspension	NP	NN		OK/0.946048
suspension	Suspension	NN	NN		OK/0.947882
called	kohlensäurehaltigen	VVD	ADJA		OK/0.938847
gamma-aminobutyric	kohlensäurehaltigen	JJ	ADJA		OK/0.853063
acid	__unaligned__	NN	__unaligned__		OK/0.934122
or	oder	CC	KON		OK/0.997919
milk	Milch	NN	NN		OK/0.993344
is	empfohlen	VBZ	VVPP		OK/0.988241
not	nicht	RB	PTKNEG		OK/0.990835
recommended	empfohlen	VVN	VVPP		OK/0.997381
due	wegen	JJ	APPR		OK/0.995167
to	wegen	TO	APPR		OK/0.991363
foaming	Schaumbildung	VVG	NN		OK/0.758148
and	bzw.	CC	KON		OK/0.482329
slow	langsamen	JJ	ADJA		OK/0.736279
fibroblast	Zerfalls	NN	NN		OK/0.437981
of	der	IN	ART		OK/0.576194
one	__unaligned__	CD	__unaligned__		OK/0.477269
side	__unaligned__	NN	__unaligned__		OK/0.677542
of	der	IN	ART		OK/0.981387
the	der	DT	ART		OK/0.989022
tablet	Tablette	NN	NN		OK/0.933313
.	.	SENT	$.		OK/0.997652

# 0.158283
In	In	IN	APPR		OK/0.956516
the	der	DT	ART		OK/0.981596
Phase	Phase-3-	NP	TRUNC		OK/0.977751
3	Phase-3-	CD	TRUNC		OK/0.861148
study	Studie	NN	NN		OK/0.993083
in	__unaligned__	IN	__unaligned__		OK/0.926721
adult	__unaligned__	JJ	__unaligned__		OK/0.859833
patients	__unaligned__	NNS	__unaligned__		OK/0.754425
with	bei	IN	APPR		OK/0.904996
GIST	GIST	NP	NN		OK/0.792410
(	(	(	$(		OK/0.982774
n	=	NN	$(		OK/0.982520
=	=	SYM	$(		OK/0.981171
312	312	CD	CARD		OK/0.923092
)	)	)	$(		OK/0.947284
have	traten	VHP	VVFIN		BAD/0.867473
experienced	traten	VVN	VVFIN		BAD/0.940862
treatment-related	behandlungsbedingte	JJ	ADJA		BAD/0.894372
cardiac	kardiale	JJ	ADJA		OK/0.725750
disorders	Störungen	NNS	NN		OK/0.987322
with	mit	IN	APPR		OK/0.998197
fatal	tödlichem	JJ	ADJA		OK/0.997258
outcome	tödlichem	NN	ADJA		OK/0.982063
in	in	IN	APPR		OK/0.986750
each	Behandlungsarm	DT	NN		OK/0.990648
treatment	__unaligned__	NN	__unaligned__		OK/0.956440
group	__unaligned__	NN	__unaligned__		OK/0.902392
(	(	(	$(		OK/0.951614
both	sowohl	DT	KON		OK/0.887997
and	auch	CC	ADV		OK/0.840523
placebo	Plazebo	NN	NN		OK/0.959542
)	)	)	$(		OK/0.986782
of	__unaligned__	IN	__unaligned__		OK/0.974114
SUTENT	SUTENT	NP	NN		OK/0.959385
in	bei	IN	APPR		OK/0.960719
1	1	CD	CARD		OK/0.987728
%	%	NN	NN		OK/0.999462
of	__unaligned__	IN	__unaligned__		OK/0.996214
patients	Patienten	NNS	NN		OK/0.978208
.	.	SENT	$.		OK/0.999817

# 0.172865
There	Die	RB	ART		OK/0.552884
is	__unaligned__	VBZ	__unaligned__		OK/0.437829
limited	__unaligned__	VVN	__unaligned__		OK/0.519856
clinical	klinische	JJ	ADJA		OK/0.955545
experience	Erfahrung	NN	NN		OK/0.966379
with	mit	IN	APPR		OK/0.995136
NovoMix	NovoMix	NP	NN		OK/0.996801
50	50	CD	CARD		OK/0.994193
during	während	IN	APPR		OK/0.993660
pregnancy	Schwangerschaft	NN	NN		OK/0.989930
is	gering	VBZ	ADJD		OK/0.510075
low	gering	JJ	ADJD		OK/0.739059
.	.	SENT	$.		OK/0.841007

# 0.744088
Schlecht	Schlecht	NP	NN		OK/0.779694
controlled	kontrollierte	VVD	ADJA		OK/0.852522
hypertension	Hypertonie	NN	NN		OK/0.951906
.	.	SENT	$.		OK/0.989207

# 0.139390
While	Während	IN	APPR		OK/0.976411
being	Während	VBG	APPR		OK/0.969945
treated	Während	VVN	APPR		OK/0.980621
with	mit	IN	APPR		OK/0.992592
Mimpara	Mimpara	NP	NE		OK/0.922785
,	,	,	$,		OK/0.945953
tell	informieren	VVP	VVFIN		OK/0.991081
your	Arzt	PP$	NN		OK/0.997730
doctor	Ihren	NN	PPOSAT		OK/0.997315
:	•	:	NN		OK/0.949352
•	•	JJ	NN		OK/0.997618
if	wenn	IN	KOUS		OK/0.999072
you	Sie	PP	PPER		OK/0.996428
to	dem	TO	ART		OK/0.978013
start	beginnen	VV	VVINF		OK/0.888851
or	oder	CC	KON		OK/0.995502
stop	aufhören	VV	VVFIN		OK/0.587777
taking	aufhören	VVG	VVFIN		OK/0.561171
smoking	Rauchen	NN	NN		OK/0.966303
because	da	IN	KOUS		OK/0.914874
this	dieses	DT	PDAT		OK/0.787292
way	Weise	NN	NN		OK/0.597901
Mimpara	Mimpara	NP	NE		OK/0.606862
works	wirkt	VVZ	VVFIN		OK/0.646592
,	,	,	$,		OK/0.944206
it	__unaligned__	PP	__unaligned__		OK/0.855841
may	kann	MD	VMFIN		OK/0.937102
influence	beeinflussen	VV	VVINF		OK/0.872599
.	.	SENT	$.		OK/0.997801

# 0.491855
-	-	:	$(		OK/0.990076
Aclasta	Aclasta	NP	VVIMP		OK/0.920652
is	ist	VBZ	VAFIN		OK/0.897301
to	aufzubewahren	TO	VVIZU		OK/0.613851
be	__unaligned__	VB	__unaligned__		OK/0.613735
stored	__unaligned__	VVN	__unaligned__		OK/0.820203
out	unzugänglich	RP	ADJD		OK/0.940630
of	unzugänglich	IN	ADJD		OK/0.981555
the	unzugänglich	DT	ADJD		OK/0.996180
reach	unzugänglich	NN	ADJD		OK/0.988202
of	unzugänglich	IN	ADJD		OK/0.995592
children	Kinder	NNS	NN		OK/0.991017
.	.	SENT	$.		OK/0.997377

# 0.012874
In	In	IN	APPR		OK/0.908313
a	einer	DT	ART		OK/0.703467
study	Studie	NN	NN		OK/0.989191
has	wurde	VHZ	VAFIN		OK/0.825059
been	wurde	VBN	VAFIN		OK/0.898660
observed	beobachtet	VVN	VVPP		OK/0.968569
after	oraler	IN	ADJA		OK/0.950350
oral	oraler	JJ	ADJA		OK/0.951758
administration	oraler	NN	ADJA		OK/0.962864
of	von	IN	APPR		OK/0.980027
8	8	CD	CARD		OK/0.990040
mg	mg	NN	NN		OK/0.999304
/	/	SYM	$(		OK/0.999467
kg	kg	NN	NN		OK/0.997877
in	bei	IN	APPR		OK/0.980307
healthy	gesunden	JJ	ADJA		OK/0.962048
beagle	Beaglehunden	NN	NN		OK/0.961024
dogs	Beaglehunden	NNS	NN		OK/0.955400
administered	Beaglehunden	VVN	NN		OK/0.778096
in	im	IN	APPRART		OK/0.806775
the	im	DT	APPRART		OK/0.817471
ECG	EKG	NP	NE		OK/0.899642
rise	Anstieg	NN	NN		OK/0.895720
in	Anstieg	IN	NN		OK/0.931470
QT	QT	NP	NN		OK/0.430701
a	__unaligned__	DT	__unaligned__		OK/0.504676
register	Intervalls	NN	NN		OK/0.333668
of	__unaligned__	IN	__unaligned__		OK/0.554106
approximately	um	RB	APPR		OK/0.726899
10	10	CD	CARD		OK/0.895664
%	%	NN	NN		OK/0.909471
;	__unaligned__	:	__unaligned__		OK/0.357356
however	.	RB	$.		OK/0.306731
,	allerdings	,	ADV		OK/0.397640
is	unwahrscheinlich	VBZ	ADJD		OK/0.530545
unlikely	unwahrscheinlich	JJ	ADJD		OK/0.708623
to	unwahrscheinlich	TO	ADJD		OK/0.825927
be	unwahrscheinlich	VB	ADJD		OK/0.767138
of	__unaligned__	IN	__unaligned__		OK/0.962461
clinical	klinischer	JJ	ADJA		OK/0.993549
significance	Bedeutung	NN	NN		OK/0.936489
.	.	SENT	$.		OK/0.999356

# 0.373216
51	51	CD	CARD		OK/0.993512
The	Die	DT	ART		OK/0.998400
solution	Injektionslösung	NN	NN		OK/0.975803
for	Injektionslösung	IN	NN		OK/0.981444
injection	Injektionslösung	NN	NN		OK/0.996328
must	darf	MD	VMFIN		OK/0.996671
be	darf	VB	VMFIN		OK/0.986718
administered	darf	VVN	VMFIN		OK/0.972794
into	Vene	IN	NN		OK/0.993048
a	Vene	DT	NN		OK/0.999932
vein	Vene	NN	NN		OK/0.994227
only	nur	RB	ADV		OK/0.646524
,	,	,	$,		OK/0.685598
and	und	CC	KON		OK/0.868913
not	nicht	RB	PTKNEG		OK/0.972046
anywhere	irgendwo	RB	ADV		OK/0.812285
else	irgendwo	RB	ADV		OK/0.810512
in	Körper	IN	NN		OK/0.882537
the	Körper	DT	NN		OK/0.912197
body	Körper	NN	NN		OK/0.891275
.	.	SENT	$.		OK/0.998352

# 0.062032
Drugs	Arzneimittel	NPS	NN		OK/0.717446
Karvezide	Serumkaliumhaushalt	NP	NN		OK/0.769261
:	:	:	$.		OK/0.895354
periodic	regelmäßige	JJ	ADJA		OK/0.762745
monitoring	__unaligned__	NN	__unaligned__		OK/0.504933
of	__unaligned__	IN	__unaligned__		OK/0.434626
serum	Serumkaliums	NN	NN		OK/0.777851
potassium	Serumkaliums	NN	NN		OK/0.925341
is	empfohlen	VBZ	VVPP		OK/0.988161
recommended	empfohlen	VVN	VVPP		OK/0.977711
when	gleichzeitiger	WRB	ADJA		BAD/0.424105
co-administering	gleichzeitiger	VVG	ADJA		BAD/0.694006
medicinal	__unaligned__	JJ	__unaligned__		BAD/0.742609
products	Arzneimitteln	NNS	NN		BAD/0.728915
Karvezide	Serumkaliumhaushalt	NN	NN		BAD/0.742896
(	(	(	$(		OK/0.954017
e.	z.	FW	APPRART		OK/0.958708
g.	Antiarrhythmika	FW	NN		OK/0.968511
digitalis	Antiarrhythmika	NN	NN		OK/0.971884
glycosides	Antiarrhythmika	NNS	NN		OK/0.959821
,	,	,	$,		OK/0.966904
antiarrhythmics	Digitalisglykoside	NP	NE		OK/0.844947
)	)	)	$(		OK/0.953836
.	.	SENT	$.		OK/0.992427

# 0.058843
The	Der	NP	ART		OK/0.999229
CHMP	CHMP	NP	NN		OK/0.993366
decided	entschied	VVD	VVFIN		OK/0.830237
that	entschied	IN/that	VVFIN		OK/0.726254
the	die	DT	ART		OK/0.837134
benefits	Vorteile	NNS	NN		OK/0.425707
of	die	IN	ART		OK/0.397529
IVEMEND	IVEMEND	NP	NN		OK/0.678744
exceed	Risiken	VVP	NN		OK/0.870327
the	Risiken	DT	NN		OK/0.993431
risks	Risiken	NNS	NN		OK/0.998164
and	und	CC	KON		OK/0.999520
they	empfahl	PP	VVFIN		OK/0.998945
recommended	empfahl	VVD	VVFIN		OK/0.997526
that	empfahl	IN/that	VVFIN		OK/0.643066
the	die	DT	ART		OK/0.735581
Marketing	Inverkehrbringen	NP	NN		OK/0.888160
Authorisation	Inverkehrbringen	NP	NN		OK/0.818369
for	Inverkehrbringen	IN	NN		OK/0.883171
IVEMEND	IVEMEND	NP	NN		OK/0.891509
be	erteilen	VB	VVINF		OK/0.743909
given	erteilen	VVN	VVINF		OK/0.652574
marketing	erteilen	NN	VVINF		OK/0.504970
authorisation	erteilen	NN	VVINF		OK/0.520763
.	.	SENT	$.		OK/0.998053

# 0.189710
One	Ein	NP	ART		OK/0.769635
such	solcher	JJ	PIAT		OK/0.878741
condition	Zustand	NN	NN		OK/0.978805
is	wird	VBZ	VAFIN		OK/0.954800
called	bezeichnet	VVN	VVPP		OK/0.997377
severe	schwere	JJ	ADJA		OK/0.970166
neutropenia	Neutropenie	NN	NN		OK/0.983842
or	oder	CC	KON		OK/0.991436
agranulocytosis	Agranulozytose	NN	NN		OK/0.919495
and	und	CC	KON		OK/0.822488
route	birgt	NN	VVFIN		OK/0.375390
carries	__unaligned__	VVZ	__unaligned__		OK/0.615831
the	__unaligned__	DT	__unaligned__		OK/0.805567
risk	Gefahr	NN	NN		OK/0.832667
of	__unaligned__	IN	__unaligned__		OK/0.763333
developing	Entwicklung	VVG	NN		OK/0.821377
serious	schwerwiegender	JJ	ADJA		OK/0.929803
infections	Infektionen	NNS	NN		OK/0.987130
.	.	SENT	$.		OK/0.999706

# 0.537934
Macugen	Macugen	NP	NN		OK/0.982977
is	wird	VBZ	VAFIN		OK/0.945756
used	verwendet	VVN	VVPP		OK/0.957945
in	bei	IN	APPR		OK/0.995406
patients	Patienten	NNS	NN		OK/0.996710
with	mit	IN	APPR		OK/0.985571
AMD	AMD	NP	NE		OK/0.951381
to	__unaligned__	TO	__unaligned__		OK/0.891096
treat	zur	VV	APPRART		OK/0.732237
all	aller	DT	PIAT		OK/0.994926
types	Arten	NNS	NN		OK/0.969135
of	Arten	IN	NN		OK/0.950133
abnormal	krankhaften	JJ	ADJA		OK/0.920295
reductions	der	NNS	ART		OK/0.898640
in	__unaligned__	IN	__unaligned__		OK/0.956742
blood	Blutgefäße	NN	NN		OK/0.998824
vessels	Blutgefäße	NNS	NN		OK/0.992353
.	.	SENT	$.		OK/0.999030

# 0.105710
21	21	CD	CARD		OK/0.953493
In	In	IN	APPR		OK/0.967570
the	der	DT	ART		OK/0.993760
initial	ersten	JJ	ADJA		OK/0.986566
post-transplant	Phase	NN	NN		OK/0.969642
period	__unaligned__	NN	__unaligned__		OK/0.988710
,	__unaligned__	,	__unaligned__		OK/0.862808
the	folgende	DT	ADJA		OK/0.941749
following	folgende	VVG	ADJA		OK/0.966369
parameters	Parameter	NNS	NN		OK/0.984126
are	sind	VBP	VAFIN		OK/0.995783
:	:	:	$.		OK/0.994881
blood	Blutdruck	NN	NN		OK/0.998548
pressure	Blutdruck	NN	NN		OK/0.995716
,	,	,	$,		OK/0.995291
ECG	EKG	NP	NE		OK/0.976018
,	,	,	$,		OK/0.949434
neurological	neurologischer	JJ	ADJA		OK/0.814142
and	__unaligned__	CC	__unaligned__		OK/0.735203
visual	neurologischer	JJ	ADJA		OK/0.863167
status	Status	NN	NN		OK/0.959982
,	__unaligned__	,	__unaligned__		OK/0.884688
fasting	Sehvermögen	VVG	NN		OK/0.894374
blood	Blutzuckerspiegel	NN	NN		OK/0.994178
glucose	__unaligned__	NN	__unaligned__		OK/0.997574
values	Nüchternwerte	NNS	NN		OK/0.992165
,	,	,	$,		OK/0.937663
electrolytes	Elektrolyte	NNS	NN		OK/0.827605
(	(	(	$(		OK/0.991698
particularly	insbesondere	RB	ADV		OK/0.982608
potassium	Kalium	NN	NN		OK/0.993576
)	)	)	$(		OK/0.998616
,	,	,	$,		OK/0.999727
liver	Leber-	NN	TRUNC		OK/0.974185
and	und	CC	KON		OK/0.999673
renal	Nierenfunktion	JJ	NN		OK/0.991734
function	Nierenfunktion	NN	NN		OK/0.989332
,	,	,	$,		OK/0.954147
haematology	hämatologische	NN	ADJA		OK/0.942544
parameters	Parameter	NNS	NN		OK/0.977444
,	,	,	$,		OK/0.987464
coagulation	Blutgerinnung	NN	NN		OK/0.972666
values	__unaligned__	NNS	__unaligned__		OK/0.987505
,	__unaligned__	,	__unaligned__		BAD/0.553532
and	und	CC	KON		OK/0.957277
plasma	Plasmaproteine	NN	NN		OK/0.870280
protein	Plasmaproteine	NN	NN		OK/0.784251
determinations	Plasmaproteine	NNS	NN		OK/0.736507
.	.	SENT	$.		OK/0.996938

# 0.509357
The	Die	DT	ART		OK/0.995647
blood	Blutspiegel	NN	NN		OK/0.971891
levels	Blutspiegel	NNS	NN		OK/0.979806
of	__unaligned__	IN	__unaligned__		OK/0.950642
pimecrolimus	Pimecrolimus	NN	NN		OK/0.961440
were	waren	VBD	VAFIN		OK/0.854636
consistently	durchweg	RB	ADV		OK/0.886901
low	niedrig	JJ	ADJD		OK/0.884388
-	-	:	$(		OK/0.912220
regardless	unabhängig	RB	ADJD		OK/0.855971
of	__unaligned__	IN	__unaligned__		OK/0.976377
extent	Ausmaß	NN	NN		OK/0.911374
of	der	IN	ART		OK/0.919263
the	der	DT	ART		OK/0.957797
treated	behandelten	VVN	ADJA		OK/0.957110
skin	Hautläsionen	NN	NN		OK/0.989445
lesions	Hautläsionen	NNS	NN		OK/0.985633
or	oder	CC	KON		OK/0.997312
the	__unaligned__	DT	__unaligned__		OK/0.964336
duration	Therapiedauer	NN	NN		OK/0.971160
of	Therapiedauer	IN	NN		OK/0.987409
therapy	Therapiedauer	NN	NN		OK/0.975092
.	.	SENT	$.		OK/0.999232

# 0.118386
25	25	CD	CARD		OK/0.957132
-	-	:	$(		OK/0.968501
63	63	CD	CARD		OK/0.989737
%	%	NN	NN		OK/0.995568
,	__unaligned__	,	__unaligned__		OK/0.912847
respectively	%	RB	NN		OK/0.896404
)	)	)	$(		OK/0.995431
.	.	SENT	$.		OK/0.967774
Following	Nach	VVG	APPR		OK/0.990563
oral	oraler	JJ	ADJA		OK/0.996963
administration	oraler	NN	ADJA		OK/0.988654
of	__unaligned__	IN	__unaligned__		OK/0.992774
sildenafil	Sildenafil	NN	NE		OK/0.972062
,	nehmen	,	VVFIN		OK/0.955741
AUC	AUC	NP	NE		OK/0.996282
and	und	CC	KON		OK/0.999105
Cmax	Cmax	NP	NE		OK/0.991138
increase	dosisproportional	NN	ADJD		OK/0.960602
in	den	IN	ART		OK/0.846016
proportion	__unaligned__	NN	__unaligned__		BAD/0.543574
with	__unaligned__	IN	__unaligned__		BAD/0.696799
dose	__unaligned__	NN	__unaligned__		BAD/0.639778
over	über	IN	APPR		BAD/0.674880
the	empfohlenen	DT	ADJA		OK/0.901199
recommended	empfohlenen	JJ	ADJA		OK/0.912089
dose	Dosisbereich	NN	NN		OK/0.915481
range	Dosisbereich	NN	NN		OK/0.728242
(	(	(	$(		OK/0.845569
25-100	Dosisbereich	CD	NN		OK/0.805618
mg	mg	NN	NN		OK/0.989428
)	)	)	$(		OK/0.989046
.	.	SENT	$.		OK/0.998355

# 0.824415
Each	Jedes	DT	PIAT		OK/0.996527
patch	Jedes	NN	PIAT		OK/0.908887
releases	Jedes	VVZ	PIAT		OK/0.926598
6	6	CD	CARD		OK/0.988365
mg	mg	NN	NN		OK/0.999244
of	Rotigotin	IN	NN		OK/0.999277
rotigotine	Rotigotin	NN	NN		OK/0.992019
per	Rotigotin	IN	NN		OK/0.959514
24	24	CD	CARD		OK/0.993615
hours	Stunden	NNS	NN		OK/0.982558
.	.	SENT	$.		OK/0.998930

# 0.079487
Compared	Verglichen	VVN	NN		OK/0.954193
to	Verglichen	TO	NN		OK/0.937657
biphasic	biphasischem	JJ	ADJA		OK/0.974671
human	Humaninsulin	JJ	NN		OK/0.946243
insulin	Humaninsulin	NN	NN		OK/0.984739
30	30	CD	CARD		OK/0.949681
resulted	führte	VVN	VVFIN		OK/0.837728
in	führte	IN	VVFIN		OK/0.886374
the	die	DT	ART		OK/0.974539
administration	Verabreichung	NN	NN		OK/0.985211
of	die	IN	ART		OK/0.972759
NovoMix	NovoMix	NP	NN		OK/0.956816
30	30	CD	CARD		OK/0.978263
before	vor	IN	APPR		OK/0.989148
breakfast	Frühstück	NN	NN		OK/0.953695
and	und	CC	KON		OK/0.986902
before	vor	IN	APPR		OK/0.918258
dinner	Abendessen	NN	NN		OK/0.435174
in	__unaligned__	IN	__unaligned__		OK/0.454398
lower	niedrigeren	JJR	ADJA		OK/0.513362
blood	Blutzuckerwerten	NN	NN		OK/0.765594
glucose	__unaligned__	NN	__unaligned__		OK/0.773840
values	__unaligned__	VVZ	__unaligned__		OK/0.926040
Reaction	postprandialen	NN	ADJA		OK/0.573012
after	nach	IN	APPR		OK/0.914678
both	beiden	DT	PIAT		OK/0.841218
meals	Mahlzeiten	NNS	NN		OK/0.772580
(	(	(	$(		OK/0.944885
breakfast	Frühstück	NN	NN		OK/0.896423
and	und	CC	KON		OK/0.992174
dinner	Abendessen	NN	NN		OK/0.934393
)	)	)	$(		OK/0.976801
.	.	SENT	$.		OK/0.996434

# 0.029017
In	Bei	IN	APPR		OK/0.739274
infections	Infektionen	NNS	NN		OK/0.686515
due	durch	JJ	APPR		OK/0.258362
to	Pseudomonas	TO	NE		OK/0.227241
Pseudomonas	aeruginosa	NP	NE		OK/0.395899
aeruginosa	aeruginosa	NP	NE		OK/0.411015
with	mit	IN	APPR		OK/0.590162
evidence	nachgewiesener	NN	ADJA		OK/0.674132
of	__unaligned__	IN	__unaligned__		OK/0.739316
susceptibility	Empfindlichkeit	NN	NN		OK/0.639967
to	Empfindlichkeit	TO	NN		OK/0.879023
ceftriaxone	Ceftriaxon	NN	NE		OK/0.994147
is	ist	VBZ	VAFIN		OK/0.991488
used	Kombination	VVN	NN		OK/0.988216
in	Kombination	IN	NN		OK/0.997674
combination	Kombination	NN	NN		OK/0.996205
with	mit	IN	APPR		OK/0.983692
aminoglycosides	Aminoglykosiden	NNS	NN		OK/0.800203
,	,	,	$,		BAD/0.628341
in	__unaligned__	IN	__unaligned__		BAD/0.941176
order	vermeiden	NN	VVINF		BAD/0.943028
to	vermeiden	TO	VVINF		BAD/0.862932
avoid	vermeiden	VV	VVINF		BAD/0.818515
a	um	DT	KOUI		BAD/0.885159
Sekundärresistenz	Sekundärresistenz	NP	NN		BAD/0.941734
.	.	SENT	$.		OK/0.992069

# 0.314297
After	Nach	IN	APPR		OK/0.958990
the	die	DT	ART		OK/0.985893
surfactant-free	Einwirkzeit	JJ	NN		OK/0.933592
imiquimod	Imiquimod-Creme	NN	NN		OK/0.979878
cream	Imiquimod-Creme	NN	NN		OK/0.992339
should	muss	MD	VMFIN		OK/0.774131
be	muss	VB	VMFIN		OK/0.834224
clearly	unbedingt	RB	ADJD		OK/0.473644
associated	__unaligned__	VVN	__unaligned__		OK/0.609640
with	mit	IN	APPR		OK/0.993842
mild	milden	JJ	ADJA		OK/0.990765
soap	Seife	NN	NN		OK/0.987352
and	Seife	CC	NN		OK/0.970657
water	Seife	NN	NN		OK/0.991200
and	und	CC	KON		OK/0.990681
rinsed	abgewaschen	VVD	VVPP		OK/0.962708
off	__unaligned__	RP	__unaligned__		OK/0.981858
with	__unaligned__	IN	__unaligned__		OK/0.977917
water	__unaligned__	NN	__unaligned__		OK/0.996218
.	.	SENT	$.		OK/0.999749

# 0.748855
75	75	CD	CARD		OK/0.997149
mg	mg	NN	NN		OK/0.987134
)	)	)	$(		OK/0.828573
and	und	CC	KON		OK/0.962992
as	als	IN	KOKOM		OK/0.958487
a	als	DT	KOKOM		OK/0.985473
powder	Pulver	NN	NN		OK/0.997951
for	Pulver	IN	NN		OK/0.998219
oral	Einnehmen	JJ	NN		OK/0.996295
suspension	Suspension	NN	NN		OK/0.990120
(	(	(	$(		OK/0.992683
12	12	CD	CARD		OK/0.971916
mg	mg	NN	NN		OK/0.991231
/	/	SYM	$(		OK/0.996340
ml	ml	NN	NN		OK/0.999119
)	)	)	$(		OK/0.997020
.	.	SENT	$.		OK/0.997263

# 0.107260
It	Es	PP	NN		OK/0.988011
is	empfohlen	VBZ	VVPP		OK/0.990103
recommended	empfohlen	VVN	VVPP		OK/0.983592
that	empfohlen	IN/that	VVPP		OK/0.853056
the	den	DT	ART		OK/0.994034
haemoglobin	Hämoglobinwert	NN	NN		OK/0.993142
should	Hämoglobinwert	MD	NN		OK/0.998907
be	Hämoglobinwert	VB	NN		OK/0.982470
monitored	Hämoglobinwert	VVN	NN		OK/0.950835
until	bis	IN	KON		OK/0.939612
every	alle	DT	PIAT		OK/0.936023
two	zwei	CD	CARD		OK/0.684178
weeks	Wochen	NNS	NN		OK/0.600377
,	__unaligned__	,	__unaligned__		OK/0.346269
and	und	CC	KON		OK/0.904130
then	anschließend	RB	ADJD		OK/0.738457
periodically	regelmäßigen	RB	ADJA		BAD/0.662121
.	.	SENT	$.		OK/0.996406

# 0.327402
The	Die	DT	ART		OK/0.904009
adverse	Nebenwirkungen	JJ	NN		OK/0.984263
reactions	Nebenwirkungen	NNS	NN		OK/0.993046
listed	aufgeführten	VVN	ADJA		OK/0.983212
in	aufgeführten	IN	ADJA		OK/0.963418
Table	Tabelle	NP	NN		OK/0.789105
2	5	CD	CARD		OK/0.424210
are	basieren	VBP	VVFIN		OK/0.732280
based	basieren	VVN	VVFIN		OK/0.965514
on	basieren	IN	VVFIN		OK/0.987991
experience	Erfahrung	NN	NN		OK/0.979135
from	aus	IN	APPR		OK/0.995859
paediatric	Kindern	JJ	NN		OK/0.957341
clinical	klinischen	JJ	ADJA		OK/0.972969
trials	Studien	NNS	NN		OK/0.972334
.	.	SENT	$.		OK/0.995579

# 0.195840
In	Bei	IN	APPR		OK/0.669538
Penicillin-Überempfindlichkeit	Penicillin-Überempfindlichkeit	NP	NN		OK/0.597020
is	ist	VBZ	VAFIN		OK/0.662935
a	eine	DT	ART		OK/0.793031
reactant	Kreuzreaktion	NN	NN		OK/0.734641
to	gegen	TO	APPR		OK/0.876708
cephalosporins	Cephalosporine	NNS	NE		OK/0.878322
and	und	CC	KON		OK/0.825234
umgekehrtmöglich	umgekehrtmöglich	NN	NE		OK/0.432138
.	.	SENT	$.		OK/0.992557

# 0.112329
The	Die	DT	ART		OK/0.997395
potential	möglichen	JJ	ADJA		OK/0.984114
effects	Wirkungen	NNS	NN		OK/0.983402
on	Wirkungen	IN	NN		OK/0.969547
Fortpflanzungs-	Fortpflanzungs-	NP	TRUNC		OK/0.582810
and	und	CC	KON		OK/0.826026
Entwicklungsfunktionen	Entwicklungsfunktionen	NP	NN		BAD/0.606860
)	sind	)	VAFIN		BAD/0.761808
have	bislang	VHP	ADV		OK/0.676960
not	nicht	RB	PTKNEG		OK/0.980190
been	worden	VBN	VAPP		OK/0.960070
extensively	umfassend	RB	ADJD		OK/0.872131
described	beschrieben	VVN	VVPP		OK/0.685728
.	.	SENT	$.		OK/0.987440

# 0.889061
What	Wofür	WP	NN		OK/0.996144
is	Wofür	VBZ	NN		OK/0.963090
Veraflox	Veraflox	NP	NN		OK/0.964909
should	sollte	MD	VMFIN		OK/0.952868
be	sollte	VB	VMFIN		OK/0.996638
used	angewendet	VVN	VVPP		OK/0.998616
for	__unaligned__	IN	__unaligned__		OK/0.974143
?	?	SENT	$.		OK/0.999433

# 0.306427
Avoid	direkten	NP	ADJA		OK/0.963996
contact	__unaligned__	NN	__unaligned__		OK/0.989591
with	mit	IN	APPR		OK/0.998288
skin	Haut	NN	NN		OK/0.981952
or	oder	CC	KON		OK/0.952978
eyes	Augen	NNS	NN		OK/0.935045
should	vermeiden	MD	VVINF		OK/0.595210
be	vermeiden	VB	VVINF		OK/0.557109
made	vermeiden	VVN	VVINF		BAD/0.845277
as	vermeiden	IN	VVINF		BAD/0.867457
provided	vermeiden	VVN	VVINF		BAD/0.862982
.	.	SENT	$.		OK/0.990630

# 0.532158
180	180	CD	CARD		OK/0.911588
•	•	NN	NN		OK/0.996713
Push	Stecken	VVP	VVFIN		OK/0.976227
the	Stecken	DT	VVFIN		OK/0.991821
needle	Nadel	NN	NN		OK/0.868031
to	auf	TO	APPR		OK/0.853331
the	die	DT	ART		OK/0.949661
tip	Spritzenspitze	NN	NN		OK/0.846121
of	__unaligned__	IN	__unaligned__		OK/0.838399
the	__unaligned__	DT	__unaligned__		OK/0.997204
syringe	__unaligned__	NN	__unaligned__		OK/0.901602
(	(	(	$(		OK/0.989347
4	4	CD	CARD		OK/0.997951
)	)	)	$(		OK/0.994299
.	.	SENT	$.		OK/0.997696

# 0.568054
Women	Frauen	NP	NN		OK/0.999591
of	gebärfähigen	IN	ADJA		OK/0.998856
childbearing	gebärfähigen	NN	ADJA		OK/0.987477
potential	gebärfähigen	NN	ADJA		OK/0.674646
must	müssen	MD	VMFIN		OK/0.987894
use	anwenden	VV	VVINF		OK/0.994233
a	eine	DT	ART		OK/0.977518
reliable	zuverlässige	JJ	ADJA		OK/0.985718
method	__unaligned__	NN	__unaligned__		OK/0.971639
of	__unaligned__	IN	__unaligned__		OK/0.980099
contraception	Verhütungsmethode	NN	NN		OK/0.976333
during	während	IN	APPR		OK/0.969156
treatment	Behandlung	NN	NN		OK/0.982054
with	mit	IN	APPR		OK/0.987484
FORSTEO	FORSTEO	NP	NN		OK/0.948571
.	.	SENT	$.		OK/0.998109

# 0.834045
seek	medizinischen	VVP	ADJA		OK/0.970630
medical	__unaligned__	JJ	__unaligned__		OK/0.973561
advice	Rat	NN	NN		OK/0.975074
,	,	,	$,		OK/0.974319
as	da	IN	KOUS		OK/0.997873
you	Sie	PP	PPER		OK/0.992491
may	möglicherweise	MD	ADV		OK/0.971742
need	brauchen	VV	VVINF		OK/0.959818
medical	medizinische	JJ	ADJA		OK/0.957548
treatment	Behandlung	NN	NN		OK/0.991435
.	.	SENT	$.		OK/0.981870

# 0.104446
Patients	Patienten	NPS	NN		OK/0.997579
who	Patienten	WP	NN		OK/0.986701
met	__unaligned__	VVD	__unaligned__		OK/0.987726
virologic	virologischen	JJ	ADJA		OK/0.994533
response	Ansprechen	NN	NN		OK/0.962710
criteria	Kriterien	NNS	NN		OK/0.705835
met	erfüllten	VVD	VVFIN		OK/0.328348
,	,	,	$,		OK/0.248782
but	jedoch	CC	ADV		OK/0.527436
not	nicht	RB	PTKNEG		OK/0.777890
serologic	serologischen	JJ	ADJA		OK/0.764370
or	oder	CC	KON		OK/0.996761
biochemical	biochemischen	JJ	ADJA		OK/0.982433
continued	setzten	JJ	VVFIN		OK/0.966572
treatment	setzten	NN	VVFIN		OK/0.899776
continued	__unaligned__	VVD	__unaligned__		OK/0.742113
blinded	verblindeten	VVN	ADJA		OK/0.653458
treatment	verblindeten	NN	ADJA		OK/0.822136
.	.	SENT	$.		OK/0.994638

# 0.228320
levels	Plasmaspiegel	NNS	NN		OK/0.962591
and	und	CC	KON		OK/0.959062
the	der	DT	ART		OK/0.995346
AUC	AUC	NN	NE		OK/0.992643
of	der	IN	ART		OK/0.945882
mirtazapine	Mirtazapin	NN	NE		OK/0.853578
by	__unaligned__	IN	__unaligned__		OK/0.910893
approximately	etwa	RB	ADV		OK/0.978568
40	40	CD	CARD		OK/0.932839
%	%	NN	NN		OK/0.599690
and	bzw.	CC	KON		OK/0.695192
108	bzw.	CD	KON		OK/0.530410
%	%	NN	NN		OK/0.852989
respectively	bzw.	RB	KON		OK/0.643643
.	bzw.	SENT	KON		OK/0.774126

# 0.043353
The	Das	DT	ART		OK/0.989094
primary	primäre	JJ	ADJA		OK/0.870644
objective	Studienziel	NN	NN		OK/0.652849
of	__unaligned__	IN	__unaligned__		OK/0.839079
this	__unaligned__	DT	__unaligned__		OK/0.900262
study	__unaligned__	NN	__unaligned__		OK/0.747583
was	war	VBD	VAFIN		OK/0.469760
to	__unaligned__	TO	__unaligned__		OK/0.472352
determine	__unaligned__	VV	__unaligned__		OK/0.620197
that	dass	DT	KOUS		OK/0.584118
degarelix	Degarelix	NN	NE		OK/0.630827
increase	zu	NN	APPR		OK/0.374023
testosterone	Testosteronsuppression	NN	NN		OK/0.423811
suppression	Testosteronsuppression	NN	NN		OK/0.334433
less	__unaligned__	JJR	__unaligned__		OK/0.956306
than	unter	IN	APPR		OK/0.986220
0.5	0,5	CD	CARD		OK/0.991741
ng	ng	NNS	ADJA		OK/0.998428
/	/	SYM	$(		OK/0.987583
ml	ml	NN	NN		OK/0.994965
,	,	,	$,		OK/0.945768
continues	anhält	VVZ	VVFIN		OK/0.682843
for	__unaligned__	IN	__unaligned__		OK/0.770993
12	12	CD	CARD		OK/0.962777
months	Monate	NNS	NN		OK/0.977585
.	.	SENT	$.		OK/0.999563

# 0.674490
Your	Ihr	PP$	PPOSAT		OK/0.928274
doctor	Arzt	NN	NN		OK/0.956798
may	kann	MD	VMFIN		OK/0.994515
adjust	anpassen	VV	VVINF		OK/0.992789
your	__unaligned__	PP$	__unaligned__		OK/0.945101
dose	Dosis	NN	NN		OK/0.986302
of	__unaligned__	IN	__unaligned__		OK/0.917821
REYATAZ	REYATAZ	NP	NE		OK/0.943997
according	gemäß	VVG	APPR		OK/0.962187
to	__unaligned__	TO	__unaligned__		OK/0.979261
your	Ihrer	PP$	PPOSAT		OK/0.995945
vasodilation	Anti-HIV-	NN	NN		OK/0.892706
.	.	SENT	$.		OK/0.998636

# 0.180799
The	Der	DT	ART		OK/0.975360
pre-filled	vorgefüllte	JJ	ADJA		OK/0.683923
ViraferonPeg	ViraferonPeg-Injektor	NP	NN		OK/0.953208
pre-filled	ViraferonPeg-Injektor	JJ	NN		OK/0.996786
pen	ViraferonPeg-Injektor	NN	NN		OK/0.988221
contains	ViraferonPeg-Injektor	VVZ	NN		OK/0.935154
a	__unaligned__	DT	__unaligned__		OK/0.838886
powder	Pulver	NN	NN		OK/0.838102
of	__unaligned__	IN	__unaligned__		OK/0.711862
peginterferon	Peginterferon	NN	NN		OK/0.897794
alfa-2b	alfa-2b	NN	VVFIN		OK/0.902052
and	__unaligned__	CC	__unaligned__		OK/0.607927
a	__unaligned__	DT	__unaligned__		OK/0.727408
solvent	__unaligned__	NN	__unaligned__		OK/0.834011
for	__unaligned__	IN	__unaligned__		OK/0.772670
solution	__unaligned__	NN	__unaligned__		OK/0.712459
at	einer	IN	ART		OK/0.909226
a	einer	DT	ART		OK/0.983086
strength	Stärke	NN	NN		OK/0.951364
of	einer	IN	ART		OK/0.992227
150	150	CD	CARD		OK/0.994471
micrograms	Mikrogramm	NNS	NN		OK/0.998462
for	Einmalanwendung	IN	NN		OK/0.998178
single	Einmalanwendung	JJ	NN		OK/0.998698
use	Einmalanwendung	NN	NN		OK/0.963313
.	.	SENT	$.		OK/0.999205

# 0.049422
Mechanism	Wirkungsmechanismus	NP	NN		OK/0.981903
of	Wirkungsmechanismus	IN	NN		OK/0.995614
action	Wirkungsmechanismus	NN	NN		OK/0.990115
and	und	CC	KON		OK/0.976429
pharmacodynamic	pharmakodynamische	JJ	ADJA		OK/0.936341
effects	Wirkungen	NNS	NN		OK/0.921676
At	Auf	IN	APPR		OK/0.912503
the	die	DT	ART		OK/0.937702
effects	Wirkungen	NNS	NN		OK/0.924262
of	die	IN	ART		OK/0.824254
tacrolimus	Tacrolimus	NNS	NN		OK/0.743980
appear	__unaligned__	VVP	__unaligned__		OK/0.469009
to	dürften	TO	VMFIN		OK/0.461326
be	__unaligned__	VB	__unaligned__		OK/0.309593
mediated	durch	VVN	APPR		OK/0.644275
by	__unaligned__	IN	__unaligned__		OK/0.371231
binding	__unaligned__	JJ	__unaligned__		OK/0.554676
protein	__unaligned__	NN	__unaligned__		OK/0.680038
(	(	(	$(		OK/0.956406
FKBP12	zytosolisches	NP	ADJA		OK/0.859311
)	)	)	$(		OK/0.982995
,	,	,	$,		OK/0.983701
which	__unaligned__	WDT	__unaligned__		OK/0.952251
is	__unaligned__	VBZ	__unaligned__		OK/0.978409
responsible	verantwortlich	JJ	ADJD		OK/0.967390
for	verantwortlich	IN	ADJD		OK/0.927885
the	für	DT	APPR		OK/0.991893
accumulation	Anreicherung	NN	NN		OK/0.977945
of	__unaligned__	IN	__unaligned__		OK/0.860162
the	__unaligned__	DT	__unaligned__		OK/0.857846
molecular	Zellinnern	JJ	NN		OK/0.825445
substance	Substanz	NN	NN		OK/0.786759
.	.	SENT	$.		OK/0.994903

# 0.727315
After	Nach	IN	APPR		OK/0.986689
reconstitution	Rekonstitution	NN	NN		OK/0.987231
,	Rekonstitution	,	NN		OK/0.967185
do	nicht	VVP	PTKNEG		OK/0.947627
not	nicht	RB	PTKNEG		OK/0.991274
store	25ºC	VV	NE		OK/0.988265
above	25ºC	IN	NE		OK/0.994059
25	25ºC	CD	NE		OK/0.831443
°	25ºC	SYM	NE		OK/0.923119
C.	25ºC	NP	NE		OK/0.947296

# 0.606175
Gastrointestinal	__unaligned__	NP	__unaligned__		BAD/0.741327
System	__unaligned__	NP	__unaligned__		BAD/0.832384
The	Das	DT	ART		OK/0.987839
occurrence	Auftreten	NN	NN		OK/0.983581
of	Auftreten	IN	NN		OK/0.979446
dose-dependent	dosisabhängigen	JJ	ADJA		OK/0.957447
side	Nebenwirkungen	NN	NN		OK/0.994146
effects	Nebenwirkungen	NNS	NN		OK/0.969321
is	wahrscheinlich	VBZ	ADJD		OK/0.937734
likely	wahrscheinlich	JJ	ADJD		OK/0.960448
.	.	SENT	$.		OK/0.996356

# 0.947220
What	Wofür	WP	NN		OK/0.995346
is	Wofür	VBZ	NN		OK/0.954428
Tygacil	Tygacil	NN	ADJD		OK/0.997979
used	angewendet	VVN	VVPP		OK/0.996067
for	angewendet	IN	VVPP		OK/0.999273
?	?	SENT	$.		OK/0.999329

# 0.518733
Store	__unaligned__	NP	__unaligned__		OK/0.953319
in	__unaligned__	IN	__unaligned__		OK/0.955715
the	__unaligned__	DT	__unaligned__		OK/0.988434
original	Original	JJ	NN		OK/0.976870
bottle	Flasche	NN	NN		OK/0.976262
in	Original	IN	NN		OK/0.992163
order	schützen	NN	VVINF		OK/0.981517
to	schützen	TO	VVINF		OK/0.994452
protect	schützen	VV	VVINF		OK/0.998006
from	schützen	IN	VVINF		OK/0.923710
light	schützen	NN	VVINF		OK/0.707149
and	vor	CC	APPR		OK/0.641261
moisture	Feuchtigkeit	NN	NN		OK/0.928650
.	.	SENT	$.		OK/0.998111

# 0.926717
Each	Jede	DT	PIAT		OK/0.999693
pre-filled	Fertigspritze	JJ	NN		OK/0.996216
syringe	Fertigspritze	NN	NN		OK/0.999707
contains	enthält	VVZ	VVFIN		OK/0.996132
6	6	CD	CARD		OK/0.996631
mg	mg	NN	NN		OK/0.998804
of	__unaligned__	IN	__unaligned__		OK/0.994066
pegfilgrastim	Pegfilgrastim	NNS	NN		OK/0.972273
in	in	IN	APPR		OK/0.989431
0.6	0,6	CD	CARD		OK/0.998018
ml	ml	NN	NN		OK/0.998821
of	Lösung	IN	NN		OK/0.981092
solution	Lösung	NN	NN		OK/0.991203
.	.	SENT	$.		OK/0.999600

# 0.453372
These	Diese	DT	PDAT		OK/0.967666
trials	Studien	NNS	NN		OK/0.951119
were	wurden	VBD	VAFIN		OK/0.978954
carried	__unaligned__	VVN	__unaligned__		OK/0.951371
out	__unaligned__	RP	__unaligned__		OK/0.831973
in	im	IN	APPRART		OK/0.957035
the	im	DT	APPRART		OK/0.978561
laboratory	Labor	NN	NN		OK/0.852109
and	und	CC	KON		OK/0.979746
typical	typischen	JJ	ADJA		OK/0.956177
for	für	IN	APPR		OK/0.963227
management	Haltungsbedingungen	NN	NN		OK/0.795984
in	Europa	IN	NE		OK/0.858642
Europe	Europa	NP	NE		OK/0.815307
.	.	SENT	$.		OK/0.998705

# 0.610821
●	●	JJ	NN		OK/0.986955
Place	Legen	NN	VVFIN		OK/0.992736
syringes	Spritzen	NNS	NN		OK/0.974972
and	und	CC	KON		OK/0.999687
vials	Durchstechflaschen	NNS	NN		OK/0.994205
on	auf	IN	APPR		OK/0.946277
a	saubere	DT	ADJA		OK/0.960831
clean	saubere	JJ	ADJA		OK/0.922778
surface	saubere	NN	ADJA		OK/0.673507
.	.	SENT	$.		OK/0.996997

# 0.029480
Dose	Dosisanpassungen	NP	NN		OK/0.995198
adjustments	Dosisanpassungen	NNS	NN		OK/0.992239
and	__unaligned__	CC	__unaligned__		OK/0.911166
continuous	__unaligned__	JJ	__unaligned__		OK/0.864105
monitoring	Überwachung	NN	NN		OK/0.987278
and	und	CC	KON		OK/0.989902
discontinuation	Absetzen	NN	NN		OK/0.967546
of	Absetzen	IN	NN		OK/0.973205
Dose	Dosisanpassung	NP	NN		OK/0.978468
adjustment	Dosisanpassung	NN	NN		OK/0.867517
in	__unaligned__	IN	__unaligned__		BAD/0.672919
addition	zielt	NN	VVFIN		BAD/0.832479
to	__unaligned__	TO	__unaligned__		BAD/0.754385
that	darauf	WDT	PAV		BAD/0.702459
,	,	,	$,		BAD/0.583367
to	__unaligned__	TO	__unaligned__		BAD/0.464629
obtain	zu	VV	PTKZU		BAD/0.798267
the	ein	DT	ART		BAD/0.826913
Treatment	Therapiefenster	NP	NN		BAD/0.755674
(	(	(	$(		OK/0.702128
mitotane	Mitotanspiegel	NN	NN		OK/0.811232
plasma	Plasma	NN	NN		OK/0.935618
levels	Mitotanspiegel	NNS	NN		OK/0.916539
between	zwischen	IN	APPR		OK/0.977257
14	14	CD	CARD		OK/0.948491
and	und	CC	KON		OK/0.998166
20	20	CD	CARD		OK/0.998665
mg	mg	NN	NN		OK/0.995536
/	/	SYM	$(		OK/0.998522
l	l	NN	NN		OK/0.998142
)	)	)	$(		OK/0.997573
,	,	,	$,		OK/0.987049
the	__unaligned__	DT	__unaligned__		OK/0.885166
optimal	optimale	JJ	ADJA		OK/0.849878
use	Nutzung	NN	NN		OK/0.950894
of	__unaligned__	IN	__unaligned__		OK/0.962349
Lysodren	Lysodren	NP	NN		OK/0.879879
with	mit	IN	APPR		OK/0.880579
minimums	annehmbarer	NNS	ADJA		BAD/0.578610
.	.	SENT	$.		OK/0.988721

# 0.195272
Each	Jede	DT	PIAT		OK/0.999646
pre-filled	Fertigspritze	JJ	NN		OK/0.991469
syringe	Fertigspritze	NN	NN		OK/0.999864
of	mit	IN	APPR		OK/0.993710
0.5	0,5	CD	CARD		OK/0.995272
ml	ml	NN	NN		OK/0.997161
solution	Lösung	NN	NN		OK/0.999110
contains	enthält	VVZ	VVFIN		OK/0.965964
180	180	CD	CARD		OK/0.994445
micrograms	Mikrogramm	NNS	NN		OK/0.999422
peginterferon	Peginterferon	JJ	NN		OK/0.997265
alfa-2a	alfa-2a	NN	NN		OK/0.995172
*	*	SYM	XY		OK/0.997937
.	.	SENT	$.		OK/0.995426
The	Die	DT	ART		OK/0.996600
strength	Stärke	NN	NN		OK/0.861559
indicates	__unaligned__	VVZ	__unaligned__		OK/0.789748
the	des	DT	ART		OK/0.877327
quantity	__unaligned__	NN	__unaligned__		OK/0.729862
of	__unaligned__	IN	__unaligned__		OK/0.858854
the	__unaligned__	DT	__unaligned__		OK/0.971367
interferon	Interferon	NN	NN		OK/0.980896
alfa-2a	alfa-2a	NN	NE		OK/0.972702
moiety	__unaligned__	NN	__unaligned__		OK/0.871141
of	Peginterferon	IN	NN		OK/0.946710
peginterferon	Peginterferon	NN	NN		OK/0.938467
alfa-2a	alfa-2a	NN	NE		OK/0.931105
without	ohne	IN	APPR		OK/0.989584
consideration	Berücksichtigung	NN	NN		OK/0.940072
of	der	IN	ART		OK/0.911751
the	der	DT	ART		OK/0.865211
pegylation	Pegylierung	NN	NN		BAD/0.602752
.	.	SENT	$.		OK/0.992736

# 0.404353
The	Die	NP	ART		OK/0.965635
studies	Studien	NNS	NN		OK/0.973895
looked	untersuchten	VVD	VVFIN		OK/0.964801
at	untersuchten	IN	VVFIN		OK/0.992384
how	lange	WRB	ADV		OK/0.982953
long	lange	RB	ADV		OK/0.982324
it	dauerte	PP	VVFIN		OK/0.805999
took	dauerte	VVD	VVFIN		OK/0.778100
until	bis	IN	KOUS		OK/0.640221
again	erneut	RB	ADJD		OK/0.804919
atrial	Vorhofflimmern	JJ	NN		OK/0.906006
fibrillation	Vorhofflimmern	NN	NN		OK/0.914997
or	oder	CC	KON		OK/0.980595
flutter	-flattern	NN	NN		OK/0.806918
.	.	SENT	$.		OK/0.997540

# 0.067172
In	Bei	IN	APPR		OK/0.963906
patients	Patienten	NNS	NN		OK/0.999422
with	mit	IN	APPR		OK/0.998216
chronic	chronischer	JJ	ADJA		OK/0.995302
renal	Nierenerkrankung	JJ	NN		OK/0.994298
failure	chronischer	NN	ADJA		OK/0.924126
,	__unaligned__	,	__unaligned__		BAD/0.764075
maintenance	Erhaltungsphase	NN	NN		BAD/0.889442
haemoglobin	Hämoglobinkonzentration	NN	NN		BAD/0.704532
concentration	Hämoglobinkonzentration	NN	NN		BAD/0.828224
the	Obergrenze	DT	NN		BAD/0.641077
upper	Obergrenze	JJ	NN		BAD/0.758631
limit	Obergrenze	NN	NN		BAD/0.556023
of	Obergrenze	IN	NN		BAD/0.600693
the	Obergrenze	DT	NN		BAD/0.629287
target	angestrebten	NN	ADJA		BAD/0.763070
haemoglobin	Hämoglobinkonzentration	NN	NN		BAD/0.666107
concentration	Hämoglobinkonzentration	NN	NN		BAD/0.716734
should	überschreiten	MD	VVINF		OK/0.750142
not	nicht	RB	PTKNEG		OK/0.797246
exceed	überschreiten	VV	VVINF		OK/0.809153
the	__unaligned__	DT	__unaligned__		OK/0.803131
target	__unaligned__	NN	__unaligned__		OK/0.757796
haemoglobin	__unaligned__	NN	__unaligned__		OK/0.956475
concentration	__unaligned__	NN	__unaligned__		OK/0.927295
recommended	empfohlene	VVN	ADJA		OK/0.958276
in	in	IN	APPR		OK/0.907773
section	Abschnitt	NN	NN		OK/0.987556
4.2	4.2	CD	CARD		OK/0.982698
.	.	SENT	$.		OK/0.999698

# 0.946533
Inject	Spritzen	NP	VVFIN		OK/0.956419
the	die	DT	ART		OK/0.997480
solution	Lösung	NN	NN		OK/0.994947
:	:	:	$.		OK/0.994573

# 0.028331
In	Bei	IN	APPR		OK/0.682234
rats	Ratten	NNS	NN		OK/0.481101
,	__unaligned__	,	__unaligned__		BAD/0.913443
are	ähnliche	VBP	ADJA		BAD/0.915150
similar	ähnliche	JJ	ADJA		OK/0.715485
to	ähnliche	TO	ADJA		OK/0.393862
those	ähnliche	DT	ADJA		OK/0.299458
in	Muttermilch	IN	NN		OK/0.362970
milk	Muttermilch	NN	NN		OK/0.434621
concentrations	Konzentrationen	NNS	NN		OK/0.696901
of	von	IN	APPR		OK/0.755978
atorvastatin	Atorvastatin	NN	NN		OK/0.859181
and	und	CC	KON		OK/0.916164
its	Metaboliten	PP$	NN		OK/0.978532
active	Metaboliten	JJ	NN		OK/0.958582
metabolites	Metaboliten	NNS	NN		OK/0.921433
are	__unaligned__	VBP	__unaligned__		BAD/0.646617
measured	gemessen	VVN	VVPP		OK/0.885628
in	Plasma	IN	NN		OK/0.984828
plasma	Plasma	NN	NN		OK/0.961732
.	.	SENT	$.		OK/0.998818

# 0.473169
How	Wie	NP	KOKOM		OK/0.997625
to	__unaligned__	TO	__unaligned__		OK/0.997853
take	__unaligned__	VV	__unaligned__		OK/0.992361
Corlentor	Corlentor	NP	NN		OK/0.975523
4	einzunehmen	CD	VVIZU		OK/0.486314
.	?	SENT	$.		OK/0.783674

# 0.190311
For	Für	IN	APPR		OK/0.921690
the	die	DT	ART		OK/0.933970
use	Anwendung	NN	NN		OK/0.931655
during	während	IN	APPR		OK/0.993397
the	ersten	DT	ADJA		OK/0.999159
first	ersten	JJ	ADJA		OK/0.997126
few	Behandlungswochen	JJ	NN		OK/0.991995
weeks	Behandlungswochen	NNS	NN		OK/0.998162
of	Behandlungswochen	IN	NN		OK/0.988584
treatment	Behandlungswochen	NN	NN		OK/0.958633
when	denen	WRB	PRELS		OK/0.697556
the	die	DT	ART		OK/0.911821
dose	Dosis	NN	NN		OK/0.850132
is	__unaligned__	VBZ	__unaligned__		OK/0.721061
being	langsam	VBG	ADJD		OK/0.871287
slowly	langsam	RB	ADJD		OK/0.955051
increased	gesteigert	VVN	VVPP		OK/0.934551
is	ist	VBZ	VAFIN		OK/0.924002
also	auch	RB	ADV		OK/0.815662
Starter	Pack	NP	NN		OK/0.721389
packs	Pack	NNS	NN		OK/0.735073
containing	Pack	VVG	NN		OK/0.630865
42	42	CD	CARD		OK/0.661963
tablets	Tabletten	NNS	NN		OK/0.706437
.	.	SENT	$.		OK/0.995593

# 0.428246
Your	Ihr	PP$	PPOSAT		OK/0.997979
doctor	Arzt	NN	NN		OK/0.997860
will	wird	MD	VAFIN		OK/0.999608
check	prüfen	VV	VVINF		OK/0.993884
your	Ihren	PP$	PPOSAT		OK/0.993949
cholesterol	Cholesterinspiegel	NN	NN		OK/0.979413
levels	Cholesterinspiegel	NNS	NN		OK/0.973912
and	und	CC	KON		OK/0.996872
,	,	,	$,		OK/0.949634
if	falls	IN	KOUS		OK/0.958135
necessary	erforderlich	JJ	ADJD		OK/0.994675
,	,	,	$,		OK/0.862230
your	Ihre	PP$	PPOSAT		OK/0.788999
Statin-Dosis	Statin-Dosis	NN	NN		OK/0.508310
.	.	SENT	$.		OK/0.994323

# 0.109287
You	Sie	PP	PPER		OK/0.982298
will	werden	MD	VAFIN		OK/0.979051
receive	erhalten	VV	VVPP		OK/0.961892
the	die	DT	ART		OK/0.837580
first	erste	JJ	ADJA		BAD/0.630832
Cyanokit-Infusion	Cyanokit-Infusion	NN	NN		BAD/0.858100
over	über	IN	APPR		BAD/0.686661
a	von	DT	APPR		BAD/0.667158
period	Dauer	NN	NN		BAD/0.560735
of	von	IN	APPR		BAD/0.345471
15	15	CD	CARD		OK/0.913016
minutes	Minuten	NNS	NN		OK/0.927725
.	.	SENT	$.		OK/0.999167

# 0.437192
The	Die	DT	ART		OK/0.992844
reduction	Reduktion	NN	NN		OK/0.893631
was	wurde	VBD	VAFIN		OK/0.955608
observed	beobachtet	VVN	VVPP		OK/0.931663
in	bei	IN	APPR		OK/0.991868
the	den	DT	ART		OK/0.970372
celecoxib	Celecoxib	NN	NE		OK/0.808181
16	16	CD	CARD		OK/0.978597
mg	mg	NN	NN		OK/0.997094
/	/	SYM	$(		OK/0.999096
kg	kg	NN	NN		OK/0.999232
/	/	SYM	$(		OK/0.998627
day	Tag	NN	NN		OK/0.987213
,	was	,	PRELS		OK/0.978378
in	bei	IN	APPR		OK/0.995468
adult	erwachsenen	JJ	ADJA		OK/0.930678
FAP	FAP-Patienten	NP	NN		OK/0.855373
patients	FAP-Patienten	NNS	NN		OK/0.751232
at	empfohlenen	IN	ADJA		OK/0.841492
the	empfohlenen	DT	ADJA		OK/0.976678
recommended	empfohlenen	JJ	ADJA		OK/0.993257
dose	Dosis	NN	NN		OK/0.998783
of	von	IN	APPR		OK/0.972742
800	800	CD	CARD		OK/0.997675
mg	mg	NN	NN		OK/0.998494
per	täglich	IN	ADJD		OK/0.996386
day	täglich	NN	ADJD		OK/0.996109
.	.	SENT	$.		OK/0.999498

# 0.499942
Many	Viele	JJ	PIS		OK/0.856510
to	__unaligned__	TO	__unaligned__		OK/0.733050
keep	können	VV	VMFIN		OK/0.527371
.	.	SENT	$.		OK/0.999023

# 0.610616
Other	Andere	JJ	PIAT		OK/0.998595
common	häufige	JJ	ADJA		OK/0.993406
side	Nebenwirkungen	NN	NN		OK/0.996431
effects	Nebenwirkungen	NNS	NN		OK/0.993125
except	außer	IN	APPR		OK/0.982547
the	den	DT	ART		OK/0.998991
skin	Hautreaktionen	NN	NN		OK/0.986668
reactions	Hautreaktionen	NNS	NN		OK/0.957647
are	sind	VBP	VAFIN		OK/0.801132
Drüsenschwellungen	Drüsenschwellungen	NP	NN		OK/0.731975
and	und	CC	KON		OK/0.973883
back	Rückenschmerzen	JJ	NN		OK/0.936650
pain	Rückenschmerzen	NN	NN		OK/0.922460
.	.	SENT	$.		OK/0.999466

# 0.049914
If	Wenn	IN	KOUS		OK/0.998663
you	Sie	PP	PPER		OK/0.972549
have	Sie	VHP	PPER		OK/0.945208
mild	leichte	JJ	ADJA		OK/0.938114
to	mäßige	TO	ADJA		OK/0.951742
moderate	mäßige	JJ	ADJA		OK/0.998212
cirrhosis	Leberzirrhose	NN	NN		OK/0.994595
of	__unaligned__	IN	__unaligned__		OK/0.993731
the	__unaligned__	DT	__unaligned__		OK/0.984925
liver	__unaligned__	NN	__unaligned__		OK/0.748945
,	,	,	$,		OK/0.811567
which	kann	WDT	VMFIN		BAD/0.977831
may	kann	MD	VMFIN		BAD/0.588744
make	dass	VV	KOUS		BAD/0.617476
your	Ihr	PP$	PPOSAT		OK/0.982340
doctor	Arzt	NN	NN		OK/0.992641
may	__unaligned__	MD	__unaligned__		BAD/0.419741
decide	entscheidet	VV	VVFIN		BAD/0.481789
to	verringern	TO	VVINF		BAD/0.867603
reduce	__unaligned__	VV	__unaligned__		BAD/0.854265
the	__unaligned__	DT	__unaligned__		BAD/0.608902
dose	Dosis	NN	NN		OK/0.773857
.	.	SENT	$.		OK/0.997583

# 0.200618
Dose	Dosisreduktion	NP	NN		OK/0.998116
reduction	Dosisreduktion	NN	NN		OK/0.998435
,	,	,	$,		OK/0.980240
depending	abhängig	VVG	ADJD		OK/0.940087
on	abhängig	IN	ADJD		OK/0.992021
the	der	DT	ART		OK/0.996558
degree	Grad	NN	NN		OK/0.973139
of	__unaligned__	IN	__unaligned__		OK/0.904701
toxicities	Toxizität	NNS	NN		OK/0.759871
on	beim	IN	APPRART		OK/0.746360
the	__unaligned__	DT	__unaligned__		OK/0.955051
patient	Patienten	NN	NN		OK/0.940302
,	,	,	$,		OK/0.956801
may	kann	MD	VMFIN		OK/0.966119
be	erfolgen	VB	VVINF		OK/0.986987
done	erfolgen	VVN	VVINF		OK/0.922294
either	entweder	RB	KON		OK/0.975948
during	während	IN	KOUS		OK/0.945531
a	__unaligned__	DT	__unaligned__		OK/0.525995
ongoing	laufenden	JJ	ADJA		OK/0.930106
cycle	Behandlungszyklus	NN	NN		OK/0.841536
of	oder	IN	KON		BAD/0.915436
the	nächsten	DT	ADJA		OK/0.959576
next	nächsten	JJ	ADJA		OK/0.914611
treatment	Behandlungszyklus	NN	NN		OK/0.997732
cycle	Behandlungszyklus	NN	NN		OK/0.982997
.	.	SENT	$.		OK/0.997705

# 0.378234
Hydrocortisone	Hydrocortisonaceponat	NP	NN		OK/0.892049
aceponate	Hydrocortisonaceponat	NN	NN		OK/0.950843
belongs	gehört	VVZ	VVFIN		OK/0.985623
to	gehört	TO	VVFIN		OK/0.944668
the	__unaligned__	DT	__unaligned__		OK/0.983728
calcium	__unaligned__	NN	__unaligned__		OK/0.806498
antagonist	__unaligned__	NN	__unaligned__		OK/0.766671
Diester-Klasse	Diester-Klasse	NP	NN		OK/0.814497
of	der	IN	ART		OK/0.941653
Glucocorticosteroide	Glucocorticosteroide	NP	NN		OK/0.618727
.	.	SENT	$.		OK/0.994793

# 0.180239
-	-	:	$(		OK/0.996191
medicines	Arzneimitteln	NNS	NN		OK/0.993024
used	Arzneimitteln	VVN	NN		OK/0.996486
to	__unaligned__	TO	__unaligned__		OK/0.958097
treat	Erektionsstörungen	VV	NN		OK/0.562412
erectile	Erektionsstörungen	JJ	NN		OK/0.421271
dysfunction	Erektionsstörungen	NN	NN		OK/0.263336
(	(	(	$(		OK/0.427483
e.	z.	FW	APPR		OK/0.504012
g.	B.	FW	NE		OK/0.787460
sildenafil	Sildenafil	NN	NE		OK/0.929178
and	und	CC	KON		OK/0.997243
tadalafil	Tadalafil	NN	NE		OK/0.990652
)	)	)	$(		OK/0.997345
;	;	:	$.		OK/0.993762

# 0.702539
8	8	CD	CARD		OK/0.996009
blister	Blisterpackungen	NN	NN		OK/0.995754
packs	Blisterpackungen	NNS	NN		OK/0.993783
containing	Blisterpackungen	VVG	NN		OK/0.946349
either	entweder	RB	KON		OK/0.992853
7	7	CD	CARD		OK/0.984991
,	,	,	$,		OK/0.991909
10	10	CD	CARD		OK/0.991981
,	,	,	$,		OK/0.992557
14	14	CD	CARD		OK/0.943953
or	oder	CC	KON		OK/0.998317
20	20	CD	CARD		OK/0.990989
tablets	Tabletten	NNS	NN		OK/0.997206
per	pro	IN	APPR		OK/0.984495
blister	Blisterpackung	NN	NN		OK/0.991018
(	(	(	$(		OK/0.992384
alu	Alu	NP	NE		OK/0.933915
/	/	SYM	$(		OK/0.987444
PP	PP	NP	VVFIN		OK/0.907720
)	)	)	$(		OK/0.972264
.	.	SENT	$.		OK/0.996126

# 0.581209
Otherwise	Andernfalls	RB	ADV		OK/0.912821
,	Andernfalls	,	ADV		OK/0.960277
the	__unaligned__	DT	__unaligned__		OK/0.980470
treatment	die	NN	ART		OK/0.979643
should	wiederaufzunehmen	MD	VVIZU		OK/0.959217
be	wiederaufzunehmen	VB	VVIZU		OK/0.859453
re-initiated	wiederaufzunehmen	VVN	VVIZU		OK/0.766830
with	mit	IN	APPR		OK/0.904500
4.6	4,6	CD	CARD		OK/0.936553
mg	mg	NN	NN		OK/0.940782
/	/	SYM	$(		OK/0.973957
24	24	CD	CARD		OK/0.980807
h	Stunden	NN	NN		OK/0.952830
.	.	SENT	$.		OK/0.999398

# 0.739901
Co-administration	gleichzeitige	NP	ADJA		OK/0.995028
of	gleichzeitige	IN	ADJA		OK/0.984091
APTIVUS	APTIVUS	NP	NE		OK/0.995409
/	/	SYM	$(		OK/0.998880
ritonavir	Ritonavir	NN	NE		OK/0.995012
and	und	CC	KON		OK/0.995439
oral	oralem	JJ	ADJA		OK/0.972839
midazolam	Midazolam	NN	NN		OK/0.974915
is	kontraindiziert	VBZ	ADJD		OK/0.905367
contraindicated	kontraindiziert	VVN	ADJD		OK/0.816260
(	(	(	$(		OK/0.998351
see	siehe	VV	VVIMP		OK/0.997161
section	Abschnitt	NN	NN		OK/0.987917
4.3	4.3	CD	CARD		OK/0.990370
)	)	)	$(		OK/0.999435
.	.	SENT	$.		OK/0.997513

# 0.082225
Women	Frauen	NP	NN		OK/0.999594
of	gebärfähigen	IN	ADJA		OK/0.999102
childbearing	gebärfähigen	NN	ADJA		OK/0.996237
potential	gebärfähigen	NN	ADJA		OK/0.971701
should	anzuraten	MD	VVIZU		OK/0.975237
be	__unaligned__	VB	__unaligned__		OK/0.958789
monitored	__unaligned__	VVN	__unaligned__		OK/0.914929
frequently	__unaligned__	RB	__unaligned__		OK/0.877992
,	,	,	$,		OK/0.846402
while	der	IN	ART		OK/0.513560
they	__unaligned__	PP	__unaligned__		OK/0.663528
are	Verhütung	VBP	NN		OK/0.733687
to	anzuwenden	TO	VVIZU		OK/0.763294
use	__unaligned__	VV	__unaligned__		OK/0.630839
effective	__unaligned__	JJ	__unaligned__		OK/0.615816
contraception	__unaligned__	NN	__unaligned__		OK/0.478502
during	während	IN	APPR		OK/0.908596
treatment	Behandlung	NN	NN		OK/0.973917
with	mit	IN	APPR		OK/0.989006
TMZ	TMZ	NP	NE		OK/0.929304
to	vermeiden	TO	VVINF		OK/0.978161
avoid	vermeiden	VV	VVINF		OK/0.944285
becoming	vermeiden	VVG	VVINF		OK/0.630486
pregnant	Schwangerschaft	JJ	NN		OK/0.475217
.	.	SENT	$.		OK/0.979222

# 0.934360
This	Der	DT	ART		OK/0.991756
vaccine	Impfstoff	NN	NN		OK/0.994734
can	kann	MD	VMFIN		OK/0.994095
be	kann	VB	VMFIN		OK/0.998644
given	gleichzeitig	VVN	ADJD		OK/0.994266
with	mit	IN	APPR		OK/0.998738
some	einigen	DT	PIAT		OK/0.971107
other	anderen	JJ	PIS		OK/0.994344
vaccines	Impfstoffen	NNS	NN		OK/0.987846
.	.	SENT	$.		OK/0.999398

# 0.407540
Absorption	Resorption	NP	NN		OK/0.588958
Following	Nach	VVG	APPR		OK/0.797257
subcutaneous	subkutaner	JJ	ADJA		OK/0.976430
administration	subkutaner	NN	ADJA		OK/0.991368
,	__unaligned__	,	__unaligned__		OK/0.997903
fondaparinux	Fondaparinux	NN	NE		OK/0.996360
is	vollständig	VBZ	ADJD		OK/0.957946
completely	vollständig	RB	ADJD		OK/0.911578
and	und	CC	KON		OK/0.973229
rapidly	schnell	RB	ADJD		OK/0.935675
absorbed	resorbiert	JJ	ADJD		OK/0.873197
(	(	(	$(		OK/0.984912
absolute	absolute	JJ	ADJA		OK/0.997397
bioavailability	Bioverfügbarkeit	NN	NN		OK/0.995200
of	__unaligned__	IN	__unaligned__		OK/0.986501
100	100	CD	CARD		OK/0.983649
%	%	NN	NN		OK/0.955069
)	)	)	$(		OK/0.970911
.	.	SENT	$.		OK/0.996990

# 0.457698
Pack	Packungen	NP	NN		OK/0.912435
sizes	Packungen	NNS	NN		OK/0.926693
of	Packungen	IN	NN		OK/0.949746
14	14	CD	CARD		OK/0.999036
,	,	,	$,		OK/0.998384
28	28	CD	CARD		OK/0.999576
,	,	,	$,		OK/0.999798
56	56	CD	CARD		OK/0.998742
,	,	,	$,		OK/0.997670
168	168	CD	CARD		OK/0.928998
modified-release	mit	NN	APPR		OK/0.923594
tablets	Tabletten	NNS	NN		OK/0.988083
and	und	CC	KON		OK/0.999015
32	32	CD	CARD		OK/0.997600
x	x	SYM	ADJA		OK/0.995898
1	1	CD	CARD		OK/0.988185
modified-release	mit	NN	APPR		OK/0.974421
tablets	Tabletten	NNS	NN		OK/0.985838
in	in	IN	APPR		OK/0.927288
perforated	zur	JJ	APPRART		OK/0.854427
unit	Einzeldosen	NN	NN		OK/0.909004
dose	__unaligned__	NN	__unaligned__		OK/0.853722
blisters	Blisterpackungen	NNS	NN		OK/0.721081
.	..	SENT	ADJA		OK/0.943735

# 0.750398
86	86	NP	CARD		OK/0.994108
Actraphane	Actraphane	NP	NN		OK/0.991961
is	ist	VBZ	VAFIN		OK/0.991743
a	Insulinmischung	DT	NN		OK/0.941843
dual-acting	Insulinmischung	JJ	NN		OK/0.841134
insulin	Insulinmischung	NN	NN		OK/0.805396
.	.	SENT	$.		OK/0.999308

# 0.171196
with	Stimulantien	IN	NN		OK/0.858984
the	__unaligned__	DT	__unaligned__		OK/0.851351
first	__unaligned__	JJ	__unaligned__		OK/0.649455
(	(	(	$(		OK/0.813233
Analeptika	Analeptika	NP	NN		OK/0.463495
)	)	)	$(		OK/0.718103
must	dürfen	MD	VMFIN		OK/0.428397
not	nicht	RB	PTKNEG		OK/0.901329
be	dürfen	VB	VMFIN		OK/0.943837
used	eingesetzt	VVN	VVPP		OK/0.891046
.	.	SENT	$.		OK/0.997259

# 0.396968
2	Weitere	CD	ADJA		OK/0.530503
/	Weitere	SYM	ADJA		OK/0.528885
3	Weitere	CD	ADJA		OK/0.544891
Other	Weitere	JJ	ADJA		OK/0.966669
information	Informationen	NN	NN		OK/0.999556
about	Informationen	IN	NN		OK/0.998205
NovoSeven	NovoSeven	NP	NN		OK/0.984351
:	:	:	$.		OK/0.996126

# 0.709873
The	Das	DT	ART		OK/0.997518
medicine	Arzneimittel	NN	NN		OK/0.991130
has	wurde	VHZ	VAFIN		OK/0.959280
been	wurde	VBN	VAFIN		OK/0.954014
developed	speziell	VVN	ADJD		OK/0.969445
especially	speziell	RB	ADJD		OK/0.995014
for	für	IN	APPR		OK/0.990767
cats	Katzen	NNS	NN		OK/0.984788
and	und	CC	KON		OK/0.995549
is	__unaligned__	VBZ	__unaligned__		OK/0.854875
not	nicht	RB	PTKNEG		OK/0.967896
used	angewendet	VVN	VVPP		OK/0.978359
for	angewendet	IN	VVPP		OK/0.991220
any	anderen	DT	PIS		OK/0.989070
other	anderen	JJ	PIS		OK/0.995773
animal	Tierarten	NN	NN		OK/0.985506
species	Tierarten	NNS	NN		OK/0.967549
.	.	SENT	$.		OK/0.999745

# 0.620738
The	Die	DT	ART		OK/0.996040
mean	Eliminationshalbwertszeit	JJ	NN		OK/0.964799
elimination	Eliminationshalbwertszeit	NN	NN		OK/0.993918
half-life	Eliminationshalbwertszeit	NN	NN		OK/0.989500
(	(	(	$(		OK/0.998474
t1	t1	NN	NE		OK/0.984930
/	/	SYM	$(		OK/0.998797
2	2	CD	CARD		OK/0.994632
)	)	)	$(		OK/0.962630
of	__unaligned__	IN	__unaligned__		OK/0.846623
tolcapone	Tolcapon	NN	NN		OK/0.825411
is	beträgt	VBZ	VVFIN		OK/0.785782
approximately	circa	RB	ADV		OK/0.803631
2	2	CD	CARD		OK/0.997860
hours	Stunden	NNS	NN		OK/0.996189
.	.	SENT	$.		OK/0.999703

# 0.707751
Truvada	Truvada	NP	NE		OK/0.981944
is	ist	VBZ	VAFIN		OK/0.996586
a	__unaligned__	DT	__unaligned__		OK/0.990932
medicine	Arzneimittel	NN	NN		OK/0.998321
containing	Arzneimittel	VVG	NN		OK/0.906922
two	zwei	CD	CARD		OK/0.997497
active	Wirkstoffen	JJ	NN		OK/0.996347
substances	Wirkstoffen	NNS	NN		OK/0.982692
,	,	,	$,		OK/0.946862
emtricitabine	Emtricitabin	NN	NE		OK/0.948891
(	(	(	$(		OK/0.990655
200	200	CD	CARD		OK/0.986942
mg	mg	NN	NN		OK/0.994515
)	)	)	$(		OK/0.982043
and	und	CC	KON		OK/0.999194
tenofovir	Tenofovir	NN	NN		OK/0.998043
disoproxil	Disoproxil	NN	NN		OK/0.952713
(	(	(	$(		OK/0.978738
245	245	CD	CARD		OK/0.996543
mg	mg	NN	NN		OK/0.998562
)	)	)	$(		OK/0.968192
.	.	SENT	$.		OK/0.997485

# 0.937780
VIRAMUNE	VIRAMUNE	NP	NN		OK/0.998318
is	ist	VBZ	VAFIN		OK/0.992253
a	ist	DT	VAFIN		OK/0.996462
medicine	Arzneimittel	NN	NN		OK/0.999789
that	Arzneimittel	WDT	NN		OK/0.993952
contains	enthält	VVZ	VVFIN		OK/0.997051
the	den	DT	ART		OK/0.995781
active	Wirkstoff	JJ	NN		OK/0.994233
substance	Wirkstoff	NN	NN		OK/0.985290
nevirapine	Nevirapin	NN	NE		OK/0.972241
.	.	SENT	$.		OK/0.999923

# 0.061121
One	Eine	CD	ART		OK/0.769303
limitations	Beschränkung	NNS	NN		OK/0.637009
regarding	hinsichtlich	VVG	APPR		OK/0.848526
food	Nahrungsaufnahme	NN	NN		OK/0.968826
intake	Nahrungsaufnahme	NN	NN		OK/0.982113
is	notwendig	VBZ	ADJD		OK/0.948453
necessary	notwendig	JJ	ADJD		OK/0.937669
,	,	,	$,		OK/0.995270
because	da	IN	ADV		OK/0.998992
it	__unaligned__	PP	__unaligned__		BAD/0.610425
has	__unaligned__	VHZ	__unaligned__		BAD/0.588442
been	__unaligned__	VBN	__unaligned__		OK/0.792254
established	__unaligned__	VVN	__unaligned__		OK/0.867614
that	dass	IN/that	KOUS		OK/0.984762
the	der	DT	ART		OK/0.988215
consumption	Verzehr	NN	NN		OK/0.585909
of	__unaligned__	IN	__unaligned__		OK/0.636644
food	Nahrungsmittel	NN	NN		OK/0.603477
on	auf	IN	APPR		OK/0.594377
the	das	DT	ART		OK/0.814808
pharmacokinetic	pharmakokinetische	JJ	ADJA		OK/0.975669
profile	pharmakokinetische	NN	ADJA		OK/0.967758
of	__unaligned__	IN	__unaligned__		OK/0.940651
perindopril	__unaligned__	NN	__unaligned__		OK/0.832853
.	.	SENT	$.		OK/0.997439

# 0.333600
The	Eine	DT	ART		OK/0.874179
total	Gesamttagesdosis	JJ	NN		OK/0.966756
daily	Gesamttagesdosis	JJ	NN		OK/0.992936
dose	Gesamttagesdosis	NN	NN		OK/0.981773
greater	über	JJR	APPR		OK/0.989767
than	über	IN	APPR		OK/0.947268
100	100	CD	CARD		OK/0.964406
mg	mg	NN	NN		OK/0.993001
/	/	SYM	$(		OK/0.996837
kg	kg	NN	NN		OK/0.990183
is	nicht	VBZ	PTKNEG		OK/0.656404
not	nicht	RB	PTKNEG		OK/0.877717
recommended	empfehlenswert	VVN	ADJD		OK/0.915906
due	aufgrund	JJ	APPR		OK/0.957379
to	aufgrund	TO	APPR		OK/0.975775
potentially	potenziell	RB	ADJD		OK/0.971553
increased	erhöhten	VVN	ADJA		OK/0.937760
risk	Gefahr	NN	NN		OK/0.907934
of	__unaligned__	IN	__unaligned__		OK/0.864535
adverse	Nebenwirkungen	JJ	NN		OK/0.866213
reactions	Nebenwirkungen	NNS	NN		OK/0.785560
.	.	SENT	$.		OK/0.999047

# 0.464068
Approximately	Etwa	RB	ADV		OK/0.991310
three	drei	CD	CARD		OK/0.977657
quarters	Viertel	NNS	NN		OK/0.979314
of	Viertel	IN	NN		OK/0.989402
whom	Viertel	WP	NN		OK/0.861210
received	erhielten	VVD	VVFIN		OK/0.882426
Yarvitan	Yarvitan	NP	ADJD		OK/0.897008
,	,	,	$,		OK/0.982869
while	während	IN	KOUS		OK/0.961258
the	die	DT	ART		OK/0.987919
Übrigen	Übrigen	NP	NN		OK/0.709562
the	__unaligned__	DT	__unaligned__		OK/0.962783
medicine	das	NN	ART		OK/0.964401
without	ohne	IN	APPR		OK/0.982169
the	den	DT	ART		OK/0.993926
active	Wirkstoff	JJ	NN		OK/0.996592
substance	Wirkstoff	NN	NN		OK/0.963025
(	(	(	$(		OK/0.998361
control	Kontrollgruppe	NN	NN		OK/0.996055
group	Kontrollgruppe	NN	NN		OK/0.968611
)	)	)	$(		OK/0.971061
.	.	SENT	$.		OK/0.995914

# 0.173406
The	Die	NP	ART		OK/0.977132
Plasmamelatoninspiegel	Plasmamelatoninspiegel	NP	NN		OK/0.795115
in	bei	IN	APPR		OK/0.966367
patients	Patienten	NNS	NN		OK/0.996325
with	mit	IN	APPR		OK/0.996922
cirrhosis	Leberzirrhose	NN	NN		OK/0.986180
of	__unaligned__	IN	__unaligned__		OK/0.951874
the	__unaligned__	DT	__unaligned__		OK/0.861931
liver	__unaligned__	NN	__unaligned__		OK/0.289146
were	waren	VBD	VAFIN		OK/0.531412
significantly	signifikant	RB	ADJD		OK/0.858991
increased	erhöht	VVN	VVPP		OK/0.879768
during	während	IN	APPR		OK/0.948122
the	Tages	DT	NN		OK/0.986139
day	Tages	NN	NN		OK/0.867097
.	.	SENT	$.		OK/0.993692

# 0.722583
19	19	CD	CARD		OK/0.983605
How	Handhabung	WRB	NN		OK/0.936782
to	Handhabung	TO	NN		OK/0.869337
handle	Handhabung	VV	NN		OK/0.907551
the	der	DT	ART		OK/0.994370
tablets	Tabletten	NNS	NN		OK/0.997570
Wear	Einmalhandschuhe	VV	NN		OK/0.982345
disposable	Einmalhandschuhe	JJ	NN		OK/0.967502
gloves	Einmalhandschuhe	NNS	NN		OK/0.984727
when	Einmalhandschuhe	WRB	NN		OK/0.977252
applying	Einmalhandschuhe	VVG	NN		OK/0.944360
the	Einmalhandschuhe	DT	NN		OK/0.983520
product	Einmalhandschuhe	NN	NN		OK/0.979509
.	.	SENT	$.		OK/0.999577

# 0.600761
The	Die	DT	ART		OK/0.954709
following	folgenden	VVG	ADJA		OK/0.996876
instructions	Anleitungen	NNS	NN		OK/0.995993
explain	erklären	VV	VVFIN		OK/0.981647
how	erklären	WRB	VVFIN		OK/0.991533
to	erklären	TO	VVFIN		OK/0.885757
use	verwenden	VV	VVINF		OK/0.773211
the	die	DT	ART		OK/0.952196
vials	Durchstechflaschen	NNS	NN		OK/0.914047
MIRCERA	MIRCERA	NN	NN		OK/0.873492
yourself	selbst	PP	ADV		OK/0.907824
.	.	SENT	$.		OK/0.996815

# 0.115587
When	vollständigem	WRB	ADJA		OK/0.722201
led	führte	VVN	VVFIN		OK/0.955602
to	__unaligned__	TO	__unaligned__		OK/0.978686
a	__unaligned__	DT	__unaligned__		OK/0.990024
decrease	Rückgang	NN	NN		OK/0.990060
in	Rückgang	IN	NN		OK/0.995641
symptoms	Symptome	NNS	NN		OK/0.979997
for	weitere	IN	ADJA		OK/0.882846
the	Behandlung	DT	NN		OK/0.965314
treatment	Behandlung	NN	NN		OK/0.993986
of	Behandlung	IN	NN		OK/0.990079
patients	Patienten	NNS	NN		OK/0.958668
with	Patienten	IN	NN		BAD/0.495086
rarely	selten	RB	ADJD		BAD/0.645319
exposed	erneuten	VVN	ADJA		BAD/0.897216
to	__unaligned__	TO	__unaligned__		OK/0.527113
the	__unaligned__	DT	__unaligned__		OK/0.877997
occurrence	Auftreten	NN	NN		OK/0.943571
of	Auftreten	IN	NN		OK/0.996144
severe	schweren	JJ	ADJA		OK/0.990028
cytokine	Zytokin-Freisetzungs-Syndroms	NN	NN		OK/0.990360
release	Zytokin-Freisetzungs-Syndroms	NN	NN		OK/0.982474
syndrome	Zytokin-Freisetzungs-Syndroms	NN	NN		OK/0.978925
.	.	SENT	$.		OK/0.999410

# 0.056759
In	In	IN	APPR		OK/0.672610
a	einer	DT	ART		OK/0.520439
taken	__unaligned__	VVN	__unaligned__		OK/0.333899
from	__unaligned__	IN	__unaligned__		OK/0.604956
a	__unaligned__	DT	__unaligned__		OK/0.713040
rising	Verträglichkeitsstudie	VVG	NN		OK/0.675554
dose	Verträglichkeitsstudie	NN	NN		OK/0.948735
tolerability	Verträglichkeitsstudie	NN	NN		OK/0.976931
study	Verträglichkeitsstudie	NN	NN		OK/0.972532
in	in	IN	APPR		OK/0.966528
a	begrenzten	DT	ADJA		OK/0.987097
limited	begrenzten	JJ	ADJA		OK/0.997374
number	Anzahl	NN	NN		OK/0.978969
of	Anzahl	IN	NN		OK/0.884890
subjects	Personen	NNS	NN		OK/0.420204
And	Einmalgaben	CC	NN		OK/0.449673
single	Einmalgaben	JJ	NN		OK/0.806462
doses	Einmalgaben	NNS	NN		OK/0.792079
of	__unaligned__	IN	__unaligned__		OK/0.872606
up	zu	IN	APPR		OK/0.986604
to	bis	TO	KON		OK/0.994267
300	300	CD	CARD		OK/0.984879
mg	mg	NN	NN		OK/0.977285
have	wurden	VHP	VAFIN		OK/0.878638
been	wurden	VBN	VAFIN		OK/0.964458
given	verabreicht	VVN	VVPP		OK/0.967509
only	nur	RB	ADV		OK/0.973452
mild	leichte	JJ	ADJA		OK/0.988338
symptoms	Symptome	NNS	NN		OK/0.987350
have	wurden	VHP	VAFIN		OK/0.990223
been	wurden	VBN	VAFIN		OK/0.976964
observed	beobachtet	VVN	VVPP		OK/0.968476
.	.	SENT	$.		OK/0.999173

# 0.042760
(	__unaligned__	(	__unaligned__		OK/0.869583
e.	B.	FW	NE		OK/0.880625
g.	B.	FW	NE		OK/0.922694
carbamazepine	Carbamazepin	NN	NE		OK/0.993411
,	Phenobarbital	,	NN		OK/0.975513
phenobarbital	Phenobarbital	NN	NN		OK/0.998534
,	Phenobarbital	,	NN		OK/0.989388
phenytoin	Phenytoin	NN	NN		OK/0.974859
and	und	CC	KON		OK/0.995158
St	Johanniskraut	NP	NN		OK/0.984247
John	Johanniskraut	NP	NN		OK/0.999584
's	Johanniskraut	POS	NN		OK/0.999150
wort	Johanniskraut	NN	NN		OK/0.997840
are	liegen	VBP	VVFIN		OK/0.931973
lacking	liegen	VVG	VVFIN		OK/0.958641
,	,	,	$,		OK/0.981352
but	aber	CC	ADV		OK/0.991665
their	ihrer	PP$	PPOSAT		OK/0.880114
concomitant	gleichzeitigen	JJ	ADJA		OK/0.818668
administration	gleichzeitigen	NN	ADJA		OK/0.662613
is	erwarten	VBZ	VVINF		BAD/0.735260
expected	erwarten	VVN	VVINF		BAD/0.709063
to	erwarten	TO	VVINF		BAD/0.863100
lead	__unaligned__	VV	__unaligned__		BAD/0.900279
to	__unaligned__	TO	__unaligned__		BAD/0.747850
reduced	reduzierte	VVN	ADJA		OK/0.609524
systemic	systemische	JJ	ADJA		OK/0.885481
exposure	Verfügbarkeit	NN	NN		BAD/0.764972
to	Verfügbarkeit	TO	NN		BAD/0.730320
bosentan	Bosentan	NN	NN		OK/0.802685
.	.	SENT	$.		OK/0.996705

# 0.442496
Do	dürfen	VVP	VMFIN		OK/0.964549
not	dürfen	RB	VMFIN		OK/0.975782
use	dürfen	VV	VMFIN		OK/0.983351
Plavix	Plavix	NP	NN		OK/0.844441
if	wenn	IN	KOUS		OK/0.992767
you	Sie	PP	PPER		OK/0.999603
notice	bemerken	VVP	VVINF		OK/0.997126
any	bemerken	DT	VVINF		OK/0.998953
visible	sichtbare	JJ	ADJA		OK/0.889565
sign	sichtbare	NN	ADJA		BAD/0.779287
of	sichtbare	IN	ADJA		BAD/0.771491
deterioration	sichtbare	NN	ADJA		BAD/0.737833
.	.	SENT	$.		OK/0.993390

# 0.812100
The	Die	DT	ART		OK/0.989083
syringe	Spritze	NN	NN		OK/0.994837
filled	__unaligned__	VVN	__unaligned__		OK/0.932676
with	__unaligned__	IN	__unaligned__		OK/0.995176
reconstituted	zubereitete	VVN	ADJA		OK/0.991121
solution	zubereitete	NN	ADJA		OK/0.984320
is	__unaligned__	VBZ	__unaligned__		OK/0.957644
to	__unaligned__	TO	__unaligned__		OK/0.981271
be	__unaligned__	VB	__unaligned__		OK/0.969933
used	verwendet	VVN	VVPP		OK/0.960164
as	sobald	RB	KOUS		OK/0.999288
soon	sobald	RB	KOUS		OK/0.996300
as	sobald	RB	KOUS		OK/0.992101
possible	möglich	JJ	ADJD		OK/0.996984
.	.	SENT	$.		OK/0.999786

# 0.137810
There	Es	RB	NN		OK/0.759074
have	wurden	VHP	VAFIN		OK/0.767407
been	wurden	VBN	VAFIN		OK/0.748255
no	keine	DT	PIAT		OK/0.998182
signs	Anzeichen	NNS	NN		OK/0.994456
of	Anzeichen	IN	NN		OK/0.992868
adverse	Arzneimittelwirkungen	JJ	NN		OK/0.988206
reactions	__unaligned__	NNS	__unaligned__		OK/0.983889
in	bei	IN	APPR		OK/0.989168
these	diesen	DT	PDAT		OK/0.818457
children	Kindern	NNS	NN		OK/0.480610
have	beobachtet	VHP	VVPP		OK/0.285087
been	beobachtet	VBN	VVPP		OK/0.371684
observed	beobachtet	VVN	VVPP		OK/0.558824
.	.	SENT	$.		OK/0.988888

# 0.784628
Precipitation	Ausfällung	NP	NN		OK/0.898189
,	,	,	$,		OK/0.973941
discoloration	Verfärbung	NN	NN		OK/0.902978
and	und	CC	KON		OK/0.996084
particles	Trübung	NNS	NN		OK/0.989744
or	Trübung	CC	NN		OK/0.988695
the	Trübung	DT	NN		OK/0.998460
solution	Trübung	NN	NN		OK/0.991899
is	Trübung	VBZ	NN		OK/0.994267
cloudy	Trübung	JJ	NN		OK/0.984717
.	.	SENT	$.		OK/0.999864

# 0.432700
An	Dort	DT	ADV		OK/0.853213
functioning	ist	NN	VAFIN		OK/0.864659
,	,	,	$,		OK/0.987115
what	__unaligned__	WP	__unaligned__		OK/0.958029
to	__unaligned__	TO	__unaligned__		OK/0.966178
do	tun	VV	VVINF		OK/0.913701
if	falls	IN	KOUS		OK/0.807259
any	auftritt	DT	VVFIN		OK/0.824180
of	Symptome	IN	NN		OK/0.814922
these	auftritt	DT	VVFIN		OK/0.727346
signs	Symptome	NNS	NN		OK/0.722335
.	.	SENT	$.		OK/0.997092

# 0.250393
31	31	CD	CARD		OK/0.985536
One	Eine	CD	ART		OK/0.817114
antiretroviral	antiretrovirale	JJ	ADJA		OK/0.819680
combination	Kombinationstherapie	NN	NN		OK/0.974518
therapy	Kombinationstherapie	NN	NN		OK/0.971416
(	(	(	$(		OK/0.992789
such	wie	JJ	KOKOM		OK/0.997289
as	wie	IN	KOKOM		OK/0.994903
Truvada	Truvada	NP	NE		OK/0.970654
)	)	)	$(		OK/0.997634
may	kann	MD	VMFIN		OK/0.991204
be	kann	VB	VMFIN		OK/0.906534
due	aufgrund	JJ	APPR		OK/0.898829
to	aufgrund	TO	APPR		OK/0.893206
changes	__unaligned__	NNS	__unaligned__		OK/0.775733
in	__unaligned__	IN	__unaligned__		OK/0.873629
the	__unaligned__	DT	__unaligned__		OK/0.982266
distribution	__unaligned__	NN	__unaligned__		OK/0.974679
of	des	IN	ART		OK/0.997180
body	Körperfetts	NN	NN		OK/0.984723
fat	Körperfetts	NN	NN		OK/0.994929
change	Körperproportionen	VV	NN		OK/0.948178
your	Ihrer	PP$	PPOSAT		OK/0.966024
body	Körperproportionen	NN	NN		OK/0.923495
shape	Körperproportionen	NN	NN		OK/0.752262
,	__unaligned__	,	__unaligned__		BAD/0.903690
is	__unaligned__	VBZ	__unaligned__		BAD/0.978519
distributed	__unaligned__	VVN	__unaligned__		BAD/0.895832
.	.	SENT	$.		OK/0.943083

# 0.240006
As	Entsprechend	IN	APPR		OK/0.578631
per	Entsprechend	IN	APPR		OK/0.736190
the	der	DT	ART		OK/0.998167
CHMP	CHMP	NP	ADJA		OK/0.995060
Guideline	Entsprechend	NP	APPR		OK/0.973523
on	Entsprechend	IN	APPR		OK/0.984430
Risk	Risikomanagementplan	NP	NN		OK/0.997019
Management	Risikomanagementplan	NP	NN		OK/0.996203
Systems	Risikomanagementplan	NPS	NN		OK/0.977069
for	für	IN	APPR		OK/0.969744
medicinal	Arzneimittel	JJ	NN		OK/0.952744
products	Arzneimittel	NNS	NN		OK/0.962504
for	Menschen	IN	NN		OK/0.985345
human	__unaligned__	JJ	__unaligned__		OK/0.987472
use	Anwendung	NN	NN		OK/0.998445
,	,	,	$,		OK/0.902957
the	die	DT	ART		OK/0.845085
updated	RMP	VVN	NN		OK/0.775089
RMP	RMP	NP	NN		OK/0.746121
should	sollen	MD	VMFIN		OK/0.962252
be	sollen	VB	VMFIN		OK/0.993765
submitted	__unaligned__	VVN	__unaligned__		OK/0.994982
at	gleichzeitig	IN	ADJD		OK/0.901280
same	__unaligned__	JJ	__unaligned__		OK/0.966184
time	__unaligned__	NN	__unaligned__		OK/0.984192
as	__unaligned__	IN	__unaligned__		OK/0.988543
the	nächsten	DT	ADJA		OK/0.996300
next	__unaligned__	JJ	__unaligned__		OK/0.946005
Periodic	PSUR	NP	NN		OK/0.949485
Safety	PSUR	NP	NN		OK/0.952570
Update	PSUR	NP	NN		OK/0.972891
Report	PSUR	NP	NN		OK/0.995380
(	(	(	$(		OK/0.991499
PSUR	PSUR	NP	NN		OK/0.994104
)	)	)	$(		OK/0.993391
.	.	SENT	$.		OK/0.998961

# 0.056947
In	In	IN	APPR		OK/0.969366
rare	seltenen	JJ	ADJA		OK/0.986168
cases	Fällen	NNS	NN		OK/0.992981
,	Fällen	,	NN		OK/0.972029
syncope	Synkope	NN	NN		OK/0.964527
(	(	(	$(		OK/0.998125
fainting	Ohnmacht	NN	NN		OK/0.975299
)	)	)	$(		OK/0.887744
have	beobachtet	VHP	VVPP		BAD/0.660289
been	beobachtet	VBN	VVPP		BAD/0.685614
observed	beobachtet	VVN	VVPP		BAD/0.651810
in	in	IN	APPR		OK/0.830073
association	Zusammenhang	NN	NN		OK/0.831771
with	mit	IN	APPR		OK/0.970580
orthostatic	orthostatischer	JJ	ADJA		OK/0.947102
hypotension	Hypotonie	NN	NN		OK/0.950832
(	(	(	$(		OK/0.996388
a	__unaligned__	DT	__unaligned__		OK/0.963852
fall	Blutdruckabfall	NN	NN		OK/0.948578
in	Blutdruckabfall	IN	NN		OK/0.990866
blood	Blutdruckabfall	NN	NN		OK/0.999052
pressure	Blutdruckabfall	NN	NN		OK/0.990042
after	nach	IN	APPR		OK/0.977098
passing	Aufrichten	VVG	NN		OK/0.752963
from	aus	IN	APPR		OK/0.942654
the	__unaligned__	DT	__unaligned__		OK/0.966795
sitting	sitzender	VVG	ADJA		BAD/0.902793
position	__unaligned__	NN	__unaligned__		BAD/0.889136
,	__unaligned__	,	__unaligned__		BAD/0.783533
or	oder	CC	KON		BAD/0.448071
respectively	liegender	RB	ADJA		BAD/0.643946
)	)	)	$(		OK/0.869017
.	.	SENT	$.		OK/0.991416

# 0.151449
Gradually	Die	RB	ART		OK/0.724467
,	__unaligned__	,	__unaligned__		OK/0.864291
the	und	DT	KON		OK/0.788022
bones	brüchig	NNS	ADJD		OK/0.869254
become	brüchig	VVP	ADJD		OK/0.916273
thin	brüchig	JJ	ADJD		OK/0.924818
and	und	CC	KON		OK/0.968583
fragile	brüchig	JJ	ADJD		OK/0.669258
,	,	,	$,		OK/0.710262
and	und	CC	KON		OK/0.727671
more	__unaligned__	RBR	__unaligned__		OK/0.708246
likely	es	JJ	PPER		OK/0.606544
to	__unaligned__	TO	__unaligned__		OK/0.755649
break	Brüche	VV	NN		OK/0.515573
(	(	(	$(		OK/0.756037
fractures	Frakturen	NNS	NN		OK/0.924694
)	)	)	$(		OK/0.951523
.	.	SENT	$.		OK/0.998443

# 0.075110
The	Die	DT	ART		OK/0.994895
matter	Angelegenheit	NN	NN		OK/0.905491
was	wurde	VBD	VAFIN		OK/0.875643
referred	Angelegenheit	VVN	NN		OK/0.840918
to	Angelegenheit	TO	NN		OK/0.746767
the	Angelegenheit	DT	NN		OK/0.567731
CMD	CMD	NP	NN		OK/0.357018
(	(	(	$(		OK/0.932856
h	h	NN	NN		OK/0.836282
)	)	)	$(		OK/0.957476
,	,	,	$,		OK/0.969230
and	und	CC	KON		OK/0.990167
the	der	DT	ART		OK/0.987259
RMS	RMS	NP	NE		OK/0.942120
resulted	führte	VVD	VVFIN		OK/0.957564
in	führte	IN	VVFIN		OK/0.909951
a	eine	DT	ART		BAD/0.458123
global	__unaligned__	JJ	__unaligned__		BAD/0.805782
assessment	Beurteilung	NN	NN		OK/0.873114
.	.	SENT	$.		OK/0.997875

# 0.816607
Daily	Tägliche	NP	ADJA		OK/0.977971
doses	Dosen	VVZ	NN		OK/0.994327
greater	über	JJR	APPR		OK/0.988337
than	über	IN	APPR		OK/0.954011
6	6	CD	CARD		OK/0.981368
mg	mg	NN	NN		OK/0.995987
of	__unaligned__	IN	__unaligned__		OK/0.999728
risperidone	Risperidon	NN	NE		OK/0.992399
have	wurden	VHP	VAFIN		OK/0.998560
not	nicht	RB	PTKNEG		OK/0.999642
been	wurden	VBN	VAFIN		OK/0.997366
studied	untersucht	VVN	VVPP		OK/0.994409
in	bei	IN	APPR		OK/0.990158
patients	Patienten	NNS	NN		OK/0.992984
with	mit	IN	APPR		OK/0.953085
manic	manischen	JJ	ADJA		OK/0.942916
episodes	Episoden	NNS	NN		OK/0.979552
.	.	SENT	$.		OK/0.999356

# 0.343989
A	Ein	DT	ART		OK/0.860627
similar	ähnlicher	JJ	ADJA		OK/0.825141
trend	Trend	NN	NN		OK/0.894058
was	wurde	VBD	VAFIN		OK/0.957216
also	auch	RB	ADV		OK/0.993741
observed	beobachtet	VVN	VVPP		OK/0.995350
in	bei	IN	APPR		OK/0.985250
the	den	DT	ART		OK/0.897221
Therapieabbruchraten	Therapieabbruchraten	NN	NN		BAD/0.559138
.	.	SENT	$.		OK/0.994124

# 0.530238
If	Falls	IN	KOUS		OK/0.994225
during	während	IN	APPR		OK/0.983202
treatment	Behandlung	NN	NN		OK/0.903979
,	__unaligned__	,	__unaligned__		OK/0.850118
an	Erhöhung	DT	NN		OK/0.989960
increase	Erhöhung	NN	NN		OK/0.999669
in	Erhöhung	IN	NN		OK/0.981991
ALT	ALT	NP	ADJA		OK/0.946542
and	und	NP	KON		OK/0.996848
/	/	SYM	$(		OK/0.997043
or	oder	CC	KON		OK/0.994522
AST	AST	NP	NE		OK/0.974718
,	,	,	$,		OK/0.975256
follow-	Nachuntersuchungen	NN	NN		OK/0.936350
up	Nachuntersuchungen	RB	NN		OK/0.932382
should	müssen	MD	VMFIN		OK/0.935304
be	müssen	VB	VMFIN		OK/0.935591
organised	Nachuntersuchungen	VVN	NN		OK/0.925218
and	und	CC	KON		OK/0.958439
dose	Dosisreduktion	NN	NN		OK/0.987358
reduction	Dosisreduktion	NN	NN		OK/0.985291
should	erwogen	MD	VVPP		OK/0.968151
be	erwogen	VB	VVPP		OK/0.976805
considered	erwogen	VVN	VVPP		OK/0.917040
.	.	SENT	$.		OK/0.996802

# 0.304902
status	Status	NN	NN		OK/0.974446
(	(	(	$(		OK/0.998191
WHO	WHO	WP	NE		OK/0.950763
PS	PS	NP	NE		OK/0.942470
=	=	SYM	$(		OK/0.983504
2	2	CD	CARD		OK/0.994203
,	__unaligned__	,	__unaligned__		OK/0.959879
n	=	NN	$(		OK/0.996508
=	=	SYM	$(		OK/0.994043
70	70	CD	CARD		OK/0.990101
)	)	)	$(		OK/0.986719
are	nicht	VBP	PTKNEG		OK/0.806536
not	nicht	RB	PTKNEG		OK/0.851608
consistent	konsistent	JJ	ADJD		OK/0.840168
,	,	,	$,		OK/0.969915
this	dieser	DT	PDAT		OK/0.961072
were	waren	VBD	VAFIN		OK/0.989234
overall	Gesamtüberleben	JJ	NN		OK/0.994004
survival	Gesamtüberleben	NN	NN		OK/0.996150
and	und	CC	KON		OK/0.998434
the	die	DT	ART		OK/0.990951
Progressionszeit	Progressionszeit	NP	NN		OK/0.621951
similar	ähnlich	JJ	ADJD		OK/0.675865
in	in	IN	APPR		OK/0.942484
both	beiden	DT	PIAT		OK/0.917364
arms	Armen	NNS	NN		OK/0.900816
.	.	SENT	$.		OK/0.997146

# 0.229509
You	Es	PP	PPER		OK/0.852609
may	kann	MD	VMFIN		OK/0.920523
need	__unaligned__	VV	__unaligned__		OK/0.950273
urgent	__unaligned__	JJ	__unaligned__		OK/0.943043
medical	ärztliche	JJ	ADJA		OK/0.915950
attention	__unaligned__	NN	__unaligned__		OK/0.907787
or	oder	CC	KON		OK/0.790644
or	Einweisung	JJ	NN		OK/0.722637
ho	Einweisung	NN	NN		BAD/0.589555
spitalisation	Einweisung	NN	NN		BAD/0.752302
.	.	SENT	$.		OK/0.989405

# 0.042884
When	Bei	WRB	APPR		OK/0.874233
treating	HIV-Infektion	VVG	NN		OK/0.892243
HIV	HIV-Infektion	NP	NN		OK/0.997548
infection	HIV-Infektion	NN	NN		OK/0.998271
,	__unaligned__	,	__unaligned__		OK/0.955498
it	es	PP	PPER		OK/0.758556
is	es	VBZ	PPER		OK/0.899532
not	nicht	RB	PTKNEG		OK/0.978043
always	immer	RB	ADV		OK/0.815310
possible	möglich	JJ	ADJD		OK/0.847274
to	__unaligned__	TO	__unaligned__		OK/0.857056
differentiate	__unaligned__	VV	__unaligned__		OK/0.835837
between	zwischen	IN	APPR		OK/0.843034
unwanted	unerwünschten	JJ	ADJA		OK/0.611426
effects	Wirkungen	NNS	NN		OK/0.702223
caused	__unaligned__	VVN	__unaligned__		OK/0.970727
by	__unaligned__	IN	__unaligned__		OK/0.956497
Zerit	Zerit	NP	NE		OK/0.937071
or	oder	CC	KON		OK/0.992176
those	solchen	DT	PIAT		OK/0.973699
with	von	IN	APPR		OK/0.957718
any	anderen	DT	PIS		OK/0.980737
other	anderen	JJ	PIS		OK/0.984577
medicines	Arzneimittel	NNS	NN		OK/0.985473
you	__unaligned__	PP	__unaligned__		OK/0.885261
may	__unaligned__	MD	__unaligned__		OK/0.795518
be	__unaligned__	VB	__unaligned__		OK/0.693499
taking	__unaligned__	VVG	__unaligned__		OK/0.397192
,	,	,	$,		OK/0.527841
or	oder	CC	KON		OK/0.457400
by	__unaligned__	IN	__unaligned__		OK/0.540737
the	der	DT	ART		OK/0.767577
complications	Komplikationen	NNS	NN		OK/0.748723
of	der	IN	ART		OK/0.808526
the	der	DT	ART		OK/0.746613
infection	Infektion	NN	NN		OK/0.845158
.	.	SENT	$.		OK/0.969741

# 0.123773
If	Wenn	IN	KOUS		OK/0.963636
Depending	wiederkehren	VVG	VVINF		BAD/0.945375
on	wiederkehren	IN	VVINF		BAD/0.898247
the	die	DT	ART		BAD/0.564012
response	__unaligned__	NN	__unaligned__		BAD/0.871377
of	__unaligned__	IN	__unaligned__		BAD/0.872760
your	__unaligned__	PP$	__unaligned__		BAD/0.931774
eczema	__unaligned__	NN	__unaligned__		BAD/0.955014
your	__unaligned__	PP$	__unaligned__		BAD/0.914679
doctor	__unaligned__	NN	__unaligned__		BAD/0.895147
will	__unaligned__	MD	__unaligned__		BAD/0.772057
decide	,	VV	$,		BAD/0.625073
treatment	Behandlung	NN	NN		OK/0.916791
with	mit	IN	APPR		OK/0.987256
Protopic	Protopic	JJ	NE		OK/0.992962
0.1	0,1	CD	CARD		OK/0.999239
%	%	NN	NN		OK/0.999545
twice	zweimal	RB	ADV		OK/0.995856
a	täglich	DT	ADJD		OK/0.999481
day	täglich	NN	ADJD		OK/0.954729
should	begonnen	MD	VVPP		OK/0.747808
be	begonnen	VB	VVPP		OK/0.722616
started	begonnen	VVN	VVPP		OK/0.568654
.	.	SENT	$.		OK/0.951995

# 0.465375
Very	Sehr	JJ	ADV		OK/0.993611
rare	selten	JJ	ADJD		OK/0.959977
Geistige	Geistige	NP	ADJA		OK/0.552485
restlessness	Unruhe	NN	NN		OK/0.884507
,	,	,	$,		OK/0.989342
decreased	Appetit	VVD	NN		OK/0.922035
appetite	Appetit	NN	NN		OK/0.965211
,	,	,	$,		OK/0.993714
weight	Gewichtsabnahme	NN	NN		OK/0.990059
loss	Gewichtsabnahme	NN	NN		OK/0.998566
,	,	,	$,		OK/0.996226
hives	Nesselsucht	NNS	NN		OK/0.945085
.	.	SENT	$.		OK/0.999512

# 0.811736
The	Der	NP	ART		OK/0.997665
Rapporteur	Berichterstatter	NP	NN		OK/0.954064
was	war	VBD	VAFIN		OK/0.959233
Dr	Dr.	NP	NN		OK/0.961599
Hudson	Hudson	NP	NE		OK/0.958512
and	und	CC	KON		OK/0.999431
Co-Rapporteur	Mitberichterstatter	NP	NN		OK/0.992832
was	war	VBD	VAFIN		OK/0.984376
Dr	Dr.	NP	NN		OK/0.968455
Ljungberg	Ljungberg	NP	NE		OK/0.933761
.	.	SENT	$.		OK/0.999671

# 0.177053
ge	er	NNS	PPER		OK/0.597892
specifically	__unaligned__	RB	__unaligned__		OK/0.768696
bound	an	VVN	APPR		OK/0.657613
to	__unaligned__	TO	__unaligned__		OK/0.808926
antithrombin	Antithrombin	NN	NN		OK/0.810159
protein	__unaligned__	NN	__unaligned__		OK/0.586982
binding	98,6	NN	CARD		OK/0.695698
(	(	(	$(		OK/0.943569
98.6	-97,0	CD	CARD		OK/0.959727
%	%	NN	NN		OK/0.997992
to	__unaligned__	TO	__unaligned__		OK/0.974404
97.0	-97,0	CD	CARD		OK/0.985504
%	%	NN	NN		OK/0.998778
in	in	IN	APPR		OK/0.994989
the	dem	DT	ART		OK/0.980308
concentration	Konzentrationsbereich	NN	NN		OK/0.991786
range	Konzentrationsbereich	NN	NN		OK/0.961752
from	__unaligned__	IN	__unaligned__		OK/0.807173
0.5	__unaligned__	CD	__unaligned__		OK/0.885697
to	__unaligned__	TO	__unaligned__		OK/0.908375
2	0,5-2	CD	CARD		OK/0.806901
mg	mg	NN	NN		OK/0.987342
/	/	SYM	$(		OK/0.998620
l	l	NN	NN		OK/0.997846
)	)	)	$(		OK/0.997192
.	.	SENT	$.		OK/0.998168

# 0.480657
Do	Nicht	VVP	PTKNEG		OK/0.993003
not	Nicht	RB	PTKNEG		OK/0.996249
use	anwenden	VV	VVINF		OK/0.999640
in	bei	IN	APPR		OK/0.998585
animals	Tieren	NNS	NN		OK/0.997449
suffering	Tieren	VVG	NN		OK/0.973018
from	gastrointestinalen	IN	ADJA		OK/0.937742
gastrointestinal	gastrointestinalen	JJ	ADJA		OK/0.963643
disorders	Störungen	NNS	NN		OK/0.994441
such	wie	JJ	KOKOM		OK/0.979732
as	wie	IN	KOKOM		OK/0.974065
irritation	Irritationen	NN	NN		OK/0.977414
and	oder	CC	KON		OK/0.919699
haemorrhage	Hämorrhagien	NN	NN		OK/0.997089
,	Hämorrhagien	,	NN		OK/0.993382
impaired	Hämorrhagien	VVN	NN		OK/0.983907
hepatic	Hämorrhagien	JJ	NN		OK/0.993779
,	Hämorrhagien	,	NN		OK/0.992494
cardiac	Hämorrhagien	JJ	NN		OK/0.977627
or	oder	CC	KON		OK/0.981516
renal	Funktionsstörungen	JJ	NN		OK/0.887125
function	Funktionsstörungen	NN	NN		OK/0.800766
and	Funktionsstörungen	CC	NN		OK/0.719395
haemorrhagic	Funktionsstörungen	JJ	NN		OK/0.756076
disorders	Funktionsstörungen	NNS	NN		OK/0.963822
.	.	SENT	$.		OK/0.998918

# 0.029969
ADROVANCE	ADROVANCE	NP	NN		OK/0.993848
70	70	CD	CARD		OK/0.991712
mg	mg	NN	NN		OK/0.997507
/	/	SYM	$(		OK/0.999011
5600	5.600	CD	CARD		OK/0.997095
IU	I.E.	NP	NE		OK/0.989343
tablets	Tabletten	NNS	NN		OK/0.939151
are	__unaligned__	VBP	__unaligned__		OK/0.362008
available	erhältlich	JJ	ADJD		OK/0.709760
as	erhältlich	IN	ADJD		OK/0.894752
rechteckartige	rechteckartige	NN	ADJA		OK/0.880992
,	,	,	$,		OK/0.909310
white	weiße	JJ	ADJA		OK/0.957691
to	bis	TO	KON		OK/0.967214
off-white	gebrochen	NN	VVPP		OK/0.919443
tablets	Tabletten	NNS	NN		OK/0.990762
marked	Umriss	VVN	NN		OK/0.949360
with	__unaligned__	IN	__unaligned__		OK/0.922833
an	__unaligned__	DT	__unaligned__		OK/0.804462
outline	__unaligned__	NN	__unaligned__		OK/0.666850
of	__unaligned__	IN	__unaligned__		OK/0.623734
a	__unaligned__	DT	__unaligned__		OK/0.645771
bone	__unaligned__	NN	__unaligned__		OK/0.697218
image	__unaligned__	NN	__unaligned__		OK/0.646231
on	Seite	IN	NN		OK/0.850320
one	Seite	CD	NN		OK/0.986490
side	Seite	NN	NN		OK/0.996782
and	und	CC	KON		OK/0.999595
"	"	``	$(		OK/0.991168
270	270	CD	CARD		OK/0.790081
'	"	''	$(		BAD/0.714604
on	auf	IN	APPR		BAD/0.525852
the	auf	DT	APPR		OK/0.871844
other	anderen	JJ	PIAT		OK/0.921384
.	.	SENT	$.		OK/0.998467

# 0.203910
in	Blisterpackungen	IN	NN		BAD/0.641765
kalt-gepresstem	kalt-gepresstem	NN	ADJA		BAD/0.786263
aluminium	Aluminium	NN	NN		BAD/0.572363
blisters	__unaligned__	NNS	__unaligned__		BAD/0.487792
in	Faltschachteln	IN	NN		BAD/0.649708
cartons	Faltschachteln	NNS	NN		BAD/0.638645
of	__unaligned__	IN	__unaligned__		BAD/0.588591
28	28	CD	CARD		OK/0.955530
or	oder	CC	KON		OK/0.998947
56	56	CD	CARD		OK/0.989128
tablets	Tabletten	NNS	NN		OK/0.996914
per	pro	IN	APPR		OK/0.995302
carton	Packung	NN	NN		OK/0.892071
.	.	SENT	$.		OK/0.999145

# 0.542695
Patients	Patienten	NPS	NN		OK/0.982167
should	sollten	MD	VMFIN		OK/0.997216
be	engmaschig	VB	ADJD		OK/0.996702
closely	engmaschig	RB	ADJD		OK/0.997098
monitored	überwacht	VVN	VVPP		OK/0.998660
to	gewährleistet	TO	VVPP		OK/0.978238
make	gewährleistet	VV	VVPP		OK/0.958058
sure	gewährleistet	JJ	VVPP		OK/0.995053
that	dass	IN/that	KOUS		OK/0.995894
NeoRecormon	NeoRecormon	NP	NN		OK/0.960351
in	in	IN	APPR		OK/0.950677
the	in	DT	APPR		OK/0.984836
lowest	niedrigst	JJS	ADJD		OK/0.945686
used	angewendet	VVN	VVPP		OK/0.889320
to	,	TO	$,		OK/0.942074
provide	adäquate	VV	ADJA		OK/0.978796
adequate	adäquate	JJ	ADJA		OK/0.987593
control	Kontrolle	NN	NN		OK/0.975057
of	Kontrolle	IN	NN		OK/0.886308
the	der	DT	ART		OK/0.988427
symptoms	Symptome	NNS	NN		OK/0.997032
of	der	IN	ART		OK/0.982911
anaemia	Anämie	NN	NN		OK/0.844611
.	.	SENT	$.		OK/0.998173

# 0.619514
100	__unaligned__	NP	__unaligned__		OK/0.957270
IU	__unaligned__	NP	__unaligned__		OK/0.977205
(	(	(	$(		OK/0.999643
International	Internationale	NP	ADJA		OK/0.993297
Units	Internationale	NP	ADJA		OK/0.986847
)	)	)	$(		OK/0.929925
.	.	SENT	$.		OK/0.970180
You	Bitte	PP	ADV		OK/0.961328
should	__unaligned__	MD	__unaligned__		OK/0.922635
use	__unaligned__	VV	__unaligned__		OK/0.891584
one	__unaligned__	CD	__unaligned__		OK/0.934168
of	__unaligned__	IN	__unaligned__		OK/0.947010
the	__unaligned__	DT	__unaligned__		OK/0.984201
6	6	CD	CARD		OK/0.984367
administration	FSH-Einheiten	NN	NN		OK/0.978395
syringes	FSH-Einheiten	NNS	NN		OK/0.981286
graduated	skaliert	VVN	VVPP		OK/0.957252
in	FSH-Einheiten	IN	NN		OK/0.986600
FSH	FSH-Einheiten	NP	NN		OK/0.983217
units	FSH-Einheiten	NNS	NN		OK/0.973183
provided	FSH-Einheiten	VVD	NN		OK/0.957556
.	.	SENT	$.		OK/0.998829

# 0.855983
It	Außerdem	PP	ADV		OK/0.946211
was	wurde	VBD	VAFIN		OK/0.969345
also	Außerdem	RB	ADV		OK/0.991429
shown	gezeigt	VVN	VVPP		OK/0.998437
that	dass	IN/that	KOUS		OK/0.992763
IntronA	IntronA	NP	NE		OK/0.976282
in	bei	IN	APPR		OK/0.987672
children	Kindern	NNS	NN		OK/0.999969
with	mit	IN	APPR		OK/0.994929
chronic	chronischer	JJ	ADJA		OK/0.998323
hepatitis	Hepatitis	NN	NN		OK/0.999923
B	Hepatitis	NN	NN		OK/0.976433
of	von	IN	APPR		OK/0.983742
benefit	Nutzen	NN	NN		OK/0.992302
.	.	SENT	$.		OK/0.999404

# 0.470897
The	In	DT	APPR		OK/0.877974
120	120	CD	CARD		OK/0.959855
mg	mg-Filmtabletten	NN	NN		OK/0.992524
film-coated	mg-Filmtabletten	NN	NN		OK/0.963503
tablets	mg-Filmtabletten	NNS	NN		OK/0.987374
are	mg-Filmtabletten	VBP	NN		OK/0.945231
marked	mg-Filmtabletten	VVN	NN		OK/0.960504
on	eingeprägt	IN	VVPP		OK/0.944848
one	__unaligned__	CD	__unaligned__		OK/0.945703
side	__unaligned__	NN	__unaligned__		OK/0.889553
with	__unaligned__	IN	__unaligned__		OK/0.815785
"	"	``	$(		OK/0.968401
120	120	CD	CARD		OK/0.947365
'	"	''	$(		OK/0.782486
.	.	SENT	$.		OK/0.910673

# 0.171634
Marketing	Pharmazeutischer	NP	NN		OK/0.996360
Authorisation	Unternehmer	NP	NN		OK/0.996696
Holder	Unternehmer	NP	NN		OK/0.994142
Eli	Eli	NP	NE		OK/0.995132
Lilly	Lilly	NP	NE		OK/0.994300
Nederland	Nederland	NP	NE		OK/0.876759
BV	BV	NP	NE		OK/0.850000
,	Grootslag	,	NN		OK/0.880969
Grootslag	Grootslag	NP	NN		OK/0.869101
1-5	Grootslag	CD	NN		OK/0.893615
,	Grootslag	,	NN		OK/0.919030
NL-3991	NL-3991	NP	NN		OK/0.848388
RA	RA	NP	NE		OK/0.834405
Houten	Houten	NP	NE		BAD/0.476515
,	__unaligned__	,	__unaligned__		BAD/0.697379
The	Niederlande	DT	NE		BAD/0.659369
Netherlands	Niederlande	NPS	NE		BAD/0.683767
.	.	SENT	$.		OK/0.997414

# 0.544422
The	Die	DT	ART		OK/0.995573
plasma	Plasma-Clearance	NN	NN		OK/0.995204
clearance	Plasma-Clearance	NN	NN		OK/0.995904
of	__unaligned__	IN	__unaligned__		OK/0.983252
montelukast	Montelukast	NNS	NN		OK/0.987023
in	bei	IN	APPR		OK/0.945137
healthy	gesunden	JJ	ADJA		OK/0.888100
adults	Erwachsenen	NNS	NN		OK/0.887499
,	__unaligned__	,	__unaligned__		OK/0.631927
a	__unaligned__	DT	__unaligned__		OK/0.897287
mean	im	NN	APPRART		OK/0.959577
of	__unaligned__	IN	__unaligned__		OK/0.974525
45	45	CD	CARD		OK/0.994175
ml	ml	NN	NN		OK/0.998450
/	/	SYM	$(		OK/0.999050
min	min	NP	VVFIN		OK/0.990261
.	.	SENT	$.		OK/0.999609

# 0.388706
A	Eine	DT	ART		OK/0.981055
small	geringe	JJ	ADJA		OK/0.964203
increase	Zunahme	NN	NN		OK/0.996251
in	Zunahme	IN	NN		OK/0.966167
the	__unaligned__	DT	__unaligned__		OK/0.927975
percentile	Abweichung	NN	NN		OK/0.746046
0	0	CD	CARD		OK/0.841883
or	oder	CC	KON		OK/0.818495
trace	Spuren	VV	NN		OK/0.610591
to	auf	TO	PTKVZ		OK/0.777336
+	+	SYM	KON		OK/0.989811
has	wurde	VHZ	VAFIN		OK/0.977122
been	wurde	VBN	VAFIN		OK/0.950680
observed	beobachtet	VVN	VVPP		OK/0.948325
in	bei	IN	APPR		OK/0.972714
the	__unaligned__	DT	__unaligned__		OK/0.978122
20	20	CD	CARD		OK/0.982836
mg	mg	NN	NN		OK/0.991582
dose	Dosis	NN	NN		OK/0.990495
.	.	SENT	$.		OK/0.999803

# 0.074966
If	el	IN	NE		BAD/0.998456
,	jedem	,	PIAT		BAD/0.960567
due	Wegen	JJ	APPR		OK/0.936699
to	Wegen	TO	APPR		OK/0.963864
the	Wegen	DT	APPR		OK/0.868553
individual	individueller	JJ	ADJA		OK/0.853080
Schwankungsmöglichkeiten	Schwankungsmöglichkeiten	NN	NN		BAD/0.997001
must	muss	MD	VMFIN		BAD/0.865011
be	muss	VB	VMFIN		BAD/0.868352
used	__unaligned__	VVN	__unaligned__		BAD/0.965565
to	Einstellung	TO	NN		BAD/0.764974
obtain	__unaligned__	VV	__unaligned__		BAD/0.859287
the	__unaligned__	DT	__unaligned__		OK/0.741305
optimum	optimalen	JJ	ADJA		OK/0.388506
therapeutic	therapeutischen	JJ	ADJA		OK/0.631993
dose	Dosis	NN	NN		OK/0.727395
in	bei	IN	APPR		OK/0.523499
patients	Patienten	NNS	NN		OK/0.393359
.	.	SENT	$.		OK/0.997073

# 0.918700
Important	Wichtige	JJ	ADJA		OK/0.996095
information	Informationen	NN	NN		OK/0.999674
about	Wichtige	IN	ADJA		OK/0.997799
some	bestimmte	DT	ADJA		OK/0.966287
of	Bestandteile	IN	NN		OK/0.970811
the	Bestandteile	DT	NN		OK/0.975046
ingredients	Bestandteile	NNS	NN		OK/0.997292
of	Bestandteile	IN	NN		OK/0.996199
Aprovel	Aprovel	NP	NN		OK/0.995129
:	:	:	$.		OK/0.998934
Aprovel	Aprovel	NP	NN		OK/0.999575
contains	enthält	VVZ	VVFIN		OK/0.999537
lactose	Lactose	NN	NN		OK/0.997524
.	.	SENT	$.		OK/0.999912

# 0.203733
In	Beim	IN	APPRART		OK/0.869568
the	primären	DT	ADJA		OK/0.998586
primary	primären	JJ	ADJA		OK/0.996839
and	und	CC	KON		OK/0.995988
secondary	sekundären	JJ	ADJA		OK/0.979000
hyperparathyroidism	Hyperparathyreoidismus	NN	NN		BAD/0.577430
the	__unaligned__	DT	__unaligned__		BAD/0.624780
parathyroid	Nebenschilddrüsen	JJ	NN		BAD/0.718431
glands	Nebenschilddrüsen	NNS	NN		BAD/0.768560
produce	produzieren	VVP	VVFIN		OK/0.666223
too	viel	RB	PIAT		OK/0.884983
much	viel	JJ	PIAT		OK/0.941568
PTH	PTH	NP	NN		OK/0.885868
.	.	SENT	$.		OK/0.998356

# 0.995130
How	Wie	NP	KOKOM		OK/0.998601
is	wird	VBZ	VAFIN		OK/0.998890
Omnitrope	Omnitrope	NP	NN		OK/0.999471
used	angewendet	VVD	VVPP		OK/0.998343
?	?	SENT	$.		OK/0.999696

# 0.287756
Activelle	Activelle	NP	NN		OK/0.793905
film-	Filmtabletten	NP	NN		OK/0.610064
coated	Filmtabletten	JJ	NN		OK/0.592565
tablets	Filmtabletten	NNS	NN		OK/0.984326
can	können	MD	VMFIN		OK/0.949039
be	können	VB	VMFIN		OK/0.950430
taken	__unaligned__	VVN	__unaligned__		OK/0.890148
with	Nahrungsmitteln	IN	NN		OK/0.972280
food	Nahrungsmitteln	NN	NN		OK/0.964295
and	und	CC	KON		OK/0.942685
drink	Getränken	NN	NN		OK/0.878127
,	,	,	$,		OK/0.952066
but	aber	CC	KON		OK/0.969685
also	auch	RB	ADV		OK/0.926173
be	__unaligned__	VB	__unaligned__		OK/0.930980
taken	eingenommen	VVN	VVPP		OK/0.972624
orally	eingenommen	RB	VVPP		OK/0.988482
with	Mahlzeiten	IN	NN		OK/0.996790
or	Mahlzeiten	CC	NN		OK/0.995266
without	Mahlzeiten	IN	NN		OK/0.885107
food	Mahlzeiten	NN	NN		OK/0.909092
.	.	SENT	$.		OK/0.997517

# 0.759729
Taking	Einnahme	VVG	NN		OK/0.837774
Invirase	Invirase	NN	NN		OK/0.972407
with	mit	IN	APPR		OK/0.996361
other	anderen	JJ	PIS		OK/0.996239
medicines	Arzneimitteln	NNS	NN		OK/0.994496
Please	Bitte	RB	ADV		OK/0.999730
tell	informieren	VVP	VVFIN		OK/0.999556
your	Arzt	PP$	NN		OK/0.999757
doctor	Ihren	NN	PPOSAT		OK/0.999884
or	Apotheker	CC	NN		OK/0.999476
pharmacist	Apotheker	NN	NN		OK/0.999651
if	wenn	IN	KOUS		OK/0.999685
you	Sie	PP	PPER		OK/0.996016
are	einnehmen	VBP	VVINF		OK/0.981041
taking	__unaligned__	VVG	__unaligned__		OK/0.986806
or	__unaligned__	CC	__unaligned__		OK/0.991314
have	kurzem	VHP	ADJA		OK/0.989017
recently	kurzem	RB	ADJA		OK/0.999810
taken	kurzem	VVN	ADJA		OK/0.999663
any	kurzem	DT	ADJA		OK/0.994878
other	kurzem	JJ	ADJA		OK/0.998199
medicines	haben	NNS	VAFIN		OK/0.998613
,	,	,	$,		OK/0.996250
even	auch	RB	ADV		OK/0.983323
those	__unaligned__	DT	__unaligned__		OK/0.994400
not	nicht	RB	PTKNEG		OK/0.998201
prescribed	verschreibungspflichtige	VVN	ADJA		OK/0.997413
.	.	SENT	$.		OK/0.999577

# 0.888438
immunosuppressive	immunsuppressiven	JJ	ADJA		OK/0.985498
therapy	Therapie	NN	NN		OK/0.978167
following	nach	VVG	APPR		OK/0.965547
organ	Organtransplantation	NN	NN		OK/0.945733
transplantation	Organtransplantation	NN	NN		OK/0.948946
.	.	SENT	$.		OK/0.998810

# 0.968222
Each	Jede	DT	PIAT		OK/0.998901
bottle	Flasche	NN	NN		OK/0.998033
contains	enthält	VVZ	VVFIN		OK/0.992871
250	250	CD	CARD		OK/0.981570
capsules	Kapseln	NNS	NN		OK/0.994726
.	.	SENT	$.		OK/0.996193

# 0.719784
A	Ein	DT	ART		OK/0.977563
specific	spezifisches	JJ	ADJA		OK/0.980561
antidote	Antidot	NN	NN		OK/0.971569
antagonising	spezifisches	VVG	ADJA		OK/0.941428
tacrolimus	Tacrolimus	NN	NN		OK/0.992376
is	ist	VBZ	VAFIN		OK/0.956235
not	nicht	RB	PTKNEG		OK/0.821989
available	verfügbar	JJ	ADJD		OK/0.883851
.	.	SENT	$.		OK/0.998941

# 0.278473
Sonata	Sonata	NP	NN		OK/0.794743
is	angezeigt	VBZ	VVPP		OK/0.786637
indicated	angezeigt	VVN	VVPP		OK/0.736535
for	angezeigt	IN	VVPP		OK/0.988902
the	Behandlung	DT	NN		OK/0.994609
treatment	Behandlung	NN	NN		OK/0.996623
of	Behandlung	IN	NN		OK/0.997095
patients	Patienten	NNS	NN		OK/0.993781
with	mit	IN	APPR		OK/0.946413
smell	Schwierigkeit	NN	NN		OK/0.527232
insomnia	Schlaflosigkeit	NN	NN		OK/0.810970
who	die	WP	ART		OK/0.938095
have	haben	VHP	VAINF		OK/0.957659
einzuschlafen	einzuschlafen	NN	VVIZU		OK/0.827908
.	.	SENT	$.		OK/0.998362

# 0.945112
Dynepo	Dynepo	NP	NN		OK/0.992779
1,000	1.000	NP	CARD		OK/0.999610
IU	IE	NP	NN		OK/0.999942
/	/	SYM	$(		OK/0.997896
0.5	0,5	CD	CARD		OK/0.997036
ml	ml	NN	NN		OK/0.998786
solution	Injektionslösung	NN	NN		OK/0.996786
for	Injektionslösung	IN	NN		OK/0.981328
injection	Injektionslösung	NN	NN		OK/0.985946
in	in	IN	APPR		OK/0.996749
a	in	DT	APPR		OK/0.998848
pre-filled	Fertigspritze	JJ	NN		OK/0.992894
syringe	Fertigspritze	NN	NN		OK/0.997152
.	.	SENT	$.		OK/0.999613

# 0.227791
Thereafter	In	RB	APPR		OK/0.518036
,	__unaligned__	,	__unaligned__		OK/0.642500
it	__unaligned__	PP	__unaligned__		OK/0.758481
can	kann	MD	VMFIN		OK/0.891304
cause	kann	VV	VMFIN		OK/0.790487
joint	Gelenkschäden	JJ	NN		OK/0.951569
damage	Gelenkschäden	NN	NN		OK/0.954643
may	kommen	MD	VVINF		OK/0.610188
occur	kommen	VV	VVINF		OK/0.649400
.	.	SENT	$.		OK/0.989913

# 0.486053
The	Die	DT	ART		OK/0.997878
concomitant	gleichzeitige	JJ	ADJA		OK/0.991622
use	gleichzeitige	NN	ADJA		OK/0.995811
of	gleichzeitige	IN	ADJA		OK/0.997951
loop	Schleifendiuretika	NN	NN		OK/0.978429
diuretics	Schleifendiuretika	NNS	NN		OK/0.965531
(	(	(	$(		OK/0.999315
e.	z.B.	FW	ADV		OK/0.954529
g	z.B.	NN	ADV		OK/0.938517
.	z.B.	SENT	ADV		OK/0.970670
,	__unaligned__	,	__unaligned__		OK/0.948768
furosemide	Furosemid	NN	NN		OK/0.844748
)	)	)	$(		OK/0.948391
may	kann	MD	VMFIN		OK/0.980757
decrease	vermindern	VV	VVINF		OK/0.950263
the	Wirkung	DT	NN		OK/0.978185
effect	Wirkung	NN	NN		OK/0.995205
of	__unaligned__	IN	__unaligned__		OK/0.895273
the	__unaligned__	DT	__unaligned__		OK/0.931152
diuretic	Diuretikums	NN	NN		OK/0.766840
.	.	SENT	$.		OK/0.996188

# 0.105952
No	keine	DT	PIAT		OK/0.996344
pharmacokinetic	pharmakokinetischen	JJ	ADJA		OK/0.990008
interaction	Interaktionsstudien	NN	NN		OK/0.979617
studies	Interaktionsstudien	NNS	NN		OK/0.936718
have	Interaktionsstudien	VHP	NN		OK/0.714290
been	Interaktionsstudien	VBN	NN		OK/0.821952
performed	Interaktionsstudien	VVN	NN		OK/0.941978
with	Mit	IN	APPR		OK/0.955366
Velmetia	Velmetia	NP	NE		OK/0.974303
;	;	:	$.		OK/0.987155
however	allerdings	RB	ADV		OK/0.835286
,	allerdings	,	ADV		OK/0.917653
such	solche	JJ	PIAT		OK/0.930018
studies	Studien	NNS	NN		OK/0.987827
have	__unaligned__	VHP	__unaligned__		BAD/0.651968
been	__unaligned__	VBN	__unaligned__		BAD/0.613524
conducted	__unaligned__	VVN	__unaligned__		BAD/0.572469
with	einzelnen	IN	ADJA		BAD/0.541046
the	die	DT	ART		OK/0.752759
individual	einzelnen	JJ	ADJA		OK/0.802077
active	Wirkstoffe	JJ	NN		OK/0.913205
substances	Wirkstoffe	NNS	NN		OK/0.973192
of	einzelnen	IN	ADJA		OK/0.992267
Velmetia	Velmetia	NP	NE		OK/0.994278
,	,	,	$,		OK/0.997153
sitagliptin	Sitagliptin	NN	NE		OK/0.994412
and	und	CC	KON		OK/0.994719
metformin	Metformin	NN	NE		OK/0.996009
.	.	SENT	$.		OK/0.999591

# 0.255430
These	Diese	DT	PDS		OK/0.882324
be	werden	VB	VAFIN		OK/0.673581
the	die	DT	ART		OK/0.930644
batch	herzustellen	NN	VVIZU		OK/0.733519
of	__unaligned__	IN	__unaligned__		OK/0.882364
the	__unaligned__	DT	__unaligned__		OK/0.997250
solution	Injektionslösung	NN	NN		OK/0.993381
for	Injektionslösung	IN	NN		OK/0.992828
injection	Injektionslösung	NN	NN		OK/0.997861
,	,	,	$,		OK/0.994484
you	Sie	PP	PPER		OK/0.898278
are	Sie	VBP	PPER		OK/0.674706
going	injizieren	VVG	VVINF		OK/0.647888
to	injizieren	TO	VVINF		OK/0.660098
inject	injizieren	VV	VVINF		OK/0.761477
.	.	SENT	$.		OK/0.999274

# 0.603310
Therefore	Daher	RB	PAV		OK/0.996527
,	Daher	,	PAV		OK/0.996509
the	die	DT	ART		OK/0.996815
use	Anwendung	NN	NN		OK/0.999219
of	die	IN	ART		OK/0.999681
voriconazole	Voriconazol	NN	NN		OK/0.993227
may	kann	MD	VMFIN		OK/0.978752
result	zu	VV	APPR		OK/0.898481
in	__unaligned__	IN	__unaligned__		OK/0.988989
an	Erhöhung	DT	NN		OK/0.969407
increase	Erhöhung	NN	NN		OK/0.997510
of	der	IN	ART		OK/0.958221
plasma	Plasmakonzentrationen	NN	NN		OK/0.900715
levels	Plasmakonzentrationen	NNS	NN		OK/0.962085
of	der	IN	ART		OK/0.946962
substances	Substanzen	NNS	NN		OK/0.996789
metabolised	metabolisiert	VVN	ADJD		OK/0.964689
by	durch	IN	APPR		OK/0.991397
CYP450	CYP450-Isoenzyme	NP	NN		OK/0.947998
isoenzymes	CYP450-Isoenzyme	NNS	NN		OK/0.866630
.	.	SENT	$.		OK/0.994819

# 0.689646
When	Wird	WRB	VAFIN		OK/0.966938
diltiazem	Diltiazem	NN	NN		OK/0.992558
,	,	,	$,		OK/0.950301
sirolimus	Sirolimus-	NNS	TRUNC		OK/0.873015
should	sollten	MD	VMFIN		OK/0.986630
be	sollten	VB	VMFIN		OK/0.996857
monitored	überwacht	VVN	VVPP		OK/0.998757
for	überwacht	IN	VVPP		OK/0.991121
dose	Dosisanpassung	NN	NN		OK/0.964041
adjustment	Dosisanpassung	NN	NN		OK/0.923299
may	evtl.	MD	NE		OK/0.903973
be	notwendig	VB	ADJD		OK/0.955526
necessary	notwendig	JJ	ADJD		OK/0.954587
.	.	SENT	$.		OK/0.998710

# 0.714251
The	Die	DT	ART		OK/0.985849
median	Die	JJ	ART		OK/0.959756
number	Zahl	NN	NN		OK/0.955846
of	Zahl	IN	NN		OK/0.988860
exposure	Expositionstage	NN	NN		OK/0.998345
days	Expositionstage	NNS	NN		OK/0.992305
)	zum	)	APPRART		OK/0.910005
for	__unaligned__	IN	__unaligned__		OK/0.960179
a	__unaligned__	DT	__unaligned__		OK/0.984302
median	Median	NN	NN		OK/0.952722
of	__unaligned__	IN	__unaligned__		OK/0.963172
9	9	CD	CARD		OK/0.995081
days	Tage	NNS	NN		OK/0.970119
(	(	(	$(		OK/0.988804
range	3	NN	CARD		OK/0.994585
3	3	CD	CARD		OK/0.992465
-	-	:	$(		OK/0.978982
18	18	CD	CARD		OK/0.985751
days	Tage	NNS	NN		OK/0.989095
)	)	)	$(		OK/0.998424
.	.	SENT	$.		OK/0.998402

# 0.290527
Crixivan	Crixivan	NP	NN		OK/0.962629
is	__unaligned__	VBZ	__unaligned__		OK/0.933919
used	Kombination	VVN	NN		OK/0.956106
in	Kombination	IN	NN		OK/0.995499
combination	Kombination	NN	NN		OK/0.995683
with	mit	IN	APPR		OK/0.999145
other	anderen	JJ	PIS		OK/0.996523
antiviral	antiviralen	JJ	ADJA		OK/0.986928
medicines	Arzneimitteln	NNS	NN		OK/0.998313
,	__unaligned__	,	__unaligned__		OK/0.939420
but	jedoch	CC	ADV		OK/0.921280
without	ohne	IN	APPR		OK/0.985315
ritonavir	Ritonavir	NN	NE		OK/0.988376
,	,	,	$,		OK/0.990544
was	war	VBD	VAFIN		OK/0.980731
effective	__unaligned__	JJ	__unaligned__		OK/0.841787
in	bei	IN	APPR		OK/0.929474
reducing	Senkung	VVG	NN		OK/0.676074
viral	Viruslast	JJ	NN		OK/0.930216
loads	Viruslast	NNS	NN		OK/0.882438
more	wirksamer	RBR	ADJD		OK/0.658706
effective	wirksamer	JJ	ADJD		OK/0.819755
than	wirksamer	IN	ADJD		OK/0.943756
the	Vergleichsarzneimittel	DT	NN		OK/0.985471
comparator	Vergleichsarzneimittel	NN	NN		OK/0.975019
medicines	Vergleichsarzneimittel	NNS	NN		OK/0.962163
.	.	SENT	$.		OK/0.990059

# 0.956665
The	Die	DT	ART		OK/0.995722
maximum	Höchstdosis	JJ	NN		OK/0.987552
dose	Höchstdosis	NN	NN		OK/0.982835
is	beträgt	VBZ	VVFIN		OK/0.998208
21.6	21,6	CD	CARD		OK/0.993758
micrograms	Mikrogramm	NNS	NN		OK/0.992732
per	pro	IN	APPR		OK/0.998680
day	Tag	NN	NN		OK/0.998830
.	.	SENT	$.		OK/0.999892

# 0.081296
Hold	Halten	VVP	VVFIN		OK/0.985575
the	Spritze	DT	NN		OK/0.996131
syringe	Spritze	NN	NN		OK/0.994786
and	und	CC	KON		OK/0.999600
needle	Kanüle	NN	NN		OK/0.931086
horizontally	waagerecht	RB	ADJD		OK/0.553742
,	,	,	$,		OK/0.452236
so	so	RB	ADV		OK/0.946660
that	dass	IN/that	KOUS		OK/0.978594
the	die	DT	ART		OK/0.980154
needle	Kanüle	NN	NN		BAD/0.513841
is	nicht	VBZ	PTKNEG		BAD/0.703401
not	nicht	RB	PTKNEG		BAD/0.627516
touching	berührt	VVG	VVPP		BAD/0.589779
the	das	DT	ART		BAD/0.392233
tray	Präparatetablett	NN	NN		BAD/0.558214
.	.	SENT	$.		OK/0.984235

# 0.850369
For	Für	IN	APPR		OK/0.988156
further	weitere	JJR	ADJA		OK/0.970862
information	Angaben	NN	NN		OK/0.956865
on	Angaben	IN	NN		OK/0.996120
dilution	Verdünnung	NN	NN		OK/0.932714
prior	vor	RB	APPR		OK/0.984301
to	vor	TO	APPR		OK/0.992696
administration	Anwendung	NN	NN		OK/0.994858
,	,	,	$,		OK/0.998870
see	siehe	VV	ADV		OK/0.988438
section	Abschnitt	NN	NN		OK/0.999350
6.6	6.6	CD	CARD		OK/0.998478
.	.	SENT	$.		OK/0.999858

# 0.988824
What	Welches	WP	PIAT		OK/0.998362
is	Welches	VBZ	PIAT		OK/0.998915
the	Welches	DT	PIAT		OK/0.999846
risk	Risiko	NN	NN		OK/0.999772
associated	Welches	VVN	PIAT		OK/0.996819
with	mit	IN	APPR		OK/0.999185
Insuman	Insuman	NP	NN		OK/0.996105
?	?	SENT	$.		OK/0.999427

# 0.193490
Your	Ihr	PP$	PPOSAT		OK/0.991701
doctor	Arzt	NN	NN		OK/0.996027
has	__unaligned__	VHZ	__unaligned__		OK/0.857059
prescribed	hat	VVN	VAFIN		OK/0.820561
Pegasys	Pegasys	NP	NN		OK/0.706557
only	nur	RB	ADV		OK/0.638696
,	__unaligned__	,	__unaligned__		OK/0.575373
nurse	Ihnen	NN	PPER		OK/0.696706
and	und	CC	KON		OK/0.986151
your	Ihren	PP$	PPOSAT		OK/0.991155
current	derzeitigen	JJ	ADJA		OK/0.960466
condition	__unaligned__	NN	__unaligned__		OK/0.887891
;	__unaligned__	:	__unaligned__		OK/0.716509
do	__unaligned__	VVP	__unaligned__		OK/0.676692
not	__unaligned__	RB	__unaligned__		OK/0.962835
change	Erkrankungszustand	VV	NN		OK/0.981844
told	verordnet	VVD	VVPP		OK/0.933380
you	verordnet	PP	VVPP		OK/0.989675
to	verordnet	TO	VVPP		OK/0.922580
.	.	SENT	$.		OK/0.953757
Do	Geben	VVP	VVFIN		OK/0.909784
not	nicht	RB	PTKNEG		OK/0.970719
pass	Dritte	VV	NN		OK/0.970827
it	Dritte	PP	NN		OK/0.976805
on	Dritte	IN	NN		OK/0.999228
to	Dritte	TO	NN		OK/0.965858
others	Dritte	NNS	NN		OK/0.947409
.	.	SENT	$.		OK/0.999549

# 0.649402
Duration	Dauer	NP	NN		OK/0.991465
of	Dauer	IN	NN		OK/0.990829
treatment	Dauer	NN	NN		OK/0.985748
in	Kindern	IN	NN		OK/0.733061
children	Kindern	NNS	NN		OK/0.994873
and	und	CC	KON		OK/0.999554
adolescents	Jugendlichen	NNS	ADJA		OK/0.997810
Genotype	Genotyp	NP	NN		OK/0.913658
1	1	CD	CARD		OK/0.964450
:	:	:	$.		OK/0.991829

# 0.114637
For	Die	IN	ART		OK/0.990397
a	__unaligned__	DT	__unaligned__		OK/0.995548
full	vollständige	JJ	ADJA		OK/0.997469
list	Auflistung	NN	NN		OK/0.997701
of	Auflistung	IN	NN		OK/0.999273
the	vollständige	DT	ADJA		OK/0.972200
side-effects	__unaligned__	NNS	__unaligned__		OK/0.893573
reported	berichteten	VVN	ADJA		OK/0.833163
with	mit	IN	APPR		OK/0.858867
NutropinAq	NutropinAq	NP	NE		OK/0.818836
hypersensitive	__unaligned__	JJ	__unaligned__		BAD/0.839482
(	zu	(	PTKZU		BAD/0.594236
allergic	__unaligned__	JJ	__unaligned__		BAD/0.573192
)	__unaligned__	)	__unaligned__		BAD/0.546756
to	__unaligned__	TO	__unaligned__		BAD/0.636348
ribavirin	__unaligned__	NN	__unaligned__		BAD/0.705648
or	der	CC	ART		BAD/0.705671
any	__unaligned__	DT	__unaligned__		BAD/0.699165
of	__unaligned__	IN	__unaligned__		BAD/0.684625
the	entnehmen	DT	VVINF		OK/0.971446
other	entnehmen	JJ	VVINF		BAD/0.713454
ingredients	entnehmen	NNS	VVINF		BAD/0.707817
.	.	SENT	$.		OK/0.997022

# 0.748450
The	Die	DT	ART		OK/0.996447
following	folgende	VVG	ADJA		OK/0.918549
table	Tabelle	NN	NN		OK/0.991284
shows	zeigt	VVZ	VVFIN		OK/0.987654
the	die	DT	ART		OK/0.983615
percentage	__unaligned__	NN	__unaligned__		OK/0.919705
of	__unaligned__	IN	__unaligned__		OK/0.993318
tablets	Tabletten	NNS	NN		OK/0.995790
per	pro	IN	APPR		OK/0.985823
day	Tag	NN	NN		OK/0.996772
for	für	IN	APPR		OK/0.994855
a	eine	DT	ART		OK/0.999294
dose	Dosis	NN	NN		OK/0.992381
of	eine	IN	ART		OK/0.985428
9	9	CD	CARD		OK/0.990286
mg	mg	NN	NN		OK/0.982101
per	pro	IN	APPR		OK/0.995336
kg	kg	NN	NN		OK/0.993840
bodyweight	Körpergewicht	NN	NN		OK/0.994841
once	einmal	RB	ADV		OK/0.990961
daily	täglich	JJ	ADJD		OK/0.982834
.	.	SENT	$.		OK/0.992126

# 0.751006
A	Eine	DT	ART		OK/0.985466
reduction	Reduktion	NN	NN		OK/0.973474
in	Reduktion	IN	NN		OK/0.961574
seizure	Anfallshäufigkeit	NN	NN		OK/0.836472
frequency	Anfallshäufigkeit	NN	NN		OK/0.985145
was	wurde	VBD	VAFIN		OK/0.966175
observed	beobachtet	VVN	VVPP		OK/0.946013
within	innerhalb	IN	APPR		OK/0.985101
the	ersten	DT	ADJA		OK/0.995407
first	ersten	JJ	ADJA		OK/0.998625
week	Woche	NN	NN		OK/0.996907
.	.	SENT	$.		OK/0.999550

# 0.915647
Important	Wichtige	JJ	ADJA		OK/0.996095
information	Informationen	NN	NN		OK/0.999675
about	Wichtige	IN	ADJA		OK/0.997803
some	bestimmte	DT	ADJA		OK/0.966398
of	Bestandteile	IN	NN		OK/0.971070
the	Bestandteile	DT	NN		OK/0.975687
ingredients	Bestandteile	NNS	NN		OK/0.998704
of	Bestandteile	IN	NN		OK/0.991521
BEROMUN	BEROMUN	NP	NE		OK/0.994558
:	:	:	$.		OK/0.994878

# 0.746533
Ingelvac	Ingelvac	NP	NE		OK/0.979680
CircoFLEX	CircoFLEX	NP	NN		OK/0.978752
may	kann	MD	VMFIN		OK/0.886710
cause	verursachen	VV	VVFIN		OK/0.985235
a	leichten	DT	ADJA		OK/0.986028
temporary	vorübergehenden	JJ	ADJA		OK/0.992176
increase	Anstieg	NN	NN		OK/0.977927
in	__unaligned__	IN	__unaligned__		OK/0.971512
body	Körpertemperatur	NN	NN		OK/0.959351
temperature	__unaligned__	NN	__unaligned__		OK/0.954936
,	,	,	$,		OK/0.984564
usually	üblicherweise	RB	ADV		OK/0.990694
on	am	IN	APPRART		OK/0.993050
the	am	DT	APPRART		OK/0.999284
day	Tag	NN	NN		OK/0.989337
of	__unaligned__	IN	__unaligned__		OK/0.984981
vaccination	Impfung	NN	NN		OK/0.999172
.	.	SENT	$.		OK/0.999089

# 0.818493
If	Falls	IN	NN		OK/0.990581
the	die	DT	ART		OK/0.995036
pain	Schmerzen	NN	NN		OK/0.906611
,	,	,	$,		OK/0.987063
talk	__unaligned__	VV	__unaligned__		OK/0.967228
to	__unaligned__	TO	__unaligned__		OK/0.963700
your	Arzt	PP$	NN		OK/0.965408
doctor	Ihren	NN	PPOSAT		OK/0.965724
.	.	SENT	$.		OK/0.999124

# 0.640489
The	Die	DT	ART		OK/0.998658
other	sonstigen	JJ	ADJA		OK/0.990080
ingredients	sonstigen	NNS	ADJA		OK/0.997030
are	sonstigen	VBP	ADJA		OK/0.970622
:	Kaliumsorbat	:	NE		OK/0.973070
potassium	Kaliumsorbat	NN	NE		OK/0.978825
sorbate	Kaliumsorbat	NNS	NE		OK/0.970355
,	,	,	$,		OK/0.997732
sorbitol	Sorbitol	NN	NE		OK/0.979566
(	(	(	$(		OK/0.998829
E420	Sorbitol	NP	NE		OK/0.962620
)	)	)	$(		OK/0.977160
,	__unaligned__	,	__unaligned__		OK/0.818863
and	und	CC	KON		OK/0.937044
purified	Gereinigtes	VVD	NN		OK/0.871495
water	Wasser	NN	NN		OK/0.988112
.	.	SENT	$.		OK/0.998439

# 0.924286
What	Welchen	WP	PIAT		OK/0.998668
benefit	Welchen	VVP	PIAT		OK/0.971690
has	Nutzen	VHZ	NN		OK/0.999176
NEVANAC	NEVANAC	NP	NE		OK/0.996793
shown	__unaligned__	VVN	__unaligned__		OK/0.994634
during	in	IN	APPR		OK/0.971950
the	__unaligned__	DT	__unaligned__		OK/0.980093
studies	Studien	NNS	NN		OK/0.996585
?	?	SENT	$.		OK/0.998501

# 0.417081
50	50	NP	CARD		OK/0.968138
Seizures	Krampfanfälle	NP	NN		OK/0.906912
Olanzapine	Olanzapin	NP	NE		OK/0.982184
should	muss	MD	VMFIN		OK/0.990735
be	muss	VB	VMFIN		OK/0.997142
used	angewendet	VVN	VVPP		OK/0.990504
with	vorsichtig	IN	ADJD		OK/0.990775
caution	vorsichtig	NN	ADJD		OK/0.991787
in	bei	IN	APPR		OK/0.994330
patients	Patienten	NNS	NN		OK/0.996938
with	mit	IN	APPR		OK/0.996607
a	Anamnese	DT	NN		OK/0.995989
history	Anamnese	NN	NN		OK/0.968565
of	Anamnese	IN	NN		OK/0.988485
seizures	Krampfanfällen	NNS	NN		OK/0.960114
or	oder	CC	KON		OK/0.832051
in	bei	IN	APPR		OK/0.599225
the	die	DT	ART		OK/0.770860
seizures	Krampfschwelle	NNS	NN		OK/0.720151
.	.	SENT	$.		OK/0.993389

# 0.797901
The	Die	DT	ART		OK/0.997872
concomitant	gleichzeitige	JJ	ADJA		OK/0.991511
use	gleichzeitige	NN	ADJA		OK/0.995293
of	gleichzeitige	IN	ADJA		OK/0.997823
hydrochlorothiazide	Hydrochlorothiazid	NN	NE		OK/0.999301
and	und	CC	KON		OK/0.938607
irbesartan	Irbesartan	NN	NE		OK/0.990631
has	keinen	VHZ	PIAT		OK/0.960551
no	keinen	DT	PIAT		OK/0.977271
effect	Effekt	NN	NN		OK/0.959155
on	Effekt	IN	NN		OK/0.995452
the	die	DT	ART		OK/0.998331
pharmacokinetics	Pharmakokinetik	NN	NN		OK/0.996050
of	Pharmakokinetik	IN	NN		OK/0.997017
Additional	Einzelwirkstoffe	JJ	NN		OK/0.964406
adverse	__unaligned__	JJ	__unaligned__		OK/0.980343
reactions	__unaligned__	NNS	__unaligned__		OK/0.981843
.	.	SENT	$.		OK/0.999310

# 0.635530
19	19	CD	CARD		OK/0.971774
and	und	CC	KON		OK/0.994709
10	10	CD	CARD		OK/0.992025
%	%	NN	NN		OK/0.997045
of	der	IN	ART		OK/0.988712
the	der	DT	ART		OK/0.987801
niedriggradigen	niedriggradigen	NN	ADJA		OK/0.831195
cervical	intraepithelialen	JJ	ADJA		OK/0.874661
intraepithelial	Neoplasien	JJ	NN		OK/0.888885
neoplasia	__unaligned__	NN	__unaligned__		OK/0.836525
(	(	(	$(		OK/0.984077
CIN	CIN	NP	NN		OK/0.948034
1	1	CD	CARD		OK/0.990325
)	)	)	$(		OK/0.998297
.	.	SENT	$.		OK/0.998420

# 0.813791
Overall	Insgesamt	NP	ADV		OK/0.994788
,	Insgesamt	,	ADV		OK/0.996421
the	die	DT	ART		OK/0.993107
severe	schwere	JJ	ADJA		OK/0.972642
neutropenia	Neutropenie	NN	NN		OK/0.997108
lasted	dauerte	VVN	VVFIN		OK/0.878003
in	in	IN	APPR		OK/0.997936
11	11	CD	CARD		OK/0.993815
%	%	NN	NN		OK/0.999205
of	__unaligned__	IN	__unaligned__		OK/0.997505
courses	Zyklen	NNS	NN		OK/0.987010
for	länger	IN	ADJD		OK/0.998827
more	länger	JJR	ADJD		OK/0.999708
than	länger	IN	ADJD		OK/0.998227
7	7	CD	CARD		OK/0.996818
days	Tage	NNS	NN		OK/0.989171
.	.	SENT	$.		OK/0.999591

# 0.692957
Clinical	Klinische	NP	ADJA		OK/0.996647
studies	Studien	NNS	NN		OK/0.991570
indicate	weisen	VVP	VVFIN		OK/0.948525
that	dass	IN/that	KOUS		OK/0.978063
Multiple-Sklerose-Patienten	Multiple-Sklerose-Patienten	NP	NN		OK/0.902578
during	während	IN	APPR		OK/0.912793
a	__unaligned__	DT	__unaligned__		OK/0.926985
Schubes	Schubes	NP	NN		OK/0.930355
Rebif	Rebif	NP	NE		OK/0.953256
concomitantly	gleichzeitig	RB	ADJD		OK/0.994715
with	mit	IN	APPR		OK/0.998116
corticosteroids	Corticosteroiden	NNS	NN		OK/0.990194
or	oder	CC	KON		OK/0.997275
ACTH	ACTH	NP	NN		OK/0.919631
.	.	SENT	$.		OK/0.999184

# 0.313575
Sodium	Natriumoxybat	NP	NN		OK/0.946057
oxybate	Natriumoxybat	NN	NN		OK/0.923381
has	hat	VHZ	VAFIN		OK/0.557937
as	Missbrauchspotential	IN	NN		BAD/0.833591
the	__unaligned__	DT	__unaligned__		BAD/0.861407
sodium	__unaligned__	NN	__unaligned__		BAD/0.853983
salt	__unaligned__	NN	__unaligned__		BAD/0.800587
.	.	SENT	$.		OK/0.996974

# 0.292239
Placebo	Placebo	NP	NN		OK/0.816237
was	wurde	VBD	VAFIN		OK/0.755264
added	zusätzlich	VVN	ADJD		OK/0.491277
to	zusätzlich	TO	ADJD		OK/0.421758
therapy	Therapie	NN	NN		OK/0.845370
that	__unaligned__	WDT	__unaligned__		OK/0.768052
included	beinhaltete	VVD	VVFIN		OK/0.800415
insulin	Insulin	NN	NN		OK/0.979533
.	.	SENT	$.		OK/0.999805

# 0.068896
Physicians	durften	NPS	VMFIN		OK/0.752568
were	durften	VBD	VMFIN		BAD/0.697790
allowed	durften	VVN	VMFIN		BAD/0.751954
to	__unaligned__	TO	__unaligned__		BAD/0.587752
the	die	DT	ART		BAD/0.477187
NRTI-Schemata	NRTI-Schemata	NP	NN		BAD/0.667406
their	ihrer	PP$	PPOSAT		BAD/0.652392
inclusion	Aufnahme	NN	NN		BAD/0.583657
in	in	IN	APPR		BAD/0.497628
the	die	DT	ART		BAD/0.497459
study	Studie	NN	NN		OK/0.782122
.	.	SENT	$.		OK/0.993818

# 0.532174
Each	Jede	DT	PIAT		OK/0.986060
vial	Durchstechflasche	NN	NN		OK/0.989598
is	ist	VBZ	VAFIN		OK/0.977548
only	nur	RB	ADV		OK/0.886189
for	für	IN	APPR		OK/0.910964
the	für	DT	APPR		OK/0.984834
patients	Patienten	NNS	NN		OK/0.950870
use	__unaligned__	VVP	__unaligned__		OK/0.633155
.	.	SENT	$.		OK/0.989438

# 0.323291
Concomitant	gleichzeitiger	NP	ADJA		OK/0.999326
administration	Anwendung	NN	NN		OK/0.997381
of	von	IN	APPR		OK/0.998393
fosamprenavir	Fosamprenavir	NN	NN		OK/0.979011
with	mit	IN	APPR		OK/0.980540
ritonavir	Ritonavir	NN	NE		OK/0.996037
,	__unaligned__	,	__unaligned__		OK/0.798124
high	hohe	JJ	ADJA		OK/0.931111
doses	Dosen	NNS	NN		OK/0.971875
(	(	(	$(		OK/0.994690
>	>	SYM	$(		BAD/0.528523
200	200	CD	CARD		OK/0.974188
mg	mg	NN	NN		OK/0.996251
/	/	SYM	$(		OK/0.999777
day	Tag	NN	NN		OK/0.999129
)	)	)	$(		OK/0.996931
of	__unaligned__	IN	__unaligned__		OK/0.940744
ketoconazole	Ketoconazol	NN	NN		OK/0.956618
or	oder	CC	KON		OK/0.998230
itraconazole	Itraconazol	NN	NN		OK/0.952249
is	empfohlen	VBZ	VVPP		OK/0.995286
not	nicht	RB	PTKNEG		OK/0.994867
recommended	empfohlen	VVN	VVPP		OK/0.987552
.	.	SENT	$.		OK/0.998069

# 0.724447
Adjustment	Anpassung	NP	NN		OK/0.992174
of	Anpassung	IN	NN		OK/0.999275
dosage	Dosierung	NN	NN		OK/0.999060
may	kann	MD	VMFIN		OK/0.987201
also	auch	RB	ADV		OK/0.995974
be	kann	VB	VMFIN		OK/0.942242
necessary	__unaligned__	JJ	__unaligned__		OK/0.956426
if	__unaligned__	IN	__unaligned__		OK/0.962786
patients	bei	NNS	APPR		OK/0.985678
change	Änderung	VVP	NN		OK/0.999009
physical	körperlichen	JJ	ADJA		OK/0.989244
activity	__unaligned__	NN	__unaligned__		OK/0.967570
or	oder	CC	KON		OK/0.998002
their	__unaligned__	PP$	__unaligned__		OK/0.981155
usual	__unaligned__	JJ	__unaligned__		OK/0.983179
diet	__unaligned__	NN	__unaligned__		OK/0.990691
if	Ernährungsgewohnheiten	IN	NN		BAD/0.985089
necessary	notwendig	JJ	ADJD		BAD/0.897165
.	.	SENT	$.		OK/0.994076

# 0.143604
80	80	CD	CARD		OK/0.994567
mg	mg	NN	NN		OK/0.997670
/	/	SYM	$(		OK/0.999754
kg	kg	NN	NN		OK/0.986401
/	pro	SYM	APPR		OK/0.860929
day	Tag	NN	NN		OK/0.963169
and	und	CC	KON		OK/0.998825
above	__unaligned__	JJ	__unaligned__		OK/0.966920
)	)	)	$(		OK/0.964049
or	oder	CC	KON		OK/0.930707
with	mit	IN	APPR		OK/0.805708
Gesamtdosen	Gesamtdosen	NP	NN		OK/0.484825
treated	behandelt	VVN	VVPP		OK/0.399376
with	behandelt	IN	VVPP		OK/0.600355
ceftriaxone	Ceftriaxon	NN	NE		OK/0.967027
and	und	CC	KON		OK/0.986740
some	einige	DT	PIAT		OK/0.995919
risk	Risikofaktoren	NN	NN		OK/0.992731
factors	Risikofaktoren	VVZ	NN		OK/0.977162
(	(	(	$(		OK/0.996764
e.	z.B.	FW	ADV		OK/0.796954
g.	z.B.	FW	ADV		OK/0.812443
impaired	eingeschränkte	JJ	ADJA		OK/0.872353
hydration	Flüssigkeitszufuhr	NN	NN		OK/0.786487
haemoglobin	__unaligned__	NN	__unaligned__		OK/0.852813
concentration	__unaligned__	NN	__unaligned__		OK/0.879428
above	über	IN	APPR		OK/0.874938
10	10	CD	CARD		OK/0.985670
g	g	NN	NN		OK/0.980646
)	)	)	$(		OK/0.966338
.	.	SENT	$.		OK/0.998909

# 0.247842
What	Wie	WP	KOKOM		OK/0.994364
Lisonorm	Lisonorm	NP	NN		OK/0.994817
looks	aussieht	VVZ	VVFIN		OK/0.999256
like	aussieht	IN	VVFIN		OK/0.998147
and	und	CC	KON		OK/0.999090
contents	Inhalt	NNS	NN		OK/0.999364
of	Inhalt	IN	NN		OK/0.992789
the	Packung	DT	NN		OK/0.997815
pack	Packung	NN	NN		OK/0.954362
The	Die	DT	ART		OK/0.996095
tablets	Tabletten	NNS	NN		OK/0.992121
are	sind	VBP	VAFIN		OK/0.991816
white	weiß	JJ	ADJD		OK/0.948804
to	,	TO	$,		OK/0.823829
off-white	weißlich	NN	ADJD		OK/0.929444
,	__unaligned__	,	__unaligned__		OK/0.990854
round	rund	NN	ADV		OK/0.997151
,	,	,	$,		OK/0.964034
flat	__unaligned__	JJ	__unaligned__		OK/0.992049
,	__unaligned__	,	__unaligned__		OK/0.954174
bevel-edged	abgeschrägtem	JJ	ADJA		OK/0.718930
tablet	abgeschrägtem	NN	ADJA		OK/0.867669
with	abgeschrägtem	IN	ADJA		OK/0.919172
a	einer	DT	ART		OK/0.978715
score	Bruchkerbe	NN	NN		OK/0.724569
line	Bruchkerbe	NN	NN		OK/0.661853
on	Seite	IN	NN		OK/0.864071
one	Seite	CD	NN		OK/0.993347
side	Seite	NN	NN		OK/0.993586
and	und	CC	KON		OK/0.999209
with	Gravur	IN	NN		OK/0.977887
an	Gravur	DT	NN		OK/0.966411
engraving	Gravur	NN	NN		OK/0.961517
"	"	``	$(		OK/0.986939
A	A	NP	NN		OK/0.989809
+	+	SYM	KON		OK/0.996816
L	L	NN	NN		OK/0.981113
"	"	''	$(		OK/0.967434
on	auf	IN	APPR		OK/0.955990
the	auf	DT	APPR		OK/0.995495
reverse	Rückseite	JJ	NN		OK/0.958773
side	__unaligned__	NN	__unaligned__		OK/0.990386
.	.	SENT	$.		OK/0.998184

# 0.618710
Optimark	Optimark	NP	NN		OK/0.960378
should	sollte	MD	VMFIN		OK/0.981972
be	sollte	VB	VMFIN		OK/0.971669
used	angewendet	VVN	VVPP		OK/0.926255
only	nur	RB	ADV		OK/0.918245
by	Ärzten	IN	NN		OK/0.989862
physicians	Ärzten	NNS	NN		OK/0.991809
who	,	WP	$,		OK/0.893340
are	__unaligned__	VBP	__unaligned__		OK/0.968224
experienced	Erfahrung	VVN	NN		OK/0.975227
in	in	IN	APPR		OK/0.999468
the	in	DT	APPR		OK/0.979583
clinical	klinischen	JJ	ADJA		OK/0.970927
MRI	MRT-Praxis	NP	NN		OK/0.888161
practice	MRT-Praxis	NN	NN		OK/0.902332
.	.	SENT	$.		OK/0.998232

# 0.668602
As	Wie	IN	KOKOM		OK/0.997402
with	bei	IN	APPR		OK/0.990033
all	jedem	DT	PIAT		OK/0.991347
protein	Proteinprodukt	NN	NN		OK/0.983184
product	Proteinprodukt	NN	NN		OK/0.995919
is	__unaligned__	VBZ	__unaligned__		OK/0.998501
possible	Überempfindlichkeitsreaktionen	JJ	NN		OK/0.989302
that	können	IN/that	VMFIN		OK/0.946420
sensitisation	Überempfindlichkeitsreaktionen	NN	NN		OK/0.950422
reactions	Überempfindlichkeitsreaktionen	NNS	NN		OK/0.971702
may	können	MD	VMFIN		OK/0.939276
occur	auftreten	VV	VVINF		OK/0.899998
by	vom	IN	APPRART		OK/0.912195
the	__unaligned__	DT	__unaligned__		OK/0.942078
allergic	Allergietyp	JJ	NN		OK/0.904719
type	Allergietyp	NN	NN		OK/0.898177
.	.	SENT	$.		OK/0.999671

# 0.291317
Xiliarx	Xiliarx	NP	NN		OK/0.992257
50	50	CD	CARD		OK/0.997654
mg	mg	NN	NN		OK/0.998810
tablets	Tabletten	NNS	NN		OK/0.998748
are	sind	VBP	VAFIN		OK/0.989136
available	Packungen	JJ	NN		OK/0.982748
in	Packungen	IN	NN		OK/0.970014
packs	Packungen	NNS	NN		OK/0.994383
containing	Packungen	VVG	NN		OK/0.990490
7	7	CD	CARD		OK/0.989424
,	,	,	$,		OK/0.998704
14	14	CD	CARD		OK/0.998804
,	,	,	$,		OK/0.998527
28	28	CD	CARD		OK/0.998518
,	,	,	$,		OK/0.999552
30	30	CD	CARD		OK/0.998554
,	,	,	$,		OK/0.999675
56	56	CD	CARD		OK/0.997257
,	,	,	$,		OK/0.998198
60	60	CD	CARD		OK/0.997610
,	,	,	$,		OK/0.989479
90	90	CD	CARD		OK/0.994633
,	,	,	$,		OK/0.990059
112	112	CD	CARD		OK/0.770960
,	,	,	$,		OK/0.782503
180	180	CD	CARD		OK/0.869286
or	oder	CC	KON		OK/0.995379
336	336	CD	CARD		OK/0.960840
tablets	Tabletten	NNS	NN		OK/0.993163
and	und	CC	KON		OK/0.978394
in	in	IN	APPR		OK/0.966071
multipacks	Bündelpackungen	NNS	NN		OK/0.721586
containing	__unaligned__	VVG	__unaligned__		OK/0.783979
336	336	CD	CARD		OK/0.785789
(	3x112	(	NE		OK/0.683959
3x112	3x112	JJ	NE		OK/0.749709
)	)	)	$(		OK/0.962587
tablets	Tabletten	NNS	NN		OK/0.945088
.	.	SENT	$.		OK/0.998751

# 0.173901
In	Bei	IN	APPR		OK/0.847115
the	der	DT	ART		OK/0.981050
formation	Bildung	NN	NN		OK/0.959942
of	der	IN	ART		OK/0.949992
the	primären	DT	ADJA		OK/0.987900
primary	primären	JJ	ADJA		OK/0.994213
metabolite	Metaboliten	NN	NN		OK/0.701939
ucb	ucb	NN	ADJA		OK/0.835718
L057	L057	JJ	NN		OK/0.595188
,	,	,	$,		OK/0.629331
no	keine	DT	PIAT		OK/0.640381
isoforms	Isoformen	NNS	NN		OK/0.510814
involved	beteiligt	VVN	VVPP		OK/0.575382
in	beteiligt	IN	VVPP		OK/0.791835
cytochrome	Cytochrom	NN	NN		OK/0.954999
P450	Cytochrom	NP	NN		OK/0.966051
P450-Systems	P450-Systems	NP	NN		OK/0.821737
.	.	SENT	$.		OK/0.989726

# 0.716052
Therefore	Daher	RB	PAV		OK/0.991952
,	__unaligned__	,	__unaligned__		OK/0.991831
in	im	IN	APPRART		OK/0.996665
case	Falle	NN	NN		OK/0.952083
of	Falle	IN	NN		OK/0.958091
overdosage	Überdosierung	NN	NN		OK/0.778699
symptomatic	symptomatische	JJ	ADJA		OK/0.974822
treatment	einzuleiten	NN	VVIZU		OK/0.987469
should	einzuleiten	MD	VVIZU		OK/0.994270
be	einzuleiten	VB	VVIZU		OK/0.995992
initiated	einzuleiten	VVN	VVIZU		OK/0.981861
.	.	SENT	$.		OK/0.998821

# 0.083301
VELCADE	VELCADE	NP	NN		OK/0.953228
is	indiziert	VBZ	VVPP		OK/0.956690
indicated	indiziert	VVN	VVPP		OK/0.939007
as	Monotherapie	IN	NN		OK/0.932286
monotherapy	Monotherapie	NN	NN		OK/0.895120
for	für	IN	APPR		OK/0.989322
the	für	DT	APPR		OK/0.995190
treatment	Behandlung	NN	NN		OK/0.997461
of	Behandlung	IN	NN		OK/0.975403
progressive	progressivem	JJ	ADJA		OK/0.951726
,	,	,	$,		OK/0.967938
multiple	Myelom	JJ	NN		OK/0.990444
myeloma	multiplem	NN	ADJA		OK/0.992260
in	bei	IN	APPR		OK/0.947370
patients	Patienten	NNS	NN		OK/0.937297
receiving	Patienten	VVG	NN		BAD/0.798682
at	mindestens	IN	ADV		OK/0.984599
least	mindestens	JJS	ADV		OK/0.992426
1	1	CD	CARD		OK/0.998678
and	__unaligned__	CC	__unaligned__		OK/0.966008
those	vorangehende	DT	ADJA		OK/0.967815
who	vorangehende	WP	ADJA		OK/0.842267
had	vorangehende	VHD	ADJA		OK/0.724956
not	vorangehende	RB	ADJA		OK/0.656902
taken	vorangehende	VVN	ADJA		OK/0.533649
with	durchlaufen	IN	VVPP		OK/0.611937
therapy	Therapie	NN	NN		OK/0.966065
and	und	CC	KON		OK/0.944185
are	bereits	VBP	ADV		BAD/0.728221
achieved	__unaligned__	VVN	__unaligned__		BAD/0.848313
a	__unaligned__	DT	__unaligned__		OK/0.920219
bone	Knochenmarktransplantation	NN	NN		OK/0.994052
marrow	Knochenmarktransplantation	NN	NN		OK/0.994084
transplant	Knochenmarktransplantation	NN	NN		OK/0.977858
or	oder	CC	KON		OK/0.986230
for	für	IN	APPR		OK/0.707351
a	__unaligned__	DT	__unaligned__		OK/0.931916
bone	Knochenmarktransplantation	NN	NN		OK/0.988551
marrow	__unaligned__	NN	__unaligned__		OK/0.978581
transplant	__unaligned__	NN	__unaligned__		OK/0.921253
.	.	SENT	$.		OK/0.999791

# 0.618486
inspect	überprüfen	VVP	VVINF		OK/0.881015
the	__unaligned__	DT	__unaligned__		OK/0.950739
vial	Durchstechflasche	NN	NN		OK/0.904346
contents	Inhalt	NNS	NN		OK/0.693852
.	.	SENT	$.		OK/0.998529

# 0.050713
You	Sie	PP	PPER		OK/0.994503
should	sollten	MD	VMFIN		OK/0.971813
use	__unaligned__	VV	__unaligned__		BAD/0.444991
ViraferonPeg	ViraferonPeg	NP	NN		BAD/0.450593
-Injektion	-Injektion	NN	NN		BAD/0.633628
site	andere	NN	PIAT		BAD/0.701906
use	benutzen	VVP	VVINF		BAD/0.553507
a	__unaligned__	DT	__unaligned__		BAD/0.595343
different	__unaligned__	JJ	__unaligned__		BAD/0.493062
site	__unaligned__	NN	__unaligned__		BAD/0.575183
each	__unaligned__	DT	__unaligned__		BAD/0.872578
time	__unaligned__	NN	__unaligned__		BAD/0.946358
in	__unaligned__	IN	__unaligned__		BAD/0.873437
order	vermeiden	NN	VVINF		BAD/0.872837
to	vermeiden	TO	VVINF		OK/0.501790
avoid	vermeiden	VV	VVINF		OK/0.626099
inflammation	Entzündungen	NN	NN		OK/0.922020
at	Injektionsstelle	IN	NN		OK/0.992092
the	Injektionsstelle	DT	NN		OK/0.999896
site	Injektionsstelle	NN	NN		OK/0.996241
of	__unaligned__	IN	__unaligned__		OK/0.979516
the	Injektionsstelle	DT	NN		OK/0.996858
injection	Injektionsstelle	NN	NN		OK/0.973377
.	.	SENT	$.		OK/0.999700

# 0.882617
sepsis	Sepsis	NN	NN		OK/0.979745
or	oder	CC	KON		OK/0.998968
risk	Risiko	NN	NN		OK/0.998796
of	Risiko	IN	NN		OK/0.965811
sepsis	Sepsis	NN	NN		OK/0.911536
.	.	SENT	$.		OK/0.998463

# 0.642935
If	Wurde	IN	VVFIN		OK/0.965426
not	nicht	RB	PTKNEG		OK/0.971346
increase	erhöht	VV	VVPP		OK/0.972687
the	die	DT	ART		OK/0.997844
dose	Dosierung	NN	NN		OK/0.991438
for	__unaligned__	IN	__unaligned__		OK/0.989048
cycle	Zyklus	NN	NN		OK/0.991335
2	2	CD	CARD		OK/0.980810
,	,	,	$,		OK/0.980363
and	auch	CC	ADV		OK/0.941835
should	sollte	MD	VMFIN		OK/0.995106
not	nicht	RB	PTKNEG		OK/0.987351
be	sollte	VB	VMFIN		OK/0.985097
increased	erhöht	VVN	VVPP		OK/0.984829
for	Zyklen	IN	NN		OK/0.981285
subsequent	Zyklen	JJ	NN		OK/0.953214
cycles	Zyklen	NNS	NN		OK/0.952868
,	__unaligned__	,	__unaligned__		OK/0.828611
the	die	DT	ART		OK/0.952808
dose	Dosierung	NN	NN		OK/0.990576
.	.	SENT	$.		OK/0.999783

# 0.881707
Page	Seite	NP	NN		OK/0.986747
2	2	CD	CARD		OK/0.992559
/	/	SYM	$(		OK/0.988675
3	3	CD	CARD		OK/0.985968
©	©	SYM	XY		OK/0.986143
EMEA	EMEA	NP	NN		OK/0.996873
2008	2008	CD	ADJA		OK/0.998986
Why	Warum	WRB	PWAV		OK/0.998119
has	Warum	VHZ	PWAV		OK/0.987520
Nobilis	Nobilis	NP	ADJA		OK/0.996589
Influenza	Influenza	NP	NN		OK/0.999427
H5N6	H5N6	NP	NN		OK/0.958192
been	zugelassen	VBN	VVPP		OK/0.982259
approved	zugelassen	VVN	VVPP		OK/0.991050
?	?	SENT	$.		OK/0.999324

# 0.896016
Second	Zweites	NP	NN		OK/0.964355
and	und	CC	KON		OK/0.999433
third	__unaligned__	JJ	__unaligned__		OK/0.993682
trimester	__unaligned__	NN	__unaligned__		OK/0.999005
of	__unaligned__	IN	__unaligned__		OK/0.997389
pregnancy	__unaligned__	NN	__unaligned__		OK/0.982828
(	siehe	(	VVIMP		OK/0.999204
see	siehe	VV	VVIMP		OK/0.996149
sections	Abschnitte	NNS	NN		OK/0.998506
4.4	4.4	CD	CARD		OK/0.999889
and	und	CC	KON		OK/0.999433
4.6	4.6	CD	CARD		OK/0.971470
)	)	)	$(		OK/0.982333
.	.	SENT	$.		OK/0.996301

# 0.089354
Imprinted	Bedruckte	NP	ADJA		OK/0.790488
capsules	Kapseln	NNS	NN		OK/0.934904
with	hellblauen	IN	ADJA		OK/0.491131
light	__unaligned__	NN	__unaligned__		OK/0.597106
,	,	,	$,		OK/0.767371
as	Kappe	RB	NN		OK/0.465276
defined	__unaligned__	VVN	__unaligned__		OK/0.602631
in	__unaligned__	IN	__unaligned__		OK/0.705071
cremefarbenen	cremefarbenen	NP	ADJA		OK/0.585802
,	,	,	$,		OK/0.856917
N-methyl-N-	Korpus	NP	NN		OK/0.807726
1	1	CD	CARD		OK/0.816166
hard	__unaligned__	JJ	__unaligned__		OK/0.852501
capsule	__unaligned__	NN	__unaligned__		OK/0.841852
with	mit	IN	APPR		OK/0.967543
yellowish	__unaligned__	JJ	__unaligned__		OK/0.973928
pellets	__unaligned__	NNS	__unaligned__		OK/0.750247
.	.	SENT	$.		OK/0.995936

# 0.124167
Since	Da	IN	ADV		OK/0.987219
olanzapine	Olanzapin	NN	NN		OK/0.912762
is	__unaligned__	VBZ	__unaligned__		BAD/0.758919
a	einen	DT	ART		BAD/0.567293
Dopamin-Antagonismus	Dopamin-Antagonismus	NP	NN		BAD/0.521371
shows	zeigt	VVZ	VVFIN		OK/0.877204
synergy	zeigt	NN	VVFIN		OK/0.778060
in	vitro	IN	NE		OK/0.945529
vitro	vitro	NN	NE		OK/0.961247
,	,	,	$,		OK/0.944863
it	kann	PP	VMFIN		OK/0.781588
may	kann	MD	VMFIN		OK/0.867360
antagonise	abschwächen	VV	VVINF		OK/0.698399
the	Wirkung	DT	NN		OK/0.774515
effects	die	NNS	ART		OK/0.754935
of	__unaligned__	IN	__unaligned__		OK/0.735627
direct	direkten	JJ	ADJA		OK/0.970945
or	oder	CC	KON		OK/0.993783
indirect	indirekten	JJ	ADJA		OK/0.998213
dopamine	Dopamin-Agonisten	NN	NN		OK/0.996547
agonists	Dopamin-Agonisten	NNS	NN		OK/0.986520
.	.	SENT	$.		OK/0.999560

# 0.120342
Vildagliptin	Vildagliptin	NP	NE		OK/0.883583
can	kann	MD	VMFIN		OK/0.956208
be	kann	VB	VMFIN		OK/0.958814
used	angewendet	VVN	VVPP		OK/0.958972
with	mit	IN	APPR		OK/0.994914
metformin	Metformin	NN	NE		OK/0.995236
in	bei	IN	APPR		OK/0.987515
type	Typ-2-Diabetikern	NN	NN		OK/0.997744
2	Typ-2-Diabetikern	CD	NN		OK/0.999277
diabetes	Typ-2-Diabetikern	NN	NN		OK/0.999462
patients	Typ-2-Diabetikern	NNS	NN		OK/0.999353
whose	deren	WP$	PRELAT		OK/0.997649
blood	Blutzucker	NN	NN		OK/0.998046
sugar	Blutzucker	NN	NN		OK/0.999732
level	Blutzucker	NN	NN		OK/0.926548
are	stellend	VBP	ADJD		OK/0.683161
not	nicht	RB	PTKNEG		OK/0.704152
satisfactorily	stellend	RB	ADJD		OK/0.752569
controlled	stellend	VVN	ADJD		OK/0.483382
on	stellend	IN	ADJD		OK/0.206878
metformin	Metformin	NN	NE		OK/0.656389
alone	allein	RB	ADV		OK/0.971938
.	.	SENT	$.		OK/0.998906

# 0.915380
Why	Warum	NP	PWAV		OK/0.999627
has	Warum	VHZ	PWAV		OK/0.982782
Onsenal	Onsenal	NP	NN		OK/0.953644
been	zugelassen	VBN	VVPP		OK/0.944762
approved	zugelassen	VVN	VVPP		OK/0.996983
?	?	SENT	$.		OK/0.999433

# 0.734244
Gender	Geschlecht	NP	NN		OK/0.986892
,	,	,	$,		OK/0.990993
Race	Rasse	NP	NN		OK/0.920044
and	und	CC	KON		OK/0.970969
Age	Alter	NP	NN		OK/0.796361
:	:	:	$.		OK/0.990534

# 0.464779
Dose	verabreichende	NP	ADJA		OK/0.998714
to	verabreichende	TO	ADJA		OK/0.998091
be	verabreichende	VB	ADJA		OK/0.999392
administered	verabreichende	VVN	ADJA		OK/0.991976
PegIntron	PegIntron	NP	NN		OK/0.625435
should	ist	MD	VAFIN		OK/0.949018
be	zu	VB	PTKZU		OK/0.985869
administered	__unaligned__	VVN	__unaligned__		OK/0.978076
as	als	IN	KOKOM		OK/0.995279
a	einmal	DT	ADV		OK/0.986458
once	einmal	RB	ADV		OK/0.775355
weekly	wöchentliche	JJ	ADJA		OK/0.989140
subcutaneous	subkutane	JJ	ADJA		OK/0.990550
injection	Injektion	NN	NN		OK/0.999298
.	.	SENT	$.		OK/0.999761

# 0.065548
The	Die	NP	ART		OK/0.801073
extensions	__unaligned__	NNS	__unaligned__		BAD/0.794907
(	vorkommenden	(	ADJA		BAD/0.856618
in	in	IN	APPR		BAD/0.402882
the	__unaligned__	DT	__unaligned__		BAD/0.357275
dominantly	Phospholipide	RB	NN		BAD/0.697572
Luminity	Luminity	JJ	NE		BAD/0.606150
(	(	(	$(		OK/0.973321
see	siehe	VV	VVIMP		OK/0.999476
section	Abschnitt	NN	NN		OK/0.999165
6.1	6.1	CD	CARD		OK/0.998619
)	)	)	$(		OK/0.992188
distribute	verteilen	VVP	VVFIN		OK/0.899164
the	endogenen	DT	ADJA		OK/0.943246
endogenous	endogenen	JJ	ADJA		OK/0.977812
Fett-pool	Fett-pool	NN	NN		OK/0.673862
in	im	IN	APPRART		OK/0.919103
the	im	DT	APPRART		OK/0.928218
tumour	Körpers	NN	NN		OK/0.872318
)	z.	)	APPRART		BAD/0.851976
.	z.	SENT	APPRART		BAD/0.834785

# 0.206629
3	3	CD	CARD		OK/0.997466
ml	ml	NN	NN		OK/0.999035
solution	Lösung	NN	NN		OK/0.998474
in	Patrone	IN	NN		OK/0.929475
a	Patrone	DT	NN		OK/0.999754
cartridge	Patrone	NN	NN		OK/0.993994
(	(	(	$(		OK/0.998827
type	Glasart	NN	NN		OK/0.993479
1	1	CD	CARD		OK/0.999361
glass	Glasart	NN	NN		OK/0.997810
)	)	)	$(		OK/0.998353
with	mit	IN	APPR		OK/0.994058
a	__unaligned__	DT	__unaligned__		OK/0.995342
plunger	Kolben	NN	NN		OK/0.980451
(	(	(	$(		OK/0.985676
bromobutyl	Brombutylgummi	NN	NN		OK/0.956908
)	)	)	$(		OK/0.994260
and	und	CC	KON		OK/0.990380
a	Stopfen	DT	NN		OK/0.931446
stopper	Stopfen	NN	NN		OK/0.984986
(	(	(	$(		OK/0.988120
bromobutyl	Brombutylgummi	NN	NN		OK/0.984058
/	/	SYM	$(		OK/0.997578
polyisoprene	Polyisopren	NN	NE		OK/0.966176
)	)	)	$(		OK/0.995900
in	Fertigpen	IN	NN		OK/0.978198
a	Fertigpen	DT	NN		OK/0.997707
pre-filled	Fertigpen	JJ	NN		OK/0.995228
pen	Fertigpen	NN	NN		OK/0.948811
(	(	(	$(		OK/0.996722
multidose	Mehrdosen-Einwegspritze	JJ	NN		OK/0.970627
disposable	Mehrdosen-Einwegspritze	JJ	NN		OK/0.978801
pen	Mehrdosen-Einwegspritze	NN	NN		OK/0.980383
)	)	)	$(		OK/0.958963
comprising	Mehrdosen-Einwegspritze	VVG	NN		OK/0.519046
a	__unaligned__	DT	__unaligned__		OK/0.608954
seal	__unaligned__	NN	__unaligned__		OK/0.467587
(	(	(	$(		OK/0.986969
polypropylene	Polypropylen	NN	NN		OK/0.957226
)	)	)	$(		OK/0.909999
.	.	SENT	$.		OK/0.997233

# 0.243379
Do	Nehmen	VVP	VVFIN		BAD/0.829563
not	Nehmen	RB	VVFIN		BAD/0.861532
take	Nehmen	VV	VVFIN		OK/0.928619
Viread	Viread	NP	NE		OK/0.936775
and	und	CC	KON		OK/0.954221
Hepsera	Hepsera	NP	NE		OK/0.590167
(	(	(	$(		OK/0.986256
adefovir	Adefovirdipivoxil	NN	NN		OK/0.969991
dipivoxil	Adefovirdipivoxil	NN	NN		OK/0.987930
)	)	)	$(		OK/0.997590
given	__unaligned__	VVN	__unaligned__		OK/0.596056
concomitantly	zusammen	RB	ADV		OK/0.826832
.	.	SENT	$.		OK/0.995184

# 0.775585
Read	Lesen	NP	VVFIN		OK/0.991072
all	Lesen	RB	VVFIN		OK/0.993760
of	__unaligned__	IN	__unaligned__		OK/0.994862
this	__unaligned__	DT	__unaligned__		OK/0.978064
leaflet	__unaligned__	NN	__unaligned__		OK/0.852085
carefully	sorgfältig	RB	ADJD		OK/0.992773
because	denn	IN	KON		OK/0.990344
it	sie	PP	PPER		OK/0.985744
contains	enthält	VVZ	VVFIN		OK/0.968686
important	wichtige	JJ	ADJA		OK/0.998109
information	Informationen	NN	NN		OK/0.997186
for	für	IN	APPR		OK/0.999015
you	Sie	PP	PPER		OK/0.980397
.	.	SENT	$.		OK/0.992526

# 0.799548
If	Wenn	IN	KOUS		OK/0.990061
you	Sie	PP	PPER		OK/0.977659
take	eingenommen	VVP	VVPP		OK/0.941828
more	mehr	JJR	ADV		OK/0.948370
Neoclarityn	Neoclarityn	NP	NE		OK/0.969265
than	als	IN	KOUS		OK/0.979738
you	Sie	PP	PPER		OK/0.988307
should	sollten	MD	VMFIN		OK/0.994721
,	,	,	$,		OK/0.998929
contact	wenden	VV	VVFIN		OK/0.925073
your	Sie	PP$	PPER		OK/0.973817
doctor	Ihren	NN	PPOSAT		OK/0.998898
or	Apotheker	CC	NN		OK/0.999735
pharmacist	Apotheker	NN	NN		OK/0.999779
.	.	SENT	$.		OK/0.999872

# 0.605675
What	Was	WP	PWS		OK/0.999139
you	müssen	PP	VMFIN		OK/0.995218
should	müssen	MD	VMFIN		OK/0.994306
know	__unaligned__	VV	__unaligned__		OK/0.998476
before	vor	IN	APPR		OK/0.997305
you	Sie	PP	PPER		OK/0.997237
take	Einnahme	VVP	NN		OK/0.996697
Prandin	Prandin	NP	NN		OK/0.978090
3	3.	CD	ADJA		OK/0.664581
.	__unaligned__	SENT	__unaligned__		OK/0.705548

# 0.015241
The	__unaligned__	DT	__unaligned__		OK/0.890627
marketing	Zulassung	NN	NN		OK/0.987159
authorisation	Zulassung	NN	NN		OK/0.987006
holder	Inhaber	NN	NN		OK/0.988397
should	muss	MD	VMFIN		OK/0.992564
these	diese	DT	PDAT		OK/0.991192
same	Schulungsmaßnahmen	JJ	NN		OK/0.828469
facility	__unaligned__	NN	__unaligned__		OK/0.881761
nationally	national	RB	ADJD		OK/0.924875
,	__unaligned__	,	__unaligned__		OK/0.910827
prior	vor	RB	APPR		OK/0.920220
to	__unaligned__	TO	__unaligned__		OK/0.810854
marketing	Markteinführung	NN	NN		BAD/0.679156
,	__unaligned__	,	__unaligned__		BAD/0.632404
the	__unaligned__	DT	__unaligned__		OK/0.826102
competent	__unaligned__	JJ	__unaligned__		OK/0.672537
authorities	__unaligned__	NNS	__unaligned__		OK/0.908325
in	in	IN	APPR		OK/0.992330
the	in	DT	APPR		OK/0.947907
Member	Abstimmung	NP	NN		OK/0.713480
States.	Abstimmung	NP	NN		OK/0.545684
with	mit	IN	APPR		OK/0.469544
the	__unaligned__	DT	__unaligned__		OK/0.382358
National	__unaligned__	NP	__unaligned__		BAD/0.896590
Competent	zuständigen	NP	ADJA		BAD/0.907463
Authorities	__unaligned__	NP	__unaligned__		BAD/0.925653
Gesundheitsbehörde	Gesundheitsbehörde	NP	NN		BAD/0.774437
the	des	DT	ART		BAD/0.621835
eventual	Mitgliedsstaates	JJ	NN		BAD/0.765992
instructions	Mitgliedsstaates	NNS	NN		BAD/0.589120
.	.	SENT	$.		OK/0.962894

# 0.413616
ergotism	Ergotismus	NN	NN		OK/0.739696
with	mit	IN	APPR		OK/0.873601
possible	möglicher	JJ	ADJA		OK/0.965179
necrosis	Nekrose	NN	NN		OK/0.964960
of	der	IN	ART		OK/0.931668
the	der	DT	ART		OK/0.991943
limb	Extremitäten	NN	NN		OK/0.722228
(	(	(	$(		OK/0.959433
inhibition	Hemmung	NN	NN		OK/0.975189
of	Hemmung	IN	NN		OK/0.954869
hepatic	hepatischen	JJ	ADJA		OK/0.949659
elimination	Elimination	NN	NN		OK/0.989393
of	__unaligned__	IN	__unaligned__		OK/0.940313
Mutterkorns	Mutterkorns	NP	NN		OK/0.960163
)	)	)	$(		OK/0.981736
.	.	SENT	$.		OK/0.996769

# 0.858084
EMEND	EMEND	NP	NN		OK/0.997121
125	125	CD	CARD		OK/0.990275
mg	mg	NN	NN		OK/0.997215
/	/	SYM	$(		OK/0.999463
80	80	CD	CARD		OK/0.993716
mg	mg	NN	NN		OK/0.981137
is	wird	VBZ	VAFIN		OK/0.985111
given	angewendet	VVN	VVPP		OK/0.941907
as	als	IN	KOKOM		OK/0.997717
part	Teil	NN	NN		OK/0.977627
of	__unaligned__	IN	__unaligned__		OK/0.990015
combination	Kombinationstherapie	NN	NN		OK/0.997062
therapy	Kombinationstherapie	NN	NN		OK/0.986980
(	siehe	(	ADV		OK/0.994180
see	siehe	VV	ADV		OK/0.999446
section	Abschnitt	NN	NN		OK/0.999395
4.2	4.2	CD	CARD		OK/0.997880
)	)	)	$(		OK/0.996742
.	.	SENT	$.		OK/0.997366

# 0.783273
What	Was	WP	PWS		OK/0.997876
you	Sie	PP	PPER		OK/0.967531
should	müssen	MD	VMFIN		OK/0.973531
consider	__unaligned__	VV	__unaligned__		OK/0.995421
before	vor	IN	APPR		OK/0.970807
you	__unaligned__	PP	__unaligned__		OK/0.964976
use	Anwendung	VVP	NN		OK/0.984183
Foscan	Foscan	NP	NE		OK/0.993367
3	3.	CD	ADJA		OK/0.889653
.	__unaligned__	SENT	__unaligned__		OK/0.937538

# 0.756619
If	guter	IN	ADJA		OK/0.991931
well	guter	RB	ADJA		OK/0.991507
tolerated	guter	VVN	ADJA		OK/0.992042
,	__unaligned__	,	__unaligned__		OK/0.992699
your	Ihr	PP$	PPOSAT		OK/0.990922
doctor	Arzt	NN	NN		OK/0.960068
may	kann	MD	VMFIN		OK/0.972195
gradually	schrittweise	RB	ADJD		OK/0.992660
increase	erhöhen	VV	VVINF		OK/0.921513
the	die	DT	ART		OK/0.998495
rate	Infusionsgeschwindigkeit	NN	NN		OK/0.981627
of	die	IN	ART		OK/0.935864
administration	Infusionsgeschwindigkeit	NN	NN		OK/0.923838
.	.	SENT	$.		OK/0.996887

# 0.527567
Posaconazole	Posaconazol	NP	NN		OK/0.953210
is	ist	VBZ	VAFIN		OK/0.969237
an	ist	DT	VAFIN		OK/0.611217
Breitband-Triazolantimykotikum	Breitband-Triazolantimykotikum	NP	NN		OK/0.616727
.	.	SENT	$.		OK/0.989193

# 0.201779
18	684	CD	CARD		OK/0.941421
Please	Sie	RB	PPER		OK/0.934342
keep	__unaligned__	VV	__unaligned__		OK/0.944395
this	dies	DT	PDS		OK/0.998885
possible	__unaligned__	JJ	__unaligned__		OK/0.967705
problem	__unaligned__	NN	__unaligned__		OK/0.912093
in	__unaligned__	IN	__unaligned__		OK/0.959667
mind	__unaligned__	NN	__unaligned__		OK/0.816060
in	in	IN	APPR		OK/0.969716
all	allen	DT	PIAT		OK/0.972320
situations	Situationen	NNS	NN		OK/0.959380
where	Situationen	WRB	NN		BAD/0.518404
you	Sie	PP	PPER		BAD/0.525523
might	könnten	MD	VMFIN		BAD/0.752837
put	__unaligned__	VV	__unaligned__		BAD/0.836418
yourself	sich	PP	PRF		BAD/0.902427
and	und	CC	KON		OK/0.969518
others	andere	NNS	PIS		OK/0.901270
at	aussetzen	IN	VVINF		OK/0.956484
risk	Risiko	NN	NN		OK/0.993166
(	(	(	$(		OK/0.982195
e.	z.	FW	APPRART		OK/0.973981
g	z.	NN	APPRART		OK/0.928504
.	z.	SENT	APPRART		OK/0.967184

# 0.177936
The	Die	DT	ART		OK/0.996892
incidences	Häufigkeiten	NNS	NN		OK/0.992001
of	__unaligned__	IN	__unaligned__		OK/0.988126
undesirable	Nebenwirkungen	JJ	NN		OK/0.934514
effects	Nebenwirkungen	NNS	NN		OK/0.927096
in	__unaligned__	IN	__unaligned__		OK/0.748850
clinical	klinischen	JJ	ADJA		OK/0.829049
trials	Studien	NNS	NN		OK/0.873258
,	__unaligned__	,	__unaligned__		OK/0.513685
considered	__unaligned__	VVD	__unaligned__		OK/0.336912
related	NeoRecormon	VVN	NN		OK/0.879051
to	__unaligned__	TO	__unaligned__		OK/0.939090
treatment	Behandlung	NN	NN		OK/0.974028
with	mit	IN	APPR		OK/0.983461
NeoRecoromon	Verbindung	NP	NN		OK/0.959918
are	sind	VBP	VAFIN		OK/0.939702
shown	__unaligned__	VVN	__unaligned__		OK/0.843169
in	__unaligned__	IN	__unaligned__		OK/0.889176
the	der	DT	ART		OK/0.996007
table	Tabelle	NN	NN		OK/0.987459
below	Tabelle	RB	NN		OK/0.979477
.	.	SENT	$.		OK/0.999486

# 0.804111
Studies	Studien	NPS	NN		OK/0.997572
morbidity	Morbidität	NN	NN		OK/0.892298
and	und	CC	KON		OK/0.981762
mortality	Mortalität	NN	NN		OK/0.985776
have	__unaligned__	VHP	__unaligned__		OK/0.970569
not	nicht	RB	PTKNEG		OK/0.988819
yet	sind	RB	VAFIN		OK/0.955376
completed	abgeschlossen	VVN	VVPP		OK/0.959801
.	.	SENT	$.		OK/0.999800

# 0.529947
Other	antihypertensive	JJ	ADJA		OK/0.976416
antihypertensive	antihypertensive	NN	ADJA		OK/0.982874
agents	antihypertensive	NNS	ADJA		OK/0.942831
:	antihypertensive	:	ADJA		OK/0.696037
the	__unaligned__	DT	__unaligned__		OK/0.983239
antihypertensive	antihypertensive	NN	ADJA		OK/0.983668
effect	Effekt	NN	NN		OK/0.999450
of	__unaligned__	IN	__unaligned__		OK/0.994822
Cozaar	Cozaar	NP	NN		OK/0.988116
Comp	Comp	NP	NN		OK/0.874368
remains	bleibt	VVZ	VVFIN		OK/0.974220
for	für	IN	APPR		OK/0.975890
24	24	CD	CARD		OK/0.937953
hours	Stunden	NNS	NN		OK/0.954552
.	.	SENT	$.		OK/0.998270

# 0.959426
Like	Wie	IN	KOKOM		OK/0.998481
all	alle	DT	PIAT		OK/0.998855
medicines	Arzneimittel	NNS	NN		OK/0.999019
,	__unaligned__	,	__unaligned__		OK/0.994457
Zarzio	Zarzio	NP	NE		OK/0.996509
can	__unaligned__	MD	__unaligned__		OK/0.993190
have	haben	VH	VAFIN		OK/0.994576
side	Nebenwirkungen	NN	NN		OK/0.997201
effects	Nebenwirkungen	NNS	NN		OK/0.996340
,	,	,	$,		OK/0.996951
although	die	IN	PRELS		OK/0.996337
not	nicht	RB	PTKNEG		OK/0.999488
everybody	bei	NN	APPR		OK/0.995789
gets	__unaligned__	VVZ	__unaligned__		OK/0.999476
them	__unaligned__	PP	__unaligned__		OK/0.998633
.	.	SENT	$.		OK/0.999314

# 0.002711
(	(	(	$(		OK/0.960604
d	d	LS	NE		OK/0.759199
)	)	)	$(		OK/0.764455
Hold	Den	VV	ART		OK/0.410630
the	__unaligned__	DT	__unaligned__		OK/0.759704
pen	Fertigpen	NN	NN		OK/0.638618
pointing	samt	VVG	APPR		BAD/0.734912
upwards	nach	RB	APPR		BAD/0.658868
and	und	CC	KON		OK/0.937708
gently	vorsichtig	RB	ADJD		OK/0.794995
with	mit	IN	APPR		OK/0.887371
your	__unaligned__	PP$	__unaligned__		OK/0.516182
finger	__unaligned__	NN	__unaligned__		OK/0.503221
so	den	IN	ART		OK/0.469895
the	die	DT	ART		OK/0.912955
cartridge	Patrone	NN	NN		OK/0.589439
with	klopfen	IN	VVINF		OK/0.281118
needle	__unaligned__	NN	__unaligned__		OK/0.441191
may	eventuell	MD	ADJD		OK/0.510169
need	__unaligned__	VV	__unaligned__		OK/0.646572
to	__unaligned__	TO	__unaligned__		OK/0.674679
allow	damit	VV	PAV		OK/0.526546
the	__unaligned__	DT	__unaligned__		OK/0.668873
faceplate	vorhandene	NN	ADJA		OK/0.324212
Luftblä-	Luftblä-	NN	NN		OK/0.360703
protein	schen	NN	VVFIN		OK/0.802936
.	.	SENT	$.		OK/0.998677

# 0.413063
Some	einigen	DT	PIAT		OK/0.993612
patients	Patienten	NNS	NN		OK/0.984765
have	sind	VHP	VAFIN		OK/0.964838
been	beobachtet	VBN	VVPP		OK/0.966250
observed	beobachtet	VVN	VVPP		OK/0.966817
during	während	IN	APPR		OK/0.968502
treatment	Behandlung	NN	NN		OK/0.990471
with	mit	IN	APPR		OK/0.991454
Elaprase	Elaprase	NP	NN		OK/0.963136
,	__unaligned__	,	__unaligned__		OK/0.746880
anaphylactoid	anaphylaktoide	JJ	ADJA		OK/0.949267
reactions	Reaktionen	NNS	NN		OK/0.984644
,	,	,	$,		OK/0.830505
which	lebensbedrohlich	WDT	ADJD		OK/0.908734
may	lebensbedrohlich	MD	ADJD		OK/0.958908
be	lebensbedrohlich	VB	ADJD		OK/0.994026
life	lebensbedrohlich	NN	ADJD		OK/0.987149
threatening	lebensbedrohlich	VVG	ADJD		OK/0.951733
,	,	,	$,		OK/0.979966
these	Diese	DT	PDAT		OK/0.977142
reactions	Reaktionen	NNS	NN		OK/0.998120
may	können	MD	VMFIN		OK/0.991854
occur	auftreten	VV	VVINF		OK/0.960508
,	jedem	,	PIS		OK/0.971687
administered	angewendeten	VVN	ADJA		OK/0.922292
intravenously	intravenös	RB	ADJD		OK/0.895774
.	.	SENT	$.		OK/0.996318

# 0.858401
Co-administration	gleichzeitige	NP	ADJA		OK/0.997938
of	gleichzeitige	IN	ADJA		OK/0.996056
lithium	Lithium	NN	NN		OK/0.964114
and	und	CC	KON		OK/0.999554
Kinzalkomb	Kinzalkomb	NP	NN		OK/0.991293
is	empfohlen	VBZ	VVPP		OK/0.996172
not	nicht	RB	PTKNEG		OK/0.969185
recommended	empfohlen	JJ	VVPP		OK/0.936208
(	siehe	(	ADV		OK/0.997230
see	siehe	VV	ADV		OK/0.997364
section	Abschnitt	NN	NN		OK/0.994747
4.4	4.4	CD	CARD		OK/0.992164
)	)	)	$(		OK/0.991901
.	.	SENT	$.		OK/0.995742

# 0.109944
Mechanism	Wirkungsweise	NP	NN		OK/0.968400
of	Wirkungsweise	IN	NN		OK/0.994872
action	Wirkungsweise	NN	NN		OK/0.996081
form	nicht-kompetitive	NN	ADJA		OK/0.974818
of	__unaligned__	IN	__unaligned__		OK/0.985889
micafungin	Micafungin	NN	NE		OK/0.907569
causes	bewirkt	NNS	VVFIN		OK/0.663069
inhibition	Hemmung	NN	NN		OK/0.806538
of	Hemmung	IN	NN		OK/0.542945
the	der	DT	ART		OK/0.779512
production	__unaligned__	NN	__unaligned__		OK/0.616258
of	__unaligned__	IN	__unaligned__		OK/0.704035
Apparatus	1,3-β-D-Glucan	NP	NE		OK/0.709176
,	,	,	$,		OK/0.863754
secreted	Grundbestandteil	VVD	NN		OK/0.792561
according	einem	VVG	ART		OK/0.908489
to	__unaligned__	TO	__unaligned__		OK/0.918623
the	der	DT	ART		OK/0.899911
Pilzzellwand	Pilzzellwand	NP	NN		BAD/0.588852
.	.	SENT	$.		OK/0.992896

# 0.942787
What	Welchen	WP	PIAT		OK/0.999069
benefit	Welchen	VVP	PIAT		OK/0.988623
has	Nutzen	VHZ	NN		OK/0.999698
Keppra	Keppra	NP	NE		OK/0.996977
shown	__unaligned__	VVN	__unaligned__		OK/0.999637
during	in	IN	APPR		OK/0.972014
the	__unaligned__	DT	__unaligned__		OK/0.980112
studies	Studien	NNS	NN		OK/0.996586
?	?	SENT	$.		OK/0.998501

# 0.102203
The	Die	DT	ART		OK/0.962434
absolute	absolute	JJ	ADJA		OK/0.961376
bioavailability	Bioverfügbarkeit	NN	NN		OK/0.987749
(	(	(	$(		OK/0.998942
70	70	CD	CARD		OK/0.998282
%	%	NN	NN		OK/0.998497
)	)	)	$(		OK/0.993044
of	von	IN	APPR		OK/0.938940
insulin	Insulinglulisin	NN	NN		OK/0.989485
glulisine	Insulinglulisin	NN	NN		OK/0.997095
was	war	VBD	VAFIN		OK/0.979876
associated	mit	VVN	APPR		OK/0.691588
with	mit	IN	APPR		OK/0.997195
low	geringen	JJ	ADJA		OK/0.999405
intra-	intra-	JJ	ADJA		OK/0.977058
individual	individuellen	JJ	ADJA		OK/0.958121
variability	Variabilität	NN	NN		OK/0.973211
(	(	(	$(		OK/0.999519
11	11	CD	CARD		OK/0.999532
%	%	NN	NN		OK/0.993376
CV	VK	NP	NE		OK/0.915417
)	)	)	$(		OK/0.966576
was	bei	VBD	APPR		BAD/0.685494
similar	ähnlich	JJ	ADJD		BAD/0.821122
between	ähnlich	IN	ADJD		BAD/0.654393
injection	Injektionsstellen	NN	NN		BAD/0.500865
sites	Injektionsstellen	NNS	NN		BAD/0.300683
.	.	SENT	$.		OK/0.984801

# 0.878978
Which	Gewährleistung	WDT	NN		OK/0.915713
measures	Gewährleistung	NNS	NN		OK/0.997733
are	Gewährleistung	VBP	NN		OK/0.998314
being	Gewährleistung	VBG	NN		OK/0.998540
taken	Gewährleistung	VVN	NN		OK/0.999838
to	Gewährleistung	TO	NN		OK/0.998819
ensure	Gewährleistung	VV	NN		OK/0.994193
the	sicheren	DT	ADJA		OK/0.996983
safe	von	JJ	APPR		OK/0.999627
use	__unaligned__	NN	__unaligned__		OK/0.994939
of	Anwendung	IN	NN		OK/0.997398
Thalidomide	Thalidomide	NP	NN		OK/0.999081
Celgene	Celgene	NP	NN		OK/0.981900
?	?	SENT	$.		OK/0.997351
